Patent Publication Number: US-2022220187-A1

Title: Chimeric receptor therapy

Description:
REFERENCE TO SEQUENCE LISTING 
     The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 10, 2022, is named 75594-348568_SL.txt and is 579,627 bytes in size. 
     BACKGROUND OF THE DISCLOSURE 
     Chimeric antigen receptor (CAR-T) cell and T cell receptor (TCR) therapies have recently undergone rapid development and have been shown to successfully direct killing of tumor cells. Such therapies are, for example, useful in treating autoimmune disorders and cancers. Indeed, several targets for such therapies have been identified to date, including but not limited to CD19, CD33, BCMA, CD44, α-Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, CD22, EGFR, Folate receptor α, Mucins such as MUC1, MUC4 or MUC16, MAGE-A1, h5T4, PSMA, TAG-72, EGFR, CD20, EGFRvIII, CD123 or VEGF-R2. Among these, CD19, CD33, MUC1, MUC16, and ROR1 have shown particular promise as targets for immunotherapy. 
     CD19 is an attractive target for immunotherapy due to several factors. It is expressed on a variety of B cell lymphomas and leukemias and on normal B cells, but it is not found on hematopoietic stem cells, plasma cells, and other healthy tissues. In addition, CD19 has a broader expression profile than that of CD20, which is the target of monoclonal antibody therapies such as rituximab, and it is thought to be a better target for antibody-drug conjugates (ADC) compared with CD20, which suffers from inefficient internalization. CD19 has also been shown to be expressed in cases where monoclonal antibody treatment (e.g., rituximab) is ineffective due to CD20 downregulation or other factors. Additionally, because CD19-targeting agents have a mode of action that is distinct from that of anti-CD20 antibodies, they could complement existing monoclonal antibody regimens. 
     CD33 is an attractive target for immunotherapy due to its high expression in cancer and minimal expression in healthy adult tissues. CD33 is overexpressed on myeloid leukemia and leukemic stem cells. CD33 is overexpressed in acute myeloid leukemia (AML), which is the most common acute leukemia in adults. 85 to 90% of AML patients show expression of CD33 on blast cells. CD33 is also overexpressed in myelodysplastic syndromes (MDS), which are cancerous conditions of the bone marrow generally found in adults in their 70s. 
     MUC1 is an attractive target for immunotherapy because it is overexpressed in breast cancer, and is absent or expressed at low levels in normal mammary glands. In addition, MUC1 is mostly aberrantly underglycosylated in cancer and the antigens on the cancer surface are different from those on normal cells. Therefore targeting MUC1 for cancer immunotherapy can exploit the differences between cancerous and normal cells. 
     MUC16 is an attractive target for immunotherapy due to its high expression in cancer and minimal expression in healthy adult tissues. MUC16 is aberrantly expressed in ovarian cancer, breast cancer, pancreatic cancer, endothermal cancer, and lung cancer. For example, MUC16 is overexpressed in over 80% of ovarian tumors, which is the most lethal of the gynecologic malignancies. Meanwhile, limited expression of MUC16 has been found on healthy tissue. The current standard of care for ovarian cancer is surgery, followed by chemotherapy with a combination of platinum agents and taxanes. However, recurrence of the disease occurs in most patients after initial treatment, resulting in a cycle of repeated surgeries and additional rounds of chemotherapy. 
     Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an attractive target for immunotherapy due to its high expression in cancer and minimal expression in healthy adult tissues. ROR1 is aberrantly expressed in multiple hematological tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and diffuse B-cell lymphoma (DLBCL) and solid tumors, including breast adenocarcinomas encompassing triple negative breast cancer (TNBC), pancreatic cancer, ovarian cancer, and lung adenocarcinoma. 
     Although many patients have durable responses with CAR-T and TCR therapies, for some patients the anti-tumor effects of such therapies are either short-lived or ineffective. Another immunotherapy that has shown promise is immune checkpoint inhibition, which can prevent the switching off of T cells and promote the activity of these cells. Examples of checkpoint inhibitor targets include but are not limited to PD1, PD-L1, CTLA-4, TIGIT, 4-1BB, PIK3IP1, CD27, CD28, CD40, CD70, CD122, CD137, OX40 (CD134), GITR, ICOS, A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA, IDO, KIR, LAG3, TIM-3, or VISTA. Among these, targeting CTLA4, PD-1, PD-L1, TIM3, TIGIT, LAG3, and/or PIK3IP1 has shown the most promise. One of the most studied checkpoint inhibition pathway is the PD-1/programmed death ligand 1 (PD-L1) pathway, which plays a vital role in how tumor cells evade immune response. Immunotherapy utilizing PD-1/PD-L1 blocking antibodies has been extensively evaluated in the clinic and has been shown to improve tumor regression across multiple malignancies, especially when administered in conjunction with CAR-T cells. However, checkpoint inhibitor blocking antibodies have not performed consistently across cancer types, may have limited access to the tumor microenvironment, require repeated administration, and may lose effectiveness over time. Genome editing is an alternate approach to eliminate PD-1 mediated CAR-T cell exhaustion, and has the advantage of restricting the PD-1 blockade to only the engineered CAR-T cells. However, gene editing adds complexity to the manufacturing process, which increases the turnaround time and cost of the cell therapy. 
     There is accordingly a continuing need in the art to obtain safer, more effective, less expensive therapies to antigen-associated diseases and conditions, including treatments that combine CAR-T and/or TCR therapy with systemic checkpoint inhibition. 
     There is also a need to devise ways of diversifying treatment regimens to provide a multi-pronged targeting of antigens in order to address complex in vivo biological issues such as loss of immunological surveillance, genetic alterations in tumor antigen composition and tumor heterogeneity (giving rise to cancer cell phenotypic differences). 
     SUMMARY OF THE DISCLOSURE 
     The present invention relates in part to a non-naturally occurring polynucleotide encoding a miRNA that inhibits the expression of an immune checkpoint protein. In certain embodiments, the miRNA targets CTLA4, PD-1, PD-L1, TIM3, TIGIT, LAG3, GITR, or PIK3IP1. In certain embodiments, the miRNA targets PD-1. 
     In certain embodiments, the polynucleotide comprises a nucleic acid sequence having at least 80% sequence identity with any one of SEQ ID NOs: 72-87 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 72-87. In certain such embodiments, the polynucleotide comprises a nucleic acid sequence having at least 80% sequence identity with any one of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 84, and 86 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 704, 705, 709, and 710. In certain embodiments, the polynucleotide comprises a nucleic acid sequence having at least 80% sequence identity with SEQ ID NO: 179 or 180 or that is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 179 or 180. In certain embodiments, the polynucleotide comprises a nucleic acid sequence having at least 80% sequence identity with SEQ ID NO: 267 or that is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 267. 
     In certain embodiments, the polynucleotide further comprises: a) a nucleic acid sequence having at least 80% sequence identity with SEQ ID NO: 292 or is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 291; and b) a nucleic acid sequence having at least 80% sequence identity with SEQ ID NO: 292 or is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 292. 
     In certain embodiments, the polynucleotide further encodes a chimeric receptor. In certain embodiments, the chimeric receptor is a T-cell receptor or a chimeric antigen receptor. 
     In certain embodiments, the chimeric antigen receptor comprises an antigen-binding domain that binds to an epitope on CD19, CD33, MUC1, MUC16, or ROR1. In certain embodiments, the antigen-binding domain binds to an epitope on ROR1. 
     In certain embodiments, the antigen-binding domain comprises a variable light chain domain comprising the amino acid sequence of any one of SEQ ID NOs: 347, 351, 355, 359, 363, 367, 371, 375, 379, 383, 387, 391, 395, 399, 403, 407, 411, 415, 419, 423, 427, 431, 435, 439, 443, 447, 451, 455, 459, and 463, or a functional fragment or variant thereof. In certain such embodiments, the variable light chain domain comprises the amino acid sequence of SEQ ID NO: 387 or a functional fragment or variant thereof. 
     In certain embodiments, the antigen-binding domain comprises a variable heavy chain domain comprising the amino acid sequence of any one of SEQ ID NOs: 349, 353, 357, 361, 365, 369, 373, 377, 381, 385, 389, 393, 397, 401, 405, 409, 413, 417, 421, 425, 429, 433, 437, 441, 445, 449, 453, 457, and 461, or a functional fragment or variant thereof. In certain such embodiments, the variable heavy chain domain comprises the amino acid sequence of SEQ ID NO: 349 or a functional fragment or variant thereof. 
     In certain embodiments, the chimeric antigen receptor comprises a spacer. In certain such embodiments, the spacer comprises a stalk region that is a CD8α hinge domain or a functional fragment or variant thereof. In certain such embodiments, the stalk region comprises the amino acid sequence of SEQ ID NO: 467 or a functional fragment or variant thereof. In certain embodiments, the spacer comprises a stalk extension region. In certain such embodiments, the stalk extension region comprises the amino acid sequence of SEQ ID NO: 473 or a functional fragment or variant thereof. 
     In certain embodiments, the chimeric antigen receptor further comprises a transmembrane domain. In certain such embodiments, the transmembrane domain comprises a CD8α transmembrane domain or a functional fragment or variant thereof. In certain such embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 475 or a functional fragment or variant thereof. 
     In certain embodiments, the chimeric antigen receptor further comprises an intracellular signaling domain. In certain such embodiments, the intracellular signaling domain comprises a CD3ζ signaling domain or a functional fragment or variant thereof. In certain such embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 479 or a functional fragment or variant thereof. 
     In certain embodiments, the intracellular signaling domain comprises a co-stimulatory domain. In certain such embodiments, the intracellular signaling domain comprises a CD28 signaling domain or a functional fragment or variant thereof. In certain embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 481 or a functional fragment or variant thereof. 
     In certain embodiments, the polynucleotide further encodes a cytokine. In certain embodiments, the cytokine is IL-15 or a functional fragment or variant thereof. In certain such embodiments, the cytokine comprises the amino acid sequence of SEQ ID NO: 519 or a functional fragment or variant thereof. 
     In certain embodiments, the IL-15, or functional fragment or variant thereof, is membrane bound. In certain such embodiments, the IL-15, or functional fragment or variant thereof, forms part of a fusion protein that also comprises IL-15Rα, or a functional fragment or variant thereof. In certain such embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 523 or a functional fragment or variant thereof. In certain embodiments, the fusion protein comprises the amino acid sequence of SEQ ID NO: 525 or a functional fragment or variant thereof. 
     In certain embodiments, the polynucleotide further encodes a cell tag. In certain embodiments, the cell tag comprises a truncated HER1, or a functional fragment or variant thereof. In certain embodiments, the truncated HER1 comprises a HER1 Domain III, or a functional fragment or variant thereof, and a truncated HER1 Domain IV, or a functional fragment or variant thereof. In certain such embodiments, the truncated HER1 comprises the amino acid sequence of SEQ ID NO: 565, or a functional fragment or variant thereof, and the amino acid sequence of SEQ ID NO: 567, or a functional fragment or variant thereof. 
     In certain embodiments, the cell tag further comprises a CD28 transmembrane domain or a functional fragment or variant thereof. In certain such embodiments, the cell tag comprises the amino acid sequence of SEQ ID NO: 571 or a functional fragment or variant thereof. 
     The present invention also relates to a vector comprising the aforementioned polynucleotide. The vector may be viral or non-viral. In certain embodiments, the vector comprises a Sleeping Beauty transposon. 
     The present invention further relates to a modified immune effector cell comprising the aforementioned polynucleotide. In certain embodiments, the cell is a T-cell. 
     The present invention additionally relates to compositions and kits comprising the aforementioned polynucleotide and/or cell. 
     A further aspect of the present invention is a method for treating a subject suffering from a disease or disorder, comprising administering the aforementioned cell to a subject in need thereof. The invention also relates to the use of the aforementioned cell in the manufacture of a medicament for the treatment of a disease or disorder. The disease or disorder may be one associated with the overexpression of an antigen, for example, CD19, CD33, ROR1, MUC1, or MUC16. In certain embodiments, the disease or disorder is one associated with the overexpression of ROR1. 
     In certain embodiments, the disease or disorder is cancer. In certain embodiments, the disease or disorder is chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, or diffuse large B-cell lymphoma, breast adenocarcinomas encompassing triple negative breast cancer, pancreatic cancer, ovarian cancer, or lung adenocarcinoma. 
     Another aspect of the present invention is a method for the detection of a disease or disorder associated with the overexpression of an antigen in a subject, the method comprising: a) contacting a sample from the subject with one or more of the antibodies, or antigen-binding fragments thereof; and b) detecting an increased level of binding of the antibody or fragment thereof to the sample as compared to such binding to a control sample lacking the disease, thereby detecting the disease in the subject. 
     A yet further aspect of the present invention is a method for the treatment of a disease or disorder, such as cancer and auto-immune disease or disorders, comprising the serial administration of cells, nucleic acids, viral vectors, or non-viral vectors comprising polynucleotides encoding chimeric antigen receptors selected from a collection of chimeric antigen receptors having different structural compositions and binding specificities for an array of antigen targets. In certain such embodiments, the method comprises a first administration of cells expressing one or more chimeric antigen receptors from the collection followed by a second administration of cells expressing one or more chimeric antigen receptors from the collection, wherein a period of time elapses between the first and second administrations. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1A  is an exemplary depiction of a vector comprising a combination of one or more checkpoint inhibitor miRNAs with a chimeric receptor (SD=Splice Donor; SA=Splice Acceptor). 
         FIG. 1B  is an exemplary depiction of hairpin and loop design of various pri-miRNAs including target miRNA and complementary sequences at various 5′ or 3′ positions.  FIG. 1C  is exemplary depiction of hairpin and loop design of various pri-miRNAs including its position in a transgene cassette. 
         FIG. 2  is a graph depicting PD1 relative RNA expression following transfection of various combinations of miRNA constructs in the presence or absence of MUC16-specific CAR. Constructs #1-8 as depicted on the X-axis are as schematically presented in Table 10. 
         FIGS. 3A, 3B and 3C  are graphs depicting normalized absolute transcript counts obtained from gene analysis of &gt;700 genes using a Nanostring human gene panel code set with CD3/CD28 bead-stimulated CD33 CAR-T cells. In  FIG. 3A , the Y-axis plots the transcript counts from CAR-T cells containing an intron coding for 2 checkpoint inhibitor miRNAs targeting PD-1 and TIGIT (CD33 CAR-mbIL15-HER1t+ miRNA (PD-1+TIGIT)), and the X-axis plots the transcripts from CAR-T cells only (not containing any checkpoint inhibitory miRNA). The circles denote the genes of interest. In  FIG. 3B , the Y-axis plots the transcript counts from PD-1 miRNA containing CAR-T cells (CD33 CAR-mbIL15-HER1t+miRNA (PD-1+PD-1)) and the X-axis plots the transcripts from CAR-T cells only.  FIG. 3C  plots the non-targeting miRNA control (CD33 CAR-mbIL15-HER1t+miRNA scrambled*) on the Y-axis and CAR-T cells without a miRNA containing intron on the X-axis. The circles denote the genes of interest and used to depict the on-target specificity of the checkpoint inhibitor miRNA designs. All three graphs were derived from one donor. * Scrambled controls are non-targeting miRNAs. 
         FIG. 4A-C  are graphs depicting the normalized absolute transcript counts obtained from gene analysis of &gt;700 genes using a Nanostring human gene panel code set with CD3/CD28 bead stimulated MUC16-specific CAR-T cells. In  FIG. 4A , the Y-axis plots the transcript counts from CAR-T cells containing an intron coding for miRNAs targeting two different sequences within PD-1 and a sequence for TIGIT (MUC16CAR-mbIL15-HER1t (collectively also referred to as “MUC16CAR”)+miRNA (PD-1/PD-1/TIGIT)), and the X-axis plots the transcripts from CAR-T cells without a miRNA-containing intron (MUC16CAR-mbIL15-HER1t). The black circles denote the genes of interest. In  FIG. 4B , the X-axis is the same, and the Y-axis plots the transcript counts from dual PD-1 targeting miRNA containing CAR-T cells (MUC16CAR-mbIL15-HER1t+miRNA (PD-1/PD-1)).  FIG. 4C  plots the non-targeting miRNA control (MUC16CAR-mbIL15-HER1t+miRNA (scrambled)) on the Y-axis and CAR-T cells without a miRNA-containing intron on the X-axis. All three graphs are from one donor. 
         FIG. 5A  is a graph depicting the number of GFP+K562 cells expressing MUC16 over time. The line with black circle filled dots at each time point denotes number GFP+ target cells in wells without CAR-T cells. The line with square open points denotes target cell counts in wells with MUC16 CAR-mbIL15-HER1t CAR-T cells without a miRNA-containing intron, ((“with CAR-T cells”)). The line with grey circle filled points denotes the target cell counts in wells with CAR-T cells containing a synthetic intron with dual PD-1 targeting miRNAs (MUC16 CAR-mbIL15-HER1t+miRNA (PD-1/PD-1) (“with CAR-T+miRNA cells”). Data are from one donor, plotted is the mean+SD of triplicate wells. *** P&lt;0.001 based on a 2-way ANOVA with Dunnett&#39;s Multiple Comparison post hoc test. 
         FIG. 5B  is a graph depicting the number of GFP+K562/MUC16+/PD-L1+/CD155+ cells over time. The line with square filled points at each time point denotes number GFP+ target cells only in wells. The line with open circle points denotes target cell counts in wells with MUC16-specific CAR-T cells without a miRNA-containing intron (MUC16 CAR-mbIL15-HER1t (with CAR-T cells)). The line with open circle filled points denotes the target cell counts in wells with CAR-T cells containing a synthetic intron with dual PD-1 and a TIGIT targeting miRNAs (MUC16CAR-mbIL15-HER1t+miRNA (PD-1/PD-1/TIGIT)(with CAR-T+miRNA cells)). Data are from one donor, plotted is the mean+SD of triplicate wells. 
         FIG. 6A-B  depicts cytokine expression levels of IFN gamma and GM-CSF in MUC16 CAR-T cells with a combination of one or more checkpoint inhibitor miRNAs following co-culture with tumor target cells (K562/MUC16t).  FIG. 6C-D  depicts cytokine expression levels of IFN gamma and GM-CSF in MUC16 CAR-T cells with a combination of one or more checkpoint inhibitor miRNAs without co-culture with tumor target cells. Constructs #1-11 as depicted on the X-axis are as schematically presented in Table 11. 
         FIG. 7  shows the tumor burden in mice treated with MUC16 CAR+mbIL-15+HER1t (shown as “MUC16 CAR”) in combination with various miRNAs. 
         FIG. 8A  demonstrates PD-1 levels in cell populations following gating hCD45/CD3+/HER1t+ expression in the blood of MUC16CAR+mbIL15+HER1t (CAR only) and MUC16CAR+mbIL15+HER1t+miRNA (PD1/PD-1) (CAR+miRNA (PD-1/PD-1)) treated mice. 
         FIG. 8B  shows PD-1 levels as measured by median fluorescent intensity (MFI) in CAR and CAR+miRNA (PD-1/PD-1) treated mice. 
         FIGS. 9A and 9B  demonstrates PD-1 and TIGIT MFI levels in cell populations following gating hCD45/CD3+/HER1t+ expression in the blood of various CAR and CAR+miRNA treated mice. Groups #1-9 as depicted on the X-axis are as schematically presented in Table 12. 
         FIG. 10A  demonstrates that the PD1 silencer module produces guide miRNAs and a corresponding decrease in PD1 mRNA expression in UltraCAR-T cells generated from 5 T cell donors. RT-qPCR results of PD1-targeting guide miRNAs are depicted. 
         FIG. 10B  demonstrates that the PD1 silencer module produced guide miRNAs and a corresponding decrease in PD1 mRNA expression in ultraCAR-T cells generated from 5 T cell donors. RT-qPCR results of PD1 mRNA are depicted. 
         FIG. 11  demonstrates that the PD1 silencing module preferentially produced PD1-targeting guide miRNAs over non-targeting passenger miRNAs. 
         FIGS. 12A-E  demonstrate that guide miRNAs are the predominant small RNA species originating from the PD1 silencer module. 
         FIG. 13  shows quantification of mature miRNAs mapping to the PD1 silencer module as a percentage of total small RNAseq reads. 
         FIGS. 14  A and B shows differential gene expression in ROR1+PD1 silencer cells compared to ROR1 UltraCAR-T control cells. 
         FIGS. 15A-D  show a comparison of predicted miRNA binding strength to transcript log fold change. 
         FIG. 16  provides an exemplary scheme for a genetic construct of the present disclosure. 
         FIG. 17  provides a schematic depiction of pathways and elements of the present disclosure. 
         FIG. 18  provides examples of pathways by which treatment regimens of the present disclosure can proceed. 
         FIG. 19  provides an indication of additional embodiments of the present disclosure. 
         FIG. 20  provides an indication of additional embodiments of the present disclosure. 
     
    
    
     DETAILED DESCRIPTION OF THE DISCLOSURE 
     The following description and examples illustrate embodiments of the present disclosure in detail. 
     It is to be understood that the present disclosure is not limited to the particular embodiments described herein and as such can vary. Those of skill in the art will recognize that there are variations and modifications of the present disclosure, which are encompassed within the scope of the present invention. 
     Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. 
     The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. 
     Although various features of the disclosure can be described in the context of a single embodiment, the features can also be provided separately or in any suitable combination. Conversely, although the present disclosure can be described herein in the context of separate embodiments for clarity, the present disclosure can also be implemented in a single embodiment. 
     The following definitions supplement those in the art and are directed to the current application and are not to be imputed to any related or unrelated case, e.g., to any commonly owned patent or application. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. 
     I. Definitions 
     In this application, the use of the singular includes the plural unless specifically stated otherwise. As used in the specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. 
     In this application, the use of “or” means “and/or” unless stated otherwise. The terms “and/or” and “any combination thereof” and their grammatical equivalents as used herein, can be used interchangeably. These terms can convey that any combination is specifically contemplated. Solely for illustrative purposes, the following phrases “A, B, and/or C” or “A, B, C, or any combination thereof” can mean “A individually; B individually; C individually; A and B; B and C; A and C; and A, B, and C.” The term “or” can be used conjunctively or disjunctively, unless the context specifically refers to a disjunctive use. 
     Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting. 
     Reference in the specification to “some embodiments,” “an embodiment,” “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the present disclosures. 
     As used in this specification and the claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the disclosure, and vice versa. Furthermore, compositions of the present disclosure can be used to achieve methods of the present disclosure. 
     The term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. In another example, the amount “about 10” includes 10 and any amounts from 9 to 11. In yet another example, the term “about” in relation to a reference numerical value can also include a range of values plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value. Alternatively, particularly with respect to biological systems or processes, the term “about” can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term “about” meaning within an acceptable error range for the particular value should be assumed. 
     A “therapeutically-effective amount” or “therapeutically-effective dose” refers to an amount or dose effective, for periods of time necessary, to achieve a desired therapeutic result. The amount can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the inventive nucleic acid sequences to elicit a desired response in the individual. 
     “Polynucleotide” or “oligonucleotide” refers to a polymeric form of nucleotides or nucleic acids of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double and single stranded DNA, triplex DNA, as well as double and single stranded RNA. It also includes modified, for example, by methylation and/or by capping, and unmodified forms of the polynucleotide. The term is also meant to include molecules that include non-naturally occurring or synthetic nucleotides as well as nucleotide analogs. 
     Unless otherwise stated, nucleic acid sequences in the text of this specification are given, when read from left to right, in the 5′ to 3′ direction. 
     The terms “transfection,” “transformation,” “nucleofection,” or “transduction” as used herein refer to the introduction of one or more exogenous polynucleotides into a host cell or organism by using physical, chemical, and/or electrical methods. The nucleic acid sequences and vectors disclosed herein can be introduced into a cell or organism by any such methods, including, for example, by electroporation, calcium phosphate co-precipitation, strontium phosphate DNA co-precipitation, liposome mediated-transfection, DEAE dextran mediated-transfection, polycationic mediated-transfection, tungsten particle-facilitated microparticle bombardment, viral, and/or non-viral mediated transfection. In some cases, the method of introducing nucleic acids into the cell or organism involves the use of viral, retroviral, lentiviral, or transposon, or transposable element-mediated (e.g., Sleeping Beauty) vectors. 
     “Polypeptide,” “peptide,” and their grammatical equivalents as used herein refer to a polymer of amino acid residues. The polypeptide can optionally include glycosylation or other modifications typical for a given protein in a given cellular environment. Polypeptides and proteins disclosed herein (including functional fragments and functional variants thereof) can comprise synthetic amino acids in place of one or more naturally-occurring amino acids. Such synthetic amino acids are known in the art, and include, for example, aminocyclohexane carboxylic acid, norleucine, α-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β-phenylserine β-hydroxyphenylalanine, phenylglycine, α-naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N′-benzyl-N′-methyl-lysine, N′,N′-dibenzyl-lysine, 6-hydroxylysine, ornithine, α-aminocyclopentane carboxylic acid, α-aminocyclohexane carboxylic acid, α-aminocycloheptane carboxylic acid, α-(2-amino-2-norbornane)-carboxylic acid, α,γ-diaminobutyric acid, α,β-diaminopropionic acid, homophenylalanine, and α-tert-butylglycine. The present disclosure further contemplates that expression of polypeptides or proteins described herein in an engineered cell can be associated with post-translational modifications of one or more amino acids of the polypeptide or protein. Non-limiting examples of post-translational modifications include phosphorylation, acylation including acetylation and formylation, glycosylation (including N-linked and O-linked), amidation, hydroxylation, alkylation including methylation and ethylation, ubiquitylation, addition of pyrrolidone carboxylic acid, formation of disulfide bridges, sulfation, myristoylation, palmitoylation, isoprenylation, farnesylation, geranylation, glypiation, lipoylation and iodination. 
     The term “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and Schirmer, R. H., Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids can be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and Schirmer, R. H., supra). Examples of conservative mutations include amino acid substitutions of amino acids within the sub-groups below, for example, lysine for arginine and vice versa such that a positive charge can be maintained; glutamic acid for aspartic acid and vice versa such that a negative charge can be maintained; serine for threonine such that a free —OH can be maintained; and glutamine for asparagine such that a free —NH2 can be maintained. Exemplary conservative amino acid substitutions are shown in the following chart: 
     
       
         
           
               
               
               
             
               
                   
                   
               
               
                   
                 Type of Amino Acid 
                 Substitutable Amino Acids 
               
               
                   
                   
               
             
            
               
                   
                 Hydrophilic 
                 Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr 
               
               
                   
                 Sulphydryl 
                 Cys 
               
               
                   
                 Aliphatic 
                 Val, Ile, Leu, Met 
               
               
                   
                 Basic 
                 Lys, Arg, His 
               
               
                   
                 Aromatic 
                 Phe, Tyr, Trp 
               
               
                   
                   
               
            
           
         
       
     
     An amino acid sequence that differs from a reference amino acid sequence by only conservative amino acid substitutions will be referred to herein as a “conservatively-substituted variant” of the reference sequence. 
     In some embodiments, the functional variants can comprise the amino acid sequence of the reference protein with at least one non-conservative amino acid substitution. The term “non-conservative mutations” involve amino acid substitutions between different groups, for example, lysine for tryptophan, or phenylalanine for serine, etc. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with, or inhibit the biological activity of, the functional variant. The non-conservative amino acid substitution can enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the homologous parent protein. Amino acid substitutability is discussed in more detail, for example, in L. Y. Yampolsky and A. Stoltzfus, “The Exchangeability of Amino acids in Proteins,” Genetics 2005 August; 170(4):1459-1472. 
     The terms “identical” and its grammatical equivalents as used herein or “sequence identity” in the context of two nucleic acid sequences or amino acid sequences of polypeptides refer to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window. A “comparison window,” as used herein, refers to a segment of at least about 20 contiguous positions, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence can be compared to a reference sequence of the same number of contiguous positions after the two sequences are aligned optimally. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman,  Adv. Appl. Math.,  2:482 (1981); by the alignment algorithm of Needleman and Wunsch,  J. Mol. Biol.,  48:443 (1970); by the search for similarity method of Pearson and Lipman,  Proc. Nat. Acad. Sci U.S.A.,  85:2444 (1988); by computerized implementations of these algorithms (including, but not limited to CLUSTAL in the PC/Gene program by Intelligentics, Mountain View Calif., GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis., U.S.A.); the CLUSTAL program is well described by Higgins and Sharp,  Gene,  73:237-244 (1988) and Higgins and Sharp, CABIOS, 5:151-153 (1989); Corpet et al.,  Nucleic Acids Res.,  16:10881-10890 (1988); Huang et al.,  Computer Applications in the Biosciences,  8:155-165 (1992); and Pearson et al.,  Methods in Molecular Biology,  24:307-331 (1994). Alignment is also often performed by inspection and manual alignment. In one class of embodiments, the polypeptides herein are at least 80%, 85%, 90%, 98% 99% or 100% identical to a reference polypeptide (i.e., the full length thereof), or a fragment thereof, e.g., as measured by BLASTP (or CLUSTAL, or any other available alignment software) using default parameters. Similarly, nucleic acids can also be described with reference to a starting nucleic acid, e.g., they can be 50%, 60%, 70%, 75%, 80%, 85%, 90%, 98%, 99% or 100% identical to a reference nucleic acid (i.e., the full length thereof) or a fragment thereof, e.g., as measured by BLASTN (or CLUSTAL, or any other available alignment software) using default parameters. When one molecule is said to have certain percentage of sequence identity with a larger molecule, it means that when the two molecules are optimally aligned, the percentage of residues in the smaller molecule finds a match residue in the larger molecule in accordance with the order by which the two molecules are optimally aligned. 
     For purposes of this specification and the claims, it is understood that the phrase “having at least 50% sequence identity with” a reference sequence, or referencing any range therein (e.g., “at least 80% sequence identity with”) encompasses the reference sequence itself. Thus, for example, a claim reciting “a nucleic acid having at least 80% sequence identity with SEQ ID NO: 0” encompasses SEQ ID NO: 0 itself. 
     The term “substantially identical” and its grammatical equivalents as applied to nucleic acid or amino acid sequences mean that a nucleic acid or amino acid sequence comprises a sequence that has at least 95% sequence identity with a reference sequence using the programs described above, e.g., BLAST, using standard parameters. 
     “Homology” is generally inferred from sequence identity between two or more nucleic acids or proteins (or sequences thereof). The precise percentage of identity between sequences that is useful in establishing homology varies with the nucleic acid and protein at issue, but as little as 25% sequence identity is routinely used to establish homology. Higher levels of sequence identity, e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% or more can also be used to establish homology. Methods for determining sequence identity percentages (e.g., BLASTP and BLASTN using default parameters) are described herein and are generally available. Nucleic acids and/or nucleic acid sequences are “homologous” when they are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. Proteins and/or protein sequences are “homologous” when their encoding DNAs are derived, naturally or artificially, from a common ancestral nucleic acid or nucleic acid sequence. The homologous molecules can be termed “homologs.” For example, any naturally occurring proteins can be modified by any available mutagenesis method. When expressed, this mutagenized nucleic acid encodes a polypeptide that is homologous to the protein encoded by the original nucleic acid. 
     Also contemplated and included herein are nucleic acid molecules that hybridize to the disclosed sequences. Hybridization conditions may be mild, moderate, or stringent, as is warranted. 
     Appropriate stringency conditions which promote DNA hybridization, for example, 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by a wash of 2×SSC at 50° C., are known or can be found in Current Protocols in Molecular Biology, John Wiley &amp; Sons, N.Y. (1989), 6.3.1-6.3.6. “Stringent hybridization conditions” are those that include a salt concentration of 1.0 M NaCl in 50% formamide, at a temperature of 37° C. for 4 to 12 hours, followed by a wash in 0.1×SSC at 60-65° C. 
     As will be appreciated by the skilled practitioner, slight changes in nucleic acid sequence do not necessarily alter the amino acid sequence of the encoded polypeptide. This disclosure embraces the degeneracy of codon usage as would be understood by one of ordinary skill in the art. For example, as known in the art, different codons will code for the same amino acid as illustrated in the following chart. 
     
       
         
           
               
               
               
             
               
                   
                   
               
               
                   
                 Amino Acid 
                 Codons 
               
               
                   
                   
               
             
            
               
                   
                 Ala/A 
                 GCT, GCC, GCA, GCG 
               
               
                   
                 Arg/R 
                 CGT, CGC, CGA, CGG, AGA, AGG 
               
               
                   
                 Asn/N 
                 AAT, AAC 
               
               
                   
                 Asp/D 
                 GAT, GAC 
               
               
                   
                 Cys/C 
                 TGT, UGC 
               
               
                   
                 Gln/Q 
                 CAA, CAG 
               
               
                   
                 Glu/E 
                 GAA, GAG 
               
               
                   
                 Gly/G 
                 GGT, GGC, GGA, GGG 
               
               
                   
                 His/H 
                 CAT, CAC 
               
               
                   
                 Ile/I 
                 ATT, ATC, ATA 
               
               
                   
                 Leu/L 
                 TTA, TTG, CTT, CTC, CTA, CTG 
               
               
                   
                 Lys/K 
                 AAA, AAG 
               
               
                   
                 Met/M 
                 ATG 
               
               
                   
                 Phe/F 
                 TTT, TTC 
               
               
                   
                 Pro/P 
                 CCT, CCC, CCA, CCG 
               
               
                   
                 Ser/S 
                 TCT, TCC, TCA, TCG, AGT, AGC 
               
               
                   
                 Thr/T 
                 ACT, ACC, ACA, ACG 
               
               
                   
                 Trp/W 
                 TGG 
               
               
                   
                 Tyr/Y 
                 TAT, TAC 
               
               
                   
                 Val/V 
                 GTT, GTC, GTA, GTG 
               
               
                   
                 START 
                 ATG 
               
               
                   
                 STOP 
                 TAG, TGA, TAA 
               
               
                   
                   
               
            
           
         
       
     
     As used herein, the phrase “codon degenerate variant” when used with reference to a nucleic acid sequence means a nucleic acid sequence that differs from the referenced sequence, but that encodes a polypeptide having the same amino acid sequence as that encoded by the referenced sequence. 
     Additionally, it will be appreciated by persons skilled in the art that partial sequences often work as effectively as full-length versions. The ways in which the nucleotide sequence can be varied or shortened are well known to persons skilled in the art, as are ways of testing the suitability or effectiveness of the altered genes. In certain embodiments, suitability and/or effectiveness of the altered gene may easily be tested by, for example, conventional gas chromatography. All such variations of the genes are therefore included as part of the present disclosure. 
     The term “isolated” and its grammatical equivalents as used herein refer to the removal of a nucleic acid from its natural environment. It is to be understood, however, that nucleic acids and proteins can be formulated with diluents or adjuvants and still for practical purposes be isolated. 
     The term “purified” and its grammatical equivalents as used herein refer to a molecule or composition, whether removed from nature (including genomic DNA and mRNA) or synthesized (including cDNA) and/or amplified under laboratory conditions, that has been increased in purity, wherein “purity” is a relative term, not “absolute purity.” For example, nucleic acids typically are mixed with an acceptable carrier or diluent when used for introduction into cells. The term “substantially purified” and its grammatical equivalents as used herein refer to a nucleic acid sequence, polypeptide, protein or other compound that is essentially free, i.e., is more than about 50% free of, more than about 70% free of, more than about 90% free of, the polynucleotides, proteins, polypeptides and other molecules that the nucleic acid, polypeptide, protein or other compound is naturally associated with. 
     “T cell” or “T lymphocyte” as used herein is a type of lymphocyte that plays a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. 
     “Transposon,” “transposable element” or “TE” refers to a vector DNA sequence that can change its position within the genome, sometimes creating or reversing mutations and altering the cell&#39;s genome size. Transposition often results in duplication of the transposon. Class I transposons are copied in two stages: first, they are transcribed from DNA to RNA, and the RNA produced is then reverse transcribed to DNA. This copied DNA is then inserted at a new position into the genome. The reverse transcription step is catalyzed by a reverse transcriptase, which can be encoded by the transposon itself. The characteristics of retrotransposons are similar to retroviruses, such as HIV. The cut-and-paste transposition mechanism of class II transposons does not involve an RNA intermediate. The transpositions are catalyzed by several transposase enzymes. Some transposases non-specifically bind to any target site in DNA, whereas others bind to specific DNA sequence targets. The transposase makes a staggered cut at the target site resulting in single-strand 5′ or 3′ DNA overhangs (sticky ends). This step cuts out the DNA transposon, which is then ligated into a new target site; this process involves activity of a DNA polymerase that fills in gaps and of a DNA ligase that closes the sugar-phosphate backbone. This results in duplication of the target site. The insertion sites of DNA transposons can be identified by short direct repeats which can be created by the staggered cut in the target DNA and filling in by DNA polymerase, followed by a series of inverted repeats important for the transposon excision by transposase. Cut-and-paste transposons can be duplicated if their transposition takes place during S phase of the cell cycle when a donor site has already been replicated, but a target site has not yet been replicated. Transposition can be classified as either “autonomous” or “non-autonomous” in both Class I and Class II transposons. Autonomous transposons can move by themselves while non-autonomous transposons require the presence of another transposon to move. This is often because non-autonomous transposons lack transposase (for class II) or reverse transcriptase (for class I). 
     “Transposase” refers an enzyme that binds to the end of a transposon and catalyzes the movement of the transposon to another part of the genome by a cut and paste mechanism or a replicative transposition mechanism. In some embodiments, the transposase&#39;s catalytic activity can be utilized to move gene(s) from a vector to the genome. 
     An “expression vector” or “vector” is any genetic element, e.g., a plasmid, a mini-circle, a nanoplasmid, chromosome, virus, transposon, behaving either as an autonomous unit of polynucleotide replication within a cell. (i.e. capable of replication under its own control) or being rendered capable of replication by insertion into a host cell chromosome, having attached to it another polynucleotide segment, so as to bring about the replication and/or expression of the attached segment. Suitable vectors include, but are not limited to, plasmids, transposons, bacteriophages and cosmids. Vectors can contain polynucleotide sequences that are necessary to effect ligation or insertion of the vector into a desired host cell and to effect the expression of the attached segment. Such sequences differ depending on the host organism; they include promoter sequences to effect transcription, enhancer sequences to increase transcription, ribosomal binding site sequences and transcription and translation termination sequences. Alternatively, expression vectors can be capable of directly expressing nucleic acid sequence products encoded therein without ligation or integration of the vector into host cell DNA sequences. In some embodiments, the vector is an “episomal expression vector” or “episome,” which is able to replicate in a host cell, and persists as an extrachromosomal segment of DNA within the host cell in the presence of appropriate selective pressure (see, e.g., Conese et al., Gene Therapy, 11:1735-1742 (2004)). Representative commercially-available episomal expression vectors include, but are not limited to, episomal plasmids that utilize Epstein Barr Nuclear Antigen 1 (EBNA1) and the Epstein Barr Virus (EBV) origin of replication (oriP). The vectors pREP4, pCEP4, pREP7, and pcDNA3.1 from Invitrogen (Carlsbad, Calif.) and pBK-CMV from Stratagene (La Jolla, Calif.) represent non-limiting examples of an episomal vector that uses T-antigen and the SV40 origin of replication in lieu of EBNA1 and oriP. A vector also can comprise a selectable marker gene. In certain embodiments where nano plasmids are utilized, strains such as R6K that utilizes an antisense RNA selection marker (e.g. sucrose tolerance) can be used. 
     The term “selectable marker gene” refers to a nucleic acid sequence that allows cells expressing the nucleic acid sequence to be specifically selected for or against, in the presence of a corresponding selective agent. Suitable selectable marker genes are known in the art and described in, e.g., International Patent Application Publications WO 1992/08796 and WO 1994/28143; Wigler et al., Proc. Natl. Acad. Sci. USA, 77: 3567 (1980); O&#39;Hare et al., Proc. Natl. Acad. Sci. USA, 78: 1527 (1981); Mulligan &amp; Berg, Proc. Natl. Acad. Sci. USA, 78: 2072 (1981); Colberre-Garapin et al., J. Mol. Biol., 150:1 (1981); Santerre et al., Gene, 30: 147 (1984); Kent et al., Science, 237: 901-903 (1987); Wigler et al., Cell, 11: 223 (1977); Szybalska &amp; Szybalski, Proc. Natl. Acad. Sci. USA, 48: 2026 (1962); Lowy et al., Cell, 22: 817 (1980); and U.S. Pat. Nos. 5,122,464 and 5,770,359. 
     The term “coding sequence” refers to a segment of a polynucleotide that encodes for protein or polypeptide. The region or sequence is bounded nearer the 5′ end by a start codon and nearer the 3′ end with a stop codon. Coding sequences can also be referred to as open reading frames. 
     The term “operably linked” refers to refers to the physical and/or functional linkage of a DNA segment to another DNA segment in such a way as to allow the segments to function in their intended manners. A DNA sequence encoding a gene product is operably linked to a regulatory sequence when it is linked to the regulatory sequence, such as, for example, promoters, enhancers and/or silencers, in a manner, that allows modulation of transcription of the DNA sequence, directly or indirectly. For example, a DNA sequence is operably linked to a promoter when it is ligated to the promoter downstream with respect to the transcription initiation site of the promoter and in the correct reading frame with respect to the transcription initiation site so as to allow transcription elongation to proceed through the DNA sequence. An enhancer or silencer is operably linked to a DNA sequence coding for a gene product when it is ligated to the DNA sequence in such a manner as to, respectively, increase or decrease the transcription of the DNA sequence. Enhancers and silencers can be located upstream or downstream of or embedded within the coding regions of the DNA sequence. A DNA for a signal sequence is operably linked to DNA coding for a polypeptide if the signal sequence is expressed as a pre-protein that participates in the secretion of the polypeptide. Linkage of DNA sequences to regulatory sequences is typically accomplished by ligation at suitable restriction sites or via adapters or linkers inserted in the sequence using restriction endonucleases known to one of skill in the art. 
     The terms “induce,” “induction” and their grammatical equivalents as used herein refer to an increase in nucleic acid sequence transcription, promoter activity and/or expression brought about by a transcriptional regulator, relative to some basal level of transcription. 
     The term “transcriptional regulator” refers to a biochemical element that acts to prevent or inhibit the transcription of a promoter-driven DNA sequence under certain environmental conditions (e.g., a repressor or nuclear inhibitory protein), or to permit or stimulate the transcription of the promoter-driven DNA sequence under certain environmental conditions (e.g., an inducer or an enhancer). 
     The term “enhancer,” as used herein, refers to a DNA sequence that increases transcription of, for example, a nucleic acid sequence to which it is operably linked. Enhancers can be located many kilobases away from the coding region of the nucleic acid sequence and can mediate the binding of regulatory factors, patterns of DNA methylation, or changes in DNA structure. A large number of enhancers from a variety of different sources are well known in the art and are available as or within cloned polynucleotides (from, e.g., depositories such as the ATCC as well as other commercial or individual sources). A number of polynucleotides comprising promoters (such as the commonly-used CMV promoter) also comprise enhancer sequences. Enhancers can be located upstream or downstream of coding sequences or within coding sequences. The term “Ig enhancers” refers to enhancer elements derived from enhancer regions mapped within the immunoglobulin (Ig) locus (such enhancers include for example, the heavy chain (mu) 5′ enhancers, light chain (kappa) 5′ enhancers, kappa and mu intronic enhancers, and 3′ enhancers (see generally Paul W. E. (ed), Fundamental Immunology, 3rd Edition, Raven Press, New York (1993), pages 353-363; and U.S. Pat. No. 5,885,827). 
     The term “promoter” refers to a region of a polynucleotide that initiates transcription of a coding sequence. Promoters are located near the transcription start sites of genes, on the same strand and upstream on the DNA (towards the 5′ region of the sense strand). Some promoters are constitutive as they are active in all circumstances in the cell, while others are regulated becoming active in response to specific stimuli, e.g., an inducible promoter. The term “promoter activity” and its grammatical equivalents as used herein refer to the extent of expression of nucleotide sequence that is operably linked to the promoter whose activity is being measured. Promoter activity can be measured directly by determining the amount of RNA transcript produced, for example by Northern blot analysis or indirectly by determining the amount of product coded for by the linked nucleic acid sequence, such as a reporter nucleic acid sequence linked to the promoter. 
     “Inducible promoter” refers to a promoter, that is induced into activity by the presence or absence of transcriptional regulators, e.g., biotic or abiotic factors. Inducible promoters are useful because the expression of genes operably linked to them can be turned on or off at certain stages of development of an organism or in a particular tissue. Non-limiting examples of inducible promoters include alcohol-regulated promoters, tetracycline-regulated promoters, steroid-regulated promoters, metal-regulated promoters, pathogenesis-regulated promoters, temperature-regulated promoters and light-regulated promoters. The inducible promoter can be part of a gene switch or genetic switch. 
     “T cell” or “T lymphocyte” as used herein is a type of lymphocyte that plays a central role in cell-mediated immunity. They can be distinguished from other lymphocytes, such as B cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. 
     As used herein, the phrase “functional fragment” when used with reference to a polypeptide refers to a fragment of such polypeptide that possesses the primary function of the referenced polypeptide. For example, a functional fragment of a polypeptide that serves as a transmembrane domain is a fragment of that polypeptide that also serves as a transmembrane domain. In certain embodiments, the functional fragment of a polypeptide is shorter than the referenced polypeptide by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. When used with reference to a nucleic acid, the phrase “functional fragment” refers to a fragment of the referenced nucleic acid that encodes a polypeptide having the same primary function as the polypeptide encoded by the referenced nucleic acid. 
     As used herein, the phrase “functional variant” when used with reference to a polypeptide refers to a polypeptide that differs from the referenced polypeptide but possesses the primary function of the referenced polypeptide. For example, a functional variant of a polypeptide that serves as a transmembrane domain is a fragment of that polypeptide that also serves as a transmembrane domain. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the referenced amino acid sequence and/or is a conservatively-substituted variant of the referenced sequence. When used with reference to a nucleic acid, the phrase “functional variant” refers to a nucleic acid that differs from the referenced nucleic acid but encodes a polypeptide having the same primary function as the polypeptide encoded by the referenced nucleic acid. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the referenced nucleic acid sequence, hybridizes under stringent hybridization conditions with the complement of the referenced nucleic acid sequence, or is a codon degenerate variant of the nucleic acid sequence. 
     The term “antibody,” also known as immunoglobulin (Ig), as used herein can refer to a monoclonal or polyclonal antibody. The term “monoclonal antibodies,” as used herein, refers to antibodies that are produced by a single clone of B-cells and bind to the same epitope. In contrast, “polyclonal antibodies” refer to a population of antibodies that is produced by different B-cells and bind to different epitopes of the same antigen. The antibodies can be from any animal origin. An antibody can be IgG (including IgG1, IgG2, IgG3, and IgG4), IgA (including IgA1 and IgA2), IgD, IgE, or IgM, and IgY. In some embodiments, the antibody can a single-chain whole antibody. An antibody typically consists of four polypeptides: two identical copies of a heavy (H) chain polypeptide and two identical copies of a light (L) chain polypeptide. Each of the heavy chains contains one N-terminal variable (V H ) region and three C-terminal constant (CH1, CH2 and CH3) regions, and each light chain contains one N-terminal variable (V L ) region and one C-terminal constant (C L ) region. The variable regions of each pair of light and heavy chains form the antigen-binding site of an antibody. The V H  and V L  regions have a similar general structure, with each region comprising four framework regions, whose sequences are relatively conserved. The framework regions are connected by three complementarity determining regions (CDRs). The three CDRs, known as CDR1, CDR2, and CDR3, form the “hypervariable region” of an antibody, which is responsible for antigen binding. These particular regions have been described by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977) and Kabat et al., Sequences of protein of immunological interest. (1991), by Chothia et al., J. Mol. Biol. 196:901-917 (1987), and by MacCallum et al., J. Mol. Biol. 262:732-745 (1996), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Preferably, the term “CDR” is a CDR as defined by Kabat, based on sequence comparisons. CDRH1, CDRH2 and CDRH3 denote the heavy chain CDRs, and CDRL1, CDRL2 and CDRL3 denote the light chain CDRs. 
     The terms “fragment of an antibody,” “antibody fragment,” “fragment of an antibody,” “antigen-binding portion” and their grammatical equivalents are used interchangeably herein to mean one or more fragments or portions of an antibody that retain the ability to specifically bind to an antigen (see, generally, Holliger et al., Nat. Biotech., 23(9):1126-1129 (2005)). The antibody fragment desirably comprises, for example, one or more CDRs, the variable region (or portions thereof), the constant region (or portions thereof), or combinations thereof. Non-limiting examples of antibody fragments include (1) a Fab fragment, which is a monovalent fragment consisting of the V L , V H , C L , and CH1 domains; (2) a F(ab′)2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the stalk region; (3) a Fv fragment consisting of the V L  and V H  domains of a single arm of an antibody; (4) a single chain Fv (scFv), which is a monovalent molecule consisting of the two domains of the Fv fragment (i.e., V L  and V H ) joined by a linker that enables the two domains to be synthesized as a single polypeptide chain (see, e.g., Bird et al., Science, 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA, 85: 5879-5883 (1988); and Osbourn et al., Nat. Biotechnol., 16: 778 (1998)) and (5) a diabody, which is a dimer of polypeptide chains, wherein each polypeptide chain comprises a V H  connected to a V L  by a peptide linker that is too short to allow pairing between the V H  and V L  on the same polypeptide chain, thereby driving the pairing between the complementary domains on different V H -V L  polypeptide chains to generate a dimeric molecule having two functional antigen-binding sites. Antibody fragments are known in the art and are described in more detail in, e.g., U.S. Pat. No. 8,603,950. 
     The terms “antigen recognition moiety,” “antigen recognition domain,” “antigen-binding domain,” and “antigen binding region” refer to a molecule or portion of a molecule that specifically binds to an antigen. In one embodiment, the antigen recognition moiety is an antibody, antibody like molecule or fragment thereof. 
     The term “proliferative disease” refers to a unifying concept in which excessive proliferation of cells and/or turnover of cellular matrix contributes significantly to the pathogenesis of the disease, including cancer. In some embodiments, the proliferative disease is cancer. 
     “Patient” or “subject” refers to a mammalian subject diagnosed with or suspected of having or developing a proliferative disorder such as cancer. In some embodiments, the term “patient” refers to a mammalian subject with a higher than average likelihood of developing a proliferative disorder such as cancer. Exemplary patients can be humans, apes, dogs, pigs, cattle, cats, horses, goats, sheep, rodents and other mammalians that can benefit from the therapies disclosed herein. Exemplary human patients can be male and/or female. “Patient in need thereof” or “subject in need thereof” means a patient diagnosed with or suspected of having a disease or disorder, for instance, but not restricted to cancer. 
     “Administering” refers to herein as providing one or more compositions described herein to a patient or a subject. By way of example and not limitation, composition administration, e.g., injection, can be performed by intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, or intramuscular (i.m.) injection. One or more such routes can be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time. Alternatively, or concurrently, administration can be by the oral route. Additionally, administration can also be by surgical deposition of a bolus or pellet of cells, or positioning of a medical device. 
     As used herein, the terms “treatment,” “treating,” and their grammatical equivalents refer to obtaining a desired pharmacologic and/or physiologic effect. In some embodiments, the effect is therapeutic, i.e., the effect partially or completely cures a disease and/or adverse symptom attributable to the disease. In some embodiments, the term “treating” can include “preventing” a disease or a condition. 
     As used herein, a “treatment interval” refers to a treatment cycle, for example, a course of administration of a therapeutic agent that can be repeated, e.g., on a regular schedule. In some embodiments, a dosage regimen can have one or more periods of no administration of the therapeutic agent in between treatment intervals. 
     The terms “administered in combination,” “co-administration,” “co-administering,” and “co-providing” as used herein, mean that two (or more) different treatments are delivered to the subject during the course of the subject&#39;s affliction with the disorder, e.g., the two or more treatments are delivered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons. In some embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, e.g., an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in the absence of the first treatment, or the analogous situation is seen with the first treatment. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment delivered is still detectable when the second is delivered. 
     In some embodiments, the first treatment and second treatment can be administered simultaneously (e.g., at the same time), in the same or in separate compositions, or sequentially. Sequential administration refers to administration of one treatment before (e.g., immediately before, less than 5, 10, 15, 30, 45, 60 minutes; 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 48, 72, 96 or more hours; 4, 5, 6, 7, 8, 9 or more days; 1, 2, 3, 4, 5, 6, 7, 8 or more weeks before) administration of an additional, e.g., secondary, treatment. The order of administration of the first and secondary treatment can also be reversed. 
     The terms “therapeutically effective amount,” therapeutic amount,” “immunologically effective amount,” “anti-tumor effective amount,” “tumor-inhibiting effective amount,” and their grammatical equivalents refer to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. The therapeutically effective amount can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of a composition described herein to elicit a desired response in one or more subjects. The precise amount of the compositions of the present disclosure to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). 
     Alternatively, the pharmacologic and/or physiologic effect of administration of one or more compositions described herein to a patient or a subject of can be “prophylactic,” i.e., the effect completely or partially prevents a disease or symptom thereof. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset). 
     As used herein, the term “immune checkpoint protein” refers to a molecule that transmits a suppressive signal or has an immunosuppressive function. Examples of such immune checkpoint proteins include, but are not limited to, CTLA-4, PD-1, PD-L1 (programmed cell death-ligand 1), PD-L2 (programmed cell death-ligand 2), LAG-3 (Lymphocyte activation gene 3), TIM3 (T cell immunoglobulin and mucin-3), BTLA (B and T lymphocyte attenuator), B7H3, B7H4, CD160, CD39, CD70, CD73, A2aR (adenosine A2a receptor), KIR (killer inhibitory receptor), VISTA (V-domain Ig-containing suppressor of T cell activation), IDO1 (Indoleamine 2,3-dioxygenase), Arginase I, TIGIT (T cell immunoglobulin and ITIM domain), CD115, and the like (see, Nature Reviews Cancer, 12, p. 252-264, 2012 and Cancer Cell, 27, p. 450-461, 2015). 
     As used herein, terms used in the identification of biological moieties may include, or may not include, a dash “-” within the term. The presence or absence of a dash does not change the intended meaning or identification of the biological moiety. By way of illustration only, and without limitation to these biological moieties, each of the following paired terms (shown with/without a dash) indicate and identify the same biological entities: CCR-4/CCR4, CD-3/CD3, CD-4/CD4, CD-33/CD33, EGFR-2/EGFR2, FLT-1/FLT1, HER-1/HER1, HER-1t/HER1t, IL-12/IL12, IL-15/IL15, IL-15Ra/IL15Rα MUC-1/MUC1, MUC-16/MUC16, ROR-1/ROR1, ROR-1R/ROR1R, TGF-Beta/TGFBeta, VEGF-1/VEGF1, VEGF-R2/VEGFR2.” 
     II. Combinations 
     In certain embodiments, miRNA(s) or polynucleotides encoding the miRNA(s) as described herein can be used in combination with a chimeric receptor or can further comprise a nucleic acid sequence encoding a chimeric receptor, respectively. In some cases, the chimeric receptor is a chimeric antigen receptor (CAR). In some instances, the CAR comprises a pattern-recognition receptor. In other cases, the chimeric receptor comprises an engineered T-cell receptor (TCR). The miRNA(s) can be used in combination with specific CARs, cytokines, and cell tags, for example MUC16-specific CAR with a fusion protein comprising IL15 and IL-15Rα (mbIL15) and truncated HER1 (HER1t), MUC1-specific CAR with mbIL15 and HER1t, or CD33-specific CAR with mbIL15 and HER1t.
     In certain embodiments, the genetic construct can include a 5′ untranslated region (5′UTR) and/or a 3′ untranslated region (3′UTR). In some embodiments, the sequences encoding the miRNA(s) can be located in the 5′UTR and/or the 3′UTR. In some embodiments, the 5′UTR and/or the 3′UTR do not contain an intron.   

     In certain embodiments, a nucleic acid sequence encoding a synthetic intron with checkpoint inhibitor miRNAs is inserted into the same genetic construct as that encoding the chimeric receptor (for example, in the portion of the construct corresponding to the 5′UTR of the mRNA encoding the chimeric receptor). An exemplary depiction of the order of polynucleotide sequences can be found in  FIG. 1A . In one embodiment, the 5′UTR contains one or more mature miRNAs. In some embodiments, the one or more mature miRNA(s) can be directed to the same immune checkpoint protein target, for example PD-1. In certain other embodiments, the mature miRNAs can be directed to more than one immune checkpoint protein target, for example PD-1 and TIGIT, PD1 and CTLA4, or TIGIT and CTLA4. 
     III. miRNA(s) 
     As used herein, the terms “miR,” “mir” and “miRNA” are used to refer to microRNA, a class of small non-coding RNA molecules that are capable of affecting the expression of a gene (the “target gene”) by modulating the translation of messenger RNA transcribed therefrom (either increasing or decreasing the gene&#39;s expression) and/or destabilizing such messenger RNA. 
     The miRNAs can be non-naturally occurring. The terms “non-naturally occurring,” “synthetic,” and “artificial,” as used to describe miRNA(s) herein, are used interchangeably and refer to an miRNA having a sequence that does not occur in nature. In some embodiments, a non-naturally occurring miRNA effectively mimics naturally-occurring miRNA. Non-naturally occurring miRNA can be designed such that the desired hairpins or loops of the corresponding naturally-occurring miRNA are maintained when a naturally-occurring mature miRNA sequence is replaced with a synthetic sequence designed to target a specific transcript. For example, the non-naturally occurring miRNA can have at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or greater sequence identity with naturally-occurring miRNA and/or can hybridize under stringent hybridization conditions with naturally-occurring miRNA. The term “miRNA,” unless otherwise indicated, refers generically to the mature, pri-, and pre-forms of a particular microRNA and functional fragments and variants thereof. 
     The term “pri-miRNA” refers to the primary miRNA transcript containing at least one RNA hairpin. Exemplary depictions of pri-miRNA are illustrated in  FIG. 1B . The RNA hairpin(s) are cleaved from the pri-miRNA in the cell nucleus to form one or more precursor miRNAs (“pre-miRNAs). This pre-miRNA is exported into the cytoplasm where the stem loop structure is cleaved to produce a double-stranded miRNA comprising a miRNA-5p strand from the former 5′ arm of the hairpin loop and a miRNA-3p strand from the former 3′ arm of the hairpin loop. The Argonaute protein then binds the double-stranded miRNA and one of the strands (either the miRNA-5p sequence or the miRNA-3p sequence) is released. The remaining bound strand become the “guide strand” whereas the released strand is known as the “passenger strand” and preferably degrades. The guide strand then goes on to interact with the messenger RNA derived from the target gene, thus affecting its translation. 
     Both the miRNA-5p and miRNA-3p strand sequences will be referred to herein as “mature miRNA” sequences. The remaining portions of the pri-miRNA (the portion thereof 5′ to the miRNA-5p sequence, the portion thereof 3′ to the miRNA-3p sequence, and the stem loop sequence in between the miRNA-5p and miRNA-3p sequences) will be collectively referred to as miRNA backbone sequences. The term “5′ backbone sequence” will be used herein to refer to the backbone sequence that, in a pri-miRNA, is 5′ of the miRNA-5p sequence. The term “3′ backbone sequence” will be used herein to refer to the backbone sequence that, in a pri-miRNA, is 3′ of the miRNA-3p sequence. The term “stem loop sequence” refers to the backbone sequence that, in a pri-miRNA, is between the miRNA-5p and miRNA-3p sequences. 
     The pri-miRNA of the present invention may be produced from naturally-occurring pri-miRNAs by removing the native mature miRNA sequences and replacing them with non-native mature miRNA sequences wherein one of the sequences is capable of serving as a guide miRNA targeting a gene of interest. In the design of a non-naturally occurring pri-miRNA, backbone miRNA nucleic acid sequences can be derived from mouse, rat, or human miRNA sequences. As a non-limiting example, backbone miRNA sequences can be derived from miR150, miR206, miR204, miR17, miR16, miR30a, miR126, miR122, miR213, miR29b1 or miR133a1. 
     Examples of backbone sequences that may be used in the practice of the present invention include, but are not limited, to those encoded by the DNA sequences listed in Table 1 below. The symbols of “X” and “Y” in Table 1 indicate nucleic acid sequences encoding, respectively, the guide miRNA (which may be either miRNA-5p or miRNA-3p) and the passenger miRNA (which may be either miRNA-5p or miRNA-3p), whereas the symbol of “n” indicates the number of nucleotides in such sequences, for example 16-30, preferably 18-25. In some embodiments, n can be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35 nucleotides. In certain embodiments, the backbone miRNA sequences are those that are encoded by sequences that hybridize under stringent hybridization conditions with the complement of any one of the sequences listed in Table 1. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Nucleic acids encoding miRNA backbone sequences 
               
            
           
           
               
               
            
               
                   
                 Nucleic acid sequences encoding 
               
               
                 Synthetic 
                 5&#39; Backbone Sequence X n -Stem Loop  
               
               
                 miRNA 
                 Sequence Y n -3&#39; Backbone Sequence 
               
               
                   
               
               
                 miR204 
                 SEQ ID NO: 1-    -SEQ ID NO: 2-    -SEQ ID NO: 3 
               
               
                 miR206 
                 SEQ ID NO: 4-    -SEQ ID NO: 5-    -SEQ ID NO: 6 
               
               
                 miR17 
                 SEQ ID NO: 7-    -SEQ ID NO: 8-    -SEQ ID NO: 9 
               
               
                 miR150 
                 SEQ ID NO: 10-    -SEQ ID NO: 11-    -SEQ ID NO: 12 
               
               
                 miR150 
                 SEQ ID NO: 13-    -SEQ ID NO: 14-    -SEQ ID NO: 15 
               
               
                 miR16 
                 SEQ ID NO: 16-    -SEQ ID NO: 17-    -SEQ ID NO: 18 
               
               
                 miR30a 
                 SEQ ID NO: 19-    -SEQ ID  
               
               
                   
                 NO: 20-    -SEQ ID NO: 21 
               
               
                 miR126 
                 SEQ ID NO: 22-    -SEQ ID NO: 23-    -SEQ ID NO: 24 
               
               
                 miR122 
                 SEQ ID NO: 25-    -SEQ ID NO: 26-    -SEQ ID NO: 27 
               
               
                 miR214 
                 SEQ ID NO: 28-    -SEQ ID NO: 29-    -SEQ ID NO: 30 
               
               
                 miR214 
                 SEQ ID NO: 31-    -SEQ ID NO: 32-    -SEQ ID NO: 33 
               
               
                 miR29b1 
                 SEQ ID NO: 34-    -SEQ ID NO: 35-    -SEQ ID NO: 36 
               
               
                 miR29b1 
                 SEQ ID NO: 37-    -SEQ ID NO: 38-    -SEQ ID NO: 39 
               
               
                 miR133a1 
                 SEQ ID NO: 40-    -SEQ ID NO: 41-    -SEQ ID NO: 42 
               
               
                 miR26a 
                 SEQ ID NO: 43-    -SEQ ID NO: 44-    -SEQ ID NO: 45 
               
               
                 miR412 
                 SEQ ID NO: 46-    -SEQ ID NO: 47-    -SEQ ID NO: 48 
               
               
                 miR-19 
                 SEQ ID NO: 49-    -SEQ ID NO: 50-    -SEQ ID NO: 51 
               
               
                 miR-21 
                 SEQ ID NO: 52-    -SEQ ID NO: 53-    -SEQ ID NO: 54 
               
               
                 miR-142 
                 SEQ ID NO: 55-    -SEQ ID NO: 56-    -SEQ ID NO: 57 
               
               
                 miR-494 
                 SEQ ID NO: 58-    -SEQ ID NO: 59-    -SEQ ID NO: 60 
               
               
                 miR-1915 
                 SEQ ID NO: 61-    -SEQ ID NO: 62-    -SEQ ID NO: 63 
               
               
                   
               
            
           
         
       
     
     While the miRNA-5p and miRNA-3p sequences hybridize with each other, they are not necessarily exactly complementary. In the design of a non-naturally occurring miRNA, compensatory mutations can be made in the miRNA-5p and/or miRNA-3p sequences so as to maintain the RNA folding and free energy of the native miRNA. In certain embodiments, the sequence encoding the miRNA-3p sequence has at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the complement to the sequence encoding the miRNA-5p sequence or is capable of hybridizing under stringent hybridization conditions with the sequence encoding the miRNA-5p sequence. 
     In certain embodiments, the target gene encodes a checkpoint inhibitor protein. Thus, the present invention relates in part to a polynucleotide encoding a non-naturally occurring miRNA that inhibits the expression of an immune checkpoint protein. In certain such embodiments, the target gene encodes CTLA4, PD-1, PD-L1, TIGIT, TIM3, LAG3, GITR, or PIK3IP1. Non-limiting examples of nucleic acid sequences encoding the guide miRNA targeting genes encoding such checkpoint inhibitors are listed in Table 2. Table 2 also lists the sequences encoding the passenger strand. As previous discussed, the guide and passenger strand are not necessarily complementary. It is contemplated that the passenger strand may also serve to target the messenger RNA associated with the target gene. It is also contemplated that sequences that sequences that hybridize under stringent hybridization conditions with the compliments of the sequences listed in Table 2 may also be used. The mature miRNA sequences used may be combined with a specific pri-miRNA backbone. Table 2 also lists backbones that can be combined with the mature guide and passenger miRNAs listed therein. 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Nucleic acid sequences encoding mature miRNA sequences 
               
            
           
           
               
               
               
               
            
               
                   
                   
                   
                 DNA encoding  
               
               
                 miRNA 
                   
                 DNA encoding  
                 passenger 
               
               
                 Target 
                 Backbone 
                 guide miRNA 
                 miRNA 
               
               
                   
               
               
                 CTLA4 
                 miR-204 
                 (SEQ ID NO: 64) 
                 (SEQ ID NO: 65) 
               
               
                 CTLA4 
                 miR-26a 
                 (SEQ ID NO: 66) 
                 (SEQ ID NO: 67) 
               
               
                 CTLA4 
                 miR-30a 
                 (SEQ ID NO: 68) 
                 (SEQ ID NO: 69) 
               
               
                 CTLA4 
                 miR-206 
                 (SEQ ID NO: 70) 
                 (SEQ ID NO: 71) 
               
               
                 PD1 
                 miR-204 
                 (SEQ ID NO: 72) 
                 (SEQ ID NO: 73) 
               
               
                 PD1 
                 miR-204 
                 (SEQ ID NO: 704) 
                   
               
               
                 PD1 
                 miR-204 
                 (SEQ ID NO: 705) 
                   
               
               
                 PD1 
                 miR-204 
                   
                 (SEQ ID NO: 706) 
               
               
                 PD1 
                 miR-204 
                   
                 (SEQ ID NO: 707) 
               
               
                 PD1 
                 miR-204 
                   
                 (SEQ ID NO: 708) 
               
               
                 PD1 
                 miR-206 
                 (SEQ ID NO: 74) 
                 (SEQ ID NO: 75) 
               
               
                 PD1 
                 miR-206 
                 (SEQ ID NO: 709) 
                   
               
               
                 PD1 
                 miR-206 
                 (SEQ ID NO: 710) 
                   
               
               
                 PD1 
                 miR-206 
                   
                 (SEQ ID NO: 711) 
               
               
                 PD1 
                 miR-206 
                   
                 (SEQ ID NO: 712) 
               
               
                 PD1 
                 miR-206 
                   
                 (SEQ ID NO: 713) 
               
               
                 PD1 
                 miR-30a 
                 (SEQ ID NO: 76) 
                 (SEQ ID NO: 77) 
               
               
                 PD1 
                 miR-412 
                 (SEQ ID NO: 78) 
                 (SEQ ID NO: 79) 
               
               
                 PD1 
                 miR122 
                 (SEQ ID NO: 80) 
                 (SEQ ID NO: 81) 
               
               
                 PD1 
                 miR-17 
                 (SEQ ID NO: 82) 
                 (SEQ ID NO: 83) 
               
               
                 PD1 
                 miR-150 
                 (SEQ ID NO: 74) 
                 (SEQ ID NO: 85) 
               
               
                 PD1 
                 miR-486 
                 (SEQ ID NO: 76) 
                 (SEQ ID NO: 87) 
               
               
                 TIGIT 
                 miR-17 
                 (SEQ ID NO: 88) 
                 (SEQ ID NO: 89) 
               
               
                 TIGIT 
                 miR-150 
                 (SEQ ID NO: 90) 
                 (SEQ ID NO: 91) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 92) 
                 (SEQ ID NO: 93) 
               
               
                 TIGIT 
                 miR29b1 
                 (SEQ ID NO: 94) 
                 (SEQ ID NO: 95) 
               
               
                 TIGIT 
                 miR214 
                 (SEQ ID NO: 96) 
                 (SEQ ID NO: 97) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 98) 
                 (SEQ ID NO: 99) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 100) 
                 (SEQ ID NO: 101) 
               
               
                 TIGIT 
                 miR-22 
                 (SEQ ID NO: 102) 
                 (SEQ ID NO: 103) 
               
               
                 TIGIT 
                 miR-16 
                 (SEQ ID NO: 104) 
                 (SEQ ID NO: 105) 
               
               
                 TIGIT 
                 miR-21 
                 (SEQ ID NO: 106) 
                 (SEQ ID NO: 107) 
               
               
                 TIGIT 
                 miR-494 
                 (SEQ ID NO: 108) 
                 (SEQ ID NO: 109) 
               
               
                 TIGIT 
                 miR-142 
                 (SEQ ID NO: 110) 
                 (SEQ ID NO: 111) 
               
               
                 TIGIT 
                 miR-19 
                 (SEQ ID NO: 112) 
                 (SEQ ID NO: 113) 
               
               
                 TIGIT 
                 miR-1915 
                 (SEQ ID NO: 114) 
                 (SEQ ID NO: 115) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 116) 
                 (SEQ ID NO: 117) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 118) 
                 (SEQ ID NO: 119) 
               
               
                 TIGIT 
                 miR-22 
                 (SEQ ID NO: 120) 
                 (SEQ ID NO: 121) 
               
               
                 TIGIT 
                 miR-142 
                 (SEQ ID NO: 122) 
                 (SEQ ID NO: 123) 
               
               
                 TIGIT 
                 miR-16 
                 (SEQ ID NO: 124) 
                 (SEQ ID NO: 125) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 126) 
                 (SEQ ID NO: 127) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 128) 
                 (SEQ ID NO: 129) 
               
               
                 TIGIT 
                 miR-21 
                 (SEQ ID NO: 130) 
                 (SEQ ID NO: 131) 
               
               
                 TIGIT 
                 miR-494 
                 (SEQ ID NO: 132) 
                 (SEQ ID NO: 133) 
               
               
                 TIGIT 
                 miR-19 
                 (SEQ ID NO: 134) 
                 (SEQ ID NO: 135) 
               
               
                 TIGIT 
                 miR-1915 
                 (SEQ ID NO: 136) 
                 (SEQ ID NO: 137) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 138) 
                 (SEQ ID NO: 139) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 140) 
                 (SEQ ID NO: 141) 
               
               
                 TIGIT 
                 miR-21 
                 (SEQ ID NO: 142) 
                 (SEQ ID NO: 143) 
               
               
                 TIGIT 
                 miR-22 
                 (SEQ ID NO: 144) 
                 (SEQ ID NO: 145) 
               
               
                 TIM3 
                 miR204 
                 (SEQ ID NO: 146) 
                 (SEQ ID NO: 147) 
               
               
                 TIM3 
                 miR206 
                 (SEQ ID NO: 148) 
                 (SEQ ID NO: 149) 
               
               
                 TIM3 
                 miR17 
                 (SEQ ID NO: 150) 
                 (SEQ ID NO: 151) 
               
               
                 TIM3 
                 miR126 
                 (SEQ ID NO: 152) 
                 (SEQ ID NO: 153) 
               
               
                 TIM3 
                 miR122 
                 (SEQ ID NO: 154) 
                 (SEQ ID NO: 155) 
               
               
                 TIM3 
                 miR214 
                 (SEQ ID NO: 156) 
                 (SEQ ID NO: 157) 
               
               
                 LAG3 
                 miR-30a 
                 (SEQ ID NO: 158) 
                 (SEQ ID NO: 159) 
               
               
                 LAG3 
                 miR122 
                 (SEQ ID NO: 160) 
                 (SEQ ID NO: 161) 
               
               
                 GITR 
                 miR206 
                 (SEQ ID NO: 162) 
                 (SEQ ID NO: 163) 
               
               
                 GITR 
                 miR29b1 
                 (SEQ ID NO: 164) 
                 (SEQ ID NO: 165) 
               
               
                 PIK3IP1 
                 miR206 
                 (SEQ ID NO: 166) 
                 (SEQ ID NO: 167) 
               
               
                 PIK3IP1 
                 miR126 
                 (SEQ ID NO: 168) 
                 (SEQ ID NO: 169) 
               
               
                 PIK3IP1 
                 miR30a 
                 (SEQ ID NO: 170) 
                 (SEQ ID NO: 171) 
               
               
                   
               
            
           
         
       
     
     In certain embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80% sequence identity with any one of SEQ ID NOs: 64-83, 85, 87-171, and 704-713 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 64-83, 85, 87-171, and 704-713. In certain such embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 704, 705, 709, and 710 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 704, 705, 709, and 710. 
     In certain embodiments, the miRNA targets PD-1. In certain such embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 72-83, 85, 87, and 704-713 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 72-83, 85, 87, and 704-713. In certain embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 704, 705, 709, and 710 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 72, 74, 76, 78, 80, 82, 704, 705, 709, and 710. 
     In certain embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 72-75 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 72-75. In certain such embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 72 or 74 or that is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 72 or 74. 
     In certain embodiments, the present invention relates to a polynucleotide comprising:
         a) a sequence encoding a 5′ miRNA backbone sequence;   b) a sequence encoding a guide miRNA sequence;   c) a sequence encoding a stem loop sequence;   d) a sequence encoding a passenger miRNA sequence; and   e) a sequence encoding a 3′ backbone sequence.       

     In certain embodiments, the sequence encoding the guide miRNA sequence has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 704, 705, 709, and 710; or is capable of hybridizing under stringent hybridization conditions to the complement of any one of such sequences. 
     In certain embodiments, the sequence encoding the passenger miRNA sequence has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of SEQ ID NOs: 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 706-708, and 711-713; or is capable of hybridizing under stringent hybridization conditions to the complement of any one of such sequences. 
     In certain embodiments, the polynucleotide encoding a pri-miRNA encodes:
         a) a guide miRNA sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 704, 705, 709, and 710, or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of such sequences; and   b) a passenger sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to, respectively, any one of SEQ ID NOs: 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 706-708, and 711-713, or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of such sequences.       

     In any of the foregoing embodiments, the sequences encoding the 5′ miRNA backbone sequence, the stem loop sequence, and the 3′ miRNA backbone sequence can each comprise:
         SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively;   SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively;   SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, respectively;   SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, respectively;   SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, respectively;   SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18, respectively;   SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21, respectively;   SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24, respectively;   SEQ ID NO: 25, SEQ ID NO: 26, and SEQ ID NO: 27, respectively;   SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30, respectively;   SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33, respectively;   SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36, respectively;   SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39, respectively;   SEQ ID NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42, respectively;   SEQ ID NO: 43, SEQ ID NO: 44, and SEQ ID NO: 45, respectively;   SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48, respectively;   SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 51, respectively;   SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54, respectively;   SEQ ID NO: 55, SEQ ID NO: 56, and SEQ ID NO: 57, respectively;   SEQ ID NO: 58, SEQ ID NO: 59, and SEQ ID NO: 60, respectively; or   SEQ ID NO: 61, SEQ ID NO: 62, and SEQ ID NO: 63, respectively;
 
or sequences having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with such sequences, or that are capable of hybridizing under stringent hybridization conditions to the complements of such sequences.
       

     Nucleic acids encoding exemplary non-naturally occurring pri-miRNA sequences targeting specific checkpoint inhibitors are described in Table 3. In certain embodiments, the non-naturally occurring pri-miRNA sequence may be a sequence that is capable of hybridizing under stringent hybridization conditions with the complement of any one of the sequences listed in Table 3. 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 Nucleic acid sequences encoding non-naturally  
               
               
                 occurring pri-miRNA sequences 
               
            
           
           
               
               
               
            
               
                 miRNA 
                 Encoded pri- 
                   
               
               
                 Target 
                 miRNA(s) 
                 DNA Sequence 
               
               
                   
               
               
                 CTLA4 
                 miR204 
                 (SEQ ID NO: 178) 
               
               
                 PD1 
                 miR204 
                 (SEQ ID NO: 179) 
               
               
                 PD1 
                 miR206 
                 (SEQ ID NO: 180) 
               
               
                 TIGIT 
                 miR17 
                 (SEQ ID NO: 181) 
               
               
                 TIGIT 
                 miR150 
                 (SEQ ID NO: 182) 
               
               
                 TIGIT 
                 miR204 
                 (SEQ ID NO: 183) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 184) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 185) 
               
               
                 TIGIT 
                 miR-22 
                 (SEQ ID NO: 186) 
               
               
                 TIGIT 
                 miR-16 
                 (SEQ ID NO: 187) 
               
               
                 TIGIT 
                 miR-16 
                 (SEQ ID NO: 188) 
               
               
                 TIGIT 
                 miR-21 
                 (SEQ ID NO: 189) 
               
               
                 TIGIT 
                 miR-494 
                 (SEQ ID NO: 190) 
               
               
                 TIGIT 
                 miR-142 
                 (SEQ ID NO: 191) 
               
               
                 TIGIT 
                 miR-19 
                 (SEQ ID NO: 192) 
               
               
                 TIGIT 
                 miR-1915 
                 (SEQ ID NO: 193) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 194) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 195) 
               
               
                 TIGIT 
                 miR-22 
                 (SEQ ID NO: 196) 
               
               
                 TIGIT 
                 miR-142 
                 (SEQ ID NO: 197) 
               
               
                 TIGIT 
                 miR-16 
                 (SEQ ID NO: 198) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 199) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 200) 
               
               
                 TIGIT 
                 miR-21 
                 (SEQ ID NO: 201) 
               
               
                 TIGIT 
                 miR-494 
                 (SEQ ID NO: 202) 
               
               
                 TIGIT 
                 miR-19 
                 (SEQ ID NO: 203) 
               
               
                 TIGIT 
                 miR-1915 
                 (SEQ ID NO: 204) 
               
               
                 TIGIT 
                 miR-204 
                 (SEQ ID NO: 205) 
               
               
                 TIGIT 
                 miR-206 
                 (SEQ ID NO: 206) 
               
               
                 TIGIT 
                 miR-21 
                 (SEQ ID NO: 207) 
               
               
                 TIGIT 
                 miR-22 
                 (SEQ ID NO: 208) 
               
               
                 TIM3 
                 miR204 
                 (SEQ ID NO: 209) 
               
               
                 TIM3 
                 miR150 
                 (SEQ ID NO: 210) 
               
               
                 TIM3 
                 miR30a 
                 (SEQ ID NO: 211) 
               
               
                 TIM3 
                 miR206 
                 (SEQ ID NO: 212) 
               
               
                 TIM3 
                 miR16 
                 (SEQ ID NO: 213) 
               
               
                 TIM3 
                 miR17 
                 (SEQ ID NO: 214) 
               
               
                 TIM3 
                 miR126 
                 (SEQ ID NO: 215) 
               
               
                 TIM3 
                 miR122 
                 (SEQ ID NO: 216) 
               
               
                 TIM3 
                 miR214 
                 (SEQ ID NO: 217) 
               
               
                 TIM3 
                 miR29b1 
                 (SEQ ID NO: 218) 
               
               
                 TIM3 
                 miR204 
                 (SEQ ID NO: 219) 
               
               
                 TIM3 
                 miR133a1 
                 (SEQ ID NO: 220) 
               
               
                 LAG3 
                 miR30a 
                 (SEQ ID NO: 221) 
               
               
                 LAG3 
                 miR206 
                 (SEQ ID NO: 222) 
               
               
                 LAG3 
                 miR204 
                 (SEQ ID NO: 223) 
               
               
                 LAG3 
                 miR150 
                 (SEQ ID NO: 224) 
               
               
                 LAG3 
                 miR17 
                 (SEQ ID NO: 225) 
               
               
                 LAG3 
                 miR122 
                 (SEQ ID NO: 226) 
               
               
                 LAG3 
                 miR126 
                 (SEQ ID NO: 227) 
               
               
                 GITR 
                 miR30a 
                 (SEQ ID NO: 228) 
               
               
                 GITR 
                 miR206 
                 (SEQ ID NO: 229) 
               
               
                 GITR 
                 miR17 
                 (SEQ ID NO: 230) 
               
               
                 GITR 
                 miR122 
                 (SEQ ID NO: 231) 
               
               
                 GITR 
                 miR150 
                 (SEQ ID NO: 232) 
               
               
                 GITR 
                 miR29 
                 (SEQ ID NO: 233) 
               
               
                 GITR 
                 miR181a1 
                 (SEQ ID NO: 234) 
               
               
                 TIGIT 
                 miR206 
                 (SEQ ID NO: 235) 
               
               
                 TIGIT 
                 miR30a 
                 (SEQ ID NO: 236) 
               
               
                 TIGIT 
                 miR133a1 
                 (SEQ ID NO: 237) 
               
               
                 TIGIT 
                 miR122 
                 (SEQ ID NO: 238) 
               
               
                 TIGIT 
                 miR29b1 
                 (SEQ ID NO: 239) 
               
               
                 TIGIT 
                 miR214 
                 (SEQ ID NO: 240) 
               
               
                 PD1 
                 miR30a 
                 (SEQ ID NO: 241) 
               
               
                 PD1 
                 miR412 
                 (SEQ ID NO: 242) 
               
               
                 PD1 
                 miR17 
                 (SEQ ID NO: 243) 
               
               
                 PD1 
                 miR122 
                 (SEQ ID NO: 244) 
               
               
                 PD1 
                 miR150 
                 (SEQ ID NO: 245) 
               
               
                 PD1 
                 miR486 
                 (SEQ ID NO: 246) 
               
               
                 PD1 
                 miR206 
                 (SEQ ID NO: 247) 
               
               
                 PD1 
                 miR122 
                 (SEQ ID NO: 248) 
               
               
                 PD1 
                 miR30a 
                 (SEQ ID NO: 249) 
               
               
                 CTLA4 
                 miR206 
                 (SEQ ID NO: 250) 
               
               
                 CTLA4 
                 miR26a 
                 (SEQ ID NO: 251) 
               
               
                 CTLA4 
                 miR30a 
                 (SEQ ID NO: 252) 
               
               
                 PIK3IP1 
                 miR206 
                 (SEQ ID NO: 253) 
               
               
                 PIK3IP1 
                 miR126 
                 (SEQ ID NO: 254) 
               
               
                 PIK3IP1 
                 miR30a 
                 (SEQ ID NO: 255) 
               
               
                 TCRa3′UTR 
                 miR150 
                 (SEQ ID NO: 256) 
               
               
                 TCRa3′UTR 
                 miR204 
                 (SEQ ID NO: 257) 
               
               
                 TCRa3′UTR 
                 miR206 
                 (SEQ ID NO: 258) 
               
               
                 TCRa3′UTR 
                 miR26a 
                 (SEQ ID NO: 259) 
               
               
                 TCRa3′UTR 
                 miR150 
                 (SEQ ID NO: 260) 
               
               
                 TCRa3′UTR 
                 miR16 
                 (SEQ ID NO: 261) 
               
               
                 TCRa3′UTR 
                 miR206 
                 (SEQ ID NO: 262) 
               
               
                 TCRa3′UTR 
                 miR26a 
                 (SEQ ID NO: 263) 
               
               
                   
               
            
           
         
       
     
     In certain such embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 178-263 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 178-263. 
     In certain embodiments, the miRNA targets PD-1. In certain such embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 179, 180, and 241-249 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 179, 180, and 241-249. In certain embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NO: 179 or 180 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 179 or 180. 
     Certain embodiments of the present relate to a polynucleotide that comprises nucleic acid sequences encoding at least two pri-miRNAs. The two or more pri-miRNAs may contain guide miRNA sequences that target the same target gene or the various guide miRNAs may target different genes. In the case of multiple pri-miRNAs, each design may be based on a different native miRNA backbone to reduce the likelihood of misfolding of one miRNA with another. Table 4 provides examples of nucleic acid sequences encoding one or more pri-miRNAs. 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Non-naturally occurring miRNA sequences 
               
               
                 comprising two or more pri-miRNAs 
               
            
           
           
               
               
               
               
            
               
                   
                 miRNA 
                 miRNA 
                   
               
               
                   
                 Target 
                 backbone 
                 DNA Sequence 
               
               
                   
                   
               
               
                   
                 PD1 
                 miR204 + 
                 (SEQ ID NO: 267) 
               
               
                   
                   
                 miR206 
               
               
                   
                 PD1 + 
                 miR204 + 
                 (SEQ ID NO: 268) 
               
               
                   
                 TIGIT 
                 miR150 
               
               
                   
                 PD1 + 
                 miR206 + 
                 (SEQ ID NO: 269) 
               
               
                   
                 TIGIT 
                 miR150 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 270) 
               
               
                   
                 PD1 
                 miR204 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 271) 
               
               
                   
                 PD1 
                 miR206 
               
               
                   
                 TIGIT + 
                 miR204 + 
                 (SEQ ID NO: 272) 
               
               
                   
                 PD1 
                 miR206 
               
               
                   
                 TIGIT + 
                 miR150 + 
                 (SEQ ID NO: 273) 
               
               
                   
                 PD1 
                 miR204 
               
               
                   
                 TIGIT + 
                 miR150 + 
                 (SEQ ID NO: 274) 
               
               
                   
                 PD1 
                 miR206 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 275) 
               
               
                   
                 PD1 + 
                 miR204 + 
               
               
                   
                 PD1 
                 miR206 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 276) 
               
               
                   
                 PD1 + 
                 miR204 + 
               
               
                   
                 PD1 
                 miR206 extra 
               
               
                   
                   
                 spacing 1 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 277) 
               
               
                   
                 PD1 + 
                 miR204 + 
               
               
                   
                 PD1 
                 miR206 extra 
               
               
                   
                   
                 spacing 2 
               
               
                   
                 PD1 + PD1 + 
                 miR204 + 
                 (SEQ ID NO: 278) 
               
               
                   
                 TIGIT 
                 miR206 + 
               
               
                   
                   
                 miR17 
               
               
                   
                 PD1 + PD1 + 
                 miR204 + 
                 (SEQ ID NO: 279) 
               
               
                   
                 TIGIT 
                 miR206 + 
               
               
                   
                   
                 miR17 extra 
               
               
                   
                   
                 spacing 1 
               
               
                   
                 PD1 + PD1 + 
                 miR204 + 
                 (SEQ ID NO: 280) 
               
               
                   
                 TIGIT 
                 miR206 + 
               
               
                   
                   
                 miR17 extra 
               
               
                   
                   
                 spacing 2 
               
               
                   
                 PD1 + 
                 miR204 + 
                 (SEQ ID NO: 281) 
               
               
                   
                 CTLA4 
                 miR26a 
               
               
                   
                 PD1 + 
                 miR204 + 
                 (SEQ ID NO: 282) 
               
               
                   
                 PD1 
                 miR206 
               
               
                   
                 PD1 + 
                 miR206 + 
                 (SEQ ID NO: 283) 
               
               
                   
                 CTLA4 
                 miR26a 
               
               
                   
                 PD1 + 
                 miR206 + 
                 (SEQ ID NO: 284) 
               
               
                   
                 CTLA4 
                 miR204 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 285) 
               
               
                   
                 CTLA4 
                 miR26a 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 286) 
               
               
                   
                 CTLA4 
                 miR204 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 287) 
               
               
                   
                 PD1 
                 miR204 
               
               
                   
                 TIGIT + 
                 miR17 + 
                 (SEQ ID NO: 288) 
               
               
                   
                 PD1 
                 206 
               
               
                   
                 TIGIT + 
                 miR204 + 
                 (SEQ ID NO: 289) 
               
               
                   
                 CTLA4 
                 miR26a 
               
               
                   
                 TIGIT + 
                 miR204 + 
                 (SEQ ID NO: 290) 
               
               
                   
                 PD1 
                 miR206 
               
               
                   
                   
               
            
           
         
       
     
     In certain such embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 267-290 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 267-290. 
     In certain such embodiments, the pri-miRNA comprises at least two pre-miRNAs that target PD-1. In certain embodiments, the present invention relates to a polynucleotide comprising a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NO: 267 or that is capable of hybridizing under stringent hybridization conditions to the complement of any one of SEQ ID NOs: 267. 
     In certain embodiments, the nucleic acid encoding the pri-miRNA(s) is contained in the same genetic construct as that comprising one or more genes encoding protein(s) of interest (e.g., a chimeric antigen receptor, a cytokine, or a cell tag). In certain embodiments, such a genetic construct includes a nucleic acid sequence encoding a 5′ untranslated region (5′UTR) directly upstream of the gene(s) of interest and the sequence encoding the miRNA is included in the 5′UTR. In certain embodiments, such a genetic construct includes a nucleic acid sequence encoding a 3′ untranslated region (3′UTR) directly downstream of the gene(s) of interest and the sequence encoding the miRNA is included in the 3′UTR. 
     In embodiments wherein the sequence encoding the pri-miRNA is included in the sequence corresponding to the 5′ UTR, the transcribed RNA can include additional sequences such as splice donor, branchpoint and/or acceptor site sequences. The inclusion of splice donor, branchpoint, and acceptor sites is important for splicing of the miRNAs from the transcribed RNA. Without splicing, the highly structured miRNA sequence is likely to impede ribosome scanning to the translation initiation sequence relating to the gene of interest. Examples of sequences encoding such splice donor/acceptor sites include SEQ ID NOs: 291 and 292, sequences having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with such sequences and sequences that are capable of hybridizing with the complement of such sequences under stringent hybridization conditions. 
     Thus, in certain embodiments, the polynucleotide of the present invention further comprises: a) a nucleic acid sequence having at least 80% sequence identity with SEQ ID NO: 291 or that is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 291; and b) a nucleic acid sequence having at least 80% sequence identity with SEQ ID NO: 292 or that is capable of hybridizing under stringent hybridization conditions to the complement of SEQ ID NO: 292. 
     IV. Chimeric Antigen Receptors (CARs) 
     In any of the foregoing embodiments, a polynucleotide of the present disclosure can further encode a chimeric receptor, such as a chimeric antigen receptor (CAR). Thus, a polynucleotide of the present disclosure can encode miRNA(s) and a CAR as described herein. In any of the embodiments of the present disclosure, a modified immune effector cell can comprise a chimeric receptor as described herein. 
     A CAR is an engineered receptor that grafts an exogenous specificity onto an immune effector cell. In some instances, a CAR comprises an extracellular domain (ectodomain) that comprises an antigen-binding domain, a transmembrane domain, and an intracellular (endodomain) domain. The intracellular domain comprises an intracellular signaling domain. In certain embodiments, the extracellular domain further comprises a spacer between the antigen-binding domain and the transmembrane domain. 
     A. Antigen-Binding Domain 
     An antigen-binding domain can comprise complementary determining regions of a monoclonal antibody and/or antigen binding fragments thereof. A complementarity determining region (CDR) is a short amino acid sequence found in the variable domains of antigen receptor (e.g., immunoglobulin and T-cell receptor) proteins that bind an antigen and therefore provides the receptor with its specificity for that particular antigen. Each polypeptide chain of an antigen receptor can contain three CDRs (CDR1, CDR2, and CDR3). 
     In certain embodiments, the antigen-binding domain comprises an antibody, or functional fragment or variant thereof, that binds to a target antigen. The functional fragment or variant may comprise the variable domain of the heavy chain of an antibody (V H ) and/or the variable domain of the light chain of an antibody (V L ), or functional fragments or variants thereof. In certain embodiments, the antigen-binding domain comprises a Fv, Fab, Fab2, Fab′, F(ab′)2, or F(ab′) 3 fragment of an antibody. In certain embodiments, the antigen-binding domain comprises a scFv, sc(Fv) 2 , a dsFv, a diabody, a minibody, a nanobody, or binding fragments thereof. In certain embodiments, the antigen-binding domain further comprises an F c  fragment of an antibody, for example it may comprise an scFv linked with an F c  fragment. 
     In some embodiments, the CAR targets an antigen that is elevated in cancer cells, in autoimmune cells, or in cells that are infected by a virus, bacteria or parasite. Pathogens that may be targeted include, without limitation,  Plasmodium , trypanosome,  Aspergillus, Candida , Hepatitis A, Hepatitis B, Hepatitis C, HSV, HPV, RSV, EBV, CMV, JC virus, BK virus, or Ebola pathogens. Autoimmune diseases can include graft-versus-host disease, rheumatoid arthritis, lupus, celiac disease, Crohn&#39;s disease, Sjogren Syndrome, polymyalgia rheumatic, multiple sclerosis, neuromyelitis optica, ankylosing spondylitis, Type 1 diabetes, alopecia areata, vasculitis, temporal arteritis, bullous pemphigoid, psoriasis, pemphigus vulgaris, and autoimmune uveitis. 
     The pathogen recognized by a CAR may be essentially any kind of pathogen, but in some embodiments, the pathogen is a fungus, bacteria, or virus. Exemplary viral pathogens include those of the families of Adenoviridae, Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Respiratory Syncytial Virus (RSV), JC virus, BK virus, HPV, HSV, HHV family of viruses, Hepatitis family of viruses, Picornaviridae, Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, 
     Orthomyxoviridae, Paramyxoviridae, Papovaviridae, Polyomavirus, Rhabdoviridae, and Togaviridae. Exemplary pathogenic viruses cause smallpox, influenza, mumps, measles, chickenpox, ebola, and rubella. Exemplary pathogenic fungi include  Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis , and  Stachybotrys . Exemplary pathogenic bacteria include  Streptococcus, Pseudomonas, Shigella, Campylobacter, Staphylococcus, Helicobacter, E. coli, Rickettsia, Bacillus, Bordetella, Chlamydia , Spirochetes, and  Salmonella . In some embodiments, the pathogen receptor Dectin-1 may be used to generate a CAR that recognizes the carbohydrate structure on the cell wall of fungi such as  Aspergillus . In another embodiment, CARs can be made based on an antibody recognizing viral determinants (e.g., the glycoproteins from CMV and Ebola) to interrupt viral infections and pathology. 
     In some embodiments, a CAR described herein comprises an antigen-binding domain that binds to an epitope on B7H4, BCMA, BTLA, CAIX, CA125, CCR4, CD3, CD4, CD5, CD7, CD16, CD19, CD20, CD22, CD24, CD25, CD28, CD30, CD33, CD38, CD40, CD44, CD44v6, CD44v7/v8, CD47, CD52, CD56, CD70, CD79b, CD80, CD81, CD86, CD123, CD133, CD137, CD138, CD151, CD171, CD174, CD276, CEA, CEACAM6, CLL-1, c-MET, CS1, CSPG4, CTLA-4, DLL3, EDB-F, EGFR, EGFR2, EGFRvIII, EGP-2, EGP-40, EphA2, FAP, FLT1, FLT4, Folate-binding Protein, Folate Receptor, Folate receptor α, α-Folate receptor, Frizzled, GD2, GD3, GHR, GHRHR, GITR, GPC3, Gp100, gp130, HBV antigens, HER1, HER2, HER3, HER4, HER1/HER3, h5T4, HPV antigens, HVEM, IGF1R, IgKAppa, IL-1-RAP, IL-2R, IL6R, IL-11Rα, IL-13R-a2, KDR, KRASG12V, LewisA, LewisY, L1-CAM, LIFRP, LRP5, LTPR, MAGE-A, MAGE-A1, MAGE-A10, MAGE-A3, MAGEA3/A6, MAGE-A4, MAGE-A6, MART-1, MCAM, mesothelin, PSCA, Mucins such as MUC1, MUC-4 or MUC16, NGFR, NKG2D, Notch-1-4, NY-ESO-1, O-acetylGD2, O-acetylGD3, OX40, P53, PD1, PDE10A, PD-L1, PD-L2, PMSA, PRAME, PSCA, PSMA, PTCH1, RANK, Robol, ROR1, ROR1R, ROR-2, TACI, TAG-72, TCRα, TCRp, TGF, TGFBeta, TGFBeta-II, TGFBR1, TGFBR2, Titin, TLR7, TLR9, TNFR1, TNFR2, TNFRSF4, TRBC1, TWEAK-R, VEGF, VEGF-R2, or WT-1. 
     In some embodiments, a CAR described herein comprises an antigen-binding domain that binds to an epitope on CD19, CD33, MUC1, MUC16, or ROR1. In some instances, a CAR described herein comprises an antigen-binding domain that binds to an epitope on CD19. In some cases, a CAR described herein comprises an antigen-binding domain that binds to an epitope on CD33. In some instances, a CAR described herein comprises an antigen-binding domain that binds to an epitope on MUC1. In some instances, a CAR described herein comprises an antigen-binding domain that binds to an epitope on MUC16. In some instances, a CAR described herein comprises an antigen-binding domain that binds to an epitope on ROR1. In further embodiments, a CAR described herein comprises an autoantigen or an antigen binding domain that binds to an epitope on HLA-A2, myelin oligodendrocyte glycoprotein (MOG), factor VIII (FVIII), MAdCAM1, SDF1, or collagen type II. 
     Antigen binding can be assessed by flow cytometry or a cell based assay or any other equivalent assay. Cell based assays may utilize a cell type expressing antigen of interest on the surface to assess antigen-binding. An antigen or a fragment thereof expressed as a soluble protein can be utilized to assess antigen-binding using flow cytometry or similar assay. Improvements in antigen-binding may be indirectly assessed by functional measurement of antigen-binding domain or a chimeric receptor. For example, improved antigen-binding of a chimeric receptor or a CAR, as described herein, can be measured by increased specific cytotoxicity against target cells expressing the antigen. 
     Cell surface expression level of a polypeptide of the present disclosure can be assessed, for example, using a flow cytometry based assay. Improved expression of an antigen-binding polypeptide can be measured as percentage of analyzed cells expressing said antigen-binding polypeptide or alternatively as average density of said antigen-binding polypeptide on the surface of a cell. Additional suitable methods that can be used for assessing cell surface expression of the antigen-binding polypeptides described herein include western blotting or any other equivalent assay. 
     1. CD19-specific Antigen-Binding Domain 
     CD19 is a cell surface glycoprotein of the immunoglobulin superfamily and is found predominately in malignant B-lineage cells. In some instances, CD19 has also been detected in solid tumors such as pancreatic cancer, liver cancer, and prostate cancer. 
     In some embodiments, the CAR comprises a CD19-specific antigen-binding domain, in which the antigen-binding domain comprises a F(ab′)2, Fab′, Fab, Fv, or scFv. In some embodiments, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by FMC63. In some embodiments the scFv and/or VH/VL domains is/are derived from FMC63. FMC63 generally refers to a mouse monoclonal IgG1 antibody raised against Nalm-1 and -16 cells expressing CD19 of human origin (Ling, N. R., el al. (1987). Leucocyte typing III. 302). 
     In some embodiments, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by JCAR014, JCAR015, JCAR017, or 19-28z CAR (Juno Therapeutics). 
     In some embodiments, the antigen-binding domain comprises a scFv antigen-binding domain that recognizes an epitope on CD19 that is also recognized by JCAR014, JCAR015, JCAR017, or 19-28z CAR (Juno Therapeutics). 
     In some embodiments, the antigen-binding domain comprises an anti-CD19 antibody described in U.S. Patent Application Publication No. 2016/0152723. In some embodiments, the antigen-binding domain comprises an anti-CD19 antibody described in International Patent Application Publication No. WO2015/123642. In some embodiments, the antigen-binding domain comprises an anti-CD19 scFv derived from clone FMC63 (Nicholson et al., Construction and characterization of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukemia and lymphoma., Mol. Immunol. 34:1157-1165 (1997)). 
     In some embodiments, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by KTE-C19 (Kite Pharma, Inc.). 
     In some embodiments, the antigen-binding domain comprises a scFv antigen-binding domain, and the antigen-binding domain recognizes an epitope on CD19 that is also recognized by KTE-C19. 
     In some embodiments, the antigen-binding domain comprises an anti-CD19 antibody described in International Patent Application Publication No. WO2015/187528 or fragment or variant thereof. 
     In some embodiments, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by CTL019 (Novartis). 
     In some embodiments, the antigen-binding domain comprises a scFv antigen-binding domain, and the antigen-binding domain recognizes an epitope on CD19 that is also recognized by CTL019. 
     In some embodiments, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by UCART19 (Cellectis). 
     In some embodiments, the antigen-binding domain comprises a scFv antigen-binding domain, and the antigen-binding domain recognizes an epitope on CD19 that is also recognized by UCART19. 
     In some embodiments, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by BPX-401 (Bellicum). 
     In some embodiments, the antigen-binding domain comprises a scFv antigen-binding domain, and the antigen-binding domain recognizes an epitope on CD19 that is also recognized by BPX-401. 
     In some cases, the antigen-binding domain recognizes an epitope on CD19 that is also recognized by blinatumomab (Amgen), coltuximabravtansine (ImmunoGen Inc./Sanofi-aventis), MOR208 (Morphosys AG/Xencor Inc.), MEDI-551 (Medimmune), denintuzumabmafodotin (Seattle Genetics), B4 (or DI-B4) (Merck Serono), taplitumomabpaptox (National Cancer Institute), XmAb 5871 (Amgen/Xencor, Inc.), MDX-1342 (Medarex) or AFM11 (Affimed).
     In some embodiments, the antigen-binding domain comprises a F(ab′) 2, Fab′, Fab, Fv, or scFv, and the antigen-binding domain recognizes an epitope on CD19 that is also recognized by blinatumomab (Amgen), coltuximabravtansine (ImmunoGen Inc./Sanofi-aventis), MOR208 (Morphosys AG/Xencor Inc.), MEDI-551 (Medimmune), denintuzumabmafodotin (Seattle Genetics), B4 (or DI-B4) (Merck Serono), taplitumomabpaptox (National Cancer Institute), XmAb 5871 (Amgen/Xencor, Inc.), MDX-1342 (Medarex) or AFM11 (Affimed).   

     In some cases, the antigen-binding domain comprises a scFv antigen-binding domain, and the antigen-binding domain recognizes an epitope on CD19 that is also recognized by FMC63, blinatumomab (Amgen), coltuximabravtansine (ImmunoGen Inc./Sanofi-aventis), MOR208 (Morphosys AG/Xencor Inc.), MEDI-551 (Medimmune), denintuzumabmafodotin (Seattle Genetics), B4 (or DI-B4) (Merck Serono), taplitumomabpaptox (National Cancer Institute), XmAb 5871 (Amgen/Xencor, Inc.), MDX-1342 (Medarex) or AFM11 (Affimed). 
     2. CD33-specific Antigen-Binding Domain 
     “CD33,” is a 67 kDa single pass transmembrane glycoprotein and is a member of the sialic acid-binding immunoglobulin-like lectins (Siglecs) super-family. CD33 is characterized by a V-set Ig-like domain responsible for sialic acid binding and a C2-set Ig-like domain in its extracellular domain. CD33 is expressed in myeloid lineage cells and has also been detected in lymphoid cells. Alternative splicing of CD33 mRNA leads to a shorter isoform (CD33m) lacking the V-set Ig-like domain as well as the disulfide bond linking the V- and C2-set Ig-like domains. In healthy subjects, CD33 is primarily expressed as a myeloid differentiation antigen found on normal multipotent myeloid precursors, unipotent colony-forming cells, monocytes and maturing granulocytes. CD33 is expressed on more than 80% of myeloid leukemia cells but not on normal hematopoietic stem cells or mature granulocytes. (Andrews, R. et al., The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors,  Blood,  68(5):1030-5 (1986)). CD33 has been reported to be expressed on malignant myeloid cells, activated T cells and activated NK cells and is found on at least a subset of blasts in the vast majority of AML patients (Pollard, J. et al., Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML,  Blood,  119(16):3705-11(2012)). In addition to broad expression on AML blasts, CD33 may be expressed on stem cells underlying AML. 
     In some embodiments, the antigen-binding domain of a CAR described herein is specific to CD33 (CD33 CAR). The CD33-specific CAR, when expressed on the cell surface, redirects the specificity of T cells to human CD33. In some embodiments, the antigen-binding domain comprises a single chain antibody fragment (scFv) comprising a variable domain light chain (VL) and variable domain heavy chain (VH) of a target antigen specific monoclonal anti-CD33 antibody joined by a flexible linker, such as a glycine-serine linker or a Whitlow linker. In some embodiments, the scFv is M195, m2H12, DRB2, and/or My9-6. In some embodiments, the scFv is humanized, for example, hM195. In some embodiments, the antigen-binding domain may comprise VH and VL that are directionally linked, for example, from N to C terminus, VH-linker-VL or VL-linker-VH. In some embodiments, the antigen-binding domain comprises a F(ab′)2, Fab′, Fab, Fv, or scFv that binds CD33. In some embodiments, the antigen-binding region recognizes an epitope on CD33 that is also recognized by Lintuzumab (Seattle Genetics), BI 836858 (Boehringer Ingelheim). 
     In some embodiments, a CAR described herein comprises an antigen-binding domain comprising a VL polypeptide. 
     In certain embodiments, the antigen-binding domain comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 293 (hM195 VL domain), SEQ ID NO: 296 (M2H12 VL domain), SEQ ID NO: 298 (DRB2 VL domain), SEQ ID NO: 300 (My9-6 VL domain) or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than any one of the aforementioned sequences by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 293, 296, 298, and 300, and/or is a conservatively-substituted variant of any one of such sequences. 
     In certain embodiments, the antigen-binding domain comprises a VL domain encoded by SEQ ID NO: 301 (nucleic acid encoding the VL domain for hM195). In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 301; hybridizes under stringent hybridization conditions with the complement of the nucleic acid sequence of SEQ ID NO: 301; or is a codon degenerate variant of SEQ ID NO: 301. 
     In some embodiments, a CAR described herein comprises an antigen-binding domain comprising a VH polypeptide. 
     In certain embodiments, the antigen-binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 294 (hM195 VH domain), SEQ ID NO: 295 (M2H12 VH domain), SEQ ID NO: 297 (DRB2 VH domain), SEQ ID NO: 299 (My9-6 VH domain) or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than any one of the aforementioned sequences by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 294, 295, 297, or 299, and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 294, 295, 297, or 299. 
     In certain embodiments, the antigen-binding domain comprises a VH domain encoded by SEQ ID NO: 302 (nucleic acid encoding the VH domain for hM195), or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 302; hybridizes under stringent hybridization conditions with the complement of the nucleic acid sequence of SEQ ID NO: 302; or is a codon degenerate variant of SEQ ID NO: 302. 
     In some embodiments, the antigen-binding domain can comprise VH and VL that are directionally linked, for example, from N to C terminus, VH-linker-VL or VL-linker-VH. Any linker as described herein can be used to link the VH and VL domains. 
     In certain embodiments, the antigen-binding domain comprises scFv. In certain such embodiments, the domain comprises the amino acid sequence of SEQ ID NO: 303, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than any one of the aforementioned sequence by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 303, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 303. 
     In certain embodiments, the antigen-binding domain is encoded by SEQ ID NO: 304, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 304; hybridizes under stringent hybridization conditions with the complement of the nucleic acid sequence of SEQ ID NO: 304; or is a codon degenerate variant of SEQ ID NO: 304. 
     3. MUC1-specific Antigen-Binding Domain 
     In one embodiment, the antigen-binding domain binds to an epitope on MUC1. In some embodiments, the anti-MUC1 antibody fragment is a Fab, Fab2, (Fab′) 2 , Fv, (Fv) 2 , scFv, scFv-F C , F C , diabody, triabody, or minibody of the anti-MUC1. In some embodiments, the anti-MUC1 antibody fragment is a single-domain antibody of the anti-MUC1 antibody. In some embodiments, the single-domain antibody is a V NAR  or V H H fragment of the anti-MUC1 antibody. 
     In some embodiments, a CAR described herein comprises an antigen-binding domain comprising a VL polypeptide of MUC1. 
     In certain embodiments, the antigen-binding domain comprises a VL domain comprising the amino acid sequence of any one of SEQ ID NOs: 310-314, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of any one of SEQ ID NOs: 310-314 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 310-314, and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 310-314. 
     In some embodiments, a CAR described herein comprises an antigen-binding domain comprising a VH polypeptide of MUC1. 
     In certain embodiments, the antigen-binding domain comprises a VH domain comprising the amino acid sequence of any one of SEQ ID NOs: 305-309, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of any one of SEQ ID NOs: 305-309 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 305-309, and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 305-309. 
     In some embodiments, the antigen binding moiety can comprise VH and VL that are directionally linked, for example, from N to C terminus, VH-linker-VL or VL-linker-VH. Any linker as described herein can be used to link the VH and VL domains. 
     4. MUC16-Specific Antigen-Binding Domain 
     In some embodiments, the antigen binding moiety of a CAR described herein is specific to MUC16 (MUC16 CAR). The MUC16-specific CAR, when expressed on the cell surface, redirects the specificity of T cells to human MUC16. 
     In certain embodiments, the antigen-binding domain comprises a VL domain comprising the amino acid sequence of any one of SEQ ID NOs: 329, 331, 333, 335, 337, 339, 341, 662, 664, 666, 668, 670, 688, 690, 692, 694, 696, 698, and 700, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of any one of the aforementioned sequences by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 329, 331, 333, 335, 337, 339, 341, 662, 664, 666, 668, 670, 688, 690, 692, 694, 696, 698, and 700; and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 329, 331, 333, 335, 337, 339, 341, 662, 664, 666, 668, 670, 688, 690, 692, 694, 696, 698, and 700. 
     In certain embodiments, the antigen-binding domain comprises a VL domain encoded by any one of SEQ ID NOs: 330, 332, 334, 336, 338, 340, 342, 663, 665, 667, 669, 671, 689, 691, 693, 695, 697, 699, and 701, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 330, 332, 334, 336, 338, 340, 342, 663, 665, 667, 669, 671, 689, 691, 693, 695, 697, 699, and 701; or hybridizes under stringent hybridization conditions with the complement of any one of SEQ ID NOs: 330, 332, 334, 336, 338, 340, 342, 663, 665, 667, 669, 671, 689, 691, 693, 695, 697, 699, and 701. 
     In certain embodiments, the antigen-binding domain comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 692, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 692 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 692; and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 692. 
     In certain embodiments, the antigen-binding domain comprises a VL domain encoded by SEQ ID NO: 693, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 693; or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 693. 
     In certain embodiments, the antigen-binding domain comprises a VH domain comprising the amino acid sequence of any one of SEQ ID NOs: 315, 317, 319, 321, 323, 325, 327, 648, 650, 652, 654, 656, 658, 660, 672, 674, 676, 678, 680, 682, 684, and 686, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of any one of the aforementioned sequences by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 315, 317, 319, 321, 323, 325, 327, 648, 650, 652, 654, 656, 658, 660, 672, 674, 676, 678, 680, 682, 684, and 686; and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 315, 317, 319, 321, 323, 325, 327, 648, 650, 652, 654, 656, 658, 660, 672, 674, 676, 678, 680, 682, 684, and 686. 
     In certain embodiments, the antigen-binding domain comprises a VH domain encoded by any one of SEQ ID NOs: 316, 318, 320, 322, 324, 326, 328, 649, 651, 653, 655, 657, 659, 661, 673, 675, 677, 679, 681, 683, 685, and 687, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 316, 318, 320, 322, 324, 326, 328, 649, 651, 653, 655, 657, 659, 661, 673, 675, 677, 679, 681, 683, 685, and 687; or hybridizes under stringent hybridization conditions with the complement of any one of SEQ ID NOs: 316, 318, 320, 322, 324, 326, 328, 649, 651, 653, 655, 657, 659, 661, 673, 675, 677, 679, 681, 683, 685, and 687. 
     In certain embodiments, the antigen-binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 676, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 676 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 676; and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 676. 
     In certain embodiments, the antigen-binding domain comprises a VH domain encoded by SEQ ID NO: 677, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 677; or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 677. 
     In some embodiments, the antigen binding moiety can comprise VH and VL that are directionally linked, for example, from N to C terminus, VH-linker-VL or VL-linker-VH. Any linker as described herein can be used to link the VH and VL domains. 
     In some embodiments, the antigen-binding domain comprises a single chain antibody fragment (scFv) comprising a variable domain light chain (VL) and variable domain heavy chain (VH) of a target antigen specific monoclonal anti-MUC16 antibody joined by a flexible linker, such as a glycine-serine linker or a Whitlow linker. In certain embodiments, the scFv comprises the VH and VL from MUC16-3 and a linker. In certain such embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 343, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 343 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 343; and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 343. 
     In certain embodiments, the antigen-binding domain comprises a scFv encoded by SEQ ID NO: 344, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 344; or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 344. 
     5. ROR1-Specific Antigen-Binding Domain 
     In some embodiments, a CAR described herein comprises an antigen-binding domain comprising the V L domain of an anti-ROR1 antibody. 
     In certain such embodiments, the antigen-binding domain may comprise an amino acid sequence of any one of SEQ ID NOs: 347, 351, 355, 359, 363, 367, 371, 375, 379, 383, 387, 391, 395, 399, 403, 407, 411, 415, 419, 423, 427, 431, 435, 439, 443, 447, 451, 455, 459, and 463, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than any one of the aforementioned sequences by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 347, 351, 355, 359, 363, 367, 371, 375, 379, 383, 387, 391, 395, 399, 403, 407, 411, 415, 419, 423, 427, 431, 435, 439, 443, 447, 451, 455, 459, and 463, and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 347, 351, 355, 359, 363, 367, 371, 375, 379, 383, 387, 391, 395, 399, 403, 407, 411, 415, 419, 423, 427, 431, 435, 439, 443, 447, 451, 455, 459, and 463. 
     In certain embodiments, the antigen-binding domain comprises a V L  domain encoded by any one of SEQ ID NOs: 348, 352, 356, 360, 364, 368, 372, 376, 380, 384, 388, 392, 396, 400, 404, 408, 412, 416, 420, 424, 428, 432, 436, 440, 444, 448, 452, 456, 460, and 464, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 348, 352, 356, 360, 364, 368, 372, 376, 380, 384, 388, 392, 396, 400, 404, 408, 412, 416, 420, 424, 428, 432, 436, 440, 444, 448, 452, 456, 460, and 464; hybridizes under stringent hybridization conditions with the complement of any one of SEQ ID NOs: 348, 352, 356, 360, 364, 368, 372, 376, 380, 384, 388, 392, 396, 400, 404, 408, 412, 416, 420, 424, 428, 432, 436, 440, 444, 448, 452, 456, 460, and 464; or is a codon degenerate variant of any one of SEQ ID NOs: 348, 352, 356, 360, 364, 368, 372, 376, 380, 384, 388, 392, 396, 400, 404, 408, 412, 416, 420, 424, 428, 432, 436, 440, 444, 448, 452, 456, 460, and 464. 
     In some embodiments, a CAR described herein comprises the VH domain of an anti-ROR1 antibody. 
     In certain such embodiments, the antigen-binding domain may comprise an amino acid sequence of any one of SEQ ID NOs: 349, 353, 357, 361, 365, 369, 373, 377, 381, 385, 389, 393, 397, 401, 405, 409, 413, 417, 421, 425, 429, 433, 437, 441, 445, 449, 453, 457, and 461, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than any one of the aforementioned sequences by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 349, 353, 357, 361, 365, 369, 373, 377, 381, 385, 389, 393, 397, 401, 405, 409, 413, 417, 421, 425, 429, 433, 437, 441, 445, 449, 453, 457, and 461, and/or is a conservatively-substituted variant of the amino acid sequence of any one of SEQ ID NOs: 349, 353, 357, 361, 365, 369, 373, 377, 381, 385, 389, 393, 397, 401, 405, 409, 413, 417, 421, 425, 429, 433, 437, 441, 445, 449, 453, 457, and 461. 
     In certain embodiments, the antigen-binding domain comprises a VH domain encoded by any one of SEQ ID NOs: 350, 354, 358, 362, 366, 370, 374, 378, 382, 386, 390, 394, 398, 402, 406, 410, 414, 418, 422, 426, 430, 434, 438, 442, 446, 450, 454, 458, and 462, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 350, 354, 358, 362, 366, 370, 374, 378, 382, 386, 390, 394, 398, 402, 406, 410, 414, 418, 422, 426, 430, 434, 438, 442, 446, 450, 454, 458, and 462; hybridizes under stringent hybridization conditions with the complement of any one of SEQ ID NOs: 350, 354, 358, 362, 366, 370, 374, 378, 382, 386, 390, 394, 398, 402, 406, 410, 414, 418, 422, 426, 430, 434, 438, 442, 446, 450, 454, 458, and 462; or is a codon degenerate variant of any one of SEQ ID NOs: 350, 354, 358, 362, 366, 370, 374, 378, 382, 386, 390, 394, 398, 402, 406, 410, 414, 418, 422, 426, 430, 434, 438, 442, 446, 450, 454, 458, and 462. 
     In certain embodiments, the antigen-binding domain comprises at least one CDR selected from those comprising the amino acid sequence of any one of the CDRs that bind ROR1 or a functional fragment or variant thereof. 
     In certain embodiments, the antigen-binding domain comprises the amino acid sequence of any one of SEQ ID NOs: 715-725, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the sequence of any one of the aforementioned sequences by at most 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 715-725, and/or is a conservatively-substituted variant of any one of SEQ ID NOs: 715-725. 
     In certain embodiments, the antigen-binding domain comprises a V H  domain comprising the amino acid sequences of SEQ ID NO: 715, SEQ ID NO: 716, and SEQ ID NO: 717. 
     In certain embodiments, the antigen-binding domain comprises a V H  domain comprising the amino acid sequences of SEQ ID NO: 718, SEQ ID NO: 719, and SEQ ID NO: 720. 
     In certain embodiments, the antigen-binding domain comprises a V L  domain comprising the amino acid sequences of SEQ ID NO: 721, SEQ ID NO: 722, and SEQ ID NO: 723. 
     In certain embodiments, the antigen-binding domain comprises a V L  domain comprising the amino acid sequences of SEQ ID NO: 724, SEQ ID NO: 725, and SEQ ID NO: 723. 
     In certain embodiments, the antigen-binding domain comprises both the aforementioned V H  and VL domains. 
     In certain embodiments, the antigen-binding domain comprises a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO: 349 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 349 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 349, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 349. 
     In certain embodiments, the antigen-binding domain comprises a V H  domain encoded by SEQ ID NO: 350, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 350; hybridizes under stringent hybridization conditions with the complement SEQ ID NO: 350; or is a codon degenerate variant of SEQ ID NO: 350. 
     In certain embodiments, the antigen-binding domain comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 387 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 387 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 387, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 387. 
     In certain embodiments, the antigen-binding domain comprises a V L  domain encoded by SEQ ID NO: 388, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 388; hybridizes under stringent hybridization conditions with the complement SEQ ID NO: 388; or is a codon degenerate variant of SEQ ID NO: 388. 
     In certain embodiments, the antigen-binding domain comprises a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO: 349 or a functional fragment or variant thereof, wherein the variable heavy chain domain comprises, in N-terminal to C-terminal order, the sequences of SEQ ID NO: 715, SEQ ID NO: 716, and SEQ ID NO: 717. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 349 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 349, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 349. 
     In certain embodiments, the antigen-binding domain comprises a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO: 349 or a functional fragment or variant thereof, wherein the variable heavy chain domain comprises, in N-terminal to C-terminal order, the sequences of SEQ ID NO: 718, SEQ ID NO: 719, and SEQ ID NO: 720. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 349 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 349, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 349. 
     In certain embodiments, the antigen-binding domain comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 387 or a functional fragment or variant thereof, wherein the variable heavy chain domain comprises, in N-terminal to C-terminal order, the sequences of SEQ ID NO: 721, SEQ ID NO: 722, and SEQ ID NO: 723. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 387 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 387, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 387. 
     In certain embodiments, the antigen-binding domain comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 387 or a functional fragment or variant thereof, wherein the variable heavy chain domain comprises, in N-terminal to C-terminal order, the sequences of SEQ ID NO: 724, SEQ ID NO: 725, and SEQ ID NO: 723. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 387 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 387, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 387. 
     In certain embodiments, the antigen-binding domain comprises a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO: 726 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 726 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 726, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 726. 
     In certain embodiments, the antigen-binding domain comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 727 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 727 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 727, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 727. 
     In certain embodiments, the antigen-binding domain comprises a variable heavy chain domain comprising the amino acid sequence of SEQ ID NO: 728 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 728 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 728, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 728. 
     In certain embodiments, the antigen-binding domain comprises a variable light chain domain comprising the amino acid sequence of SEQ ID NO: 729 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 729 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 729, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 729. 
     In certain embodiments, the antigen-binding domain comprises a linker that links the V H  and VL domains. In certain such embodiments, the linker comprises: (a) the amino acid sequence of SEQ ID NO: 424 ((G 4 S) 3 ) or a conservatively-substituted variant thereof; or (b) an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 424. In certain such embodiments, the linker is encoded by SEQ ID NO: 425, hybridizes under stringent conditions to the complement of SEQ ID NO: 425, or is a codon degenerate version of SEQ ID NO: 425. Any linker as described herein can be used to link the VH and VL domains. 
     In certain embodiments, the antigen-binding domain comprises an scFv. In certain such embodiments, the domain comprises an amino acid sequence of SEQ ID NO: 465, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 465 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 465, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 465. 
     In certain embodiments, the antigen-binding domain comprises an scFv encoded by SEQ ID NO: 466, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 466; hybridizes under stringent hybridization conditions with the complement SEQ ID NO: 466; or is a codon degenerate variant of SEQ ID NO: 466. 
     6. EGFRvIII-Specific Antigen-Binding Domain 
     In another embodiment, a CAR described herein is a EGFRvIII-specific CAR. “EGFRvIII”, “EGFR variant III”, “EGFR type III mutant”, “EGFR.D2-7” or “de2-7EGFR” is a mutated form of epidermal growth factor receptor (EGFR; ErbB-1; HER1), a transmembrane protein that is a receptor for members of the epidermal growth factor (EGF) family of extracellular protein ligands in human and non-human subjects. EGFRvIII is characterized by a deletion of exons 2-7 of the wild type EGFR gene, which results in an in-frame deletion of 267 amino acids in the extracellular domain of the full length wild type EGFR protein. EGFRvIII also contains a novel glycine residue inserted at the fusion junction compared to wild type EGFR. The truncated receptor EGFRvIII is unable to bind any known EGFR ligand; however, it shows constitutive tyrosine kinase activity. This constitutive activation is important to its pro-oncogenic effect. A kinase-deficient EGFRvIII is unable to confer a similar oncogenic advantage. EGFRvIII is highly expressed in glioblastoma (GBM) and can be detected in some other solid tumor types but not in normal tissues. 
     In some embodiments, the antigen binding moiety of a CAR described herein is specific to EGFRvIII (EGFRvIII CAR). The EGFRvIII-specific CAR, when expressed on the cell surface, redirects the specificity of T cells to human EGFRvIII. In embodiments, the antigen binding domain comprises a single chain antibody fragment (scFv) comprising a variable domain light chain (VL) and variable domain heavy chain (VH) of a target antigen specific monoclonal anti-EGFRvIII antibody joined by a flexible linker, such as a glycine-serine linker or a Whitlow linker. In some embodiments, the antigen binding moiety may comprise VH and VL that are directionally linked, for example, from N to C terminus, VH-linker-VL or VL-linker-VH. 
     B. Spacer 
     In some embodiments, a chimeric antigen receptor of the present disclosure further includes a spacer that is used to link the antigen-binding domain to the transmembrane domain. In some embodiments, the spacer is flexible enough to allow the antigen-binding domain to orient in different directions to facilitate antigen recognition. 
     In certain embodiments, a chimeric antigen receptor comprising a spacer has improved functional activity compared to an otherwise identical antigen-binding polypeptide lacking the spacer. In certain embodiments, a chimeric antigen receptor comprising a spacer has increased expression on a cell surface compared to an otherwise identical polypeptide lacking the spacer. In an embodiment, a chimeric antigen receptor comprising a spacer is a polypeptide that, were it not for the spacer, would not express on the cell membrane surface and/or would not be able to bind its target due to lack of proximity or steric hindrance. 
     In certain embodiments, the spacer comprises a stalk region, for example a hinge region from an antibody. In some instances, the stalk region comprises the hinge region from an IgG, for example IgG1. In alternative instances, the stalk region comprises the CH 2 CH 3  region of immunoglobulin and, optionally, portions of CD3. In some cases, the stalk region comprises a CD8α hinge region (SEQ ID NO: 426), an IgG4-Fc 12 amino acid hinge region (SEQ ID NO: 631), or an IgG4 hinge region as described in WO2016/073755. The stalk region can be an extracellular portion of the CAR that links the antigen-binding domain to the cell surface and/or transmembrane region. 
     In some embodiments, the stalk region can be from about 20 to about 300 amino acids in length. In some cases, the stalk region can be about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or greater amino acids in length. In other cases, the stalk region can be about: 100, 125, 150, 175, 200, 225, 250, 275 or 300 amino acids in length. In some cases a stalk region can be less than 20 amino acids in length. 
     In some embodiments, the stalk region comprises a CD8α hinge domain, a CD28 hinge domain or a CTLA-4 hinge domain, or a functional fragment or variant thereof. 
     In certain embodiments, the stalk region comprises a CD8α hinge region, or a functional fragment or variant thereof. In certain such embodiments, the spacer comprises the amino acid sequence of SEQ ID NO: 426 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 467 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 467, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 467. 
     In certain embodiments, the CD8α hinge region, or functional fragment or variant thereof, is encoded by SEQ ID NO: 468, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 468, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 468, or is a codon degenerate variant of SEQ ID NO: 468. 
     In some embodiments, the stalk region can be capable of dimerizing with a homologous stalk region of a second CAR. 
     In certain embodiments, in addition to a stalk region, the spacer may comprise one or more stalk extension region(s). In certain embodiments, the stalk extension region is a polypeptide that is homologous to the stalk region. For example, it may comprise at least one amino acid residue substitution as compared with the stalk region. In some embodiments, the stalk region comprises a sequence with at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to the stalk region to which it is attached, for example a CD8α hinge domain, a CD28 hinge domain, or a CTLA-4 hinge domain. 
     In some embodiments, the spacer comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 stalk extension regions. 
     In certain embodiments, the stalk region can be linked to the stalk extension region by way of a linker. 
     In certain embodiments, the stalk extension region can comprise about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times the length of the stalk region as measured by number of amino acids. 
     In some embodiments, the stalk region comprises at least one dimerization site. In certain embodiments, the stalk region may comprise one or more dimerization sites to form homo- or hetero-dimerized chimeric polypeptides. In other embodiments, the stalk region or one or more stalk extension regions may contain mutations that eliminate dimerization sites altogether. 
     In certain embodiments, the stalk extension region has at least one fewer dimerization site as compared to a stalk region. For example, if a stalk region comprises two dimerization sites, a stalk extension region can comprise one or zero dimerization sites. As another example, if a stalk region comprises one dimerization site, a stalk extension region can comprise zero dimerization sites. In some examples, a stalk extension region lacks a dimerization site. In some cases, one or more dimerization site(s) can be membrane proximal. In other cases, one or more dimerization site(s) can be membrane distal. 
     In certain embodiments, the dimerization site is a cysteine residue capable of forming a disulfide bond. In certain embodiments, the stalk extension region is capable of forming fewer disulfide bond(s) as compared to a stalk region. For example, if a stalk region is capable of forming two disulfide bonds, a stalk extension region may be capable of forming one or no disulfide bonds. As another example, if a stalk region is capable of forming one disulfide bond, a stalk extension region may be capable of forming no such bonds. 
     Each of the stalk extension regions can be about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or greater amino acids in length. 
     In certain embodiments, the stalk extension region is homologous to the CD8α hinge region. In certain such embodiments, the stalk extension region comprises the amino acid sequence of SEQ ID NO: 469 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 469 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 469, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 469. 
     In certain embodiments, the stalk extension region is encoded by any one of SEQ ID NOs: 470-472, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 470-472, hybridizes under stringent hybridization conditions with the complement of any one of SEQ ID NOs: 470-472, or is a codon degenerate variant of any one of SEQ ID NOs: 470-472. 
     In certain embodiments, the spacer comprises a stalk region and 1 to 3 stalk extension regions. In certain such embodiments, the spacer comprises a stalk region and 2 stalk extension regions, for example a CD8α hinge region and 2 stalk extension regions wherein each stalk extension region is homologous to the CD8α hinge region. 
     In some embodiments, each of the stalk region and stalk extension region(s) can be derived from at least one of a CD8α hinge domain, a CD28 hinge domain, a CTLA-4 hinge domain, a LNGFR extracellular domain, IgG1 hinge, IgG4 hinge and CH2-CH3 domain. The stalk and stalk extension region(s) can be separately derived from any combination of CD8α hinge domain, CD28 hinge domain, CTLA-4 hinge domain, LNGFR extracellular domain, IgG1 hinge, IgG4 hinge or CH2-CH3 domain. As an example, the stalk region can be derived from CD8α hinge domain and at least one stalk extension region can be derived from CD28 hinge domain thus creating a hybrid spacer. As another example, the stalk region can be derived from an IgG1 hinge or IgG4 hinge and at least one stalk extension region can be derived from a CH2-CH3 domain of IgG. 
     In certain such embodiments, the spacer comprises the amino acid sequence of SEQ ID NO: 473 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 473 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 473, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 473. 
     In certain embodiments, the spacer is encoded by SEQ ID NO: 474, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 474, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 474, or is a codon degenerate variant of SEQ ID NO: 474. 
     C. Transmembrane Domain 
     The transmembrane domain can be derived from either a natural or a synthetic source. Where the source is natural, the domain can, for example, be derived from any membrane-bound or transmembrane protein. Suitable transmembrane domains include transmembrane domains from a TCR-alpha chain, a TCR-beta chain, a TCR-γ1 chain, a TCR-δ chain, a TCR-zeta chain, CD28, CD3 epsilon, CD3ζ CD45, CD4, CD5, CD8α, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS, GITR, CD152 (CTLA-4), or CD154, or a functional fragment or variant thereof. Alternatively, the transmembrane domain can be synthetic, and can comprise hydrophobic residues such as leucine and valine. In some embodiments, a triplet of phenylalanine, tryptophan and valine is found at one or both termini of a synthetic transmembrane domain. In some embodiments, the transmembrane domain comprises a CD8α transmembrane domain, a CD152 (CTLA-4), TCRγ 1 , TCRδ or a CD3ζ transmembrane domain. 
     Optionally, a short oligonucleotide or polypeptide linker, in some embodiments between 2 and 10 amino acids in length, may link the transmembrane domain with the intracellular signaling domain of a CAR. In some embodiments, the linker is a glycine-serine linker. 
     In some embodiments, the transmembrane domain comprises a CD8α transmembrane domain or a CD3ζ transmembrane domain, or a functional fragments or variants thereof. 
     In certain embodiments, the transmembrane domain comprises a CD8α transmembrane domain, or a functional fragment or variant thereof. In certain such embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 475 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 475 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 475, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 475. 
     In certain embodiments, the CD8α transmembrane domain, or functional fragment or variant thereof, is encoded by SEQ ID NO: 476 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 476, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 476, or is a codon degenerate variant of SEQ ID NO: 476. 
     In certain embodiments, the transmembrane domain comprises a CD28 transmembrane domain, or a functional fragment or variant thereof. In certain such embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 477 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 477 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 477, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 477. 
     In certain embodiments, the CD28 transmembrane domain, or functional fragment or variant thereof, is encoded by SEQ ID NO: 478 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 478, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 478, or is a codon degenerate variant of SEQ ID NO: 438. 
     D. Intracellular Signaling Domain 
     The intracellular signaling domain of the CAR may be responsible for activation of at least one of the normal effector functions of the immune cell in which the CAR has been placed. The term “effector function” refers to a specialized function of a cell. Effector function of a T cell, for example, can be cytolytic activity or helper activity including the secretion of cytokines. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion can be used in place of the intact chain as long as it transduces the effector function signal. In some embodiments, the intracellular domain further comprises a signaling domain for T-cell activation. 
     In some embodiments, the intracellular cell signaling domain interacts with a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), or a regulatory T cell. 
     The intracellular domain can comprise an amino acid sequence derived from FCER1G, CD19, CD40, KIR3DL1, KIR3DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, SIRPA, FCRL1, FCRL2, FCRL3, FCRL4, FCRL5, FCRL6, FCGR1A, FCGR2A, FCGR2B, FCGR3A, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, PILRB, NCR1, NCR2, NCR3, NKG2A, NKG2C, NKG2D, DAP12, FCER1G, DAP10, CD84, CD19, KIR3DL1, KIR3DL2, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL2, KIR3DL3, SIRPA, FCRL1, FCRL2, FCRL3, FCRL4, FCRL5, FCRL6, CD4, CD8A, CD8B, LAT, FCGR1A, FCGR2A, FCGR2B, FCGR3A, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, NCR1, NCR2, NCR3, LY9, NKG2C, TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD3ζ, CD5, CD22, CD79a, CD79b or CD66d, or a functional fragment or variant thereof. In some cases, the signaling domain for T-cell activation comprises a domain derived from CD3ζ. or a functional fragment or variant thereof. 
     In certain embodiments, the intracellular signaling domain comprises a CD3ζ domain, or a functional fragment or variant thereof. In certain such embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 479 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 479 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 479, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 479. 
     In certain embodiments, the CD3 domain, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 480 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 480, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 480, or is a codon degenerate variant of SEQ ID NO: 480. 
     The intracellular signaling domain can further comprise one or more co-stimulatory domains. Exemplary co-stimulatory domains include, but are not limited to, CD8, CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, OX40 (CD134), and CD3-zeta co-stimulatory domains and functional fragments or variants thereof. In some instances, a CAR described herein comprises one or more, or two or more of co-stimulatory domains selected from CD8, CD27, CD28, 4-1BB (CD137), ICOS, DAP10, DAP12, and OX40 (CD134) co-stimulatory domains and functional fragments or variants thereof. In some instances, a CAR described herein comprises one or more, or two or more of co-stimulatory domains selected from CD27, CD28, 4-1BB (CD137), ICOS, and OX40 (CD134) co-stimulatory domains and functional fragments or variants thereof. In some instances, a CAR described herein comprises one or more, or two or more of co-stimulatory domains selected from CD8, CD28, 4-1BB (CD137), DAP10, and DAP12 co-stimulatory domains and functional fragments or variants thereof. In some instances, a CAR described herein comprises one or more, or two or more co-stimulatory domains selected from CD28 and 4-1BB (CD137) co-stimulatory domains and functional fragments or variants thereof. In some instances, a CAR described herein comprises CD28 and 4-1BB (CD137) co-stimulatory domains or their respective functional fragments or variants. In some instances, a CAR described herein comprises CD28 and OX40 (CD134) co-stimulatory domains or their respective functional fragments and variants. In some instances, a CAR described herein comprises CD8 and CD28 co-stimulatory domains or their respective functional fragments and variants. In some instances, a CAR described herein comprises a CD28 co-stimulatory domains or a functional fragment or variant thereof. In some instances, a CAR described herein comprises a 4-1BB (CD137) co-stimulatory domain or a functional fragment or variant thereof. In some instances, a CAR described herein comprises an OX40 (CD134) co-stimulatory domain or a functional fragment or variant thereof. In some instances, a CAR described herein comprises a CD8 co-stimulatory domain or a functional fragment or variant thereof. In some instances, the CAR described herein comprises a DAP10 co-stimulatory domain or a functional fragment or variant thereof. In some instances, the CAR described herein comprises a DAP12 co-stimulatory domain or a functional fragment or variant thereof. 
     In certain embodiments, the intracellular signaling domain comprises a CD28 co-stimulatory domain, or a functional fragment or variant thereof. In certain such embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 481 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 481 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 481, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 481. 
     In certain embodiments, the CD28 co-stimulatory domain, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 482 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 482, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 482, or is a codon degenerate variant of SEQ ID NO: 442. 
     In certain embodiments, the intracellular signaling domain comprises a 4-1BB co-stimulatory domain, or a functional fragment or variant thereof. In certain such embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 483 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 483 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 483, and/or is a conservatively-substituted variant of SEQ ID NO: 483. 
     In certain embodiments, the 4-1BB co-stimulatory domain, or functional fragment or variant thereof, is encoded by SEQ ID NO: 484 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 484, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 484, or is a codon degenerate variant of SEQ ID NO: 484. 
     In certain embodiments, the intracellular signaling domain comprises a DAP10 co-stimulatory domain, or a functional fragment or variant thereof. In certain embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 485 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 485 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 485, and/or is a conservatively-substituted variant of SEQ ID NO: 485. 
     In certain embodiments, the DAP10 co-stimulatory domain, or functional fragment or variant thereof, is encoded by the sequence of SEQ ID NO: 486, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 486, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 486, or is a codon degenerate variant of SEQ ID NO: 486. 
     In certain embodiments, the intracellular signaling domain comprises a DAP12 co-stimulatory domain, or a functional fragment or variant thereof. In certain embodiments, the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 487 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 487 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 487, and/or is a conservatively-substituted variant of SEQ ID NO: 487. 
     In certain embodiments, the DAP12 co-stimulatory domain, or functional fragment or variant thereof, is encoded by the sequence of SEQ ID NO: 488, or functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 488, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 488, or is a codon degenerate variant of SEQ ID NO: 488. 
     In certain embodiments, the intracellular signaling domain comprises both a CD28 co-signaling domain and a 4-1BB co-signaling domain, or respective functional fragments or variants thereof, as described above. 
     E. Signal Peptide 
     In an embodiment, a signal peptide directs the nascent CAR protein into the endoplasmic reticulum. This is, for example, if the receptor is to be glycosylated and anchored in the cell membrane. Any eukaryotic signal peptide sequence is envisaged to be functional. Generally, the signal peptide natively attached to the protein or, in the case of a fusion protein, the component closest to the N-terminus is used (e.g., in a scFv with the V L  component at closest to the N-terminus, the native signal of the light chain is used). In some embodiments, the signal peptide is native for GM-CSFRa (SEQ ID NO: 489) or IgK (SEQ ID NO: 491), IgE (SEQ ID NO: 493) or a functional fragment or variant thereof. Other signal peptides that can be used include those native to CD8α (SEQ ID NO: 495) and CD28. In some embodiments, the signal peptide is that native to Mouse Ig V H  region 3 (SEQ ID NO: 497), β2M signal peptide (SEQ ID NO: 499), Azurocidin (SEQ ID NO: 501), Human Serum Albumin signal peptide (SEQ ID NO: 503), A2M receptor associated protein signal peptide (SEQ ID NO: 505), IGHV3-23 (SEQ ID NO: 507), IGKV1-D33 (HuL1) (SEQ ID NO: 509), IGKV1-D33 (L14F) (HuH7) (SEQ ID NO: 511), or a functional fragment or variant thereof. 
     In certain embodiments, the CAR is linked to a GM-CSFRa signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the GM-CSFRa signal peptide has the amino acid sequence of SEQ ID NO: 489 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 489 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 489, and/or is a conservatively-substituted variant of SEQ ID NO: 489. 
     In certain embodiments, the GM-CSFRa signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 490 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 490, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 490, or is a codon degenerate variant of SEQ ID NO: 490. 
     In certain embodiments, the CAR is linked to an IgK signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the IgK signal peptide has the amino acid sequence of SEQ ID NO: 491 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 491 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 491, and/or is a conservatively-substituted variant of SEQ ID NO: 491. 
     In certain embodiments, the Igκ signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 492 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 492, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 492, or is a codon degenerate variant of SEQ ID NO: 492. 
     In certain embodiments, the CAR is linked to an IgE signal peptide native to IgE (“IgE signal peptide”), or a functional fragment or variant thereof. In certain such embodiments, the IgE signal peptide the amino acid sequence of SEQ ID NO: 493 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 493 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 493, and/or is a conservatively-substituted variant of SEQ ID NO: 493. 
     In certain embodiments, the IgE signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 494 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 494, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 494, or is a codon degenerate variant of SEQ ID NO: 494. 
     In certain embodiments, the CAR is linked to an CD8α signal peptide native to CD8α, or a functional fragment or variant thereof. In certain such embodiments, the CD8α signal peptide comprises the amino acid sequence of SEQ ID NO: 495 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 495 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 495, and/or is a conservatively-substituted variant of SEQ ID NO: 495. 
     In certain embodiments, the CD8α signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 496 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 496, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 496 or is a codon degenerate variant of SEQ ID NO: 496. 
     In certain embodiments, the CAR is linked to a Mouse Ig VH region 3 signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the Mouse Ig VH region 3 signal peptide has the amino acid sequence of SEQ ID NO: 497 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 497 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 497, and/or is a conservatively-substituted variant of SEQ ID NO: 497. 
     In certain embodiments, the Mouse Ig VH region 3 signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 498 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 498, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 498, or is a codon degenerate variant of SEQ ID NO: 498. 
     In certain embodiments, the CAR is linked to a β2M signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the β2M signal peptide has the amino acid sequence of SEQ ID NO: 499 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 499 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 499, and/or is a conservatively-substituted variant of SEQ ID NO: 499. 
     In certain embodiments, the β2M signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 500 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 500, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 500, or is a codon degenerate variant of SEQ ID NO: 500. 
     In certain embodiments, the CAR is linked to an Azurocidin signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the Azurocidin signal peptide has the amino acid sequence of SEQ ID NO: 501 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 501 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 501, and/or is a conservatively-substituted variant of SEQ ID NO: 501. 
     In certain embodiments, the Azurocidin signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 502 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 502, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 502, or is a codon degenerate variant of SEQ ID NO: 502. 
     In certain embodiments, the CAR is linked to a human serum albumin signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the human serum albumin signal peptide has the amino acid sequence of SEQ ID NO: 503 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 503 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 503, and/or is a conservatively-substituted variant of SEQ ID NO: 503. 
     In certain embodiments, the human serum albumin signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 504 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 504, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 504, or is a codon degenerate variant of SEQ ID NO: 504. 
     In certain embodiments, the CAR is linked to an A2M receptor associated protein signal peptide, or a functional fragment or variant thereof. In certain such embodiments, A2M receptor associated protein signal peptide has the amino acid sequence of SEQ ID NO: 505 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 505 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 505, and/or is a conservatively-substituted variant of SEQ ID NO: 505. 
     In certain embodiments, the A2M receptor associated protein signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 506 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 506, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 506, or is a codon degenerate variant of SEQ ID NO: 506. 
     In certain embodiments, the CAR is linked to an IGHV3-23 signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the IGHV3-23 signal peptide has the amino acid sequence of SEQ ID NO: 507 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 507 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 507, and/or is a conservatively-substituted variant of SEQ ID NO: 507. 
     In certain embodiments, the IGHV3-23 signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 508 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 508, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 508, or is a codon degenerate variant of SEQ ID NO: 508. 
     In certain embodiments, the CAR is linked to an IGKV1-D33 signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the IGKV1-D33 signal peptide has the amino acid sequence of SEQ ID NO: 509 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 509 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 509, and/or is a conservatively-substituted variant of SEQ ID NO: 509. 
     In certain embodiments, the IGKV1-D33 signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 510 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 510, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 510, or is a codon degenerate variant of SEQ ID NO: 510. 
     In certain embodiments, the CAR is linked to an IGHV3-33 (L14F) signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the IGHV3-33 (L14F) signal peptide has the amino acid sequence of SEQ ID NO: 511 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 511 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 511, and/or is a conservatively-substituted variant of SEQ ID NO: 511. 
     In certain embodiments, the IGHV3-33 (L14F) signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 512 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 512, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 512, or is a codon degenerate variant of SEQ ID NO: 512. 
     In certain embodiments, the CAR is linked to an TVB2 (T21A) signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the TVB2 (T21A) signal peptide has the amino acid sequence of SEQ ID NO: 513 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 513 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 513, and/or is a conservatively-substituted variant of SEQ ID NO: 513. 
     In certain embodiments, the TVB2 (T21A) signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 514 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 514, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 514, or is a codon degenerate variant of SEQ ID NO: 514. 
     In certain embodiments, the CAR is linked to an CD52 signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the CD52 signal peptide has the amino acid sequence of SEQ ID NO: 515 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 515 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 515, and/or is a conservatively-substituted variant of SEQ ID NO: 515. 
     In certain embodiments, the CD52 signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 516 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 516, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 516, or is a codon degenerate variant of SEQ ID NO: 516. 
     In certain embodiments, the CAR is linked to an LNGFR signal peptide, or a functional fragment or variant thereof. In certain such embodiments, the LNGFR signal peptide has the amino acid sequence of SEQ ID NO: 517 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 517 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 517, and/or is a conservatively-substituted variant of SEQ ID NO: 517. 
     In certain embodiments, the LNGFR signal peptide, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 518 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 518, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 518, or is a codon degenerate variant of SEQ ID NO: 518. 
     F. Exemplary CAR Constructs 
     By way of example, but not limitation, the CAR can comprise an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with any one of SEQ ID NOs: 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, and 629 or a conservatively-substituted variant thereof. By way of further example, but not limitation, a polynucleotide encoding the CAR can comprise a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence of any one of SEQ ID NOs: 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628, and 630; a sequence that hybridizes under stringent hybridization conditions with the complement of any one of such sequences; or a codon degenerate variant of any one of such sequences. 
     In certain embodiments, the CAR can comprise an amino acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 623 or a conservatively-substituted variant thereof. In certain such embodiments, the polynucleotide encoding the CAR can comprise a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the sequence of SEQ ID NO: 624; a sequence that hybridizes under stringent hybridization conditions with the complement of any one of such sequences; or a codon degenerate variant of any one of such sequences. 
     CARs and CAR construction as well as compositions are also described, for example, in:
     Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide, Edited by: Daniel W. Lee and Nirali N. Shah, 2020 (ISBN 978-0-323-66181-2; DOI https://doi.org/10.1016/C2017-0-04066-1);   Second Generation Cell and Gene-based Therapies, Biological Advances, Clinical Outcomes and Strategies for Capitalisation, Editors-in-Chief: Alain A. Vertés, Devyn M. Smith, Nathan J. Dowden, 2020 (ISBN 978-0-12-812034-7; DOI https://doi.org/10.1016/C2016-0-02070-3);   Basics of Chimeric Antigen Receptor (CAR) Immunotherapy, Author: Mumtaz Yaseen Balkhi, 2020 (ISBN 978-0-12-819573-4, DOI https://doi.org/10.1016/C2018-0-05356-6);   Engineering and Design of Chimeric Antigen Receptors, Authors: Sonia Guedan, Hugo Calderon, Avery D. Posey, Jr., and Marcela V. Maus,  Molecular Therapy: Methods  &amp;  Clinical Development , Vol. 12, March (2019) (https://www.cell.com/molecular-therapy-family/methods/pdf/S2329-0501(18)30133-5.pdf);   Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov, Authors: Eider F Moreno Cortes, Caleb K Stein, Paula A Lengerke Diaz, Cesar A Ramirez-Segura, Januario E. Castro, MD,  Blood  (2019) 134 (Supplement_1): 5629 (https://doi.org/10.1182/blood-2019-132273);   WO2020209934 (PCT/US2020/017794)—Novel chimeric antigen receptors and libraries (MIT);   WO2020037142 (PCT/US2019/046691)—Compositions and methods for high-throughput activation screening to boost t cell effector function (Yale);   WO2015123642 (PCT/US2015/016057)—Chimeric antigen receptors and methods of making (Univ. TX);   WO2020014366 (PCT/US2019/041213)—Ror-1 specific chimeric antigen receptors and uses thereof (Precigen);   WO2019236577 (PCT/US2019/035384)—Muc16 specific chimeric antigen receptors and uses thereof (Precigen)   WO2019079486 (PCT/US2018/056334)—Polypeptide compositions comprising spacers (Precigen)   WO2017214333 (PCT/US2017/036440)—Cd33 specific chimeric antigen receptors (Precigen)   

     V. Cytokine 
     In some embodiments, the modified immune effector cell of the present invention can comprise a cytokine. The cytokine may, for example, be encoded by the polynucleotide of the present disclosure. For example, the polynucleotide may encode the miRNA(s), CAR and cytokine, or the miRNA(s) and cytokine. 
     In some cases, the cytokine comprises at least one chemokine, interferon, interleukin, lymphokine, tumor necrosis factor, or variant or combination thereof. In certain embodiments, the cytokine is an interferon, GM-CSF, G-CSF, M-CSF, LT-beta, TNF-alpha, growth factors, hGH, and/or a ligand of human Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, IFN-alpha, IFN-beta, or IFN-gamma. 
     In certain embodiments, the cytokine is an interleukin. In some cases the interleukin is IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-35, or a functional variant or fragment thereof. 
     In certain embodiments, the cytokine may be IL-12, or a functional fragment or variant thereof. In some embodiments, the IL-12 is a single chain IL-12 (sclL-12), protease sensitive IL-12, destabilized IL-12, membrane bound IL-12, intercalated IL-12. In some instances, the IL-12 variants are as described in WO2015/095249, WO2016/048903, WO2017/062953. 
     In certain embodiments, the cytokine may be IL-15, or a functional fragment or variant thereof. In certain embodiments, the IL-15, or functional fragment or variant thereof, is membrane-bound. Such may occur when IL-15, or a functional fragment or variant thereof, is bound to membrane-bound IL-15Rα, or a functional fragment or variant thereof. Thus, certain embodiments of the present invention may involve a fusion protein comprising IL-15 and IL-15Rα, or their respective functional fragments or variants. 
     In certain embodiments, the IL-15, or functional fragment or variant thereof, comprises the amino acid sequence of SEQ ID NO: 519, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 519 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 519, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 519. 
     In certain embodiments, the IL-15, or functional fragment or variant thereof, is encoded by a nucleic acid comprising the sequence of SEQ ID NO: 520, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 520, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 520, or is a codon degenerate variant of SEQ ID NO: 520. 
     In certain embodiments, the IL-15Rα, or functional fragment or variant thereof, comprises the amino acid sequence of SEQ ID NO: 521 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 521 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 521, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 521. 
     In certain embodiments, the IL-15Rα, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 522, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 522, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 522, or is a codon degenerate variant of SEQ ID NO: 522. 
     In certain embodiments, the IL-15, or functional fragment or variant thereof, is linked to the IL-15Rα, or functional fragment thereof by way of a linker. 
     In certain embodiments, the linker comprises the amino acid sequence of SEQ ID NO: 529 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than SEQ ID NO: 529 by at most 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 529, and/or is a conservatively-substituted variant of SEQ ID NO: 529. 
     In certain embodiments, the linker is encoded by a nucleic acid comprising SEQ ID NO: 530 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 530, hybridizes under stringent hybridization conditions with SEQ ID NO: 530, or is a codon degenerate variant of SEQ ID NO: 530. 
     In certain embodiments, the fusion protein comprising IL-15 and IL-15Rα comprises the amino acid sequence of SEQ ID NO: 523 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 523 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 523, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 523. 
     In certain embodiments, the fusion protein comprising IL-15 and IL-15Rα is encoded by a nucleic acid comprising SEQ ID NO: 524 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 524, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 524, or is a codon degenerate variant of SEQ ID NO: 603. 
     In certain embodiments, the cytokine is linked to a signal peptide. Any signal for use in eukaryotic cells, including those described above for use with the CARs may be linked to the cytokine. In certain embodiments, the cytokine is linked to an IgE signal peptide. 
     In certain embodiments, the fusion protein comprising IL-15 and IL-15Rα comprises the amino acid sequence of SEQ ID NO: 525 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 525 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 525, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 525. 
     In certain embodiments, the fusion protein comprising IL-15 and IL-15Rα is encoded by a nucleic acid comprising SEQ ID NO: 526 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 526, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 526, or is a codon degenerate variant of SEQ ID NO: 526. 
     VI. Cell Tag 
     In some embodiments, the modified immune effector cell of the present invention can comprise a cell tag. The cell tag may, for example, be encoded by the polynucleotide of the present disclosure. For example, the polynucleotide may encode the miRNA(s), CAR and/or cytokine described herein as well as a cell tag. In some aspects, the cell tag is used as a kill switch, selection marker, a biomarker, or a combination thereof. 
     In certain embodiments, the cell tag is capable of being bound by a predetermined binding partner. In certain such embodiments, the cell tag is non-immunogenic. In certain such embodiments, the cell tag comprises a polypeptide that is truncated so that it is non-immunogenic. 
     In certain embodiments, the administration of the predetermined binding partner allows for depletion of infused CAR-T cells. For example, the administration of cetuximab or any antibody that recognizes HER1 allows for the elimination of cells expressing a cell tag comprising truncated non-immunogenic HER1. The truncation of the HER1 sequence eliminates the potential for EGF ligand binding, homo- and hetero-dimerization of EGFR, and/or EGFR-mediated signaling while keeping cetuximab-binding ability intact (Ferguson, K., 2008. A structure-based view of Epidermal Growth Factor Receptor regulation.  Annu Rev Biophys , Volume 37, pp. 353-373). 
     In certain embodiments, the cell tag comprises at least one of a truncated non-immunogenic HER1 polypeptide, a truncated non-immunogenic LNGFR polypeptide, a truncated non-immunogenic CD20 polypeptide, or a truncated non-immunogenic CD52 polypeptide, or a functional fragment or variant thereof. 
     In certain embodiments, the cell tag comprises a truncated non-immunogenic HER1 polypeptide comprising a HER1 Domain III and a truncated HER1 Domain IV. Such domains and the nucleic acid sequences encoding the same include those described in WO 2018/226897. 
     In certain embodiments, the HER1 Domain III comprises the amino acid sequence of SEQ ID NO: 604 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 565 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 565, and/or is a conservatively-substituted variant the amino acid sequence of sequence of SEQ ID NO: 565. 
     In certain embodiments, the HER1 Domain III, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 566 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 566, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 566, or is a codon degenerate variant of SEQ ID NO: 566. 
     In certain embodiments, the truncated HER1 Domain IV comprises the amino acid sequence of SEQ ID NO: 567 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 567 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 567, and/or is a conservatively-substituted variant the amino acid sequence of sequence of SEQ ID NO: 567. 
     In certain embodiments, the truncated HER1 Domain IV, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 568 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 568, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 568, or is a codon degenerate variant of SEQ ID NO: 568. 
     In certain such embodiments, the truncated non-immunogenic HER1 comprises the amino acid sequence of SEQ ID NO: 569 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 569 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 569, and/or is a conservatively-substituted variant the amino acid sequence of sequence of SEQ ID NO: 569. 
     In certain embodiments, the truncated non-immunogenic HER1, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 570 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 570, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 570, or is a codon degenerate variant of SEQ ID NO: 570. 
     In certain embodiments, the cell tag comprises a truncated non-immunogenic CD20, or CD20t-1, or a functional fragment or variant thereof. In certain such embodiments, the cell tag comprises the amino acid sequence of SEQ ID NO: 573, SEQ ID NO: 575, or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequences of SEQ ID NO: 573 or SEQ ID NO: 575 by at most 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 573 or SEQ ID NO: 575, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 573 or SEQ ID NO: 575. 
     In certain embodiments, the truncated non-immunogenic CD20, or CD20t-1, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 574 or SEQ ID NO: 576 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 574 or SEQ ID NO: 576, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 574 or SEQ ID NO: 576, or is a codon degenerate variant of SEQ ID NO: 574 or SEQ ID NO: 576. 
     In certain embodiments, the cell tag further comprises a transmembrane domain. The transmembrane domain can be derived from either a natural or a synthetic source. Where the source is natural, the domain can, for example, be derived from any membrane-bound or transmembrane protein. Suitable transmembrane domains can include the transmembrane domain(s) of alpha, beta or zeta chain of the T-cell receptor; or a transmembrane domain from CD28, CD3 epsilon, CD3, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 or CD154, or a functional fragment or variant thereof. Alternatively, the transmembrane domain can be synthetic, and can comprise hydrophobic residues such as leucine and valine. In some embodiments, a triplet of phenylalanine, tryptophan and valine is found at one or both termini of a synthetic transmembrane domain. 
     In some embodiments, the transmembrane domain comprises a CD28 transmembrane domain, or a functional fragment or variant thereof. In certain such embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 477 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 477 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 477, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 477. 
     In certain embodiments, the CD28 transmembrane domain, or functional fragment or variant thereof, is encoded by a nucleic acid comprising SEQ ID NO: 478, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 478, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 478, or is a codon degenerate variant of SEQ ID NO: 478. 
     In certain embodiments, the cell tag comprises a truncated HER1, or functional fragment or variant thereof, and a transmembrane domain, or a functional fragment or variant thereof. In some embodiments, the cell comprises the amino acid sequence of SEQ ID NO: 571 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 571 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 571, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 571. 
     In certain embodiments, the cell tag is encoded by a nucleic acid comprising SEQ ID NO: 572, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 572, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 572, or is a codon degenerate variant of SEQ ID NO: 572. 
     In certain embodiments, the cell tag is linked with a signal peptide. The signal peptide can be any signal peptide suitable for use in a eukaryotic cell including those described with respect to CARs herein. In certain embodiments, the signal peptide is a Igic signal peptide comprising the amino acid sequence of SEQ ID NO: 491, or a functional fragment or variant thereof 
     VII. Genetic Construct 
     As shown in  FIG. 16 , an exemplary polynucleotide is provided which can be used as template for the expression of various genes and other regulatory elements in cells. It should be understood that various elements can be included or omitted in the polynucleotide and that different options are shown for various exemplary sites in the polynucleotide. 
     As shown, the polynucleotide can include an integration signal for attP/attB phage integration of the polynucleotide into a bacterial genome. The polynucleotide can further include a 5′ homology arm or 5′ terminal repeat and a 3′ homology arm or 3′ terminal repeat. The polynucleotide can further include insulators, boundary elements and S/MAR positioned 3′ adjacent to the 5′ homology arm or 5′ terminal repeat and 5′ adjacent to the 3′ homology arm or 3′ terminal repeat. Between the insulators, boundary elements, or S/MAR, the polynucleotide can include, from 5′ to 3′, a promoter which can include a silencer, enhancer, TF binding modules and a core promoter; a 5′ untranslated region which can include stability modules, translation control elements, and intron-embedded elements such as miRNA encoding sequences; one or more genes which can include signal peptides, extracellular domains, transmembrane domains, signaling domains, antibody domains, peptide linkers, inteins and epitope tags; and a 3′ untranslated region that can include stability modules, translation control, 3′ end processing signals and a transcription terminator. It should be understood that the genes to be expressed can be separated by IRES, cleavage peptides, or ribosomal skipping peptides. 
     The CAR may be encoded in the same genetic construct with the miRNA, the cytokine, and/or the cell tag. An advantage of having two or more of such components expressed using one genetic construct is stoichiometric expression of such components. 
     A. Linkers 
     In certain embodiments, the polypeptides of the present invention (e.g., the CAR, the cytokine, and the cell tag) are linked by linker polypeptide(s). The linkers may also be used to link domains of a polypeptide (e.g., the VH and VL domains of a CAR, the truncated HER1 and transmembrane domains of the cell tag, and the IL-15 and IL-15Rα domains). 
     Linkers suitable in the present invention include flexible linkers, rigid linkers, and in vivo cleavable linkers. In some cases, the linker acts to link functional domains together (as in flexible and rigid linkers) or to release a free functional domain in vivo as in in vivo cleavable linkers. 
     As noted, in some cases, the linker sequence may include a flexible linker. Flexible linkers can be applied when a joined domain requires a certain degree of movement or interaction. Flexible linkers can be composed of small, non-polar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids. A flexible linker can have sequences consisting primarily of stretches of Gly and Ser residues (“GS” linker). An example of a flexible linker can have the sequence of (Gly-Gly-Gly-Gly-Ser)n. By adjusting the copy number “n”, the length of this exemplary GS linker can be optimized to achieve appropriate separation of functional domains, or to maintain necessary inter-domain interactions. For example, (Gly-Gly-Gly-Gly-Ser)n, wherein n is 4 is a (G4S)4 linker as shown in SEQ ID NO: 608 or a conservatively substituted amino acid sequence thereof. Besides GS linkers, other flexible linkers can be utilized for recombinant fusion proteins. In some cases, flexible linkers can contain additional amino acids such as Thr and Ala to maintain flexibility. In other cases, polar amino acids such as Lys and Glu can be used to improve solubility. 
     Flexible linkers can be suitable choices when certain movements or interactions are desired for fusion protein domains. In addition, although flexible linkers do not have rigid structures, in some cases they can serve as a passive linker to keep a distance between functional domains. The length of a flexible linker may be adjusted to allow for proper folding or to achieve optimal biological activity of the fusion proteins. 
     A rigid linker can be utilized to maintain a fixed distance between domains of a polypeptide. Examples of rigid linkers include Alpha helix-forming linkers, Pro-rich sequence, (XP)n, X-Pro backbone, A(EAAAK)nA (n=2−5) (SEQ ID NO: 563) and functional fragments and variants thereof, to name a few. Rigid linkers can exhibit relatively stiff structures by adopting α-helical structures or by containing multiple Pro residues in some cases. 
     A linker useful in the present invention can be cleavable in some cases. In other cases, the linker is not cleavable. Linkers that are not cleavable can covalently join functional domains together to act as one molecule throughout an in vivo processes or an ex vivo process. A linker can also be cleavable in vivo. A cleavable linker can be introduced to release free functional domains in vivo. 
     A cleavable linker can be cleaved by the presence of reducing reagents, proteases, to name a few. For example, a reduction of a disulfide bond can be utilized to produce a cleavable linker. In the case of a disulfide linker, a cleavage event through disulfide exchange with a thiol, such as glutathione, could produce a cleavage. In some cases, a cleavable linker can allow for targeted cleavage. For example, an in vivo cleavage of a linker in a recombinant fusion protein can also be carried out by proteases that can be expressed in vivo under pathological conditions (e.g., cancer or inflammation), in specific cells or tissues, or constrained within certain cellular compartments. A cleavable linker can comprise a hydrazone, peptides, a disulfide, or a thioesther. For example, a hydrazone can confer serum stability. In other cases, a hydrazone can allow for cleavage in an acidic compartment. An acidic compartment can have a pH up to 7. A linker can also include a thioether. A thioether can be nonreducible A thioether can be designed for intracellular proteolytic degradation. Examples of cleavable linkers include Furinlink, fmdv, and 2A linkers (e.g., P2A, GSG-P2A, FP2A, T2A, and Furin-T2A), or functional fragments or variants thereof. 
     A fmdv linker may comprise the amino acid sequence of SEQ ID NO: 539 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 539 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 539, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 539. 
     In certain embodiments, the fmdv linker is encoded by a nucleic acid comprising SEQ ID NO: 540, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 540, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 540, or is a codon degenerate variant of SEQ ID NO: 540. 
     A P2A linker may comprise the amino acid sequence of SEQ ID NO: 547 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 547 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 547, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 547. 
     In certain embodiments, the P2A linker is encoded by a nucleic acid comprising SEQ ID NO: 548, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 548, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 548, or is a codon degenerate variant of SEQ ID NO: 548. 
     A GSG-P2A linker may comprise the amino acid sequence of SEQ ID NO: 549 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 549 by at most 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 549, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 549. 
     In certain embodiments, the GSG-P2A linker is encoded by a nucleic acid comprising SEQ ID NO: 550, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 550, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 550, or is a codon degenerate variant of SEQ ID NO: 550. 
     A FP2A linker may comprise the amino acid sequence of SEQ ID NO: 555 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 555 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 555, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 555. 
     In certain embodiments, the FP2A linker is encoded by a nucleic acid comprising SEQ ID NO: 556, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 556, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 556, or is a codon degenerate variant of SEQ ID NO: 556. 
     A T2A linker may comprise the amino acid sequence of SEQ ID NO: 541 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 541 by at most 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 541, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 541. 
     In certain embodiments, the T2A linker is encoded by a nucleic acid comprising SEQ ID NO: 475428, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 542, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 54, or is a codon degenerate variant of SEQ ID NO: 542. 
     In some embodiments, the linker comprises a furin polypeptide and a 2A polypeptide, wherein the furin polypeptide and the 2A polypeptide are connected by a polypeptide linker comprising at least three hydrophobic amino acids. Such linkers are called “Furin-T2A” linkers. In some cases, the at least three hydrophobic amino acids are selected from the list consisting of glycine (Gly)(G), alanine (Ala)(A), valine (Val)(V), leucine (Leu)(L), isoleucine (Ile)(I), proline (Pro)(P), phenylalanine (Phe)(F), methionine (Met)(M), tryptophan (Trp)(W). In some cases, the polypeptide linker can include one or more GS linker sequences, for instance (GS)n, (SG)n, and (GSG)n, wherein n can be any number from zero to thirty. 
     A Furin-T2A linker may comprise the amino acid sequence of SEQ ID NO: 543 or 545 or a functional fragment or variant thereof. In certain embodiments, the functional fragment is shorter than the amino acid sequence of SEQ ID NO: 543 or 545 by at most 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues at the N- and/or C-terminus. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with the amino acid sequence of SEQ ID NO: 543 or 545, and/or is a conservatively-substituted variant of the amino acid sequence of SEQ ID NO: 543 or 545. 
     In certain embodiments, the Furin-T2A linker is encoded by a nucleic acid comprising SEQ ID NO: 544 or 546, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 544 or 546, hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 544 or 546, or is a codon degenerate variant of SEQ ID NO: 544 or 546. 
     A linker can be an engineered linker. For example, a linker can be designed to comprise chemical characteristics such as hydrophobicity. Methods of designing linkers can be computational. In some cases, computational methods can include graphic techniques. Computation methods can be used to search for suitable peptides from libraries of three-dimensional peptide structures derived from databases. For example, a Brookhaven Protein Data Bank (PDB) can be used to span the distance in space between selected amino acids of a linker. 
     Further exemplary linkers are provided in the Sequence Listing. 
     In some cases, at least two linker sequences can be included in the same protein. For example, polypeptides of interest within a fusion protein can be separated by at least two linkers. In some cases, polypeptides can be separated by 2, 3, 4, 5, 6, 7, 8, 9, or up to 10 linkers. 
     The CAR, cell tag, and/or cytokine of the present invention may be expressed as a fusion protein. In such embodiments, such components may be linked together using a self-cleaving peptide, for example a 2A peptide. 
     In certain embodiments, the self-cleaving peptide is a T2A peptide, or a functional fragment or variant thereof. 
     In certain embodiments, the self-cleaving peptide is a Furin-T2A peptide, or a functional fragment or variant thereof. 
     In certain such embodiments, the CAR, the cytokine, and the cell tag are expressed as a fusion protein with the CAR and the cytokine linked by a self-cleaving linker, for example one comprising Furin-T2A, and the cytokine and cell tag linked by a self-cleaving linker, for example one comprising T2A. 
     B. Promoters 
     The polynucleotide of the invention can be present in the construct in operable linkage with a promoter. Appropriate promoters can be selected based on the host cell and effect sought. Suitable promoters include constitutive and inducible promoters. The promoters can be tissue specific, such promoters being well known in the art. 
     Examples of constitutive promoters for use in the present invention include immediate early cytomegalovirus (CMV) promoter; human elongation growth factor 1 alpha 1 (hEF1A1); simian virus 40 (SV40) early promoter; mouse mammary tumor virus (MMTV); human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter; MoMuLV promoter; avian leukemia virus promoter; Epstein-Barr virus immediate early promoter; Rous sarcoma virus promoter; and human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the creatine kinase promoter; and functional fragments and variants thereof. 
     In certain embodiments, the promoter is a hEF1A1 promoter. A hEF1A1 promoter may comprise the sequence of SEQ ID NO: 577, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 577, or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 577. In certain embodiments, the promoter is a CMV promoter. A CMV promoter may comprise the sequence of SEQ ID NO: 578, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 578, or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 578. 
     In contrast to constitutive promoters, the use of an inducible promoter provides a molecular switch capable of turning on the expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as a RHEOSWITCH® gene switch. 
     VIII. Vectors and Delivery Systems 
     In certain embodiments, the polynucleotide of the present invention can be delivered to a target cell by any suitable delivery system, including non-viral and viral delivery systems. In some embodiments, a vector can include a polynucleotide of the present disclosure encoding the miRNA, CAR, cytokine, cell tag, or any combination thereof. 
     In certain cases, the miRNA(s), CAR, cytokine, and/or cell tag are expressed in separate vectors. In other aspects, the miRNA(s), CAR, cytokine, and/or cell tag are expressed from one single vector. In certain cases, the CAR and the miRNA(s) are expressed in separate vectors. In other aspects, the miRNA(s), CAR and cytokine are expressed from one single vector. In specific cases, the vectors can be lentiviral vectors, retroviral vectors, Sleeping Beauty transposons or vectors containing sequences for serine recombinase mediated integration. In some aspects, the vector is a plasmid, a mini-circle DNA or a nanoplasmid. 
     In certain embodiments, where the vector is a plasmid, mini-circle DNA or a nanoplasmid, the plasmid, mini-circle DNA or nanoplasmid can further include a bacterial origin of replication. In certain embodiments, the bacterial origin of replication can be from a ColE1 plasmid. In certain embodiments, the bacterial origin of replication comprises the sequence of SEQ ID NO: 579, or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 579, or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 579. 
     In order to assess the expression of one or more miRNA(s) and a CAR described herein or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors or non-viral vectors. In other aspects, the selectable marker can be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes can be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neomycin resistance gene (neo) and ampicillin resistance gene and the like. In some embodiments, a truncated epidermal growth factor receptor (HER1t or HER1t-1) tag can be used as a selectable marker gene. 
     Reporter genes can be used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells. Suitable reporter genes include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tei et al., FEBS Letters 479: 79-82 (2000)). Suitable expression systems are well known and can be prepared using known techniques or obtained commercially. In general, the construct with the minimal 5′ flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions can be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription. 
     In some embodiments, a viral vector described herein can comprise a hEF1A1 promoter to drive expression of transgenes, a bovine growth hormone polyA sequence to enhance transcription, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), as well as LTR sequences derived from the pFUGW plasmid. 
     A. Methods for Introducing Nucleic Acids into Cells 
     Methods of introducing and expressing genes into a cell are well known. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means. 
     1. Physical Methods 
     Physical methods for introducing a polynucleotide into a host cell, for instance an immune effector cell, include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (2001)). In some embodiments, a method for the introduction of a polynucleotide into a host cell is calcium phosphate transfection or polyethylenimine (PEI) Transfection. In some embodiments, a method for introduction of a polynucleotide into a host cell is electroporation. 
     a. Electroporation (EP) Buffers 
     Various buffers can be used for electroporation. The buffers disclosed herein were found to have improved properties, including enhanced transfection capabilities, notwithstanding that these buffers comprise fewer components as compared to other known electroporation buffers. 
     Table 4 provides differing amounts of monobasic and dibasic phosphate used as buffering agents. Table 5 provides buffers 1-20 which contain buffering agents and glucose. Table Z provides buffers 21-37 which contain buffering agents and mannitol. Table 7 provides pH, conductivity, and osmolality for Buffers 1, 2 and 3 compared to a control buffer (Mirus Bio™ Ingenio™ electroporation solution, Catalog No. MIR-50117; Mirus Bio LLC, Madison, Wis., USA) (“Control 1”). 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Differing Amounts of Monobasic and Dibasic 
               
               
                 Phosphate Used as a Buffering Agent 
               
            
           
           
               
               
               
            
               
                 0.2M NaH 2 PO 4   
                 0.2M Na 2 HPO 4   
                   
               
               
                 (mL) 
                 (mL) 
                 pH 
               
               
                   
               
            
           
           
               
               
               
            
               
                 92.0 
                 8.0 
                 5.8 
               
               
                 90.0 
                 10.0 
                 5.9 
               
               
                 87.7 
                 12.3 
                 6.0 
               
               
                 85.5 
                 15.0 
                 6.1 
               
               
                 81.5 
                 19.5 
                 6.2 
               
               
                 77.5 
                 22.5 
                 6.3 
               
               
                 73.5 
                 26.5 
                 6.4 
               
               
                 68.5 
                 31.5 
                 6.5 
               
               
                 62.5 
                 37.5 
                 6.6 
               
               
                 56.5 
                 43.5 
                 6.7 
               
               
                 51.0 
                 49.0 
                 6.8 
               
               
                 45.0 
                 55.0 
                 6.9 
               
               
                 39.0 
                 61.0 
                 7.0 
               
               
                 33.0 
                 67.0 
                 7.1 
               
               
                 28.0 
                 72.0 
                 7.2 
               
               
                 23.0 
                 77.0 
                 7.3 
               
               
                 19.0 
                 81.0 
                 7.4 
               
               
                 16.0 
                 84.0 
                 7.5 
               
               
                 13.0 
                 87.0 
                 7.6 
               
               
                 10.5 
                 89.5 
                 7.7 
               
               
                 8.5 
                 91.5 
                 7.8 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 Buffers 1 through 20 - Buffering Agents and Glucose 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 Na 2 HPO 4 / 
                   
                   
                   
               
               
                 Sample 
                 Glucose 
                 HEPES 
                 NaH 2 PO 4   
                 KCl 
                 MgCl 2   
                 DMSO 
               
               
                 No. 
                 (mM) 
                 (mM) 
                 (mM) 
                 (mM) 
                 (mM) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 1 
                 30 
                 5 
                 105 
                 10 
                 20 
                 0 
               
               
                 2 
                 31 
                 0 
                 90 
                 5 
                 15 
                 0 
               
               
                 3 
                 30 
                 10 
                 90 
                 5 
                 15 
                 0 
               
               
                 4 
                 25 
                 10 
                 120 
                 15 
                 25 
                 0 
               
               
                 5 
                 30 
                 25 
                 50 
                 2 
                 10.5 
                 5 
               
               
                 6 
                 0 
                 5 
                 160 
                 10 
                 10.5 
                 0 
               
               
                 7 
                 0 
                 5 
                 160 
                 2 
                 20 
                 5 
               
               
                 8 
                 15 
                 25 
                 160 
                 10 
                 20 
                 5 
               
               
                 9 
                 30 
                 5 
                 160 
                 2 
                 1 
                 2.5 
               
               
                 10 
                 15 
                 15 
                 105 
                 6 
                 10.5 
                 2.5 
               
               
                 11 
                 30 
                 25 
                 50 
                 10 
                 1 
                 0 
               
               
                 12 
                 30 
                 5 
                 50 
                 6 
                 20 
                 5 
               
               
                 13 
                 30 
                 15 
                 160 
                 10 
                 1 
                 5 
               
               
                 14 
                 15 
                 5 
                 50 
                 2 
                 1 
                 0 
               
               
                 15 
                 0 
                 5 
                 50 
                 10 
                 1 
                 5 
               
               
                 16 
                 0 
                 25 
                 50 
                 10 
                 20 
                 2.5 
               
               
                 17 
                 30 
                 25 
                 160 
                 2 
                 20 
                 0 
               
               
                 18 
                 0 
                 15 
                 50 
                 2 
                 20 
                 0 
               
               
                 19 
                 0 
                 25 
                 160 
                 6 
                 1 
                 0 
               
               
                 20 
                 0 
                 25 
                 105 
                 2 
                 1 
                 5 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Buffers 21 through 37 - Buffering Agents and Mannitol 
               
            
           
           
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 Na 2 HPO 4 / 
                   
                   
                   
               
               
                 Sample 
                 Mannitol 
                 HEPES 
                 NaH 2 PO 4   
                 KCl 
                 MgCl 2   
                 DMSO 
               
               
                 No. 
                 (mM) 
                 (mM) 
                 (mM) 
                 (mM) 
                 (mM) 
                 (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
            
               
                 21 
                 5 
                 25 
                 160 
                 6 
                 1 
                 0 
               
               
                 22 
                 150 
                 25 
                 50 
                 2 
                 10.5 
                 5 
               
               
                 23 
                 5 
                 15 
                 50 
                 2 
                 20 
                 0 
               
               
                 24 
                 150 
                 25 
                 50 
                 10 
                 1 
                 0 
               
               
                 25 
                 5 
                 25 
                 105 
                 2 
                 1 
                 5 
               
               
                 26 
                 77.5 
                 5 
                 50 
                 2 
                 1 
                 0 
               
               
                 27 
                 150 
                 5 
                 160 
                 2 
                 1 
                 2.5 
               
               
                 28 
                 150 
                 15 
                 160 
                 10 
                 1 
                 5 
               
               
                 29 
                 5 
                 5 
                 50 
                 10 
                 1 
                 5 
               
               
                 30 
                 150 
                 25 
                 160 
                 2 
                 20 
                 0 
               
               
                 31 
                 150 
                 5 
                 105 
                 10 
                 20 
                 0 
               
               
                 32 
                 77.5 
                 15 
                 105 
                 6 
                 10.5 
                 2.5 
               
               
                 33 
                 77.5 
                 25 
                 160 
                 10 
                 20 
                 5 
               
               
                 34 
                 150 
                 5 
                 50 
                 6 
                 20 
                 5 
               
               
                 35 
                 5 
                 25 
                 50 
                 10 
                 20 
                 2.5 
               
               
                 36 
                 5 
                 5 
                 160 
                 10 
                 10.5 
                 0 
               
               
                 37 
                 5 
                 5 
                 160 
                 2 
                 20 
                 5 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 7 
               
             
            
               
                   
               
               
                 Composition, pH, Conductivity, and Osmolality 
               
               
                 of Buffers 1, 2, and 3 Compared to Control 1 
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 Na2HPO4/ 
                   
                   
                   
                   
                 osm 
               
               
                 Sample 
                 Glucose 
                 HEPES 
                 NaH2PO4 
                 KCl 
                 MgCl2 
                   
                 Conductivity 
                 (mOsm/ 
               
               
                 No. 
                 (mM) 
                 (mM) 
                 (mM) 
                 (mM) 
                 (mM) 
                 pH 
                 (ms/cm) 
                 kgH20) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                 1 
                 30 
                 5 
                 105 
                 10 
                 20 
                 7.0 
                 14.3 
                 340 
               
               
                 2 
                 31 
                 0 
                 90 
                 5 
                 15 
                 7.1 
                 11.6 
                 280 
               
               
                 3 
                 30 
                 10 
                 90 
                 5 
                 15 
                 7.1 
                 12.8 
                 292 
               
               
                 Control 1 
                 X 
                 X 
                   
                   
                   
                 7.3 
                 16.9 
                 575 
               
               
                   
               
            
           
         
       
     
     In some embodiments, the buffer comprises a solvent, such as water. In some embodiments, the water may be purified and/or sterilized. For example, the water may be subjected to deionization (e.g., capacitive deionization or electrodeionization), reverse osmosis, carbon filtering, microfiltration, ultrafiltration, and/or ultraviolet sterilization. In some embodiments, the water is deionized. In some embodiments, the water is of a quality designated as “water for injection”; also known as “sterile water for injection.” Water for injection is generally made by distillation or reverse osmosis. Water for injection is a sterile, nonpyrogenic, solute-free preparation of water, chemically designated “H2O,” and having a pH of between about 5.0 and about 7.0, preferably about 5.5. 
     In some embodiments, the solvent comprises between 0.1% and 99.9% by volume of the total buffer volume. For example, the solvent may comprise at least about 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.1% by volume of the total buffer volume. 
     In some embodiments, the buffer comprises a solute, for example a sugar or an organic compound derived from sugar, for example a sugar alcohol. In embodiments wherein the buffer comprises a sugar, the sugar may comprise a monosaccharide, a disaccharide, and/or a polysaccharide. In some embodiments, the sugar comprises a monosaccharide, for example glucose, fructose, and/or galactose. In some embodiments, the sugar comprises a disaccharide, for example sucrose, lactose, and maltose. In some embodiments, the sugar comprises a polysaccharide, for example cellulose or starch. In embodiments wherein the buffer comprises a sugar alcohol, the sugar alcohol may comprise mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol, and/or hydrogenated starch hydrolysates (HSH). 
     In some embodiments, the sugar is present in an amount less than about 50 millimolar (mM). For example, the sugar may be present in an amount less than about 45 mM, 40 mM, 35 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM. In some embodiments, the sugar is present in an amount that ranges between about 10 mM and about 50 mM, about 10 mM and about 40 mM, about 10 mM and about 20 mM, or about 25 mM and about 35 mM. In some embodiments, the sugar is present in an amount of about 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, or 35 mM. 
     In some embodiments, the sugar is glucose. In these embodiments, the glucose may be present in an amount less than about 50 millimolar (mM). For example, the glucose may be present in an amount less than about 45 mM, 40 mM, 35 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM. In some embodiments, the glucose is present in an amount that ranges between about 10 mM and about 50 mM, about 10 mM and about 40 mM, about 10 mM and about 20 mM, or about 25 mM and about 35 mM. In some embodiments, the glucose is present in an amount of about 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, or 35 mM. In certain embodiments, the glucose is present in an amount of about 30 mM or 31 mM. 
     In some embodiments, the sugar is mannitol. In these embodiments, the mannitol may be present in an amount less than about 50 millimolar (mM). For example, the mannitol may be present in an amount less than about 45 mM, 40 mM, 35 mM, 30 mM, 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM. In some embodiments, the mannitol is present in an amount that ranges between about 10 mM and about 50 mM, about 10 mM and about 40 mM, about 10 mM and about 20 mM, or about 25 mM and about 35 mM. In some embodiments, the mannitol is present in an amount of about 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 30 mM, 31 mM, 32 mM, 33 mM, 34 mM, or 35 mM. 
     In some embodiments, the EP buffer comprises one or more chloride salts, for example potassium chloride (KCl) and/or magnesium chloride (MgCl 2 ). In some embodiments, the buffer further comprises one or more buffering agents, for example, Na 2 HPO 4 , NaH 2 PO 4 , or Na 2 HPO 4 /NaH 2 PO 4 . In some embodiments, the buffer further comprises one or more of HEPES and/or DMSO. In other embodiments, the buffer specifically excludes one or more buffering agents commonly found in commercial electroporation (EP) buffers. For example, in some embodiments, the buffer excludes one or both of DMSO and/or HEPES. 
     In some embodiments, the buffer comprises water (H 2 O), glucose, KCl, MgCl 2 , and Na 2 HPO 4 /NaH 2 PO 4 . In some embodiments, the buffer comprises water (H 2 O), glucose, KCl, MgCl 2 , Na 2 HPO 4 /NaH 2 PO 4 , and HEPES. In other embodiments, the buffer comprises water (H 2 O), glucose, KCl, MgCl 2 , Na 2 HPO 4 /NaH 2 PO 4 , HEPES, and DMSO. 
     In some embodiments, the buffer consists essentially of water (H 2 O), glucose, KCl, MgCl 2 , and Na 2 HPO 4 /NaH 2 PO 4 . In some embodiments, the buffer consists essentially of water (H 2 O), glucose, KCl, MgCl 2 , Na 2 HPO 4 /NaH 2 PO 4 , and HEPES. In other embodiments, the buffer consists essentially of water (H 2 O), glucose, KCl, MgCl 2 , Na 2 HPO 4 /NaH 2 PO 4 , HEPES, and DMSO. 
     In some embodiments, the buffer consists of water (H 2 O), glucose, KCl, MgCl 2 , and Na 2 HPO 4 /NaH 2 PO 4 . In some embodiments, the buffer consists of water (H 2 O), glucose, KCl, MgCl 2 , Na 2 HPO 4 /NaH 2 PO 4 , and HEPES. In other embodiments, the buffer consists of water (H 2 O), glucose, KCl, MgCl 2 , Na 2 HPO 4 /NaH 2 PO 4 , HEPES, and DMSO. 
     In some embodiments, the buffering agent has a pH ranging from about 6.0 to 8.0, 6.5 to 8.0, 7.0 to 8.0, 7.5 to 8.0, 6.0 to 7.5, 6.0 to 7.0, 6.0 to 6.5, 6.5 to 7.5, or 6.5 to 7.0. In some embodiments, the buffering agent has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. 
     In some embodiments, the buffer comprising the one or more buffering agents has a pH ranging from about 6.0 to 8.0, 6.5 to 8.0, 7.0 to 8.0, 7.5 to 8.0, 6.0 to 7.5, 6.0 to 7.0, 6.0 to 6.5, 6.5 to 7.5, or 6.5 to 7.0. In some embodiments, the buffer has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. 
     In some embodiments, the buffer comprises one or both of Na 2 HPO 4  and/or NaH 2 PO 4 . In embodiments wherein the buffer comprises both buffering agents, the ratio of the two (i.e., Na 2 HPO 4 /NaH 2 PO 4 ) may be about 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 9:1, 8:1, 7:1, 6:1 5:1, 4:1, 3:1, 2:1, or 2:3. In some embodiments, the ratio of Na 2 HPO 4 /NaH 2 PO 4  has a pH of 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9. 
     In some embodiments, a mixture of Na 2 HPO 4  and NaH 2 PO 4  (also referred to “Na 2 HPO 4 /NaH 2 PO 4 ” or “sodium phosphate”) may be present in the buffer in an amount ranging from about 50 mM and 160 mM, 60 mM to 150 mM, 70 mM to 140 mM, 75 mM to 130 mM, 80 mM to 125 mM, 90 mM to 125 mM, 90 mM to 120 mM, 90 mM to 115 mM, or 90 mM to 105 mM. In some embodiments, the Na 2 HPO 4 /NaH 2 PO 4  is present in an amount of at least 50 mM, 60 mM, 70 mM, 80 mM, 90 mM, or 100 mM. In some embodiments, the Na 2 HPO 4 /NaH 2 PO 4  is present in an amount of 80 mM, 81 mM, 82 mM, 83 mM, 84 mM, 85 mM, 86 mM, 87 mM, 88 mM, 89 mM, 90 mM, 91 mM, 92 mM, 93 mM, 94 mM, 95 mM, 96 mM, 97 mM, 98 mM, 99 mM, 100 mM, 101 mM, 102 mM, 103 mM, 104 mM, 105 mM, 106 mM, 107 mM, 108 mM, 109 mM, 110 mM, 111 mM, 112 mM, 113 mM, 114 mM, 115 mM, 116 mM, 117 mM, 118 mM, 119 mM, or 120 mM. In certain embodiments, the Na 2 HPO 4 /NaH 2 PO 4  is present in an amount of 90 mM or 105 mM. 
     In embodiments wherein the buffer comprises KCl, the KCl may be present in an amount less than about 30 mM. For example, the KCl may be present in an amount less than about 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM. In some embodiments, the KCl is present in an amount that ranges between about 1 mM and about 30 mM, about 2 mM and about 25 mM, about 3 mM and about 20 mM, about 4 mM and about 15 mM, about 5 mM and about 10 mM, or about 5 mM to about 15 mM. In some embodiments, the KCl is present in an amount of about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, or 15 mM. In certain embodiments, the KCl is present in an amount of about 5 mM or 10 mM. In some embodiments, the KCl has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9. 
     In embodiments wherein the buffer comprises MgCl 2 , the MgCl 2  may be present in an amount less than about 50 mM. For example, the MgCl 2  may be present in an amount less than about 45 mM, 35 mM, 30 mM 25 mM, 20 mM, 15 mM, 10 mM, or 5 mM. In some embodiments, the MgCl 2  is present in an amount that ranges between about 5 mM and about 50 mM, about 6 mM and about 45 mM, about 7 mM and about 40 mM, about 8 mM and about 35 mM, about 9 mM and about 30 mM, about 10 mM and about 25 mM, or about 15 mM and about 25 mM. In some embodiments, the MgCl 2  is present in an amount of about 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, 15 mM, 16 mM, 17 mM, 18 mM, 19 mM, 20 mM, 21 mM, 22 mM, 23 mM, 24 mM, 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, or 30 mM. In certain embodiments, the MgCl 2  is present in an amount of about 15 mM or 20 mM. In some embodiments, the MgCl 2  has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9. 
     In embodiments wherein the buffer comprises HEPES, the HEPES may be present in an amount less than about 30 mM. For example, the HEPES may be present in an amount less than about 25 mM, 20 mM, 15 mM, 10 mM, 5 mM, 4 mM, 3 mM, 2 mM, 1 mM, 0.5 mM, or 0.1 mM. In some embodiments, the HEPES is present in an amount that ranges between about 1 mM and about 30 mM, about 2 mM and about 25 mM, about 3 mM and about 20 mM, about 4 mM and about 15 mM, about 5 mM and about 10 mM. In some embodiments, the HEPES is present in an amount of about 0.1 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, 10 mM, 11 mM, 12 mM, 13 mM, 14 mM, or 15 mM. In certain embodiments, the HEPES is present in an amount of 0 mM, 5 mM, or 10 mM. In some embodiments, the HEPES has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9. 
     In embodiments wherein the buffer comprises DMSO, the DMSO may be present in an amount equal to or less than 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% by volume of the total buffer volume. In some embodiments, DMSO is present from about 0% to about 2.5% by volume of the total buffer volume. In some embodiments, DMSO is present in an amount ranging from about 0.1% to 5%, 1% to 5%, 2% to 5%, 3% to 5%, or 4% to 5% by volume of the total buffer volume. In some embodiments, the DMSO has a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, or 7.9. In other embodiments, DMSO is not included in the buffer at all. 
     In certain embodiments, the buffer comprises a sugar in an amount equal to or less than 50 mM; HEPES in an amount equal to or less than 25 mM; Na 2 HPO 4 /NaH 2 PO 4  in an amount equal to or less than 160 mM; KCl in an amount equal to or less than 10 mM; MgCl 2  in an amount equal to or less than 20 mM; and DMSO in an amount equal to or less than 5% by volume of the total buffer volume. In some of these embodiments, the sugar may comprise a monosaccharide and/or a sugar alcohol. In some of these embodiments, the sugar is mannitol and/or glucose. In some of these embodiments, the sugar is glucose. In some embodiments, the buffer does not comprise DMSO. 
     In certain embodiments, the buffer comprises a sugar in an amount of at least about 15 mM; HEPES in an amount equal to or less than 25 mM; Na 2 HPO 4 /NaH 2 PO 4  in an amount of at least about 90 mM; KCl in an amount of at least about 2 mM; MgCl 2  in an amount of at least 15 mM; and DMSO in an amount equal to or less than 5% by volume of the total buffer volume. In some of these embodiments, the sugar may comprise a monosaccharide and/or a sugar alcohol. In some of these embodiments, the sugar is mannitol and/or glucose. In some of these embodiments, the sugar is glucose. In some embodiments, the buffer does not comprise DMSO. 
     In certain embodiments, the buffer comprises a sugar in an amount ranging from about 15 mM to about 35 mM; KCl in an amount ranging from about 5 mM to about 10 mM; MgCl 2  in an amount ranging from about 10.5 mM to about 20 mM; Na 2 HPO 4 /NaH 2 PO 4  in an amount ranging from about 90 mM to about 105 mM; HEPES in an amount equal to or less than 25 mM; and DMSO in an amount equal to or less than 5% by volume of the total buffer volume. In some of these embodiments, the sugar may comprise a monosaccharide and/or a sugar alcohol. In some of these embodiments, the sugar is mannitol and/or glucose. In some of these embodiments, the sugar is glucose. In some embodiments, the buffer does not comprise DMSO. 
     In certain embodiments, the buffer comprises glucose in an amount of about 15 mM; KCl in an amount of about 6 mM; MgCl 2  in an amount of about 10.5 mM Na 2 HPO 4 /NaH 2 PO 4  in an amount of about 105 mM; HEPES in an amount ranging from about 15 mM; and DMSO in an amount of about 2.5% by volume of total buffer volume. 
     In certain embodiments, the buffer comprises glucose in an amount of about 30 mM; KCl in an amount of about 10 mM; MgCl 2  in an amount of about 20 mM; Na 2 HPO 4 /NaH 2 PO 4  in an amount of about 105 mM; and HEPES in an amount of about 5 mM. In some embodiments, DMSO is specifically excluded from the buffer. 
     In certain embodiments, the buffer comprises glucose in an amount of about 31 mM; KCl in an amount of about 5 mM; and MgCl 2  in an amount of about 15 mM; and Na 2 HPO 4 /NaH 2 PO 4  in an amount of about 90 mM. In some embodiments, one or more of HEPES and DMSO is/are specifically excluded from the buffer. 
     In certain embodiments, the buffer comprises glucose in an amount of about 30 mM; KCl in an amount of about 5 mM; and MgCl 2  in an amount of about 15 mM; Na 2 HPO 4 /NaH 2 PO 4  in an amount of about 90 mM; and HEPES in an amount of about 10 mM. In some embodiments, DMSO is specifically excluded from the buffer. 
     In certain embodiments, the buffer comprises glucose in an amount of about 25 mM; KCl in an amount of about 15 mM; and MgCl 2  in an amount of about 25 mM; Na 2 HPO 4 /NaH 2 PO 4  in an amount of about 120 mM; and HEPES in an amount of about 10 mM. In some embodiments, DMSO is specifically excluded from the buffer. 
     In certain embodiments, the pH of the buffer may be adjusted. In some embodiments, the buffer is adjusted to a pH of between 6.5 and 8. In some embodiments, the buffer is adjusted to a pH between about 7.0 and 7.6. In some embodiments, the buffer is adjusted to a pH between about 6.9 and 7.2, or between about 7.0 and 7.1. In some embodiments, the buffer is adjusted to a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In certain embodiments, the buffer is adjusted to a pH of about 7.0 or 7.1. 
     In certain embodiments, the conductivity of the buffer is between about 7.0 ms/cm to about 16.0 ms/cm, about 9.0 ms/cm to about 16.0 ms/cm, about 11.0 ms/cm to about 16.0 ms/cm, or about 13.0 ms/cm to about 16.0 ms/cm. In some embodiments, the conductivity of the buffer is between about 7.0 ms/cm to about 15.0 ms/cm, about 9.0 ms/cm to about 15.0 ms/cm, about 11.0 ms/cm to about 15.0 ms/cm, or about 13.0 ms/cm to about 15.0 ms/cm. In some embodiments, the conductivity of the buffer is about 7.0 ms/cm, about 7.1 ms/cm, about 7.2 ms/cm, about 7.3 ms/cm, about 7.4 ms/cm, about 7.5 ms/cm, about 7.6 ms/cm, about 7.7 ms/cm, about 7.8 ms/cm, about 7.9 ms/cm, about 8.0 ms/cm, about 8.1 ms/cm, about 8.2 ms/cm, about 8.3 ms/cm, about 8.4 ms/cm, about 8.5 ms/cm, about 8.6 ms/cm, about 8.7 ms/cm, about 8.8 ms/cm, about 8.9 ms/cm, about 9.0 ms/cm, about 9.1 ms/cm, about 9.2 ms/cm, about 9.3 ms/cm, about 9.4 ms/cm, about 9.5 ms/cm, about 9.6 ms/cm, about 9.7 ms/cm, about 9.8 ms/cm, about 9.9 ms/cm, about 10.0 ms/cm, about 10.1 ms/cm, about 10.2 ms/cm, about 10.3 ms/cm, about 10.4 ms/cm, about 10.5 ms/cm, about 10.6 ms/cm, about 10.7 ms/cm, about 10.8 ms/cm, about 10.9 ms/cm, about 11.0 ms/cm, about 11.1 ms/cm, about 11.2 ms/cm, about 11.3 ms/cm, about 11.4 ms/cm, about 11.5 ms/cm, about 11.6 ms/cm, about 11.7 ms/cm, about 11.8 ms/cm, about 11.9 ms/cm, about 12.0 ms/cm, about 12.1 ms/cm, about 12.2 ms/cm, about 12.3 ms/cm, about 12.4 ms/cm, about 12.5 ms/cm, about 12.6 ms/cm, about 12.7 ms/cm, about 12.8 ms/cm, about 12.9 ms/cm, about 13.0 ms/cm, about 13.1 ms/cm, about 13.2 ms/cm, about 13.3 ms/cm, about 13.4 ms/cm, about 13.5 ms/cm, about 13.6 ms/cm, about 13.7 ms/cm, about 13.8 ms/cm, about 13.9 ms/cm, about 14.0 ms/cm, about 14.1 ms/cm, about 14.2 ms/cm, about 14.3 ms/cm, about 14.4 ms/cm, about 14.5 ms/cm, about 14.6 ms/cm, about 14.7 ms/cm, about 14.8 ms/cm, about 14.9 ms/cm, about 15.0 ms/cm, about 15.1 ms/cm, about 15.2 ms/cm, about 15.3 ms/cm, about 15.4 ms/cm, about 15.5 ms/cm, about 15.6 ms/cm, about 15.7 ms/cm, about 15.8 ms/cm, about 15.9 ms/cm, or about 16.0 ms/cm. In certain embodiments, the conductivity of the buffer is about 11.6, 12.8, or 14.3. 
     In some embodiments, the osmolality of the buffer is lower than the osmolality of the cells being transfected (i.e., also known as “intracellular osmolality”). In some embodiments, the osmolality of the buffer ranges from about 250 mOsm/kg H 2 O to about 1255 mOsm/kg H 2 O, about 250 mOsm/kg H 2 O to about 1100 mOsm/kg H 2 O, about 250 mOsm/kg H 2 O to about 900 mOsm/kg H 2 O, about 250 mOsm/kg H 2 O to about 700 mOsm/kg H 2 O, about 250 mOsm/kg H 2 O to about 500 mOsm/kg H 2 O, about 250 mOsm/kg H 2 O to about 400 mOsm/kg H 2 O, or about 250 mOsm/kg H 2 O to about 360 mOsm/kg H 2 O. In some embodiments, the osmolality is about 360 mOsm/kg H 2 O to about 1255 mOsm/kg H 2 O, about 360 mOsm/kg H 2 O to about 1100 mOsm/kg H 2 O, about 360 mOsm/kg H 2 O to about 900 mOsm/kg H 2 O, about 360 mOsm/kg H 2 O to about 700 mOsm/kg H 2 O, about 360 mOsm/kg H 2 O to about 500 mOsm/kg H 2 O, about 360 mOsm/kg H 2 O to about 400 mOsm/kg H 2 O. In some embodiments, the osmolality is about 250 mOsm/kg H 2 O, 255 mOsm/kg H 2 O, 260 mOsm/kg H 2 O, 270 mOsm/kg H 2 O, 275 mOsm/kg H 2 O, about 280 mOsm/kg H 2 O, about 285 mOsm/kg H 2 O, about 290 mOsm/kg H 2 O, about 300 mOsm/kg H 2 O, about 305 mOsm/kg H 2 O, about 310 mOsm/kg H 2 O, about 315 mOsm/kg H 2 O, about 320 mOsm/kg H 2 O, about 325 mOsm/kg H 2 O, about 330 mOsm/kg H 2 O, about 335 mOsm/kg H 2 O, about 340 mOsm/kg H 2 O, about 345 mOsm/kg H 2 O, about 350 mOsm/kg H 2 O, about 355 mOsm/kg H 2 O, about 360 mOsm/kg H 2 O, about 365 mOsm/kg H 2 O, about 370 mOsm/kg H 2 O, about 375 mOsm/kg H 2 O, about 380 mOsm/kg H 2 O, about 385 mOsm/kg H 2 O, about 390 mOsm/kg H 2 O, about 395 mOsm/kg H 2 O, or about 400 mOsm/kg H 2 O. In certain embodiments, the osmolality is about 280 mOsm/kg H 2 O, about 292 mOsm/kg H 2 O, about 340 mOsm/kg H 2 O, or about 362 mOsm/kg H 2 O. 
     In some embodiments, the buffer is selected from one or more of the exemplary buffers set forth in Tables 5 and 6. In certain embodiments, the buffer is selected from Buffer 1, Buffer 2, or Buffer 3. 
     In some embodiments, the buffer of the invention is used in conjunction with an UltraPorator™ electroporation apparatus and cartridge (or, cassette); see, PCT/US20/59984 (filed Nov. 11, 2020) and U.S. patent application Ser. No. 17/095,028 (filed Nov. 11, 2020). This apparatus is designed to enable rapid manufacturing for a range of gene and cell therapies. UltraPorator™ is a high-throughput, semi-closed electroporation system for electroporation of large quantities of cells in a single operation. The UltraPorator™ system is an advancement over current electroporation devices by significantly reducing the processing time and contamination risk. For example, UltraPorator may be utilized as a scale-up and commercialization solution for decentralized chimeric antigen receptor (CAR) T-cell manufacturing, such as in the UltraCAR-T™ manufacturing of T-cells reprogrammed to target cancer antigens in vivo. 
     Buffers of the invention are surprisingly effective in producing high cell transfection efficiencies when electroporation is performed using the buffers in the UltraPorator™ electroporation apparatus and/or cartridge (or, cassette); see, PCT/US20/59984 (filed Nov. 11, 2020) and U.S. patent application Ser. No. 17/095,028. 
     b. Methods Utilizing the EP Buffer and Recombinant Cells Produced Using Those Methods 
     In another aspect of the invention, a method is provided that utilizes the buffer according to the invention to introduce biologically active material (e.g., DNA or RNA) into cells via electric current (i.e., electroporation). The method comprises forming a suspension by combining cells obtained from a human along with an exogenous biological material into the buffer of the invention, and then applying an electric current in the form of a voltage pulse to the suspension, thereby facilitating the introduction of the biological material into the cells. 
     In certain embodiments, the voltage pulse may have a field strength of up to 1 to 10 kV*cm-1 and a duration of 5 to 250 μs and a current density of at least 2 A*cm-2. In certain embodiments, the voltage pulse permits the biologically active material (e.g., DNA) to be transfected directly into the cell nucleus of animal and human cells. In certain embodiments, a current flow following the voltage pulse without interruption, having a current density of 2 to 14 A*cm-2, preferably up to 5 A*cm-2, and a duration of 1 to 100 ms, may also be applied. 
     Using the method according to the invention, the transfection of biologically active material into cells, including into the nucleus of animal cells, may be optimized. In this case, the biologically active material (e.g., nucleic acids, polypeptides, or the like) can be introduced into quiescent or dividing animal cells with a high efficiency. 
     In some embodiments, the cells are exposed to the buffer for less than 10 minutes. For example, the cells may be exposed to the buffer for less than 9 minutes, less than 8 minutes, less than 7 minutes, less than 6 minutes, less than 5 minutes, less than 4 minutes, less than 3 minutes, less than 2 minutes, or less than 1 minute. 
     In some embodiments, the method is used to introduce biologically active material into primary human blood cells, pluripotent precursor cells of human blood, as well as primary human fibroblasts and endothelial cells. In some embodiments, the cells are human blood cells, for example immune cells. In certain embodiments, the immune cells are neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages, dendritic cells, natural killer cells, and lymphocytes (B cells and T cells), or some combination thereof. In some embodiments, the lymphocytes are T-cells. In certain embodiments, the cells are obtained from a patient. 
     In some embodiments, the biological material includes a nucleic acid, peptide, polypeptide, protein, enzyme, RNP, or some combination thereof. In some embodiments, the biological material is heterologous to the cells. In some embodiments, the biological material is partially or fully synthetic. 
     In some embodiments, the nucleic acid is selected from DNA or RNA. In some embodiments, the DNA may comprise cDNA. In some embodiments, the RNA may comprise mRNA, tRNA, mRNA, lncRNA, sRNA, or a combination thereof. In some embodiments, the nucleic acid is a recombinant nucleic acid. In some embodiments, the peptide comprises a polypeptide, protein, enzyme, antibody, antibody fragment, or combination thereof. In some embodiments, the peptide is recombinant. 
     Methods utilizing the buffer of the invention result in desirably high transfection yields, especially as compared to methods utilizing other electroporation buffers. In some embodiments, the transfection yield with a buffer of the invention is at least about 1.1 times that of the transfection yield with a control (prior art) buffer. For example, the transfection yield with a buffer of the invention may be about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 2.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 times higher than that of a control (prior art) buffer. In some embodiments, the transfection yield with a buffer of the invention may be greater than 5 times than that of a control (prior art) buffer, such as 6, 7, 8, 9, or 10 times higher. In certain embodiments, the transfection yield with a buffer of the invention is 1.35, 1.41, 1.46, 1.97, 1.98, 2.05, 2.12, 2.40, or 2.44 times higher than that of a control (prior art) buffer. 
     Methods utilizing the buffer of the invention result in desirably high transfected cell recovery yields, especially as compared to methods utilizing other electroporation buffers. In some embodiments, the transfected cell recovery yield with a buffer of the invention is at least about 1.1 times that of the transfected cell recovery yield with a control (prior art) buffer. For example, the transfected cell recovery yield with a buffer of the invention may be about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 2.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 higher than that of a control (prior art) buffer. In some embodiments, the transfected cell recovery yield with a buffer of the invention may be greater than 5 times than that of a control (prior art) buffer. In certain embodiments, the transfected cell recovery yield with a buffer of the invention is 1.53, 1.66, 1.72, 1.80, 2.06, 2.17, 2.23, 2.34, or 2.61 times higher than that of a control (prior art) buffer. 
     In another aspect of the invention, recombinant cells are provided. In some embodiments, recombinant immune cells are produced using the method of the invention. In certain embodiments, the recombinant immune cell is a modified T-cell. In some embodiments, the modified T-cell is a chimeric antigen receptor (CAR) T-cell. In some embodiments, the CAR-T cell is administered to a patient for therapeutic purposes. 
     c. Electroporation Apparatuses and Their Methods of Use 
     An exemplary electroporation apparatus comprises: one or more chambers configured to store the buffer and cells during an electroporation process; one or more pairs of electrodes configured to generate electric fields within the one or more chambers during the electroporation process, each electric field corresponding to one chamber; and a flow channel configured to transport the cells during a cell collection process after the electroporation process. 
     In some embodiments, the apparatus comprises one chamber, two chambers, three chambers, four chambers, five chambers, six chambers, seven chambers, eight chambers, nine chambers, ten chambers, or ten or more chambers. In certain embodiments, the apparatus utilizes continuous flow or a microfluidic system. 
     In some embodiments, the electroporation apparatus further comprises a pump for pumping a liquid medium from the flow channel into at least one of the chambers during a collection process, wherein the liquid medium is obtained at the inlet port. In some embodiments, the pump comprises a valve or valves connecting the one or more chambers to the flow channel. In some embodiments, the valve or valves are opened one at a time. In some embodiments, the valve or valves permit only one-directional flow of fluid. In some embodiments, each valve corresponds to one chamber. In some embodiments, each valve corresponding to the chamber valves is a pinch-valve or pinch-type valve. In some embodiments, each of the valves operates using a spring motion, a lever motion, or a piston motion. 
     In some embodiments, the one or more chambers comprises a given chamber; each electrode of the pair of electrodes is located on opposite sides of the given chamber; and each electrode of the pair of electrodes comprises both an interior portion inside the given chamber and an exterior portion external to the given chamber. 
     In some embodiments, the electroporation apparatus further comprises: an inlet port; an outlet port; and one or more flanking flow channels connecting the inlet port and the outlet port to the flow channel. 
     In some embodiments, the electroporation apparatus further comprises: a pump for pumping a liquid medium from the flow channel into at least one of the chambers during a collection process, wherein the liquid medium is obtained at the inlet port. 
     In some embodiments, the electroporation apparatus further comprises: a surface comprising a one or more openings leading to the one or more chambers; and an airflow channel below the openings and connecting airflow between the chambers. 
     In some embodiments, the electroporation apparatus further comprises: a vent or air filter connecting the airflow channel to an exterior of the electroporation apparatus. 
     In some embodiments, the electroporation apparatus further comprises: a seal configured to cover the one or more openings. In some embodiments, each chamber in the electroporation apparatus comprises a shape which narrows toward the respective valve(s). In some embodiments, the electroporation apparatus further comprises a pair of electrodes wherein each electrode of the electrode pair is located on opposite sides of each chamber. The distance between the two electrodes in an electrode pair is referred to as the “gap distance” or “separation distance.” This distance spans the width of the chamber. 
     In some embodiments, each of the one or more chambers comprises a gap distance of about 0.1 mm to about 20 mm, about 0.5 mm to about 10 mm, about 1 mm to about 7 mm, or about 1 mm to about 4 mm. In some embodiments, the gap distance is about 0.5 mm, 1.0 mm, 1.5 mm, 2.0 mm, 2.5 mm, 3.0 mm, 3.5 mm, 4.0 mm, 4.5 mm, 5.0 mm, 5.5 mm, 6.0 mm, 6.5 mm, 7.0 mm, 7.5 mm, or 8.0 mm. In some embodiments, a gap distance of about 2.5 mm, 2.6 mm, 2.7 mm, 2.8 mm, 2.9 mm, 3.0 mm, 3.1 mm, 3.2 mm, 3.3 mm, 3.4 mm, 3.5 mm, 3.6 mm, 3.7 mm, 3.8 mm, 3.9 mm, or 4.0 mm. In some embodiments, the gap distance is less than about 4 mm, less than about 3.5 mm, less than about 3.0 mm, less than about 2.5 mm, less than about 2.0 mm, less than about 1.5 mm, or less than about 1.0 mm. In some embodiments, a gap distance of less than about 4.0 mm improves the electroporation performance of the buffer provided herein. 
     In some embodiments, each electrode of the pair of electrodes of the electroporation apparatus comprises: an interior portion inside the given chamber; and an exterior portion external to the given chamber, wherein each pair of electrodes is configured to connect to an electric circuit. In some embodiments, the interior portion inside the given chamber has an elliptical face and comprises a gold coating. 
     In some embodiments, each chamber of the electroporation apparatus is configured to store a volume of at least about 50 μL, at least about 100 μL, at least about 150 at least about μL, at least about 200 μL, at least about 250 μL, at least about 300 μL, at least about 350 μL, at least about 400 μL, at least about 450 μL, at least about 150 μL, at least about 500 μL, at least about 550 μL, at least about 600 μL, at least about 650 μL, at least about 700 μL, at least about 750 μL, at least about 800 μL, at least about 850 μL, at least about 900 μL, at least about 950 μL, or at least about 1000 μL (1.0 mL). 
     In some embodiments, the chambers of the electroporation apparatus, in combination, are configured to store at least about 500 μL, at least about 1.0 mL, at least about 1.2 mL, at least about 1.4 mL, at least about 1.6 mL, at least about 1.8 mL, at least about 2.0 mL, at least about 2.2 mL, at least about 2.4 mL, at least about 2.6 mL, at least about 2.8 mL, at least about 3.0 mL, at least about 3.2 mL, at least about 3.4 mL, at least about 3.6 mL, at least about 3.8 mL, at least about 4.0 mL, at least about 4.2 mL, at least about 4.4 mL, at least about 4.6 mL, at least about 4.8 mL, at least about 5.0 mL, at least about 5.2 mL, at least about 5.4 mL, at least about 5.6 mL, at least about 5.8 mL, at least about 6.0 mL, at least about 6.2 mL, at least about 6.4 mL, at least about 6.6 mL, at least about 6.8 mL, or at least about 7.0 mL of cells in liquid suspension for electroporation. 
     In some embodiments, the cells involved in the electroporation process comprises a population selected from a group consisting of: at least 1×10 8  cells, at least 2×10 8  cells, at least 3×10 8  cells, at least 4×10 8  cells, at least 5×10 8  cells, at least 6×10 8  cells, at least 7×10 8  cells, at least 8×10 8  cells, at least 9×10 8  cells, at least 1×10 9  cells, at least 2×10 9  cells, at least 3×10 9  cells, at least 4×10 9  cells, at least 5×10 9  cells, at least 6×10 9  cells, at least 7×10 9  cells, at least 8×10 9  cells, at least 9×10 9  cells, at least 1×10 10  cells, at least 2×10 10  cells, at least 3×10 10  cells, at least 4×10 10  cells, at least 5×10 10  cells, at least 6×10 10  cells, at least 7×10 10  cells, at least 8×10 10  cells, at least 9×10 1 ° cells, at least 1×10 11  cells, at least 2×10 11  cells, at least 3×10 11  cells, at least 4×10 11  cells, at least 5×10 11  cells, at least 6×10 11  cells, at least 7×10 11  cells, at least 8×10 11  cells, at least 9×10 11  cells, at least 1×10 12  cells, at least 2×10 12  cells, at least 3×10 12  cells, at least 4×10 12  cells, at least 5×10 12  cells, at least 6×10 12  cells, at least 7×10 12  cells, at least 8×10 12  cells, and at least 9×10 12 . 
     In some embodiments, the apparatus of the invention comprises an UltraPorator™ electroporation apparatus and cartridge (see, PCT/US20/59984 and U.S. patent application Ser. No. 17/095,028). As noted above, the UltraPorator™ electroporation apparatus is designed to enable rapid manufacturing for a range of gene and cell therapies. The apparatus may be utilized as a scale-up and commercialization solution for decentralized CAR T-cell manufacturing, such as in the UltraCAR-T™ manufacturing of T-cells reprogrammed to target cancer antigens in vivo. 
     In some embodiments, the apparatus of the invention is used in a method of electroporation, the method comprising: executing an electroporation process by generating an electric field within a chamber using a pair of electrodes, wherein the chamber is configured to store the buffer and cells during the electroporation process; and executing a cell collection process by: opening a valve connected to the chamber; and transporting the buffer and cells to an outlet port using a flow channel connected to the valve, wherein the chamber, the electrode pair, the valve, the outlet port, and the flow channel are each located within an electroporation apparatus. 
     In some embodiments, the step of executing a cell collection process further comprises: pumping, through use of a pump, a liquid medium from the flow channel into the chamber, wherein the liquid medium is obtained at an inlet port, and wherein the inlet port and the outlet port are connected to the flow channel by a flanking flow channel within the electroporation apparatus. 
     In some embodiments, the cell collection process further comprises: draining the chamber into the flow channel, wherein pressure within the chamber is maintained via a vent or air filter connected to an air flow channel running between the chamber and another chamber. 
     In some embodiments, the method of electroporation further comprises: depositing the cells into an opening leading to the chamber holding the buffer; applying a seal to the opening; and connecting the electrode pair to at least one circuit by, for example, inserting the electroporation apparatus into a docking station. 
     In some embodiments, the method utilizes one or more of the exemplary buffers set forth in Tables 5 and 6. In certain embodiments, the method utilizes Buffer 1, Buffer 2, or Buffer 3. 
     In some embodiments, the method is performed in an UltraPorator™ electroporation apparatus (see, PCT/US20/59984 and U.S. patent application Ser. No. 17/095,028). In certain embodiments, the method is performed in an UltraPorator™ electroporation apparatus and utilizes one or more of the exemplary buffers set forth in Tables 5 and 6. In certain embodiments, the method is performed in an UltraPorator™ electroporation apparatus and utilizes Buffer 1, Buffer 2, or Buffer 3 (as set forth in Table 5). 
     d. Electroporation Systems 
     In another aspect of the invention, a system for electroporation is provided. In some embodiments, the system for electroporation comprises an electroporation apparatus, as described herein, and an electroporation buffer, as described herein. In some embodiments, the electroporation system comprises and UltraPorator™ electroporation apparatus and cartridge (see, PCT/US20/59984 and U.S. patent application Ser. No. 17/095,028). As noted above, the UltraPorator™ electroporation apparatus is designed to enable rapid manufacturing for a range of gene and cell therapies. The device may be utilized as a scale-up and commercialization solution for decentralized CAR T-cell manufacturing, such as in the UltraCAR-T™ manufacturing of T-cells reprogrammed to target cancer antigens in vivo. 
     In some embodiments, the system for electroporation further comprises a buffer is from one or more of the exemplary buffers set forth in Tables 5 and 6. In certain embodiments, the system for electroporation comprises a buffer selected from Buffer 1, Buffer 2, or Buffer 3. It has been found that systems comprising an UltraPorator™ device and one of Buffers 1, 2, or 3 result in surprisingly high cell transfection efficiencies, as compared to systems comprising an UltraPorator™ device and a control buffer. 
     e. Kits for Electroporation 
     In another aspect of the invention, a kit for electroporation is provided. The kit may include any of the buffers as described herein. In some embodiments, the kit comprises one or more of the exemplary buffers set forth in Tables 5 and 6. In certain embodiments, the kit comprises a buffer selected from Buffer 1, Buffer 2, or Buffer 3. 
     In some embodiments, the kit includes one or more containers filled with a buffer according to the invention and other suitable reagents and/or devices. For example, the kit may additionally comprise a vector comprising a nucleic acid of interest. In some embodiments, the kit may include a dropper, pipette, and/or cuvette. In some embodiments, the buffer may be packaged in aliquoted containers or as a stock solution. 
     In some embodiments, the kit further comprises packaging to safely transport the buffer and any additional reagents and/or devices. In some embodiments, the kit includes information about the contents of the buffer and any additional reagents. Further, the kit may comprise written materials, for example a user manual or answers to frequently asked questions. 
     2. Chemical Methods 
     Chemical methods for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). 
     3. Viral Vectors and Delivery Methods 
     In the case where a viral delivery system is utilized, an exemplary delivery vehicle is a liposome. Lipid formulations can be used for the introduction of the nucleic acids into a host cell (in vitro, ex vivo, or in vivo). In another aspect, the nucleic acid can be associated with a lipid. The nucleic acid associated with a lipid can be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they can be present in a bilayer structure, as micelles, or with a “collapsed” structure. They can also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which can be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes. 
     Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine (“DMPC”) can be obtained from Sigma, St. Louis, Mo.; dicetyl phosphate (“DCP”) can be obtained from K &amp; K Laboratories (Plainview, N.Y.); cholesterol (“Chol”) can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) and other lipids can be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about −20° C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. “Liposome” is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., Glycobiology 5: 505-10 (1991)). However, compositions that have different structures in solution than the normal vesicular structure are also encompassed. For example, the lipids can assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes. 
     Also provided herein are viral-based delivery systems, in which a nucleic acid of the present invention is inserted. Representative viral expression vectors include, but are not limited to, the adenovirus-based vectors (e.g., the adenovirus-based Per.C6 system available from Crucell, Inc. (Leiden, The Netherlands)), adeno-associated virus based vectors, lentivirus-based vectors (e.g., the lentiviral-based pLPI from Life Technologies (Carlsbad, Calif.)), retroviral vectors (e.g., the pFB-ERV plus pCFB-EGSH), and herpes virus-based vectors. In an embodiment, the viral vector is a lentivirus vector. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity. In general, and in embodiments, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193). 
     In some embodiments, a lentiviral vector is provided comprising a backbone and a nucleic acid sequence encoding one or more miRNA(s) and a CAR. Optionally, the vector further comprises a nucleic acid encoding a cytokine and a cell tag such as truncated HER1, CD20t-1 or a full length CD20. 
     In some embodiments, the nucleic acid encoding one or more miRNA(s) and a CAR is cloned into a vector comprising lentiviral backbone components. Exemplary backbone components include, but are not limited to, pFUGW, and pSMPUW. The pFUGW lentiviral vector backbone is a self-inactivating (SIN) lentiviral vector backbone and has unnecessary HIV-1 viral sequences removed resulting in reduced potential for the development of neoplasia, harmful mutations, and regeneration of infectious particles. In some embodiments, the vector encoding one or more miRNA(s) and a CAR also encodes a cytokine in a single construct. In some embodiments, the one or more miRNA(s) and a CAR and cytokine are encoded on two separate lentiviral vectors. In some embodiments, the cytokine is expressed with a cell tag. In some embodiments, one or more miRNA(s) and a CAR can be co-expressed with the cytokine and the cell tag from a single lentiviral vector. In further embodiments, one or more miRNA(s) and a CAR can be under the control of an inducible promoter. In another embodiment, the cytokine can be under the control of an inducible promoter. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as RHEOSWITCH® gene switch. 
     Other suitable vectors include integrating expression vectors, which can randomly integrate into the host cell&#39;s DNA, or can include a recombination site to enable the specific recombination between the expression vector and the host cell&#39;s chromosome. Such integrating expression vectors can utilize the endogenous expression control sequences of the host cell&#39;s chromosomes to effect expression of the desired protein. Examples of vectors that integrate in a site specific manner include, for example, components of the flp-in system from Invitrogen (Carlsbad, Calif.) (e.g., pcDNA™5/FRT), or the cre-lox system, such as can be found in the pExchange-6 Core Vectors from Stratagene (La Jolla, Calif.). Examples of vectors that randomly integrate into host cell chromosomes include, for example, pcDNA3.1 (when introduced in the absence of T-antigen) from Invitrogen (Carlsbad, Calif.), and pCI or pFN10A (ACT) FLEXI™ from Promega (Madison, Wis.). Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription. 
     In some embodiments, the cell tag gene is cloned into a lentiviral plasmid backbone in frame with the CAR gene. In other embodiments, the cell tag is cloned into a separate lentiviral vector. 
     4. Non-Viral Vectors and Delivery Systems 
     a. Sleeping Beauty Transposon System 
     A polynucleotide encoding one or more miRNA(s) alone or a polynucleotide encoding one or more miRNA(s) and a chimeric receptor, cytokine, and/or cell tag as described herein can be introduced into immune effector cells using non-viral based delivery systems, such as the “Sleeping Beauty (SB) Transposon System,” which refers to a synthetic DNA transposon system for introducing DNA sequences into the chromosomes of vertebrates. An exemplary Sleeping Beauty transposon system is described for example, in U.S. Pat. Nos. 6,489,458 and 8,227,432. As used herein, the Sleeping Beauty transposon system can comprise Sleeping Beauty transposase polypeptides as well as derivatives, functional fragments, and variants thereof, and Sleeping Beauty transposon polynucleotides, derivatives, and functional variants and fragments thereof. In certain embodiments, the Sleeping Beauty transposase is encoded by an mRNA. In some embodiments, the mRNA encodes for a SB10, SB11, SB100x or SB110 transposase. In some embodiments, the mRNA comprises a cap and a poly-A tail. 
     DNA transposons translocate from one DNA site to another in a simple, cut-and-paste manner. Transposition is a precise process in which a defined DNA segment is excised from one DNA molecule and moved to another site in the same or different DNA molecule or genome. As with other Tc 1/mariner-type transposases, SB transposase inserts a transposon into a TA dinucleotide base pair in a recipient DNA sequence. The insertion site can be elsewhere in the same DNA molecule, or in another DNA molecule (or chromosome). In mammalian genomes, including humans, there are approximately 200 million TA sites. The TA insertion site is duplicated in the process of transposon integration. This duplication of the TA sequence is a hallmark of transposition and used to ascertain the mechanism in some experiments. The transposase can be encoded either within the transposon or the transposase can be supplied by another source, in which case the transposon becomes a non-autonomous element. Non-autonomous transposons are most useful as genetic tools because after insertion they cannot independently continue to excise and re-insert. Sleeping Beauty transposons envisaged to be used as non-viral vectors for introduction of genes into genomes of vertebrate animals and for gene therapy. 
     Briefly, the Sleeping Beauty system (Hackett et al., Mol Ther 18:674-83, (2010)) was adapted to genetically modify the immune effector cells (Cooper et al., Blood 105:1622-31, (2005)). In one embodiment, this involves two steps: (i) the electro-transfer of DNA plasmids expressing a Sleeping Beauty transposon (Jin et al., Gene Ther 18:849-56, (2011); Kebriaei et al., Hum Gene Ther 23:444-50, (2012)) and Sleeping Beauty transposase and (ii) the propagation and expansion of T cells stably expressing integrants on designer artificial antigen-presenting cells (AaPC) derived from the K562 cell line (also known as AaPCs (Activating and Propagating Cells). In another, embodiment, the second step (ii) is eliminated and the genetically modified T cells are cryopreserved or immediately infused into a patient. 
     In one embodiment, the Sleeping Beauty transposon systems are described for example in Hudecek et al., Critical Reviews in Biochemistry and Molecular Biology, 52:4, 355-380 (2017), Singh et al., Cancer Res (8):68 (2008). Apr. 15, 2008 and Maiti et al., J Immunother. 36(2): 112-123 (2013). 
     In some embodiments, one or more miRNA(s), a CAR, a cytokine, and a cell tag can be encoded by a single transposon DNA plasmid vector. In some embodiments, the one or more miRNA(s), CAR, cytokine, and cell tag can be encoded by different transposon DNA plasmid vectors. In further embodiments, one or more miRNA(s) and a CAR can be under the control of an inducible promoter. In another embodiment, the cytokine can be under the control of an inducible promoter. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as RHEOSWITCH® gene switch further described below. In certain embodiments, the CAR, cytokine, and cell tag can be configured in one, two or more transposons. 
     In some embodiments, the MUC16, CD33, or ROR1-specific CARs and other genetic elements are delivered to a cell using the SB11 transposon system, the SB100X transposon system, the SB110 transposon system, the piggyBac transposon system (see, e.g., U.S. Pat. Nos. 6,489,458; 8,227,432, 9,228,180, Wilson et al, “PiggyBac Transposon-mediated Gene Transfer in Human Cells,” Molecular Therapy 15:139-145 (2007) and WO 2016/145146) and/or the piggyBat transposon system (see, e.g., Mitra et al., “Functional characterization of piggyBat from the bat  Myotis lucifugus  unveils an active mammalian DNA transposon,” Proc. Natl. Acad. Sci USA 110:234-239 (2013). Additional transposases and transposon systems are provided in U.S. Pat. Nos. 7,148,203; 8,227,432; U.S. Patent Publn. No. 2011/0117072; Mates et al.,  Nat Genet,  41(6):753-61 (2009). doi: 10.1038/ng.343. Epub 2009 May 3 , Gene Ther.,  18(9):849-56 (2011). doi: 10.1038/gt.2011.40. Epub 2011 Mar. 31 and in Ivics et al.,  Cell.  91(4):501-10, (1997). 
     In certain embodiments, the vector is a Sleeping Beauty plasmid that comprises a left transposon repeat region and a right transposon repeat region. In certain embodiments, the left transposon repeat region comprises a nucleic acid comprising SEQ ID NO: 580 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 580, or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 580. In certain embodiments, the right transposon repeat region comprises a nucleic acid comprising SEQ ID NO: 581 or a functional fragment or variant thereof. In certain embodiments, the functional variant has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NO: 581, or hybridizes under stringent hybridization conditions with the complement of SEQ ID NO: 581. 
     b. Recombinase-Based Delivery Systems 
     In other embodiments, nucleic acids encoding one or more miRNA(s), a CAR, a cytokine, and/or a cell tag can be integrated into the immune effector cell&#39;s DNA through a recombinase and integrating expression vectors. Such vectors can randomly integrate into the host cell&#39;s DNA, or can include a recombination site to enable the specific recombination between the expression vector and the host cell&#39;s chromosome. Such integrating expression vectors can utilize the endogenous expression control sequences of the host cell&#39;s chromosomes to effect expression of the desired protein. In some embodiments, targeted integration is promoted by the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site. For example, targeted integration using the donor polynucleotides described herein can be achieved following conventional transfection techniques, e.g. techniques used to create gene knockouts or knockins by homologous recombination. In other embodiments, targeted integration is promoted both by the presence of sequences on the donor polynucleotide that are homologous to sequences flanking the integration site, and by contacting the cells with donor polynucleotide in the presence of a site-specific recombinase. By a site-specific recombinase, or simply a recombinase, it is meant a polypeptide that catalyzes conservative site-specific recombination between its compatible recombination sites. As used herein, a site-specific recombinase includes native polypeptides as well as derivatives, variants and/or fragments that retain activity, and native polynucleotides, derivatives, variants, and/or fragments that encode a recombinase that retains activity. 
     The recombinases can be introduced into a target cell before, concurrently with, or after the introduction of a targeting vector. The recombinase can be directly introduced into a cell as a protein, for example, using liposomes, coated particles, or microinjection. Alternately, a polynucleotide, either DNA or messenger RNA, encoding the recombinase can be introduced into the cell using a suitable expression vector. The targeting vector components described above are useful in the construction of expression cassettes containing sequences encoding a recombinase of interest. However, expression of the recombinase can be regulated in other ways, for example, by placing the expression of the recombinase under the control of a regulatable promoter (i.e., a promoter whose expression can be selectively induced or repressed). 
     A recombinase can be from the Integrase or Resolvase families. The Integrase family of recombinases has over one hundred members and includes, for example, FLP, Cre, and lambda integrase. The Integrase family, also referred to as the tyrosine family or the lambda integrase family, uses the catalytic tyrosine&#39;s hydroxyl group for a nucleophilic attack on the phosphodiester bond of the DNA. Typically, members of the tyrosine family initially nick the DNA, which later forms a double strand break. Examples of tyrosine family integrases include Cre, FLP, SSV1, and lambda (λ) integrase. In the resolvase family, also known as the serine recombinase family, a conserved serine residue forms a covalent link to the DNA target site (Grindley, et al., (2006) Ann Rev Biochem 16:16). 
     In one embodiment, the recombinase is an isolated polynucleotide sequence comprising a nucleic acid sequence that encodes a recombinase selecting from the group consisting of a SPβc2 recombinase, a SF370.1 recombinase, a Bxb1 recombinase, an A118 recombinase and a ϕRv1 recombinase. Examples of serine recombinases are described in detail in U.S. Pat. No. 9,034,652. 
     Recombinases for use in the practice of the present invention can be produced recombinantly or purified as previously described. Polypeptides having the desired recombinase activity can be purified to a desired degree of purity by methods known in the art of protein ammonium sulfate precipitation, purification, including, but not limited to, size fractionation, affinity chromatography, HPLC, ion exchange chromatography, heparin agarose affinity chromatography (e.g., Thorpe &amp; Smith, Proc. Nat. Acad. Sci. 95:5505-5510, 1998.) 
     In one embodiment, the recombinases can be introduced into the eukaryotic cells that contain the recombination attachment sites at which recombination is desired by any suitable method. Methods of introducing functional proteins, e.g., by microinjection or other methods, into cells are well known in the art. Introduction of purified recombinase protein ensures a transient presence of the protein and its function, which is often a preferred embodiment. Alternatively, a gene encoding the recombinase can be included in an expression vector used to transform the cell, in which the recombinase-encoding polynucleotide is operably linked to a promoter which mediates expression of the polynucleotide in the eukaryotic cell. The recombinase polypeptide can also be introduced into the eukaryotic cell by messenger RNA that encodes the recombinase polypeptide. It is generally preferred that the recombinase be present for only such time as is necessary for insertion of the nucleic acid fragments into the genome being modified. Thus, the lack of permanence associated with most expression vectors is not expected to be detrimental. One can introduce the recombinase gene into the cell before, after, or simultaneously with, the introduction of the exogenous polynucleotide of interest. In one embodiment, the recombinase gene is present within the vector that carries the polynucleotide that is to be inserted; the recombinase gene can even be included within the polynucleotide. 
     In one embodiment, a method for site-specific recombination comprises providing a first recombination site and a second recombination site; contacting the first and second recombination sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination sites, the first recombination site is attP or attB, the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a  Listeria monocytogenes  phage recombinase, a  Streptococcus pyogenes  phage recombinase, a  Bacillus subtilis  phage recombinase, a  Mycobacterium tuberculosis  phage recombinase and a  Mycobacterium smegmatis  phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP, and when the first recombination attachment site is attP, the second recombination attachment site is attB 
     Further embodiments provide for the introduction of a site-specific recombinase into a cell whose genome is to be modified. One embodiment relates to a method for obtaining site-specific recombination in an eukaryotic cell comprises providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination attachment site is attB or attP, and the recombinase is selected from the group consisting of a  Listeria monocytogenes  phage recombinase, a  Streptococcus pyogenes  phage recombinase, a  Bacillus subtilis  phage recombinase, a  Mycobacterium tuberculosis  phage recombinase and a  Mycobacterium smegmatis  phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP, and when the first recombination attachment site is attP, the second recombination attachment site is attB. In an embodiment the recombinase is selected from the group consisting of an A118 recombinase, a SF370.1 recombinase, a SPβc2 recombinase, a ϕRv1 recombinase, and a Bxb1 recombinase. In one embodiment the recombination results in integration. 
     c. Other Non-Viral Delivery Systems 
     In other embodiments, nucleic acids encoding one or more miRNA(s), a CAR, a cytokine, and/or a cell tag, can be integrated into the immune effector cell&#39;s DNA through gene editing systems that utilize CRISPR, TALEN or Zinc-Finger nucleases. 
     Regardless of the method used to introduce exogenous nucleic acids into a host cell, in order to confirm the presence of the recombinant DNA sequence in the host cell, a variety of assays can be performed. Such assays include, for example, “molecular biological” assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify peptides or proteins or nucleic acids falling within the scope of the invention. 
     IX. Engineered T-Cell Receptor (TCR) 
     In some embodiments, the chimeric receptor comprises an engineered T-cell receptor. The T cell receptor (TCR) is composed of two chains (aβ or γδ) that pair on the surface of the T cell to form a heterodimeric receptor. In some instances, the αβ TCR is expressed on most T cells in the body and is known to be involved in the recognition of specific MHC-restricted antigens. Each α and β chain are composed of two domains: a constant domain (C) that anchors the protein to the cell membrane and is associated with invariant subunits of the CD3 signaling apparatus; and a variable domain (V) that confers antigen recognition through six loops, referred to as complementarity determining regions (CDRs). In some instances, each of the V domains comprises three CDRs; e.g., CDR1, CDR2 and CDR3 with CDR3 as the hypervariable region. These CDRs interact with a complex formed between an antigenic peptide bound to a protein encoded by the major histocompatibility complex (pepMHC) (e.g., HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, or HLA-DRB1 complex). In some instances, the constant domain further comprises a joining region that connects the constant domain to the variable domain. In some cases, the beta chain further comprises a short diversity region which makes up part of the joining region. 
     Both the α and β chains are highly variable, although the T-cell receptor α chain contains a constant (preserved region), i.e., the Vα 24-Ja18 junction (amino acid sequence GSTLGR or a conservatively substituted amino acid sequence thereof). 
     In some cases, such TCR are reactive to specific tumor antigen, e.g. NY-ESO, Mage A3, Titin, MART-1, HPV, HBV, MAGE-A4, MAGE-A10, MAGE A3/A6, gp100, MAGE-A 1, or PRAME. In other cases, such TCR are reactive to specific neoantigens expressed within a patient&#39;s tumor (i.e. patient-specific, somatic, non-synonymous mutations expressed by tumors). In some cases, engineered TCRs can be affinity-enhanced. 
     In some embodiments, a TCR is described using the International Immunogenetics (IMGT) TCR nomenclature, and links to the IMGT public database of TCR sequences. For example, there can be several types of alpha chain variable (Vα) regions and several types of beta chain variable (Vβ) regions distinguished by their framework, CDR1, CDR2, and CDR3 sequences. As such, a Vα type can be referred to in IMGT nomenclature by a unique TRAV number. For example, “TRAV21” defines a TCR Vα region having unique framework and CDR1 and CDR2 sequences, and a CDR3 sequence, which is partly defined by an amino acid sequence which is preserved from TCR to TCR but which also includes an amino acid sequence which varies from TCR to TCR Similarly, “TRBV5-1” defines a TCR Vβ region having unique framework and CDR1 and CDR2 sequences, but with only a partly defined CDR3 sequence. 
     In some cases, the beta chain diversity region is referred to in IMGT nomenclature by the abbreviation TRBD. 
     In some instances, the unique sequences defined by the IMGT nomenclature are widely known and accessible to those working in the TCR field. For example, they can be found in the IMGT public database and in “T cell Receptor Factsbook”, (2001) LeFranc and LeFranc, Academic Press, ISBN 0-12-441352-8. 
     In some embodiments, an αβ heterodimeric TCR is, for example, transfected as full length chains having both cytoplasmic and transmembrane domains. In some cases, the TCRs contain an introduced disulfide bond between residues of the respective constant domains, as described, for example, in WO 2006/000830. 
     In some instances, TCRs described herein are in single chain format, for example see WO 2004/033685. Single chain formats include αβ TCR polypeptides of the Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, Vα-L-Vβ-Cβ, Vα-Cα-L-Vβ-Cβ types, wherein Vα and Vβ are TCR α and β variable regions respectively, Cα and Cβ are TCR α and β constant regions respectively, and L is a linker sequence. In certain embodiments single chain TCRs of the invention may have an introduced disulfide bond between residues of the respective constant domains, as described in WO 2004/033685. 
     In some embodiments, the TCR can be an αβ TCR. In some embodiments, the TCR can be a γδ TCR. It should be understood that a TCR of the present disclosure can bind to any of the antigen targets described herein. 
     In some embodiments, the TCR may be any one of the Vδ1, Vδ2, and Vδ1negVδ2neg TCR subsets. In some embodiments, the engineered cell may express any combination of a Vδ1, Vδ2, Vδ3, Vδ5, Vδ7, or Vδ8 TCR chain with a Vγ2, Vγ3, Vγ7, Vγ8, Vγ9, Vγ10, or Vγ11 TCR chain. In some embodiments, the engineered cell may have essentially identical genetic material. In one aspect, the engineered cell may not contain a chimeric antigen receptor. 
     The TCR described herein may be associated with a detectable label, a therapeutic agent or a PK modifying moiety. Exemplary detectable labels for diagnostic purposes include, but are not limited to, fluorescent labels, radiolabels, enzymes, nucleic acid probes and contrast reagents. 
     In some cases, each chain of TCR disclosed herein, for example αβ or γδ, comprises a modified spacer region connecting the constant region of a TCR chain to the transmembrane region. In some cases, a spacer region of each chain of TCR disclosed herein comprises 1) a stalk region and 1 or more stalk extension region(s) adjacent to said stalk region. The stalk and stalk extension regions may, for example, be those as previously described for use in chimeric antigen receptors. In some embodiments, each chain of TCR disclosed herein incorporates a spacer that comprises a stalk region (s) and up to 20 stalk extension regions. 
     In some instances, the stalk region comprises the extracellular hinge region from TCRα or TCRβ chain or the stalk region comprises a sequence with at least 80% homology to the extracellular hinge region from TCRα or TCRβ chain. In alternative instances, the stalk region comprises any portion of extracellular region of TCRα or TCRβ constant region with at least 80% homology to the extracellular region of TCRα or TCRβ constant region respectively. For example, the stalk region can comprise a sequence with at least 80%, 85%, 90%, 95%, or greater than 95% homology to the any portion of extracellular region of TCRα or TCRβ constant region. 
     TCR chain heterodimers are formed by inter-chain disulfide bonds in extracellular hinge region of a and (3 chains. In some embodiments, the stalk region comprises a dimerization site. A dimerization site can comprise a disulfide bond formation site. A dimerization site can comprise cysteine residue(s). A stalk region can be capable of forming a disulfide bond. Such a disulfide bond can be formed at a disulfide bond forming site or a dimerization site. In some examples, the dimerization occurs between a and (3 chains of TCR. 
     In some embodiments, a stalk extension region is used to link the stalk region to the transmembrane region TCR α and (3 chains. In certain embodiments, a stalk extension region is used to link the stalk region to constant region of TCR α and β chains. In certain embodiments, the stalk region and the stalk extension region(s) can be connected via a linker. 
     In some instances, the stalk extension domain comprises a sequence that is partially homologous to the stalk region. In some instances, each of the stalk extension region comprises a sequence that is homologous to the stalk region, except that the stalk extension region lacks the dimerization site of the stalk region. In some cases, each of the stalk extension region comprises a sequence identical to the stalk region. In other cases, each of the stalk extension regions comprise a sequence identical to the stalk region with at least one amino acid residue substitution relative to the stalk region. In some cases, each of the stalk extension region is not capable of forming a disulfide bond or is not capable of dimerization with a homologous stalk extension region. 
     In other embodiments, one stalk extension region can be connected to another stalk extension region via a linker. Examples of such linkers can include glycine-serine rich linkers. 
     In some embodiments, the addition of stalk extension region(s) prevents mispairing of transgenic TCR α and β chains with native TCR α and β chains expressed by T cells that are genetically modified. 
     In some embodiments, a modified immune effector cell of the present disclosure can comprise a TCR of the present disclosure and a cytokine of the present disclosure. In certain embodiments, the modified immune effector cell can comprise a TCR and a fusion protein comprising IL-15 and IL-15Rα, or a fusion protein comprising functional fragments or variants of such domains. 
     X. Immune Checkpoint Inhibitors 
     In some embodiments, an engineered cell of the present disclosure can include an immune checkpoint inhibitor. In certain embodiments, a polynucleotide of the present disclosure can further encode an immune checkpoint inhibitor. In certain embodiments, an engineered cell of the present disclosure can comprise such a polynucleotide. 
     In certain embodiments, the immune checkpoint inhibitor can be an antibody or a functional fragment or variant thereof. In certain embodiments, the immune checkpoint inhibitor can inhibit the activity of an immune checkpoint protein such as PD1, PD-L1, CTLA-4, TIGIT, 4-1BB, PIK3IP1, CD27, CD28, CD40, CD70, CD122, CD137, OX40 (CD134), GITR, ICOS, A2AR, B7-H 3  (CD276), B7-H 4  (VTCN1), BTLA, IDO, KIR, LAGS, TIM-3, or VISTA. 
     In some embodiments, the immune checkpoint inhibitor can be an anti-CTLA-4 antibody. The anti-CTLA-4 antibody (e.g., ipilimumab) has shown durable anti-tumor activities and prolonged survival in participants with advanced melanoma, resulting in its Food and Drug Administration (FDA) approval in 2011. See Hodi et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. (2010) Aug. 19; 363(8):711-23. In some embodiments, the one or more checkpoint inhibitors can be an anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody can be a full-length atezolizumab (anti-PD-L1), avelumab (anti-PD-L1), durvalumab (anti-PD-L1), or a fragment or a variant thereof. In some embodiments, the one or more checkpoint inhibitors can be any one or more of CD27 inhibitor, CD28 inhibitor, CD40 inhibitor, CD122 inhibitor, CD137 inhibitor, OX40 (also known as CD134) inhibitor, GITR inhibitor, ICOS inhibitor, or any combination thereof. In some embodiments, the one or more checkpoint inhibitors can be any one or more of A2AR inhibitor, B7-H 3  (also known as CD276) inhibitor, B7-H 4  (also known as VTCN1) inhibitor, BTLA inhibitor, IDO inhibitor, KIR inhibitor, LAG3 inhibitor, TIM-3 inhibitor, VISTA inhibitor, or any combination thereof. 
     In some embodiments, the immune checkpoint inhibitor is an anti-PD-L1 antibody, an anti-CTLA-4 antibody, an anti-CD28 antibody, an anti-TIGIT antibody, an anti-LAG3 antibody, an anti-TIM3 antibody, an anti-GITR antibody, an anti-4-1BB antibody, or an anti-OX-40 antibody. In some embodiments, the additional therapeutic agent is an anti-TIGIT antibody. In some embodiments, the immune checkpoint inhibitor is an anti-PD-L1 antibody selected from the group consisting of: BMS935559 (MDX-1105), atexolizumab (MPDL3280A), durvalumab (MEDI4736), and avelumab (MSB0010718C). In some embodiments, the immune checkpoint inhibitor is an anti-CTLA-4 antibody selected from the group consisting of: ipilimumab (YERVOY) and tremelimumab. In some embodiments, the additional therapeutic agent is an anti-LAG-3 antibody selected from the group consisting of: BMS-986016 and LAG525. In some embodiments, the immune checkpoint inhibitor is an anti-OX-40 antibody selected from the group consisting of: MEDI6469, MEDI0562, and MOXR0916. In some embodiments, the additional therapeutic agent is an anti-4-1BB antibody selected from the group consisting of: PF-05082566. 
     In some embodiments, the engineered cell can include an immune checkpoint inhibitor comprising a PD1-binding moiety. In some embodiments, the PD1-binding moiety (referred to herein as an “anti-PD-1”) is selected from an antibody identified in Table 8 (below), or a functional fragment or variant thereof. 
     
       
         
           
               
             
               
                 TABLE 8 
               
             
            
               
                   
               
               
                 PD-1 Antibodies 
               
            
           
           
               
               
               
               
            
               
                 Name 
                 Also Known as 
                 Company 
                 Reference(s) 
               
               
                   
               
               
                 cemiplimab 
                 Libtayo, cemiplimab. 
                 Regeneron, Sanofi 
                 WO 2015/112800 
               
               
                   
                 REGN2810 
               
               
                 pembrolizumab 
                 Keytruda, MK-3475, 
                 Merck (MSD), 
                 WO 2008/156712, 
               
               
                   
                 SCH 900475, 
                 Schering-Plough 
                 U.S. Pat. No. 8,354,509. 
               
               
                   
                 lambrolizumab 
                   
                 U.S. Pat. No. 8,952,136, 
               
               
                   
                   
                   
                 U.S. Pat. No. 8,900,587 
               
               
                 nivolumab 
                 Opdivo, ONO-4538, 
                 BMS, Medarex, Ono 
                 U.S. Pat. No. 8,728,474. 
               
               
                   
                 MDX-1106, BMS- 
                   
                 U.S. Pat. No. 8,779,105, 
               
               
                   
                 936558, 5C4 
                   
                 U.S. Pat. No. 8.008,449, 
               
               
                   
                   
                   
                 U.S. Pat. No. 9,067,999, 
               
               
                   
                   
                   
                 U.S. Pat. No. 9,073,994 
               
               
                 toripalimab 
                 JS001, JS-001, TAB001, 
                 Junmeng Biosciences, 
                 Si-Yang Liu et al.,  J.   
               
               
                   
                 triprizumab 
                 Shanghai Junshi, 
                   Hematol. Oncol . 10: 136 
               
               
                   
                   
                 TopAlliance Bio 
                 (2017) 
               
               
                 sintilimab 
                 Tyvyt, IBI308 
                 Adimab, Innovent, 
                 WO 2017/024465, WO 
               
               
                   
                   
                 Lilly 
                 2017/025016, WO 
               
               
                   
                   
                   
                 2017/132825, WO 
               
               
                   
                   
                   
                 2017/133540 
               
               
                 LY3434172 
                 — 
                 Lilly, Zymeworks 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03936959 
               
               
                 JTX-4014 
                 — 
                 Jounce Therapeutics 
                 U.S. 2018/0118829; 
               
               
                   
                   
                 Inc. 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03790488; 
               
               
                   
                   
                   
                 Papdopolous et al.,  Cancer   
               
               
                   
                   
                   
                 
                   Immunol Immunother 
                 
               
               
                   
                   
                   
                 70(3): 763-772 (2021)) 
               
               
                 609 A 
                 609A 
                 3S Bio; Sunshine 
                 ClinicalTrials.gov 
               
               
                   
                   
                 Guojian Pharma 
                 Identifier: NCT03998345 
               
               
                 Sym021 
                 — 
                 Symphogen A/S 
                 Gjetting et al., mAbs 11(4): 
               
               
                   
                   
                   
                 666-680 (2019 
               
               
                 LZM009 
                 — 
                 Livzon Pharmaceutical 
                 ClinicalTrials.gov 
               
               
                   
                   
                 Group 
                 Identifier: NCT03286296 
               
               
                 budigalimab 
                 ABBV-181, PR- 
                 Abbvie 
                 Powderly et al.,  Annals of   
               
               
                   
                 1648817 
                   
                   Oncology  29(8) (2018); 
               
               
                   
                   
                   
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03000257 
               
               
                 IB 
                 IBI-318 
                 Innovent, Lilly 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03875157 
               
               
                 SCT-I10A 
                 — 
                 Sinocelltech Ltd. 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03821363 
               
               
                 SG001 
                 — 
                 CSPC ZhongQi 
                 ClinicalTrials.gov 
               
               
                   
                   
                 Pharmaceutical 
                 Identifier: NCT03852823 
               
               
                   
                   
                 Technology Co., Ltd. 
               
               
                 AMP-224 
                 GSK-2661380 
                 Astra Zeneca, Glaxo 
                 Floudas et al.,  Clin.   
               
               
                   
                   
                 Smith Kline 
                   Colorectal Cancer  18(4) 
               
               
                   
                   
                   
                 (2019) 
               
               
                 AMG 404 
                 AMG404 
                 Amgen 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03853109 
               
               
                 AK112 
                 — 
                 Akesobio Australia Pty 
                 ClinicalTrials.gov 
               
               
                   
                   
                 Ltd 
                 Identifier: NCT04047290 
               
               
                 CS1003 
                 — 
                 CStone Pharma 
                 Li et al.,  Acta   
               
               
                   
                   
                   
                   Pharmacologica Sinica  42: 
               
               
                   
                   
                   
                 142-148 (2021) 
               
               
                 MEDI0680 
                 AMP-514 
                 Astra Zeneca, 
                 WO 2012/145493, WO 
               
               
                   
                   
                 Amplimmune, 
                 2014/194293 
               
               
                   
                   
                 Medimmune 
               
               
                 RO7121661 
                 — 
                 Roche 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03708328 
               
               
                 F520 
                 — 
                 Shandong New Time 
                 ClinicalTrials.gov 
               
               
                   
                   
                 Pharmaceutical Co. 
                 Identifier: NCT03657381 
               
               
                 sasanlimab 
                 PF-06801591, RN-888 
                 Pfizer 
                 Cho et al.,  Annals of   
               
               
                   
                   
                   
                   Oncology  30(5) (2019) 
               
               
                 BI 754091 
                 BI754091 
                 Boehringer Ingelheim 
                 Kang et al.,  J. Clin . 
               
               
                   
                   
                   
                   Oncology  38(15) (2020) 
               
               
                 cetrelimab 
                 JNJ-63723283 
                 Janssen Biotech 
                 Rutkowski et al.,  J. Clin.   
               
               
                   
                   
                   
                   Oncology  37: 8 (2019) 
               
               
                 HerinCAR-PD-1 
                 — 
                 Ningbo Cancer 
                 ClinicalTrials.gov 
               
               
                   
                   
                 Hospital 
                 Identifier: NCT02873390 
               
               
                 HX008 
                 — 
                 Taizhou Hanzhong Bio 
                 Zhang et al,  mAbs  12(1) 
               
               
                   
                   
                   
                 (2020); ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03704246 
               
               
                 zimberelimab 
                 WBP3055, GLS-010, 
                 Arcus, Guangzhou 
                 US 2019/0270815, Si- 
               
               
                   
                 AB122 
                 Gloria Bio, Harbin 
                 Yang Liu et al.,  J.   
               
               
                   
                   
                 Gloria Pharma, WuXi 
                   Hematol. Oncol . 10: 136 
               
               
                   
                   
                 Biologies 
                 (2017) 
               
               
                 retifanlimab 
                 MGA012, 
                 Incyte, MacroGenics 
                 WO 2017/19846 
               
               
                   
                 INCMGA00012 
               
               
                 balstilimab 
                 AGEN2034, AGEN- 
                 Agenus, Ludwig Inst., 
                 WO 2017/040790 
               
               
                   
                 2034 
                 Sloan-Kettering 
               
               
                 pidilizumab 
                 CT-011, hBat-1, 
                 CureTech, Medivation, 
                 Rosenblatt et al.,  J   
               
               
                   
                 MDV9300 
                 Teva 
                   Immunother . 34(5): 409- 
               
               
                   
                   
                   
                 418 (2011) 
               
               
                 teripalimab 
                 — 
                 Henan Cancer Hospital 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03985670 
               
               
                 CBT-501 
                 GB226, GB 226, 
                 CBT Pharmaceuticals, 
                 ClinicalTrials.gov 
               
               
                   
                 Genolimzumab, 
                 Genor 
                 Identifier: 
               
               
                   
                 Genormab 
                   
                 NCT03053466. 
               
               
                 BAT1306 
                 — 
                 Bio-Thera Solutions 
                 Wu et al.,  J. Clin. Oncol . 
               
               
                   
                   
                   
                 37(4)(2019) 
               
               
                 tislelizumab 
                 BGB-A317 
                 BeiGene, Celgene 
                 WO 2015/35606, 
               
               
                   
                   
                   
                 US 2015/0079109 
               
               
                 AK105 
                 — 
                 Akeso, HanX Bio 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT03866967 
               
               
                 spartalizumab 
                 PDR001, BAP049 
                 Dana-Farber, Novartis 
                 WO 2015/112900; Lin et 
               
               
                   
                   
                   
                 al.,  Ann. of Oncology , 29: 8 
               
               
                   
                   
                   
                 (2018) 
               
               
                 prolgolimab 
                 BCD-100 
                 Biocad 
                 Kaplon et 
               
               
                   
                   
                   
                 al.,  mAbs  10(2): 183-203 
               
               
                   
                   
                   
                 (2018) 
               
               
                 serplulimab 
                 HLX10 
                 Henlix Biotech 
                 ClinicalTrials.gov 
               
               
                   
                   
                   
                 Identifier: NCT04297995 
               
               
                 dostarlimab 
                 ANB011, TSR-042, 
                 AnaptysBio, Tesaro 
                 WO 2014/179664 
               
               
                   
                 ABT1, WBP-285 
               
               
                 camrelizumab 
                 SHR-1210 
                 Incyte, Jiangsu 
                 WO 2015/085847; Si-Yang 
               
               
                   
                   
                 Hengrui, Shanghai 
                 Liu et al.,  J. Hematol . 
               
               
                   
                   
                 Hengrui 
                 Oncol. 10: 136(2017) 
               
               
                 IBI319 
                 IBI-319 
                 Innovent Biologies 
                 ClinicalTrials.gov 
               
               
                   
                   
                 (Suzhou) Co. Ltd., 
                 Identifier: NCT04708210 
               
               
                   
                   
                 Lilly 
               
               
                 KY1043 
                 — 
                 Kymab 
                 Van Krinks, Kymab poster 
               
               
                   
                   
                   
                 no. P625, “KY1043, a 
               
               
                   
                   
                   
                 novel PD-L1 IL-2 
               
               
                   
                   
                   
                 immunocytokine directed 
               
               
                   
                   
                   
                 towards CD25, delivers 
               
               
                   
                   
                   
                 potent anti-tumour activity 
               
               
                   
                   
                   
                 in vitro and in vivo” 
               
               
                 STI-1110 
                 — 
                 Sorrento Therapeutics 
                 WO 2014/194302 
               
               
                 CA05100948 
                 Antibody 948 
                 UCB Biopharma 
                 U.S. Pat. No. 8.993,731 
               
               
                 Nb97 
                 MY2935, MY2626 
                 Fudan University, 
                 Xian et al.,  Biochem . &amp; 
               
               
                   
                   
                 Novamab 
                 
                   Biophys. Res. Comm&#39;s 
                 
               
               
                   
                   
                   
                 519(3), 267-273 (2019) 
               
               
                 ENUM 388D4 
                 — 
                 Enumeral 
                 Scheuplein et al., 
               
               
                   
                   
                   
                   Immunology , Abstract 
               
               
                   
                   
                   
                 4871 (2016) 
               
               
                 hAb-10D3 
                 hAb-10D3 
                 BPS Bioscience 
                 U.S. Pat. No. 10,759,859 
               
               
                 Unknown 
                 — 
                 Isis Innovation 
                 WO 2010/029434 
               
               
                 ANB030 
                 — 
                 AnaptysBio Inc. 
                 Grebinoski et al.,  Current   
               
               
                   
                   
                   
                   Opinion in Immunol . 67: 1- 
               
               
                   
                   
                   
                 9 (2020) 
               
               
                 MCLA-134 
                 — 
                 Merus N.V. 
                 WO 2019/009727 
               
               
                 hAb21 
                 — 
                 Suzhou Stainwei 
                 U.S. 2020/0277376 
               
               
                   
                   
                 Biotech Inc. 
               
               
                 — 
                 — 
                 Ampsource 
                 U.S. 2019/0367617 
               
               
                 — 
                 — 
                 Reyoung(Suzhou) 
                 U.S. 2019/0071501 
               
               
                   
                   
                 Biology Science &amp; 
               
               
                   
                   
                 Technology Co. 
               
               
                 — 
                 — 
                 Xencor, Inc. 
                 WO 2018/071918 
               
               
                 — 
                 — 
                 Crown Bio science Inc. 
                 WO 2016/014688 
               
               
                 — 
                 — 
                 Beijing Hanmi 
                 U.S. 2020/0299412 
               
               
                 — 
                 — 
                 Beijing Hanmi 
                 U.S. 2021/0032343 
               
               
                 — 
                 — 
                 Beijing Hanmi 
                 U.S. 2019/0367615 
               
               
                 — 
                 — 
                 MabQuest 
                 WO 2016/020856 
               
               
                 — 
                 — 
                 Fuso Pharma, 
                 WO 2018/034226 
               
               
                   
                   
                 Hokkaido U. 
               
               
                 — 
                 — 
                 Eureka Therapeutics, 
                 WO 2016/210129 
               
               
                   
                   
                 Inc., Sloan-Kettering 
               
               
                 — 
                 — 
                 Sutro Biopharma, Inc. 
                 WO 2016/077397 
               
               
                 — 
                 — 
                 Y-Biologics 
                 U.S. 2019/0248900 
               
               
                 — 
                 — 
                 Harbour Biomed Ltd. 
                 WO 2017/016497 
               
               
                 — 
                 — 
                 Shanghai 
                 Liu et al.,  Sci. Rep  9(1) 
               
               
                   
                   
                 PharmaExplorer Co. 
                 (2019) 
               
               
                 — 
                 — 
                 Bio X Cell 
                 Grasselly et al.,  Front   
               
               
                   
                   
                   
                   Immunol  9: 2100 (2018) 
               
               
                 — 
                 — 
                 Tongji University 
                 Cai et al.,  Invest. New   
               
               
                   
                   
                   
                   Drugs  37(5): 799-809 
               
               
                   
                   
                   
                 (2019) 
               
               
                 — 
                 — 
                 Janssen Biotech 
                 U.S. 2018/0355061 
               
               
                 — 
                 — 
                 Shanghai Henlius 
                 U.S. 2019/0218295 
               
               
                   
                   
                 Biotech, Inc. 
               
               
                 — 
                 — 
                 Ultrahuman Nine Ltd. 
                 WO 2019/170898 
               
               
                 — 
                 — 
                 CytomX 
                 WO 2017/011580 
               
               
                 — 
                 — 
                 Nanjing Legend 
                 WO 2017/133633 
               
               
                   
                   
                 Biotech 
               
               
                 — 
                 — 
                 Aduro Biotech 
                 U.S. Pat. No. 10,494,436 
               
               
                 — 
                 — 
                 Sutro Biopharm 
                 U.S. Pat. No. 10,822,414 
               
               
                 — 
                 — 
                 Versitech Ltd. 
                 U.S. Pat. No. 10,047,137 
               
               
                 — 
                 — 
                 STCube &amp; Co., 
                 WO 2016/160792 
               
               
                   
                   
                 University of Texas 
               
               
                 — 
                 — 
                 Tayu Huaxia Biotech 
                 U.S. 2019/0144543 
               
               
                   
                   
                 Medivcal Group Co. 
               
               
                 — 
                 — 
                 Hangzhou Sumgen 
                 U.S. 2019/0016799 
               
               
                   
                   
                 Biotechnology 
               
               
                 — 
                 — 
                 Jiangsu Hengrui 
                 WO 2015/085847 
               
               
                   
                   
                 Medicine Co, Shanghai 
               
               
                   
                   
                 Hengrui 
               
               
                   
                   
                 Pharmaceutical Co 
               
               
                 — 
                 — 
                 Salubris (Chengdu) 
                 WO 2019/201169 
               
               
                   
                   
                 Biotech Co. 
               
               
                 — 
                 — 
                 Kadmon Corp. 
                 U.S. Pat. No. 10,407,502 
               
               
                 — 
                 — 
                 Augusta University 
                 WO 2019/051164 
               
               
                   
                   
                 Research Institute 
               
               
                 — 
                 — 
                 Abbvie Biotherapeutics 
                 WO 2018/053106 
               
               
                   
                   
                 Inc. 
               
               
                 — 
                 — 
                 Lyvgen Biopharma 
                 WO 2017/087599 
               
               
                   
                   
                 Holdings Ltd. 
               
               
                 — 
                 — 
                 Crescendo Biologies 
                 WO 2018/127711 
               
               
                   
                   
                 Ltd. 
               
               
                 — 
                 — 
                 Zhejiang Teruisi 
                 U.S. 2019/0322747 
               
               
                   
                   
                 Pharmaceutics Inc. 
               
               
                 — 
                 — 
                 Biosion Inc. 
                 WO 2019/204132 
               
               
                 — 
                 — 
                 Celgene Corp. 
                 U.S. 2017/0088618 
               
               
                 — 
                 — 
                 Asia Biotech Pte. Ltd. 
                 WO 2017/058115 
               
               
                 — 
                 — 
                 The Brigham and 
                 U.S. Pat. No. 10,934,352 
               
               
                   
                   
                 Women&#39;s Hospital 
               
               
                 — 
                 — 
                 Singapore Immunology 
                 Seidel et al.,  Front. Oncol . 
               
               
                   
                   
                 Network (SIgN), 
                 28 (2018) 
               
               
                   
                   
                 Institute of Medical 
               
               
                   
                   
                 Biology, Agency for 
               
               
                   
                   
                 Science, Technology 
               
               
                   
                   
                 and Research 
               
               
                   
                   
                 (A*STAR) 
               
               
                 — 
                 — 
                 Chinese People 
                 Sun et al.,  J Gastrointest   
               
               
                   
                   
                 Liberation Army 
                   Oncol . 11(6): 1421-1430 
               
               
                   
                   
                 General Hospital 
                 (2020) 
               
               
                 — 
                 — 
                 Immunomedics Inc. 
                 U.S. Pat. No. 10,669,338 
               
               
                 — 
                 — 
                 Xiangtan Tenghua Bio 
                 WO 2018/162944 
               
               
                 — 
                 — 
                 Beijing Dongfang 
                 U.S. 2019/0144541 
               
               
                   
                   
                 Biotech 
               
               
                 — 
                 — 
                 REMD Biotherapeutics 
                 WO 2018/119474 
               
               
                 — 
                 — 
                 Rinat Neuroscience 
                 U.S. Pat. No. 10,155,037 
               
               
                   
                   
                 Corp. 
               
               
                 — 
                 — 
                 Medimmune, Wyeth 
                 WO 2004/056875 
               
               
                 — 
                 — 
                 Fudan University 
                 Yuan et al.,  Invest. New   
               
               
                   
                   
                   
                   Drugs  39(1): 34-51 (2021) 
               
               
                   
               
            
           
         
       
     
     XI. Gene Switch 
     Provided herein are gene switch polypeptides, polynucleotides encoding ligand-inducible gene switch polypeptides, and methods and systems incorporating these polypeptides and/or polynucleotides. The term “gene switch” refers to the combination of a response element associated with a promoter, and for instance, an ecdysone receptor (EcR) based system which, in the presence of one or more ligands, modulates the expression of a gene into which the response element and promoter are incorporated. Tightly regulated inducible gene expression systems or gene switches are useful for various applications such as gene therapy, large scale production of proteins in cells, cell based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals. Such inducible gene expression systems can include ligand inducible heterologous gene expression systems. 
     In some embodiments, the polynucleotide or an additional polynucleotide encodes polypeptides for a gene switch system for ligand-inducible control of heterologous gene expression, wherein the gene switch polypeptides include: (a) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain; and (b) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain; wherein the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. 
     In some embodiments, the gene switch system comprises: (a) a first gene switch polypeptide comprising a transactivation domain; (b) a second gene switch polypeptide comprising a DNA binding domain fused to a ligand binding domain; and (c) at least one heterologous polypeptide; wherein one of said first gene switch polypeptide, said second gene switch polypeptide and said heterologous polypeptide is connected by a linker to another one of said first gene switch polypeptide, said second gene switch polypeptide and said heterologous polypeptide, and wherein said polypeptide linker comprises a cleavable linker or ribosome skipping linker sequence. 
     The heterologous polypeptide may, for example, be a chimeric receptor (e.g., a CAR), a cell tag, or a cytokine as described herein. 
     In certain embodiments, the gene switch system is of the type described in WO 2018/132494. 
     In some embodiments, the DNA binding domain comprises at least one of GAL4 (GAL4 DBD), a LexA DBD, a transcription factor DBD, a steroid/thyroid hormone nuclear receptor superfamily member DBD, a bacterial LacZ DBD, and a yeast DBD. In other embodiments, the DNA binding domain comprises the amino acid sequence of SEQ ID NO: 638 or a functional fragment or variant thereof. In some embodiments, the transactivation domain comprises at least one of a VP16 transactivation domain and a B42 acidic activator transactivation domain. In other cases, the transactivation domain comprises an amino acid sequence as shown in SEQ ID NO: 632 or a functional fragment or variant thereof. In some embodiments, at least one of the first nuclear receptor ligand binding domain and the second nuclear receptor ligand binding domain comprises at least one of an ecdysone receptor (EcR), a ubiquitous receptor, an orphan receptor 1, a NER-1, a steroid hormone nuclear receptor 1, a retinoid X receptor interacting protein-15, a liver X receptor (3, a steroid hormone receptor like protein, a liver X receptor, a liver X receptor α, a farnesoid X receptor, a receptor interacting protein 14, and a farnesol receptor, or a functional fragment or variant thereof. In some embodiments, at least one of the first nuclear receptor ligand binding domain, the second nuclear receptor ligand binding domain, and the ligand binding domain is derived from the Ecdysone Receptor polypeptide sequence of SEQ ID NOs: 640 or 642 or a functional fragment or variant thereof. In some embodiments, the nuclear receptor ligand binding domain is a RxR domain of SEQ ID NO: 634 or a functional fragment or variant thereof. 
     In some embodiments, the polynucleotide encodes at least one of GAL4 (GAL4 DBD), a LexA DBD, a transcription factor DBD, a steroid/thyroid hormone nuclear receptor superfamily member DBD, a bacterial LacZ DBD, and a yeast DBD, or a functional fragment or variant thereof. In other embodiments, the DNA binding domain is encoded by a nucleotide sequence as shown in SEQ ID NO: 639 or a functional fragment or variant thereof. In some embodiments, the polynucleotide encodes at least one of a VP16 transactivation domain and a B42 acidic activator transactivation domain. In other cases, the transactivation domain is encoded by a nucleotide sequence as shown in SEQ ID NO: 633 or a functional fragment or variant thereof. In some embodiments, at least one of the first nuclear receptor ligand binding domain, the second nuclear receptor ligand binding domain, and the ligand binding domain is encoded by SEQ ID NO: 641 or 643 or a functional fragment or variant thereof. In some embodiments, at least one of the first nuclear receptor ligand binding domain, the second nuclear receptor ligand binding domain, and the ligand binding domain is encoded by SEQ ID NO: 635 or a functional fragment or variant thereof. 
     In yet another embodiment, the first gene switch polypeptide comprises a GAL4 DBD, or a functional fragment or variant thereof, fused to an EcR nuclear receptor ligand binding domain, or a functional fragment or variant thereof, and the second gene switch polypeptide comprises a VP16 transactivation domain, or a functional fragment or variant thereof, fused to a retinoid receptor X (RXR) nuclear receptor ligand binding domain, or a functional fragment or variant thereof. In some cases, the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker, which is selected from the group consisting of 2A, GSG-2A, GSG linker (SEQ ID NO: 531), SGSG linker (SEQ ID NO: 533), furinlink variants and derivatives thereof. 
     In some cases, at least one of the first nuclear receptor ligand binding domain and the second nuclear receptor ligand binding domain comprise any one of amino acid sequences as shown in SEQ ID NOs: 640 or 642 or a functional fragment or variant thereof. In some embodiments, the first gene switch polypeptide comprises a GAL4 DBD, or a functional fragment or variant thereof, fused to an EcR nuclear receptor ligand binding domain, or a functional fragment or variant thereof, and the second gene switch polypeptide comprises a VP16 transactivation domain, or a functional fragment or variant thereof, fused to a retinoid receptor X (RXR) nuclear receptor ligand binding domain, or a functional fragment or variant thereof. In some embodiments, the Gal4 DBD, or a functional fragment or variant thereof, fused to the EcR nuclear receptor ligand binding domain, or a functional fragment or variant thereof, comprises an amino acid sequence as shown in SEQ ID NOs: 644 or 646, or a functional fragment or variant thereof, and the VP16 transactivation domain, or a functional fragment or variant thereof, fused to the retinoid receptor X (RXR) nuclear receptor ligand binding domain, or a functional fragment or variant thereof, comprises an amino acid sequence as shown in SEQ ID NO: 636, or a functional fragment or variant thereof. 
     In some cases, at least one of the first nuclear receptor ligand binding domain and the second nuclear receptor ligand binding domain are encoded by the amino acid sequences as shown in SEQ ID NOs: 641 or 643, or a functional fragment or variant thereof. In some embodiments, the Gal4 DBD, or a functional fragment or variant thereof, fused to the EcR nuclear receptor ligand binding domain, or a functional fragment or variant thereof, is encoded by the nucleotide sequence as shown in SEQ ID NOs: 645 or 647, or a functional fragment or variant thereof, and the VP16 transactivation domain, or a functional fragment or variant thereof, fused to the retinoid receptor X (RXR) nuclear receptor ligand binding domain, or a functional fragment or variant thereof, is encoded by the nucleotide sequence of SEQ ID NO: 637, or a functional fragment or variant thereof. 
     In any of the foregoing gene switch embodiments, the linker can be a cleavable linker, a ribosome skipping linker sequence or an IRES linker. In some cases, the linker is an IRES linker and is encoded by a nucleic acid comprising the sequence of SEQ ID NOs: 702 or 703 or a functional fragment or variant thereof. In other cases, the linker is a cleavable linker or ribosome skipping linker sequence. In some embodiments, the cleavable linker or the ribosome skipping linker sequence comprises one or more of a 2A linker, p2A linker, T2A linker, F2A linker, E2A linker, GSG-2A linker, GSG linker, SGSG linker, furinlink linker variants and derivatives thereof. In other embodiments, the cleavable linker or said ribosome skipping linker sequence has a sequence as shown in any one of SEQ ID NOs: 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553, 555, 557 and 559 or is encoded by the sequence as shown in any one of SEQ ID NOs: 528, 530, 532, 534, 536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, and 560. 
     In any of the gene switch embodiments, expression of at least one of the first gene switch polypeptide, the second gene switch polypeptide, the antigen-binding polypeptide, and the heterologous polypeptide of any of the compositions as provided herein can be modulated by a promoter, where the promoter is a tissue-specific promoter or an EF1A promoter or functional fragment or variant thereof. In some cases, the promoter comprises the sequence of SEQ ID NOs: 58 and 59 of WO 2018/132494, or a functional fragment or variant thereof. In other cases, the promoter is a tissue-specific promoter comprising a T-cell-specific response element. In another case, the tissue-specific promoter comprises one or more NFAT response element(s). In yet another case, the NFAT response element has a sequence of any one of SEQ ID NOs: 51 to 57 of WO 2018/132494 or a functional fragment or variant thereof. 
     In an embodiment, expression of the at least one heterologous polypeptide is modified by an inducible promoter. In some embodiments, the inducible promoter has a sequence of any one of SEQ ID NOs: 40 to 64 of WO 2018/132494 or a functional fragment or variant thereof. In other embodiments, the inducible promoter is modulated by at least one of the first gene switch polypeptide and the second gene switch polypeptide. 
     It should be understood that any of the foregoing polynucleotides can be included in a vector as described herein. 
     Also provided herein is a method of regulating the expression of a heterologous gene in an effector cell, the method comprising: (a) introducing into the effector cell one or more polynucleotides encoding the polypeptides of the first and second gene switch polypeptides as described herein and the heterologous polypeptide; and (b) contacting the effector cell with a ligand in an amount sufficient to induce expression of the gene encoding the heterologous polypeptide. 
     In certain embodiments, the ligand in the method of regulating the expression of the heterologous gene in the effector cell as provided herein comprises at least one of: (2S,3R,5R,9R,10R,13R,14S,17R)-17-[(2S,3R)-3,6-dihydroxy-6-methylheptan-2-yl]-2,3,14-trihydroxy-10,13-dimethyl-2,3,4,5,9,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-6-one; N′-(3,5-Dimethylbenzoyl)-N′-[(3R)-2,2-dimethyl-3-hexanyl]-2-ethyl-3-methoxybenzohydrazide; 5-Methyl-2,3-dihydro-benzo[1,4] dioxine-6-carboxylic acid N′-(3,5-dimethyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide; 5-Methyl-2,3-dihydro-benzo [1,4] dioxine-6-carboxylic acid N′-(3,5-dimethoxy-4-methyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide; 5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethyl-benzoyl)-hydrazide; 5-Methyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(1-tert-butyl-butyl)-N′-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide; 5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethyl-benzoyl)-N′-(1-ethyl-2,2-dimethyl-propyl)-hydrazide; 5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N′-(3,5-dimethoxy-4-methyl-benzoyl)-N ‘-(1-ethyl-2,2-dimethyl-propyl)-hydrazide; 5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N’-(1-tert-butyl-butyl)-N ‘-(3,5-dimethyl-benzoyl)-hydrazide; 5-Ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid N’-(1-tert-butyl-butyl)-N ‘-(3,5-dimethoxy-4-methyl-benzoyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N’-(3-methoxy-2-methyl-benzoyl)-hydrazide; 3,5-Dimethoxy-4-methyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide; 3,5-Dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide; 3,5-Dimethoxy-4-methyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide; 3,5-Dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide; 2-Methoxy-nicotinic acid N-(1-tert-butyl-pentyl)-N′-(4-ethyl-benzoyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(2,2-dimethyl-1-phenyl-propyl)-N′-(4-ethyl-benzoyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-pentyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide; and 3,5-Dimethoxy-4-methyl-benzoic acid N-(1-tert-butyl-pentyl)-N′-(3-methoxy-2-methyl-benzoyl)-hydrazide. 
     In some cases, the expression of the gene encoding the polypeptide in the effector cell as provided herein is reduced or eliminated in the absence of the ligand, as compared to the expression in the presence of the ligand. In certain cases, the expression of said heterologous polypeptide is restored by providing additional amounts of the ligand. 
     In some embodiments, the one or more expression cassettes of the gene switch system further comprise one or more of the following: (a) one or more recombinase attachment sites; and (b) a sequence encoding a serine recombinase. In other embodiments, the one or more expression cassettes further comprise one or more of the following: (a) a non-inducible promoter; and (b) an inducible promoter. 
     In some embodiments, one of the first and second gene switch polypeptides can be connected to the heterologous polypeptide by a linker. 
     In some embodiments, the first and second gene switch polypeptides are connected by a polypeptide linker that is an IRES linker. 
     In some embodiments, the expression cassette can further comprise a second gene encoding a second heterologous polypeptide. 
     In some embodiments, the gene switch system as provided is for integrating a heterologous gene in a host cell, wherein upon contacting the host cell with the one or more expression cassettes in the presence of the serine recombinase and the one or more recombinase attachment sites, the heterologous gene is integrated in the host cell. In certain embodiments, the gene switch system further comprises a ligand, wherein the heterologous gene is expressed in the host cell upon contact of the host cell by the ligand. In certain embodiments, the one or more recombinase attachment sites can comprise a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB). In some cases, the serine recombinase can be SF370. 
     In some cases, the expression cassette has the sequence of any one of SEQ ID NOs: 131 to 126 of WO 2018/132494 or a functional fragment or variant thereof. 
     In certain embodiments, the inducible promoter of the gene switch system can be activated by the transactivation domain. It should be understood that the gene switch system can be included in a single vector or in multiple vectors. 
     An early version of EcR-based gene switch used  Drosophila melanogaster  EcR (DmEcR) and  Mus musculus  RXR (MmRXR) polypeptides and showed that these receptors in the presence of steroid, ponasteroneA, transactivate reporter genes in mammalian cell lines and transgenic mice (Christopherson et al., 1992; No et al., 1996). Later, Suhr et al., 1998 showed that non-steroidal ecdysone agonist, tebufenozide, induced high level of transactivation of reporter genes in mammalian cells through  Bombyx mori  EcR (BmEcR) in the absence of exogenous heterodimer partner. 
     International Patent Applications No. PCT/US97/05330 (WO 97/38117) and PCT/US99/08381 (WO99/58155) disclose methods for modulating the expression of an exogenous gene in which a DNA construct comprising the exogenous gene and an ecdysone response element is activated by a second DNA construct comprising an ecdysone receptor that, in the presence of a ligand therefor, and optionally in the presence of a receptor capable of acting as a silent partner, binds to the ecdysone response element to induce gene expression. In this example, the ecdysone receptor was isolated from  Drosophila melanogaster . Typically, such systems require the presence of the silent partner, preferably retinoid X receptor (RXR), in order to provide optimum activation. In mammalian cells, insect ecdysone receptor (EcR) is capable of heterodimerizing with mammalian retinoid X receptor (RXR) and, thereby, be used to regulate expression of target genes or heterologous genes in a ligand dependent manner. International Patent Application No. PCT/US98/14215 (WO 99/02683) discloses that the ecdysone receptor isolated from the silk moth  Bombyx mori  is functional in mammalian systems without the need for an exogenous dimer partner. 
     U.S. Pat. No. 6,265,173 discloses that various members of the steroid/thyroid superfamily of receptors can combine with  Drosophila melanogaster  ultraspiracle receptor (USP) or fragments thereof comprising at least the dimerization domain of USP for use in a gene expression system. U.S. Pat. No. 5,880,333 discloses a  Drosophila melanogaster  EcR and ultraspiracle (USP) heterodimer system used in plants in which the transactivation domain and the DNA binding domain are positioned on two different hybrid proteins. In each of these cases, the transactivation domain and the DNA binding domain (either as native EcR as in International Patent Application No. PCT/US98/14215 or as modified EcR as in International Patent Application No. PCT/US97/05330) were incorporated into a single molecule and the other heterodimeric partners, either USP or RXR, were used in their native state. 
     International Patent Application No. PCT/US01/0905 discloses an ecdysone receptor-based inducible gene expression system in which the transactivation and DNA binding domains are separated from each other by placing them on two different proteins results in greatly reduced background activity in the absence of a ligand and significantly increased activity over background in the presence of a ligand. This two-hybrid system is a significantly improved inducible gene expression modulation system compared to the two systems disclosed in applications PCT/US97/05330 and PCT/US98/14215. The two-hybrid system is believed to exploit the ability of a pair of interacting proteins to bring the transcription activation domain into a more favorable position relative to the DNA binding domain such that when the DNA binding domain binds to the DNA binding site on the gene, the transactivation domain more effectively activates the promoter (see, for example, U.S. Pat. No. 5,283,173). The two-hybrid gene expression system comprises two gene expression cassettes; the first encoding a DNA binding domain fused to a nuclear receptor polypeptide, and the second encoding a transactivation domain fused to a different nuclear receptor polypeptide. In the presence of ligand, it is believed that a conformational change is induced which promotes interaction of the antibody with the TGF-β cytokine trap, thereby resulting in dimerization of the DNA binding domain and the transactivation domain. Since the DNA binding and transactivation domains reside on two different molecules, the background activity in the absence of ligand is greatly reduced. 
     Certain modifications of the two-hybrid system could also provide improved sensitivity to non-steroidal ligands for example, diacylhydrazines, when compared to steroidal ligands for example, ponasterone A (“PonA”) or muristerone A (“MurA”). That is, when compared to steroids, the non-steroidal ligands provided higher gene transcription activity at a lower ligand concentration. Furthermore, the two-hybrid system avoids some side effects due to overexpression of RXR that can occur when unmodified RXR is used as a switching partner. In a preferred two-hybrid system, native DNA binding and transactivation domains of EcR or RXR are eliminated and as a result, these hybrid molecules have less chance of interacting with other steroid hormone receptors present in the cell, thereby resulting in reduced side effects. 
     The ecdysone receptor (EcR) is a member of the nuclear receptor superfamily and is classified into subfamily 1, group H (referred to herein as “Group H nuclear receptors”). The members of each group share 40-60% amino acid identity in the E (ligand binding) domain (Laudet et al., A Unified Nomenclature System for the Nuclear Receptor Subfamily, 1999; Cell 97: 161-163). In addition to the ecdysone receptor, other members of this nuclear receptor subfamily 1, group H include: ubiquitous receptor (UR), Orphan receptor 1 (OR-1), steroid hormone nuclear receptor 1 (NER-1), RXR interacting protein-15 (RIP-15), liver x receptor β (LXRβ), steroid hormone receptor like protein (RLD-1), liver x receptor (LXR), liver x receptor α (LXRα), farnesoid x receptor (FXR), receptor interacting protein 14 (RIP-14), and farnesol receptor (HRR-1). 
     In some cases, an inducible promoter (“IP”) can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as Intrexon Corporation&#39;s RHEOSWITCH® gene switch. In some cases, a gene switch can be selected from ecdysone-based receptor components as described in, but without limitation to, any of the systems described in: PCT/US2001/009050 (WO 2001/070816); U.S. Pat. Nos. 7,091,038; 7,776,587; 7,807,417; 8,202,718; PCT/US2001/030608 (WO 2002/029075); U.S. Pat. Nos. 8,105,825; 8,168,426; PCT/US52002/005235 (WO 2002/066613); U.S. application Ser. No. 10/468,200 (U.S. Pub. No. 20120167239); PCT/US2002/005706 (WO 2002/066614); U.S. Pat. Nos. 7,531,326; 8,236,556; 8,598,409; PCT/US2002/005090 (WO 2002/066612); U.S. Pat. No. 8,715,959 (U.S. Pub. No. 20060100416); PCT/US2002/005234 (WO 2003/027266); U.S. Pat. Nos. 7,601,508; 7,829,676; 7,919,269; 8,030,067; PCT/US2002/005708 (WO 2002/066615); U.S. application Ser. No. 10/468,192 (U.S. Pub. No. 20110212528); PCT/US2002/005026 (WO 2003/027289); U.S. Pat. Nos. 7,563,879; 8,021,878; 8,497,093; PCT/US2005/015089 (WO 2005/108617); U.S. Pat. Nos. 7,935,510; 8,076,454; PCT/US2008/011270 (WO 2009/045370); U.S. application Ser. No. 12/241,018 (U.S. Pub. No. 20090136465); PCT/US2008/011563 (WO 2009/048560); U.S. application Ser. No. 12/247,738 (U.S. Pub. No. 20090123441); PCT/US2009/005510 (WO 2010/042189); U.S. application Ser. No. 13/123,129 (U.S. Pub. No. 20110268766); PCT/US2011/029682 (WO 2011/119773); U.S. application Ser. No. 13/636,473 (U.S. Pub. No. 20130195800); PCT/US2012/027515 (WO 2012/122025); WO 2018/132494 (PCT/US2018/013196); and, U.S. Pat. No. 9,402,919. 
     As used herein, the term “ligand,” as applied to ligand-activated ecdysone receptor-based gene switches are small molecules of varying solubility (such as diacylhydrazine compounds) having the capability of activating a gene switch to stimulate gene expression (i.e., therein providing ligand inducible expression of polynucleotides (e.g., mRNAs, miRNAs, etc) and/or polypeptides). Examples of such ligands include, but are not limited to those described in: WO 2004/072254 (PCT/US2004/003775); WO 2004/005478 (PCT/US2003/021149); WO 2005/017126 (PCT/US2004/005149); WO 2004/078924 (PCT/US2004/005912); WO 2008/153801 (PCT/US2008/006757); WO 2009/114201 (PCT/US2009/001639); WO 2013/036758 (PCT/US2012/054141); WO 2014/144380 (PCT/US2014/028768); and, WO 2016/044390 (PCT/US2015/050375). 
     Examples of ligands also include, without limitation, an ecdysteroid, such as ecdysone, 20-hydroxyecdysone, ponasterone A, muristerone A, and the like, 9-cis-retinoic acid, synthetic analogs of retinoic acid, N, N′-diacylhydrazines such as those disclosed in U.S. Pat. Nos. 6,258,603; 6,013,836; 5,117,057; 5,530,028; 5,378,726; 7,304,161; 7,851,220; 8,748,125; 9,272,986; 7,456,315; 7,563,928; 8,524,948; 9,102,648; 9,169,210; 9,255,273; and, 9,359,289; oxadiazolines as described in U.S. Pat. Nos. 8,669,072; and, 8,895,306; dibenzoylalkyl cyanohydrazines such as those disclosed in European Application No. 2,461,809; N-alkyl-N,N′-diaroylhydrazines such as those disclosed in U.S. Pat. No. 5,225,443; N-acyl-N-alkylcarbonylhydrazines such as those disclosed in European Application No. 234,994; N-aroyl-N-alkyl-N′-aroylhydrazines such as those described in U.S. Pat. No. 4,985,461; amidoketones such as those described in U.S. Pat. Nos. 7,375,093; 8,129,355; and, 9,802,936; and other similar materials including 3,5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide, 8-O-acetylharpagide, oxysterols, 22(R) hydroxycholesterol, 24(S) hydroxycholesterol, 25-epoxycholesterol, T0901317, 5-alpha-6-alpha-epoxycholesterol-3-sulfate (ECHS), 7-ketocholesterol-3-sulfate, famesol, bile acids, 1,1-biphosphonate esters, juvenile hormone III, and the like. Examples of diacylhydrazine ligands useful in the present invention include RG-115819 (3,5-Dimethyl-benzoic acid N-(1-ethyl-2,2-dimethyl-propyl)-N′-(2-methyl-3-methoxybenzoyl)-hydrazide), RG-115932 ((R)-3,5-Dimethyl-benzoic acid N-(1-tert-butyl-butyl)N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide), and RG-115830 (3,5-Dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide). See, e.g., WO 2008/153801 (PCT/US2008/006757); and, WO 2013/036758 (PCT/US2012/054141). 
     For example, a ligand for the ecdysone receptor-based gene switch may be selected from any suitable ligands. Both naturally occurring ecdysone or ecdysone analogs (e.g., 20-hydroxyecdysone, muristerone A, ponasterone A, ponasterone B, ponasterone C, 26-iodoponasterone A, inokosterone or 26-mesylinokosterone) and non-steroid inducers may be used as a ligand for gene switch of the present invention. U.S. Pat. No. 6,379,945, describes an insect steroid receptor isolated from  Heliothis virescens  (“HEcR”) which is capable of acting as a gene switch responsive to both steroid and certain non-steroidal inducers. Non-steroidal inducers have a distinct advantage over steroids, in this and many other systems which are responsive to both steroids and non-steroid inducers, for several reasons including, for example: lower manufacturing cost, metabolic stability, absence from insects, plants, or mammals, and environmental acceptability. U.S. Pat. No. 6,379,945 describes the utility of two dibenzoylhydrazines, 1,2-dibenzoyl-1-tert-butyl-hydrazine and tebufenozide (N-(4-ethylbenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-tert-butyl-hydrazine) as ligands for an ecdysone-based gene switch. Also included in the present invention as a ligand are other dibenzoylhydrazines, such as those disclosed in U.S. Pat. No. 5,117,057. Use of tebufenozide as a chemical ligand for the ecdysone receptor from  Drosophila melanogaster  is also disclosed in U.S. Pat. No. 6,147,282. Additional, non-limiting examples of ecdysone ligands are 3,5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide, 8-O-acetylharpagide, a 1,2-diacyl hydrazine, an N′-substituted-N,N′-disubstituted hydrazine, a dibenzoylalkyl cyanohydrazine, an N-substituted-N-alkyl-N,N-diaroyl hydrazine, an N-substituted-N-acyl-N-alkyl, carbonyl hydrazine or an N-aroyl-N′-alkylN′-aroyl hydrazine. (See U.S. Pat. No. 6,723,531). 
     In one embodiment, the ligand for an ecdysone-based gene switch system is a diacylhydrazine ligand or chiral diacylhydrazine ligand. The ligand used in the gene switch system may be compounds of Formula I 
     
       
         
         
             
             
         
       
     
     wherein A is alkoxy, arylalkyloxy or aryloxy; B is optionally substituted aryl or optionally substituted heteroaryl; and R1 and R2 are independently optionally substituted alkyl, arylalkyl, hydroxyalkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclo, optionally substituted aryl or optionally substituted heteroaryl; or pharmaceutically acceptable salts, hydrates, crystalline forms or amorphous forms thereof. 
     In another embodiment, the ligand may be enantiomerically enriched compounds of Formula II 
     
       
         
         
             
             
         
       
     
     wherein A is alkoxy, arylalkyloxy, aryloxy, arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; B is optionally substituted aryl or optionally substituted heteroaryl; and R1 and R2 are independently optionally substituted alkyl, arylalkyl, hydroxyalkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclo, optionally substituted aryl or optionally substituted heteroaryl; with the proviso that R1 does not equal R2; wherein the absolute configuration at the asymmetric carbon atom bearing R1 and R2 is predominantly S; or pharmaceutically acceptable salts, hydrates, crystalline forms or amorphous forms thereof. 
     In certain embodiments, the ligand may be enantiomerically enriched compounds of Formula III 
     
       
         
         
             
             
         
       
     
     wherein A is alkoxy, arylalkyloxy, aryloxy, arylalkyl, optionally substituted aryl or optionally substituted heteroaryl; B is optionally substituted aryl or optionally substituted heteroaryl; and R1 and R2 are independently optionally substituted alkyl, arylalkyl, hydroxyalkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclo, optionally substituted aryl or optionally substituted heteroaryl; with the proviso that R1 does not equal R2; wherein the absolute configuration at the asymmetric carbon atom bearing R1 and R2 is predominantly R; or pharmaceutically acceptable salts, hydrates, crystalline forms or amorphous forms thereof. 
     In one embodiment, a ligand may be (R)-3,5-dimethyl-benzoic acid N-(1-tertbutyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide having an enantiomeric excess of at least 95% or a pharmaceutically acceptable salt, hydrate, crystalline form or amorphous form thereof. 
     The diacylhydrazine ligands of Formula I and chiral diacylhydrazine ligands of Formula II or III, when used with an ecdysone-based gene switch system, provide the means for external temporal regulation of expression of a therapeutic polypeptide or therapeutic polynucleotide of the present invention. See U.S. Pat. Nos. 8,076,517; 8,884,060; and, 9,598,355. 
     The ligands used in the present invention may form salts. The term “salt(s)” as used herein denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, when a compound of Formula I, II or III contains both a basic moiety and an acidic moiety, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are used, although other salts are also useful, e.g., in isolation or purification steps which may be employed during preparation. Salts of the compounds of Formula I, II or III may be formed, for example, by reacting a compound with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. 
     The ligands which contain a basic moiety may form salts with a variety of organic and inorganic acids. Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates (formed with maleic acid), methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like. 
     The ligands which contain an acidic moiety may form salts with a variety of organic and inorganic bases. Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydrabamines (formed with N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glucamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. 
     Non-limiting examples of the ligands for the inducible gene expression system also includes those utilizing the FK506 binding domain are FK506, Cyclosporin A, or Rapamycin. FK506, rapamycin, and their analogs are disclosed in U.S. Pat. Nos. 6,649,595; 6,187,757; 7,276,498; and, 7,273,874. 
     In some embodiments, a diacylhydrazine ligand for inducible gene expression is administered at unit daily dose of about 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100 or 120 mg. In some embodiments, the diacylhydrazine ligand is administered at a unit daily dose of about 5 mg. In some embodiments, the diacylhydrazine ligand is administered at a unit daily dose of about 10 mg. In some embodiments, the diacylhydrazine ligand is administered at a unit daily dose of about 15 mg. In some embodiments, the diacylhydrazine ligand is administered daily at a unit daily dose of about 20 mg. 
     In some embodiments, the cytokine, cell tag and/or CAR can be under the control of an inducible promoter for gene transcription. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as RHEOSWITCH® gene switch. In some cases, the gene switch system used may be the one described in WO 2018/132494. 
     In some embodiments, the cytokines described above can be under the control of an inducible promoter for gene transcription. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as RHEOSWITCH® gene switch. In some cases, the gene switch system used may be the one described in WO 2018/132494. 
     In some embodiments, the modified immune effector cells as described herein can be under the control of an inducible promoter for gene transcription. In one aspect, the inducible promoter can be a gene switch ligand inducible promoter. In some cases, an inducible promoter can be a small molecule ligand-inducible two polypeptide ecdysone receptor-based gene switch, such as RHEOSWITCH® gene switch as described in WO2018/132494. 
     XII. Modified Immune Effector Cells 
     Provided herein are modified immune effector cells expressing one or more miRNAs, CARs, cytokines, and/or cell tags as described herein. In some embodiments, modified immune effector cells are modified T cells and/or natural killer (NK) cells. T cells or T lymphocytes are a subtype of white blood cells that are involved in cell-mediated immunity. Exemplary T cells include T helper cells, cytotoxic T cells, TH17 cells, stem memory T cells (TSCM), naïve T cells, memory T cells, effector T cells, regulatory T cells, or natural killer T cells. In certain aspects, the embodiments described herein include making and/or expanding the modified immune effector cells (e.g., T-cells, Tregs, NK-cell or NK T-cells). Such may be accomplished by transfecting the cells with an expression vector containing a DNA (or RNA) construct encoding the one or more miRNAs, CARs, cytokines, and/or cell tags as described herein. It should be understood that the cells of the present disclosure can be human or animal cells. 
     T helper cells (TH cells) assist other white blood cells in immunologic processes, including maturation of B cells into plasma cells and memory B cells, and activation of cytotoxic T cells and macrophages. In some instances, TH cells are known as CD4+ T cells due to expression of the CD4 glycoprotein on the cell surfaces. T helper cells become activated when they are presented with peptide antigens by MHC class II molecules, which are expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in the active immune response. These cells can differentiate into one of several subtypes, including TH1, TH2, TH3, TH17, Th9, or TFH, which secrete different cytokines to facilitate different types of immune responses. Signaling from the APC directs T cells into particular subtypes. 
     Cytotoxic T cells (TC cells or CTLs) destroy virus-infected cells and tumor cells, and are also implicated in transplant rejection. These cells are also known as CD8+ T cells since they express the CD8 glycoprotein on their surfaces. These cells recognize their targets by binding to antigen associated with MHC class I molecules, which are present on the surface of all nucleated cells. Through IL-10, adenosine, and other molecules secreted by regulatory T cells, the CD8+ cells can be inactivated to an anergic state, which prevents autoimmune diseases. 
     Memory T cells are a subset of antigen-specific T cells that persist long-term after an infection has resolved. They quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen, thus providing the immune system with “memory” against past infections. Memory T cells comprise subtypes: stem memory T cells (TSCM), central memory T cells (TCM cells) and two types of effector memory T cells (TEM cells and TEMRA cells). Memory cells can be either CD4+ or CD8+. Memory T cells can express the cell surface proteins CD45RO, CD45RA and/or CCR7. 
     Regulatory T cells (Treg cells), formerly known as suppressor T cells, play a role in the maintenance of immunological tolerance. Their major role is to shut down T cell-mediated immunity toward the end of an immune reaction and to suppress autoreactive T cells that escaped the process of negative selection in the thymus. 
     Natural killer T cells (NKT cells) bridge the adaptive immune system with the innate immune system. Unlike conventional T cells that recognize peptide antigens presented by major histocompatibility complex (MHC) molecules, NKT cells recognize glycolipid antigen presented by a molecule called CD1d. Once activated, these cells can perform functions ascribed to both Th and Tc cells (i.e., cytokine production and release of cytolytic/cell killing molecules). They are also able to recognize and eliminate some tumor cells and cells infected with herpes viruses. 
     Natural killer (NK) cells are a type of cytotoxic lymphocyte of the innate immune system. In some instances, NK cells provide a first line defense against viral infections and/or tumor formation. NK cells can detect MHC presented on infected or cancerous cells, triggering cytokine release, and subsequently induce lysis and apoptosis. NK cells can further detect stressed cells in the absence of antibodies and/or MHC, thereby allowing a rapid immune response. 
     A. Immune Effector Cell Sources 
     In certain aspects, the embodiments described herein include methods of making and/or expanding the modified (antigen-specific redirected) immune effector cells (e.g., T-cells, Tregs, NK-cell or NK T-cells) that comprise transfecting the cells with an expression vector containing a DNA (or RNA) construct encoding the CAR, then, optionally, stimulating the cells with feeder cells, recombinant antigen, or an antibody to the receptor to cause the cells to proliferate. In certain aspects, the cell (or cell population) engineered to express a CAR is a stem cell, CD34+ cord blood cells, iPS cell, T cell differentiated from iPS cell, immune effector cell or a precursor of these cells. 
     Sources of immune effector cells can include both allogeneic and autologous sources. In some cases immune effector cells can be differentiated from stem cells or induced pluripotent stem cells (iPSCs). Thus, cells for engineering according to the embodiments can be isolated from umbilical cord blood, peripheral blood, human embryonic stem cells, or iPSCs. For example, allogeneic T cells can be modified to include a chimeric antigen receptor (and optionally, to lack functional TCR). In some aspects, the immune effector cells are primary human T cells such as T cells derived from human peripheral blood mononuclear cells (PBMC). PBMCs can be collected from the peripheral blood or after stimulation with G-CSF (Granulocyte colony stimulating factor) from the bone marrow, or umbilical cord blood. In one aspect, the immune effector cells are Pan T cells. Following transfection or transduction (e.g., with a CAR expression construct), the cells can be immediately infused or can be cryo-preserved. In certain aspects, following transfection or transduction, the cells can be preserved in a cytokine bath that can include IL-2 and/or IL-21 until ready for infusion. In certain aspects, following transfection, the cells can be propagated for days, weeks, or months ex vivo as a bulk population within about 1, 2, 3, 4, 5 days or more following gene transfer into cells. In a further aspect, following transfection, the transfectants are cloned and a clone demonstrating presence of a single integrated or episomally maintained expression cassette or plasmid, and expression of the chimeric antigen receptor is expanded ex vivo. The clone selected for expansion demonstrates the capacity to specifically recognize and lyse antigen-expressing target cells. The recombinant T cells can be expanded by stimulation with IL-2, or other cytokines that bind the common gamma-chain (e.g., IL-7, IL-12, IL-15, IL-21, and others). The recombinant T cells can be expanded by stimulation with artificial antigen presenting cells. The recombinant T cells can be expanded on artificial antigen presenting cell or with an antibody, such as OKT3, which cross links CD3 on the T cell surface. Subsets of the recombinant T cells can be further selected with the use of magnetic bead based isolation methods and/or fluorescence activated cell sorting technology and further cultured with the AaPCs. In a further aspect, the genetically modified cells can be cryopreserved. In some embodiments, the genetically modified cells are not cryopreserved. 
     T cells can also be obtained from a number of sources, including bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments of the present invention, any number of T cell lines available in the art, can be used. In certain embodiments of the present invention, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll® separation. In some embodiments, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, the cells collected by apheresis can be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment of the invention, the cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, the wash solution lacks calcium and can lack magnesium or can lack many if not all divalent cations. Initial activation steps in the absence of calcium lead to magnified activation. As those of ordinary skill in the art would readily appreciate a washing step can be accomplished by methods known to those in the art, such as by using a semi-automated “flow-through” centrifuge (for example, the Cobe 2991 cell processor, the Baxter CytoMate, or the Haemonetics Cell Saver 5) according to the manufacturer+s instructions. After washing, the cells can be resuspended in a variety of biocompatible buffers, such as, for example, Ca 2+ -free, Mg 2+ -free PBS, PlasmaLyte A, or other saline solution with or without buffer. Alternatively, the undesirable components of the apheresis sample can be removed and the cells directly resuspended in culture media. 
     In another embodiment, T cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL® gradient or by counterflow centrifugal elutriation. A specific subpopulation of T cells, such as CD 3+ , CD 28+ , CD 4+ , CD 8+ , CD45RA + , and CD45RO +  T cells, can be further isolated by positive or negative selection techniques. In another embodiment, CD14+ cells are depleted from the T-cell population. For example, in one embodiment, T cells are isolated by incubation with anti-CD3/anti-CD28 (i.e., 3×28)-conjugated beads, such as DYNABEADS® M-450 CD3/CD28 T, for a time period sufficient for positive selection of the desired T cells. In one embodiment, the time period is about 30 minutes. In a further embodiment, the time period ranges from 30 minutes to 36 hours or longer and all integer values there between. In a further embodiment, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another embodiment, the time period is 10 to 24 hours. In one embodiment, the incubation time period is 24 hours. For isolation of T cells from patients with leukemia, use of longer incubation times, such as 24 hours, can increase cell yield. Longer incubation times can be used to isolate T cells in any situation where there are few T cells as compared to other cell types, such in isolating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immune-compromised individuals. Further, use of longer incubation times can increase the efficiency of capture of CD8+ T cells. Thus, by simply shortening or lengthening the time T cells are allowed to bind to the CD3/CD28 beads and/or by increasing or decreasing the ratio of beads to T cells (as described further herein), subpopulations of T cells can be preferentially selected for or against at culture initiation or at other time points during the process. Additionally, by increasing or decreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on the beads or other surface, subpopulations of T cells can be preferentially selected for or against at culture initiation or at other desired time points. The skilled artisan would recognize that multiple rounds of selection can also be used in the context of this invention. In certain embodiments, it can be desirable to perform the selection procedure and use the “unselected” cells in the activation and expansion process. “Unselected” cells can also be subjected to further rounds of selection. 
     Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, it can be desirable to enrich for or positively select for regulatory T cells which typically express CD4 + , CD25 + , CD62L hi , GITR + , and FoxP3 + . Alternatively, in certain embodiments, T regulatory cells are depleted by anti-CD25 conjugated beads or other similar method of selection. 
     For isolation of a desired population of cells by positive or negative selection, the concentration of cells and surface (e.g., particles such as beads) can be varied. In certain embodiments, it can be desirable to significantly decrease the volume in which beads and cells are mixed together (i.e., increase the concentration of cells), to ensure maximum contact of cells and beads. For example, in one embodiment, a concentration of 2 billion cells/ml is used. In one embodiment, a concentration of 1 billion cells/ml is used. In a further embodiment, greater than 100 million cells/ml is used. In a further embodiment, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet another embodiment, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further embodiments, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that can weakly express target antigens of interest, such as CD28-negative T cells, or from samples where there are many tumor cells present (i.e., leukemic blood, tumor tissue, etc.). Such populations of cells can have therapeutic value and would be desirable to obtain. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression. 
     In a related embodiment, it can be desirable to use lower concentrations of cells. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), interactions between the particles and cells is minimized. This selects for cells that express high amounts of desired antigens to be bound to the particles. For example, CD4+ T cells express higher levels of CD28 and are more efficiently captured than CD8+ T cells in dilute concentrations. In one embodiment, the concentration of cells used is 5×10 6 /ml. In other embodiments, the concentration used can be from about 1×10 5 /ml to 1×10 6 /ml, and any integer value in between. 
     In other embodiments, the cells can be incubated on a rotator for varying lengths of time at varying speeds at either 2-10° C. or at room temperature. 
     T cells for stimulation can also be frozen after a washing step. After the washing step that removes plasma and platelets, the cells can be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and will be useful in this context, one method involves using PBS containing 20% DMSO and 8% human serum albumin, or culture media containing 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or 31.25% Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitable cell freezing media containing for example, Hespan and PlasmaLyte A, the cells then are frozen to −80° C. at a rate of 1° C. per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing can be used as well as uncontrolled freezing immediately at −20° C. or in liquid nitrogen. In certain embodiments, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation using the methods of the present invention. 
     Also provided in certain embodiments is the collection of blood samples or apheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as T cells, isolated and frozen for later use in T cell therapy for any number of diseases or conditions that would benefit from T cell therapy, such as those described herein. In one embodiment a blood sample or an apheresis is taken from a generally healthy subject. In certain embodiments, a blood sample or an apheresis is taken from a generally healthy subject who is at risk of developing a disease, but who has not yet developed a disease, and the cells of interest are isolated and frozen for later use. In certain embodiments, the T cells can be expanded, frozen, and used at a later time. In certain embodiments, samples are collected from a patient shortly after diagnosis of a particular disease as described herein but prior to any treatments. In a further embodiment, the cells are isolated from a blood sample or an apheresis from a subject prior to any number of relevant treatment modalities, including but not limited to treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation. These drugs inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin) (Liu et al.,  Cell  66:807-815, (1991); Henderson et al.,  Immun  73:316-321, (1991); Bierer et al.,  Curr. Opin. Immun  5:763-773, (1993)). In a further embodiment, the cells are isolated for a patient and frozen for later use in conjunction with (e.g., before, simultaneously or following) bone marrow or stem cell transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cells are isolated prior to and can be frozen for later use for treatment following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. 
     In a further embodiment of the present invention, T cells are obtained from a patient directly following treatment. In this regard, it has been observed that following certain cancer treatments, in particular treatments with drugs that damage the immune system, shortly after treatment during the period when patients would normally be recovering from the treatment, the quality of T cells obtained can be optimal or improved for their ability to expand ex vivo. Likewise, following ex vivo manipulation using the methods described herein, these cells can be in a preferred state for enhanced engraftment and in vivo expansion. Thus, it is contemplated within the context of the present invention to collect blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery phase. Further, in certain embodiments, mobilization (for example, mobilization with GM-CSF) and conditioning regimens can be used to create a condition in a subject wherein repopulation, recirculation, regeneration, and/or expansion of particular cell types is favored, especially during a defined window of time following therapy. Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system. 
     B. Activation and Expansion of Immune Effector Cells 
     Whether prior to or after engineering of the immune effector cells to express a CAR described herein, the cells can be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. 
     Generally, the immune effector cells described herein are expanded by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the cells. In particular, cell populations can be stimulated as described herein, such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. To stimulate proliferation of either CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28 antibody. Examples of an anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diaclone, Besancon, France) can be used as can other methods commonly known in the art (Berg et al., Transplant Proc. 30(8):3975-3977, (1998); Haanen et al.,  J. Exp. Med.  190(9):13191328, (1999); Garland et al.,  J. Immunol Meth.  227(1-2):53-63, (1999)). 
     In certain embodiments, the primary stimulatory signal and the co-stimulatory signal for the immune effector cell can be provided by different protocols. For example, the agents providing each signal can be in solution or coupled to a surface. When coupled to a surface, the agents can be coupled to the same surface (i.e., in “cis” formation) or to separate surfaces (i.e., in “trans” formation). Alternatively, one agent can be coupled to a surface and the other agent in solution. In one embodiment, the agent providing the co-stimulatory signal is bound to a cell surface and the agent providing the primary activation signal is in solution or coupled to a surface. In certain embodiments, both agents can be in solution. In another embodiment, the agents can be in soluble form, and then cross-linked to a surface, such as a cell expressing Fc receptors or an antibody or other binding agent which will bind to the agents. In this regard, see for example, U.S. Patent Application Publication Nos. 20040101519 and 20060034810 for artificial antigen presenting cells (aAPCs) that are contemplated for use in activating and expanding T cells in the present invention. 
     In one embodiment, the two agents are immobilized on beads, either on the same bead, i.e., “cis,” or to separate beads, i.e., “trans.” By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof and the agent providing the co-stimulatory signal is an anti-CD28 antibody or antigen-binding fragment thereof; and both agents are co-immobilized to the same bead in equivalent molecular amounts. In one embodiment, a 1:1 ratio of each antibody bound to the beads for CD4 +  T cell expansion and T cell growth is used. In certain aspects of the present invention, a ratio of anti CD3:CD28 antibodies bound to the beads is used such that an increase in T cell expansion is observed as compared to the expansion observed using a ratio of 1:1. In one particular embodiment an increase of from about 1 to about 3 fold is observed as compared to the expansion observed using a ratio of 1:1. In one embodiment, the ratio of CD3:CD28 antibody bound to the beads ranges from 100:1 to 1:100 and all integer values there between. In one aspect of the present invention, more anti-CD28 antibody is bound to the particles than anti-CD3 antibody, i.e., the ratio of CD3:CD28 is less than one. In certain embodiments of the invention, the ratio of anti CD28 antibody to anti CD3 antibody bound to the beads is greater than 2:1. In one particular embodiment, a 1:100 CD3:CD28 ratio of antibody bound to beads is used. In another embodiment, a 1:75 CD3:CD28 ratio of antibody bound to beads is used. In a further embodiment, a 1:50 CD3:CD28 ratio of antibody bound to beads is used. In another embodiment, a 1:30 CD3:CD28 ratio of antibody bound to beads is used. In some embodiments, a 1:10 CD3:CD28 ratio of antibody bound to beads is used. In another embodiment, a 1:3 CD3:CD28 ratio of antibody bound to the beads is used. In yet another embodiment, a 3:1 CD3:CD28 ratio of antibody bound to the beads is used. 
     Ratios of particles to cells from 1:500 to 500:1 and any integer values in between can be used to stimulate T cells or other target cells. As those of ordinary skill in the art can readily appreciate, the ratio of particles to cells can depend on particle size relative to the target cell. For example, small sized beads could only bind a few cells, while larger beads could bind many. In certain embodiments the ratio of cells to particles ranges from 1:100 to 100:1 and any integer values in-between and in further embodiments the ratio comprises 1:9 to 9:1 and any integer values in between, can also be used to stimulate T cells. The ratio of anti-CD3- and anti-CD28-coupled particles to T cells that result in T cell stimulation can vary as noted above, however certain values include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, and 15:1 with one ratio being at least 1:1 particles per T cell. In one embodiment, a ratio of particles to cells of 1:1 or less is used. In one particular embodiment, the particle:cell ratio is 1:5. In further embodiments, the ratio of particles to cells can be varied depending on the day of stimulation. For example, in one embodiment, the ratio of particles to cells is from 1:1 to 10:1 on the first day and additional particles are added to the cells every day or every other day thereafter for up to 10 days, at final ratios of from 1:1 to 1:10 (based on cell counts on the day of addition). In one particular embodiment, the ratio of particles to cells is 1:1 on the first day of stimulation and adjusted to 1:5 on the third and fifth days of stimulation. In another embodiment, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:5 on the third and fifth days of stimulation. In another embodiment, the ratio of particles to cells is 2:1 on the first day of stimulation and adjusted to 1:10 on the third and fifth days of stimulation. In another embodiment, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:10 on the third and fifth days of stimulation. One of skill in the art will appreciate that a variety of other ratios can be suitable for use in the present invention. In particular, ratios will vary depending on particle size and on cell size and type. 
     In further embodiments described herein, the immune effector cells, such as T cells, are combined with agent-coated beads, the beads and the cells are subsequently separated, and then the cells are cultured. In an alternative embodiment, prior to culture, the agent-coated beads and cells are not separated but are cultured together. In a further embodiment, the beads and cells are first concentrated by application of a force, such as a magnetic force, resulting in increased ligation of cell surface markers, thereby inducing cell stimulation. 
     By way of example, cell surface proteins can be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3×28 beads) to contact the T cells. In one embodiment the cells (for example, 10 4  to 10 9  T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1, or MACS® MicroBeads from Miltenyi Biotec) are combined in a buffer, for example, PBS (without divalent cations such as, calcium and magnesium). Again, those of ordinary skill in the art can readily appreciate any cell concentration can be used. For example, the target cell can be very rare in the sample and comprise only 0.01% of the sample or the entire sample (i.e., 100%) can comprise the target cell of interest. Accordingly, any cell number is within the context of the present invention. In certain embodiments, it can be desirable to significantly decrease the volume in which particles and cells are mixed together (i.e., increase the concentration of cells), to ensure maximum contact of cells and particles. For example, in one embodiment, a concentration of about 2 billion cells/ml is used. In another embodiment, greater than 100 million cells/ml is used. In a further embodiment, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet another embodiment, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further embodiments, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that can weakly express target antigens of interest, such as CD28-negative T cells. Such populations of cells can have therapeutic value and would be desirable to obtain in certain embodiments. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression. 
     In one embodiment described herein, the mixture can be cultured for several hours (about 3 hours) to about 14 days or any hourly integer value in between. In another embodiment, the mixture can be cultured for 21 days. In one embodiment of the invention the beads and the T cells are cultured together for about eight days. In another embodiment, the beads and T cells are cultured together for 2-3 days. Several cycles of stimulation may also be desired such that culture time of T cells can be 60 days or more. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) that can contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-.gamma., IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFbeta, and TNF-alpha or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, AIM-V, DMEM, MEM, alpha-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% CO 2 ). 
     Ex vivo procedures are well known and are discussed more fully below. Briefly, cells are isolated from a mammal (for example, a human) and genetically modified (i.e., transduced or transfected in vitro) with a vector expressing a CAR disclosed herein. The CAR-modified cell can be administered to a mammalian recipient to provide a therapeutic benefit. The mammalian recipient can be a human and the CAR-modified cell can be autologous with respect to the recipient. Alternatively, the cells can be allogeneic, syngeneic or xenogeneic with respect to the recipient. 
     The procedure for ex vivo expansion of hematopoietic stem and progenitor cells is described in U.S. Pat. No. 5,199,942, can be applied to the cells of the present invention. Other suitable methods are known in the art, therefore the present invention is not limited to any particular method of ex vivo expansion of the cells. Briefly, ex vivo culture and expansion of effector cells comprises: (1) collecting CD34+ hematopoietic stem and progenitor cells from a mammal from peripheral blood harvest or bone marrow explants; and (2) expanding such cells ex vivo. In addition to the cellular growth factors described in U.S. Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3 and c-kit ligand, can be used for culturing and expansion of the cells. 
     Effector cells that have been exposed to varied stimulation times can exhibit different characteristics. For example, typical blood or apheresed peripheral blood mononuclear cell products have a helper T cell population (T H , CD4±) that is greater than the cytotoxic or suppressor T cell population (Tc, CD8±). Ex vivo expansion of T cells by stimulating CD3 and CD28 receptors produces a population of T cells that prior to about days 8-9 consists predominately of T H  cells, while after about days 8-9, the population of T cells comprises an increasingly greater population of Tc cells. Accordingly, depending on the purpose of treatment, infusing a subject with a T cell population comprising predominately of T H  cells can be advantageous. Similarly, if an antigen-specific subset of Tc cells has been isolated it can be beneficial to expand this subset to a greater degree. 
     Further, in addition to CD4 and CD8 markers, other phenotypic markers vary significantly, but in large part, reproducibly during the course of the cell expansion process. Thus, such reproducibility enables the ability to tailor an activated T cell product for specific purposes. 
     In some cases, immune effector cells of the embodiments (e.g., T-cells) are co-cultured with activating and propagating cells (AaPCs), to aid in cell expansion. AaPCs can also be referred to as artificial Antigen Presenting cells (aAPCs). For example, antigen presenting cells (APCs) are useful in preparing therapeutic compositions and cell therapy products of the embodiments. In one aspect, the AaPCs can be genetically modified K562 cells. For general guidance regarding the preparation and use of antigen-presenting systems, see, e.g., U.S. Pat. Nos. 6,225,042, 6,355,479, 6,362,001 and 6,790,662; U.S. Patent Application Publication Nos. 2009/0017000 and 2009/0004142; and International Publication No. WO2007/103009. In yet a further aspect of the embodiments, culturing the genetically modified CAR cells comprises culturing the genetically modified CAR cells in the presence of dendritic cells or activating and propagating cells (AaPCs) that stimulate expansion of the CAR-expressing immune effector cells. In still further aspects, the AaPCs comprise a CAR-binding antibody or fragment thereof expressed on the surface of the AaPCs. The AaPCs can comprise additional molecules that activate or co-stimulate T-cells in some cases. The additional molecules can, in some cases, comprise membrane-bound Cy cytokines. In yet still further aspects, the AaPCs are inactivated or irradiated, or have been tested for and confirmed to be free of infectious material. In still further aspects, culturing the genetically modified CAR cells in the presence of AaPCs comprises culturing the genetically modified CAR cells in a medium comprising soluble cytokines, such as IL-15, IL-21 and/or IL-2. The cells can be cultured at a ratio of about 10:1 to about 1:10; about 3:1 to about 1:5; about 1:1 to about 1:3 (immune effector cells to AaPCs); or any range derivable therein. For example, the co-culture of T cells and AaPCs can be at a ratio of about 1:1, about 1:2 or about 1:3. 
     In one aspect, the AaPCs can express CD137L. In some aspects, the AaPCs can further express the antigen that is targeted by the CAR cell, for example MUC16, CD33, or ROR1 (full length, truncate or any variant thereof). In other aspects, the AaPCs can further express CD64, CD86, or mIL15. In certain aspects, the AaPCs can express at least one anti-CD3 antibody clone, such as, for example, OKT3 and/or UCHT1. In one aspect, the AaPCs can be inactivated (e.g., irradiated). In one aspect, the AaPCs have been tested and confirmed to be free of infectious material. Methods for producing such AaPCs are known in the art. In one aspect, culturing the CAR-modified T cell population with AaPCs can comprise culturing the cells at a ratio of about 10:1 to about 1:10; about 3:1 to about 1:5; about 1:1 to about 1:3 (T cells to AaPCs); or any range derivable therein. For example, the co-culture of T cells and AaPCs can be at a ratio of about 1:1, about 1:2 or about 1:3. In one aspect, the culturing step can further comprise culturing with an aminobisphosphonate (e.g., zoledronic acid). 
     In one aspect, the population of genetically modified CAR cells is immediately infused into a subject or cryopreserved. In another aspect, the population of genetically modified CAR cells is placed in a cytokine bath prior to infusion into a subject. In a further aspect, the population of genetically modified CAR cells is cultured and/or stimulated for no more than 1, 2, 3, 4, 5, 6, 7, 14, 21, 28, 35 42 days, 49, 56, 63 or 70 days. In some embodiments, the population of CAR-T cells is cultured and/or stimulated for at least 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or more days. In some embodiments, the population of CAR-T cells is cultured and/or stimulated for at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or more days. In some embodiments, the population of CAR expressing effector cells is cultured and/or stimulated for at least 7, 14, 21, 28, 35, 42, 49, 56, 63 or more days. In an embodiment, a stimulation includes the co-culture of the genetically modified CAR-T cells with AaPCs to promote the growth of CAR positive T cells. In another aspect, the population of genetically modified CAR cells is stimulated for not more than: 1× stimulation, 2× stimulation, 3× stimulation, 4× stimulation, 5× stimulation, 5× stimulation, 6× stimulation, 7× stimulation, 8× stimulation, 9× stimulation or 10× stimulation. In some instances, the genetically modified cells are not cultured ex vivo in the presence of AaPCs. In some specific instances, the method of the embodiment further comprises enriching the cell population for CAR-expressing immune effector cells (e.g., T-cells) after the transfection and/or culturing step. The enriching can comprise fluorescence-activated cell sorting (FACS) to sort for CAR-expressing cells. In a further aspect, the sorting for CAR-expressing cells comprises use of a CAR-binding antibody. The enriching can also comprise depletion of CD56+ cells. In yet still a further aspect of the embodiment, the method further comprises cryopreserving a sample of the population of genetically modified CAR cells. 
     In some cases, AaPCs are incubated with a peptide of an optimal length that allows for direct binding of the peptide to the MHC molecule without additional processing. Alternatively, the cells can express an antigen of interest (i.e., in the case of MHC-independent antigen recognition). Furthermore, in some cases, APCs can express an antibody that binds to either a specific CAR polypeptide or to CAR polypeptides in general (e.g., a universal activating and propagating cell (uAPC). Such methods are disclosed in WO2014/190273. In addition to peptide-MHC molecules or antigens of interest, the AaPC systems can also comprise at least one exogenous assisting molecule. Any suitable number and combination of assisting molecules can be employed. The assisting molecule can be selected from assisting molecules such as co-stimulatory molecules and adhesion molecules. Exemplary co-stimulatory molecules include CD70 and B7.1 (B7.1 was previously known as B7 and also known as CD80), which among other things, bind to CD28 and/or CTLA-4 molecules on the surface of T cells, thereby affecting, for example, T-cell expansion, Th1 differentiation, short-term T-cell survival, and cytokine secretion such as interleukin (IL)-2. Adhesion molecules can include carbohydrate-binding glycoproteins such as selectins, transmembrane binding glycoproteins such as integrins, calcium-dependent proteins such as cadherins, and single-pass transmembrane immunoglobulin (Ig) superfamily proteins, such as intercellular adhesion molecules (ICAMs) that promote, for example, cell-to-cell or cell-to-matrix contact. Exemplary adhesion molecules include LFA-3 and ICAMs, such as ICAM-1. Techniques, methods, and reagents useful for selection, cloning, preparation, and expression of exemplary assisting molecules, including co-stimulatory molecules and adhesion molecules, are exemplified in, e.g., U.S. Pat. Nos. 6,225,042, 6,355,479, and 6,362,001. 
     Cells selected to become AaPCs, preferably have deficiencies in intracellular antigen-processing, intracellular peptide trafficking, and/or intracellular MHC Class I or Class II molecule-peptide loading, or are poikilothermic (i.e., less sensitive to temperature challenge than mammalian cell lines), or possess both deficiencies and poikilothermic properties. Preferably, cells selected to become AaPCs also lack the ability to express at least one endogenous counterpart (e.g., endogenous MHC Class I or Class II molecule and/or endogenous assisting molecules as described above) to the exogenous MHC Class I or Class II molecule and assisting molecule components that are introduced into the cells. Furthermore, AaPCs preferably retain the deficiencies and poikilothermic properties that were possessed by the cells prior to their modification to generate the AaPCs. Exemplary AaPCs either constitute or are derived from a transporter associated with antigen processing (TAP)-deficient cell line, such as an insect cell line. An exemplary poikilothermic insect cells line is a Drosophila cell line, such as a Schneider 2 cell line (see, e.g., Schneider 1972 Illustrative methods for the preparation, growth, and culture of Schneider 2 cells, are provided in U.S. Pat. Nos. 6,225,042, 6,355,479, and 6,362,001. 
     In one embodiment, AaPCs are also subjected to a freeze-thaw cycle. In an exemplary freeze-thaw cycle, the AaPCs can be frozen by contacting a suitable receptacle containing the AaPCs with an appropriate amount of liquid nitrogen, solid carbon dioxide (i.e., dry ice), or similar low-temperature material, such that freezing occurs rapidly. The frozen APCs are then thawed, either by removal of the AaPCs from the low-temperature material and exposure to ambient room temperature conditions, or by a facilitated thawing process in which a lukewarm water bath or warm hand is employed to facilitate a shorter thawing time. Additionally, AaPCs can be frozen and stored for an extended period of time prior to thawing. Frozen AaPCs can also be thawed and then lyophilized before further use. Preferably, preservatives that might detrimentally impact the freeze-thaw procedures, such as dimethyl sulfoxide (DMSO), polyethylene glycols (PEGs), and other preservatives, are absent from media containing AaPCs that undergo the freeze-thaw cycle, or are essentially removed, such as by transfer of AaPCs to media that is essentially devoid of such preservatives. 
     In further embodiments, xenogenic nucleic acid and nucleic acid endogenous to the AaPCs, can be inactivated by crosslinking, so that essentially no cell growth, replication or expression of nucleic acid occurs after the inactivation. In one embodiment, AaPCs are inactivated at a point subsequent to the expression of exogenous MHC and assisting molecules, presentation of such molecules on the surface of the AaPCs, and loading of presented MHC molecules with selected peptide or peptides. Accordingly, such inactivated and selected peptide loaded AaPCs, while rendered essentially incapable of proliferating or replicating, retain selected peptide presentation function. Preferably, the crosslinking also yields AaPCs that are essentially free of contaminating microorganisms, such as bacteria and viruses, without substantially decreasing the antigen-presenting cell function of the AaPCs. Thus crosslinking maintains the important AaPC functions of while helping to alleviate concerns about safety of a cell therapy product developed using the AaPCs. For methods related to crosslinking and AaPCs, see for example, U.S. Patent Application Publication No. 20090017000. 
     In certain embodiments there are further provided an engineered antigen presenting cell (APC). Such cells can be used, for example, as described above, to propagate immune effector cells ex vivo. In further aspects, engineered APCs can, themselves be administered to a patient and thereby stimulate expansion of immune effector cells in vivo. Engineered APCs of the embodiments can, themselves, be used as a therapeutic agent. In other embodiments, the engineered APCs can used as a therapeutic agent that can stimulate activation of endogenous immune effector cells specific for a target antigen and/or to increase the activity or persistence of adoptively transferred immune effector cells specific to a target antigen. 
     As used herein the term “engineered APC” refers to cell(s) that comprises at least a first transgene, wherein the first transgene encodes a HLA. Such engineered APCs can further comprise a second transgene for expression of an antigen, such that the antigen is presented at the surface on the APC in complex with the HLA. In some aspects, the engineered APC can be a cell type that presented antigens (e.g., a dendritic cell). In further aspects, engineered APC can be produced from a cell type that does not normally present antigens, such a T-cell or T-cell progenitor (referred to as “T-APC”). Thus, in some aspects, an engineered APC of the embodiments comprises a first transgene encoding a target antigen and a second transgene encoding a human leukocyte antigen (HLA), such that the HLA is expressed on the surface of the engineered APC in complex with an epitope of the target antigen. In certain specific aspects, the HLA expressed in the engineered APC is HLA-A2. 
     In some aspects, an engineered APC of the embodiments can further comprise at least a third transgene encoding co-stimulatory molecule. The co-stimulatory molecule can be a co-stimulatory cytokine that can be a membrane-bound Cy cytokine. In certain aspects, the co-stimulatory cytokine is IL-15, such as membrane-bound IL-15. In some further aspects, an engineered APC can comprise an edited (or deleted) gene. For example, an inhibitory gene, such as PD-1, LIM-3, CTLA-4 or a TCR, can be edited to reduce or eliminate expression of the gene. An engineered APC of the embodiments can further comprise a transgene encoding any target antigen of interest. For example, the target antigen can be an infectious disease antigen or a tumor-associated antigen (TAA). 
     C. Rapid Manufacturing 
     In one embodiment of the present disclosure, the immune effector cells described herein are modified at a point-of-care site. In one embodiment of the present disclosure, the immune effector cells described herein are modified at or near a point-of-care site. In some cases, modified immune effector cells are also referred to as engineered T cells. In some cases, the facility or treatment site is at a hospital, at a facility (e.g., a medical facility), or at a treatment site near a subject in need of treatment. The subject undergoes apheresis and peripheral blood mononuclear cells (PBMCs) or a sub population of PBMC can be enriched for example, by elutriation or Ficoll separation. Enriched PBMC or a subpopulation of PBMC can be cryopreserved in any appropriate cryopreservation solution prior to further processing. In one instance, the elutriation process is performed using a buffer solution containing human serum albumin. Immune effector cells, such as T cells can be isolated by selection methods described herein. In one instance, the selection method for T cells includes beads specific for CD3 or beads specific for CD4 and CD8 on T cells. In one case, the beads can be paramagnetic beads. The harvested immune effector cells can be cryopreserved in any appropriate cryopreservation solution prior to modification. The immune effector cells can be thawed up to 24 hours, 36 hours, 48 hours, 72 hours or 96 hours ahead of infusion. The thawed cells can be placed in cell culture buffer, for example in cell culture buffer (e.g. RPMI) supplemented with fetal bovine serum (FBS) or human serum AB or placed in a buffer that includes cytokines such as IL-2 and IL-21, prior to modification. In another aspect, the harvested immune effector cells can be modified immediately without the need for cryopreservation. In one aspect, the elutriation step is eliminated completely. 
     In some cases, the immune effector cells are modified by engineering/introducing a one or more miRNA(s), a chimeric receptor, one or more cell tag(s), and/or cytokine(s) into the immune effector cells and then rapidly infused into a subject. In some cases, the sources of immune effector cells can include both allogeneic and autologous sources. In one case, the immune effector cells can be T cells or NK cells. In one case, the chimeric receptor can be a CAR. In another case, the cytokine can be IL-15 (for example, as part of a fusion protein with IL-15Rα) or IL-12. In yet another case, expression of cytokine is modulated by ligand inducible gene-switch expression systems described herein. For example, a ligand such as veledimex can be delivered to the subject to modulate the expression of the cytokine. 
     In another aspect, veledimex is provided at 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg or 100 mg. In a further aspect, lower doses of veledimex are provided, for example, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg or 20 mg. In one embodiment, veledimex is administered to the subject 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days prior to infusion of the modified immune effector cells. In a further embodiment, veledimex is administered about once every 12 hours, about once every 24 hours, about once every 36 hours or about once every 48 hours, for an effective period of time to a subject post infusion of the modified immune effector cells. In one embodiment, an effective period of time for veledimex administration is about: 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days. In other embodiments, veledimex can be re-administered after a rest period, after a drug holiday or when the subject experiences a relapse. 
     In certain cases, where an adverse effect on a subject is observed or when treatment is not needed, the cell tag can be activated, for example via cetuximab, for conditional in vivo ablation of modified immune effector cells comprising cell tags such as truncated epidermal growth factor receptor tags as described herein. 
     In some embodiments, such immune effectors cells are modified by the constructs as described herein through electroporation. In one instance, electroporation is performed with electroporators such as Lonza&#39;s Nucleofector™ electroporators. In other embodiments, the vector comprising the above-mentioned constructs is a non-viral or viral vector. In one case, the non-viral vector includes a Sleeping Beauty transposon-transposase system. In one instance, the immune effector cells are electroporated using a specific sequence. For example, the immune effector cells can be electroporated with one transposon followed by the DNA encoding the transposase followed by a second transposon. In another instance, the immune effector cells can be electroporated with all transposons and transposase at the same time. In another instance, the immune effector cells can be electroporated with a transposase followed by both transposons or one transposon at a time. While undergoing sequential electroporation, the immune effector cells can be rested for a period of time prior to the next electroporation step. 
     In some cases, the modified immune effector cells do not undergo a propagation and activation step. In some cases, the modified immune effector cells do not undergo an incubation or culturing step (e.g. ex vivo propagation). In some cases, the modified immune effector cells are place in PBS/EDTA buffer. In certain cases, the modified immune effector cells are placed in a buffer that includes IL-2 and IL-21 prior to infusion. In other instances, the modified immune effector cells are placed or rested in cell culture buffer, for example in cell culture buffer (e.g. RPMI) supplemented with fetal bovine serum (FBS) prior to infusion. Prior to infusion, the modified immune effector cells can be harvested, washed and formulated in saline buffer in preparation for infusion into the subject. 
     In one instance, the subject has been lymphodepleted prior to infusion. In other instances, lymphodepletion is not required and the modified immune effector cells are rapidly infused into the subject. 
     In a further instance, the subject undergoes minimal lymphodepletion. Minimal lymphodepletion herein refers to a reduced lymphodepletion protocol such that the subject can be infused within 1 day, 2 days or 3 days following the lymphodepletion regimen. In one instance, a reduced lymphodepletion protocol can include lower doses of fludarabine and/or cyclophosphamide. In another instance, a reduced lymphodepletion protocol can include a shortened period of lymphodepletion, for example 1 day or 2 days. 
     In some embodiments, the subject is not lymphodepleted prior to infusion. 
     In one embodiment, the immune effector cells are modified by engineering/introducing one or more miRNA(s), a chimeric receptor and a cytokine into said immune effector cells and then rapidly infused into a subject. In other cases, the immune effector cells are modified by engineering/introducing one or more miRNA(s), a chimeric receptor and a cytokine into said cells and then infused within at least: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 hours into a subject. In other cases, immune effector cells are modified by engineering/introducing one or more miRNA(s), a chimeric receptor and a cytokine into the immune effector cells and then infused in 0 days, &lt;1 day, &lt;2 days, &lt;3 days, &lt;4 days, &lt;5 days, &lt;6 days or &lt;7 days into a subject. 
     In other embodiments, a method of stimulating the proliferation and/or survival of engineered cells comprises obtaining a sample of cells from a subject, and transfecting cells of the sample of cells with one or more polynucleotides that comprise one or more transposons. In one embodiment, the transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the gene switch polypeptides comprise i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain. In some embodiments, the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject. 
     In one instance, a method of in vivo propagation of engineered cells comprises obtaining a sample of cells from a subject, and transfecting cells of the sample of cells with one or more polynucleotides that comprise one or more transposons. In one embodiment, the transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate said one or more polynucleotides into the genome of said cells, to provide a population of engineered cells. In an embodiment, the gene switch polypeptides comprise i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain. In some embodiments, the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject. 
     In another embodiment, a method of enhancing in vivo persistence of engineered cells in a subject in need thereof comprises obtaining a sample of cells from a subject, and transfecting cells of the sample of cells with one or more polynucleotides that comprise one or more transposons. In some cases, one or more transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, and a transposase effective to integrate the DNA into the genome of said cells, to provide a population of engineered cells. In some cases, one or more transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate the DNA into the genome of said cells, to provide a population of engineered cells. In some cases, the gene switch polypeptides comprise i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain, wherein the first gene switch polypeptide and the second gene switch polypeptide are connected by a linker. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject. 
     XIII. Kits and Compositions 
     One aspect of the disclosure relates to kits and compositions that comprise: a CAR, a cytokine, a cell tag, and/or one or more miRNAs as described previously, or nucleic acids encoding the same. In another aspect, the kits and compositions can include RHEOSWITCH® gene switch components. These kits and compositions can include multiple vectors each encoding different proteins or subsets of proteins. These vectors can be viral, non-viral, episomal, or integrating. In some embodiments, the vectors are transposons, e.g., Sleeping Beauty transposons. In other embodiments, the vectors can comprise sequences for serine recombinase-mediated integration. 
     In some embodiments, the kits and compositions include not only vectors but also cells and agents such as interleukins, cytokines, interleukins and chemotherapeutics, adjuvants, wetting agents, or emulsifying agents. In one embodiment the cells are T cells. In one embodiment the kits and composition includes IL-2. In one embodiment, the kits and compositions include IL-21. In one embodiment, the kits and compositions include Bcl-2, STAT3 or STATS inhibitors. In some embodiments, the kit includes IL-15, for example as part of a fusion protein with IL-15Rα. 
     Disclosed herein, in certain embodiments, are kits and articles of manufacture for use with one or more methods described herein. Such kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. In one embodiment, the containers are formed from a variety of materials such as glass or plastic. 
     The articles of manufacture provided herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, bags, containers, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment. 
     For example, the container(s) include CAR-T cells (e.g., MUC16-, CD33-, and ROR1-specific CAR-T cells described herein), and optionally in addition with cytokines and/or chemotherapeutic agents disclosed herein. Such kits optionally include an identifying description or label or instructions relating to its use in the methods described herein. 
     A kit typically includes labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included. 
     In some embodiments, a label is on or associated with the container. In one embodiment, a label is on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label is associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. In one embodiment, a label is used to indicate that the contents are to be used for a specific therapeutic application. The label also indicates directions for use of the contents, such as in the methods described herein. 
     The present invention relates also to pharmaceutical compositions comprising a modified immune effector cell as described above. In certain embodiments, the composition comprising an immune effector cell (e.g., T cell) modified with sequences comprising one or more miRNA(s), a CAR, one or more cell tags, and/or one or more cytokines and optionally, components of the gene switch system as described herein. In certain embodiments, the immune effector cell is modified with Sleeping Beauty transposon(s) and Sleeping Beauty transposase. For example, the Sleeping Beauty transposon or transposons can include one or more miRNA(s), a CAR, one or more cell tags, one or more cytokines and optionally, components of the gene switch system as described herein. Therefore, in some instances, the modified T-cell can elicit a CAR-mediated T-cell response. 
     The cells activated and expanded as described herein can be utilized in the treatment and prevention of diseases that arise in individuals who are immunocompromised. In particular, the modified T cells of the invention are used in the treatment of malignancies. In certain embodiments, the cells of the invention are used in the treatment of patients at risk for developing malignancies. Thus, the methods for the treatment or prevention of malignancies comprising administering to a subject in need thereof, a therapeutically effective amount of the modified T cells of the invention. In embodiments, the cells activated and expanded as described herein can be utilized in the treatment of malignancies. 
     In addition to using a cell-based vaccine in terms of ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response directed against an antigen in a patient. 
     Briefly, pharmaceutical compositions described herein can comprise a population comprising modified immune effector cells as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions can comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; 
     adjuvants (e.g., aluminum hydroxide); and preservatives. In some embodiments, compositions of the present invention are formulated for intravenous administration. 
     Pharmaceutical compositions described herein can be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient&#39;s disease. 
     When “an immunologically effective amount”, or “therapeutic amount” is indicated, the precise amount of the compositions described herein to be administered can be determined by a physician with consideration of individual differences in age, weight, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising the T cells described herein can be administered at a dosage of 10 4  to 10 9  cells/kg body weight, 10 5  to 10 6  cells/kg body weight, including all integer values within those ranges. T cell compositions can also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, (1988)). The optimal dosage and treatment regime for a particular patient can readily be determined by one skilled in the art of medicine by monitoring the patient for signs of disease and adjusting the treatment accordingly. 
     In certain embodiments, it can be desired to administer activated T cells to a subject and then subsequently redraw blood (or have an apheresis performed), activate T cells therefrom, and reinfuse the patient with these activated and expanded T cells. This process can be carried out multiple times every few weeks. In certain embodiments, T cells can be activated from blood draws of from 10 cc to 400 cc. In certain embodiments, T cells are activated from blood draws of 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80 cc, 90 cc, or 100 cc. Not to be bound by theory, using this multiple blood draw/multiple reinfusion protocol can serve to select out certain populations of T cells. In another embodiment, it can be desired to administer activated T cells of the subject composition following lymphodepletion of the patient, either via radiation or chemotherapy. 
     Formulations described herein can benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof. 
     A “carrier” or “carrier materials” include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility with the polynucleotides, vectors, and/or cells disclosed herein, and the release profile properties of the desired dosage form. Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like. “Pharmaceutically compatible carrier materials” can include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, polyvinylpyrrollidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphotidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugars sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, and the like. See, e.g., Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington&#39;s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams &amp; Wilkins 1999). 
     “Dispersing agents,” and/or “viscosity modulating agents” include materials that control the diffusion and homogeneity of a drug through liquid media or a granulation method or blend method. In some embodiments, these agents also facilitate the effectiveness of a coating or eroding matrix. Exemplary diffusion facilitators/dispersing agents include, e.g., hydrophilic polymers, electrolytes, Tween® 60 or 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and the carbohydrate-based dispersing agents such as, for example, hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcelluloses (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinyl pyrrolidone/vinyl acetate copolymer (S630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, F88®, and F108®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Corporation, Parsippany, N.J.)), polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyvinylpyrrolidone/vinyl acetate copolymer (S-630), polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, sodium carboxymethylcellulose, methylcellulose, polysorbate-80, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e.g., sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, carbomers, polyvinyl alcohol (PVA), alginates, chitosans and combinations thereof. Plasticizers such as cellulose or triethyl cellulose can also be used as dispersing agents. Dispersing agents particularly useful in liposomal dispersions and self-emulsifying dispersions are dimyristoyl phosphatidyl choline, natural phosphatidyl choline from eggs, natural phosphatidyl glycerol from eggs, cholesterol and isopropyl myristate. 
     Combinations of one or more erosion facilitator with one or more diffusion facilitator can also be used in the present compositions. 
     The term “diluent” refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (which also can provide pH control or maintenance) are utilized as diluents in the art, including, but not limited to a phosphate buffered saline solution. In certain embodiments, diluents increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling. Such compounds include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose-based diluents, confectioner&#39;s sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like. 
     “Filling agents” include compounds such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like. 
     “Lubricants” and “glidants” are compounds that prevent, reduce or inhibit adhesion or friction of materials. Exemplary lubricants include, e.g., stearic acid, calcium hydroxide, talc, sodium stearyl fumerate, a hydrocarbon such as mineral oil, or hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, glycerol, talc, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol (e.g., PEG-4000) or a methoxypolyethylene glycol such as Carbowax™ sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica such as Syloid™, Cab-O-Sil®, a starch such as corn starch, silicone oil, a surfactant, and the like. 
     “Plasticizers” are compounds used to soften the microencapsulation material or film coatings to make them less brittle. Suitable plasticizers include, e.g., polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethyl cellulose and triacetin. In some embodiments, plasticizers can also function as dispersing agents or wetting agents. 
     “Solubilizers” include compounds such as triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium doccusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cyclodextrins, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide and the like. 
     “Stabilizers” include compounds such as any antioxidation agents, buffers, acids, preservatives and the like. 
     “Suspending agents” include compounds such as polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, vinyl pyrrolidone/vinyl acetate copolymer (S630), polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose acetate stearate, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e.g., sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone and the like. 
     “Surfactants” include compounds such as sodium lauryl sulfate, sodium docusate, Tween 60 or 80, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF), and the like. Some other surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40. In some embodiments, surfactants can be included to enhance physical stability or for other purposes. 
     “Viscosity enhancing agents” include, e.g., methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose acetate stearate, hydroxypropylmethyl cellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof. 
     “Wetting agents” include compounds such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium doccusate, triacetin, Tween 80, vitamin E TPGS, ammonium salts and the like. 
     XIV. Methods of Treatment 
     The present invention also relates to a method of treating a disease or disorder comprising administering a modified immune effector cell of the present disclosure to a subject in need thereof. In certain embodiments, the cell is administered in a therapeutically effective amount. 
     The present invention also relates to the use of a modified immune effector cell of the present disclosure in the manufacture of a medicament for the treatment of a disease or disorder. 
     In some embodiments, the disease can be cancer. In certain aspects, the cancer can be hematological or a solid tumor. In other instances, the cancer is a hematologic malignancy. In some cases, the cancer is a metastatic cancer. In some cases, the cancer is a relapsed or refractory cancer. In certain aspects, the cancer is selected from B cell cancer, e.g., multiple myeloma, Waldenstrom&#39;s macroglobulinemia, the heavy chain diseases, such as, for example, alpha chain disease, gamma chain disease, and mu chain disease, benign monoclonal gammopathy, and immunocytic amyloidosis, melanomas, breast cancer, lung cancer, bronchus cancer, colorectal cancer, prostate cancer (e.g., metastatic, hormone refractory prostate cancer), pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, cancer of hematological tissues, and the like. Other non-limiting examples of types of cancers that can be treated by the methods of the present disclosure include human sarcomas and carcinomas, e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing&#39;s sarcoma, Ewing&#39;s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, colorectal cancer, pancreatic cancer, breast cancer, beast adenocarcinomas e.g. triple negative breast cancer, ovarian cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, liver cancer, hepatocellular carcinoma (HCC), choriocarcinoma, seminoma, embryonal carcinoma, Wilms&#39; tumor, cervical cancer, bone cancer, brain tumor, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma; leukemias, e.g., acute myeloid leukemia, acute lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and acute myelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic and erythroleukemia); chronic leukemia (chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia); diffuse large B-cell lymphoma; and polycythemia vera, lymphoma (Hodgkin&#39;s disease and non-Hodgkin&#39;s disease), multiple myeloma, Waldenstrom&#39;s macroglobulinemia, and heavy chain disease. 
     In some instances, the cancer is a solid tumor. Exemplary solid tumors include, but are not limited to, anal cancer; appendix cancer; bile duct cancer (i.e., cholangiocarcinoma); bladder cancer; brain tumor; breast cancer; cervical cancer; colon cancer; cancer of Unknown Primary (CUP); esophageal cancer; eye cancer; fallopian tube cancer; gastroenterological cancer; kidney cancer; liver cancer; lung cancer; medulloblastoma; melanoma; oral cancer; ovarian cancer; pancreatic cancer; parathyroid disease; penile cancer; pituitary tumor; prostate cancer; rectal cancer; skin cancer; stomach cancer; testicular cancer; throat cancer; thyroid cancer; uterine cancer; vaginal cancer; or vulvar cancer. 
     In some instances, the cancer is a hematologic malignancy. In some cases, a hematologic malignancy comprises a lymphoma, a leukemia, a myeloma, or a B-cell malignancy. In some cases, a hematologic malignancy comprises a lymphoma, a leukemia or a myeloma. In some instances, exemplary hematologic malignancies include chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, non-CLL/SLL lymphoma, prolymphocytic leukemia (PLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom&#39;s macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt&#39;s lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis. In some embodiments, the hematologic malignancy comprises a myeloid leukemia. In some embodiments, the hematologic malignancy comprises acute myeloid leukemia (AML) or chronic myeloid leukemia (CML). 
     In some instances, disclosed herein are methods of administering to a subject having a hematologic malignancy selected from chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high risk CLL, non-CLL/SLL lymphoma, prolymphocytic leukemia (PLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Waldenstrom&#39;s macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt&#39;s lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis a modified effector cell described herein. In some instances, disclosed herein are methods of administering to a subject having a hematologic malignancy selected from AML or CML a modified effector cell to the subject. 
     In still other embodiments, the epithelial cancer is non-small-cell lung cancer, nonpapillary renal cell carcinoma, cervical carcinoma, ovarian carcinoma (e.g., serous ovarian carcinoma), or breast carcinoma. The epithelial cancers can be characterized in various other ways including, but not limited to, serous, endometrioid, mucinous, clear cell, brenner, or undifferentiated. In some embodiments, the methods and compositions of the present disclosure are used in the treatment, diagnosis, and/or prognosis of lymphoma or its subtypes, including, but not limited to, mantle cell lymphoma. 
     In some embodiments, the disease or disorder is associated with the overexpression of an antigen. In certain embodiments, the antigen is CD19, CD33, ROR1, MUC1, or MUC16. In some embodiments, the disease is ovarian cancer, a myelodysplastic syndrome (MDS). 
     In some embodiments, disclosed herein are methods of administering a modified effector cell comprising a polypeptide described herein to a subject having a disorder, for instance a cancer. In some cases, the cancer is a cancer associated with an expression of CD19, CD20, CD33, CD44, BCMA, CD123, EGFRvIII, α-Folate receptor, CAIX, CD30, ROR1, CEA, EGP-2, EGP-40, HER2, HER3, Folate-binding Protein, GD2, GD3, IL-13R-a2, KDR, EDB-F, mesothelin, GPC3, CSPG4, HER1/HER3, HER2, CD44v6, CD44v7/v8, CD20, CD174, CD138, L1-CAM, FAP, c-MET, PSCA, CS1, CD38, IL-11Rα, EphA2, CLL-1, CD22, EGFR, Folate receptor α, Mucins such as MUC1 or MUC16, MAGE-A1, h5T4, PSMA, CSPG4, TAG-72 or VEGF-R2. 
     In some embodiments, the disease is associated with the overexpression of MUC16. In certain such embodiments, the disease is ovarian cancer, breast cancer, pancreatic cancer, endometrial cancer, or lung cancer. 
     In some embodiments, the disease is associated with the overexpression of CD33. In certain such embodiments, the disease is acute myeloid leukemia (AML) or a myelodysplastic syndrome (MDS). 
     In some embodiments, the disease is associated with the overexpression of ROR1. In certain such embodiments, the disease involves a hematological tumor, for example chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL). In certain such embodiments, the disease involves a solid tumor, for example breast adenocarcinomas encompassing triple negative breast cancer (TNBC), pancreatic cancer, ovarian cancer, and lung adenocarcinoma. 
     In another embodiment, a method of treating a subject with a solid tumor comprises obtaining a sample of cells from a subject, transfecting cells of the sample with one or more polynucleotides that comprise one or more transposons, and administering the population of engineered cells to the subject. In one instance, lymphodepletion is not required prior to administration of the engineered cells to a subject. In some embodiments, genetically modified T cells can be expanded and transferred into patients treated with or without preconditioning lymphodepletion according to well-known protocols. In some cases, the one or more transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, and a transposase effective to integrate the DNA into the genome of the cells. In some cases, the one or more transposons encode one or more miRNA(s), a chimeric antigen receptor (CAR), a cytokine, one or more cell tags, gene switch polypeptides for ligand-inducible control of the cytokine and a transposase effective to integrate the DNA into the genome of the cells. In some cases, the gene switch polypeptides comprise: i) a first gene switch polypeptide that comprises a DNA binding domain fused to a first nuclear receptor ligand binding domain, and ii) a second gene switch polypeptide that comprises a transactivation domain fused to a second nuclear receptor ligand binding domain, wherein the first gene switch polypeptide and second gene switch polypeptide are connected by a linker. In some cases, the cells are transfected via electroporation. In some cases, the polynucleotides encoding the gene switch polypeptides are modulated by a promoter. In some cases, the promoter is a tissue-specific promoter or an EF1A promoter or functional variant thereof. In some cases, the tissue-specific promoter comprises a T cell specific response element or an NFAT response element. In some cases, the cytokine comprises at least one of IL-1, IL-2, IL-15, IL-12, IL-21, a fusion of IL-15, IL-15R or an IL-15 variant. In some cases, the cytokine is in secreted form. In some cases, the cytokine is in membrane-bound form. In some cases, the cells are NK cells, NKT cells, T-cells or T-cell progenitor cells. In some cases, the cells are administered to a subject (e.g. by infusing the subject with the engineered cells). In some cases, the method further comprises administering an effective amount of a ligand (e.g. veledimex) to induce expression of the cytokine. In some cases, the transposase is salmonid-type Tc 1-like transposase. In some cases, the transposase is SB11 or SB100x transposase. In other cases, the transposase is PiggyBac. In some cases, the cell tag comprises at least one of a HER1 truncated variant or a CD20 truncated variant. 
     Studies conducted in patients with metastatic melanoma demonstrated that lymphodepletion prior to adoptive cell transfer dramatically improves the efficacy of therapy with in vitro expanded tumor-infiltrating lymphocytes (TILs). Muranski P, et al., “Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?” Nat Clin Pract Oncol. 2006; 3(12):668-681. Lymphodepletion likely works by multiple mechanisms, including eliminating sinks for homeostatic cytokines, such as interleukin-2 (IL-2), IL-7, and IL-15, eradicating immunosuppressive elements, such as regulatory T cells and myeloid-derived suppressor cells, inducing costimulatory molecules and downregulating indoleamine 2,3-dioxygenase in tumor cells, and promoting expansion, function, and persistence of adoptively transferred T cells. These experiences led to the use of lymphodepletion in clinical trials with CAR T-cell therapy. Kochenderfer et al showed an association between an increase in serum IL-15 levels post-lymphodepletion and clinical response after anti-CD19 CAR T-cell therapy. Kochenderfer J N, et al., “Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels,”  J Clin Oncol.  2017; 35(16):1803-1813. Turtle and colleagues showed that the addition of fludarabine to cyclophosphamide (Cy/Flu) in the lymphodepleting regimen was associated with improved anti-CD19 CAR T-cell expansion and persistence and better clinical outcome compared with non-Flu lymphodepleting regimens in patients with non-Hodgkin lymphoma. Turtle C J, et al., “Immunotherapy of non-Hodgkin&#39;s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells,”  Sci Transl Med.  2016; (8)355-355ra116. Other studies indicated that the magnitude of the CAR T-cell expansion in vivo with respect to both the peak and the area under the curve over the first month may be associated with response and/or durability. Neelapu S S, et al., “Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma,”  N Engl J Med.  2017; 377(26):2531-2544. 
     In some embodiments, the subject is subjected to lymphodepletion before the step of administering the modified immune effector cells to the subject. As used herein, “lymphodepletion” involves methods that reduce the number of lymphocytes in a subject, for example by administration of a lymphodepletion agent. Examples of lymphodepletion include nonmyeloablative lymphodepleting chemotherapy, myeloablative lymphodepleting chemotherapy. Lymphodepletion can also be attained by partial body or whole body fractioned radiation therapy. A lymphodepletion agent can be a chemical compound or composition capable of decreasing the number of functional lymphocytes in a mammal when administered to the mammal. One example of such an agent is one or more chemotherapeutic agents. Such agents and dosages are known, and can be selected by a treating physician depending on the subject to be treated. Examples of lymphodepletion agents include, but are not limited to, fludarabine, cyclophosphamide, cladribine, denileukin diftitox, or combinations thereof. In some embodiments, the subject is not subjected to lymphodepletion before the step of administering the modified immune effector cells to the subject. 
     In some embodiments, lymphodepletion is performed by administration of cyclophosphamide at a dose of about 10 mg/kg to about 100 mg/kg, preferably about 40 mg/kg to about 80 mg/kg, for example about 60 mg/kg. In such embodiments, the cyclophosphamide can be administered concomitantly with fludarabine at a dose of about 10 mg/m 2  to about 50 mg/m 2 , preferably about 20 mg/m 2  to about 40 mg/m 2 , for example about 30 mg/m 2 . In some embodiments, lymphodepletion is performed by administration of fludarabine at a dose of about 10 mg/m 2  to about 50 mg/m 2 , preferably about 20 mg/m 2  to about 40 mg/m 2 , for example about 30 mg/m 2 . In such embodiments, the fludarabine can be administered concomitantly with cyclophosphamide at a dose of about 200 mg/m 2  to about 900 mg/m 2 , preferably about 400 to about 600 mg/m 2 , for example 500 mg/m 2 . 
     In some embodiments, patients or subjects are not lymphodepleted prior to blood being withdrawn to produce the autologous modified immune effector cells. 
     In some embodiments, the modified immune effector cells are autologous to the subject. In some embodiments, the modified immune effector cells are allogeneic to the subject. 
     In some embodiments, an amount of modified immune effector cells that is administered to a subject in need thereof and the amount is determined based on the efficacy and the potential of inducing a cytokine-associated toxicity. 
     The administration of compositions described herein can be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein can be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In one embodiment, the T cell compositions of the present invention are administered to a patient by intradermal or subcutaneous injection. In another embodiment, the immune effector cell compositions of the present invention are administered by i.v. injection. The compositions of T cells can be injected directly into a lymph node, or site of primary tumor or metastasis. 
     The dosage of the above treatments to be administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The scaling of dosages for human administration can be performed according to art-accepted practices. For example, the dose of the above treatment can be in the range of 1×10 4  CAR+ cells/kg to 5×10 6  CAR+ cells/kg. Exemplary doses can be 1×10 2  CAR+ cells/kg, 1×10 3  CAR+ cells/kg, 1×10 4  CAR+ cells/kg, 1×10 5  CAR+ cells/kg, 3×10 5  CAR+ cells/kg, 1×10 6  CAR+ cells/kg, 5×10 6  CAR+ cells/kg, 1×10 7  CAR+ cells/kg, 1×10 8  CAR+ cells/kg or 1×10 9  CAR+ cells/kg. The appropriate dose can be adjusted accordingly for an adult or a pediatric patient. 
     Alternatively, a typical amount of immune effector cells administered to a mammal (e.g., a human) can be, for example, in the range of one hundred, one thousand, ten thousand, one million to 100 billion cells; however, amounts below or above this exemplary range are within the scope of the invention. For example, the dose of inventive host cells can be about 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the foregoing values), about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the foregoing values), about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells, or a range defined by any two of the foregoing values). 
     Therapeutic or prophylactic efficacy can be monitored by periodic assessment of treated patients. For repeated administrations over several days or longer, depending on the condition, the treatment is repeated until a desired suppression of disease symptoms occurs. However, other dosage regimens can be useful and are within the scope of the invention. The desired dosage can be delivered by a single bolus administration of the composition, by multiple bolus administrations of the composition, or by continuous infusion administration of the composition. 
     In some embodiments, an amount of modified effector cells is administered to a subject in need thereof and the amount is determined based on the efficacy and the potential of inducing a cytokine-associated toxicity. In another embodiment, the modified effector cells are CARP and CD3 +  cells. In some cases, an amount of modified effector cells comprises about 10 4  to about 10 9  modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10 4  to about 10 5  modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10 5  to about 10 6  modified effector cells/kg. In some cases, an amount of modified effector cells comprises about 10 6  to about 10 7  modified effector cells/kg. In some cases, an amount of modified effector cells comprises &gt;10 4  but ≤10 5  modified effector cells/kg. In some cases, an amount of modified effector cells comprises &gt;10 5  but ≤10 6  modified effector cells/kg. In some cases, an amount of modified effector cells comprises &gt;10 6  but ≤10 7  modified effector cells/kg. 
     In one embodiment, the modified immune effector cells are targeted to the cancer via regional delivery directly to the tumor tissue. For example, in ovarian cancer, the modified immune effector cells can be delivered intraperitoneally (IP) to the abdomen or peritoneal cavity. Such IP delivery can be performed via a port or pre-existing port placed for delivery of chemotherapy drugs. Other methods of regional delivery of modified immune effector cells can include catheter infusion into resection cavity, ultrasound guided intratumoral injection, hepatic artery infusion or intrapleural delivery. 
     In one embodiment, a subject in need thereof, can begin therapy with a first dose of modified immune effector cells delivered via IP followed by a second dose of modified immune effector cells delivered via IV. In a further embodiment, the second dose of modified immune effector cells can be followed by subsequent doses which can be delivered via IV or IP. In one embodiment, the duration between the first and second or further subsequent dose can be about: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 days. In one embodiment, the duration between the first and second or further subsequent dose can be about: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months. In another embodiment, the duration between the first and second or further subsequent dose can be about: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years. 
     In another embodiment, a catheter can be placed at the tumor or metastasis site for further administration of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 doses of modified immune effector cells. In some cases, doses of modified effector cells can comprise about 10 2  to about 10 9  modified effector cells/kg. In cases where toxicity is observed, doses of modified effector cells can comprise about 10 2  to about 10 5  modified effector cells/kg. In some cases, doses of modified effector cells can start at about 10 2  modified effector cells/kg and subsequent doses can be increased to about: 10 4 , 10 5 , 10 6 , 10 7 , 10 8  or 10 9  modified effector cells/kg. 
     The immune effector cells expressing the disclosed nucleic acid sequences, or a vector comprising the those nucleic acid sequences, can be administered with one or more additional therapeutic agents, which can be co-administered to the mammal. By “co-administering” is meant administering one or more additional therapeutic agents and the inventive host cells or the inventive vector sufficiently close in time to enhance the effect of one or more additional therapeutic agents, or vice versa. In this regard, the immune effector cells described herein or a vector described herein can be administered simultaneously with one or more additional therapeutic agents, or first, and the one or more additional therapeutic agents can be administered second, or vice versa. Alternatively, the disclosed immune effector cells or the vectors described herein and the one or more additional therapeutic agents can be administered simultaneously. 
     An example of a therapeutic agents that can be included in or co-administered with the inventive host cells and/or the inventive vectors are interleukins, cytokines, interferons, adjuvants and chemotherapeutic agents. In some embodiments, the additional therapeutic agents are IFN-alpha, IFN-beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta, TNF-alpha, growth factors, and hGH, a ligand of human Toll-like receptor TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10. 
     A. Modified Immune Effector Cell Doses 
     In some embodiments, an amount of modified immune effector cells administered comprises about 10 2  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some embodiments, an amount of modified immune effector cells administered comprises about 10 3  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some embodiments, an amount of modified immune effector cells administered comprises about 10 4  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 5  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 5  to about 10 8  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 5  to about 10 7  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 6  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 6  to about 10 8  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 7  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 5  to about 10 6  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 6  to about 10 7  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 7  to about 10 8  modified effector cells/kg of the subject&#39;s body weight. In some cases, an amount of modified effector cells comprises about 10 8  to about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 9  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 8  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 7  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 6  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 5  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 4  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 3  modified effector cells/kg of the subject&#39;s body weight. In some instances, an amount of modified effector cells comprises about 10 2  modified effector cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified immune effector cells are modified CAR-T cells. In some instances, the modified CAR-T cells further comprise one or more miRNA(s) as described herein. In some cases, an amount of modified CAR-T cells comprises about 10 4  to about 10 9  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 5  to about 10 9  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 5  to about 10 8  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 5  to about 10 7  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 6  to about 10 9  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 6  to about 10 8  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 7  to about 10 9  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 5  to about 10 6  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 6  to about 10 7  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 7  to about 10 8  modified CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of modified CAR-T cells comprises about 10 8  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of modified CAR-T cells comprises about 10 9  modified CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of modified CAR-T cells comprises about 10 8  modified CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of modified CAR-T cells comprises about 10 7  modified CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of modified CAR-T cells comprises about 10 6  modified CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of modified CAR-T cells comprises about 10 5  modified CAR-T cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified CAR-T cells are CD19-specific CAR-T cells. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 5  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 5  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 5  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 6  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 6  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 7  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 5  to about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 6  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 7  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD19-specific CAR-T cells comprises about 10 8  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD19-specific CAR-T cells comprises about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD19-specific CAR-T cells comprises about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD19-specific CAR-T cells comprises about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD19-specific CAR-T cells comprises about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD19-specific CAR-T cells comprises about 10 5  CAR-T cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified CAR-T cells are CD33-specific CAR-T cells. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 5  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 5  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 5  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 6  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 6  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 7  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 5  to about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 6  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 7  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of CD33-specific CAR-T cells comprises about 10 8  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD33-specific CAR-T cells comprises about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD33-specific CAR-T cells comprises about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD33-specific CAR-T cells comprises about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD33-specific CAR-T cells comprises about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of CD33-specific CAR-T cells comprises about 10 5  CAR-T cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified CAR-T cells are MUC1-specific CAR-T cells. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 5  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 5  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 5  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 6  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 6  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 7  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 5  to about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 6  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 7  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC1-specific CAR-T cells comprises about 10 8  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC1-specific CAR-T cells comprises about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC1-specific CAR-T cells comprises about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC1-specific CAR-T cells comprises about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC1-specific CAR-T cells comprises about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC1-specific CAR-T cells comprises about 10 5  CAR-T cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified CAR-T cells are MUC16-specific CAR-T cells. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 5  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 5  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 5  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 6  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 6  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 7  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 5  to about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 6  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 7  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of MUC16-specific CAR-T cells comprises about 10 8  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC16-specific CAR-T cells comprises about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC16-specific CAR-T cells comprises about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC16-specific CAR-T cells comprises about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC16-specific CAR-T cells comprises about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of MUC16-specific CAR-T cells comprises about 10 5  CAR-T cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified CAR-T cells are ROR1-specific CAR-T cells. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 5  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 5  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 5  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 6  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 6  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 7  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 5  to about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 6  to about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 7  to about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some cases, an amount of ROR1-specific CAR-T cells comprises about 10 8  to about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of ROR1-specific CAR-T cells comprises about 10 9  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of ROR1-specific CAR-T cells comprises about 10 8  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of ROR1-specific CAR-T cells comprises about 10 7  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of ROR1-specific CAR-T cells comprises about 10 6  CAR-T cells/kg of the subject&#39;s body weight. In some instances, an amount of ROR1-specific CAR-T cells comprises about 10 5  CAR-T cells/kg of the subject&#39;s body weight. 
     In some embodiments, the modified T cells are engineered TCR T-cells. In some cases, an amount of engineered TCR T-cells comprises about 10 5  to about 10 9  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 5  to about 10 8  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 5  to about 10 7  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 6  to about 10 9  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 6  to about 10 8  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 7  to about 10 9  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 5  to about 10 6  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 6  to about 10 7  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 7  to about 10 8  TCR cells/kg of the subject&#39;s body weight. In some cases, an amount of engineered TCR cells comprises about 10 8  to about 10 9  TCR cells/kg of the subject&#39;s body weight. In some instances, an amount of engineered TCR cells comprises about 10 9  TCR cells/kg of the subject&#39;s body weight. In some instances, an amount of engineered TCR cells comprises about 10 8  TCR cells/kg of the subject&#39;s body weight. In some instances, an amount of engineered TCR cells comprises about 10 7  TCR cells/kg of the subject&#39;s body weight. In some instances, an amount of engineered TCR cells comprises about 10 6  TCR cells/kg of the subject&#39;s body weight. In some instances, an amount of engineered TCR cells comprises about 10 5  TCR cells/kg of the subject&#39;s body weight. 
     It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. 
     In some embodiments, the cancer whose phenotype is determined by the method of the present disclosure is an epithelial cancer such as, but not limited to, bladder cancer, breast cancer, cervical cancer, colon cancer, gynecologic cancers, renal cancer, laryngeal cancer, lung cancer, oral cancer, head and neck cancer, ovarian cancer, pancreatic cancer, prostate cancer, or skin cancer. In other embodiments, the cancer is breast cancer, prostate cancer, lung cancer, or colon cancer. 
     B. Combination Therapies 
     In certain embodiments, the modified immune effector cells and compositions thereof described herein may be used, alone or with other therapies, to treat cancers that have about 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95%, 96%, 97%, 98%, or 99% average response rate to standard therapy (including but not limited to chemotherapy, chemotherapy and current clinical trial therapies). Such cancers include but are not limited to, Hodgkin&#39;s lymphoma, melanoma, non-small cell lung cancer (NSCLC), microsatellite instability (MSI)-high or mismatch repair (MMR)-deficient solid tumors, CSCC, RCC, CRC, melanoma, Merkel cell cancer, bladder cancer, RCC, hepatocellular carcinoma (HCC), head &amp; neck cancer (H&amp;N), cervical cancer, gastric cancer, small cell lung cancer (SCLC), endometrial cancer, mesothelioma, ovarian cancer, triple negative breast cancer (TNBC), breast cancer, colorectal cancer (CRC), pancreatic cancer, prostate cancer. 
     In some embodiments, the compositions described herein can be administered as a combination therapy with an additional therapeutic agent. In some embodiments, an additional therapeutic agent comprises a biological molecule, such as an antibody. For example, treatment can involve the combined administration of the modified immune effector cells as described herein with antibodies against tumor-associated antigens including, but not limited to, antibodies that bind EGFR, HER2/ErbB2, and/or VEGF. In certain embodiments, the additional therapeutic agent is an antibody specific for a cancer stem cell marker. In certain embodiments, the additional therapeutic agent is an antibody that is an angiogenesis inhibitor (e.g., an anti-VEGF or VEGF receptor antibody). In certain embodiments, the additional therapeutic agent is bevacizumab (AVASTIN), ramucirumab, trastuzumab (HERCEPTIN), pertuzumab (OMNITARG), panitumumab (VECTIBIX), nimotuzumab, zalutumumab, or cetuximab (ERBITUX). In some embodiments, an additional therapeutic agent comprises an agent such as a small molecule. For example, treatment can involve the combined administration of the modified immune effector cells as described herein with a small molecule that acts as an inhibitor against tumor-associated antigens including, but not limited to, EGFR, HER2 (ErbB2), and/or VEGF. In some embodiments, the modified immune effector cells as described herein administered in combination with a protein kinase inhibitor selected from the group consisting of: gefitinib (IRESSA), erlotinib (TARCEVA), sunitinib (SUTENT), lapatanib, vandetanib (ZACTIMA), AEE788, CI-1033, cediranib (RECENTIN), sorafenib (NEXAVAR), and pazopanib (GW786034B). In some embodiments, an additional therapeutic agent comprises an mTOR inhibitor. In another embodiment, the additional therapeutic agent is chemotherapy or other inhibitors that reduce the number of T RE G cells. In certain embodiments, the therapeutic agent is cyclophosphamide or an anti-CTLA4 antibody. In another embodiment, the additional therapeutic reduces the presence of myeloid-derived suppressor cells. In a further embodiment, the additional therapeutic is carbotaxol. In a further embodiment, the additional therapeutic agent is ibrutinib. In some embodiments, an additional therapeutic agent comprises an anti-PD-1 or anti-PDL1 inhibitor. In some embodiments, the method can further comprise one or more checkpoint inhibitors in combination with modified immune effector cells as described herein. In some embodiments, the additional checkpoint inhibitor can be an anti-CTLA-4 antibody. The anti-CTLA-4 antibody (e.g., ipilimumab) has shown durable anti-tumor activities and prolonged survival in participants with advanced melanoma, resulting in its Food and Drug Administration (FDA) approval in 2011. See Hodi et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. (2010) Aug. 19; 363(8):711-23. In some embodiments, the one or more checkpoint inhibitors can be an anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody can be a full length atezolizumab (anti-PD-L1), avelumab (anti-PD-L1), durvalumab (anti-PD-L1), or a fragment or a variant thereof. In some embodiments, the one or more checkpoint inhibitors can be any one or more of CD27 inhibitor, CD28 inhibitor, CD40 inhibitor, CD122 inhibitor, CD137 inhibitor, OX40 (also known as CD134) inhibitor, GITR inhibitor, ICOS inhibitor, or any combination thereof. In some embodiments, the one or more checkpoint inhibitors can be any one or more of A2AR inhibitor, B7-H3 (also known as CD276) inhibitor, B7-H4 (also known as VTCN1) inhibitor, BTLA inhibitor, IDO inhibitor, KIR inhibitor, LAG3 inhibitor, TIM-3 inhibitor, VISTA inhibitor, or any combination thereof. 
     In certain embodiments, an additional therapeutic agent comprises a second immunotherapeutic agent. In some embodiments, the additional immunotherapeutic agent includes, but is not limited to, a colony stimulating factor, an interleukin, an antibody that blocks immunosuppressive functions (e.g., an anti-CTLA-4 antibody, anti-CD28 antibody, anti-CD3 antibody, anti-PD-L1 antibody, anti-TIGIT antibody), an antibody that enhances immune cell functions (e.g., an anti-GITR antibody, an anti-OX-40 antibody, an anti-CD40 antibody, or an anti-4-1BB antibody), a toll-like receptor (e.g., TLR4, TLR7, TLR9), a soluble ligand (e.g., GITRL, GITRL-Fc, OX-40L, OX-40L-Fc, CD40L, CD40L-Fc, 4-1BB ligand, or 4-1BB ligand-Fc), or a member of the B7 family (e.g., CD80, CD86). In some embodiments, the additional immunotherapeutic agent targets CTLA-4, CD28, CD3, PD-L1, TIGIT, GITR, OX-40, CD-40, or 4-1BB. 
     In some embodiments, the additional therapeutic agent is an additional immune checkpoint inhibitor. As used herein, “an immune checkpoint inhibitor” is an agent that inhibits the activity of an immune checkpoint protein. In some embodiments, the additional immune checkpoint inhibitor is an anti-PD-L1 antibody, an anti-CTLA-4 antibody, an anti-CD28 antibody, an anti-TIGIT antibody, an anti-LAG3 antibody, an anti-TIM3 antibody, an anti-GITR antibody, an anti-4-1BB antibody, or an anti-OX-40 antibody. In some embodiments, the additional therapeutic agent is an anti-TIGIT antibody. In some embodiments, the additional therapeutic agent is an anti-PD-L1 antibody selected from the group consisting of: BMS935559 (MDX-1105), atexolizumab (MPDL3280A), durvalumab (MEDI4736), and avelumab (MSB0010718C). In some embodiments, the additional therapeutic agent is an anti-CTLA-4 antibody selected from the group consisting of: ipilimumab (YERVOY) and tremelimumab. In some embodiments, the additional therapeutic agent is an anti-LAG-3 antibody selected from the group consisting of: BMS-986016 and LAG525. In some embodiments, the additional therapeutic agent is an anti-OX-40 antibody selected from the group consisting of: MEDI6469, MEDI0562, and MOXR0916. In some embodiments, the additional therapeutic agent is an anti-4-1BB antibody selected from the group consisting of: PF-05082566. In some embodiments, the modified immune effector cells as described herein can be administered in combination with a biologic molecule selected from the group consisting of: cytokines, adrenomedullin (AM), angiopoietin (Ang), BMPs, BDNF, EGF, erythropoietin (EPO), FGF, GDNF, granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), stem cell factor (SCF), GDF9, HGF, HDGF, IGF, migration-stimulating factor, myostatin (GDF-8), NGF, neurotrophins, PDGF, thrombopoietin, TGF-α, TGF-β, TNF-α, VEGF, P1GF, gamma-IFN, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-12, IL-15, and IL-18. 
     XVI. Personalized Therapy 
     In an embodiment, the invention involves the detection of a disease or disorder associated with the overexpression of an antigen in a subject. The method of detection comprises: a) contacting a sample from a subject with one or more of the antibodies, or antigen-binding fragments thereof, that are described herein; and b) detecting an increased level of binding of the antibody or fragment thereof to the sample as compared to such binding to a control sample lacking the disease, thereby detecting the disease in the subject. In certain embodiments, the disease is cancer. In certain such embodiments, the cancer is selected from the group of ovarian cancer and breast cancer. While not intending to limit the method of detection, in one embodiment detection of binding is immunohistochemical, for example by enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS), Western blot, immunoprecipitation, and/or radiographic imaging. 
     In an embodiment of the invention, a collection approach is used to transform the personalized cell therapy landscape for patients, including cancer patients. The approach includes the use of a developed and validated collection of non-viral plasmids to target tumor-associated antigens. These design and manufacturing advantages include the use of UltraCAR-T™ technology for generation of genetically modified cells, coupled with the capabilities of the UltraPorator™ electroporation system. These methods, compounds and compositions allow therapies and treatment options to assist cancer centers and physicians deliver personalized, autologous genetically modified cell treatments with overnight manufacturing to cancer patients. Based on the patient&#39;s cancer indication and/or biomarker profile, one or more non-viral plasmids may be selected from the library to build a personalized UltraCAR-T cell treatment. After initial treatment, this approach has potential to allow re-dosing of UltraCAR-T cells targeting the same or new tumor antigen(s) based on the treatment response and the changes in antigen expression of the patient&#39;s tumor. The combination of the advanced UltraVector™ DNA construction platform and the ease of overnight manufacturing gives this library approach an advantage over traditional T-cell therapies. 
     Provided herein is a method for the treatment of a disease or disorder comprising the serial administration of polynucleotides encoding a chimeric antigen receptor or a cell comprising the same. The disease or disorder may, for example, be a cancer or auto-immune disease or disorders. The polynucleotides may be present in a viral or non-viral vector. The chimeric antigen receptors selected from a collection of chimeric antigen receptors having different structural compositions and binding specificities for an array of antigen targets. 
     In certain embodiments, the collection of chimeric antigen receptors comprises a chimeric antigen receptor that targets at least one of the following antigens: BCMA, CAIX, CA125, CCR4, CD3, CD4, CD5, CD7, CD16, CD19, CD20, CD22, CD24, CD25, CD28, CD30, CD33, CD38, CD40, CD44, CD44v6, CD44v7/v8, CD47, CD52, CD56, CD70, CD79b, CD80, CD81, CD86, CD123, CD133, CD138, CD151, CD171, CD174, CD276, CEA, CEACAM6, CLL-1, c-MET, CS1, CSPG4, CTLA-4, DLL3, EDB-F, EGFR, EGFR2, EGFRvIII, EGP-2, EGP-40, EphA2, FAP, FLT1, FLT4, Folate-binding Protein, Folate Receptor, Folate receptor α, α-Folate receptor, Frizzled, GD2, GD3, GHR, GHRHR, GITR, GPC3, Gp100, gp130, HBV antigens, HER1, HER2, HER3, HER4, h5T4, HVEM, IGF1R, IgKAppa, IL-1-RAP, IL-2R, IL6R, IL-11Rα, IL-13R-a2, KDR, KRASG12V, LewisA, LewisY, L1-CAM, LIFRP, LRP5, LTPR, MAGE-A, MAGE-A1, MAGE-A10, MAGE-A3, MAGEA3/A6, MAGE-A4, MAGE-A6, MART-1, MCAM, mesothelin, PSCA, Mucins such as MUC1, MUC4 or MUC16, NGFR, NKG2D, Notch-1-4, NY-ESO-1, O-acetylGD2, O-acetylGD3, OX40, P53, PD1, PDE10A, PD-L1, PD-L2, PRAME, PSMA, PTCH1, RANK, Robol, ROR1, ROR1R, ROR-2, TACI, TAG-72, TCRα, TCRp, TGF, TGFBeta, TGFBeta-II, TGFBR1, TGFBR2, Titin, TLR7, TLR9, TNFR1, TNFR2, TNFRSF4, TRBC1, TWEAK-R, VEGF, VEGF-R2, and WT-1. In certain embodiments, the collection of chimeric antigen receptors comprises a chimeric antigen receptor that targets at least one of the following antigens: B7H4, BCMA, BTLA, CA125, CAIX, CCR4, CD123, CD133, CD137, CD138, CD151, CD16, CD171, CD174, CD19, CD20, CD22, CD24, CD25, CD276, CD28, CD3, CD30, CD33, CD38, CD4, CD40, CD44, CD44v6, CD44v7/v8, CD47, CD5, CD52, CD56, CD7, CD70, CD79b, CD80, CD81, CD86, CEA, CEACAM6, CLL-1, c-MET, CS1, CSPG4, CTLA-4, DLL3, EDB-F, EGFR, EGFR2, EGFRvIII, EGP-2, EGP-40, EphA2, HER1, HER2, HER3, HER4, FAP, FLT1, FLT4, Folate receptor α, Folate-binding protein, folate receptor, Frizzled, GD2, GD3, GHR, GHRHR, GITR, Gp100, gp130, GPC3, h5T4, HBV antigens, HER1/HER3, HPV antigens, HVEM, IGF1R, IgKAppa, IL-11Rα, IL-13R-a2, IL-1-RAP, IL-2R, IL6R, KDR, KRASG12V, L1-CAM, LewisA, LewisY, LIFRP, LRP5, LTPR, MAGE-A, MAGE-A1, MAGE-A10, MAGE-A3, MAGEA3/A6, MAGE-A4, MAGE-A6, MART-1, MCAM, Mesothelin, mucins such as MUC1 and MUC16, NGFR, NKG2D, Notch 1-4, NY-ESO-1, O-acetylGD2, O-acetylGD3, OX40, P53, PD1, PDE10A, PD-L1, PD-L2, PMSA, PRAME, PSCA, PSMA, PTCH1, RANK, Robol, ROR1, ROR1R, ROR-2, TACI, TAG-72, TCRα, TCRp, TGF, TGFβ, TGFβ-II, TGFBR1, TGFBR2, Titin, TLR7, TLR9, TNFR1, TNFR2, TNFRSF4, TRBC1, TWEAK-R, VEGF, VEGF-R2, and WT-1. 
     In certain embodiments, the method comprises a first administration of cells expressing one or more chimeric antigen receptors from the collection followed by a second administration of cells expressing one or more chimeric antigen receptors from the collection, wherein a period of time elapses between the first and second administrations. In certain embodiments, the same one or more CARs in the first administration are administered again. In certain other embodiments, at least one of the CARs expressed by cells in the second administration is different from CARs in the first administration. In certain embodiments, the invention comprises a third, fourth, fifth, sixth, seventh, eighth, ninth, tenth or any additional number of rounds of administration of cells expressing CARs selected from the collection, wherein in each subsequent round of administration a different CAR is administered which was not administered in a previous round of treatment. 
     In certain embodiments, the dose of the cells is autologous. In certain embodiments, the dose of cells is allogenic. In certain embodiments, one dose of the cells is autologous and another dose is allogenic. 
     In certain embodiments, prior to a second or subsequent administration of a CAR or CARs, a period of time is allowed to elapse that is sufficient for biologic or therapeutic activity of one or more CARs in a preceding administration to become diminished from peak biologic or therapeutic activity, become negligible or become undetectable. In certain embodiments, a subsequent administration of a CAR takes place at least one day following the previous administration of a CAR. 
     The polynucleotide encoding the CAR may be introduced into the cells of a subject by way of viral transduction, non-viral transfection or electroporation methods of delivery. 
     In certain embodiments, the polynucleotide encoding the CAR may be administered as part of a vector, such as those described herein. In certain embodiments of the invention, one or more polynucleotides encoding a CAR further comprises nucleotide sequences encoding a cytokine, a cell tag, and/or a gene switch, as described previously. In certain embodiments, the vector comprises the polynucleotide encoding the CAR and one or more polynucleotides encoding the cytokine, cell tag, and/or a gene switch. 
     In certain embodiments, the vector is a “regulatory approved vector,” meaning that it has been approved by a Regulatory Authority, national, supra-national (e.g., the U.S. Food and Drug Administration (FDA), the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, wherein such approval is necessary or sufficient for the manufacture, distribution, use or sale of a vector in a regulatory jurisdiction. In certain embodiments, such a “regulatory approved vector” means a vector which has been approved, at a minimum, for use in human clinical safety trials (sometimes referred to as “phase 1 clinical trial”) in a regulatory jurisdiction. “Clinical safety” or “Phase 1” trial means a trial to assess at least safety, optionally to assess safety and dosages, for analysis of side effects associated with the test article, optionally to assess side effects in conjunction with varying dosages. In certain embodiments, “regulatory approved vector” means a vector which has been approved, at a minimum, for use in “Phase 2” studies. A “Phase 2” study is one in which the test article is administered to a larger group human subjects (as compared to a smaller Phase 1 group of subjects) for evaluation of a larger group of patients (typically up to a few hundred) with a disease, disorder or condition for which the test article is developed, to initially assess its effectiveness and to further study its safety. In certain embodiments, a Phase 2 study is to assess the optimal dose or doses of a test article to maximize benefits, while minimizing risks. In certain embodiments, “regulatory approved vector” means a vector which has been approved, at a minimum, for use in “Phase 3” studies. A Phase 3 study (sometimes referred to as “pivotal trials”) typically involves about 300 to 3,000 participants from a patient population for which the test article is intended to be used. Participants in a Phase 3 study are typically assigned to receive either the test article or a placebo (a substance that has no therapeutic effect). A Phase 3 study is intended to demonstrate whether or not a test article offers a treatment benefit to a specific population and to provide more detailed safety data, and to serve as the basis for product labeling in regard to diseases or conditions for which the test article may be used. In certain embodiments, “regulatory approved vector” means a vector which has been approved for commercial manufacturing, use or sale for treatment of a disease, disorder or condition in humans by a regulatory authority in the regulatory jurisdiction (e.g., approval by U.S. FDA for manufacturing, use or sale in the United States of America). In certain embodiments, the “regulatory approved vector” is a regulatory approved lentivirus vector, a regulatory approved retroviral vector, or a regulatory approved non-viral vector. In some embodiments, the regulatory approved vector is a non-viral vector that is a Sleeping Beauty vector. 
     In certain embodiments, the regulatory authority governs approval of pharmaceuticals, biologics, or other medicines or medical treatments in a country selected from the United Arab Emirates, Antigua and Barbuda, Albania, Armenia, Angola, Austria, Australia, Azerbaijan, Bosnia and Herzegovina, Barbados, Belgium, Burkina Faso, Bulgaria, Bahrain, Benin, Brunei Darussalam, Brazil, Botswana, Belarus, Belize, Canada, Central African Republic, Congo, Switzerland, Cote d&#39;Ivoire, Chile, Cameroon, China (People&#39;s Republic of China (PCR)), Colombia, Costa Rica, Cuba, Cyprus, Czech, Germany, Djibouti, Denmark, Dominica, Dominican Republic, Algeria, Ecuador, Estonia, Egypt, Spain, Finland, France, Gabon, United Kingdom, Grenada, Georgia, Ghana, Gambia, Guinea, Equatorial Guinea, Greece, Guatemala, Guinea-Bissau, Honduras, Croatia, Hungary, Indonesia, Ireland, Israel, India, Iran (Islamic Republic of), Iceland, Italy, Jordan, Japan, Kenya, Kyrgyzstan, Cambodia, Comoros, Saint Kitts and Nevis, Democratic People&#39;s Republic of Korea, Republic of Korea, Kuwait, Kazakhstan, Lao People&#39;s Democratic Republic, Saint Lucia, Liechtenstein, Sri Lanka, Liberia, Lesotho, Lithuania, Luxembourg, Latvia, Libya, Morocco, Monaco, Republic of Moldova, Montenegro, Madagascar, North Macedonia, Mali, Mongolia, Mauritania, Malta, Malawi, Mexico, Malaysia, Mozambique, Namibia, Niger, Nigeria, Nicaragua, Netherlands, Norway, New Zealand, Oman, Panama, Peru, Papua New Guinea, Philippines, Poland, Portugal, Qatar, Romania, Serbia, Russian Federation, Rwanda, Saudi Arabia, Seychelles, Sudan, Sweden, Singapore, Slovenia, Slovakia, Sierra Leone, San Marino, Senegal, Sao Tome and Principe, El Salvador, Syrian Arab Republic, Eswatini, Chad, Togo, Thailand, Tajikistan, Turkmenistan, Tunisia, Turkey, Trinidad and Tobago, United Republic of Tanzania, Ukraine, Uganda, United States of America, Uzbekistan, Saint Vincent and the Genadines, Viet Nam, Samoa, South Africa, Zambia, Zimbabwe, Afghanistan, Andorra, ARIPO, Bangladesh, Bolivia, Cayman Islands, Ethiopia, Fiji, Gibraltar, Guam, Haiti, Iraq, Lebanon, Martinique, Micronesia, federated states of, Nauru, OAPI, Palestinian territory, occupied (Gaza), Pitcairn, Saint Barthélemy, Somalia, Taiwan, Tonga, Vanuatu, Yemen, Åland Islands, Anguilla, Aruba, Bermuda, Burundi, Congo (Democratic Republic of the), Eurasian Patent Organization, French Guiana, Greenland, Guernsey, Holy see (Vatican), Jamaica, Macau, Mauritius, Montserrat, Nepal, Pakistan, Palestinian territory, occupied (West Bank), Puerto Rico, Saint Helena, South Sudan, Timor-Leste, Tuvalu, Venezuela, American Samoa, Argentina, Bahamas, Bhutan, Cape Verde, Eritrea, European Union, French Polynesia, Guadeloupe, Guyana, Hong Kong, Kiribati, Maldives, Mayotte, Myanmar, New Caledonia, Palau, Paraguay, Réunion, Saint Pierre and Miquelon, Suriname, Tokelau, Uruguay, and Western Sahara. 
     In certain embodiments, the regulatory authority is selected from a multinational organization, such as the World Health Organization, the Pan-American Health Organization, the World Trade Organization (WTO), the International Conference on Harmonization (ICH), and the World Intellectual Property Organization (WIPO); and a national health authority, such as, in Asia and the Pacific, the Australian Government: Department of Health and Ageing, Australian Government: Therapeutic Goods Administration (TGA), Brunei: Ministry of Health, People&#39;s Republic of China: State Food and Drug Administration, People&#39;s Republic of China: Ministry of Health, People&#39;s Republic of China: National Medical Products Administration, People&#39;s Republic of China: National Institute for the Control of Pharmaceutical and Biological Products, People&#39;s Republic of China: Ministry of Agriculture, Fiji: Ministry of Health, Hong Kong: Department of Health, India: Ministry of Consumer Affairs, Food &amp; Public Distribution, India: Central Drug Standards Control Organization (CDSCO), India: Ministry of Food and Consumer Affairs, Indonesia: Ministry of Health, Japan: Ministry of Health, Labor and Welfare, Japan: Pharmaceuticals and Medical Devices Evaluation Agency, Korea: Food and Drug Administration, Malaysia: Ministry of Health, Malaysia: National Pharmaceutical Regulatory Agency, New Zealand: Ministry of Health, New Zealand: Medicines and Medical Devices Safety Authority, New Zealand: Food Safety Authority, Papua New Guinea: Department of Health, Philippines: Department of Health, Philippines: National Food Authority, Singapore: Ministry of Health, Singapore: Health Sciences Authority, Sri Lanka: Ministry of Health, Taiwan: Department of Health, Taiwan: National Laboratories of Foods and Drugs, Thailand: Ministry of Public Health, Thailand: Food and Drug Administration, Thailand: Ministry of Agriculture and Co-operatives, in Europe, the European Medicines Agency (EMA), European Commission Directorate General: Medicinal Products for Veterinary Use, Andorra: Ministry of Health and Welfare, Armenia: Ministry of Health, Armenia: Drug and Medical Technology Agency, Austria: Secretariat of Health, Belgium: Health, Food Chain Safety and Environment, Belgium: Pharmaceutical Inspectorate, Belgium: Federal Agency for the Safety of the Food Chain, Bulgaria: Ministry of Health, Bulgaria: Drug Agency, Croatia: Ministry of Health and Social Care, Czech Republic: Ministry of Health, Czech Republic: State Institute for Drug Control, Denmark: Ministry of Health, Denmark: Danish Medicines Agency, Denmark: Veterinary and Food Administration, Estonia: State Agency of Medicines, Finland: Ministry of Social Affairs and Health, Finnish Medicines Agency, France: Ministry of Health, France: National Agency for Veterinary Medicinal Products, Georgia: Ministry of Labor, Health and Social Affairs, Germany: Ministry of Health, Germany: Federal Institute for Drugs and Medical Devices, Germany: Robert Koch Institute, Germany: Paul Ehrlich Institute, Germany: Federal Institute for Risk Assessment, Germany: Ministry of Consumer Protection, Food and Agriculture, Greece: Ministry of Health and Social Solidarity, Greece: National Organization for Medicines, Hungary: Ministry of Health, Social and Family Affairs, Hungary: National Institute of Pharmacy, Iceland: Ministry for Health and Social Security, Icelandic Medicines Agency, Iceland: The Environment Agency, Ireland: Department of Health and Children, Irish Medicines Board, Italy: Ministry of Health, Italy: National Institute of Health, Latvia: State Agency of Medicines, Lithuania: Ministry of Health, Lithuania: State Medicines Control Agency, Luxembourg: Ministry of Health, Malta: Ministry of Health, Elderly and Community Care, Netherlands: Ministry of Health, Welfare and Sport, Netherlands: Medicines Evaluation Board, Netherlands: Inspectorate for Health Protection and Veterinary Public Health, Norway: Ministry of Health and Care Services, Norway: Norwegian Board of Health Supervision, Norway: Norwegian Medicines Agency, Norway: Ministry of Agriculture and Food, Poland: Ministry of Health and Social Security, Poland: Drug Institute, Portugal: Ministry of Health, Portugal: National Authority of Medicines and Health Products, Romania: Ministry of Health and the Family, Russian Federation: Scientific Centre for Expert Evaluation of Medicinal Products, Russian Federation: State Institute of Drugs and Good Practices, San Marino, Ministry of Health and Social Security, National Insurance and Gender Equality (in Italian), Slovak Republic: Ministry of Health, Slovak Republic: State Institute for Drug Control, Slovak Republic: State Veterinary and Food Administration, Slovenia: Ministry of Health, Slovenia: Institute of Public Health, Spain: Ministry of Health and Consumption; Spanish Agency for Medicines and Health Products, Sweden: Medical Products Agency, Sweden: National Board of Health and Welfare, Sweden: National Food Administration, Switzerland: Federal Office of Public Health, Switzerland: Agency for Therapeutic Products, Switzerland: Federal Veterinary Office, Turkey: Ministry of Health (in Turkish), Ukraine: Ministry of Health, UK: Department of Health, UK: Health Protection Agency, UK: Medicines and Healthcare Products Regulatory Agency (MHRA), UK: National Institute for Biological Standards and Control, UK: Veterinary Medicines Directorate, in the Middle East, the Bahrain: Ministry of Health, Israel: Ministry of Health, Israel: Ministry of Industry, Trade and Labor, Jordan: Ministry of Health, Lebanon: Ministry of Public Health, Palestinian Authority: Ministry of Health, Saudi Arabia: Ministry of Health, United Arab Emirates: Ministry of Health, United Arab Emirates: Federal Department of Pharmacies, Yemen: Ministry of Public Health &amp; Population, in Africa, the Benin: Ministry of Health, Botswana: Ministry of Health, Egypt: Ministry of Agriculture and Land Reclamation, Ghana: Ministry of Health, Ghana: Ministry of Food and Agriculture, Kenya: Ministry of Health, Maldives: Ministry of Health, Mauritius: Ministry of Health &amp; Quality of Life, Mauritius: Ministry of Agro Industry and Food Security, Morocco: Ministry of Public Health, Namibia: Ministry of Health and Social Services, Senegal: Ministry of Health and Prevention, South Africa: Department of Health, Swaziland: Ministry of Health and Social Welfare, Tanzania: Ministry of Health, Tunisia: Ministry of Public Health, Tunisia: Office of Pharmacy and Medicines, Uganda: Ministry of Health, Zimbabwe: Ministry of Health and Child Welfare, and in the Americas, the Argentina: Ministry of Health, Argentina: National Administration of Drugs, Foods and Medical Technology, Belize: Ministry of Health, Bolivia: Ministry of Health and Social Welfare, Brazil: Ministry of Health, Brazil: National Health Surveillance Agency, Brazil: Fundacao Oswaldo Cruz, Canada: Health Canada, Canada: Health Products and Food Branch, Chile: Health Ministry, Chile: Institute of Public Health, Colombia: Ministry of Health, Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos, Costa Rica: Ministry of Health, Dominican Republic: Ministry of Agriculture, Ecuador: Ministry of Public Health, El Salvador: Ministry of Public Health and Social Assistance, El Salvador: Ministry of Agriculture, Guatemala: Ministry of Health, Guyana: Ministry of Health, Guyana: National Bureau of Standards, Jamaica: Ministry of Health, Mexico: Ministry of Health, Mexico: Federal Commission for the Protection Against Sanitary Risks, Netherlands Antilles: Department of Public Health and Environmental Protection, Nicaragua: Ministry of Health, Panama: Ministry of Health, Peru: Ministry of Health, Peru: General Directorate of Medicines, Supplies and Drugs, St. Lucia: Ministry of Agriculture, Lands Forestry and Fisheries, Trinidad and Tobago: Ministry of Health, Trinidad &amp; Tobago: Bureau of Standards, United States of America (USA/U.S.): Food and Drug Administration (FDA), Uruguay: Ministry of Public Health, and the Venezuela: Ministry of Health and Social Development. Other exemplary regulatory authorities can also be found at http://iaocr.com/clinical-research-regulations/regulatory-authority-links/ and https://www.pda.org/scientific-and-regulatory-resources/global-regulatory-authority-websites. 
     In certain embodiments, cells expressing one or more CARs are isolated for continued ex vivo expansion and/or are cryopreserved for future use. 
     The present invention also relates to a composition comprising a chimeric antigen receptor as described above. 
     The present invention further relates to a kit comprising a first vector encoding a CAR as described above and a second vector encoding a CAR as described above. 
     EXAMPLES 
     These Examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein. The following table includes abbreviations and special terms that apply to the Examples only. These abbreviations and special terms are not otherwise limiting, and neither replace nor narrow the broader definitions set forth above, which shall continue to apply to the claims. 
     
       
         
           
               
             
               
                 TABLE 9 
               
             
            
               
                   
               
               
                 Abbreviations and Special Terms for Use in the Examples 
               
            
           
           
               
               
            
               
                 Abbreviation of 
                   
               
               
                 Special Term 
                 Explanation 
               
               
                   
               
               
                 Artificial 
                 A non-naturally occurring miRNA designed to target 
               
               
                 miRNA 
                 a specific gene 
               
               
                 CAR-T 
                 Chimeric Antigen Receptor T Cell 
               
               
                 Guide miRNA 
                 The mature miRNA processed from the pre-miRNA that 
               
               
                   
                 is complementary to an intended target gene 
               
               
                 LFC 
                 Log2 fold change 
               
               
                 Mature miRNA 
                 The fully processed 21-23nt miRNA 
               
               
                 mbIL15 
                 A fusion protein comprising IL-15 and IL-15Rα, 
               
               
                   
                 the protein comprising the amino acid sequence of 
               
               
                   
                 SEQ ID NO: 525 
               
               
                 miRNA 
                 microRNA, a small RNA species generally 21-23nt 
               
               
                   
                 in length that is complementary to a target mRNA 
               
               
                   
                 transcript and reduces expression of the target 
               
               
                   
                 transcript through either RNA degradation or 
               
               
                   
                 inhibition of translation 
               
               
                 Passenger 
                 A mature miRNA that may be processed from the side 
               
               
                 miRNA 
                 opposite of the guide miRNA in the RNA stem-loop 
               
               
                 PD1 Silencer 
                 A genetic module encoded within the VVN-5351 trans- 
               
               
                 Module 
                 gene cassette designed to reduce expression of PD1 
               
               
                   
                 within ROR1 + PD1 silencer cells. The module 
               
               
                   
                 consists of a splice unit containing a non-coding 
               
               
                   
                 RNA that is processed by internal cellular machinery 
               
               
                   
                 into 2 unique microRNAs with homology to PD1 mRNA. 
               
               
                 Pre-miRNA 
                 Precursor miRNA, which is the intermediate miRNA 
               
               
                   
                 species that has undergone the first processing step 
               
               
                   
                 to remove the RNA stem-loop structure from the primary 
               
               
                   
                 mRNA transcript. Pre-miRNA undergoes a second pro- 
               
               
                   
                 cessing step in which the mature miRNA is cleaved and 
               
               
                   
                 loaded into the RNA-induced silencing complex (RISC). 
               
               
                 R0R1 + PD1 
                 ROR1 CAR-T cells expressing mbIL15 and HER1t with 
               
               
                 silencer cells 
                 anti-PD-1 miRNAs 
               
               
                 Pri-miRNA/ 
                 The primary transcript encoding RNA stem-loop struc- 
               
               
                 pri-miRNA 
                 tures that are processed by the endogenous cellular 
               
               
                 scaffold 
                 machinery into precursor and then mature miRNA. The 
               
               
                   
                 artificial pri-miRNA sequence and structures are 
               
               
                   
                 based on endogenous human pri-miRNAs, herein referred 
               
               
                   
                 to as a scaffold, with the natural guide and passenger 
               
               
                   
                 strands replaced with a guide miRNA to target PD1 
               
               
                   
                 and a passenger miRNA to maintain the predicted 
               
               
                   
                 folded RNA structure. 
               
               
                 UTR 
                 Untranslated region 
               
               
                 VVN-5351 
                 A DNA transposon plasmid encoding the ROR1 
               
               
                   
                 UltraCAR-T transgene cassette plus a dual PD1- 
               
               
                   
                 targeting miRNA in the 5′UTR encoded within a 
               
               
                   
                 synthetic splice unit. 
               
               
                 VVN-5355 
                 A DNA transposon plasmid encoding the ROR1 
               
               
                   
                 UltraCAR-T transgene cassette. 
               
               
                   
               
            
           
         
       
     
     Example 1. PD1 Module Design 
     The PD1-silencing module of miRNA-expressing ROR1 UltraCAR-T cells encodes two artificial miRNAs designed to specifically reduce expression of PD-1 mRNA within UltraCAR-T cells while avoiding off-target silencing of other endogenous transcripts. The two artificial miRNAs of miRNA-expressing ROR1 UltraCAR-T cells are encoded within a dual primary miRNA (pri-miRNA) sequence placed within a 5′ UTR splice unit of the UltraCAR-T transgene cassette ( FIG. 1B ). The dual pri-miRNA forms stem-loop structures that are recognized and processed by cellular complexes to generate two unique 21-24 nucleotide mature guide miRNAs that are homologous to specific sequences within the PD1 target transcript. Interaction of the guide miRNAs with the PD1 target sequence is expected to trigger the silencing of PD1 by induction of RNA degradation or translational inhibition (Guo et al, 2010). 
     The guide miRNAs encoded within miRNA-expressing ROR1 UltraCAR-T cells were designed to be highly specific for the PD1 target transcript NM_005018.3 by implementation of an internally-designed computational workflow using a combination of twenty-one ranking parameters based on three validated rules-based siRNA prediction algorithms (Amarzguioui and Prydz, 2004; Reynolds et al, 2004; Ui-Tei et al, 2004). Multi-level specificity profiling was performed against the human reference exome (RefSeq) and the activated T-cell transcriptome (Zhao et al, 2014) to ensure that the mature miRNAs are highly specific for the PD1 target gene. To further reduce risk of off-target silencing by the non-PD1 targeting passenger strand miRNAs, pri-miRNA scaffolds were selected that produce a high ratio of guide:passenger miRNA (Miniarikova et al, 2016). The PD1-targeting guide miRNA PD1_1843 was incorporated into a pri-miRNA scaffold based on human miRNA hsa-miR-204 (accession #MI0000284) while the PD1_2061 guide miRNA was incorporated into the hsa-miR-206 (accession #MI0000490) scaffold. Mutations were created on the passenger strand side of each pri-miRNA to assure the specific miRNA structure was maintained and that thermodynamic stability was not substantially altered. RNA structures were predicted using CLC Main Workbench software. The PD1 silencing module contains the miR204 PD1_1843 pri-miRNA placed directly upstream of miR206 PD1_2061 pri-miRNA within a synthetic splice unit in the 5′ UTR of the CAR-T transgene expression cassette. The splice units were ordered as gBlock from IDT and can be cloned into Sleeping Beauty CAR vectors and can be cut using ClaI/NheI for cloning into the 5′UTR of any other Sleeping Beauty CAR vector. 
     Example 2. Reduction of PD1 Transcript Expression by miRNAs 
     Primary human T cells were transfected with the constructs listed in Table 10 and expanded in vitro with the use of AaPC cells expressing cognate antigen that were grown in large batches and then frozen into aliquots. The generated CAR-T cells were then further activated using anti-CD3/anti-CD28 beads at a bead:T cell ratio of 1:1 and 1×10 6  T cells/mL for 48 hrs prior to harvesting the cells for RNA isolation. RNA isolation was performed according to manufacturer&#39;s recommended protocol (Qiagen) then subjected to RT-qPCR analysis using the SuperScript VILO Master Mix with ezDNase (Invitrogen) and TaqMan FAST Advanced master mix for qPCR to evaluate PD-1 expression levels using specific primer/probes (Human PD1: Hs00169472_m1; Human TIGIT: Hs00545087_m1; and Human ACTb: Hs99999903_m1). All samples were also normalized to beta-actin expression levels. The relative expression values are based upon MET method by normalizing to construct #1 (MUC16 CAR-T cells only). Results are shown in  FIG. 2 . Shown is the mean±SD from 3 donors. 
     
       
         
           
               
             
               
                 TABLE 10 
               
             
            
               
                   
               
               
                 Description of constructs 1-8 as utilized in FIG. 
               
               
                 2 sequences of miRNA are as described in Table 4) 
               
            
           
           
               
               
               
            
               
                 Construct 
                   
                   
               
               
                 # 
                 miRNA 
                 Effector Genes 
               
               
                   
               
               
                 1 
                 N/A 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                 2 
                 Scrambled 1 (SEQ ID NO: 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 586) 
               
               
                 3 
                 Scrambled 2 (SEQ ID NO: 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 582) 
               
               
                 4 
                 miR204 PD1 + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 
               
               
                 5 
                 miR17 TIGIT 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                 6 
                 miR150 TIGIT + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 
               
               
                 7 
                 miR204 PD1 + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 + miR17 TIGIT 
               
               
                 8 
                 N/A 
                 MUC16 CAR + HER1t 
               
               
                   
               
            
           
         
       
     
     The data demonstrates the specificity of PD-1 checkpoint inhibitor miRNA targeting the intended sequence. CAR constructs that expressed the scrambled miRNA (Constructs 2 and 3) along with the CAR construct that did not express mbIL-15 (construct #8) did not show any decrease in PD-1 expression whereas CAR constructs that contain PD-1 miRNA (construct 4) or a combination of PD-1 and TIGIT miRNA (constructs 6 and 7) did show a decrease in PD-1 expression. On the other hand, the CAR construct containing only a TIGIT miRNA sequence (construct 5) did not show any decrease in PD-1 mRNA expression levels further demonstrating the specificity in targeting. 
     Example 3. Downregulation of Targeted mRNA 
     Primary human T cells were transfected with a vector encoding CD33-specific CAR or a vector encoding MUC16-specific CAR. The vectors comprise a synthetic intron containing miRNA sequences that target PD-1, PD-1 and/or TIGIT or a non-targeting scrambled control miRNA. T cell cultures were in vitro expanded using antigen presenting cells with cognate tumor antigen that were K562 cells modified to express either CD33 or MUC16 plus other co-stimulatory molecules (based on “Clone 1”) and at a ratio of 1:1 (AaPC:T cell). The generated CAR+ cells were then stimulated with anti-CD3/anti-CD28 beads (1:1 bead:T cell ratio) in the absence of cytokines for 48 hrs. RNA was isolated using Qiagen kits (AllPrep Universal DNA/RNA/miRNA kit #80224) as per manufacturer&#39;s protocol and utilized for the Human PanCancer Immune gene set panel Kit from Nanostring. Briefly, the RNA was hybridized with capture and reporter probe sets and samples processed then hybridized to the slide using the nCounter Prep Station and transcript counts were generated by the nCounter Digital Analyzer according to the manufacturer&#39;s protocol. Data validation, QC and normalization were performed by nSolver software (Nanostring Technologies). 
     The distribution of the transcript count data on the graph would be a line (from lower left to top right corner) with the slope of 1 if the samples were identical. Data points falling off this line represent variations in transcript counts between the two samples. Counts that were found below the main line represent reduced expression whereas counts above the main line represent increased expression to the sample being compared. The transcript targeted by the miRNA, either PD-1 or TIGIT expressed in the CAR-T cells, specifically showed lower expression of the transcripts of their respective targeted genes compared to the CAR-T cells without the miRNA. See  FIG. 3A-B . In addition, to further demonstrate the specificity of targeting, the CAR-T cells with the scrambled control miRNA had no alterations to the transcript levels of either PD-1 or TIGIT, as the data distribution in this graph remained close to the diagonal indicating very little variation in transcript levels. See  FIG. 3C . Similar results were observed in T cells transfected with the MUC16 CAR vector comprising a synthetic intron containing miRNA sequences that target PD-1, PD-1 and/or TIGIT (see  FIG. 4A-C ). 
     Example 4. Enhancement of Tumor Cell Cytotoxicity Effect of miRNA MUC16 CAR-T Cells 
     Primary human T cells were transfected with a vector encoding MUC16-specific CAR and miRNA sequences that target two sequences within the PD-1 transcript, or with a vector that encodes the MUC16-specific CAR but not an miRNA. CAR-T cells used in this assay were in vitro expanded, normalized for CAR expression then seeded in triplicates with GFP+ K562 cells expressing MUC16 (“tumor cells”) in 96 well plates at the 3:1 E:T ratios. The plate was loaded into the IncuCyteS3 instrument and 4 images per well were taken every 2 hr for 7 days. The IncuCyte Software was used to analyze the data and normalize the GFP+ cell counts/image to the 0 hr time point. 
     The outgrowth assay determines the rate of target cell growth in the presence or absence of CAR-T cells over the course of 7 days in culture. The lower target cell count in cultures containing CAR-T cells indicate the CAR-T cytolytic activity.  FIG. 5A  depicts the difference between the tumor target cells only (black circle, filled) and the cells expressing the MUC16-specific CAR only (open square), demonstrating the killing capacity of the MUC16 CAR-T cells. The cells further expressing miRNA targeting PD-1 (grey circle filled) further demonstrates improved cytolytic activity, based upon the sustained low GFP+ counts over the time course evaluation, compared to the cells expressing MUC16 specific CAR only (open square). This data demonstrates the enhanced cytolytic activity of CAR-T cells containing PD-1 targeting miRNA. 
     A similar experiment was conducted utilizing GFP+ K562 cells expressing MUC16, PD-L1, and CD155. As shown in  FIG. 5B , the difference between the tumor target cells only (square, filled) and cells expressing the CAR only (circle, open), demonstrates the killing capacity of the MUC16 CAR-T cells. The CAR-T cells incorporating miRNAs targeting both PD-1 and TIGIT (circle, filled) further demonstrates improved cytolytic activity, based upon the sustained low GFP+ counts over the time course evaluation, compared to the MUC16 CAR-T cells only (circle, filled). This data demonstrates the enhanced cytolytic activity of CAR-T cells containing 3 targeting miRNAs (2 for PD-1 and 1 for TIGIT) in a single construct. 
     Example 5. Improvement of Cytokine Expression 
     Primary human T cells were transfected with vectors encoding MUC16-specific CAR but not miRNA targeting sequences, and vectors encoding MUC16-specific CAR and single or combinations of miRNA targeting sequences of PD-1 and TIGIT (see Table 11). In vitro expanded CAR-T cells were in vitro expanded, normalized for CAR expression then seeded in triplicates in 96 well plates with K562 tumor target cells expressing truncated MUC16 9MUC16t) at an effector to target ratio of 1:1 or the CAR-T cells were cultured in media alone. Culture supernatants were collected after co-culturing for 3 days. Culture supernatants were collected and interferon-gamma (IFNγ) and granulocyte/macrophage-colony stimulating factor (GM-CSF) was assessed by multiplex cytokine analysis (Luminex) according to manufacturer&#39;s protocol. Shown in  FIG. 6  is the mean±SD from duplicate wells. 
     For the CAR-T cell constructs cultured in media only had basal levels of IFNγ and GM-CSF detected. No cytokines were observed from the use of target cells or media only. The supernatants following co-culture of MUC16 CAR-T cells only (Vector 1) with the tumor cells provided a baseline value for expression levels of IFNγ and GM-CSF. With the inclusion of checkpoint inhibitor miRNA into the CAR constructs, improved cytokine expression may be observed, particularly through inhibition via the PD-1 pathway. In the constructs that contained dual PD-1 (Construct #3) or the combination of a single PD-1 and TIGIT miRNA (Construct #6) or dual PD-1 and a TIGIT miRNA (Constructs #10 and 11) provided higher levels of cytokine expression. 
     
       
         
           
               
             
               
                 TABLE 11 
               
             
            
               
                   
               
               
                 Description of Constructs #1-11 in FIGS. 6A-D 
               
               
                 (sequences of miRNA are as described in Table 4) 
               
            
           
           
               
               
               
            
               
                 Constructs 
                 miRNA 
                 Effector genes 
               
               
                   
               
            
           
           
               
               
               
            
               
                 1 
                 N/A 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                 2 
                 Scrambled control 1 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                 3 
                 miR204 PD1 + miR206 PD1 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                 4 
                 miR17 TIGIT 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                 5 
                 miR17 TIGIT + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 
               
               
                 6 
                 miR150 TIGIT + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 
               
               
                 7 
                 miR17 TIGIT + miR204 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 + miR206 PD1 
               
               
                 8 
                 miR17 TIGIT + miR204 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 + miR206 PD1extended 
               
               
                   
                 v1 
               
               
                 9 
                 miR17 TIGIT + miR204 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 + miR206 PD1extended 
               
               
                   
                 v2 
               
               
                 10 
                 miR204 PD1 + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 + miR17 TIGIT 
               
               
                 11 
                 miR204 PD1 + miR206 
                 MUC16 CAR-mbIL15-HER1t 
               
               
                   
                 PD1 + miR17 TIGITextended 
               
               
                   
                 v1 
               
               
                   
               
            
           
         
       
     
     Example 6. Tumor Burden in Treated Mice 
     Non-obese diabetic/severe combined immunodeficiency (NOD/SCID) gamma mice (NSG) mice were intraperitoneally implanted with fLUC-GFP+SK-OV-3 tumor cells expressing MUCt on Day 0. Tumor burden was monitored in these mice throughout the study using an in vivo imaging system (IVIS) by luminescence with an IVIS Spectrum instrument (Perkin Elmer). IVIS data was analyzed using the Living Image Software (Version 4.1) based upon a defined region of interest to obtain total flux values (photons/sec). Prior to administration of the CAR-T cells, mice were randomized based upon tumor burden and body weight into the different groups then administered the test articles on Day 6 All CARs tested expressed the MUC16-specific CAR along with mbIL15 and HER1t and are referred to as MUC16 CAR. All test articles were normalized to a 0.5×10 6  CAR-T cells/mouse and administered intraperitoneally. IVIS imaging was performed twice/week to monitor overall tumor burden in the mice. Data shown is the mean±SEM from n=4-8 mice/group. 
     As shown in  FIG. 7 , mice given saline only (gray-filled circles), had continuous tumor growth as evidenced by the increasing total flux levels observed throughout the course of the study. Eventually, these mice succumbed to the tumor burden and were euthanized. Mice given the MUC16 CAR only (black-filled squares) were able to control tumor burden. CAR-T cells expressing the checkpoint inhibitor miRNA to PD-1 and TIGIT within the constructs (open squares and circles) were found to maintain anti-tumor activity, based upon the decrease in tumor flux values to background levels. In addition, the CAR-T cells expressing the checkpoint inhibitor miRNA to PD-1 and TIGIT showed a faster time frame and the rate of tumor burden decrease compared to the MUC16 CAR only construct. 
     Example 7. In Vivo Phenotyping Experiment 
     SKOV-3/MUC16 tumor bearing mice were administered CAR-T cells (expressing MUC16-specific CAR, mbIL15 and HER1t) of either CAR only or CAR with PD-1/PD-1 miRNA on Study Day 6. Whole blood from mice were taken on Study Day 31 for phenotypic evaluation by flow cytometry of the administered CAR-T cells. Briefly, cocktails of fluorescently conjugated antibodies were used to stain the whole blood samples then concurrently fixed along with red blood cells lysis using a one-step Fix/Lyse buffer. The fixed samples were read on the flow cytometer (BD LSRFortessaX-20) instrument. CAR-T cells were identified based upon gating of hCD45/CD3+/HER1t+ expression. In,  FIG. 8A , the sample of CAR only (dotted line) shows high PD-1 expression, whereas the CAR with PD-1/PD-1 miRNA (solid line) shows a significant decrease in the level of PD-1 expression detected. To further quantify the reduced expression of PD-1 detected on the CAR+ miRNA (PD-1/PD-1) group, the median fluorescent intensity (MFI) was examined ( FIG. 8B ). The mean MFI of PD1 expression in mice given CAR-T cells (stripe bar) only was ˜709 whereas the mean MFI of the CAR-T cells with a PD-1/PD-1 miRNA (solid bar) was reduced down to ˜236. The mean±SEM from 5-8 mice is shown. 
     Example 8. Specific PD-1 and TIGIT Downregulation 
     SKOV-3 tumor bearing mice were administered CAR-T cells (expressing MUC16-specific CAR (“MUC16 CAR”), mbIL15 and HER1t) of either CAR only or CAR with different checkpoint miRNA inhibitors (PD-1 and TIGIT) on Study Day 6. See Table 12. 
     
       
         
           
               
             
               
                 TABLE 12 
               
             
            
               
                   
               
               
                 Description of Groups #1-9 in FIGS. 9A-B 
               
            
           
           
               
               
            
               
                 Group 
                 CAR-T Cells 
               
               
                   
               
               
                 1 
                 Saline control 
               
               
                 2 
                 MUC16 CAR/mbIL15/HER1t 
               
               
                 3 
                 MUC16 CAR/mbIL15/HER1t + anti-PD1 
               
               
                 4 
                 MUC16 CAR/mbIL15/HER1t + scrambled miRNA 2 
               
               
                 5 
                 MUC16 CAR/mbIL15/HER1t + miR206 PD1 
               
               
                 6 
                 MUC16 CAR/mbIL15/HER1t + miR17 TIGIT 
               
               
                 7 
                 MUC16 CAR/mbIL15/HER1t + miR204 PD1/miR206 
               
               
                   
                 PD1 
               
               
                 8 
                 MUC16 CAR/mbIL15/HER1t + miR150 TIGIT/miR206 
               
               
                   
                 PD-1 
               
               
                 9 
                 MUC16 CAR/mbIL15/HER1t + miR204 PD1/miR206 
               
               
                   
                 PD1/miR150 TIGIT 
               
               
                   
               
            
           
         
       
     
     Whole blood from mice were taken on Study Day 45 (D45) for phenotypic evaluation by flow cytometry of the administered CAR-T cells. Briefly, cocktails of fluorescently conjugated antibodies, which included specific antibodies for human PD-1 and human TIGIT, were used to stain the whole blood samples then fixed using a one step Fix/Lyse buffer. The fixed samples were read on the flow cytometer (BD LSRFortessaX-20) instrument. CAR-T cells were identified in the mouse based upon gating of hCD45/CD3+/HER1t+ expression. To further evaluate the specificity of miRNA used in the CAR vector for the checkpoint inhibitor, the median fluorescent intensity (MFI) for expression of PD-1 and TIGIT was analyzed ( FIGS. 9A  and B). The MFI for PD-1 is shown on the left and the MFI for TIGIT is shown on the right for a quantitative assessment of the expression levels for the same set of vectors. As shown in  FIG. 9A , reduced expression of PD-1 was seen on the CAR-T cells for the groups indicated with the down arrows (solid line for PD-1), which are constructs with a PD-1 miRNA (single, double and in combination with another miRNA checkpoint inhibitor), when compared to the CAR vector only. On the right side (downward dashed arrows) highlights cell populations with a reduced expression of TIGIT expression seen on the CAR-T cells. The downregulated expression of TIGIT corresponded to the samples that contained a miRNA for TIGIT (either as a single or in combination with other checkpoint miRNA inhibitors). The mean±SEM from 5-8 mice is shown. 
     Example 9. Expression of PD1-Targeting miRNAs in ROR1-Targeted CAR-T Cells 
     Briefly, miRNA-expressing ROR1 UltraCAR-T cells or control ROR1 UltraCAR-T cells were generated from T cells from five donors. PanT cells from five healthy donors were transfected with an indicated transposon vector (VVN-5355 or VVN-5351) plus SB11 transposase vector, and expanded by weekly stimulations for 4 weeks (˜35 days before adding beads) with ROR1 antigen presenting cells. Following a rest period of 7-8 days, UltraCAR-T cells were activated with CD3/CD28 dynabeads (1:1 bead: T cell ratio, T cells at 1×10 6  cells/mL) for 48 hours prior to RNA harvest, 7-8 days after the last AaPC stimulation. Expression of PD1-targeting guide miRNAs and the impact on PD1 mRNA expression were verified by RT-qPCR. Small RNAseq, which is an established method to identify the predicted and alternate miRNA sequences that may arise from a pri-miRNA (Borel et al, 2018; Miniarikova et al, 2016), was performed to compare expression levels of the PD1-targeting guide miRNAs to additional small RNA species, such as passenger miRNA, that may be generated from the PD1 silencer module. Small RNAseq was also used to assess potential changes on global endogenous miRNA expression (Mueller et al, 2012). RNAseq analysis was performed to evaluate global transcript expression and to identify changes in molecular pathway signaling or off-target gene silencing attributed to the PD1 silencer. In silico miRNA target prediction was performed using the miRanda algorithm to identify most likely targets of miRNAs generated from the PD1 silencer module. Expression of the predicted target genes was evaluated by RNAseq. Details of each method is included in the sections below. 
     To characterize expression of miRNAs encoded by the PD1 silencer and impact on PD1 transcript levels, RT-qPCR and small RNAseq were performed. To characterize changes in specific genes or cellular pathways, RNAseq was performed. 
     Nucleic acids were purified from cell pellets using Qiagen&#39;s AllPrep DNA/RNA/miRNA Universal kit (Cat #80224) following the manufacturers protocol. Total RNA was eluted in 50 uL nuclease-free water and concentration measured on a Nanodrop™ 2000 spectrophotometer. 
     To quantify the expression of PD1 guide and passenger miRNAs, total RNA was used as input for cDNA synthesis using Qiagen&#39;s miRCURY LNA RT Kit (#339340). Per the manufacturer&#39;s protocol, cDNA was diluted 1:60 with nuclease-free water and 3 μL of the diluted cDNA was used as input for qPCR using miRCURY LNA SYBR Green PCR Kit (Qiagen #339345) with custom miRCURY LNA primers specific to the two PD1 guide miRNAs. An endogenous miRNA, hsa-let-7a-5p, was quantified as a reference small RNA to allow for input normalization (Qiagen product #339306 with custom #YP00205727). Samples were run in a 384 well format on a QuantStudio 6 Flex instrument. Relative quantification (dCT) calculations were performed in Microsoft Excel and data graphed in GraphPad Prism 9. Calculations for dCT were performed on each technical replicate as follows: 
         dCT=CT (guide miRNA)− CT ( hsa -let-7 a )
 
       ddCT= dCT (miRNACART replicate)− dCT (average of  VVN -5355 technical replicates)
 
       Fold Change=2{circumflex over ( )}-ddCT
 
     The VVN-5355 ROR1 UltraCAR-T control sample serves as the reference control sample for comparison to miRNA expressing ROR1 UltraCAR-T cells within each donor set. Average fold change and standard deviation of technical replicates was calculated and reported in  FIG. 10A . 
     To quantify and compare the production of guide and passenger miRNAs originating from the PD1 silencing module, RT-qPCR was performed as described above, except this second experiment included primer assays to detect the passenger miRNAs as well as an additional endogenous reference small RNA, RNU1A1. Expression calculations were performed to compare expression of each guide or passenger strand mature miRNA relative to the average of the endogenous control small RNAs as follows: 
         dCT=CT (mature miRNA)− CT (average of  hsa -let-7 a  and  RNU 1 A 1)
 
       Fold change=2{circumflex over ( )}- dCT  
 
     Average fold change was calculated from three technical replicates. These values are plotted in  FIG. 11  with mean and standard deviation shown for the donor sample sets tested. 
     To quantify the expression of endogenous PD1 mRNA, cDNA synthesis was performed using a final RNA concentration of 5 ng/μL using Invitrogen&#39;s SuperScript IV VILO Master Mix with ezDNase enzyme kit (#11766050). Multiplex Taqman qPCR was performed using Invitrogen&#39;s TaqMan MastAdvanced Master Mix (#4444963) with 1 microliter of cDNA and Invitrogen (ThermoFisher Scientific) Taqman assays. Human PD1 Taqman assay (Invitrogen #Hs00169472_m1) was FAM labeled and the internal normalizer gene, ACTb (Invitrogen #Hs99999903_m1), which was VIC-labelled. Samples were run in a 384 well format on a QuantStudio 6 Flex instrument. Relative quantification (dCT) calculations were performed in Microsoft Excel as described above and data graphed in GraphPad Prism 9. 
     
       
         
           
               
             
               
                 TABLE 13 
               
             
            
               
                   
               
               
                 Test and Control Articles 
               
            
           
           
               
               
               
            
               
                 Sample Name 
                 Description 
                 Designation 
               
               
                   
               
               
                 VVN-5355 
                 CAR-T cells generated using  Sleeping   
                 Control 
               
               
                   
                   Beauty  transposon plasmid VVN-5355, 
               
               
                   
                 which contains a transgene cassette 
               
               
                   
                 to express ROR1-specific CAR + 
               
               
                   
                 mbIL-15 + HER1t. 
               
               
                 VVN-5351 
                 CAR-T cells generated using  Sleeping   
                 Test 
               
               
                   
                   Beauty  transposon plasmid VVN-5351, 
                 Article 
               
               
                   
                 which contains a transgene cassette 
               
               
                   
                 to express ROR1-specific CAR + 
               
               
                   
                 mbIL-15 + HER1t plus a PD1 
               
               
                   
                 silencer module. 
               
               
                   
               
            
           
         
       
     
     The PD1 Silencer Module is designed to produce two mature guide miRNAs that bind to the PD1 transcript to silence PD1 expression. Expression of the two PD1-targeting guide miRNAs, referred to as PD1_1843 and PD1_2061, was confirmed in miRNA expressing ROR1 UltraCAR-T cells generated from multiple donors ( FIG. 10A ). A corresponding reduction in PD1 mRNA expression was verified in the miRNA-expressing ROR1 UltraCAR-T cells from all donors tested ( FIG. 10B ). This result demonstrated that the PD1 Silencer module produces the intended guide miRNAs and functions as designed. 
     To reduce the risk of silencing genes other than PD1, the PD1 silencer module was designed using pri-miRNA scaffolds that preferentially produce PD1-targeting guide miRNA over the non-targeting passenger miRNA. Both guide and passenger mature miRNAs were quantified from miRNA expressing ROR1 UltraCAR-T cells by RT-qPCR, which verified PD1 targeting guide miRNAs as the predominant species compared to non-targeting passenger strand miRNA ( FIG. 4 ). The strong processing preference for the PD1 targeted guide miRNA was confirmed by small RNAseq, with 99.7% of reads mapping to the PD1 Silencer Module matching the intended PD1 targeting guide miRNAs ( FIGS. 12  A-E). Furthermore, the start and stop position of the miRNAs was as expected, with miRNAs of 21-23 nucleotides detected that had the same 5′ end and variable length at the 3′ end ( FIGS. 12  A-E). The extremely low incidence of passenger strand miRNAs and lack of unexpected small RNAs generated by aberrant RNA processing substantially reduced the risk for off-target gene silencing. 
     To ensure that expression of the PD1 Silencer module does not overwhelm the internal cellular RNAi machinery, endogenous miRNA counts were compared from miRNA expressing ROR1 UltraCAR-T cells vs control ROR1 UltraCAR-T cells. Examination of the top twenty expressed endogenous miRNAs demonstrated no statistically significant changes in expression across the samples (Table 15). Furthermore, the mature miRNAs generated from the PD1 silencer module accounted for approximately 4% of all quantified small RNAs ( FIG. 13 ). The data indicated that expression of miRNAs from the PD1 silencer module did not saturate the cellular RNAi machinery and had no detectable impact on global endogenous miRNA expression. 
     
       
         
           
               
             
               
                 TABLE 14 
               
             
            
               
                   
               
               
                 Small RNAseq Comparison of Guide and Passenger miRNA Counts 
               
            
           
           
               
               
               
            
               
                   
                 Normalized 
                   
               
               
                 Mature miRNA_Length (Sequence) 
                 Mean 
                 % Total 
               
               
                   
               
               
                 Guide PD1_204_21nt (TTCAGGAATGGGTTCCAAGGA; SEQ 
                 486,432.3 
                 88.2% 
               
               
                 ID NO: 704) 
                   
                   
               
               
                 Guide PD1_204_22nt (TTCAGGAATGGGTTCCAAGGAT; 
                  12,763.5 
                   
               
               
                 SEQ ID NO: 72) 
                   
                   
               
               
                 Guide PD1_204_23nt (TTCAGGAATGGGTTCCAAGGATG; 
                  59,759.4 
                   
               
               
                 SEQ ID NO: 705) 
                   
                   
               
               
                   
               
               
                 Passenger PD1_204_21nt (TCCTGGAAGCTATTCCTGACG; 
                     380.6 
                  0.1% 
               
               
                 SEQ ID NO: 706) 
                   
                   
               
               
                 Passenger PD1_204_22nt (TCCTGGAAGCTATTCCTGACGT; 
                      20.2 
                   
               
               
                 SEQ ID NO: 707) 
                   
                   
               
               
                 Passenger PD1_204_23nt 
                      54.7 
                   
               
               
                 (TCCTGGAAGCTATTCCTGACGTT; SEQ ID NO: 708) 
                   
                   
               
               
                   
               
               
                 Guide PD1_206_21nt (TATAATATAATAGAACCACAG; SEQ 
                   3,752.7 
                 11.5% 
               
               
                 ID NO: 709) 
                   
                   
               
               
                 Guide PD1_206_22nt (TATAATATAATAGAACCACAGG; 
                  49,181.3 
                   
               
               
                 SEQ ID NO: 74) 
                   
                   
               
               
                 Guide PD1_206_23nt (TATAATATAATAGAACCACAGGA; 
                  19,695.3 
                   
               
               
                 SEQ ID NO: 710) 
                   
                   
               
               
                   
               
               
                 Passenger PD1_206_21nt (TGTGGTTCTGTTATATCCATA; 
                   1,581.0 
                  0.3% 
               
               
                 SEQ ID NO: 711) 
                   
                   
               
               
                 Passenger PD1_206_22nt (TGTGGTTCTGTTATATCCATAT; 
                       3.1 
                   
               
               
                 SEQ ID NO: 712) 
                   
                   
               
               
                 Passenger PD1_206_23nt 
                      13.2 
                   
               
               
                 (TGTGGTTCTGTTATATCCATATA; SEQ ID NO: 713) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 15 
               
             
            
               
                   
               
               
                 Top 20 Expressed Endogenous Mature 
               
               
                 miRNAs Detected by Small RNAseq 
               
            
           
           
               
               
               
               
               
            
               
                   
                   
                   
                 Log2 Fold 
                 P-value 
               
               
                   
                 Endogenous miRNA 
                 Base Mean 
                 Change 
                 Adjusted 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 hsa-miR-181a-5p 
                 796180.25 
                 0.11 
                 0.7948 
               
               
                   
                 hsa-miR-191-5p 
                 421094.34 
                 −0.19 
                 0.5622 
               
               
                   
                 hsa-miR-21-5p 
                 386727.78 
                 0.03 
                 0.9411 
               
               
                   
                 hsa-miR-92a-3p 
                 368149.34 
                 0.26 
                 0.2298 
               
               
                   
                 hsa-miR-142-5p 
                 345451.62 
                 0.08 
                 0.8549 
               
               
                   
                 hsa-miR-146b-5p 
                 286127.09 
                 0.24 
                 0.5471 
               
               
                   
                 hsa-miR-16-5p 
                 261883.66 
                 0.00 
                 0.9954 
               
               
                   
                 hsa-miR-146a-5p 
                 229059.23 
                 −0.27 
                 0.4569 
               
               
                   
                 hsa-let-7f-5p 
                 188491.61 
                 0.16 
                 0.6018 
               
               
                   
                 hsa-miR-22-3p 
                 123453.58 
                 −0.01 
                 0.9899 
               
               
                   
                 hsa-miR-26a-5p 
                 110714.77 
                 0.19 
                 0.5166 
               
               
                   
                 hsa-let-7a-5p 
                 104253.31 
                 0.00 
                 0.9921 
               
               
                   
                 hsa-miR-155-5p 
                 72533.08 
                 −0.29 
                 0.2298 
               
               
                   
                 hsa-miR-181b-5p 
                 67527.35 
                 0.12 
                 0.7687 
               
               
                   
                 hsa-let-7i-5p 
                 64631.72 
                 0.30 
                 0.2116 
               
               
                   
                 hsa-miR-21-3p 
                 52519.27 
                 0.25 
                 0.5358 
               
               
                   
                 hsa-miR-186-5p 
                 52479.56 
                 −0.20 
                 0.4189 
               
               
                   
                 hsa-miR-25-3p 
                 50411.16 
                 0.02 
                 0.9696 
               
               
                   
                 hsa-miR-27a-3p 
                 47911.68 
                 −0.10 
                 0.7818 
               
               
                   
                 hsa-let-7g-5p 
                 47159.42 
                 0.01 
                 0.9811 
               
               
                   
                   
               
            
           
         
       
     
     Example 10: PD1 Silencer Module Specifically Reduces Expression of PD-1 
     An in silico miRNA target prediction algorithm, miRanda (Betel et al, 2008; Betel et al, 2010), was used to predict the most likely target transcripts for the guide and passenger miRNAs generated from the PD1 silencer module. The algorithm assigned a score for each potential miRNA target gene, with higher scores indicating higher likelihood of silencing by the input miRNA sequence. A summary of the top ten hits for each mature miRNA generated from the PD1 silencing module is listed in Table 16. PD1 is the only gene with perfect homology to any of the guide and passenger miRNAs and has the highest predicted miRanda score of any potential target gene. Expression of each predicted target gene was characterized from the RNAseq differential expression data set. PD1 was the most downregulated of all predicted target genes, with a log2 fold change (LFC) of −2.63 (˜84% PD1 reduction in miRNA expressing ROR1 UltraCAR-T cells compared to control ROR1 CAR-T cells) and a highly significant adjusted p-value. The expression of other predicted target genes was unchanged; those genes with adjusted p-values below 0.05 had LFC in the range of −0.33 to 0.22, which is an expression decrease or increase of &lt;20%. One exception is a weakly predicted target gene of PD1_2061 guide miRNA, HDAC9, which has a LFC of ˜1.51. HDAC9 is a transcriptional repressor that is mechanistically linked to PD1 expression through BCL6 (Xie et al, 2017; Gil et al, 2016). It is likely that HDAC9 is not directly targeted by PD1_2061 guide miRNA, and that the reduction in HDAC9 is an indirect effect of reduced PD1 expression. 
     
       
         
           
               
             
               
                 TABLE 16 
               
             
            
               
                   
               
               
                 In silico Predicted miRNA Target Genes 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 free 
                 % 
                 Base 
                   
                   
                   
                   
               
               
                   
                 Target 
                 miRanda 
                 energy 
                 Identity 
                 Mean 
                 log2 
                   
                   
                 Adjusted 
               
               
                 miRNA 
                 Gene 
                 Score 
                 kcal/mol 
                 to Target 
                 Count 
                 FoldChange 
                 lfcSE 
                 P value 
                 P Value 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 PD1_1843 
                 PD1 
                 200 
                 −41.9 
                 100.0 
                 84 
                 −2.63 
                 0.293 
                 2.51E−19 
                 2.64E−16 
               
               
                 miR204 
                 MIER3 
                 184 
                 −32.1 
                 84.2 
                 1073 
                 0.01 
                 0.063 
                 0.9104 
                 0.9688 
               
               
                 Guide 
                 SLFN12L 
                 182 
                 −34.2 
                 89.5 
                 1404 
                 −0.22 
                 0.068 
                 0.0015 
                 0.0134 
               
               
                 miRNA 
                 FMO4 
                 180 
                 −28.5 
                 84.2 
                 15 
                 −0.18 
                 0.461 
                 0.6975 
                 NA 
               
               
                   
                 GIGYF1 
                 180 
                 −33.5 
                 84.2 
                 2749 
                 −0.07 
                 0.046 
                 0.1123 
                 0.3211 
               
               
                   
                 FAM83G 
                 180 
                 −31.5 
                 84.2 
                 171 
                 0.33 
                 0.144 
                 0.0214 
                 0.1026 
               
               
                   
                 PPRC1 
                 180 
                 −31.2 
                 84.2 
                 2679 
                 −0.18 
                 0.045 
                 0.0001 
                 0.0011 
               
               
                   
                 PRMT9 
                 180 
                 −29.1 
                 84.2 
                 335 
                 0.09 
                 0.100 
                 0.3704 
                 0.6432 
               
               
                   
                 MGAT4B 
                 179 
                 −29.3 
                 88.9 
                 4480 
                 −0.21 
                 0.063 
                 0.0007 
                 0.0076 
               
               
                   
                 BRWD1 
                 179 
                 −25.0 
                 88.9 
                 1816 
                 0.05 
                 0.052 
                 0.3581 
                 0.6328 
               
               
                 PD1_1843 
                 DOCK9 
                 179 
                 −28.5 
                 83.3 
                 1239 
                 −0.12 
                 0.077 
                 0.1240 
                 0.3428 
               
               
                 miR204 
                 NFYA 
                 179 
                 −27.5 
                 83.3 
                 1615 
                 −0.02 
                 0.052 
                 0.7446 
                 0.8911 
               
               
                 Passenger 
                 IFIT5 
                 178 
                 −30.4 
                 89.5 
                 379 
                 −0.11 
                 0.102 
                 0.2629 
                 0.5351 
               
               
                 miRNA 
                 OTUB2 
                 178 
                 −33.7 
                 84.2 
                 248 
                 −0.32 
                 0.131 
                 0.0154 
                 0.0805 
               
               
                   
                 UBIAD1 
                 177 
                 −32.1 
                 88.9 
                 1064 
                 −0.07 
                 0.066 
                 0.3085 
                 0.5859 
               
               
                   
                 MYO15A 
                 176 
                 −29.5 
                 93.3 
                 11 
                 −0.25 
                 0.510 
                 0.6263 
                 NA 
               
               
                   
                 ADRB2 
                 175 
                 −27.1 
                 83.3 
                 62 
                 0.61 
                 0.264 
                 0.0206 
                 0.0997 
               
               
                   
                 HIC2 
                 175 
                 −28.5 
                 83.3 
                 312 
                 −0.01 
                 0.102 
                 0.8962 
                 0.9621 
               
               
                   
                 NECTIN3 
                 175 
                 −33.5 
                 72.2 
                 662 
                 0.05 
                 0.081 
                 0.5587 
                 0.7864 
               
               
                   
                 TBC1D10C 
                 175 
                 −27.3 
                 77.8 
                 7562 
                 0.03 
                 0.041 
                 0.4409 
                 0.7056 
               
               
                 PD1_2061 
                 PD1 
                 200 
                 −34.3 
                 100.0 
                 84 
                 −2.63 
                 0.293 
                 2.51E−19 
                 2.64E−16 
               
               
                 miR206 
                 LCOR 
                 180 
                 −16.7 
                 84.2 
                 1321 
                 −0.19 
                 0.064 
                 0.0029 
                 0.0230 
               
               
                 Guide 
                 STARD4 
                 179 
                 −16.7 
                 88.9 
                 6871 
                 −0.18 
                 0.055 
                 0.0013 
                 0.0120 
               
               
                 miRNA 
                 UQCRC2 
                 179 
                 −19.1 
                 81.0 
                 4759 
                 0.03 
                 0.043 
                 0.4641 
                 0.7216 
               
               
                   
                 EXD2 
                 178 
                 −17.5 
                 88.2 
                 58 
                 0.18 
                 0.265 
                 0.5055 
                 0.7511 
               
               
                   
                 NOL8 
                 177 
                 −18.6 
                 88.9 
                 2190 
                 −0.08 
                 0.050 
                 0.1007 
                 0.2996 
               
               
                   
                 ATP23 
                 176 
                 −18.6 
                 84.2 
                 318 
                 0.22 
                 0.100 
                 0.0265 
                 0.1201 
               
               
                   
                 ELAPOR2 
                 176 
                 −20.6 
                 84.2 
                 70 
                 −0.08 
                 0.211 
                 0.7139 
                 0.8793 
               
               
                   
                 HDAC9 
                 176 
                 −19.5 
                 84.2 
                 73 
                 −1.51 
                 0.280 
                 6.77E−08 
                 3.53E−06 
               
               
                   
                 WDR47 
                 176 
                 −19.6 
                 79.0 
                 625 
                 0.08 
                 0.089 
                 0.3892 
                 0.6617 
               
               
                 PD1_2061 
                 COG2 
                 172 
                 −18.9 
                 93.3 
                 1244 
                 0.06 
                 0.060 
                 0.3399 
                 0.6170 
               
               
                 miR206 
                 NRG4 
                 171 
                 −25.6 
                 77.8 
               
               
                 Passenger 
                 AGBL3 
                 170 
                 −19.2 
                 79.0 
                 49 
                 0.01 
                 0.250 
                 0.9811 
                 0.9934 
               
               
                 miRNA 
                 PDK3 
                 170 
                 −20.9 
                 100.0 
                 605 
                 0.18 
                 0.081 
                 0.0256 
                 0.1169 
               
               
                   
                 PDXK 
                 170 
                 −21.7 
                 82.4 
                 1786 
                 0.22 
                 0.058 
                 0.0002 
                 0.0022 
               
               
                   
                 N4BP2 
                 169 
                 −25.1 
                 77.8 
                 2834 
                 −0.33 
                 0.051 
                 1.86E−10 
                 1.95E−08 
               
               
                   
                 ZNF271P 
                 169 
                 −23.8 
                 83.3 
                 777 
                 0.03 
                 0.074 
                 0.7197 
                 0.8812 
               
               
                   
                 NFKB1 
                 168 
                 −18.8 
                 88.2 
                 7889 
                 −0.11 
                 0.039 
                 0.0036 
                 0.0269 
               
               
                   
                 XYLT1 
                 168 
                 −26.9 
                 82.4 
                 5281 
                 0.08 
                 0.051 
                 0.1100 
                 0.3177 
               
               
                   
                 CNOT6 
                 167 
                 −20.1 
                 72.2 
                 2030 
                 −0.24 
                 0.052 
                 0.0000 
                 0.0001 
               
               
                   
               
            
           
         
       
     
     It is expected that changes in PD1 expression will impact expression of other genes in downstream pathways. As expected, analysis of RNAseq data confirmed the differential expression of several genes in miRNA expressing ROR1 UltraCAR-T cells compared to the control ROR1 UltraCAR-T cells ( FIGS. 14A  and B, Table 17). To elucidate direct versus indirect changes in gene expression, the differential expression (LFC) in miRNA expressing ROR1 UltraCAR-T cells compared to control ROR1 CAR-T cells was plotted against the predicted binding potential (predicted free energy) of the PD1 miRNAs for genes, which were in silico predicted as potential PD1 miRNA targets ( FIGS. 15A-D ). Genes with a highly negative free energy and a statistically significant reduction in expression are likely to be directly targeted by miRNA, while downregulated genes with a weak free energy are likely to be indirectly impacted by the miRNAs. PD1 is clearly separated from all other genes in the plots with a strong reduction in expression and high miRNA binding potential, which suggests a strong and preferential direct targeting of PD1, but not other genes, by the PD1 silencer miRNAs. 
     
       
         
           
               
             
               
                 TABLE 17 
               
             
            
               
                   
               
               
                 Top 10 Down- and Up-Regulated Genes in ROR1 + PD1 
               
               
                 Silencer Cells Relative to Control ROR1 UltraCAR-T Cells 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                 base 
                 Log2Fold 
                   
                   
                   
                   
               
               
                 Ensembl_ID 
                 Symbol 
                 Mean 
                 Change 
                 lfcSE 
                 stat 
                 pvalue 
                 padj 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 ENSG00000188389 
                 PDCD1 
                 84.2 
                 −2.6 
                 0.3 
                 −9.0 
                 2.51E−19 
                 2.64E−16 
               
               
                 ENSG00000172020 
                 GAP43 
                 71.6 
                 −2.2 
                 0.4 
                 −5.7 
                 1.37E−08 
                 9.21E−07 
               
               
                 ENSG00000171951 
                 SCG2 
                 110.5 
                 −2.2 
                 0.4 
                 −6.1 
                 1.13E−09 
                 9.89E−08 
               
               
                 ENSG00000105974 
                 CAV1 
                 172.3 
                 −2.1 
                 0.5 
                 −4.2 
                 2.93E−05 
                 5.78E−04 
               
               
                 ENSG00000136193 
                 SCRN1 
                 37.4 
                 −1.9 
                 0.5 
                 −3.8 
                 0.000136 
                 1.97E−03 
               
               
                 ENSG00000130287 
                 NCAN 
                 206.1 
                 −1.7 
                 0.4 
                 −4.4 
                 1.23E−05 
                 2.84E−04 
               
               
                 ENSG00000156052 
                 GNAQ 
                 145.0 
                 −1.7 
                 0.2 
                 −7.8 
                 6.88E−15 
                 2.18E−12 
               
               
                 ENSG00000135898 
                 GPR55 
                 84.5 
                 −1.6 
                 0.3 
                 −5.7 
                 1.47E−08 
                 9.48E−07 
               
               
                 ENSG00000152495 
                 CAMK4 
                 856.5 
                 −1.6 
                 0.2 
                 −7.5 
                 9.08E−14 
                 2.21E−11 
               
               
                 ENSG00000102271 
                 KLHL4 
                 184.3 
                 −1.6 
                 0.3 
                 −4.7 
                 3.00E−06 
                 8.90E−05 
               
               
                 ENSG00000165025 
                 SYK 
                 120.2 
                 1.6 
                 0.4 
                 4.0 
                 6.65E−05 
                 1.10E−03 
               
               
                 ENSG00000276597 
                 TRBV11-3 
                 123.1 
                 1.6 
                 0.6 
                 2.7 
                 0.006913 
                 4.44E−02 
               
               
                 ENSG00000082781 
                 ITGB5 
                 329.1 
                 1.7 
                 0.3 
                 5.7 
                 1.45E−08 
                 9.44E−07 
               
               
                 ENSG00000244242 
                 IFITM10 
                 555.8 
                 1.7 
                 0.2 
                 7.6 
                 4.18E−14 
                 1.10E−11 
               
               
                 ENSG00000143842 
                 SOX13 
                 116.9 
                 1.7 
                 0.2 
                 7.6 
                 3.87E−14 
                 1.06E−11 
               
               
                 ENSG00000180549 
                 FUT7 
                 318.7 
                 1.7 
                 0.4 
                 4.3 
                 1.71E−05 
                 3.71E−04 
               
               
                 ENSG00000137474 
                 MYO7A 
                 1057.3 
                 1.8 
                 0.2 
                 8.2 
                 3.56E−16 
                 1.62E−13 
               
               
                 ENSG00000177508 
                 IRX3 
                 317.9 
                 1.8 
                 0.5 
                 3.3 
                 0.001046 
                 1.03E−02 
               
               
                 ENSG00000136689 
                 IL1RN 
                 242.1 
                 1.9 
                 0.5 
                 4.0 
                 5.65E−05 
                 9.70E−04 
               
               
                 ENSG00000189013 
                 KIR2DL4 
                 800.0 
                 1.9 
                 0.3 
                 6.4 
                 1.51E−10 
                 1.62E−08 
               
               
                   
               
            
           
         
       
     
     Example 11 
     In one instance a patient is diagnosed with a particular cancer. In this example the patient is diagnosed with breast cancer. The patient is identified to receive a particular chimeric antigen receptor therapy. The patient provides an initial blood sample for isolation of the desired cell type. In this example, the isolated cell type is a T-cell. In this example only a portion of the isolated T-cells are transfected with the desired initial CAR selected from the collection of CARs. The remaining T-cells are coded and stored in appropriate condition for potential future use by the patient. The remaining T-cells are transfected through an appropriate means. In this example, the transfection occurs through a non-viral means. In particular, the non-viral means utilizes a single sleeping beauty vector that encodes for at least the selected CAR, a T-cell expansion cytokine, and a termination switch. The patient is treated within 48 hours from the initial T-cell isolation. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. In the event there is an expansion of the cancer, in this example breast cancer, the patient is reevaluated. The patient may be redosed with the initial CAR, however, in the event the evaluation demonstrates that after the initial or potential redose there is antigen escape the protocol will call for a dosing of a new CAR from the CAR collection. In this instance, the patient&#39;s stored T-cells will be selected for use in the transfection of the newly selected CAR. The patient will be able to be redosed in a timely fashion. Further as the patient has already received each portion of the follow-on therapy except the newly selected CAR, the risk of toxicities and or adverse events is reduced. Further the knowledge of previous T-cell expansion for this patient is informed by the levels of expansion from the initial CAR selection. This further allows for a potential change in the dosage size, be it greater or less than the initial dose. 
     Example 12 
     In one instance a patient is not diagnosed with a particular cancer, but rather a specific antigen has been identified as causing undesired proliferation of cells or expansion of an infective agent. The initial CAR is selected based on antigen being presented in the patient. The patient provides an initial blood sample for isolation of the desired cell type. In this example, the isolated cell type is a T-cell. In this example all of the isolated T-cells are transfected with the desired initial CAR selected from the collection of CARs. The T-cells are transfected through an appropriate means. In this example, the transfection occurs through a non-viral means. In particular, the non-viral means utilizes a single sleeping beauty vector that encodes for at least the selected CAR, a T-cell expansion cytokine, and a kill switch. The patient is treated within 48 hours from the initial T-cell isolation. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. Following further evaluation the patient demonstrates that there is antigen escape. The patient is then dosed with a new CAR from the CAR collection following collection of new T-cells. Further as the patient has already received each portion of the follow-on therapy except the newly selected CAR, the risk of toxicities and or adverse events is reduced. Further the knowledge of previous T-cell expansion for this patient is informed by the levels of expansion from the initial CAR selection. This further allows for a potential change in the dosage size, be it greater or less than the initial dose. 
     Example 13 
     The clinician develops a treatment plan for a patient that involves use of an initial CAR from the CAR collection. The treatment plan includes a dosing of different CARs from the collection in consecutive manner to prevent antigen escape. 
     Example 14 
     In one instance a patient is diagnosed with a particular cancer. In this example the patient is diagnosed with pancreatic cancer. The patient is identified to receive a particular chimeric antigen receptor therapy. The patient provides an initial blood sample for isolation of the desired cell type. In this example, the isolated cell type is a T-cell. In this example the isolated T-cell&#39;s are transfected with the desired initial CAR selected from the collection of CARs. The T-cells are transfected through a non-viral means utilizing a single sleeping beauty vector that encodes for at least the selected CAR, a T-cell expansion cytokine, and a kill switch. The patient is treated within 48 hours from the initial T-cell isolation. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. In this instance, the patient through reevaluation is noted to suffer antigen escape. In this instance the patient requires dosing with a new CAR. However, due to the condition of the patient a sufficient sample of autologous T-cell may not be obtained. As a result the method allows for the inclusion of allogenic T-cells to be incorporated to the therapy. The CAR from the library is transduced into the allogenic T-cells and the patient is dosed in a timely fashion. Further as the patient has already received each portion of the follow-on therapy, the risk of toxicities and or adverse events is reduced. 
     Example 15 
     In one instance a patient is not diagnosed with a particular cancer, but rather a specific antigen has been identified as causing undesired proliferation of cells or expansion of an infective agent. The initial CAR is selected based on antigen being presented in the patient. The patient is unable to provide an initial blood sample for isolation of the desired cell type due to the current health of the patient. As such, allogenic T-cells are transfected with the desired initial CAR selected from the collection of CARs. The T-cells are transfected through an appropriate means utilizing a single attsite vector that encodes for at least the selected CAR, a T-cell expansion cytokine, and a termination switch. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. Following further evaluation the patient demonstrates that there is antigen escape. The patient is then dosed with a new CAR using the same source of allogenic T-cells. Further as the patient has already received each portion of the follow-on therapy except the newly selected CAR, the risk of toxicities and or adverse events is reduced. Further the knowledge of previous T-cell expansion for this patient is informed by the levels of expansion from the initial CAR selection. This further allows for a potential change in the dosage size, be it greater or less than the initial dose. 
     Example 16 
     The clinician develops a treatment plan for a patient that involves use of an initial CAR from the CAR collection. The treatment plan includes a dosing of different CARs from the collection in consecutive manner to prevent antigen escape. This treatment plan may include the use of both autologous and allogenic cells. 
     Example 17 
     In one instance a patient is diagnosed with a specific antigen has been identified as causing undesired proliferation of cells or expansion of an infective agent. The initial CAR is selected based on antigen being presented in the patient. The patient is unable to provide an initial blood sample for isolation of the desired cell type due to the current health of the patient. As such, allogenic cells are transfected with the desired initial CAR selected from the collection of CARs. The cells are transfected through an appropriate means utilizing a single sleeping beauty vector that encodes for at least the selected CAR and a termination switch. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. Following further evaluation the patient demonstrates that there is antigen escape. The patient is then dosed with a new CAR using a source of allogenic T-cells or if the patient show sufficient improvement autologous T-cells. 
     Example 18 
     In one instance a patient is not diagnosed with a particular cancer, but rather a specific antigen has been identified as causing undesired proliferation of cells or expansion of an infective agent. The initial CAR is selected based on antigen being presented in the patient. The patient provides an initial blood sample for isolation of T-cells. The T-cells are transfected with the desired initial CAR selected from the collection of CARs utilizing a single sleeping beauty vector that encodes for the selected CAR, a T-cell expansion cytokine, and a kill switch. The patient is treated within 48 hours from the initial T-cell isolation. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. Following further evaluation the patient demonstrates that there is antigen escape. The patient is then dosed with the same CAR and a new CAR from the CAR collection. 
     Example 19 
     In one instance a patient is diagnosed with a particular cancer. In this example the patient is diagnosed with AML. The patient is identified to receive a particular chimeric antigen receptor therapy. The patient provides an initial blood sample for isolation of the desired cell type. The cells are transfected with the desired two different CARs selected from the collection of CARs. The cells are transfected through a non-viral means utilizing a single vector that encodes for both selected CARs and a kill switch. 
     Once the above round of treatment is complete the patient is followed in accordance with monitoring protocols. In this instance, the patient through reevaluation is noted to suffer antigen escape. In this instance the patient requires dosing with a new CAR. However, due to the condition of the patient a sufficient sample of autologous cell may not be obtained. As a result the method allows for the inclusion of allogenic T-cells to be incorporated to the therapy. The CAR from the library is transduced into the allogenic cells and the patient is dosed in a timely fashion. 
     
       
         
           
               
            
               
                   
               
               
                 Nucleic Acid Sequences Encoding Backbone miRNA Sequences 
               
            
           
           
               
               
               
               
            
               
                 Synthetic 
                 DNA encoding 5′ 
                 DNA encoding stem 
                 DNA encoding 3′ 
               
               
                 miRNA 
                 backbone sequence 
                 loop 
                 backbone sequence 
               
               
                   
               
               
                 miR204 
                 AGGAGGGTGGGGGTGG 
                 GAGAATATATGAAGG 
                 GTTCAATTGTCATCACTG 
               
               
                   
                 AGGCAAGCAGAGGACTT 
                 (SEQ ID NO: 2) 
                 GCATCTTTTTTGATCATTG 
               
               
                   
                 CCTGATCGCGTACCCATG 
                   
                 CACCATCATCAAATGCAT 
               
               
                   
                 GCTACAGTCTTTCTTCATG 
                   
                 TGGGATAACCATGAC 
               
               
                   
                 TGACTCGTGGAC 
                   
                 (SEQ ID NO: 3) 
               
               
                   
                 (SEQ ID NO: 1) 
                   
                   
               
               
                   
               
               
                 miR206 
                 GATGCTACAAGTGGCCCA 
                 TATGGATTACTTTGCTA 
                 TTTCGGCAAGTGCCTCCT 
               
               
                   
                 CTTCTGAGATGCGGGCTG 
                 (SEQ ID NO: 5) 
                 CGCTGGCCCCAGGGTACC 
               
               
                   
                 CTTCTGGATGACACTGCT 
                   
                 ACCCGGAGCACAGGTTTG 
               
               
                   
                 TCCCGAGG 
                   
                 GTGACCTT 
               
               
                   
                 (SEQ ID NO: 4) 
                   
                 (SEQ ID NO: 6) 
               
               
                   
               
               
                 miR17 
                 TTAGCAGGAAAAAAGAG 
                 TGATATGTGCAT 
                 GCATTATGGTGACAGCTG 
               
               
                   
                 AACATCACCTTGTAAAAC 
                 (SEQ ID NO: 8) 
                 CCTCGGGAAGCCAAGTTG 
               
               
                   
                 TGAAGATTGTGACCAGTC 
                   
                 GGCTTTAAAGTGCAGGG 
               
               
                   
                 AGAATAATGT 
                   
                 CCTGCTGATGT 
               
               
                   
                 (SEQ ID NO: 7) 
                   
                 (SEQ ID NO: 9) 
               
               
                   
               
               
                 miR150 
                 AGGGACTGGGCCCACGG 
                 CTGGGCTCAG 
                 CAGGGACCTGGGGACCC 
               
               
                   
                 GGAGGCAGCGTCCCCGA 
                 (SEQ ID NO: 11) 
                 CGGCACCGGCAGGCCCC 
               
               
                   
                 GGCAGCAGCGGCAGCGG 
                   
                 AAGGGGTGAGGTGAGCG 
               
               
                   
                 CGGCTCCTCTCCCCATGG 
                   
                 GGCATTGGGACCTCCCCT 
               
               
                   
                 CCCTG 
                   
                 CCCTGTACTC 
               
               
                   
                 (SEQ ID NO: 10) 
                   
                 (SEQ ID NO: 12) 
               
               
                   
               
               
                 miR150 
                 AGGGACTGGGCCCACGG 
                 TGCTGGGCTCAGACC 
                 GGACCTGGGGACCCCGG 
               
               
                   
                 GGAGGCAGCGTCCCCGA 
                 (SEQ ID NO: 14) 
                 CACCGGCAGGCCCCAAG 
               
               
                   
                 GGCAGCAGCGGCAGCGG 
                   
                 GGGTGAGGTGAGCGGGC 
               
               
                   
                 CGGCTCCTCTCCCCATGG 
                   
                 ATTGGGACCTCCCCTCCC 
               
               
                   
                 CC 
                   
                 TGTACTC 
               
               
                   
                 (SEQ ID NO: 13) 
                   
                 (SEQ ID NO: 15) 
               
               
                   
               
               
                 miR16 
                 CTTCTGAAGAAAATATAT 
                 TTAAGATTCTAAAATTATC 
                 AAGTAAGGTTGACCATAC 
               
               
                   
                 TTCTTTTTATTCATAGCTC 
                 T 
                 TCTACAGTTGTGTTTTAAT 
               
               
                   
                 TTATGATAGCAATGTCAG 
                 (SEQ ID NO: 17) 
                 GTATATTAATGTTACTAAT 
               
               
                   
                 CAGTGCCT 
                   
                 GTGTTTT 
               
               
                   
                 (SEQ ID NO: 16) 
                   
                 (SEQ ID NO: 18) 
               
               
                   
               
               
                 miR30a 
                 CAGGTTAACCCAACAGAA 
                 CTGTGAAGCCACAGATG 
                 TGCCTACTGCCTCGGACT 
               
               
                   
                 GGCTAAAGAAGGTATATT 
                 GG 
                 TCAAGGGGCTACTTTAGG 
               
               
                   
                 GCTGTTGACAGTGAGCG 
                 (SEQ ID NO: 20) 
                 AGCAATTATCTTGTTTA 
               
               
                   
                 AC 
                   
                 (SEQ ID NO: 21) 
               
               
                   
                 (SEQ ID NO: 19) 
                   
                   
               
               
                   
               
               
                 miR126 
                 CCGGGGTCCTGTCTGCAT 
                 CTGTGACACTTCAAAC 
                 CCGTCCACGGCACCGCAT 
               
               
                   
                 CCAGCGCAGCATTCTGGA 
                 (SEQ ID NO: 23) 
                 CGAAAACGCCGCTGAGA 
               
               
                   
                 AGACGCCACGCCTCCGCT 
                   
                 CCTCAGCCTTGACCTCCCT 
               
               
                   
                 GGCGACGG 
                   
                 CAGCGTGG 
               
               
                   
                 (SEQ ID NO: 22) 
                   
                 (SEQ ID NO: 24) 
               
               
                   
               
               
                 miR122 
                 CAATGGTGGAATGTGGA 
                 TGTCTAAACTAT 
                 TAGCTACTGCTAGGCAAT 
               
               
                   
                 GGTGAAGTTAACACCTTC 
                 (SEQ ID NO: 26) 
                 CCTTCCCTCGATAAATGTC 
               
               
                   
                 GTGGCTACAGAGTTTCCT 
                   
                 TTGGCATCGTTTGCTTTG 
               
               
                   
                 TAGCAGAGCTG 
                   
                 AGCAAGAAGGTTCATCTG 
               
               
                   
                 (SEQ ID NO: 25) 
                   
                 ATATCAGTCTTCTCAATCT 
               
               
                   
                   
                   
                 (SEQ ID NO: 27) 
               
               
                   
               
               
                 miR214 
                 ACAGGCTGATTGTATCTG 
                 GCAGAACATCCGCTCACC 
                 CACATGACAACCCAGCCT 
               
               
                   
                 TCTATGAGCAAAGGAAAC 
                 TGT 
                 GAATGACAACCAGCCATT 
               
               
                   
                 CTGAAGGAACCAAGGGC 
                 (SEQ ID NO: 29) 
                 GAAAGAAAGCAGCCCTC 
               
               
                   
                 CTGGCTGGACAGAGTTGT 
                   
                 ACACCATAGCATCTA 
               
               
                   
                 CATGTG 
                   
                 (SEQ ID NO: 30) 
               
               
                   
                 (SEQ ID NO: 28) 
                   
                   
               
               
                   
               
               
                 miR214 
                 ACAGGCTGATTGTATCTG 
                 AGAACATCCGCTCACCT 
                 CACATGACAACCCAGCCT 
               
               
                   
                 TCTATGAGCAAAGGAAAC 
                 (SEQ ID NO: 32) 
                 GAATGACAACCAGCCATT 
               
               
                   
                 CTGAAGGAACCAAGGGC 
                   
                 GAAAGAAAGCAGCCCTC 
               
               
                   
                 CTGGCTGGACAGAGTTGT 
                   
                 ACACCATAGCATCTA 
               
               
                   
                 CATGTGTC 
                   
                 (SEQ ID NO: 33) 
               
               
                   
                 (SEQ ID NO: 31) 
                   
                   
               
               
                   
               
               
                 miR29b1 
                 GGGTTTATTGTAAGAGAG 
                 GATTTAAATAGTGATTGT 
                 CTTGGGGGAGACCAGCT 
               
               
                   
                 CATTATGAAGAAAAAAAT 
                 C 
                 GCGCTGCACTACCAACAG 
               
               
                   
                 AGATCATAAAGCTTCTTC 
                 (SEQ ID NO: 35) 
                 CAAAAGAAGTGAATGGG 
               
               
                   
                 AGG 
                   
                 ACAGCT 
               
               
                   
                 (SEQ ID NO: 34) 
                   
                 (SEQ ID NO: 36) 
               
               
                   
               
               
                 miR29b1 
                 GGGTTTATTGTAAGAGAG 
                 TTTAAATAGTGATTG 
                 GTTCTTGGGGGAGACCA 
               
               
                   
                 CATTATGAAGAAAAAAAT 
                 (SEQ ID NO: 38) 
                 GCTGCGCTGCACTACCAA 
               
               
                   
                 AGATCATAAAGCTTCTTC 
                   
                 CAGCAAAAGAAGTGAAT 
               
               
                   
                 AGGAA 
                   
                 GGGACAGCT 
               
               
                   
                 (SEQ ID NO: 37) 
                   
                 (SEQ ID NO: 39) 
               
               
                   
               
               
                 miR133a1 
                 TTTACCAATGAAAAGCAT 
                 TCGCCTCTTCAATGGA 
                 TAGCTATGCATTGATTAC 
               
               
                   
                 TTAACTGTTTTGGATTCCA 
                 (SEQ ID NO: 41) 
                 TACGGGACAACCAACGTT 
               
               
                   
                 AACTAGCAGCACTACAAT 
                   
                 TTCATTTGTGAATATCAAT 
               
               
                   
                 GCTTTGCTA 
                   
                 TACTTGCCA 
               
               
                   
                 (SEQ ID NO: 40) 
                   
                 (SEQ ID NO: 42) 
               
               
                   
               
               
                 miR26a 
                 TGAAGCCACAGGAGCCA 
                 GTGCAGGTCCCAATG 
                 CGGGGACGCGGGCCTGG 
               
               
                   
                 AGAGCAGGAGGACCAAG 
                 (SEQ ID NO: 44) 
                 ACGCCGGCATCCGGGCTC 
               
               
                   
                 GCCCTGGCGAAGGCCGT 
                   
                 AGGACCCCCCTCTCTGCC 
               
               
                   
                 GGCCTCG 
                   
                 AGAGGC 
               
               
                   
                 (SEQ ID NO: 43) 
                   
                 (SEQ ID NO: 45) 
               
               
                   
               
               
                 miR412 
                 GTCTTGGAGGCTGGGGC 
                 GTTTCT 
                 GCCGTCCGTATCCGCTGC 
               
               
                   
                 ACCTCGGGGAAGGACGC 
                 (SEQ ID NO: 47) 
                 AGCCTGTGGGGCCTGCG 
               
               
                   
                 CGGCATCAGCACCATTCT 
                   
                 GGCCGGGGAGCCGATCG 
               
               
                   
                 GGGGTACGGGGATGGA 
                   
                 CGCTTCAGCTCAGCGCCT 
               
               
                   
                 (SEQ ID NO: 46) 
                   
                 (SEQ ID NO: 48) 
               
               
                   
               
               
                 miR-19 
                 CCAATAATTCAAGCCAAG 
                 TACAAGAAGAATGTAGT 
                 TGGTGGCCTGCTATTTCC 
               
               
                   
                 CAAGTATATAGGTGTTTT 
                 (SEQ ID NO: 50) 
                 TTCAAATGAATGATTTTTA 
               
               
                   
                 AATAGTTTTTGTTTGCAGT 
                   
                 CTAATTTTGTGTACTTTTA 
               
               
                   
                 CCTCTG 
                   
                 TTGTG 
               
               
                   
                 (SEQ ID NO: 49) 
                   
                 (SEQ ID NO: 51) 
               
               
                   
               
               
                 miR-21 
                 TGTCTGCTTGTTTTGCCTA 
                 CTGTTGAATCTCATGG 
                 TCTGACATTTTGGTATCTT 
               
               
                   
                 CCATCGTGACATCTCCAT 
                 (SEQ ID NO: 53) 
                 TCATCTGACCATCCATATC 
               
               
                   
                 GGCTGTACCACCTTGTCG 
                   
                 CAATGTTCTCATTTAAACA 
               
               
                   
                 GG 
                   
                 (SEQ ID NO: 54) 
               
               
                   
                 (SEQ ID NO: 52) 
                   
                   
               
               
                   
               
               
                 miR-142 
                 GGAGTCAGGAGGCCTGG 
                 AACAGCACTGGAGGG 
                 GATGAGTGTACTGTGGG 
               
               
                   
                 GCAGCCTGAAGAGTACA 
                 (SEQ ID NO: 56) 
                 CTTCGGAGATCACGCCAC 
               
               
                   
                 CGCCGACGGACAGACAG 
                   
                 TGCTGCCGCCCGCTGCCC 
               
               
                   
                 ACAGTGCAGTCACC 
                   
                 GCCACCATCTTC 
               
               
                   
                 (SEQ ID NO: 55) 
                   
                 (SEQ ID NO: 57) 
               
               
                   
               
               
                 miR-494 
                 CAGTTCTGTTTTGATTTTT 
                 TCTTTATTTATGA 
                 TTTTTTAGTATCAAATCCC 
               
               
                   
                 TTTGTTTGTTTTTTGATCA 
                 (SEQ ID NO: 59) 
                 ACCCTGGAGGCACTTCCT 
               
               
                   
                 GTGCTAATCTTCGATACT 
                   
                 GTTCCTGATGCAGCCTTC 
               
               
                   
                 CGAAGGA 
                   
                 AGGGAGG 
               
               
                   
                 (SEQ ID NO: 58) 
                   
                 (SEQ ID NO: 60) 
               
               
                   
               
               
                 miR-1915 
                 CGGACCACGGTGTCCCCT 
                 GTGCACCCGTG 
                 GCGGCCCTAGCGACCTGC 
               
               
                   
                 TCTCTCCAGCTGGGGGTC 
                 (SEQ ID NO: 62) 
                 GGCGGCGCCGGGAAAGC 
               
               
                   
                 TCGGGTCCTGGCGCTGAG 
                   
                 CCTGCCTCTGCAGCGGGT 
               
               
                   
                 AGGCCGC 
                   
                 CCCAGGGGTC 
               
               
                   
                 (SEQ ID NO: 61) 
                   
                 (SEQ ID NO: 63) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
            
               
                   
               
               
                 Nucleic acid sequences encoding mature miRNA sequences 
               
            
           
           
               
               
               
               
            
               
                 miRNA 
                   
                   
                 DNA encoding passenger 
               
               
                 Target 
                 Backbone 
                 DNA encoding guide miRNA 
                 miRNA 
               
               
                   
               
               
                 CTLA4 
                 miR-204 
                 AATATAGTCTTCTCCCTCGCTT 
                 AAGCAGGGACAGGACTATATT 
               
               
                   
                   
                 (SEQ ID NO: 64) 
                 (SEQ ID NO: 65) 
               
               
                   
               
               
                 CTLA4 
                 miR-26a 
                 AATATAGTCTTCTCCCTCGCTT 
                 GAGCGAGGGATAGGACTATACT 
               
               
                   
                   
                 (SEQ ID NO: 66) 
                 (SEQ ID NO: 67) 
               
               
                   
               
               
                 CTLA4 
                 miR-30a 
                 AATATAGTCTTCTCCCTCGCTG 
                 CAGTGAGGGAAGACTATGTT 
               
               
                   
                   
                 (SEQ ID NO: 68) 
                 (SEQ ID NO: 69) 
               
               
                   
               
               
                 CTLA4 
                 miR-206 
                 AATATAGTCTTCTCCCTCGCTG 
                 CAGCGAGGGAGAAGATTAC 
               
               
                   
                   
                 (SEQ ID NO: 70) 
                 CATT 
               
               
                   
                   
                   
                 (SEQ ID NO: 71) 
               
               
                   
               
               
                 PD1 
                 miR-204 
                 TTCAGGAATGGGTTCCAAGGAT 
                 ATCCTGGAAGCTATTCCTGAC 
               
               
                   
                   
                 (SEQ ID NO: 72) 
                 (SEQ ID NO: 73) 
               
               
                   
               
               
                 PD1 
                 miR-206 
                 TATAATATAATAGAACCACAGG 
                 CCTGTGGTTCTGTTATATCCA 
               
               
                   
                   
                 (SEQ ID NO: 74) 
                 TA 
               
               
                   
                   
                   
                 (SEQ ID NO: 75) 
               
               
                   
               
               
                 PD1 
                 miR-30a 
                 TTCAGGAATGGGTTCCAAGGAG 
                 CTCCTTGGACCATTCCTGAA 
               
               
                   
                   
                 (SEQ ID NO: 76) 
                 (SEQ ID NO: 77) 
               
               
                   
               
               
                 PD1 
                 miR-412 
                 TTCAGGAATGGGTTCCAAGGAATT 
                 AATGTCCTGAAGCCATTCAT 
               
               
                   
                   
                 (SEQ ID NO: 78) 
                 GGA 
               
               
                   
                   
                   
                 (SEQ ID NO: 79) 
               
               
                   
               
               
                 PD1 
                 miR122 
                 TTCAGGAATGGGTTCCAAGGAG 
                 CTCCTTGGAACACATTCCTAC 
               
               
                   
                   
                 (SEQ ID NO: 80) 
                 A 
               
               
                   
                   
                   
                 (SEQ ID NO: 81) 
               
               
                   
               
               
                 PD1 
                 miR-17 
                 TTCAGGAATGGGTTCCAAGGAAG 
                 CTTCTTGGTACACGTTCCTGC 
               
               
                   
                   
                 (SEQ ID NO: 82) 
                 TCA 
               
               
                   
                   
                   
                 (SEQ ID NO: 83) 
               
               
                   
               
               
                 PD1 
                 miR-150 
                 TATAATATAATAGAACCACAGG 
                 ACGTGTGGTTTATCCTGTTGT 
               
               
                   
                   
                 (SEQ ID NO: 74) 
                 A 
               
               
                   
                   
                   
                 (SEQ ID NO: 85) 
               
               
                   
               
               
                 PD1 
                 miR-486 
                 TATAATATAATAGAACCACAGG 
                 CCAGCTTGTGGTTCTATTATG 
               
               
                   
                   
                 (SEQ ID NO: 74) 
                 TTATA 
               
               
                   
                   
                   
                 (SEQ ID NO: 87) 
               
               
                   
               
               
                 TIGIT 
                 miR-17 
                 AGATCCACGTTACTCACCCTAG 
                 CTAGGGTGTGTCATGTGGAT 
               
               
                   
                   
                 (SEQ ID NO: 88) 
                 GAA 
               
               
                   
                   
                   
                 (SEQ ID NO: 89) 
               
               
                   
               
               
                 TIGIT 
                 miR-150 
                 AGATCCACGTTACTCACCCGTG 
                 ACCCGGGTGATAATATGGAT 
               
               
                   
                   
                 (SEQ ID NO: 90) 
                 CT 
               
               
                   
                   
                   
                 (SEQ ID NO: 91) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 AGATCCACGTTACTCACCCCCT 
                 AGGGGTGAGAAGCGTGGAT 
               
               
                   
                   
                 (SEQ ID NO: 92) 
                 CC 
               
               
                   
                   
                   
                 (SEQ ID NO: 93) 
               
               
                   
               
               
                 TIGIT 
                 miR29b1 
                 AGATCCACGTTACTCACCCTTA 
                 TAGGTGAGTTACGTGGATCT 
               
               
                   
                   
                 (SEQ ID NO: 94) 
                 GTT 
               
               
                   
                   
                   
                 (SEQ ID NO: 95) 
               
               
                   
               
               
                 TIGIT 
                 miR214 
                 AGATCCACGTTACTCACCCTGC 
                 GTAGGGTGAGACTCGTGGA 
               
               
                   
                   
                 (SEQ ID NO: 96) 
                 TCT 
               
               
                   
                   
                   
                 (SEQ ID NO: 97) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 ACCACGATGACTGCTGTGCAGA 
                 TCTGCGTAGCAGTCATCGCC 
               
               
                   
                   
                 (SEQ ID NO: 98) 
                 GGT 
               
               
                   
                   
                   
                 (SEQ ID NO: 99) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 ACCACGATGACTGCTGTGCAGA 
                 TCTGATGGCCGTCATCGTGGC 
               
               
                   
                   
                 (SEQ ID NO: 100) 
                 (SEQ ID NO: 101) 
               
               
                   
               
               
                 TIGIT 
                 miR-22 
                 ACCACGATGACTGCTGTGCAGA 
                 TCTGTACAGCAGCATCGATG 
               
               
                   
                   
                 (SEQ ID NO: 102) 
                 GT 
               
               
                   
                   
                   
                 (SEQ ID NO: 103) 
               
               
                   
               
               
                 TIGIT 
                 miR-16 
                 ACCACGATGACTGCTGTGCAGA 
                 TGCGCAGCTGTTCATCGTGGT 
               
               
                   
                   
                 (SEQ ID NO: 104) 
                 (SEQ ID NO: 105) 
               
               
                   
               
               
                 TIGIT 
                 miR-21 
                 ACCACGATGACTGCTGTGCAGA 
                 CTGCGAAGCAGCATCGTGGC 
               
               
                   
                   
                 (SEQ ID NO: 106) 
                 (SEQ ID NO: 107) 
               
               
                   
               
               
                 TIGIT 
                 miR-494 
                 ACCACGATGACTGCTGTGCAGA 
                 TCTGCAACGCAGTCTCGCTGG 
               
               
                   
                   
                 (SEQ ID NO: 108) 
                 (SEQ ID NO: 109) 
               
               
                   
               
               
                 TIGIT 
                 miR-142 
                 ACCACGATGACTGCTGTGCAGA 
                 GATGCACAGCAATCATCGTG 
               
               
                   
                   
                 (SEQ ID NO: 110) 
                 GT 
               
               
                   
                   
                   
                 (SEQ ID NO: 111) 
               
               
                   
               
               
                 TIGIT 
                 miR-19 
                 ACCACGATGACTGCTGTGCAGAT 
                 ATCTGCACAGCAGTTCGTGG 
               
               
                   
                   
                 (SEQ ID NO: 112) 
                 (SEQ ID NO: 113) 
               
               
                   
               
               
                 TIGIT 
                 miR-1915 
                 ACCACGATGACTGCTGTGCAGA 
                 TCTGCCAATAGCTGTAATCG 
               
               
                   
                   
                 (SEQ ID NO: 114) 
                 TGG 
               
               
                   
                   
                   
                 (SEQ ID NO: 115) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 TATCGTTCACGGTCAGCGACTG 
                 CAGTCGTTGACTGTGGACTT 
               
               
                   
                   
                 (SEQ ID NO: 116) 
                 ATA 
               
               
                   
                   
                   
                 (SEQ ID NO: 117) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 TATCGTTCACGGTCAGCGACTG 
                 CAGTGCTGAACGTGAACGATC 
               
               
                   
                   
                 (SEQ ID NO: 118) 
                 (SEQ ID NO: 119) 
               
               
                   
               
               
                 TIGIT 
                 miR-22 
                 TATCGTTCACGGTCAGCGACTG 
                 TAGTCGCTGACTTGAACAGA 
               
               
                   
                   
                 (SEQ ID NO: 120) 
                 TA 
               
               
                   
                   
                   
                 (SEQ ID NO: 121) 
               
               
                   
               
               
                 TIGIT 
                 miR-142 
                 TATCGTTCACGGTCAGCGACT 
                 TGTCGCTGACAGTGAACGATA 
               
               
                   
                   
                 (SEQ ID NO: 122) 
                 (SEQ ID NO: 123) 
               
               
                   
               
               
                 TIGIT 
                 miR-16 
                 TATCGTTCACGGTCAGCGACTG 
                 GTCGCTGAGCGCTGAACGATG 
               
               
                   
                   
                 (SEQ ID NO: 124) 
                 (SEQ ID NO: 125) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 TAACTCAGGACATTGAAGTAGT 
                 ACTACTTCAATGTCCTGACCT 
               
               
                   
                   
                 (SEQ ID NO: 126) 
                 TA 
               
               
                   
                   
                   
                 (SEQ ID NO: 127) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 TAACTCAGGACATTGAAGTAGT 
                 ACTATTCAGAGTCCTGAGTTC 
               
               
                   
                   
                 (SEQ ID NO: 128) 
                 (SEQ ID NO: 129) 
               
               
                   
               
               
                 TIGIT 
                 miR-21 
                 TAACTCAGGACATTGAAGTAGT 
                 CTACTCCAATGCCTGAGTTG 
               
               
                   
                   
                 (SEQ ID NO: 130) 
                 (SEQ ID NO: 131) 
               
               
                   
               
               
                 TIGIT 
                 miR-494 
                 TAACTCAGGACATTGAAGTAGT 
                 ACTACTGTAATGTCTGACGTT 
               
               
                   
                   
                 (SEQ ID NO: 132) 
                 (SEQ ID NO: 133) 
               
               
                   
               
               
                 TIGIT 
                 miR-19 
                 TAACTCAGGACATTGAAGTAGTC 
                 GACTACTTCAATGTTGAGTT 
               
               
                   
                   
                 (SEQ ID NO: 134) 
                 (SEQ ID NO: 135) 
               
               
                   
               
               
                 TIGIT 
                 miR-1915 
                 AGATCCACGTTACTCACCCTAG 
                 CTAGGCAGTGAGCAAAGTG 
               
               
                   
                   
                 (SEQ ID NO: 136) 
                 GATC 
               
               
                   
                   
                   
                 (SEQ ID NO: 137) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 AGATCCACGTTACTCACCCTAG 
                 CTAGGTGAGAAACGTGGATCG 
               
               
                   
                   
                 (SEQ ID NO: 138) 
                 (SEQ ID NO: 139) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 AGATCCACGTTACTCACCCTAG 
                 CTAGGGTGAGTAACGTGGCC 
               
               
                   
                   
                 (SEQ ID NO: 140) 
                 TCT 
               
               
                   
                   
                   
                 (SEQ ID NO: 141) 
               
               
                   
               
               
                 TIGIT 
                 miR-21 
                 AGATCCACGTTACTCACCCTAG 
                 TAGGGCGAGTACGTGGATCG 
               
               
                   
                   
                 (SEQ ID NO: 142) 
                 (SEQ ID NO: 143) 
               
               
                   
               
               
                 TIGIT 
                 miR-22 
                 AGATCCACGTTACTCACCCTAG 
                 CTAGGGTGAGTACGTGGCAT 
               
               
                   
                   
                 (SEQ ID NO: 144) 
                 CT 
               
               
                   
                   
                   
                 (SEQ ID NO: 145) 
               
               
                   
               
               
                 TIM3 
                 miR204 
                 CATTATGCCTGGGATTTGGATC 
                 GATCAGATCGCAGGCATAATT 
               
               
                   
                   
                 (SEQ ID NO: 146) 
                 (SEQ ID NO: 147) 
               
               
                   
               
               
                 TIM3 
                 miR206 
                 CATTATGCCTGGGATTTGGATC 
                 GATCCGGATCCTAGGTATCC 
               
               
                   
                   
                 (SEQ ID NO: 148) 
                 ATG 
               
               
                   
                   
                   
                 (SEQ ID NO: 149) 
               
               
                   
               
               
                 TIM3 
                 miR17 
                 CATTATGCCTGGGATTTGGATCG 
                 CGGCCAGAACCAAGGCATAA 
               
               
                   
                   
                 (SEQ ID NO: 150) 
                 GTA 
               
               
                   
                   
                   
                 (SEQ ID NO: 151) 
               
               
                   
               
               
                 TIM3 
                 miR126 
                 CATTATGCCTGGGATTTGGATC 
                 ACTCCAAATCCCGTGCATAA 
               
               
                   
                   
                 (SEQ ID NO: 152) 
                 TCG 
               
               
                   
                   
                   
                 (SEQ ID NO: 153) 
               
               
                   
               
               
                 TIM3 
                 miR122 
                 CATTATGCCTGGGATTTGGATC 
                 GATTCGAATCCAAGGCATAT 
               
               
                   
                   
                 (SEQ ID NO: 154) 
                 GG 
               
               
                   
                   
                   
                 (SEQ ID NO: 155) 
               
               
                   
               
               
                 TIM3 
                 miR214 
                 TAATTCACATCCCTTTCATCAG 
                 ATGATGAAAGGACAGTGAA 
               
               
                   
                   
                 (SEQ ID NO: 156) 
                 TTA 
               
               
                   
                   
                   
                 (SEQ ID NO: 157) 
               
               
                   
               
               
                 LAG3 
                 miR-30a 
                 TAGTCGTTGGGTAAAGTCGCCA 
                 TGGTGACTTCTCAACGATTA 
               
               
                   
                   
                 (SEQ ID NO: 158) 
                 (SEQ ID NO: 159) 
               
               
                   
               
               
                 LAG3 
                 miR122 
                 GTTGCTTTCCGCTAAGTGGTGA 
                 TCACCACTTAGAGGAAAGCC 
               
               
                   
                   
                 (SEQ ID NO: 160) 
                 TC 
               
               
                   
                   
                   
                 (SEQ ID NO: 161) 
               
               
                   
               
               
                 GITR 
                 miR206 
                 TTTGCAGTGGCCTTCGTGGCCC 
                 GGGCTATGAAGGCCATTGA 
               
               
                   
                   
                 (SEQ ID NO: 162) 
                 GAAA 
               
               
                   
                   
                   
                 (SEQ ID NO: 163) 
               
               
                   
               
               
                 GITR 
                 miR29b1 
                 AGCCTCCCGTCCTAAGACCCCAC 
                 GTGGGTCTTAGGTCGGGAG 
               
               
                   
                   
                 (SEQ ID NO: 164) 
                 CTGCT 
               
               
                   
                   
                   
                 (SEQ ID NO: 165) 
               
               
                   
               
               
                 PIK3IP1 
                 miR206 
                 TGAACGACCAGTGTTTAACCGG 
                 CCGGTTGAACATTGGTTGCC 
               
               
                   
                   
                 (SEQ ID NO: 166) 
                 TCA 
               
               
                   
                   
                   
                 (SEQ ID NO: 167) 
               
               
                   
               
               
                 PIK3IP1 
                 miR126 
                 TTCTCCTTGGAGTTCATCCGCG 
                 ATGAACTTAGAGGAGACG 
               
               
                   
                   
                 (SEQ ID NO: 168) 
                 (SEQ ID NO: 169) 
               
               
                   
               
               
                 PIK3IP1 
                 miR30a 
                 TTCTCCTTGGAGTTCATCCGCG 
                 CGCGGATGATCCAAGGAGGA 
               
               
                   
                   
                 (SEQ ID NO: 170) 
                 (SEQ ID NO: 171) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
            
               
                   
               
               
                 Nucleic acid sequences encoding non-naturally occurring pri-miRNA 
               
               
                 sequences 
               
            
           
           
               
               
               
            
               
                 miRNA 
                 Encoded pri- 
                   
               
               
                 Target 
                 miRNA(s) 
                 DNA Sequence 
               
               
                   
               
               
                 CTLA4 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACAATA 
               
               
                   
                   
                 TAGTCTTCTCCCTCGCTTGAGAATATATGAAGGAAGCAGGGAC 
               
               
                   
                   
                 AGGACTATATTGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 178) 
               
               
                   
               
               
                 PD1 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCA 
               
               
                   
                   
                 GGAATGGGTTCCAAGGATGAGAATATATGAAGGATCCTGGAA 
               
               
                   
                   
                 GCTATTCCTGACGTTCAATTGTCATCACTGGCATCTTTTTTGATC 
               
               
                   
                   
                 ATTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 179) 
               
               
                   
               
               
                 PD1 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATAT 
               
               
                   
                   
                 GGATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCA 
               
               
                   
                   
                 AGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGT 
               
               
                   
                   
                 TTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 180) 
               
               
                   
               
               
                 TIGIT 
                 miR17 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATT 
               
               
                   
                   
                 GTGACCAGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTG 
               
               
                   
                   
                 ATATGTGCATCTAGGGTGTGTCATGTGGATGAAGCATTATGGT 
               
               
                   
                   
                 GACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGG 
               
               
                   
                   
                 CCTGCTGATGT 
               
               
                   
                   
                 (SEQ ID NO: 181) 
               
               
                   
               
               
                 TIGIT 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGAGATCCACGTTA 
               
               
                   
                   
                 CTCACCCGTGCTGGGCTCAGACCCGGGTGATAATATGGATCTC 
               
               
                   
                   
                 AGGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGA 
               
               
                   
                   
                 GGTGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 182) 
               
               
                   
               
               
                 TIGIT 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACAGAT 
               
               
                   
                   
                 CCACGTTACTCACCCCCTGAGAATATATGAAGGAGGGGTGAGA 
               
               
                   
                   
                 AGCGTGGATCCGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 183) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGTCTGCGTAGCAGTCATCGCCGGTTA 
               
               
                   
                   
                 TGGATTACTTTGCTAACCACGATGACTGCTGTGCAGATTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 184) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACACCA 
               
               
                   
                   
                 CGATGACTGCTGTGCAGAGAGAATATATGAAGGTCTGATGGCC 
               
               
                   
                   
                 GTCATCGTGGCGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 185) 
               
               
                   
               
               
                 TIGIT 
                 miR-22 
                 CATTTTCCCTCCCTTTCCCTTAGGAGCCTGTTCCTCTCACGCCCTC 
               
               
                   
                   
                 ACCTGGCTGAGCCGCATCTGTACAGCAGCATCGATGGTTATGTC 
               
               
                   
                   
                 CTGACCCAGCTAACCACGATGACTGCTGTGCAGATGCCCTCTGC 
               
               
                   
                   
                 CCCTGGCTTCGAGGAGGAGGAGGAGCTGCTTTCCCCATCATCT 
               
               
                   
                   
                 GGAAGGTG 
               
               
                   
                   
                 (SEQ ID NO: 186) 
               
               
                   
               
               
                 TIGIT 
                 miR-16 
                 cttcTGAAGAAAATATATTTCTTTTTATTCATAGCTCTTATGATAG 
               
               
                   
                   
                 CAATGTCAGCAGTGCCTACCACGATGACTGCTGTGCAGATTAA 
               
               
                   
                   
                 GATTCTAAAATTATCTTGCGCAGCTGTTCATCGTGGTAGTAAGG 
               
               
                   
                   
                 TTGACCATACTCTACAGTTGTGTTTTAATGTATATTAATGTTACT 
               
               
                   
                   
                 AATGTGTTTT 
               
               
                   
                   
                 (SEQ ID NO: 187) 
               
               
                   
               
               
                 TIGIT 
                 miR-16 
                 cttcTGAAGAAAATATATTTCTTTTTATTCATAGCTCTTATGATAG 
               
               
                   
                   
                 CAATGTCAGCAGTGCCTACCACGATGACTGCTGTGCAGATTAA 
               
               
                   
                   
                 GATTCTAAAATTATCTTGCGCAGCTGTTCATCGTGGTAAGTAAG 
               
               
                   
                   
                 GTTGACCATACTCTACAGTTGTGTTTTAATGTATATTAATGTTAC 
               
               
                   
                   
                 TAATGTGTTTT 
               
               
                   
                   
                 (SEQ ID NO: 188) 
               
               
                   
               
               
                 TIGIT 
                 miR-21 
                 TGTCTGCTTGTTTTGCCTACCATCGTGACATCTCCATGGCTGTAC 
               
               
                   
                   
                 CACCTTGTCGGGACCACGATGACTGCTGTGCAGACTGTTGAATC 
               
               
                   
                   
                 TCATGGCTGCGAAGCAGCATCGTGGCTCTGACATTTTGGTATCT 
               
               
                   
                   
                 TTCATCTGACCATCCATATCCAATGTTCTCATTTAAACA 
               
               
                   
                   
                 (SEQ ID NO: 189) 
               
               
                   
               
               
                 TIGIT 
                 miR-494 
                 CAGTTCTGTTTTGATTTTTTTTGTTTGTTTTTTGATCAGTGCTAAT 
               
               
                   
                   
                 CTTCGATACTCGAAGGATCTGCAACGCAGTCTCGCTGGTCTTTA 
               
               
                   
                   
                 TTTATGAACCACGATGACTGCTGTGCAGATTTTTTAGTATCAAA 
               
               
                   
                   
                 TCCCACCCTGGAGGCACTTCCTGTTCCTGATGCAGCCTTCAGGG 
               
               
                   
                   
                 AGG 
               
               
                   
                   
                 (SEQ ID NO: 190) 
               
               
                   
               
               
                 TIGIT 
                 miR-142 
                 GGAGTCAGGAGGCCTGGGCAGCCTGAAGAGTACACGCCGACG 
               
               
                   
                   
                 GACAGACAGACAGTGCAGTCACCACCACGATGACTGCTGTGCA 
               
               
                   
                   
                 GAACAGCACTGGAGGGATGCACAGCAATCATCGTGGTGATGA 
               
               
                   
                   
                 GTGTACTGTGGGCTTCGGAGATCACGCCACTGCTGCCGCCCGC 
               
               
                   
                   
                 TGCCCGCCACCATCTTC 
               
               
                   
                   
                 (SEQ ID NO: 191) 
               
               
                   
               
               
                 TIGIT 
                 miR-19 
                 CCAATAATTCAAGCCAAGCAAGTATATAGGTGTTTTAATAGTTT 
               
               
                   
                   
                 TTGTTTGCAGTCCTCTGATCTGCACAGCAGTTCGTGGTACAAGA 
               
               
                   
                   
                 AGAATGTAGTACCACGATGACTGCTGTGCAGATTGGTGGCCTG 
               
               
                   
                   
                 CTATTTCCTTCAAATGAATGATTTTTACTAATTTTGTGTACTTTTA 
               
               
                   
                   
                 TTGTG 
               
               
                   
                   
                 (SEQ ID NO: 192) 
               
               
                   
               
               
                 TIGIT 
                 miR-1915 
                 CGGACCACGGTGTCCCCTTCTCTCCAGCTGGGGGTCTCGGGTCC 
               
               
                   
                   
                 TGGCGCTGAGAGGCCGCACCACGATGACTGCTGTGCAGAGTGC 
               
               
                   
                   
                 ACCCGTGTCTGCCAATAGCTGTAATCGTGGGCGGCCCTAGCGA 
               
               
                   
                   
                 CCTGCGGCGGCGCCGGGAAAGCCCTGCCTCTGCAGCGGGTCCC 
               
               
                   
                   
                 AGGGGTC 
               
               
                   
                   
                 (SEQ ID NO: 193) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCAGTCGTTGACTGTGGACTTATATA 
               
               
                   
                   
                 TGGATTACTTTGCTATATCGTTCACGGTCAGCGACTGTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 194) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTATC 
               
               
                   
                   
                 GTTCACGGTCAGCGACTGGAGAATATATGAAGGCAGTGCTGAA 
               
               
                   
                   
                 CGTGAACGATCGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 195) 
               
               
                   
               
               
                 TIGIT 
                 miR-22 
                 CATTTTCCCTCCCTTTCCCTTAGGAGCCTGTTCCTCTCACGCCCTC 
               
               
                   
                   
                 ACCTGGCTGAGCCGCATAGTCGCTGACTTGAACAGATATATGTC 
               
               
                   
                   
                 CTGACCCAGCTATATCGTTCACGGTCAGCGACTGTGCCCTCTGC 
               
               
                   
                   
                 CCCTGGCTTCGAGGAGGAGGAGGAGCTGCTTTCCCCATCATCT 
               
               
                   
                   
                 GGAAGGTG 
               
               
                   
                   
                 (SEQ ID NO: 196) 
               
               
                   
               
               
                 TIGIT 
                 miR-142 
                 GGAGTCAGGAGGCCTGGGCAGCCTGAAGAGTACACGCCGACG 
               
               
                   
                   
                 GACAGACAGACAGTGCAGTCACCTATCGTTCACGGTCAGCGAC 
               
               
                   
                   
                 TAACAGCACTGGAGGGTGTCGCTGACAGTGAACGATAGATGA 
               
               
                   
                   
                 GTGTACTGTGGGCTTCGGAGATCACGCCACTGCTGCCGCCCGC 
               
               
                   
                   
                 TGCCCGCCACCATCTTC 
               
               
                   
                   
                 (SEQ ID NO: 197) 
               
               
                   
               
               
                 TIGIT 
                 miR-16 
                 cttcTGAAGAAAATATATTTCTTTTTATTCATAGCTCTTATGATAG 
               
               
                   
                   
                 CAATGTCAGCAGTGCCTTATCGTTCACGGTCAGCGACTGTTAAG 
               
               
                   
                   
                 ATTCTAAAATTATCTGTCGCTGAGCGCTGAACGATGAAGTAAG 
               
               
                   
                   
                 GTTGACCATACTCTACAGTTGTGTTTTAATGTATATTAATGTTAC 
               
               
                   
                   
                 TAATGTGTTTT 
               
               
                   
                   
                 (SEQ ID NO: 198) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGACTACTTCAATGTCCTGACCTTATAT 
               
               
                   
                   
                 GGATTACTTTGCTATAACTCAGGACATTGAAGTAGTTTTCGGCA 
               
               
                   
                   
                 AGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGT 
               
               
                   
                   
                 TTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 199) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTAAC 
               
               
                   
                   
                 TCAGGACATTGAAGTAGTGAGAATATATGAAGGACTATTCAGA 
               
               
                   
                   
                 GTCCTGAGTTCGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 200) 
               
               
                   
               
               
                 TIGIT 
                 miR-21 
                 TGTCTGCTTGTTTTGCCTACCATCGTGACATCTCCATGGCTGTAC 
               
               
                   
                   
                 CACCTTGTCGGGTAACTCAGGACATTGAAGTAGTCTGTTGAATC 
               
               
                   
                   
                 TCATGGCTACTCCAATGCCTGAGTTGTCTGACATTTTGGTATCTT 
               
               
                   
                   
                 TCATCTGACCATCCATATCCAATGTTCTCATTTAAACA 
               
               
                   
                   
                 (SEQ ID NO: 201) 
               
               
                   
               
               
                 TIGIT 
                 miR-494 
                 CAGTTCTGTTTTGATTTTTTTTGTTTGTTTTTTGATCAGTGCTAAT 
               
               
                   
                   
                 CTTCGATACTCGAAGGAACTACTGTAATGTCTGACGTTTCTTTAT 
               
               
                   
                   
                 TTATGATAACTCAGGACATTGAAGTAGTTTTTTTAGTATCAAATC 
               
               
                   
                   
                 CCACCCTGGAGGCACTTCCTGTTCCTGATGCAGCCTTCAGGGAGG 
               
               
                   
                   
                 (SEQ ID NO: 202) 
               
               
                   
               
               
                 TIGIT 
                 miR-19 
                 CCAATAATTCAAGCCAAGCAAGTATATAGGTGTTTTAATAGTTT 
               
               
                   
                   
                 TTGTTTGCAGTCCTCTGGACTACTTCAATGTTGAGTTTACAAGA 
               
               
                   
                   
                 AGAATGTAGTTAACTCAGGACATTGAAGTAGTCTGGTGGCCTG 
               
               
                   
                   
                 CTATTTCCTTCAAATGAATGATTTTTACTAATTTTGTGTACTTTTA 
               
               
                   
                   
                 TTGTG 
               
               
                   
                   
                 (SEQ ID NO: 203) 
               
               
                   
               
               
                 TIGIT 
                 miR-1915 
                 CGGACCACGGTGTCCCCTTCTCTCCAGCTGGGGGTCTCGGGTCC 
               
               
                   
                   
                 TGGCGCTGAGAGGCCGCAGATCCACGTTACTCACCCTAGGTGC 
               
               
                   
                   
                 ACCCGTGCTAGGCAGTGAGCAAAGTGGATCGCGGCCCTAGCGA 
               
               
                   
                   
                 CCTGCGGCGGCGCCGGGAAAGCCCTGCCTCTGCAGCGGGTCCC 
               
               
                   
                   
                 AGGGGTC 
               
               
                   
                   
                 (SEQ ID NO: 204) 
               
               
                   
               
               
                 TIGIT 
                 miR-204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACAGAT 
               
               
                   
                   
                 CCACGTTACTCACCCTAGGAGAATATATGAAGGCTAGGTGAGA 
               
               
                   
                   
                 AACGTGGATCGGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 205) 
               
               
                   
               
               
                 TIGIT 
                 miR-206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCTAGGGTGAGTAACGTGGCCTCTT 
               
               
                   
                   
                 ATGGATTACTTTGCTAAGATCCACGTTACTCACCCTAGTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 206) 
               
               
                   
               
               
                 TIGIT 
                 miR-21 
                 TGTCTGCTTGTTTTGCCTACCATCGTGACATCTCCATGGCTGTAC 
               
               
                   
                   
                 CACCTTGTCGGGAGATCCACGTTACTCACCCTAGCTGTTGAATC 
               
               
                   
                   
                 TCATGGTAGGGCGAGTACGTGGATCGTCTGACATTTTGGTATCT 
               
               
                   
                   
                 TTCATCTGACCATCCATATCCAATGTTCTCATTTAAACA 
               
               
                   
                   
                 (SEQ ID NO: 207) 
               
               
                   
               
               
                 TIGIT 
                 miR-22 
                 CATTTTCCCTCCCTTTCCCTTAGGAGCCTGTTCCTCTCACGCCCTC 
               
               
                   
                   
                 ACCTGGCTGAGCCGCACTAGGGTGAGTACGTGGCATCTTATGT 
               
               
                   
                   
                 CCTGACCCAGCTAAGATCCACGTTACTCACCCTAGTGCCCTCTG 
               
               
                   
                   
                 CCCCTGGCTTCGAGGAGGAGGAGGAGCTGCTTTCCCCATCATC 
               
               
                   
                   
                 TGGAAGGTG 
               
               
                   
                   
                 (SEQ ID NO: 208) 
               
               
                   
               
               
                 TIM3 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACCATT 
               
               
                   
                   
                 ATGCCTGGGATTTGGATCGAGAATATATGAAGGGATCAGATCG 
               
               
                   
                   
                 CAGGCATAATTGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 209) 
               
               
                   
               
               
                 TIM3 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGCATTATGCCTGG 
               
               
                   
                   
                 GATTTGGATCCTGGGCTCAGACCTCCAAATCCACACATAGTGCA 
               
               
                   
                   
                 GGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGAG 
               
               
                   
                   
                 GTGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 210) 
               
               
                   
               
               
                 TIM3 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACCATTATGCCTGGGATTTGGATCCTGTGAAGC 
               
               
                   
                   
                 CACAGATGGGGATCCAGATCAGGCATAGTGGCTGCCTACTGCC 
               
               
                   
                   
                 TCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 211) 
               
               
                   
               
               
                 TIM3 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGGATCCGGATCCTAGGTATCCATGTA 
               
               
                   
                   
                 TGGATTACTTTGCTACATTATGCCTGGGATTTGGATCTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 212) 
               
               
                   
               
               
                 TIM3 
                 miR16 
                 CTTCTGAAGAAAATATATTTCTTTTTATTCATAGCTCTTATGATA 
               
               
                   
                   
                 GCAATGTCAGCAGTGCCTCATTATGCCTGGGATTTGGATCTTAA 
               
               
                   
                   
                 GATTCTAAAATTATCTTCCGAATCACATGGCATAATGAAGTAAG 
               
               
                   
                   
                 GTTGACCATACTCTACAGTTGTGTTTTAATGTATATTAATGTTAC 
               
               
                   
                   
                 TAATGTGTTTT 
               
               
                   
                   
                 (SEQ ID NO: 213) 
               
               
                   
               
               
                 TIM3 
                 miR17 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATT 
               
               
                   
                   
                 GTGACCAGTCAGAATAATGTCATTATGCCTGGGATTTGGATCGT 
               
               
                   
                   
                 GATATGTGCATCGGCCAGAACCAAGGCATAAGTAGCATTATGG 
               
               
                   
                   
                 TGACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGG 
               
               
                   
                   
                 GCCTGCTGATGT 
               
               
                   
                   
                 (SEQ ID NO: 214) 
               
               
                   
               
               
                 TIM3 
                 miR126 
                 CCGGGGTCCTGTCTGCATCCAGCGCAGCATTCTGGAAGACGCC 
               
               
                   
                   
                 ACGCCTCCGCTGGCGACGGACTCCAAATCCCGTGCATAATCGCT 
               
               
                   
                   
                 GTGACACTTCAAACCATTATGCCTGGGATTTGGATCCCGTCCAC 
               
               
                   
                   
                 GGCACCGCATCGAAAACGCCGCTGAGACCTCAGCCTTGACCTC 
               
               
                   
                   
                 CCTCAGCGTGG 
               
               
                   
                   
                 (SEQ ID NO: 215) 
               
               
                   
               
               
                 TIM3 
                 miR122 
                 CAATGGTGGAATGTGGAGGTGAAGTTAACACCTTCGTGGCTAC 
               
               
                   
                   
                 AGAGTTTCCTTAGCAGAGCTGCATTATGCCTGGGATTTGGATCT 
               
               
                   
                   
                 GTCTAAACTATGATTCGAATCCAAGGCATATGGTAGCTACTGCT 
               
               
                   
                   
                 AGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTGA 
               
               
                   
                   
                 GCAAGAAGGTTCATCTGATATCAGTCTTCTCAATCT 
               
               
                   
                   
                 (SEQ ID NO: 216) 
               
               
                   
               
               
                 TIM3 
                 miR214 
                 ACAGGCTGATTGTATCTGTCTATGAGCAAAGGAAACCTGAAGG 
               
               
                   
                   
                 AACCAAGGGCCTGGCTGGACAGAGTTGTCATGTGATGATGAAA 
               
               
                   
                   
                 GGACAGTGAATTAGCAGAACATCCGCTCACCTGTTAATTCACAT 
               
               
                   
                   
                 CCCTTTCATCAGCACATGACAACCCAGCCTGAATGACAACCAGC 
               
               
                   
                   
                 CATTGAAAGAAAGCAGCCCTCACACCATAGCATCTA 
               
               
                   
                   
                 (SEQ ID NO: 217) 
               
               
                   
               
               
                 TIM3 
                 miR29b1 
                 GGGTTTATTGTAAGAGAGCATTATGAAGAAAAAAATAGATCAT 
               
               
                   
                   
                 AAAGCTTCTTCAGGACGATGGAAGGGTTGTGAACGTTAGATTT 
               
               
                   
                   
                 AAATAGTGATTGTCTAATTCACATCCCTTTCATCAGTCTTGGGG 
               
               
                   
                   
                 GAGACCAGCTGCGCTGCACTACCAACAGCAAAAGAAGTGAATG 
               
               
                   
                   
                 GGACAGCT 
               
               
                   
                   
                 (SEQ ID NO: 218) 
               
               
                   
               
               
                 TIM3 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTAATT 
               
               
                   
                   
                 CACATCCCTTTCATCAGGAGAATATATGAAGGCTGAGGAAGAG 
               
               
                   
                   
                 GTGTGAATTCGTTCAATTGTCATCACTGGCATCTTTTTTGATCAT 
               
               
                   
                   
                 TGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 219) 
               
               
                   
               
               
                 TIM3 
                 miR133a1 
                 TTTACCAATGAAAAGCATTTAACTGTTTTGGATTCCAAACTAGC 
               
               
                   
                   
                 AGCACTACAATGCTTTGCTAGTGATGAATAGGCTGCGAATTATC 
               
               
                   
                   
                 GCCTCTTCAATGGATAATTCACATCCCTTTCATCAGTAGCTATGC 
               
               
                   
                   
                 ATTGATTACTACGGGACAACCAACGTTTTCATTTGTGAATATCA 
               
               
                   
                   
                 ATTACTTGCCA 
               
               
                   
                   
                 (SEQ ID NO: 220) 
               
               
                   
               
               
                 LAG3 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACTAGTCGTTGGGTAAAGTCGCCACTGTGAAGC 
               
               
                   
                   
                 CACAGATGGGTGGTGACTTCTCAACGATTAGCTGCCTACTGCCT 
               
               
                   
                   
                 CGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 221) 
               
               
                   
               
               
                 LAG3 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGTGGCGATTTTACCCAATGCTCTATA 
               
               
                   
                   
                 TGGATTACTTTGCTATAGTCGTTGGGTAAAGTCGCCATTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 222) 
               
               
                   
               
               
                 LAG3 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTAGT 
               
               
                   
                   
                 CGTTGGGTAAAGTCGCCAGAGAATATATGAAGGTGGCACTTTC 
               
               
                   
                   
                 CTCAACGACTCGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 223) 
               
               
                   
               
               
                 LAG3 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGTAGTCGTTGGG 
               
               
                   
                   
                 TAAAGTCGCCACTGGGCTCAGACCGCGACTTACCACACGACTAC 
               
               
                   
                   
                 AGGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGA 
               
               
                   
                   
                 GGTGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 224) 
               
               
                   
               
               
                 LAG3 
                 miR17 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATT 
               
               
                   
                   
                 GTGACCAGTCAGAATAATGTGTTGCTTTCCGCTAAGTGGTGAGT 
               
               
                   
                   
                 GATATGTGCATCTCCCACTCAGAGGAAAGCACTAGCATTATGGT 
               
               
                   
                   
                 GACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGG 
               
               
                   
                   
                 CCTGCTGATGT 
               
               
                   
                   
                 (SEQ ID NO: 225) 
               
               
                   
               
               
                 LAG3 
                 miR122 
                 CAATGGTGGAATGTGGAGGTGAAGTTAACACCTTCGTGGCTAC 
               
               
                   
                   
                 AGAGTTTCCTTAGCAGAGCTGGTTGCTTTCCGCTAAGTGGTGAT 
               
               
                   
                   
                 GTCTAAACTATTCACCACTTAGAGGAAAGCCTCTAGCTACTGCT 
               
               
                   
                   
                 AGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTGA 
               
               
                   
                   
                 GCAAGAAGGTTCATCTGATATCAGTCTTCTCAATCT 
               
               
                   
                   
                 (SEQ ID NO: 226) 
               
               
                   
               
               
                 LAG3 
                 miR126 
                 CCGGGGTCCTGTCTGCATCCAGCGCAGCATTCTGGAAGACGCC 
               
               
                   
                   
                 ACGCCTCCGCTGGCGACGGGAACCACTTAGCGCGAAGCAAGGC 
               
               
                   
                   
                 TGTGACACTTCAAACGTTGCTTTCCGCTAAGTGGTGACCGTCCA 
               
               
                   
                   
                 CGGCACCGCATCGAAAACGCCGCTGAGACCTCAGCCTTGACCT 
               
               
                   
                   
                 CCCTCAGCGTGG 
               
               
                   
                   
                 (SEQ ID NO: 227) 
               
               
                   
               
               
                 GITR 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACTTTGCAGTGGCCTTCGTGGCCCCTGTGAAGC 
               
               
                   
                   
                 CACAGATGGGGGGTCACGAGCCACTGCGAAGCTGCCTACTGCC 
               
               
                   
                   
                 TCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 228) 
               
               
                   
               
               
                 GITR 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGGGGCTATGAAGGCCATTGAGAAAT 
               
               
                   
                   
                 ATGGATTACTTTGCTATTTGCAGTGGCCTTCGTAGCCCTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 229) 
               
               
                   
               
               
                 GITR 
                 miR17 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATT 
               
               
                   
                   
                 GTGACCAGTCAGAATAATGTTTTGCAGTGGCCTTCGTGGCCCGT 
               
               
                   
                   
                 GATATGTGCATCGGTCACGTAGACTACTGCACTCGCATTATGGT 
               
               
                   
                   
                 GACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGG 
               
               
                   
                   
                 CCTGCTGATGT 
               
               
                   
                   
                 (SEQ ID NO: 230) 
               
               
                   
               
               
                 GITR 
                 miR122 
                 CAATGGTGGAATGTGGAGGTGAAGTTAACACCTTCGTGGCTAC 
               
               
                   
                   
                 AGAGTTTCCTTAGCAGAGCTGTTTGCAGTGGCCTTCGTGGCCCT 
               
               
                   
                   
                 GTCTAAACTATGGGTCACGAAGACCACTGCCCATAGCTACTGCT 
               
               
                   
                   
                 AGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTGA 
               
               
                   
                   
                 GCAAGAAGGTTCATCTGATATCAGTCTTCTCAATCT 
               
               
                   
                   
                 (SEQ ID NO: 231) 
               
               
                   
               
               
                 GITR 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGAGCCTCCCGTCC 
               
               
                   
                   
                 TAAGACCCCACTGGGCTCAGACAGGGTCTTGGAAAGGAGGCTC 
               
               
                   
                   
                 AGGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGA 
               
               
                   
                   
                 GGTGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 232) 
               
               
                   
               
               
                 GITR 
                 miR29 
                 GGGTTTATTGTAAGAGAGCATTATGAAGAAAAAAATAGATCAT 
               
               
                   
                   
                 AAAGCTTCTTCAGGGTGGGTCTTAGGTCGGGAGCTGCTGATTT 
               
               
                   
                   
                 AAATAGTGATTGTCAGCCTCCCGTCCTAAGACCCCACCTTGGGG 
               
               
                   
                   
                 GAGACCAGCTGCGCTGCACTACCAACAGCAAAAGAAGTGAATG 
               
               
                   
                   
                 GGACAGCT 
               
               
                   
                   
                 (SEQ ID NO: 233) 
               
               
                   
               
               
                 GITR 
                 miR181a1 
                 TCTCCCATCCCCTTCAGATACTTACAGATACTGTAAAGTGAGTA 
               
               
                   
                   
                 GAATTCTGAGTTTTGAGGTTGCTTCAGTGAGCCTCCCGTCCTAA 
               
               
                   
                   
                 GACCCCACTTGGAATTAAAATCAAGTGGGTCTTGACGGGTGGC 
               
               
                   
                   
                 ACCCTATGGCTAACCATCATCTACTCCATGGTGCTCAGAATTCG 
               
               
                   
                   
                 CTGAAGACAGGAAACCAAAGGTGGACACACCAGG 
               
               
                   
                   
                 (SEQ ID NO: 234) 
               
               
                   
               
               
                 TIGIT 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCCAGGGTGAGTAACGTGGCCTCTT 
               
               
                   
                   
                 ATGGATTACTTTGCTAAGATCCACGTTACTCACCCTGGTTTCGG 
               
               
                   
                   
                 CAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAG 
               
               
                   
                   
                 GTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 235) 
               
               
                   
               
               
                 TIGIT 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACAGATCCACGTTACTCACCCAAGCTGTGAAGC 
               
               
                   
                   
                 CACAGATGGGCTTGGGTGAGACGTGGATCTGCTGCCTACTGCC 
               
               
                   
                   
                 TCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 236) 
               
               
                   
               
               
                 TIGIT 
                 miR133a1 
                 TTTACCAATGAAAAGCATTTAACTGTTTTGGATTCCAAACTAGC 
               
               
                   
                   
                 AGCACTACAATGCTTTGCTAGAGGGGTGTATACCGCGGATCTTC 
               
               
                   
                   
                 GCCTCTTCAATGGAAGATCCACGTTACTCACCCCTGTAGCTATG 
               
               
                   
                   
                 CATTGATTACTACGGGACAACCAACGTTTTCATTTGTGAATATC 
               
               
                   
                   
                 AATTACTTGCCA 
               
               
                   
                   
                 (SEQ ID NO: 237) 
               
               
                   
               
               
                 TIGIT 
                 miR122 
                 CAATGGTGGAATGTGGAGGTGAAGTTAACACCTTCGTGGCTAC 
               
               
                   
                   
                 AGAGTTTCCTTAGCAGAGCTGAGATCCACGTTACTCACCCTTGT 
               
               
                   
                   
                 GTCTAAACTATCAAGGGTGAGTCACGTGGAGATTAGCTACTGC 
               
               
                   
                   
                 TAGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTG 
               
               
                   
                   
                 AGCAAGAAGGTTCATCTGATATCAGTCTTCTCAATCT 
               
               
                   
                   
                 (SEQ ID NO: 238) 
               
               
                   
               
               
                 TIGIT 
                 miR29b1 
                 GGGTTTATTGTAAGAGAGCATTATGAAGAAAAAAATAGATCAT 
               
               
                   
                   
                 AAAGCTTCTTCAGGAAAGATCCACGTTACTCACCCTTAGATTTA 
               
               
                   
                   
                 AATAGTGATTGTCTAGGTGAGTTACGTGGATCTGTTCTTGGGG 
               
               
                   
                   
                 GAGACCAGCTGCGCTGCACTACCAACAGCAAAAGAAGTGAATG 
               
               
                   
                   
                 GGACAGCT 
               
               
                   
                   
                 (SEQ ID NO: 239) 
               
               
                   
               
               
                 TIGIT 
                 miR214 
                 ACAGGCTGATTGTATCTGTCTATGAGCAAAGGAAACCTGAAGG 
               
               
                   
                   
                 AACCAAGGGCCTGGCTGGACAGAGTTGTCATGTGTCAGATCCA 
               
               
                   
                   
                 CGTTACTCACCCTGCAGAACATCCGCTCACCTGTAGGGTGAGAC 
               
               
                   
                   
                 TCGTGGATCTGTCACATGACAACCCAGCCTGAATGACAACCAGC 
               
               
                   
                   
                 CATTGAAAGAAAGCAGCCCTCACACCATAGCATCTA 
               
               
                   
                   
                 (SEQ ID NO: 240) 
               
               
                   
               
               
                 PD1 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACTTCAGGAATGGGTTCCAAGGAGCTGTGAAGC 
               
               
                   
                   
                 CACAGATGGGCTCCTTGGACCATTCCTGAAGCTGCCTACTGCCT 
               
               
                   
                   
                 CGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 241) 
               
               
                   
               
               
                 PD1 
                 miR412 
                 GTCTTGGAGGCTGGGGCACCTCGGGGAAGGACGCCGGCATCA 
               
               
                   
                   
                 GCACCATTCTGGGGTACGGGGATGGATTCAGGAATGGGTTCCA 
               
               
                   
                   
                 AGGAATTGTTTCTAATGTCCTGAAGCCATTCATGGAGCCGTCCG 
               
               
                   
                   
                 TATCCGCTGCAGCCTGTGGGGCCTGCGGGCCGGGGAGCCGATC 
               
               
                   
                   
                 GCGCTTCAGCTCAGCGCCT 
               
               
                   
                   
                 (SEQ ID NO: 242) 
               
               
                   
               
               
                 PD1 
                 miR17 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATT 
               
               
                   
                   
                 GTGACCAGTCAGAATAATGTTTCAGGAATGGGTTCCAAGGAAG 
               
               
                   
                   
                 TGATATGTGCATCTTCTTGGTACACGTTCCTGCTCACATTATGGT 
               
               
                   
                   
                 GACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGG 
               
               
                   
                   
                 CCTGCTGATGT 
               
               
                   
                   
                 (SEQ ID NO: 243) 
               
               
                   
               
               
                 PD1 
                 miR122 
                 CAATGGTGGAATGTGGAGGTGAAGTTAACACCTTCGTGGCTAC 
               
               
                   
                   
                 AGAGTTTCCTTAGCAGAGCTGTTCAGGAATGGGTTCCAAGGAG 
               
               
                   
                   
                 TGTCTAAACTATCTCCTTGGAACACATTCCTACATAGCTACTGCT 
               
               
                   
                   
                 AGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTGA 
               
               
                   
                   
                 GCAAGAAGGTTCATCTGATATCAGTCTTCTCAATCT 
               
               
                   
                   
                 (SEQ ID NO: 244) 
               
               
                   
               
               
                 PD1 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGTATAATATAATA 
               
               
                   
                   
                 GAACCACAGGCTGGGCTCAGACGTGTGGTTTATCCTGTTGTAC 
               
               
                   
                   
                 AGGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGA 
               
               
                   
                   
                 GGTGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 245) 
               
               
                   
               
               
                 PD1 
                 miR486 
                 TGTGGTGCTGGGGGCTTCAGCGGCCGGCTCTGATCTCCATCCTC 
               
               
                   
                   
                 CCTGGGGCATATAATATAATAGAACCACAGGGCCCTTCATGCTG 
               
               
                   
                   
                 CCCAGCTTGTGGTTCTATTATGTTATAACTCGGGGTGGGAGTCA 
               
               
                   
                   
                 GCAGGAGGTGAGGGGGCATGGTGGCCCCAGTGCAGC 
               
               
                   
                   
                 (SEQ ID NO: 246) 
               
               
                   
               
               
                 PD1 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCGTGCTGAACTGGTATCGAAATGT 
               
               
                   
                   
                 ATGGATTACTTTGCTACATGCGGTACCAGTTTAGCACGTTTCGG 
               
               
                   
                   
                 CAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAG 
               
               
                   
                   
                 GTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 247) 
               
               
                   
               
               
                 PD1 
                 miR122 
                 CAATGGTGGAATGTGGAGGTGAAGTTAACACCTTCGTGGCTAC 
               
               
                   
                   
                 AGAGTTTCCTTAGCAGAGCTGCATGCGGTACCAGTTTAGCACGT 
               
               
                   
                   
                 GTCTAAACTATCGTGCTAGACTTGTACTGTCAGTAGCTACTGCT 
               
               
                   
                   
                 AGGCAATCCTTCCCTCGATAAATGTCTTGGCATCGTTTGCTTTGA 
               
               
                   
                   
                 GCAAGAAGGTTCATCTGATATCAGTCTTCTCAATCT 
               
               
                   
                   
                 (SEQ ID NO: 248) 
               
               
                   
               
               
                 PD1 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACCATGCGGTACCAGTTTAGCACGCTGTGAAGC 
               
               
                   
                   
                 CACAGATGGGCGTGCTAGAGGTGTCGCATGGCTGCCTACTGCC 
               
               
                   
                   
                 TCGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 249) 
               
               
                   
               
               
                 CTLA4 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCAGCGAGGGAGAAGATTACCATTT 
               
               
                   
                   
                 ATGGATTACTTTGCTAAATATAGTCTTCTCCCTCGCTGTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 250) 
               
               
                   
               
               
                 CTLA4 
                 miR26a 
                 TGAAGCCACAGGAGCCAAGAGCAGGAGGACCAAGGCCCTGGC 
               
               
                   
                   
                 GAAGGCCGTGGCCTCGAATATAGTCTTCTCCCTCGCTTGTGCAG 
               
               
                   
                   
                 GTCCCAATGGAGCGAGGGATAGGACTATACTCGGGGACGCGG 
               
               
                   
                   
                 GCCTGGACGCCGGCATCCGGGCTCAGGACCCCCCTCTCTGCCA 
               
               
                   
                   
                 GAGGC 
               
               
                   
                   
                 (SEQ ID NO: 251) 
               
               
                   
               
               
                 CTLA4 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACAATATAGTCTTCTCCCTCGCTGCTGTGAAGCC 
               
               
                   
                   
                 ACAGATGGGCAGTGAGGGAAGACTATGTTGCTGCCTACTGCCT 
               
               
                   
                   
                 CGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 252) 
               
               
                   
               
               
                 PIK3IP1 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCCGGTTGAACATTGGTTGCCTCATA 
               
               
                   
                   
                 TGGATTACTTTGCTATGAACGACCAGTGTTTAACCGGTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 253) 
               
               
                   
               
               
                 PIK3IP1 
                 miR126 
                 CCGGGGTCCTGTCTGCATCCAGCGCAGCATTCTGGAAGACGCC 
               
               
                   
                   
                 ACGCCTCCGCTGGCGACGGGACGGATGAACTTAGAGGAGACG 
               
               
                   
                   
                 CTGTGACACTTCAAACTTCTCCTTGGAGTTCATCCGCGCCGTCCA 
               
               
                   
                   
                 CGGCACCGCATCGAAAACGCCGCTGAGACCTCAGCCTTGACCT 
               
               
                   
                   
                 CCCTCAGCGTGG 
               
               
                   
                   
                 (SEQ ID NO: 254) 
               
               
                   
               
               
                 PIK3IP1 
                 miR30a 
                 CAGGTTAACCCAACAGAAGGCTAAAGAAGGTATATTGCTGTTG 
               
               
                   
                   
                 ACAGTGAGCGACTTCTCCTTGGAGTTCATCCGCGCTGTGAAGCC 
               
               
                   
                   
                 ACAGATGGGCGCGGATGATCCAAGGAGGAGCTGCCTACTGCCT 
               
               
                   
                   
                 CGGACTTCAAGGGGCTACTTTAGGAGCAATTATCTTGTTTA 
               
               
                   
                   
                 (SEQ ID NO: 255) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGATACACATCAGA 
               
               
                   
                   
                 ATCCTTACTGCTGGGCTCAGACCGTAAGGATCTCCTGTGTATCA 
               
               
                   
                   
                 GGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGAG 
               
               
                   
                   
                 GCGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 256) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGC 
               
               
                   
                   
                 GTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACATAC 
               
               
                   
                   
                 ACATCAGAATCCTTACTTGAGAATATATGAAGGAGGTAGGATA 
               
               
                   
                   
                 CTGATGTGTACGTTCAATTGTCATCACTGGCATCTTTTTTGATCA 
               
               
                   
                   
                 TTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 257) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCGGTAAGGATTCTGATGTAATATTA 
               
               
                   
                   
                 TGGATTACTTTGCTAATACACATCAGAATCCTTACTGTTTCGGCA 
               
               
                   
                   
                 AGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGT 
               
               
                   
                   
                 TTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 258) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR26a 
                 TGAAGCCACAGGAGCCAAGAGCAGGAGGACCAAGGCCCTGGC 
               
               
                   
                   
                 GAAGGCCGTGGCCTCGATACACATCAGAATCCTTACTTGTGCAG 
               
               
                   
                   
                 GTCCCAATGGAGTAAGGATCCTGATGTGTCTCGGGGACGCGGG 
               
               
                   
                   
                 CCTGGACGCCGGCATCCGGGCTCAGGACCCCCCTCTCTGCCAG 
               
               
                   
                   
                 AGGC 
               
               
                   
                   
                 (SEQ ID NO: 259) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAG 
               
               
                   
                   
                 CGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGTTGTTGAAGGC 
               
               
                   
                   
                 GTTTGCACATGCTGGGCTCAGACCTGTGCAATGCGATCAATAG 
               
               
                   
                   
                 CAGGGACCTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTG 
               
               
                   
                   
                 AGGCGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 260) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR16 
                 CTTCTGAAGAAAATATATTTCTTTTTATTCATAGCTCTTATGATA 
               
               
                   
                   
                 GCAATGTCAGCAGTGCCTTTGTTGAAGGCGTTTGCACATGTTAA 
               
               
                   
                   
                 GATTCTAAAATTATCTTGTGCGGAAGCACTTCAATAAAAGTAAG 
               
               
                   
                   
                 GTTGACCATACTCTACAGTTGTGTTTTAATGTATATTAATGTTAC 
               
               
                   
                   
                 TAATGTGTTTT 
               
               
                   
                   
                 (SEQ ID NO: 261) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR206 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGG 
               
               
                   
                   
                 ATGACACTGCTTCCCGAGGCGTGTGTGAACGCCTTCACATAATA 
               
               
                   
                   
                 TGGATTACTTTGCTATTGTTGAAGGCGTTTGCACATGTTTCGGC 
               
               
                   
                   
                 AAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 262) 
               
               
                   
               
               
                 TCRa3′UTR 
                 miR26a 
                 TGAAGCCACAGGAGCCAAGAGCAGGAGGACCAAGGCCCTGGC 
               
               
                   
                   
                 GAAGGCCGTGGCCTCGTTGTTGAAGGCGTTTGCACATTGTGCA 
               
               
                   
                   
                 GGTCCCAATGGGTGTGCAAAGGTCTTCAATCACGGGGACGCGG 
               
               
                   
                   
                 GCCTGGACGCCGGCATCCGGGCTCAGGACCCCCCTCTCTGCCA 
               
               
                   
                   
                 GAGGC 
               
               
                   
                   
                 (SEQ ID NO: 263) 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
            
               
                   
               
               
                 Non-naturally occurring miRNA sequences (two or more pri-miRNAs) 
               
            
           
           
               
               
               
            
               
                 miRNA 
                 miRNA 
                   
               
               
                 Target 
                 backbone 
                 DNA Sequence 
               
               
                   
               
               
                 PD1 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                   
                 miR206 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCC 
               
               
                   
                   
                 AAGGATGAGAATATATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTT 
               
               
                   
                   
                 CTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATG 
               
               
                   
                   
                 GATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCT 
               
               
                   
                   
                 CCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 267) 
               
               
                   
               
               
                 PD1 + TIGIT 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                   
                 miR150 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCC 
               
               
                   
                   
                 AAGGATGAGAATATATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACAGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGC 
               
               
                   
                   
                 AGCAGCGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGAGATCCACGTTA 
               
               
                   
                   
                 CTCACCCGTGCTGGGCTCAGACCCGGGTGATAATATGGATCTCAGGGAC 
               
               
                   
                   
                 CTGGGGACCCCGGCACCGGCAGGCCCCAAGGGGTGAGGTGAGCGGGCA 
               
               
                   
                   
                 TTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 268) 
               
               
                   
               
               
                 PD1 + TIGIT 
                 miR206 + 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACA 
               
               
                   
                 miR150 
                 CTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATGGATTACTTTGC 
               
               
                   
                   
                 TATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCC 
               
               
                   
                   
                 CCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTTAGGGACTGGGCCC 
               
               
                   
                   
                 ACGGGGAGGCAGCGTCCCCGAGGCAGCAGCGGCAGCGGCGGCTCCTCT 
               
               
                   
                   
                 CCCCATGGCCCTGAGATCCACGTTACTCACCCGTGCTGGGCTCAGACCCG 
               
               
                   
                   
                 GGTGATAATATGGATCTCAGGGACCTGGGGACCCCGGCACCGGCAGGC 
               
               
                   
                   
                 CCCAAGGGGTGAGGTGAGCGGGCATTGGGACCTCCCCTCCCTGTACTC 
               
               
                   
                   
                 (SEQ ID NO: 269) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                   
                 miR204 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                   
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTAGGAGGGTGGGG 
               
               
                   
                   
                 GTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCCATGGCTACAGTCT 
               
               
                   
                   
                 TTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCCAAGGATGAGAATA 
               
               
                   
                   
                 TATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATTGTCATCACTGGCA 
               
               
                   
                   
                 TCTTTTTTGATCATTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 270) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                   
                 miR206 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                   
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTGATGCTACAAGTG 
               
               
                   
                   
                 GCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACACTGCTTCCCGAGGC 
               
               
                   
                   
                 CTGTGGTTCTGTTATATCCATATATGGATTACTTTGCTATATAATATAATA 
               
               
                   
                   
                 GAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCC 
               
               
                   
                   
                 GGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 271) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                   
                 miR206 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACAGATCCACGTTACTCAC 
               
               
                   
                   
                 CCCCTGAGAATATATGAAGGAGGGGTGAGAAGCGTGGATCCGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTT 
               
               
                   
                   
                 CTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATG 
               
               
                   
                   
                 GATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCT 
               
               
                   
                   
                 CCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 272) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR150 + 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAGCGGCA 
               
               
                   
                 miR204 
                 GCGGCGGCTCCTCTCCCCATGGCCCTGAGATCCACGTTACTCACCCGTGC 
               
               
                   
                   
                 TGGGCTCAGACCCGGGTGATAATATGGATCTCAGGGACCTGGGGACCCC 
               
               
                   
                   
                 GGCACCGGCAGGCCCCAAGGGGTGAGGTGAGCGGGCATTGGGACCTCC 
               
               
                   
                   
                 CCTCCCTGTACTCAGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCT 
               
               
                   
                   
                 GATCGCGTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCA 
               
               
                   
                   
                 GGAATGGGTTCCAAGGATGAGAATATATGAAGGATCCTGGAAGCTATTC 
               
               
                   
                   
                 CTGACGTTCAATTGTCATCACTGGCATCTTTTTTGATCATTGCACCATCAT 
               
               
                   
                   
                 CAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 273) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR150 + 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGCAGCGGCA 
               
               
                   
                 miR206 
                 GCGGCGGCTCCTCTCCCCATGGCCCTGAGATCCACGTTACTCACCCGTGC 
               
               
                   
                   
                 TGGGCTCAGACCCGGGTGATAATATGGATCTCAGGGACCTGGGGACCCC 
               
               
                   
                   
                 GGCACCGGCAGGCCCCAAGGGGTGAGGTGAGCGGGCATTGGGACCTCC 
               
               
                   
                   
                 CCTCCCTGTACTCGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGC 
               
               
                   
                   
                 TTCTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATAT 
               
               
                   
                   
                 GGATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTGCC 
               
               
                   
                   
                 TCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 274) 
               
               
                   
               
               
                 TIGIT + 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                 PD1 + PD1 
                 miR204 + 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                 miR206 
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTAGGAGGGTGGGG 
               
               
                   
                   
                 GTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCCATGGCTACAGTCT 
               
               
                   
                   
                 TTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCCAAGGATGAGAATA 
               
               
                   
                   
                 TATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATTGTCATCACTGGCA 
               
               
                   
                   
                 TCTTTTTTGATCATTGCACCATCATCAAATGCATTGGGATAACCATGACGA 
               
               
                   
                   
                 TGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACACTG 
               
               
                   
                   
                 CTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATGGATTACTTTGCTAT 
               
               
                   
                   
                 ATAATATAATAGAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCCCCA 
               
               
                   
                   
                 GGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 275) 
               
               
                   
               
               
                 TIGIT + 
                 miR17 + 
                 TTAGGATGAGTTGAGATCCCAGTGATCTTCTCGCTAAGAGTTTCCTGCCT 
               
               
                 PD1 + PD1 
                 miR204 + 
                 GGGCAAGGAGGAAATTAGCAGGAAAAAAGAGAACATCACCTTGTAAAA 
               
               
                   
                 miR206 extra 
                 CTGAAGATTGTGACCAGTCAGAATAATGTAGATCCACGTTACTCACCCTA 
               
               
                   
                 spacing 1 
                 GTGATATGTGCATCTAGGGTGTGTCATGTGGATGAAGCATTATGGTGAC 
               
               
                   
                   
                 AGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGAT 
               
               
                   
                   
                 GTAGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTAC 
               
               
                   
                   
                 CCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCAGGAATGGGTT 
               
               
                   
                   
                 CCAAGGATGAGAATATATGAAGGATCCTGGAAGCTATTCCTGACGTTCA 
               
               
                   
                   
                 ATTGTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATT 
               
               
                   
                   
                 GGGATAACCATGACGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCT 
               
               
                   
                   
                 GCTTCTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATAT 
               
               
                   
                   
                 ATGGATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTG 
               
               
                   
                   
                 CCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 CTTCCTCATCAGGGCTTTGTGCCAGCAAATGACTCCCTCACCAAGGAAGC 
               
               
                   
                   
                 AAGAGCCTCTGAATCCCATCTGGGCTCTTCCTGAACACCCCTATCTCCCCC 
               
               
                   
                   
                 TCT 
               
               
                   
                   
                 (SEQ ID NO: 276) 
               
               
                   
               
               
                 TIGIT + 
                 miR17 + 
                 TTAGGGATTATGCTGAATTTGTATGGTTTATAGTTGTTAGAGTTTGAGGT 
               
               
                 PD1 + PD1 
                 miR204 + 
                 GTTAATTCTAATTATCTATTTCAAATTTTAGCAGGAAAAAAGAGAACATC 
               
               
                   
                 miR206 extra 
                 ACCTTGTAAAACTGAAGATTGTGACCAGTCAGAATAATGTAGATCCACGT 
               
               
                   
                 spacing 2 
                 TACTCACCCTAGTGATATGTGCATCTAGGGTGTGTCATGTGGATGAAGCA 
               
               
                   
                   
                 TTATGGTGACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGG 
               
               
                   
                   
                 GCCTGCTGATGTAGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCT 
               
               
                   
                   
                 GATCGCGTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCA 
               
               
                   
                   
                 GGAATGGGTTCCAAGGATGAGAATATATGAAGGATCCTGGAAGCTATTC 
               
               
                   
                   
                 CTGACGTTCAATTGTCATCACTGGCATCTTTTTTGATCATTGCACCATCAT 
               
               
                   
                   
                 CAAATGCATTGGGATAACCATGACGATGCTACAAGTGGCCCACTTCTGA 
               
               
                   
                   
                 GATGCGGGCTGCTTCTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGT 
               
               
                   
                   
                 TATATCCATATATGGATTACTTTGCTATATAATATAATAGAACCACAGGTT 
               
               
                   
                   
                 TCGGCAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGT 
               
               
                   
                   
                 TTGGTGACCTTCTTCCTCATCAGGGCTTTGTGCCAGCAAATGACTCCCTCA 
               
               
                   
                   
                 CCAAGGAAGCAAGAGCCTCTGAATCCCATCTGGGCTCTTCCTGAACACCC 
               
               
                   
                   
                 CTATCTCCCCCTCT 
               
               
                   
                   
                 (SEQ ID NO: 277) 
               
               
                   
               
               
                 PD1 + PD1 + 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                 TIGIT 
                 miR206 + 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCC 
               
               
                   
                 miR17 
                 AAGGATGAGAATATATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTT 
               
               
                   
                   
                 CTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATG 
               
               
                   
                   
                 GATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCT 
               
               
                   
                   
                 CCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTTTTA 
               
               
                   
                   
                 GCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACCAGT 
               
               
                   
                   
                 CAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCTAGG 
               
               
                   
                   
                 GTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAGCCA 
               
               
                   
                   
                 AGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGT 
               
               
                   
                   
                 (SEQ ID NO: 278) 
               
               
                   
               
               
                 PD1 + PD1 + 
                 miR204 + 
                 TTAGGATGAGTTGAGATCCCAGTGATCTTCTCGCTAAGAGTTTCCTGCCT 
               
               
                 TIGIT 
                 miR206 + 
                 GGGCAAGGAGGAAAAGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTT 
               
               
                   
                 miR17 extra 
                 CCTGATCGCGTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTT 
               
               
                   
                 spacing 1 
                 CAGGAATGGGTTCCAAGGATGAGAATATATGAAGGATCCTGGAAGCTAT 
               
               
                   
                   
                 TCCTGACGTTCAATTGTCATCACTGGCATCTTTTTTGATCATTGCACCATC 
               
               
                   
                   
                 ATCAAATGCATTGGGATAACCATGACGATGCTACAAGTGGCCCACTTCTG 
               
               
                   
                   
                 AGATGCGGGCTGCTTCTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTG 
               
               
                   
                   
                 TTATATCCATATATGGATTACTTTGCTATATAATATAATAGAACCACAGGT 
               
               
                   
                   
                 TTCGGCAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGG 
               
               
                   
                   
                 TTTGGTGACCTTTTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGA 
               
               
                   
                   
                 AGATTGTGACCAGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGA 
               
               
                   
                   
                 TATGTGCATCTAGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCT 
               
               
                   
                   
                 GCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTCT 
               
               
                   
                   
                 TCCTCATCAGGGCTTTGTGCCAGCAAATGACTCCCTCACCAAGGAAGCAAG 
               
               
                   
                   
                 AGCCTCTGAATCCCATCTGGGCTCTTCCTGAACACCCCTATCTCCCCCTCT 
               
               
                   
                   
                 (SEQ ID NO: 279) 
               
               
                   
               
               
                 PD1 + PD1 + 
                 miR204 + 
                 TGGAGAGGAGGGTGGGGGTGGAGGCAAGCAGAGGACCTCCTGATCAT 
               
               
                 TIGIT 
                 miR206 + 
                 GTACCCATAGGACAGGGTGATGGAAAGGAGGGTGGGGGTGGAGGCAA 
               
               
                   
                 miR17 extra 
                 GCAGAGGACTTCCTGATCGCGTACCCATGGCTACAGTCTTTCTTCATGTG 
               
               
                   
                 spacing 2 
                 ACTCGTGGACTTCAGGAATGGGTTCCAAGGATGAGAATATATGAAGGAT 
               
               
                   
                   
                 CCTGGAAGCTATTCCTGACGTTCAATTGTCATCACTGGCATCTTTTTTGAT 
               
               
                   
                   
                 CATTGCACCATCATCAAATGCATTGGGATAACCATGACGATGCTACAAGT 
               
               
                   
                   
                 GGCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACACTGCTTCCCGAG 
               
               
                   
                   
                 GCCTGTGGTTCTGTTATATCCATATATGGATTACTTTGCTATATAATATAA 
               
               
                   
                   
                 TAGAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCCCCAGGGTACCAC 
               
               
                   
                   
                 CCGGAGCACAGGTTTGGTGACCTTTTAGCAGGAAAAAAGAGAACATCAC 
               
               
                   
                   
                 CTTGTAAAACTGAAGATTGTGACCAGTCAGAATAATGTAGATCCACGTTA 
               
               
                   
                   
                 CTCACCCTAGTGATATGTGCATCTAGGGTGTGTCATGTGGATGAAGCATT 
               
               
                   
                   
                 ATGGTGACAGCTGCCTCGGGAAGCCAAGTTGGGCTTTAAAGTGCAGGGC 
               
               
                   
                   
                 CTGCTGATGTCTTCCTCATCAGGGCTTTGTGCCAGCAAATGACTCCCTCAC 
               
               
                   
                   
                 CAAGGAAGCAAGAGCCTCTGAATCCCATCTGGGCTCTTCCTGAACACCCC 
               
               
                   
                   
                 TATCTCCCCCTCT 
               
               
                   
                   
                 (SEQ ID NO: 280) 
               
               
                   
               
               
                 PD1 + CTLA4 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                   
                 miR26a 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCC 
               
               
                   
                   
                 AAGGATGAGAATATATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACTGAAGCCACAGGAGCCAAGAGCAGGAGGACCAAGGCC 
               
               
                   
                   
                 CTGGCGAAGGCCGTGGCCTCGAATATAGTCTTCTCCCTCGCTTGTGCAGG 
               
               
                   
                   
                 TCCCAATGGAGCGAGGGATAGGACTATACTCGGGGACGCGGGCCTGGA 
               
               
                   
                   
                 CGCCGGCATCCGGGCTCAGGACCCCCCTCTCTGCCAGAGGC 
               
               
                   
                   
                 (SEQ ID NO: 281) 
               
               
                   
               
               
                 PD1 + PD1 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                   
                 miR206 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCC 
               
               
                   
                   
                 AAGGATGAGAATATATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTT 
               
               
                   
                   
                 CTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATG 
               
               
                   
                   
                 GATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCT 
               
               
                   
                   
                 CCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 282) 
               
               
                   
               
               
                 PD1 + CTLA4 
                 miR206 + 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACA 
               
               
                   
                 miR26a 
                 CTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATGGATTACTTTGC 
               
               
                   
                   
                 TATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCC 
               
               
                   
                   
                 CCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTTTGAAGCCACAGGA 
               
               
                   
                   
                 GCCAAGAGCAGGAGGACCAAGGCCCTGGCGAAGGCCGTGGCCTCGAAT 
               
               
                   
                   
                 ATAGTCTTCTCCCTCGCTTGTGCAGGTCCCAATGGAGCGAGGGATAGGA 
               
               
                   
                   
                 CTATACTCGGGGACGCGGGCCTGGACGCCGGCATCCGGGCTCAGGACCC 
               
               
                   
                   
                 CCCTCTCTGCCAGAGGC 
               
               
                   
                   
                 (SEQ ID NO: 283) 
               
               
                   
               
               
                 PD1 + CTLA4 
                 miR206 + 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACA 
               
               
                   
                 miR204 
                 CTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATGGATTACTTTGC 
               
               
                   
                   
                 TATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCC 
               
               
                   
                   
                 CCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTTAGGAGGGTGGGG 
               
               
                   
                   
                 GTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCCATGGCTACAGTCT 
               
               
                   
                   
                 TTCTTCATGTGACTCGTGGACAATATAGTCTTCTCCCTCGCTTGAGAATAT 
               
               
                   
                   
                 ATGAAGGAAGCAGGGACAGGACTATATTGTTCAATTGTCATCACTGGCA 
               
               
                   
                   
                 TCTTTTTTGATCATTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 284) 
               
               
                   
               
               
                 TIGIT + 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                 CTLA4 
                 miR26a 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                   
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTTGAAGCCACAGGA 
               
               
                   
                   
                 GCCAAGAGCAGGAGGACCAAGGCCCTGGCGAAGGCCGTGGCCTCGAAT 
               
               
                   
                   
                 ATAGTCTTCTCCCTCGCTTGTGCAGGTCCCAATGGAGCGAGGGATAGGA 
               
               
                   
                   
                 CTATACTCGGGGACGCGGGCCTGGACGCCGGCATCCGGGCTCAGGACCC 
               
               
                   
                   
                 CCCTCTCTGCCAGAGGC 
               
               
                   
                   
                 (SEQ ID NO: 285) 
               
               
                   
               
               
                 TIGIT + 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                 CTLA4 
                 miR204 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                   
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTAGGAGGGTGGGG 
               
               
                   
                   
                 GTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCCATGGCTACAGTCT 
               
               
                   
                   
                 TTCTTCATGTGACTCGTGGACAATATAGTCTTCTCCCTCGCTTGAGAATAT 
               
               
                   
                   
                 ATGAAGGAAGCAGGGACAGGACTATATTGTTCAATTGTCATCACTGGCA 
               
               
                   
                   
                 TCTTTTTTGATCATTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 286) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                   
                 miR204 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                   
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTAGGAGGGTGGGG 
               
               
                   
                   
                 GTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCCATGGCTACAGTCT 
               
               
                   
                   
                 TTCTTCATGTGACTCGTGGACTTCAGGAATGGGTTCCAAGGATGAGAATA 
               
               
                   
                   
                 TATGAAGGATCCTGGAAGCTATTCCTGACGTTCAATTGTCATCACTGGCA 
               
               
                   
                   
                 TCTTTTTTGATCATTGCACCATCATCAAATGCATTGGGATAACCATGAC 
               
               
                   
                   
                 (SEQ ID NO: 287) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR17 + 
                 TTAGCAGGAAAAAAGAGAACATCACCTTGTAAAACTGAAGATTGTGACC 
               
               
                   
                 206 
                 AGTCAGAATAATGTAGATCCACGTTACTCACCCTAGTGATATGTGCATCT 
               
               
                   
                   
                 AGGGTGTGTCATGTGGATGAAGCATTATGGTGACAGCTGCCTCGGGAAG 
               
               
                   
                   
                 CCAAGTTGGGCTTTAAAGTGCAGGGCCTGCTGATGTGATGCTACAAGTG 
               
               
                   
                   
                 GCCCACTTCTGAGATGCGGGCTGCTTCTGGATGACACTGCTTCCCGAGGC 
               
               
                   
                   
                 CTGTGGTTCTGTTATATCCATATATGGATTACTTTGCTATATAATATAATA 
               
               
                   
                   
                 GAACCACAGGTTTCGGCAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCC 
               
               
                   
                   
                 GGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 288) 
               
               
                   
               
               
                 TIGIT + 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                 CTLA4 
                 miR26a 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACAGATCCACGTTACTCAC 
               
               
                   
                   
                 CCCCTGAGAATATATGAAGGAGGGGTGAGAAGCGTGGATCCGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACTGAAGCCACAGGAGCCAAGAGCAGGAGGACCAAGGCC 
               
               
                   
                   
                 CTGGCGAAGGCCGTGGCCTCGAATATAGTCTTCTCCCTCGCTTGTGCAGG 
               
               
                   
                   
                 TCCCAATGGAGCGAGGGATAGGACTATACTCGGGGACGCGGGCCTGGA 
               
               
                   
                   
                 CGCCGGCATCCGGGCTCAGGACCCCCCTCTCTGCCAGAGGC 
               
               
                   
                   
                 (SEQ ID NO: 289) 
               
               
                   
               
               
                 TIGIT + PD1 
                 miR204 + 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATCGCGTACCC 
               
               
                   
                 miR206 
                 ATGGCTACAGTCTTTCTTCATGTGACTCGTGGACAGATCCACGTTACTCAC 
               
               
                   
                   
                 CCCCTGAGAATATATGAAGGAGGGGTGAGAAGCGTGGATCCGTTCAATT 
               
               
                   
                   
                 GTCATCACTGGCATCTTTTTTGATCATTGCACCATCATCAAATGCATTGGG 
               
               
                   
                   
                 ATAACCATGACGATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTT 
               
               
                   
                   
                 CTGGATGACACTGCTTCCCGAGGCCTGTGGTTCTGTTATATCCATATATG 
               
               
                   
                   
                 GATTACTTTGCTATATAATATAATAGAACCACAGGTTTCGGCAAGTGCCT 
               
               
                   
                   
                 CCTCGCTGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                 (SEQ ID NO: 290) 
               
               
                   
               
            
           
         
       
     
     Splice donor and splice acceptor site sequences 
     
       
         
           
               
               
             
               
                   
               
             
            
               
                 5′ side of intron 
                 AGGTAAGAGTCGATCG (SEQ ID NO: 291) 
               
               
                 (SEQ ID NO: 291) 
                   
               
               
                   
               
               
                 3′ side of intron 
                 ACGCGTTACTAACTGGTACCTCTTTTTTTTTT 
               
               
                 (SEQ ID NO: 292) 
                 TTGATATCCTGCAGGC (SEQ ID NO: 292) 
               
               
                   
               
            
           
         
       
     
     Additional miRNA Sequences 
     
       
         
           
               
               
             
               
                   
               
               
                   
                 SEQ 
               
               
                   
                 ID 
               
               
                 Mature miRNA_Length (Sequence) 
                 NO: 
               
               
                   
               
             
            
               
                 Guide PD1_204_21nt (TTCAGGAATGGGTTCCAAGGA) 
                 704 
               
               
                   
               
               
                 Guide PD1_204_23nt (TTCAGGAATGGGTTCCAAGGATG) 
                 705 
               
               
                   
               
               
                 Passenger PD1_204_21nt (TCCTGGAAGCTATTCCTGACG) 
                 706 
               
               
                   
               
               
                 Passenger PD1_204_22nt (TCCTGGAAGCTATTCCTGACG 
                 707 
               
               
                 T) 
                   
               
               
                   
               
               
                 Passenger PD1_204_23nt (TCCTGGAAGCTATTCCTGACG 
                 708 
               
               
                 TT) 
                   
               
               
                   
               
               
                 Guide PD1_206_21nt (TATAATATAATAGAACCACAG) 
                 709 
               
               
                   
               
               
                 Guide PD1_206_23nt (TATAATATAATAGAACCACAGGA) 
                 710 
               
               
                   
               
               
                 Passenger PD1_206_21nt (TGTGGTTCTGTTATATCCATA) 
                 711 
               
               
                   
               
               
                 Passenger PD1_206_22nt (TGTGGTTCTGTTATATCCATA 
                 712 
               
               
                 T) 
                   
               
               
                   
               
               
                 Passenger PD1_206_23nt (TGTGGTTCTGTTATATCCATA 
                 713 
               
               
                 TA) 
               
               
                   
               
            
           
         
       
     
     Exemplary anti-CD33 VH and VL Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                   
                 SEQ 
                 Amino Acid 
                 SEQ 
                   
               
               
                 Name 
                 ID NO 
                 Sequence 
                 ID NO 
                 Nucleotide Sequence 
               
               
                   
               
             
            
               
                 hM195 VL 
                 293 
                 DIQMTQSPSSLSASVG 
                 301 
                 GACATTCAGATGACCCAGTCTCCGAGCTCTCTGTC 
               
               
                   
                   
                 DRVTITCRASESVDNY 
                   
                 CGCATCAGTAGGAGACAGGGTCACCATCACATGC 
               
               
                   
                   
                 GISFMNWFQQKPGKA 
                   
                 AGAGCCAGCGAAAGTGTCGACAATTATGGCATTA 
               
               
                   
                   
                 PKLLIYAASNQGSGVPS 
                   
                 GCTTTATGAACTGGTTCCAACAGAAACCCGGGAA 
               
               
                   
                   
                 RFSGSGSGTDFTLTISSL 
                   
                 GGCTCCTAAGCTTCTGATTTACGCTGCATCCAACC 
               
               
                   
                   
                 QPDDFATYYCQQSKEV 
                   
                 AAGGCTCCGGGGTACCCTCTCGCTTCTCAGGCAG 
               
               
                   
                   
                 PWTFGQGTKVEIK 
                   
                 TGGATCTGGGACAGACTTCACTCTCACCATTTCAT 
               
               
                   
                   
                   
                   
                 CTCTGCAGCCTGATGACTTCGCAACCTATTACTGT 
               
               
                   
                   
                   
                   
                 CAGCAAAGTAAGGAGGTTCCGTGGACGTTCGGTC 
               
               
                   
                   
                   
                   
                 AAGGGACCAAGGTGGAGATCAAA 
               
               
                   
               
               
                 hM195 VH 
                 294 
                 QVQLVQSGAEVKKPGS 
                 302 
                 CAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGTG 
               
               
                   
                   
                 SVKVSCKASGYTFTDY 
                   
                 AAGAAGCCTGGGAGCTCAGTGAAGGTTTCCTGCA 
               
               
                   
                   
                 NMHWVRQAPGQGLE 
                   
                 AAGCTTCTGGCTACACCTTCACTGACTACAACATG 
               
               
                   
                   
                 WIG Y IYPYNGGTGYNQ 
                   
                 CACTGGGTGAGGCAGGCTCCTGGCCAAGGCCTG 
               
               
                   
                   
                 KFKSKATITADESTNTA 
                   
                 GAATGGATTGGATATATTTATCCTTACAATGGTG 
               
               
                   
                   
                 YMELSSLRSEDTAVYYC 
                   
                 GTACCGGCTACAACCAGAAGTTCAAGAGCAAGG 
               
               
                   
                   
                 ARGRPAMDYWGQGT 
                   
                 CCACAATTACAGCAGACGAGAGTACTAACACAGC 
               
               
                   
                   
                 LVTVSS 
                   
                 CTACATGGAACTCTCCAGCCTGAGGTCTGAGGAC 
               
               
                   
                   
                   
                   
                 ACTGCAGTCTATTACTGCGCAAGAGGGCGCCCCG 
               
               
                   
                   
                   
                   
                 CTATGGACTACTGGGGCCAAGGGACTCTGGTCAC 
               
               
                   
                   
                   
                   
                 TGTCTCTTCA 
               
               
                   
               
               
                 M2H12 VH 
                 295 
                 QVQLQQSGPELVRPGT 
                   
                   
               
               
                   
                   
                 FVKISCKASGYTFTNYDI 
                   
                   
               
               
                   
                   
                 NWVNQRPGQGLEWI 
                   
                   
               
               
                   
                   
                 GWIYPGDGSTKYNEKF 
                   
                   
               
               
                   
                   
                 KAKATLTADKSSSTAYL 
                   
                   
               
               
                   
                   
                 QLNNLTSENSAVYFCA 
                   
                   
               
               
                   
                   
                 SGYEDAMDYWGQGT 
                   
                   
               
               
                   
                   
                 SVTVSS 
                   
                   
               
               
                   
               
               
                 M2H12 VL 
                 296 
                 DIKMTQSPSSMYASLG 
                   
                   
               
               
                   
                   
                 ERVIINCKASQDINSYLS 
                   
                   
               
               
                   
                   
                 WFQQKPGKSPKTLIYR 
                   
                   
               
               
                   
                   
                 ANRLVDGVPSRFSGSG 
                   
                   
               
               
                   
                   
                 SGQDYSLTISSLEYEDM 
                   
                   
               
               
                   
                   
                 GIYYCLQYDEFPLTFGA 
                   
                   
               
               
                   
                   
                 GTKLELKR 
                   
                   
               
               
                   
               
               
                 DRB2 VH 
                 297 
                 EVKLQESGPELVKPGAS 
                   
                   
               
               
                   
                   
                 VKMSCKASGYKFTDYV 
                   
                   
               
               
                   
                   
                 VHWLKQKPGQGLEWI 
                   
                   
               
               
                   
                   
                 GYINPYNDGTKYNEKF 
                   
                   
               
               
                   
                   
                 KGKATLTSDKSSSTAY 
                   
                   
               
               
                   
                   
                 MEVSSLTSEDSAVYYC 
                   
                   
               
               
                   
                   
                 ARDYRYEVYGMDYWG 
                   
                   
               
               
                   
                   
                 QGTSVTVSS 
                   
                   
               
               
                   
               
               
                 DRB2 VL 
                 298 
                 DIVLTQSPTIMSASPGE 
                   
                   
               
               
                   
                   
                 RVTMTCTASSSVNYIH 
                   
                   
               
               
                   
                   
                 WYQQKSGDSPLRWIF 
                   
                   
               
               
                   
                   
                 DTSKVASGVPARFSGS 
                   
                   
               
               
                   
                   
                 GSGTSYSLTISTMEAED 
                   
                   
               
               
                   
                   
                 AATYYCQQWRSYPLTF 
                   
                   
               
               
                   
                   
                 GDGTRLELKRADAAPT 
                   
                   
               
               
                   
                   
                 VS 
                   
                   
               
               
                   
               
               
                 My9-6 VH 
                 299 
                 QVQLQQPGAEVVKPG 
                   
                   
               
               
                   
                   
                 ASVKMSCKASGYTFTS 
                   
                   
               
               
                   
                   
                 YYIHWIKQTPGQGLEW 
                   
                   
               
               
                   
                   
                 VGVIYPGNDDISYNQK 
                   
                   
               
               
                   
                   
                 FKGKATLTADKSSTTAY 
                   
                   
               
               
                   
                   
                 MQLSSLTSEDSAVYYC 
                   
                   
               
               
                   
                   
                 AREVRLRYFDVWGAG 
                   
                   
               
               
                   
                   
                 TTVTVSS 
                   
                   
               
               
                   
               
               
                 My9-6 VL 
                 300 
                 NIMLTQSPSSLAVSAG 
                   
                   
               
               
                   
                   
                 EKVTMSCKSSQSVFFSS 
                   
                   
               
               
                   
                   
                 SQKNYLAWYQQIPGQ 
                   
                   
               
               
                   
                   
                 SPKLLIYWASTRESGVP 
                   
                   
               
               
                   
                   
                 DRFTGSGSGTDFTLTIS 
                   
                   
               
               
                   
                   
                 SVQSEDLAIYYCHQYLS 
                   
                   
               
               
                   
                   
                 SRTFGGGTKLEIKR 
                   
                   
               
               
                   
               
               
                 hM195 
                 303 
                 DIQMTQSPSSLSA 
                 304 
                 GACATTCAGATGACCCAGTCTCCGAGCTCTCTGTC 
               
               
                 scFv 
                   
                 SVGDRVTITCRAS 
                   
                 CGCATCAGTAGGAGACAGGGTCACCATCACATGC 
               
               
                   
                   
                 ESVDNYGISFMN 
                   
                 AGAGCCAGCGAAAGTGTCGACAATTATGGCATTA 
               
               
                   
                   
                 WFQQKPGKAPKL 
                   
                 GCTTTATGAACTGGTTCCAACAGAAACCCGGGAA 
               
               
                   
                   
                 LIYAASNQGSGVP 
                   
                 GGCTCCTAAGCTTCTGATTTACGCTGCATCCAACC 
               
               
                   
                   
                 SRFSGSGSGTDFT 
                   
                 AAGGCTCCGGGGTACCCTCTCGCTTCTCAGGCAG 
               
               
                   
                   
                 LTISSLQPDDFATY 
                   
                 TGGATCTGGGACAGACTTCACTCTCACCATTTCAT 
               
               
                   
                   
                 YCQQSKEVPWTF 
                   
                 CTCTGCAGCCTGATGACTTCGCAACCTATTACTGT 
               
               
                   
                   
                 GQGTKVEIKGGGG 
                   
                 CAGCAAAGTAAGGAGGTTCCGTGGACGTTCGGTC 
               
               
                   
                   
                 SGGGGSGGGGSQ 
                   
                 AAGGGACCAAGGTGGAGATCAAAGGTGGCGGTG 
               
               
                   
                   
                 VQLVQSGAEVKKP 
                   
                 GCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGAT 
               
               
                   
                   
                 GSSVKVSCKASGY 
                   
                 CTCAGGTTCAGCTGGTGCAGTCTGGAGCTGAGGT 
               
               
                   
                   
                 TFTDYNMHWVRQ 
                   
                 GAAGAAGCCTGGGAGCTCAGTGAAGGTTTCCTGC 
               
               
                   
                   
                 APGQGLEWIGYIY 
                   
                 AAAGCTTCTGGCTACACCTTCACTGACTACAACAT 
               
               
                   
                   
                 PYNGGTGYNQKF 
                   
                 GCACTGGGTGAGGCAGGCTCCTGGCCAAGGCCT 
               
               
                   
                   
                 KSKATITADESTNT 
                   
                 GGAATGGATTGGATATATTTATCCTTACAATGGT 
               
               
                   
                   
                 AYMELSSLRSEDT 
                   
                 GGTACCGGCTACAACCAGAAGTTCAAGAGCAAG 
               
               
                   
                   
                 AVYYCARGRPAM 
                   
                 GCCACAATTACAGCAGACGAGAGTACTAACACAG 
               
               
                   
                   
                 DYWGQGTLVTVSS 
                   
                 CCTACATGGAACTCTCCAGCCTGAGGTCTGAGGA 
               
               
                   
                   
                   
                   
                 CACTGCAGTCTATTACTGCGCAAGAGGGCGCCCC 
               
               
                   
                   
                   
                   
                 GCTATGGACTACTGGGGCCAAGGGACTCTGGTCA 
               
               
                   
                   
                   
                   
                 CTGTCTCTTCA 
               
               
                   
               
            
           
         
       
     
     Exemplary anti-MUC1 VH and VL Sequences 
     
       
         
           
               
               
               
             
               
                   
               
               
                   
                 SEQ ID 
                   
               
               
                 Name 
                 NO 
                 Amino Acid Sequence 
               
               
                   
               
             
            
               
                 Anti-MUC1 
                 305 
                 QVQLVQSGAEVKKPGSSVKVSCKASGYAFSNFWMNWVRQAPGQGLEWMGQI 
               
               
                 VH1 
                   
                 YPGDGDTNYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSYYRSAWFA 
               
               
                   
                   
                 YWGQGTLVTVSS 
               
               
                   
               
               
                 Anti-MUC1 
                 306 
                 QVQLVQSGAEVKKPGASVKVSCKASGYAFSNFWMNWVRQAPGQGLEWMGQI 
               
               
                 VH2 
                   
                 YPGDGDTNYNGKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSYYRSAWF 
               
               
                   
                   
                 AYWGQGTLVTVSS 
               
               
                   
               
               
                 Anti-MUC1 
                 307 
                 QVQLVQSGAEVKKPGASVKVSCKASGYAFSNFWMNWVRQAPGQGLEWMGQI 
               
               
                 VH3 
                   
                 YPGDGDTNYNGKFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSYYRSAWF 
               
               
                   
                   
                 AYWGQGTLVTVSS 
               
               
                   
               
               
                 Anti-MUC1 
                 308 
                 QVQLVQSGAEVKKPGATVKISCKVSGYAFSNFWMNWVQQAPGKGLEWMGQIY 
               
               
                 VH4 
                   
                 PGDGDTNYNGKFKGRVTITADTSTDTAYMELSSLRSEDTAVYYCARSYYRSAWFAY 
               
               
                   
                   
                 WGQGTLVTVSR 
               
               
                   
               
               
                 Anti-MUC1 
                 309 
                 EVQLVQSGAEVKKPGESLKISCKGSGYAFSNFWMNWVRQMPGKGLEWMGQIY 
               
               
                 VH5 
                   
                 PGDGDTNYNGKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSYYRSAWFA 
               
               
                   
                   
                 YWGQGTLVTVSL 
               
               
                   
               
               
                 Anti-MUC1 
                 310 
                 EIVLTQSPDFQSVTPKEKVTITCRASQSIGTSIHWYQQKPDQSPKLLIKYASESISGVP 
               
               
                 VL1 
                   
                 SRFSGSGSGTDFTLTINSLEAEDAATYYCQQSNNWPLTFGQGTKVEIK 
               
               
                   
               
               
                 Anti-MUC1 
                 311 
                 EIVMTQSPATLSVSPGERATLSCRASQSIGTSIHWYQQKPGQAPRLLIYYASESISGI 
               
               
                 VL2 
                   
                 PARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSNNWPLTFGGGTKVEIK 
               
               
                   
               
               
                 Anti-MUC1 
                 312 
                 EIVLTQSPATLSLSPGERATLSCRASQSIGTSIHWYQQKPGQAPRLLIYYASESISGIP 
               
               
                 VL3 
                   
                 ARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSNNWPLTFGGGTKVEIK 
               
               
                   
               
               
                 Anti-MUC1 
                 313 
                 AIQLTQSPSSLSASVGDRVTITCRASQSIGTSIHWYQQKPGKAPKLLIYYASESISGVP 
               
               
                 VL4 
                   
                 SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNNWPLTFGGGTKVEIK 
               
               
                   
               
               
                 Anti-MUC1 
                 314 
                 DIVMTQSPSLLSASTGDRVTISCRASQSIGTSIHWYQQKPGKAPELLIYYASESISGV 
               
               
                 VL5 
                   
                 PSRFSGSGSGTDFTLTISCLQSEDFATYYCQQSNNWPLTFGQGTKVEIK 
               
               
                   
               
            
           
         
       
     
     Exemplary anti-MUC16 Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                   
                 SEQ 
                 Amino Acid 
                 SEQ 
                   
               
               
                 Name 
                 ID NO 
                 Sequence 
                 ID NO 
                 Nucleotide Sequence 
               
               
                   
               
             
            
               
                 Anti- 
                 315 
                 QVQLQESGPGLVKPS 
                 316 
                 CAGGTGCAACTGCAGGAATCAGGTCCAGGCTTG 
               
               
                 MUC16 
                   
                 QTLSLTCTVSGYSIVSH 
                   
                 GTCAAGCCATCGCAGACTCTTAGTCTGACATGCA 
               
               
                 VH1 
                   
                 YYWSWIRQHPGKGLE 
                   
                 CCGTGAGTGGCTATAGCATCGTGTCGCACTATTA 
               
               
                   
                   
                 WIGYISSDGSNYYNPSL 
                   
                 TTGGTCTTGGATCAGGCAGCATCCAGGAAAGGG 
               
               
                   
                   
                 KSLVTISVDTSKNQFSL 
                   
                 ACTGGAGTGGATCGGGTACATTAGCAGCGATGG 
               
               
                   
                   
                 KLSSVTAADTAVYYCV 
                   
                 GAGCAACTATTACAACCCATCTCTGAAGTCCCTGG 
               
               
                   
                   
                 RGVDYWGQGTMVTV 
                   
                 TAACTATTAGCGTGGATACAAGCAAAAATCAGTT 
               
               
                   
                   
                 SS 
                   
                 TTCATTAAAGCTCTCTTCAGTGACCGCAGCTGATA 
               
               
                   
                   
                   
                   
                 CCGCCGTCTATTATTGCGTGCGGGGGGTGGACTA 
               
               
                   
                   
                   
                   
                 CTGGGGTCAGGGCACCATGGTTACTGTGTCATCA 
               
               
                   
               
               
                 Anti- 
                 317 
                 QVQLQESGPGLVKPSD 
                 318 
                 CAGGTACAGCTGCAGGAGAGTGGCCCTGGTTTA 
               
               
                 MUC16 
                   
                 TLSLTCAVSGYSIVSHY 
                   
                 GTAAAGCCATCAGATACACTTTCACTTACCTGCGC 
               
               
                 VH2 
                   
                 YWGWIRQPPGKGLE 
                   
                 CGTGTCTGGTTATTCTATCGTGAGCCACTATTACT 
               
               
                   
                   
                 WIGYISSDGSNYYNPSL 
                   
                 GGGGATGGATCCGCCAGCCCCCTGGCAAAGGTCT 
               
               
                   
                   
                 KSRVTMSVDTSKNQFS 
                   
                 TGAGTGGATTGGCTATATAAGTTCGGATGGCAGT 
               
               
                   
                   
                 LKLSSVTAVDTAVYYCV 
                   
                 AACTATTACAATCCTTCTCTGAAGAGCCGTGTCAC 
               
               
                   
                   
                 RGVDYWGQGTMVTV 
                   
                 TATGAGCGTGGACACTAGCAAAAACCAGTTCAGC 
               
               
                   
                   
                 SS 
                   
                 CTGAAGCTGTCCTCCGTCACCGCCGTAGACACCG 
               
               
                   
                   
                   
                   
                 CTGTCTACTATTGTGTTAGGGGGGTGGACTACTG 
               
               
                   
                   
                   
                   
                 GGGCCAAGGCACCATGGTCACGGTGAGCAGC 
               
               
                   
               
               
                 Anti- 
                 319 
                 EVQLVESGGGLVQPG 
                 320 
                   
               
               
                 MUC16 
                   
                 GSLRLSCAASGYSIVSH 
                   
                   
               
               
                 VH3 
                   
                 YYMSWVRQAPGKGLE 
                   
                   
               
               
                   
                   
                 WVSVISSDGSNYYADS 
                   
                   
               
               
                   
                   
                 VKGRFTISRDNSKNTLY 
                   
                   
               
               
                   
                   
                 LQMNSLRAEDTAVYYC 
                   
                   
               
               
                   
                   
                 VRGVDYWGQGTLVTV 
                   
                   
               
               
                   
                   
                 SS 
                   
                   
               
               
                   
               
               
                 Anti- 
                 321 
                 EVQLVESGGGLVQPG 
                 322 
                 GAGGTGCAGCTCGTCGAGTCCGGAGGCGGTCTG 
               
               
                 MUC16 
                   
                 RSLRLSCAASGYSIVSH 
                   
                 GTGCAACCCGGCCGTTCTTTGCGGCTGAGTTGCG 
               
               
                 VH4 
                   
                 YYMHWVRQAPGKGL 
                   
                 CTGCCAGTGGGTATAGCATCGTGAGTCACTATTA 
               
               
                   
                   
                 EWVSAISSDGSNEYAD 
                   
                 CATGCATTGGGTTCGTCAAGCCCCTGGCAAGGGA 
               
               
                   
                   
                 SVEGRFTISRDNAKNSL 
                   
                 CTAGAGTGGGTGTCCGCCATCTCCTCAGACGGTA 
               
               
                   
                   
                 YLQMNSLRAEDTAVYY 
                   
                 GTAATGAGTACGCGGACAGCGTAGAGGGTAGAT 
               
               
                   
                   
                 CVRGVDYWGQGTLVT 
                   
                 TCACCATTTCTCGGGACAATGCCAAAAATAGTCTA 
               
               
                   
                   
                 VSS 
                   
                 TACCTCCAAATGAATTCCCTTAGGGCCGAAGACA 
               
               
                   
                   
                   
                   
                 CTGCCGTGTACTACTGTGTTCGGGGCGTGGACTA 
               
               
                   
                   
                   
                   
                 CTGGGGGCAGGGGACATTGGTGACTGTGAGCTC 
               
               
                   
                   
                   
                   
                 A 
               
               
                   
               
               
                 Anti- 
                 323 
                 QVQLQESGPGLVKPS 
                 324 
                 CAGGTCCAACTGCAGGAATCTGGCCCCGGACTGG 
               
               
                 MUC16 
                   
                 QTLSLTCTVSGYSIVSH 
                   
                 TTAAACCATCTCAGACACTCTCCCTGACCTGCACC 
               
               
                 VH5 
                   
                 YYWSWIRQHPGKGLE 
                   
                 GTGTCTGGATACAGCATCGTTTCTCATTATTACTG 
               
               
                   
                   
                 WIGYISSDGSNEYNPSL 
                   
                 GTCATGGATTAGGCAGCATCCCGGAAAAGGGCTT 
               
               
                   
                   
                 KSLVTISVDTSKNQFSL 
                   
                 GAATGGATTGGCTACATCTCCTCCGACGGCTCCA 
               
               
                   
                   
                 KLSSVTAADTAVYFCV 
                   
                 ATGAGTACAACCCATCACTTAAATCTCTGGTCACG 
               
               
                   
                   
                 RGVDYWGQGTMVTV 
                   
                 ATAAGCGTAGACACATCTAAAAATCAGTTCTCATT 
               
               
                   
                   
                 SS 
                   
                 AAAGCTCAGCTCTGTTACAGCTGCCGACACCGCT 
               
               
                   
                   
                   
                   
                 GTGTACTTCTGTGTGCGAGGGGTTGACTACTGGG 
               
               
                   
                   
                   
                   
                 GGCAGGGCACAATGGTGACAGTGTCTTCC 
               
               
                   
               
               
                 Anti- 
                 325 
                 QVQLVQSGAEVKKPG 
                 326 
                 CAGGTTCAACTGGTTCAGTCCGGAGCCGAGGTCA 
               
               
                 MUC16 
                   
                 SSVKVSCKASGYSIVSH 
                   
                 AAAAGCCTGGATCCTCTGTGAAGGTGTCATGTAA 
               
               
                 VH6 
                   
                 YYISWVRQAPGQGLE 
                   
                 GGCTTCTGGCTACAGCATCGTCTCACATTATTACA 
               
               
                   
                   
                 WMGGISSDGSNNYA 
                   
                 TATCTTGGGTGCGACAGGCCCCCGGCCAGGGGCT 
               
               
                   
                   
                 QKFQGRVTITADESTS 
                   
                 CGAGTGGATGGGAGGTATTTCCTCCGACGGGAG 
               
               
                   
                   
                 TAYMELSSLRS 
                   
                 TAACAATTACGCTCAGAAATTTCAGGGCCGGGTG 
               
               
                   
                   
                 EDTAVYYCVRGVDYW 
                   
                 ACCATTACCGCCGACGAAAGTACAAGCACCGCTT 
               
               
                   
                   
                 GQGTLVTVSS 
                   
                 ATATGGAATTAAGCTCTTTAAGATCAGAGGACAC 
               
               
                   
                   
                   
                   
                 GGCTGTGTACTACTGTGTAAGGGGCGTGGATTAC 
               
               
                   
                   
                   
                   
                 TGGGGTCAGGGGACGCTCGTCACCGTCTCGAGC 
               
               
                   
               
               
                 Anti- 
                 327 
                 QVQLQESGPGLVKPSE 
                 328 
                 CAGGTCCAGCTCCAGGAATCCGGCCCAGGGTTGG 
               
               
                 MUC16 
                   
                 TLSLTCTVSGYSIVSHYY 
                   
                 TGAAGCCTTCGGAGACCCTGTCTCTGACATGCAC 
               
               
                 VH7 
                   
                 WSWIRQPPGKGLEWI 
                   
                 AGTCAGCGGCTATAGTATCGTCTCCCACTATTATT 
               
               
                   
                   
                 GYISSDGSNNYNPSLKS 
                   
                 GGTCTTGGATTCGGCAACCTCCAGGCAAGGGGTT 
               
               
                   
                   
                 RVTISVDTSKNQFSLKL 
                   
                 AGAATGGATTGGATACATCTCAAGCGATGGGTCC 
               
               
                   
                   
                 SSVTAADTAVYYCVRG 
                   
                 AATAACTACAACCCAAGTCTCAAAAGTAGAGTGA 
               
               
                   
                   
                 VDYWGQGTTVTVSS 
                   
                 CTATCTCTGTGGATACCAGTAAAAACCAGTTTTCA 
               
               
                   
                   
                   
                   
                 CTCAAGTTGAGTTCCGTCACCGCCGCCGACACAG 
               
               
                   
                   
                   
                   
                 CCGTTTACTACTGTGTTCGGGGAGTGGACTACTG 
               
               
                   
                   
                   
                   
                 GGGCCAAGGTACCACGGTTACCGTGAGCAGC 
               
               
                   
               
               
                 Anti- 
                 648 
                 QVQLQESGPGLVKPSD 
                 649 
                 CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTG 
               
               
                 MUC16 
                   
                 TLSLTCAVSGYSIVSHY 
                   
                 GTGAAGCCCAGCGACACCCTGAGCCTGACCTGCG 
               
               
                 VH8 
                   
                 YWHWIRQPPGKGLE 
                   
                 CCGTGAGCGGCTACAGCATCGTGAGCCACTACTA 
               
               
                   
                   
                 WMGYISSDGSNDFNP 
                   
                 CTGGCACTGGATCAGACAGCCCCCCGGCAAGGG 
               
               
                   
                   
                 SLKTRITISRDTSKNQFS 
                   
                 CCTGGAGTGGATGGGCTACATCAGCAGCGACGG 
               
               
                   
                   
                 LKLSSVTAVDTAVYYCV 
                   
                 CAGCAACGACTTCAACCCCAGCCTGAAGACCAGA 
               
               
                   
                   
                 RGVDYWGQGTLVTVSS 
                   
                 ATCACCATCAGCAGAGACACCAGCAAGAACCAGT 
               
               
                   
                   
                   
                   
                 TCAGCCTGAAGCTGAGCAGCGTGACCGCCGTGG 
               
               
                   
                   
                   
                   
                 ACACCGCCGTGTACTACTGCGTGAGAGGCGTGGA 
               
               
                   
                   
                   
                   
                 CTACTGGGGCCAGGGCACCCTGGTGACCGTGAG 
               
               
                   
                   
                   
                   
                 CAGC 
               
               
                   
               
               
                 Anti- 
                 650 
                 QVQLQESGPGLVKPS 
                 651 
                 CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTG 
               
               
                 MUC16 
                   
                 QTLSLTCAVYGYSIVSH 
                   
                 GTGAAGCCCAGCCAGACCCTGAGCCTGACCTGCG 
               
               
                 VH9 
                   
                 YYWSWIRQPPGKGLE 
                   
                 CCGTGTACGGCTACAGCATCGTGAGCCACTACTA 
               
               
                   
                   
                 WIGEISSDGSNNYNPS 
                   
                 CTGGAGCTGGATCAGACAGCCCCCCGGCAAGGG 
               
               
                   
                   
                 LKSRVTISVDTSKNQFS 
                   
                 CCTGGAGTGGATCGGCGAGATCAGCAGCGACGG 
               
               
                   
                   
                 LKLSSVTAADTAVYYCV 
                   
                 CAGCAACAACTACAACCCCAGCCTGAAGAGCAGA 
               
               
                   
                   
                 RGVDYWGQGTLVTVSS 
                   
                 GTGACCATCAGCGTGGACACCAGCAAGAACCAGT 
               
               
                   
                   
                   
                   
                 TCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGA 
               
               
                   
                   
                   
                   
                 CACCGCCGTGTACTACTGCGTGAGAGGCGTGGAC 
               
               
                   
                   
                   
                   
                 TACTGGGGCCAGGGCACCCTGGTGACCGTGAGC 
               
               
                   
                   
                   
                   
                 AGC 
               
               
                   
               
               
                 Anti- 
                 652 
                 QVQLQESGPGLVKPSE 
                 653 
                 CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTG 
               
               
                 MUC16 
                   
                 TLSLTCAVSGYSIVSHY 
                   
                 GTGAAGCCCAGCGAGACCCTGAGCCTGACCTGCG 
               
               
                 VH10 
                   
                 YWGWIRQPPGKGLE 
                   
                 CCGTGAGCGGCTACAGCATCGTGAGCCACTACTA 
               
               
                   
                   
                 WIGSISSDGSNYYNPSL 
                   
                 CTGGGGCTGGATCAGACAGCCCCCCGGCAAGGG 
               
               
                   
                   
                 KSRVTISVDTSKNQFSL 
                   
                 CCTGGAGTGGATCGGCAGCATCAGCAGCGACGG 
               
               
                   
                   
                 KLSSVTAADTAVYYCV 
                   
                 CAGCAACTACTACAACCCCAGCCTGAAGAGCAGA 
               
               
                   
                   
                 RGVDYWGQGTLVTVSS 
                   
                 GTGACCATCAGCGTGGACACCAGCAAGAACCAGT 
               
               
                   
                   
                   
                   
                 TCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGA 
               
               
                   
                   
                   
                   
                 CACCGCCGTGTACTACTGCGTGAGAGGCGTGGAC 
               
               
                   
                   
                   
                   
                 TACTGGGGCCAGGGCACCCTGGTGACCGTGAGC 
               
               
                   
                   
                   
                   
                 AGC 
               
               
                   
               
               
                 Anti- 
                 654 
                 QVQLVESGGGVVQPG 
                 655 
                 CAGGTGCAGCTGGTGGAGAGCGGCGGCGGCGT 
               
               
                 MUC16 
                   
                 RSLRLSCAASGYSIVSH 
                   
                 GGTGCAGCCCGGCAGAAGCCTGAGACTGAGCTG 
               
               
                 VH11 
                   
                 YYWNWVRQAPGKGL 
                   
                 CGCCGCCAGCGGCTACAGCATCGTGAGCCACTAC 
               
               
                   
                   
                 EWVAYISSDGSNEYNP 
                   
                 TACTGGAACTGGGTGAGACAGGCCCCCGGCAAG 
               
               
                   
                   
                 SLKNRFTISRDNSKNTL 
                   
                 GGCCTGGAGTGGGTGGCCTACATCAGCAGCGAC 
               
               
                   
                   
                 YLQMNSLRAEDTAVYY 
                   
                 GGCAGCAACGAGTACAACCCCAGCCTGAAGAAC 
               
               
                   
                   
                 CVRGVDYWGQGTTVT 
                   
                 AGATTCACCATCAGCAGAGACAACAGCAAGAACA 
               
               
                   
                   
                 VSS 
                   
                 CCCTGTACCTGCAGATGAACAGCCTGAGAGCCGA 
               
               
                   
                   
                   
                   
                 GGACACCGCCGTGTACTACTGCGTGAGAGGCGT 
               
               
                   
                   
                   
                   
                 GGACTACTGGGGCCAGGGCACCACCGTGACCGT 
               
               
                   
                   
                   
                   
                 GAGCAGC 
               
               
                   
               
               
                 Anti- 
                 656 
                 QVQLQESGPGLVKPS 
                 657 
                 CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTG 
               
               
                 MUC16 
                   
                 QTLSLTCTVSGYSIVSH 
                   
                 GTGAAGCCCAGCCAGACCCTGAGCCTGACCTGCA 
               
               
                 VH12 
                   
                 YYWNWIRQHPGKGLE 
                   
                 CCGTGAGCGGCTACAGCATCGTGAGCCACTACTA 
               
               
                   
                   
                 WIGYISSDGSNEYNPSL 
                   
                 CTGGAACTGGATCAGACAGCACCCCGGCAAGGG 
               
               
                   
                   
                 KNLVTISVDTSKNQFSL 
                   
                 CCTGGAGTGGATCGGCTACATCAGCAGCGACGG 
               
               
                   
                   
                 KLSSVTAADTAVYYCV 
                   
                 CAGCAACGAGTACAACCCCAGCCTGAAGAACCTG 
               
               
                   
                   
                 RGVDYWGQGTMVTV 
                   
                 GTGACCATCAGCGTGGACACCAGCAAGAACCAGT 
               
               
                   
                   
                 SS 
                   
                 TCAGCCTGAAGCTGAGCAGCGTGACCGCCGCCGA 
               
               
                   
                   
                   
                   
                 CACCGCCGTGTACTACTGCGTGAGAGGCGTGGAC 
               
               
                   
                   
                   
                   
                 TACTGGGGCCAGGGCACCATGGTGACCGTGAGC 
               
               
                   
                   
                   
                   
                 AGC 
               
               
                   
               
               
                 Anti- 
                 658 
                 QVQLQESGPGLVKPSD 
                 659 
                 CAGGTGCAGCTGCAGGAGAGCGGCCCCGGCCTG 
               
               
                 MUC16 
                   
                 TLSLTCAVSGYSIVSHY 
                   
                 GTGAAGCCCAGCGACACCCTGAGCCTGACCTGCG 
               
               
                 VH13 
                   
                 YWNWIRQPPGKGLE 
                   
                 CCGTGAGCGGCTACAGCATCGTGAGCCACTACTA 
               
               
                   
                   
                 WIGYISSDGSNEYNPSL 
                   
                 CTGGAACTGGATCAGACAGCCCCCCGGCAAGGG 
               
               
                   
                   
                 KNRVTMSVDTSKNQF 
                   
                 CCTGGAGTGGATCGGCTACATCAGCAGCGACGG 
               
               
                   
                   
                 SLKLSSVTAVDTAVYYC 
                   
                 CAGCAACGAGTACAACCCCAGCCTGAAGAACAG 
               
               
                   
                   
                 VRGVDYWGQGTMVT 
                   
                 AGTGACCATGAGCGTGGACACCAGCAAGAACCA 
               
               
                   
                   
                 VSS 
                   
                 GTTCAGCCTGAAGCTGAGCAGCGTGACCGCCGTG 
               
               
                   
                   
                   
                   
                 GACACCGCCGTGTACTACTGCGTGAGAGGCGTG 
               
               
                   
                   
                   
                   
                 GACTACTGGGGCCAGGGCACCATGGTGACCGTG 
               
               
                   
                   
                   
                   
                 AGCAGC 
               
               
                   
               
               
                 Anti- 
                 660 
                 EVQLLESGGGLVQPGG  
                 661 
                 GAGGTGCAGCTGCTGGAGAGCGGCGGCGGCCTG 
               
               
                 MUC16 
                   
                 SLRLSCAASGYSIVSHY 
                   
                 GTGCAGCCCGGCGGCAGCCTGAGACTGAGCTGC 
               
               
                 VH14 
                   
                 YWNWVRQAPGKGLE 
                   
                 GCCGCCAGCGGCTACAGCATCGTGAGCCACTACT 
               
               
                   
                   
                 WVSYISSDGSNEYNPS 
                   
                 ACTGGAACTGGGTGAGACAGGCCCCCGGCAAGG 
               
               
                   
                   
                 LKNRFTISRDNSKNTLY 
                   
                 GCCTGGAGTGGGTGAGCTACATCAGCAGCGACG 
               
               
                   
                   
                 LQMNSLRAEDTAVYYC 
                   
                 GCAGCAACGAGTACAACCCCAGCCTGAAGAACA 
               
               
                   
                   
                 VRGVDYWGQGTLVTV 
                   
                 GATTCACCATCAGCAGAGACAACAGCAAGAACAC 
               
               
                   
                   
                 SS 
                   
                 CCTGTACCTGCAGATGAACAGCCTGAGAGCCGAG 
               
               
                   
                   
                   
                   
                 GACACCGCCGTGTACTACTGCGTGAGAGGCGTG 
               
               
                   
                   
                   
                   
                 GACTACTGGGGCCAGGGCACCCTGGTGACCGTG 
               
               
                   
                   
                   
                   
                 AGCAGC 
               
               
                   
               
               
                 Anti- 
                 672 
                 VKLQESGGGFVKPGG 
                 673 
                 GTGAAGCTGCAAGAGTCCGGCGGAGGCTTTG 
               
               
                 MUC16 
                   
                 SLKVSCAASGFTFSSY 
                   
                 TGAAGCCTGGCGGCTCTCTGAAAGTGTCCTGT 
               
               
                 VH 
                   
                 AMSWVRLSPEMRLE 
                   
                 GCCGCCAGCGGCTTCACCTTTAGCAGCTACGCC 
               
               
                   
                   
                 WVATISSAGGYIFYSD 
                   
                 ATGAGCTGGGTCCGACTGAGCCCTGAGATGAG 
               
               
                   
                   
                 SVQGRFTISRDNAKN 
                   
                 ACTGGAATGGGTCGCCACCATCAGTAGCGCAGG 
               
               
                   
                   
                 TLHLQMGSLRSGDTA 
                   
                 CGGCTACATCTTCTACAGCGACTCTGTGCAGGGC 
               
               
                   
                   
                 MYYCARQGFGNYGDY 
                   
                 AGATTCACCATCAGCCGGGACAACGCCAAGAAC 
               
               
                   
                   
                 YAMDYWGQGTTVTV 
                   
                 ACCCTGCACCTCCAGATGGGCAGTCTGAGAAGC 
               
               
                   
                   
                 SS 
                   
                 GGCGATACCGCCATGTACTACTGCGCCAGACAA 
               
               
                   
                   
                   
                   
                 GGCTTCGGCAACTACGGCGACTACTATGCCATG 
               
               
                   
                   
                   
                   
                 GATTACTGGGGCCAGGGCACCACCGTGACAGT 
               
               
                   
                   
                   
                   
                 CTCTTCT 
               
               
                   
               
               
                 Anti- 
                 674 
                 VKLEESGGGFVKPGG 
                 675 
                 GTGAAGCTGGAAGAGTCCGGCGGAGGCTTTG 
               
               
                 MUC16 
                   
                 SLKISCAASGFTFRNY 
                   
                 TGAAGCCTGGCGGAAGCCTGAAGATCAGCTGTG 
               
               
                 VH 
                   
                 AMSWVRLSPEMRL 
                   
                 CCGCCAGCGGCTTCACCTTCAGAAACTACGCC 
               
               
                   
                   
                 EWVATISSAGGYIFY 
                   
                 ATGAGCTGGGTCCGACTGAGCCCCGAGATGAGA 
               
               
                   
                   
                 SDSVQGRFTISRDNA 
                   
                 CTGGAATGGGTCGCCACAATCAGCAGCGCAGGC 
               
               
                   
                   
                 KNTHLQMGSLRSGD 
                   
                 GGCTACATCTTCTACAGCGATAGCGTGCAGGGC 
               
               
                   
                   
                 TAMYYCARQGFGNY 
                   
                 AGATTCACCATCAGCCGGGACAACGCCAAGAA 
               
               
                   
                   
                 GDYYAMDYWGQGT 
                   
                 CACCCTGCACCTCCAGATGGGC 
               
               
                   
                   
                 TVTVSS 
                   
                 AGTCTGAGATCTGGCGACACCGCCATGTACTACT 
               
               
                   
                   
                   
                   
                 GGCCAGACAAGGCTTCGGCAACTACGGCGACTA 
               
               
                   
                   
                   
                   
                 CTATGCCATGGATTACTGGGGCCAGGGCACCAC 
               
               
                   
                   
                   
                   
                 CGTGACAGTCTCTTCT 
               
               
                   
               
               
                 Anti- 
                 676 
                 DVQLLESGPGLVRPS 
                 677 
                 GACGTGCAACTTCTGGAGAGCGGGCCAGGGCT 
               
               
                 MUC16 
                   
                 QSLSLTCSVTGYSIVSH 
                   
                 AGTCAGGCCCTCCCAGTCGCTTTCACTGACTTG 
               
               
                 VH 
                   
                 YYWNWIRQFPGNKLE 
                   
                 CAGTGTGACCGGTTACTCTATTGTGAGTCACTA 
               
               
                   
                   
                 WMGYISSDGSNEYNP 
                   
                 CTATTGGAACTGGATTCGGCAGTTCCCAGGCA 
               
               
                   
                   
                 SLKNRISISLDTSKNQF 
                   
                 ACAAACTGGAATGGATGGGGTACATATCTTCC 
               
               
                   
                   
                 FLKFDFVTTADTATYF 
                   
                 GATGGCTCGAATGAATATAACCCATCATTGAAA 
               
               
                   
                   
                 CVRGVDYWGQGTTLT 
                   
                 AATCGTATTTCCATCAGTCTGGATACGAGTAA 
               
               
                   
                   
                 VSS 
                   
                 AAACCAGTTTTTCCTCAAATTCGATTTCGTGAC 
               
               
                   
                   
                   
                   
                 TACAGCAGATACTGCCACATACTTCTGTGTAC 
               
               
                   
                   
                   
                   
                 GAGGTGTCGATTATTGGGGACAGGGCACAACG 
               
               
                   
                   
                   
                   
                 CTGACCGTAAGTTCT 
               
               
                   
               
               
                 Anti- 
                 678 
                 DVQLQESGPGLVNPS 
                 679 
                 GACGTTCAGCTGCAAGAGTCTGGCCCTGGCCT 
               
               
                 MUC16 
                   
                 QSLSLTCTVTGYSITN 
                   
                 GGTCAATCCTAGCCAGAGCCTGAGCCTGACAT 
               
               
                 VH 
                   
                 DYAWNWIRQFPGNK 
                   
                 GTACCGTGACCGGCTACAGCATCACCAACGAC 
               
               
                   
                   
                 LEWMGYINYSGYTT 
                   
                 TACGCCTGGAACTGGATCAGACAGTTCCCCGG 
               
               
                   
                   
                 YNPSLKSRISITRDTS 
                   
                 CAACAAGCTGGAATGGATGGGCTACATCAAC 
               
               
                   
                   
                 KNQFFLHLNSVTTED 
                   
                 TACAGCGGCTACACCACCTACAATCCCAGCCTG 
               
               
                   
                   
                 TATYYCARWDGGLTY 
                   
                 AAGTCCCGGATCTCCATCACCAGAGACACCAG 
               
               
                   
                   
                 WGQGTLVTVSA 
                   
                 CAAGAACCAGTTCTTCCTGCACCTGAACAGC 
               
               
                   
                   
                   
                   
                 GTGACCACCGAGGATACCGCCACCTACTACTG 
               
               
                   
                   
                   
                   
                 CGCTAGATGGGATGGCGGCCTGACATATTGGG 
               
               
                   
                   
                   
                   
                 GCCAGGGAACACTGGTCACCGTGTCTGCT 
               
               
                   
               
               
                 Anti- 
                 680 
                 EVQLVESGGGLVQPG 
                 681 
                 GAGGTGCAGCTGGTGGAGAGCGGCGGCGGC 
               
               
                 MUC16 
                   
                 GSLRLSCAASGYSITND 
                   
                 CTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAG 
               
               
                 VH 
                   
                 YAWNWVRQAPGKG 
                   
                 CTGCGCCGCCAGCGGCTACAGCATCACCAACGA 
               
               
                   
                   
                 LEWVGYINYSGYTTYN 
                   
                 CTACGCCTGGAACTGGGTGAGGCAGGCCCCCG 
               
               
                   
                   
                 PSLKSRFTISRDNSKNT 
                   
                 GCAAGGGCCTGGAGTGGGTGGGCTACATCAA 
               
               
                   
                   
                 LYLQMNSLRAEDTAV 
                   
                 CTACAGCGGCTACACCACCTACAACCCCAGCCTG 
               
               
                   
                   
                 YYCARWDGGLTYWG 
                   
                 AAGAGCAGGTTCACCATCAGCAGGGACAACAGC 
               
               
                   
                   
                 QGTLVTVSS 
                   
                 AAGAACACCCTGTACCTGCAGATGAACAGCCTG 
               
               
                   
                   
                   
                   
                 AGGGCCGAGGACACCGCCGTGTACTACTGCGC 
               
               
                   
                   
                   
                   
                 CAGGTGGGACGGCGGCCTGACCTACTGGGGCC 
               
               
                   
                   
                   
                   
                 AGGGCACCCTGGTGACCGTGAGCAGC 
               
               
                   
               
               
                 Anti- 
                 682 
                 EVQLVESGGGLVQPG 
                 683 
                 GAGGTGCAGCTGGTGGAGAGCGGCGGCGGC 
               
               
                 MUC16 
                   
                 GSLRLSCAASGYSITND 
                   
                 CTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAG 
               
               
                 VH 
                   
                 YAWNWVRQAPGKG 
                   
                 CTGCGCCGCCAGCGGCTACAGCATCACCAACGA 
               
               
                   
                   
                 LEWVGYINYSGYTTYN 
                   
                 CTACGCCTGGAACTGGGTGAGGCAGGCCCCCG 
               
               
                   
                   
                 PSLKSRFTISRDNSKNT 
                   
                 GCAAGGGCCTGGAGTGGGTGGGCTACATCAA 
               
               
                   
                   
                 FYLQMNSLRAEDTAV 
                   
                 CTACAGCGGCTACACCACCTACAACCCCAGCCTG 
               
               
                   
                   
                 YYCARWDGGLTYWG 
                   
                 AAGAGCAGGTTCACCATCAGCAGGGACAACAGC 
               
               
                   
                   
                 QGTLVTVSS 
                   
                 AAGAACACCTTCTACCTGCAGATGAACAGCCTG 
               
               
                   
                   
                   
                   
                 AGGGCCGAGGACACCGCCGTGTACTACTGCGC 
               
               
                   
                   
                   
                   
                 CAGGTGGGACGGCGGCCTGACCTACTGGGGCC 
               
               
                   
                   
                   
                   
                 AGGGCACCCTGGTGACCGTGAGCAGC 
               
               
                   
               
               
                 Anti- 
                 684 
                 EVQLQQSGAELVKPG 
                 685 
                 GAGGTTCAGCTGCAGCAGTCTGGCGCCGAACTT 
               
               
                 MUC16 
                   
                 ASVKLSCTASGFNIKD 
                   
                 GTGAAACCTGGCGCCTCTGTGAAGCTGAGCTGT 
               
               
                 VH 
                   
                 TYMHWVKQRPEQGL 
                   
                 ACCGCCAGCGGCTTCAACATCAAGGACACCTAC 
               
               
                   
                   
                 EWIGRVDPANGNTK 
                   
                 ATGCACTGGGTCAAGCAGAGGCCTGAGCAGGG 
               
               
                   
                   
                 YDPKFQGKATLTADT 
                   
                 CCTCGAATGGATCGGAAGAGTGGATCCCGCCA 
               
               
                   
                   
                 SSNTAYLQLSSLTSEDT 
                   
                 ACGGCAACACCAAATACGACCCCAAGTTCCAGG 
               
               
                   
                   
                 AVYFCVRDYYGHTYG 
                   
                 GCAAAGCCACACTGACCGCCGACACCTCTAGCA 
               
               
                   
                   
                 FAFCDQGTTLTVSA 
                   
                 ACACAGCCTACCTGCAGCTGTCCAGCCTGACCTC 
               
               
                   
                   
                   
                   
                 TGAAGATACCGCCGTGTACTTCTGCGTGCGGGA 
               
               
                   
                   
                   
                   
                 CTACTACGGCCATACCTACGGCTTCGCCTTCTGC 
               
               
                   
                   
                   
                   
                 GACCAAGGCACAACCCTGACAGTGTCTGCT 
               
               
                   
               
               
                 Anti- 
                 686 
                 EVQLVESGGGLVQPG 
                 687 
                 GAGGTGCAGCTGGTTGAATCTGGCGGAGGACT 
               
               
                 MUC16 
                   
                 GSLRLSCAASGFNIKD 
                   
                 GGTTCAGCCTGGCGGATCTCTGAGACTGTCTTG 
               
               
                 VH 
                   
                 TYMHWVRQAPGKGL 
                   
                 TGCCGCCAGCGGCTTCAACATCAAGGACACCTA 
               
               
                   
                   
                 EWVGRVDPANGNTK 
                   
                 CATGCACTGGGTCCGACAGGCCCCTGGCAAAGG 
               
               
                   
                   
                 YDPKFQGRFTISADTS 
                   
                 ACTTGAGTGGGTTGGAAGAGTGGACCCCGCCAA 
               
               
                   
                   
                 KNTAYLQMNSLRAED 
                   
                 CGGCAACACCAAATACGACCCCAAGTTCCAGGG 
               
               
                   
                   
                 TAVYYCVRDYYGHTY 
                   
                 CAGATTCACCATCAGCGCCGACACCAGCAAGAA 
               
               
                   
                   
                 GFAFWGQGTLVTVSS 
                   
                 CACCGCCTACCTGCAGATGAACAGCCTGAGAG 
               
               
                   
                   
                   
                   
                 CCGAGGACACCGCCGTGTACTATTGCGTGCG 
               
               
                   
                   
                   
                   
                 GGATTACTACGGCCATACCTACGGCTTCGCCT 
               
               
                   
                   
                   
                   
                 TTTGGGGCCAGGGCACACTGGTTACCGTTAGCT 
               
               
                   
                   
                   
                   
                 CT 
               
               
                   
               
               
                 Anti- 
                 329 
                 DIQMTQSPSSLSASVG 
                 330 
                 GACATACAGATGACTCAGAGCCCCTCCTCACTCTC 
               
               
                 MUC16 
                   
                 DRVTITCQASRDINNFL 
                   
                 GGCATCAGTCGGCGACAGGGTCACAATTACCTGT 
               
               
                 VL1 
                   
                 NWYQQKPGKAPKLLIY 
                   
                 CAGGCTTCTCGCGACATTAATAACTTCCTGAATTG 
               
               
                   
                   
                 RANNLETGVPSRFSGS 
                   
                 GTATCAGCAAAAGCCCGGGAAGGCCCCTAAGCT 
               
               
                   
                   
                 GSGTDFTFTISSLQPED 
                   
                 GTTGATTTATAGAGCAAATAATCTCGAAACCGGC 
               
               
                   
                   
                 IATYFCLQYGDLYTFGG 
                   
                 GTGCCCAGTAGGTTTAGCGGGTCCGGGAGCGGA 
               
               
                   
                   
                 GTKVEIK 
                   
                 ACAGACTTCACATTCACCATTTCTAGTTTGCAGCC 
               
               
                   
                   
                   
                   
                 CGAAGACATTGCTACATATTTTTGCCTGCAGTACG 
               
               
                   
                   
                   
                   
                 GGGATCTCTACACTTTCGGGGGCGGAACAAAGGT 
               
               
                   
                   
                   
                   
                 TGAGATAAAA 
               
               
                   
               
               
                 Anti- 
                 331 
                 DIQMTQSPSSLSASVG 
                 332 
                 GATATTCAAATGACGCAGTCACCCTCATCGCTCTC 
               
               
                 MUC16 
                   
                 DRVTITCQASRDINNFL 
                   
                 TGCGTCAGTAGGGGATCGTGTCACGATAACCTGT 
               
               
                 VL2 
                   
                 NWYQQKPGKAPKLLIY 
                   
                 CAAGCATCAAGGGACATCAACAACTTCCTCAACT 
               
               
                   
                   
                 RANNLETGVPSRFSGS 
                   
                 GGTACCAACAGAAGCCTGGCAAGGCACCTAAACT 
               
               
                   
                   
                 GSGTDFTFTISSLQPED 
                   
                 CCTGATCTACCGGGCTAACAACCTAGAAACCGGG 
               
               
                   
                   
                 IATYYCLQYGDLYTFGG 
                   
                 GTTCCGAGCCGATTCAGTGGGTCTGGAAGCGGG 
               
               
                   
                   
                 GTKVEIK 
                   
                 ACAGACTTTACGTTCACTATTAGTTCGCTACAGCC 
               
               
                   
                   
                   
                   
                 CGAAGACATTGCGACATATTACTGTCTTCAGTATG 
               
               
                   
                   
                   
                   
                 GGGATTTGTATACCTTTGGGGGAGGCACCAAGGT 
               
               
                   
                   
                   
                   
                 AGAGATAAAG 
               
               
                   
               
               
                 Anti- 
                 333 
                 DIQMTQSPSSLSASVG 
                 334 
                 GACATCCAGATGACTCAGAGCCCGTCTTCTCTATC 
               
               
                 MUC16 
                   
                 DRVTITCRASRDINNFL 
                   
                 CGCAAGTGTAGGCGATCGTGTCACCATCACATGC 
               
               
                 VL3 
                   
                 GWYQQKPGKAPKRLI 
                   
                 CGGGCTTCCCGGGATATCAACAACTTCCTTGGGT 
               
               
                   
                   
                 YRANSLQSGVPSRFSG 
                   
                 GGTATCAGCAGAAGCCCGGAAAAGCCCCCAAAC 
               
               
                   
                   
                 SGSGTEFTLTISSLQPE 
                   
                 GGCTCATCTACAGAGCGAATTCCCTGCAGTCAGG 
               
               
                   
                   
                 DFATYYCLQYGDLYTF 
                   
                 TGTCCCCAGTAGGTTCAGCGGATCAGGCTCGGGG 
               
               
                   
                   
                 GQGTKVEIK 
                   
                 ACCGAATTCACTCTGACCATTAGCTCACTGCAGCC 
               
               
                   
                   
                   
                   
                 TGAGGATTTCGCTACTTACTATTGCCTGCAATACG 
               
               
                   
                   
                   
                   
                 GCGATCTGTACACTTTCGGGCAGGGCACCAAGGT 
               
               
                   
                   
                   
                   
                 GGAAATAAAA 
               
               
                   
               
               
                 Anti- 
                 335 
                 EIVLTQSPGTLSLSPGE 
                 336 
                 GAAATCGTACTGACCCAGTCTCCCGGAACCCTGA 
               
               
                 MUC16 
                   
                 RATLSCRASRDINNFLA 
                   
                 GTCTCTCACCCGGCGAGCGCGCAACACTGTCGTG 
               
               
                 VL4 
                   
                 WYQQKPGQAPRLLIYR 
                   
                 TAGGGCCAGTAGGGACATAAATAACTTCCTAGCC 
               
               
                   
                   
                 ANSRATGIPDRFSGSG 
                   
                 TGGTACCAACAAAAACCGGGTCAGGCTCCAAGAC 
               
               
                   
                   
                 SGTDFTLTISRLEPEDF 
                   
                 TGTTGATCTATAGAGCTAACTCCAGGGCCACCGG 
               
               
                   
                   
                 AVYYCLQYGDLYTFGQ 
                   
                 CATCCCAGACCGATTCTCAGGCTCCGGATCTGGA 
               
               
                   
                   
                 GTKVEIK 
                   
                 ACCGACTTCACGCTCACCATTAGCCGACTAGAACC 
               
               
                   
                   
                   
                   
                 TGAGGACTTTGCTGTATACTATTGCCTGCAGTACG 
               
               
                   
                   
                   
                   
                 GCGACCTGTATACCTTTGGACAGGGTACCAAGGT 
               
               
                   
                   
                   
                   
                 CGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 337 
                 EIVLTQSPATLSLSPGE 
                 338 
                 GAGATCGTACTTACGCAGAGCCCAGCAACTCTGT 
               
               
                 MUC16 
                   
                 RATLSCRASRDINNFLA 
                   
                 CTCTGTCCCCCGGAGAACGGGCCACCCTGTCGTG 
               
               
                 VL5 
                   
                 WYQQKPGQAPRLLIYR 
                   
                 CCGGGCCAGCCGTGATATTAATAATTTCCTGGCCT 
               
               
                   
                   
                 ANNRATGIPARFSGSG 
                   
                 GGTATCAACAAAAACCGGGGCAGGCTCCTCGACT 
               
               
                   
                   
                 PGTDFTLTISSLEPEDFA 
                   
                 GTTGATCTACCGGGCCAACAATAGAGCAACTGGT 
               
               
                   
                   
                 VYYCLQYGDLYTFGGG 
                   
                 ATCCCTGCTCGCTTCTCCGGCAGTGGGCCAGGTA 
               
               
                   
                   
                 TKVEIK 
                   
                 CAGACTTCACCCTGACTATTTCGTCACTCGAACCA 
               
               
                   
                   
                   
                   
                 GAAGACTTTGCCGTGTATTATTGCTTACAATACGG 
               
               
                   
                   
                   
                   
                 GGATCTGTACACTTTCGGAGGAGGAACTAAGGTC 
               
               
                   
                   
                   
                   
                 GAAATTAAG 
               
               
                   
               
               
                 Anti- 
                 339 
                 EIVLTQSPDFQSVTPKE 
                 340 
                 GAGATCGTGCTGACCCAGAGCCCCGACTTCCAGA 
               
               
                 MUC16 
                   
                 KVTITCRASRDINNFLH 
                   
                 GCGTGACCCCCAAGGAGAAGGTGACCATCACCTG 
               
               
                 VL6 
                   
                 WYQQKPDQSPKLLIKR 
                   
                 CAGAGCCAGCAGAGACATCAACAACTTCCTGCAC 
               
               
                   
                   
                 ANQSFSGVPSRFSGSG 
                   
                 TGGTACCAGCAGAAGCCCGACCAGAGCCCCAAG 
               
               
                   
                   
                 SGTDFTLTINSLEAEDA 
                   
                 CTGCTGATCAAGAGAGCCAACCAGAGCTTCAGCG 
               
               
                   
                   
                 ATYYCLQYGDLYTFGQ 
                   
                 GCGTGCCCAGCAGATTCAGCGGCAGCGGCAGCG 
               
               
                   
                   
                 GTKVEIK 
                   
                 GCACCGACTTCACCCTGACCATCAACAGCCTGGA 
               
               
                   
                   
                   
                   
                 GGCCGAGGACGCCGCCACCTACTACTGCCTGCAG 
               
               
                   
                   
                   
                   
                 TACGGCGACCTGTACACCTTCGGCCAGGGCACCA 
               
               
                   
                   
                   
                   
                 AGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 341 
                 DIQMTQSPSSLSASVG 
                 342 
                 GACATCCAGATGACCCAGAGCCCCAGCAGCCTGA 
               
               
                 MUC16 
                   
                 DRVTITCRASRDINNFL 
                   
                 GCGCCAGCGTGGGCGACAGAGTGACCATCACCT 
               
               
                 VL7 
                   
                 AWFQQKPGKAPKSLIY 
                   
                 GCAGAGCCAGCAGAGACATCAACAACTTCCTGGC 
               
               
                   
                   
                 RANSLQSGVPSRFSGS 
                   
                 CTGGTTCCAGCAGAAGCCCGGCAAGGCCCCCAAG 
               
               
                   
                   
                 GSGTDFTLTISSLQPED 
                   
                 AGCCTGATCTACAGAGCCAACAGCCTGCAGAGCG 
               
               
                   
                   
                 FATYYCLQYGDLYTFG 
                   
                 GCGTGCCCAGCAGATTCAGCGGCAGCGGCAGCG 
               
               
                   
                   
                 GGTKVEIK 
                   
                 GCACCGACTTCACCCTGACCATCAGCAGCCTGCA 
               
               
                   
                   
                   
                   
                 GCCCGAGGACTTCGCCACCTACTACTGCCTGCAG 
               
               
                   
                   
                   
                   
                 TACGGCGACCTGTACACCTTCGGCGGCGGCACCA 
               
               
                   
                   
                   
                   
                 AGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 662 
                 DIQMTQSPSSLSASVG 
                 663 
                 GACATCCAGATGACCCAGAGCCCCAGCAGCCTGA 
               
               
                 MUC16 
                   
                 DRVTITCRASRDINNFL 
                   
                 GCGCCAGCGTGGGCGACAGAGTGACCATCACCT 
               
               
                 VL8 
                   
                 AWYQQKPGKAPKLLL 
                   
                 GCAGAGCCAGCAGAGACATCAACAACTTCCTGGC 
               
               
                   
                   
                 YRANRLESGVPSRFSG 
                   
                 CTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAA 
               
               
                   
                   
                 SGSGTDYTLTISSLQPE 
                   
                 GCTGCTGCTGTACAGAGCCAACAGACTGGAGAG 
               
               
                   
                   
                 DFATYYCLQYGDLYTF 
                   
                 CGGCGTGCCCAGCAGATTCAGCGGCAGCGGCAG 
               
               
                   
                   
                 GGGTKVEIK 
                   
                 CGGCACCGACTACACCCTGACCATCAGCAGCCTG 
               
               
                   
                   
                   
                   
                 CAGCCCGAGGACTTCGCCACCTACTACTGCCTGC 
               
               
                   
                   
                   
                   
                 AGTACGGCGACCTGTACACCTTCGGCGGCGGCAC 
               
               
                   
                   
                   
                   
                 CAAGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 664 
                 DIQMTQSPSSLSASVG 
                 665 
                 GACATCCAGATGACCCAGAGCCCCAGCAGCCTGA 
               
               
                 MUC16 
                   
                 DRVTITCKASRDINNFL 
                   
                 GCGCCAGCGTGGGCGACAGAGTGACCATCACCT 
               
               
                 VL9 
                   
                 SWYQQKPGKAPKLLIY 
                   
                 GCAAGGCCAGCAGAGACATCAACAACTTCCTGAG 
               
               
                   
                   
                 RANRLVDGVPSRFSGS 
                   
                 CTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAA 
               
               
                   
                   
                 GSGTDFTFTISSLQPED 
                   
                 GCTGCTGATCTACAGAGCCAACAGACTGGTGGAC 
               
               
                   
                   
                 IATYYCLQYGDLYTFGG 
                   
                 GGCGTGCCCAGCAGATTCAGCGGCAGCGGCAGC 
               
               
                   
                   
                 GTKVEIK 
                   
                 GGCACCGACTTCACCTTCACCATCAGCAGCCTGCA 
               
               
                   
                   
                   
                   
                 GCCCGAGGACATCGCCACCTACTACTGCCTGCAG 
               
               
                   
                   
                   
                   
                 TACGGCGACCTGTACACCTTCGGCGGCGGCACCA 
               
               
                   
                   
                   
                   
                 AGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 666 
                 DIQMTQSPSSLSASVG 
                 667 
                 GACATCCAGATGACCCAGAGCCCCAGCAGCCTGA 
               
               
                 MUC16 
                   
                 DRVTITCKAS RDINNF L 
                   
                 GCGCCAGCGTGGGCGACAGAGTGACCATCACCT 
               
               
                 VL10 
                   
                 SWYQQKPGKAPKLLIY 
                   
                 GCAAGGCCAGCAGAGACATCAACAACTTCCTGAG 
               
               
                   
                   
                   RAN RLVDGVPSRFSGS 
                   
                 CTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAA 
               
               
                   
                   
                 GSGTDFTLTISSLQPED 
                   
                 GCTGCTGATCTACAGAGCCAACAGACTGGTGGAC 
               
               
                   
                   
                 FATYY CLQYGDLYT FG 
                   
                 GGCGTGCCCAGCAGATTCAGCGGCAGCGGCAGC 
               
               
                   
                   
                 QGTKVEIK 
                   
                 GGCACCGACTTCACCCTGACCATCAGCAGCCTGC 
               
               
                   
                   
                   
                   
                 AGCCCGAGGACTTCGCCACCTACTACTGCCTGCA 
               
               
                   
                   
                   
                   
                 GTACGGCGACCTGTACACCTTCGGCCAGGGCACC 
               
               
                   
                   
                   
                   
                 AAGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 668 
                 EIVLTQSPGTLSLSPGE 
                 669 
                 GAGATCGTGCTGACCCAGAGCCCCGGCACCCTGA 
               
               
                 MUC16 
                   
                 RATLSCKASRDINNFLS 
                   
                 GCCTGAGCCCCGGCGAGAGAGCCACCCTGAGCT 
               
               
                 VL11 
                   
                 WYQQKPGQAPRLLIYR 
                   
                 GCAAGGCCAGCAGAGACATCAACAACTTCCTGAG 
               
               
                   
                   
                 ANRLVDGIPDRFSGSG 
                   
                 CTGGTACCAGCAGAAGCCCGGCCAGGCCCCCAG 
               
               
                   
                   
                 SGTDFTLTISRLEPEDF 
                   
                 ACTGCTGATCTACAGAGCCAACAGACTGGTGGAC 
               
               
                   
                   
                 AVYYCLQYGDLYTFGQ 
                   
                 GGCATCCCCGACAGATTCAGCGGCAGCGGCAGC 
               
               
                   
                   
                 GTKVEIK 
                   
                 GGCACCGACTTCACCCTGACCATCAGCAGACTGG 
               
               
                   
                   
                   
                   
                 AGCCCGAGGACTTCGCCGTGTACTACTGCCTGCA 
               
               
                   
                   
                   
                   
                 GTACGGCGACCTGTACACCTTCGGCCAGGGCACC 
               
               
                   
                   
                   
                   
                 AAGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 670 
                 EIVLTQSPATLSLSPGE 
                 671 
                 GAGATCGTGCTGACCCAGAGCCCCGCCACCCTGA 
               
               
                 MUC16 
                   
                 RATLSCKASRDINNFLS 
                   
                 GCCTGAGCCCCGGCGAGAGAGCCACCCTGAGCT 
               
               
                 VL12 
                   
                 WYQQKPGQAPRLLIYR 
                   
                 GCAAGGCCAGCAGAGACATCAACAACTTCCTGAG 
               
               
                   
                   
                 ANRLVDGIPARFSGSG 
                   
                 CTGGTACCAGCAGAAGCCCGGCCAGGCCCCCAG 
               
               
                   
                   
                 SGTDFTLTISSLEPEDFA 
                   
                 ACTGCTGATCTACAGAGCCAACAGACTGGTGGAC 
               
               
                   
                   
                 VYYCLQYGDLYTFGQG 
                   
                 GGCATCCCCGCCAGATTCAGCGGCAGCGGCAGC 
               
               
                   
                   
                 TKVEIK 
                   
                 GGCACCGACTTCACCCTGACCATCAGCAGCCTGG 
               
               
                   
                   
                   
                   
                 AGCCCGAGGACTTCGCCGTGTACTACTGCCTGCA 
               
               
                   
                   
                   
                   
                 GTACGGCGACCTGTACACCTTCGGCCAGGGCACC 
               
               
                   
                   
                   
                   
                 AAGGTGGAGATCAAG 
               
               
                   
               
               
                 Anti- 
                 688 
                 DIELTQSPSSLAVSAGE 
                 689 
                 GACATCGAGCTGACACAGAGCCCATCTAGCCTG 
               
               
                 MUC16 VL 
                   
                 KVTMSCKSSQSLLNSR 
                   
                 GCTGTGTCTGCCGGCGAGAAAGTGACCATGAG 
               
               
                   
                   
                 TRKNQLAWYQQKPG 
                   
                 CTGCAAGAGCAGCCAGAGCCTGCTGAACAGCC 
               
               
                   
                   
                 QSPELLIYWASTRQSG 
                   
                 GGACCAGAAAGAATCAGCTGGCCTGGTATCAGC 
               
               
                   
                   
                 VPDRFTGSGSGTDFTL 
                   
                 AGAAGCCCGGCCAATCTCCTGAGCTGCTGATCT 
               
               
                   
                   
                 TISSVQAEDLAVYYCQ 
                   
                 ACTGGGCCAGCACAAGACAGAGCGGCGTGCC 
               
               
                   
                   
                 QSYNLLTFGPGTKLEV 
                   
                 CGATAGATTCACAGGATCTGGCAGCGGCACCG 
               
               
                   
                   
                 KR 
                   
                 ACTTCACCCTGACAATCAGTTCTGTGCAGGCCG 
               
               
                   
                   
                   
                   
                 AGGACCTGGCCGTG 
               
               
                   
                   
                   
                   
                 TACTACTGTCAGCAGAGCTACAACCTGCTGACCT 
               
               
                   
                   
                   
                   
                 TCGGACCCGGCACCAAGCTGGAAGTGAAGAGA 
               
               
                   
               
               
                 Anti- 
                 690 
                 DIELTQSPSSLAVSAGE 
                 691 
                 GACATCGAGCTGACACAGAGCCCATCTAGCCTG 
               
               
                 MUC16 VL 
                   
                 KVTMSCKSSQSLLNSR 
                   
                 GCTGTGTCTGCCGGCGAGAAAGTGACCATGA 
               
               
                   
                   
                 TRKNQLAWYQQKTG 
                   
                 GCTGCAAGAGCAGCCAGAGCCTGCTGAACAGC 
               
               
                   
                   
                 QSPELLIYWASTRQSG 
                   
                 CGGACCAGAAAGAATCAGCTGGCCTGGTATCA 
               
               
                   
                   
                 VPDRFTGSGSGTDFTL 
                   
                 GCAGAAAACCGGACAGAGCCCCGAGCTGCTG 
               
               
                   
                   
                 TISSVQAEDLAVYYCQ 
                   
                 ATCTACTGGGCCAGCACAAGACAGAGCGGCGTG 
               
               
                   
                   
                 QSYNLLTFGPGTKLEIKR 
                   
                 CCCGATAGATTCACAGGATCTGGCAGCGGCACC 
               
               
                   
                   
                   
                   
                 GACTTCACCCTGACAATCAGTTCTGTGCAGGCC 
               
               
                   
                   
                   
                   
                 GAGGACCTGGCCGTGTACTACTGTCAGCAGAGC 
               
               
                   
                   
                   
                   
                 TACAACCTGCTGACCTTCGGACCCGGCACCAAG 
               
               
                   
                   
                   
                   
                 CTGGAAATCAAGAGA 
               
               
                   
               
               
                 Anti- 
                 692 
                 DIKMAQSPSSVNASL 
                 693 
                 GACATCAAGATGGCTCAGTCCCCTTCTAGCGT 
               
               
                 MUC16 VL 
                   
                 GERVTITCKASRDINN 
                   
                 GAATGCTTCGCTAGGGGAGCGTGTGACCATCAC 
               
               
                   
                   
                 FLSWFHQKPGKSTL 
                   
                 ATGTAAAGCATCACGCGACATAAATAATTTCCTT 
               
               
                   
                   
                 IYRANRLVDGVPSRFS 
                   
                 TCCTGGTTTCATCAGAAACCGGGCAAGTCGCCTA 
               
               
                   
                   
                 GSGSGQDYSFTISSLEY 
                   
                 AGACGCTGATTTACAGAGCAAATCGGTTGGTAG 
               
               
                   
                   
                 EDVGIYYCLQYGDLYTF 
                   
                 ATGGAGTGCCAAGCAGATTCAGCGGGAGCGG 
               
               
                   
                   
                 GGGTKLEIK 
                   
                 AAGTGGACAGGATTATAGCTTCACTATTTCATC 
               
               
                   
                   
                   
                   
                 CCTGGAATACGAGGACGTAGGTATCTATTATTG 
               
               
                   
                   
                   
                   
                 CCTCCAGTATGGCGATCTTTACACATTTGGTGGG 
               
               
                   
                   
                   
                   
                 GGGACTAAGCTGGAGATTAAG 
               
               
                   
               
               
                 Anti- 
                 694 
                 DIQMTQSSSFLSVSLG 
                 695 
                 GACATCCAGATGACCCAGAGCAGCAGCTTCCTG 
               
               
                 MUC16 VL 
                   
                 GRVTITCKASDLIHN 
                   
                 AGCGTGTCCCTTGGCGGCAGAGTGACCATCAC 
               
               
                   
                   
                 WLAWYQQKPGNAPR 
                   
                 CTGTAAAGCCAGCGACCTGATCCACAACTGGCT 
               
               
                   
                   
                 LLISGATSLETGVPSRF 
                   
                 GGCCTGGTATCAGCAGAAGCCTGGCAACGCTCC 
               
               
                   
                   
                 SGSGSGNDYTLSIASLQ 
                   
                 CAGACTGCTGATTAGCGGCGCCACCTCTCTGGA 
               
               
                   
                   
                 TEDAATYYCQQYWTT 
                   
                 AACAGGCGTGCCAAGCAGATTTTCCGGCAGCGG 
               
               
                   
                   
                 PFTFGSGTKLEIK 
                   
                 CTCCGGCAACGACTACACACTGTCTATTGCCAG 
               
               
                   
                   
                   
                   
                 CCTGCAGACCGAGGATGCCGCCACCTATTACTG 
               
               
                   
                   
                   
                   
                 CCAGCAGTACTGGACCACACCTTTCACCTTTG 
               
               
                   
                   
                   
                   
                 GCAGCGGCACCAAGCTGGAAATCAAG 
               
               
                   
               
               
                 Anti- 
                 696 
                 DIQMTQSPSSLSASV 
                 697 
                 GACATCCAGATGACCCAGAGCCCCAGCAGCCTGA 
               
               
                 MUC16 VL 
                   
                 GDRVTITCKASDLIHN 
                   
                 GCGCCAGCGTGGGCGACAGGGTGACCATCACCT 
               
               
                   
                   
                 WLAWYQQKPGKAPK 
                   
                 GCAAGGCCAGCGACCTGATCCACAACTGGCTGGC 
               
               
                   
                   
                 LLISGATSLETGVPSRFS 
                   
                 CTGGTACCAGCAGAAGCCCGGCAAGGCCCCCAA 
               
               
                   
                   
                 GSGSGTDFTLTISSLQP 
                   
                 GCTGCTGATCAGCGGCGCCACCAGCCTGGAGACC 
               
               
                   
                   
                 EDFATYYCQQYWTTPF 
                   
                 GGCGTGCCCAGCAGGTTCAGCGGCAGCGGCAGC 
               
               
                   
                   
                 TFGQGTKVEIKR 
                   
                 GGCACCGACTTCACCCTGACCATCAGCAGCCTG 
               
               
                   
                   
                   
                   
                 CAGCCCGAGGACTTCGCCACCTACTACTGCCAG 
               
               
                   
                   
                   
                   
                 CAGTACTGGACCACCCCCTTCACCTTCGGCCAG 
               
               
                   
                   
                   
                   
                 GGCACCAAGGTGGAGATCAAGAGG 
               
               
                   
               
               
                 Anti- 
                 698 
                 DIVLTQSPAIMSASLG 
                 699 
                 GACATCGTGCTGACACAGAGCCCTGCCATCATG 
               
               
                 MUC16 VL 
                   
                 ERVTMTCTASSSVSS 
                   
                 TCTGCCAGCCTCGGCGAGCGAGTGACCATGACA 
               
               
                   
                   
                 SYLHWYQQKPGSSP 
                   
                 TGTACAGCCAGCAGCAGCGTGTCCAGCAGCTAC 
               
               
                   
                   
                 KLWIYSTSNLASGVPG 
                   
                 CTGCATTGGTATCAGCAGAAGCCCGGCAGCAGC 
               
               
                   
                   
                 RFSGSGSGTSYSLTIS 
                   
                 CCCAAGCTGTGGATCTACAGCACAAGCAATCTG 
               
               
                   
                   
                 SMEAEDAATYYCH 
                   
                 GCCAGCGGCGTGCCAGGCAGATTTTCTGGTTC 
               
               
                   
                   
                 QYHRSPYTFGGGTKV 
                   
                 TGGCAGCGGCACCAGCTACAGCCTGACAATCAG 
               
               
                   
                   
                 EIKR 
                   
                 CAGCATGGAAGCCGAGGATGCCGCCACCTAC 
               
               
                   
                   
                   
                   
                 TACTGCCACCAGTACCACAGAAGCCCCTACACC 
               
               
                   
                   
                   
                   
                 TTTGGCGGAGGCACCAAGGTGGAAATCAAGC 
               
               
                   
                   
                   
                   
                 GG 
               
               
                   
               
               
                 Anti- 
                 700 
                 DIQMTQSPSSLSASV 
                 701 
                 GACATCCAGATGACACAGAGCCCTAGCAGCCTG 
               
               
                 MUC16 VL 
                   
                 GDRVTITCTASSSVSSS 
                   
                 TCTGCCAGCGTGGGAGACAGAGTGACCATCACC 
               
               
                   
                   
                 YLHWYQQKPGKAPKL 
                   
                 TGTACAGCCAGCAGCAGCGTGTCCAGCAGCTAC 
               
               
                   
                   
                 LIYSTSNLASGVPSRFS 
                   
                 CTGCATTGGTATCAGCAGAAGCCCGGCAAGGCC 
               
               
                   
                   
                 GSGSGTDFTLTISSLQ 
                   
                 CCTAAGCTGCTGATCTACAGCACCAGCAATCTGG 
               
               
                   
                   
                 PEDFATYYCHQYHRSP 
                   
                 CCAGCGGCGTGCCAAGCAGATTTTCTGGCTCT 
               
               
                   
                   
                 YTFGQGTKVEIKR 
                   
                 GGCAGCGGCACCGACTTCACCCTGACCATATCT 
               
               
                   
                   
                   
                   
                 AGCCTGCAGCCTGAGGACTTCGCCACCTACTAC 
               
               
                   
                   
                   
                   
                 TGCCACCAGTACCACAGAAGCCCCTACACCTTT 
               
               
                   
                   
                   
                   
                 GGCCAGGGCACCAAGGTGGAAATCAAGCGG 
               
               
                   
               
               
                 Anti- 
                 343 
                 DIKMAQSPSSVNA 
                 344 
                 GACATCAAGATGGCTCAGTCCCCTTCTAGCGTGA 
               
               
                 MUC16 
                   
                 SLGERVTITCKASR 
                   
                 ATGCTTCGCTAGGGGAGCGTGTGACCATCACATG 
               
               
                 scFv 
                   
                 DINNFLSWFHQKP 
                   
                 TAAAGCATCACGCGACATAAATAATTTCCTTTCCT 
               
               
                   
                   
                 GKSPKTLIYRANRL 
                   
                 GGTTTCATCAGAAACCGGGCAAGTCGCCTAAGAC 
               
               
                   
                   
                 VDGVPSRFSGSGS 
                   
                 GCTGATTTACAGAGCAAATCGGTTGGTAGATGGA 
               
               
                   
                   
                 GQDYSFTISSLEYE 
                   
                 GTGCCAAGCAGATTCAGCGGGAGCGGAAGTGGA 
               
               
                   
                   
                 DVGIYYCLQYGDL 
                   
                 CAGGATTATAGCTTCACTATTTCATCCCTGGAATA 
               
               
                   
                   
                 YTFGGGTKLEIKG 
                   
                 CGAGGACGTAGGTATCTATTATTGCCTCCAGTAT 
               
               
                   
                   
                 GGGSGGGGSGGG 
                   
                 GGCGATCTTTACACATTTGGTGGGGGGACTAAGC 
               
               
                   
                   
                 GSDVQLLESGPGL 
                   
                 TGGAGATTAAG 
               
               
                   
                   
                 VRPSQSLSLTCSVT 
                   
                 GGCGGAGGCGGAAGCGGAGGCGGAGGCTCCGG 
               
               
                   
                   
                 GYSIVSHYYWNWI 
                   
                 CGGAGGCGGAAGCGACGTGCAACTTCTGGAGAG 
               
               
                   
                   
                 RQFPGNKLEWMG 
                   
                 CGGGCCAGGGCTAGTCAGGCCCTCCCAGTCGCTT 
               
               
                   
                   
                 YISSDGSNEYNPSL 
                   
                 TCACTGACTTGCAGTGTGACCGGTTACTCTATTGT 
               
               
                   
                   
                 KNRISISLDTSKNQ 
                   
                 GAGTCACTACTATTGGAACTGGATTCGGCAGTTC 
               
               
                   
                   
                 FFLKFDFVTTADT 
                   
                 CCAGGCAACAAACTGGAATGGATGGGGTACATA 
               
               
                   
                   
                 ATYFCVRGVDYW 
                   
                 TCTTCCGATGGCTCGAATGAATATAACCCATCATT 
               
               
                   
                   
                 GQGTTLTVSS 
                   
                 GAAAAATCGTATTTCCATCAGTCTGGATACGAGT 
               
               
                   
                   
                   
                   
                 AAAAACCAGTTTTTCCTCAAATTCGATTTCGTGAC 
               
               
                   
                   
                   
                   
                 TACAGCAGATACTGCCACATACTTCTGTGTACGA 
               
               
                   
                   
                   
                   
                 GGTGTCGATTATTGGGGACAGGGCACAACGCTG 
               
               
                   
                   
                   
                   
                 ACCGTAAGTTCT 
               
               
                   
               
            
           
         
       
     
     Exemplary anti-ROR1 Variable Heavy (VH) and Variable Light (VL) Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                   
                   
                 Amino acid sequence 
                   
                 Nucleotide sequence 
               
               
                   
               
             
            
               
                 hROR1 VH_04 
                 345 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 346 
                 GAGGTGCAGCTCGTGGAAT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CCGGCGGTGGCCTGGTGCA 
               
               
                   
                   
                 VSAISRGGTTYYADSVKGRFTISRD 
                   
                 GCCGGGCGGCAGTCTTCGA 
               
               
                   
                   
                 NSKNTLYLQMNSLRAEDTAVYYCG 
                   
                 CTCTCCTGTGCGGCGTCAG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTTACGTTCAGTTCTTAT 
               
               
                   
                   
                   
                   
                 GCCATGAGCTGGGTGAGGC 
               
               
                   
                   
                   
                   
                 AAGCTCCCGGTAAGGGACT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTCTCTGCTATC 
               
               
                   
                   
                   
                   
                 AGCCGGGGAGGTACGACCT 
               
               
                   
                   
                   
                   
                 ACTACGCTGACTCCGTAAAA 
               
               
                   
                   
                   
                   
                 GGAAGATTTACCATAAGTC 
               
               
                   
                   
                   
                   
                 GTGACAATTCCAAAAACACT 
               
               
                   
                   
                   
                   
                 CTATACTTACAGATGAACTC 
               
               
                   
                   
                   
                   
                 GCTCAGGGCCGAAGATACC 
               
               
                   
                   
                   
                   
                 GCAGTCTACTATTGTGGGA 
               
               
                   
                   
                   
                   
                 GATACGATTACGACGGCTA 
               
               
                   
                   
                   
                   
                 CTATGCTATGGATTATTGGG 
               
               
                   
                   
                   
                   
                 GTCAGGGTACGCTCGTGAC 
               
               
                   
                   
                   
                   
                 GGTGTCCTCC 
               
               
                   
               
               
                 hROR1 VL_04 
                 347 
                 DIQMTQSPSSLSASVGDRVTITCQA 
                 348 
                 GATATTCAAATGACGCAAA 
               
               
                   
                   
                 SPDINSYLNWYQQKPGKAPKLLIYR 
                   
                 GTCCCAGCAGCCTCTCCGCC 
               
               
                   
                   
                 ANNLETGVPSRFSGSGSGTDFTLTI 
                   
                 TCCGTTGGAGACAGGGTGA 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 CTATTACATGCCAAGCCAGC 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCCGATATTAATAGCTACTT 
               
               
                   
                   
                   
                   
                 AAATTGGTATCAGCAGAAA 
               
               
                   
                   
                   
                   
                 CCTGGGAAGGCACCTAAAC 
               
               
                   
                   
                   
                   
                 TTCTCATCTACCGCGCTAAC 
               
               
                   
                   
                   
                   
                 AATCTGGAGACCGGCGTGC 
               
               
                   
                   
                   
                   
                 CGTCTAGATTTTCCGGCTCT 
               
               
                   
                   
                   
                   
                 GGATCAGGGACCGATTTTA 
               
               
                   
                   
                   
                   
                 CTCTGACAATTAGTTCCCTG 
               
               
                   
                   
                   
                   
                 CAACCCGAAGACATCGCCA 
               
               
                   
                   
                   
                   
                 CTTATTATTGCCTGCAATAT 
               
               
                   
                   
                   
                   
                 GATGAGTTTCCTTACACATT 
               
               
                   
                   
                   
                   
                 TGGTCAGGGAACTAAACTA 
               
               
                   
                   
                   
                   
                 GAGATTAAG 
               
               
                   
               
               
                 hROR1 VH_05 
                 349 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 350 
                 GAAGTGCAACTGGTCGAGT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CTGGGGGCGGCCTTGTGCA 
               
               
                   
                   
                 VSSISRGGTTYYPDSVKGRFTISRDN 
                   
                 ACCTGGAGGCAGCCTTCGA 
               
               
                   
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 CTCAGTTGCGCCGCGTCTG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GTTTTACCTTCTCCTCTTACG 
               
               
                   
                   
                   
                   
                 CGATGAGCTGGGTTCGCCA 
               
               
                   
                   
                   
                   
                 GGCCCCCGGCAAGGGACTT 
               
               
                   
                   
                   
                   
                 GAGTGGGTTAGTTCGATCT 
               
               
                   
                   
                   
                   
                 CCCGCGGAGGCACCACATA 
               
               
                   
                   
                   
                   
                 TTATCCTGACTCGGTTAAGG 
               
               
                   
                   
                   
                   
                 GACGCTTCACTATCTCTAGG 
               
               
                   
                   
                   
                   
                 GACAATTCAAAGAACACAC 
               
               
                   
                   
                   
                   
                 TGTATCTCCAAATGAACTCC 
               
               
                   
                   
                   
                   
                 TTGCGGGCCGAGGACACTG 
               
               
                   
                   
                   
                   
                 CTGTGTATTATTGCGGACG 
               
               
                   
                   
                   
                   
                 ATACGACTACGATGGGTAT 
               
               
                   
                   
                   
                   
                 TACGCCATGGATTACTGGG 
               
               
                   
                   
                   
                   
                 GGCAAGGTACACTGGTCAC 
               
               
                   
                   
                   
                   
                 TGTGAGTTCG 
               
               
                   
               
               
                 hROR1 VL_05 
                 351 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 352 
                 GATATTCAGATGACCCAGTC 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 ACCTTCGAGTCTGAGCGCA 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 TCCGTGGGCGACAGAGTGA 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 CCATTACCTGTAAGGCCAGC 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCGGACATTAACAGCTACCT 
               
               
                   
                   
                   
                   
                 ATCGTGGTATCAGCAAAAG 
               
               
                   
                   
                   
                   
                 CCTGGTAAGGCCCCTAAACT 
               
               
                   
                   
                   
                   
                 CCTTATCTACAGGGCTAATA 
               
               
                   
                   
                   
                   
                 GGTTGGTAGACGGGGTGCC 
               
               
                   
                   
                   
                   
                 TAGCCGGTTCTCTGGTTCCG 
               
               
                   
                   
                   
                   
                 GCAGCGGTACGGACTTTAC 
               
               
                   
                   
                   
                   
                 TCTGACCATAAGCTCTCTGC 
               
               
                   
                   
                   
                   
                 AACCAGAAGACATCGCAAC 
               
               
                   
                   
                   
                   
                 ATACTACTGTTTACAATACG 
               
               
                   
                   
                   
                   
                 ACGAATTTCCTTATACCTTT 
               
               
                   
                   
                   
                   
                 GGCCAGGGGACCAAGTTAG 
               
               
                   
                   
                   
                   
                 AGATCAAG 
               
               
                   
               
               
                 hROR1 VH_06 
                 353 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 354 
                 GAGGTTCAGCTGGTCGAGT 
               
               
                   
                   
                 SGFTFSSYAIIWVRQAPGKGLEWV 
                   
                 CCGGGGGAGGCTTAGTGCA 
               
               
                   
                   
                 ARISRGGTTRYADSVKGRFTISADT 
                   
                 GCCAGGAGGCAGTCTGCGG 
               
               
                   
                   
                 SKETAYLQMNSLRAEDTAVYYCGR 
                   
                 CTCTCTTGCGCTGCAAGTGG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 CTTCACATTCAGTTCATACG 
               
               
                   
                   
                   
                   
                 CAATCATCTGGGTTCGACA 
               
               
                   
                   
                   
                   
                 GGCTCCTGGTAAGGGCCTC 
               
               
                   
                   
                   
                   
                 GAATGGGTCGCAAGGATAT 
               
               
                   
                   
                   
                   
                 CACGAGGTGGAACCACTAG 
               
               
                   
                   
                   
                   
                 ATACGCAGACTCTGTTAAG 
               
               
                   
                   
                   
                   
                 GGCAGGTTCACAATTAGCG 
               
               
                   
                   
                   
                   
                 CGGATACCTCCAAGGAGAC 
               
               
                   
                   
                   
                   
                 TGCTTATTTACAGATGAACT 
               
               
                   
                   
                   
                   
                 CTCTGAGAGCCGAGGACAC 
               
               
                   
                   
                   
                   
                 TGCTGTTTACTACTGCGGCC 
               
               
                   
                   
                   
                   
                 GATACGATTACGACGGATA 
               
               
                   
                   
                   
                   
                 TTACGCAATGGATTACTGG 
               
               
                   
                   
                   
                   
                 GGCCAGGGCACGCTGGTGA 
               
               
                   
                   
                   
                   
                 CAGTTTCATCG 
               
               
                   
               
               
                 hROR1 VL_06 
                 355 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 356 
                 GATATCCAGATGACTCAGA 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 GTCCCAGTAGCCTGTCGGC 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 AAGCGTCGGAGATCGGGTC 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 ACAATTACCTGCAAAGCTA 
               
               
                   
                   
                 GTKLEIK 
                   
                 GTCCTGATATTAATTCTTAC 
               
               
                   
                   
                   
                   
                 TTGTCCTGGTATCAGCAGA 
               
               
                   
                   
                   
                   
                 AGCCTGGTAAGGCCCCTAA 
               
               
                   
                   
                   
                   
                 GTTGCTCATCTATCGGGCTA 
               
               
                   
                   
                   
                   
                 ACCGGCTGGTGGACGGTGT 
               
               
                   
                   
                   
                   
                 TCCCTCTAGATTCTCAGGGA 
               
               
                   
                   
                   
                   
                 GTGGAAGCGGCACTGACTT 
               
               
                   
                   
                   
                   
                 CACCCTGACTATATCGAGCC 
               
               
                   
                   
                   
                   
                 TTCAGCCAGAGGACATTGC 
               
               
                   
                   
                   
                   
                 CACATACTACTGTCTGCAAT 
               
               
                   
                   
                   
                   
                 ATGATGAATTTCCATATACA 
               
               
                   
                   
                   
                   
                 TTCGGACAAGGTACAAAGT 
               
               
                   
                   
                   
                   
                 TAGAAATTAAG 
               
               
                   
               
               
                 hROR1 VH_07 
                 357 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 358 
                 GAAGTCCAACTGGTGGAGT 
               
               
                   
                   
                 SGFTFSSYAIIWVRQAPGKGLEWV 
                   
                 CTGGCGGGGGCTTGGTGCA 
               
               
                   
                   
                 ARISRGGTTRYADSVKGRFTISADT 
                   
                 GCCCGGTGGCTCCCTTAGG 
               
               
                   
                   
                 SKETAYLQMNSLRAEDTAVYYCGR 
                   
                 CTGTCTTGCGCTGCCAGCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GGTTCACATTCAGCTCCTAT 
               
               
                   
                   
                   
                   
                 GCGATTATATGGGTCCGAC 
               
               
                   
                   
                   
                   
                 AGGCACCCGGCAAGGGATT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTGGCTCGCATC 
               
               
                   
                   
                   
                   
                 AGCAGAGGCGGCACTACTC 
               
               
                   
                   
                   
                   
                 GTTACGCCGACTCCGTGAA 
               
               
                   
                   
                   
                   
                 AGGCAGATTCACCATCAGT 
               
               
                   
                   
                   
                   
                 GCAGACACATCCAAGGAAA 
               
               
                   
                   
                   
                   
                 CCGCATATCTTCAGATGAAT 
               
               
                   
                   
                   
                   
                 AGCCTGCGAGCGGAGGATA 
               
               
                   
                   
                   
                   
                 CCGCCGTCTATTATTGCGGA 
               
               
                   
                   
                   
                   
                 CGCTATGATTACGACGGTT 
               
               
                   
                   
                   
                   
                 ATTATGCTATGGACTACTGG 
               
               
                   
                   
                   
                   
                 GGCCAGGGCACACTTGTGA 
               
               
                   
                   
                   
                   
                 CCGTCAGTAGC 
               
               
                   
               
               
                 hROR1 VL_07 
                 359 
                 DIQMTQSPSSLSASVGDRVTITCRA 
                 360 
                 GACATTCAAATGACGCAAA 
               
               
                   
                   
                 SPDINSYVAWYQQKPGKAPKLLIYR 
                   
                 GCCCTAGTAGCTTGTCAGCT 
               
               
                   
                   
                 ANFLESGVPSRFSGSRSGTDFTLTIS 
                   
                 TCTGTGGGGGACCGTGTCA 
               
               
                   
                   
                 SLQPEDFATYYCLQYDEFPYTFGQG 
                   
                 CAATCACTTGTCGGGCCTCT 
               
               
                   
                   
                 TKVEIK 
                   
                 CCAGATATAAACTCCTACGT 
               
               
                   
                   
                   
                   
                 TGCTTGGTATCAGCAGAAG 
               
               
                   
                   
                   
                   
                 CCCGGAAAGGCTCCGAAAT 
               
               
                   
                   
                   
                   
                 TGTTGATTTATCGCGCTAAT 
               
               
                   
                   
                   
                   
                 TTCTTAGAGTCAGGAGTGC 
               
               
                   
                   
                   
                   
                 CCAGCCGGTTCTCAGGGTC 
               
               
                   
                   
                   
                   
                 TCGCTCTGGAACCGACTTCA 
               
               
                   
                   
                   
                   
                 CACTCACTATTTCTAGCCTA 
               
               
                   
                   
                   
                   
                 CAGCCTGAGGATTTTGCAA 
               
               
                   
                   
                   
                   
                 CTTACTACTGTCTACAGTAC 
               
               
                   
                   
                   
                   
                 GACGAGTTTCCGTACACTTT 
               
               
                   
                   
                   
                   
                 CGGACAGGGGACCAAGGT 
               
               
                   
                   
                   
                   
                 GGAGATCAAG 
               
               
                   
               
               
                 hROR1 VH_08 
                 361 
                 QVQLVQSGGGLVKPGGSLRLSCAA 
                 362 
                 CAAGTACAGCTCGTGCAGA 
               
               
                   
                   
                 SGFTFSSYAMSWVRQIPGKGLEW 
                   
                 GCGGCGGTGGCCTGGTGAA 
               
               
                   
                   
                 VSSISRGGTTYYPDSVKGRFTISRDN 
                   
                 GCCAGGAGGTAGTCTTAGA 
               
               
                   
                   
                 VKNTLYLQMSSLRAEDTAVYYCGR 
                   
                 CTGAGCTGTGCGGCTTCTG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTMVTVSS 
                   
                 GTTTCACGTTCAGCAGTTAT 
               
               
                   
                   
                   
                   
                 GCTATGTCCTGGGTTAGGC 
               
               
                   
                   
                   
                   
                 AAATCCCCGGCAAAGGATT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTTAGCAGTATC 
               
               
                   
                   
                   
                   
                 TCAAGGGGGGGAACCACAT 
               
               
                   
                   
                   
                   
                 ATTATCCTGACTCTGTCAAA 
               
               
                   
                   
                   
                   
                 GGACGGTTTACAATCAGCC 
               
               
                   
                   
                   
                   
                 GCGATAACGTTAAAAATAC 
               
               
                   
                   
                   
                   
                 CCTCTACCTCCAGATGTCTT 
               
               
                   
                   
                   
                   
                 CGCTCCGCGCTGAAGATAC 
               
               
                   
                   
                   
                   
                 AGCGGTTTACTACTGTGGC 
               
               
                   
                   
                   
                   
                 AGATACGACTACGACGGTT 
               
               
                   
                   
                   
                   
                 ATTACGCCATGGACTACTG 
               
               
                   
                   
                   
                   
                 GGGACAGGGAACTATGGTC 
               
               
                   
                   
                   
                   
                 ACAGTTAGCTCT 
               
               
                   
               
               
                 hROR1 VL_08 
                 363 
                 DIKMTQSPSSLSASVGDRVTITCKA 
                 364 
                 GACATCAAAATGACGCAGT 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKTLIYR 
                   
                 CACCTAGTAGCCTCTCCGCC 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 TCGGTTGGCGATCGGGTAA 
               
               
                   
                   
                 SSLQYEDMAIYYCLQYDEFPYTFGD 
                   
                 CCATTACCTGCAAAGCATCT 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCAGACATAAATAGTTATCT 
               
               
                   
                   
                   
                   
                 TAGTTGGTATCAACAGAAA 
               
               
                   
                   
                   
                   
                 CCTGGCAAAGCTCCTAAGA 
               
               
                   
                   
                   
                   
                 CCCTCATCTACCGCGCTAAC 
               
               
                   
                   
                   
                   
                 CGCCTCGTGGATGGTGTTC 
               
               
                   
                   
                   
                   
                 CAAGTCGGTTCTCAGGAAG 
               
               
                   
                   
                   
                   
                 CGGCAGTGGCACAGACTTT 
               
               
                   
                   
                   
                   
                 ACACTGACAATTAGTTCCCT 
               
               
                   
                   
                   
                   
                 CCAGTATGAGGATATGGCC 
               
               
                   
                   
                   
                   
                 ATATATTACTGCCTTCAGTA 
               
               
                   
                   
                   
                   
                 TGATGAGTTTCCATACACAT 
               
               
                   
                   
                   
                   
                 TCGGAGACGGTACAAAGGT 
               
               
                   
                   
                   
                   
                 GGAGATCAAG 
               
               
                   
               
               
                 hROR1 VH_09 
                 365 
                 QVSLRESGGGLVQPGRSLRLSCTAS 
                 366 
                 CAAGTGAGCCTCCGGGAGA 
               
               
                   
                   
                 GFTFSSYAMTWVRQAPGKGLEWV 
                   
                 GTGGGGGCGGTCTGGTCCA 
               
               
                   
                   
                 ASISRGGTTHFADSVKGRFTISRDN 
                   
                 ACCAGGACGGTCACTGCGG 
               
               
                   
                   
                 SNNTLYLQMDNVRDEDTAIYYCGR 
                   
                 CTGTCATGCACTGCCAGCG 
               
               
                   
                   
                 YDYDGYYAMDYWGRGTLVTVSS 
                   
                 GCTTCACATTTAGCTCTTAC 
               
               
                   
                   
                   
                   
                 GCCATGACTTGGGTCCGCC 
               
               
                   
                   
                   
                   
                 AAGCTCCCGGTAAGGGACT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTGGCCAGCATT 
               
               
                   
                   
                   
                   
                 AGCAGGGGTGGTACAACCC 
               
               
                   
                   
                   
                   
                 ACTTCGCGGATTCAGTTAA 
               
               
                   
                   
                   
                   
                 GGGGAGATTCACTATCTCC 
               
               
                   
                   
                   
                   
                 AGGGATAATTCCAACAACA 
               
               
                   
                   
                   
                   
                 CGCTGTACCTTCAGATGGAT 
               
               
                   
                   
                   
                   
                 AACGTGAGAGACGAGGATA 
               
               
                   
                   
                   
                   
                 CCGCGATATACTACTGTGG 
               
               
                   
                   
                   
                   
                 CCGCTATGACTACGATGGTT 
               
               
                   
                   
                   
                   
                 ATTATGCTATGGATTACTGG 
               
               
                   
                   
                   
                   
                 GGGCGGGGCACCCTGGTG 
               
               
                   
                   
                   
                   
                 ACTGTGTCCTCG 
               
               
                   
               
               
                 hROR1 VL_09 
                 367 
                 DIVMTQSPSSLSASVGDRVTITCRA 
                 368 
                 GATATCGTGATGACACAGT 
               
               
                   
                   
                 SPDINSYLAWYQQKPGKAPKLLIYR 
                   
                 CACCTAGCTCCCTGAGCGCA 
               
               
                   
                   
                 ANSLQSGVPSRFSGSGSGTEFTLTIS 
                   
                 AGCGTGGGGGATAGGGTT 
               
               
                   
                   
                 SLQPEDFATYYCLQYDEFPYTFGQG 
                   
                 ACCATAACTTGCAGGGCCA 
               
               
                   
                   
                 TKLEMK 
                   
                 GTCCCGACATCAATAGTTAT 
               
               
                   
                   
                   
                   
                 TTGGCCTGGTATCAACAGA 
               
               
                   
                   
                   
                   
                 AGCCTGGGAAGGCACCTAA 
               
               
                   
                   
                   
                   
                 GTTGCTTATTTATAGGGCTA 
               
               
                   
                   
                   
                   
                 ACTCGTTACAGAGCGGTGT 
               
               
                   
                   
                   
                   
                 GCCAAGTCGGTTCTCAGGC 
               
               
                   
                   
                   
                   
                 TCAGGGTCCGGGACCGAGT 
               
               
                   
                   
                   
                   
                 TCACCCTGACCATCAGTAGC 
               
               
                   
                   
                   
                   
                 TTGCAGCCAGAAGATTTTG 
               
               
                   
                   
                   
                   
                 CCACCTACTACTGTCTTCAA 
               
               
                   
                   
                   
                   
                 TACGATGAGTTTCCTTACAC 
               
               
                   
                   
                   
                   
                 TTTTGGACAGGGCACCAAA 
               
               
                   
                   
                   
                   
                 CTAGAGATGAAG 
               
               
                   
               
               
                 hROR1 VH_10 
                 369 
                 QVQLVESGGGVVQPGRSLRLSCAA 
                 370 
                 CAGGTTCAACTGGTAGAAT 
               
               
                   
                   
                 SGFTFSSYAMNWVRQAPAKGLEW 
                   
                 CCGGCGGAGGTGTAGTGCA 
               
               
                   
                   
                 VAIISRGGTQYYADSVKGRFTISRD 
                   
                 GCCTGGAAGGTCATTACGG 
               
               
                   
                   
                 NSKNTLYLQMNGLRAEDTAVYYCG 
                   
                 TTAAGTTGCGCCGCCTCCG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 GGTTCACATTTAGCAGCTAT 
               
               
                   
                   
                   
                   
                 GCTATGAACTGGGTGCGCC 
               
               
                   
                   
                   
                   
                 AGGCCCCTGCGAAAGGACT 
               
               
                   
                   
                   
                   
                 CGAATGGGTTGCCATCATC 
               
               
                   
                   
                   
                   
                 AGCCGAGGAGGCACACAGT 
               
               
                   
                   
                   
                   
                 ATTATGCCGATTCTGTGAAG 
               
               
                   
                   
                   
                   
                 GGTCGTTTTACTATTTCCAG 
               
               
                   
                   
                   
                   
                 AGACAACAGTAAAAATACG 
               
               
                   
                   
                   
                   
                 CTGTACCTGCAAATGAACG 
               
               
                   
                   
                   
                   
                 GATTGAGGGCTGAGGATAC 
               
               
                   
                   
                   
                   
                 CGCCGTGTACTACTGTGGA 
               
               
                   
                   
                   
                   
                 CGCTACGACTATGATGGGT 
               
               
                   
                   
                   
                   
                 ACTACGCGATGGACTATTG 
               
               
                   
                   
                   
                   
                 GGGGCAAGGAACCCTTGTA 
               
               
                   
                   
                   
                   
                 ACCGTTAGTTCA 
               
               
                   
               
               
                 hROR1 VL_10 
                 371 
                 EIVLTQSPDFQSVTPKEKVTITCRAS 
                 372 
                 GAGATCGTTTTGACACAGA 
               
               
                   
                   
                 PDINSYLSWYQQKPDQSPKLLIKRA 
                   
                 GCCCCGATTTCCAGAGCGT 
               
               
                   
                   
                 NQSFSGVPSRFSGSGSGTDFTLTIN 
                   
                 CACGCCCAAGGAGAAGGTC 
               
               
                   
                   
                 SLEAEDAAAYYCLQYDEFPYTFGPG 
                   
                 ACCATCACCTGCCGAGCCA 
               
               
                   
                   
                 TKVDIK 
                   
                 GCCCCGACATCAACAGTTAT 
               
               
                   
                   
                   
                   
                 CTTTCATGGTATCAACAGAA 
               
               
                   
                   
                   
                   
                 ACCTGATCAGAGCCCTAAG 
               
               
                   
                   
                   
                   
                 CTGCTGATTAAGCGCGCCA 
               
               
                   
                   
                   
                   
                 ACCAGAGCTTCTCAGGGGT 
               
               
                   
                   
                   
                   
                 TCCTTCACGGTTTTCCGGGT 
               
               
                   
                   
                   
                   
                 CAGGCAGCGGGACTGACTT 
               
               
                   
                   
                   
                   
                 CACGTTGACCATTAACTCTT 
               
               
                   
                   
                   
                   
                 TGGAGGCTGAGGATGCTGC 
               
               
                   
                   
                   
                   
                 TGCCTATTACTGCCTTCAGT 
               
               
                   
                   
                   
                   
                 ACGACGAGTTCCCCTATACA 
               
               
                   
                   
                   
                   
                 TTTGGTCCTGGAACAAAAG 
               
               
                   
                   
                   
                   
                 TGGATATAAAG 
               
               
                   
               
               
                 hROR1 VH_11 
                 373 
                 QVQLVQSGAEVKKPGASVKVSCKA 
                 374 
                 CAGGTGCAGCTCGTCCAGA 
               
               
                   
                   
                 SGFTFSSYAMHWVRQAPGQGLE 
                   
                 GCGGAGCCGAAGTGAAGA 
               
               
                   
                   
                 WMGNISRGGTTNYAEKFKNRVTM 
                   
                 AGCCGGGAGCATCAGTGAA 
               
               
                   
                   
                 TRDTSISTAYMELSRLRSDDTAVYY 
                   
                 AGTTTCCTGCAAAGCAAGT 
               
               
                   
                   
                 CGRYDYDGYYAMDYWGQGTLVT 
                   
                 GGCTTCACTTTCAGCAGTTA 
               
               
                   
                   
                 VSS 
                   
                 CGCGATGCACTGGGTGCGG 
               
               
                   
                   
                   
                   
                 CAGGCACCAGGTCAGGGAC 
               
               
                   
                   
                   
                   
                 TGGAATGGATGGGGAACAT 
               
               
                   
                   
                   
                   
                 CTCTCGCGGCGGAACAACC 
               
               
                   
                   
                   
                   
                 AATTACGCAGAGAAGTTTA 
               
               
                   
                   
                   
                   
                 AGAATCGCGTTACGATGAC 
               
               
                   
                   
                   
                   
                 CAGAGACACTTCTATTAGTA 
               
               
                   
                   
                   
                   
                 CAGCCTATATGGAGTTGTC 
               
               
                   
                   
                   
                   
                 GCGTCTGAGAAGCGACGAT 
               
               
                   
                   
                   
                   
                 ACCGCTGTCTACTATTGCGG 
               
               
                   
                   
                   
                   
                 CCGGTACGATTATGACGGC 
               
               
                   
                   
                   
                   
                 TACTATGCAATGGATTACTG 
               
               
                   
                   
                   
                   
                 GGGACAGGGCACACTTGTG 
               
               
                   
                   
                   
                   
                 ACAGTGTCTAGT 
               
               
                   
               
               
                 hROR1 VL_11 
                 375 
                 DIVMTQSPLSLPVTPGEPASISCRSS 
                 376 
                 GACATTGTGATGACTCAGT 
               
               
                   
                   
                 PDINSYLEWYLQKPGQSPQLLIYRA 
                   
                 CTCCACTCAGCCTGCCTGTC 
               
               
                   
                   
                 NDRFSGVPDRFSGSGSGTDFTLKIS 
                   
                 ACGCCCGGCGAACCCGCTT 
               
               
                   
                   
                 RVEAEDVGVYYCLQYDEFPYTFGQ 
                   
                 CTATCTCTTGTAGGAGTAGC 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCTGATATCAACAGCTACCT 
               
               
                   
                   
                   
                   
                 CGAATGGTATCTCCAGAAA 
               
               
                   
                   
                   
                   
                 CCTGGTCAGAGCCCCCAGC 
               
               
                   
                   
                   
                   
                 TCTTGATCTATAGAGCAAAC 
               
               
                   
                   
                   
                   
                 GACAGGTTCTCTGGCGTGC 
               
               
                   
                   
                   
                   
                 CTGATAGGTTTTCCGGTAGT 
               
               
                   
                   
                   
                   
                 GGCAGCGGAACCGACTTCA 
               
               
                   
                   
                   
                   
                 CACTTAAGATTTCAAGGGTC 
               
               
                   
                   
                   
                   
                 GAGGCCGAGGACGTGGGG 
               
               
                   
                   
                   
                   
                 GTGTATTACTGCTTACAGTA 
               
               
                   
                   
                   
                   
                 CGATGAGTTTCCGTATACAT 
               
               
                   
                   
                   
                   
                 TCGGGCAAGGCACAAAGGT 
               
               
                   
                   
                   
                   
                 GGAAATTAAG 
               
               
                   
               
               
                 hROR1 VH_12 
                 377 
                 EVQLVESGGGLVQPGGSLRLSCTG 
                 378 
                 GAAGTGCAACTGGTCGAAA 
               
               
                   
                   
                 SGFTFSSYAMHWLRQVPGEGLEW 
                   
                 GTGGAGGGGGACTAGTGC 
               
               
                   
                   
                 VSGISRGGTIDYADSVKGRFTISRD 
                   
                 AGCCCGGAGGGTCACTGAG 
               
               
                   
                   
                 DAKKTLSLQMNSLRAEDTAVYYCG 
                   
                 GCTATCATGCACCGGCTCTG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTMVTVSS 
                   
                 GTTTTACTTTTTCCAGCTAT 
               
               
                   
                   
                   
                   
                 GCCATGCACTGGCTCAGAC 
               
               
                   
                   
                   
                   
                 AGGTTCCGGGGGAAGGACT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTTAGCGGAATC 
               
               
                   
                   
                   
                   
                 TCCAGAGGCGGAACTATTG 
               
               
                   
                   
                   
                   
                 ACTACGCAGACAGCGTGAA 
               
               
                   
                   
                   
                   
                 AGGTAGGTTTACCATCAGC 
               
               
                   
                   
                   
                   
                 AGGGACGATGCTAAAAAGA 
               
               
                   
                   
                   
                   
                 CCCTGTCACTTCAAATGAAT 
               
               
                   
                   
                   
                   
                 AGCCTGAGAGCTGAGGATA 
               
               
                   
                   
                   
                   
                 CGGCCGTGTATTACTGTGG 
               
               
                   
                   
                   
                   
                 ACGCTATGACTACGATGGA 
               
               
                   
                   
                   
                   
                 TATTACGCAATGGACTACTG 
               
               
                   
                   
                   
                   
                 GGGCCAGGGAACAATGGT 
               
               
                   
                   
                   
                   
                 GACCGTCTCAAGC 
               
               
                   
               
               
                 hROR1 VL_12 
                 379 
                 EIVLTQSPATLSVSPGERATLSCRAS 
                 380 
                 GAGATCGTCCTGACCCAGA 
               
               
                   
                   
                 PDINSYLAWYQQKPGQAPRLLFSR 
                   
                 GCCCAGCTACTTTGTCAGTT 
               
               
                   
                   
                 ANNRATGIPARFTGSGSGTDFTLTI 
                   
                 TCGCCAGGCGAGCGGGCCA 
               
               
                   
                   
                 SSLEPEDFAIYYCLQYDEFPYTFGQG 
                   
                 CACTGAGCTGTAGGGCTTC 
               
               
                   
                   
                 TKVEIK 
                   
                 TCCTGATATCAATTCTTACC 
               
               
                   
                   
                   
                   
                 TGGCCTGGTATCAACAGAA 
               
               
                   
                   
                   
                   
                 ACCGGGACAGGCCCCTCGC 
               
               
                   
                   
                   
                   
                 CTGCTGTTCTCCCGCGCCAA 
               
               
                   
                   
                   
                   
                 CAATAGGGCGACTGGCATA 
               
               
                   
                   
                   
                   
                 CCAGCTCGGTTTACTGGGA 
               
               
                   
                   
                   
                   
                 GTGGGTCAGGCACTGATTT 
               
               
                   
                   
                   
                   
                 CACGCTTACAATCAGTAGCC 
               
               
                   
                   
                   
                   
                 TGGAGCCCGAAGACTTCGC 
               
               
                   
                   
                   
                   
                 CATCTACTACTGTTTACAAT 
               
               
                   
                   
                   
                   
                 ACGATGAGTTCCCCTATACC 
               
               
                   
                   
                   
                   
                 TTCGGCCAAGGGACCAAGG 
               
               
                   
                   
                   
                   
                 TGGAGATCAAG 
               
               
                   
               
               
                 hROR1 VH_13 
                 381 
                 EVQLVESGGGVVQPGRSLRLSCAA 
                 382 
                 GAAGTGCAGCTAGTAGAAA 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 GTGGTGGTGGGGTCGTGCA 
               
               
                   
                   
                 VASISRGGTQYYADSVKGRFTISRD 
                   
                 GCCAGGCCGCTCGCTCAGG 
               
               
                   
                   
                 NSKNTLYLQMNGLRAEDTAVYYCG 
                   
                 CTGTCTTGCGCTGCGAGTG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 GTTTCACATTCTCTTCATAC 
               
               
                   
                   
                   
                   
                 GCCATGAGCTGGGTGAGAC 
               
               
                   
                   
                   
                   
                 AGGCTCCCGGCAAGGGCCT 
               
               
                   
                   
                   
                   
                 CGAATGGGTCGCATCTATA 
               
               
                   
                   
                   
                   
                 AGCAGAGGCGGAACCCAGT 
               
               
                   
                   
                   
                   
                 ACTACGCTGACAGTGTGAA 
               
               
                   
                   
                   
                   
                 GGGTCGCTTTACAATCTCAC 
               
               
                   
                   
                   
                   
                 GGGACAACAGTAAAAACAC 
               
               
                   
                   
                   
                   
                 CCTCTATCTACAGATGAATG 
               
               
                   
                   
                   
                   
                 GCTTGCGAGCTGAAGACAC 
               
               
                   
                   
                   
                   
                 GGCTGTGTATTATTGCGGG 
               
               
                   
                   
                   
                   
                 CGCTATGACTATGATGGTTA 
               
               
                   
                   
                   
                   
                 CTACGCTATGGATTACTGG 
               
               
                   
                   
                   
                   
                 GGCCAGGGCACCCTGGTTA 
               
               
                   
                   
                   
                   
                 CTGTTTCATCA 
               
               
                   
               
               
                 hROR1 VL_13 
                 383 
                 EIVLTQSPDFQSVTPKEKVTITCRAS 
                 384 
                 GAAATAGTCCTGACCCAGA 
               
               
                   
                   
                 PDINSYLPWYQQKPDQSPKLLIKRA 
                   
                 GCCCAGACTTCCAGTCCGT 
               
               
                   
                   
                 NQSFSGVPSRFSGSGSGTDFTLTIN 
                   
                 GACCCCTAAGGAGAAGGTT 
               
               
                   
                   
                 SLEAEDAAAYYCLQYDEFPYTFGPG 
                   
                 ACTATCACTTGCAGGGCAA 
               
               
                   
                   
                 TKVDIK 
                   
                 GCCCTGACATAAATTCATAC 
               
               
                   
                   
                   
                   
                 CTGCCATGGTATCAGCAGA 
               
               
                   
                   
                   
                   
                 AGCCAGACCAGTCGCCGAA 
               
               
                   
                   
                   
                   
                 GCTATTAATCAAACGCGCCA 
               
               
                   
                   
                   
                   
                 ACCAGTCTTTTAGCGGCGTA 
               
               
                   
                   
                   
                   
                 CCATCCCGATTCTCAGGTTC 
               
               
                   
                   
                   
                   
                 GGGGTCCGGGACCGATTTC 
               
               
                   
                   
                   
                   
                 ACACTCACGATAAACTCCCT 
               
               
                   
                   
                   
                   
                 TGAGGCAGAGGATGCAGC 
               
               
                   
                   
                   
                   
                 GGCTTACTACTGTTTACAGT 
               
               
                   
                   
                   
                   
                 ACGACGAGTTTCCATATACG 
               
               
                   
                   
                   
                   
                 TTCGGCCCCGGCACGAAGG 
               
               
                   
                   
                   
                   
                 TAGATATCAAG 
               
               
                   
               
               
                 hROR1 VH_14 
                 385 
                 EVQLVESGGGLVQPGGSLRLSCAT 
                 386 
                 GAAGTGCAGCTGGTGGAGT 
               
               
                   
                   
                 SGFTFSSYAMSWMRQAPGKGLE 
                   
                 CTGGCGGCGGTCTGGTGCA 
               
               
                   
                   
                 WVASISRGGTTYYADSVKGRFTISV 
                   
                 GCCCGGCGGCTCTCTGCGC 
               
               
                   
                   
                 DKSKNTLYLQMNSLRAEDTAVYYC 
                   
                 CTCTCCTGTGCCACCTCTGG 
               
               
                   
                   
                 GRYDYDGYYAMDYWGQGTLVTVSS 
                   
                 TTTTACATTCTCCTCCTACGC 
               
               
                   
                   
                   
                   
                 TATGTCCTGGATGCGGCAA 
               
               
                   
                   
                   
                   
                 GCCCCCGGCAAGGGCCTAG 
               
               
                   
                   
                   
                   
                 AGTGGGTCGCCTCAATCAG 
               
               
                   
                   
                   
                   
                 CAGGGGCGGGACGACTTAT 
               
               
                   
                   
                   
                   
                 TATGCCGATTCAGTTAAGG 
               
               
                   
                   
                   
                   
                 GGAGATTCACAATTTCCGT 
               
               
                   
                   
                   
                   
                 GGATAAATCCAAGAATACC 
               
               
                   
                   
                   
                   
                 TTATACCTCCAGATGAACTC 
               
               
                   
                   
                   
                   
                 TCTGCGGGCCGAAGATACG 
               
               
                   
                   
                   
                   
                 GCCGTATATTATTGTGGGA 
               
               
                   
                   
                   
                   
                 GGTATGACTACGACGGATA 
               
               
                   
                   
                   
                   
                 TTACGCCATGGATTATTGG 
               
               
                   
                   
                   
                   
                 GGGCAGGGGACACTTGTTA 
               
               
                   
                   
                   
                   
                 CAGTGAGTTCC 
               
               
                   
               
               
                 hROR1 VL_14 
                 387 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 388 
                 GATATACAGATGACACAGA 
               
               
                   
                   
                 SPDINSYLNWYQQKPGKAPKLLIYR 
                   
                 GCCCTTCAAGTTTATCTGCA 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDYTLTI 
                   
                 AGCGTCGGCGATCGTGTTA 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGA 
                   
                 CAATAACTTGCAAGGCATCT 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCCGACATCAATTCCTACCT 
               
               
                   
                   
                   
                   
                 CAACTGGTATCAGCAGAAG 
               
               
                   
                   
                   
                   
                 CCTGGGAAGGCTCCTAAGC 
               
               
                   
                   
                   
                   
                 TGCTTATTTACAGAGCAAAT 
               
               
                   
                   
                   
                   
                 CGCCTGGTGGACGGCGTGC 
               
               
                   
                   
                   
                   
                 CCAGTCGGTTTTCCGGGTCT 
               
               
                   
                   
                   
                   
                 GGGAGCGGAACGGATTACA 
               
               
                   
                   
                   
                   
                 CACTGACCATCTCAAGCCTG 
               
               
                   
                   
                   
                   
                 CAACCCGAAGACTTCGCTAC 
               
               
                   
                   
                   
                   
                 ATATTACTGCCTTCAGTATG 
               
               
                   
                   
                   
                   
                 ATGAGTTCCCATATACCTTC 
               
               
                   
                   
                   
                   
                 GGCGCTGGGACCAAGGTG 
               
               
                   
                   
                   
                   
                 GAGATAAAG 
               
               
                   
               
               
                 hROR1 
                 389 
                 EVQLVESGGGLVQPGGSLRLSCASS 
                 390 
                 GAGGTCCAGCTCGTCGAAT 
               
               
                 VH_14-1 
                   
                 GFTFSSYAMSWRRQAPGKGLEWV 
                   
                 CTGGCGGAGGTTTAGTGCA 
               
               
                   
                   
                 AGISRGGTTSYADSVKGRFTISSDD 
                   
                 ACCAGGCGGGTCGCTCCGA 
               
               
                   
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 TTAAGTTGTGCGTCCAGTG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTCACCTTCTCCAGCTAC 
               
               
                   
                   
                   
                   
                 GCCATGTCGTGGAGGCGAC 
               
               
                   
                   
                   
                   
                 AGGCTCCTGGCAAAGGCTT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTTGCTGGTATC 
               
               
                   
                   
                   
                   
                 TCCCGAGGAGGCACCACTA 
               
               
                   
                   
                   
                   
                 GTTACGCTGACAGTGTAAA 
               
               
                   
                   
                   
                   
                 AGGACGTTTCACTATTTCCT 
               
               
                   
                   
                   
                   
                 CTGACGACAGCAAGAACAC 
               
               
                   
                   
                   
                   
                 ACTCTATCTGCAAATGAATA 
               
               
                   
                   
                   
                   
                 GTCTCCGTGCTGAGGACAC 
               
               
                   
                   
                   
                   
                 AGCCGTGTATTATTGCGGG 
               
               
                   
                   
                   
                   
                 CGGTATGATTACGACGGCT 
               
               
                   
                   
                   
                   
                 ACTACGCTATGGACTACTG 
               
               
                   
                   
                   
                   
                 GGGCCAGGGAACTCTGGTC 
               
               
                   
                   
                   
                   
                 ACTGTGAGCTCT 
               
               
                   
               
               
                 hROR1 
                 391 
                 DIQMTQSPSSLSASVGDRVTITCRA 
                 392 
                 GATATACAGATGACTCAAA 
               
               
                 VL 14-1 
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 GTCCTAGCTCCTTGAGCGCC 
               
               
                   
                   
                 ANTLESGVPSRFSGSGSGTDFTLTIS 
                   
                 TCAGTGGGAGATCGGGTCA 
               
               
                   
                   
                 SLQPEDFATYYCLQYDEFPYTFGQG 
                   
                 CTATAACTTGTAGAGCCTCA 
               
               
                   
                   
                 TKIEIK 
                   
                 CCAGATATAAACTCCTATCT 
               
               
                   
                   
                   
                   
                 CTCTTGGTATCAGCAGAAG 
               
               
                   
                   
                   
                   
                 CCCGGCAAAGCACCAAAGC 
               
               
                   
                   
                   
                   
                 TCTTGATCTATAGAGCTAAT 
               
               
                   
                   
                   
                   
                 ACGCTAGAGAGCGGAGTGC 
               
               
                   
                   
                   
                   
                 CTTCACGGTTTTCTGGTTCC 
               
               
                   
                   
                   
                   
                 GGGAGCGGAACCGACTTTA 
               
               
                   
                   
                   
                   
                 CCCTTACAATTTCTAGCCTC 
               
               
                   
                   
                   
                   
                 CAGCCAGAGGACTTCGCAA 
               
               
                   
                   
                   
                   
                 CTTACTATTGTCTCCAGTAT 
               
               
                   
                   
                   
                   
                 GATGAATTTCCTTACACCTT 
               
               
                   
                   
                   
                   
                 CGGCCAAGGGACCAAGATC 
               
               
                   
                   
                   
                   
                 GAGATAAAG 
               
               
                   
               
               
                 hROR1 
                 393 
                 EVQLVESGGGLVQPGGSLRLSCASS 
                 394 
                 GAGGTGCAGCTCGTTGAGT 
               
               
                 VH_14-2 
                   
                 GFTFSSYAMSWVRQAPGKGLEWV 
                   
                 CCGGTGGGGGGCTGGTGC 
               
               
                   
                   
                 AGISRGGTTSYADSVKGRFTISADT 
                   
                 AGCCTGGCGGGTCTCTCCG 
               
               
                   
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 CCTCTCTTGTGCCTCCTCCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTTACCTTCAGCAGCTAT 
               
               
                   
                   
                   
                   
                 GCTATGTCATGGGTGCGGC 
               
               
                   
                   
                   
                   
                 AGGCACCAGGCAAAGGTCT 
               
               
                   
                   
                   
                   
                 GGAATGGGTCGCTGGGATC 
               
               
                   
                   
                   
                   
                 AGTAGAGGCGGCACAACCT 
               
               
                   
                   
                   
                   
                 CCTATGCCGACAGCGTTAA 
               
               
                   
                   
                   
                   
                 GGGGAGGTTCACAATCTCG 
               
               
                   
                   
                   
                   
                 GCTGATACAAGCAAGAACA 
               
               
                   
                   
                   
                   
                 CTCTGTATCTCCAAATGAAC 
               
               
                   
                   
                   
                   
                 AGTCTCCGGGCAGAGGACA 
               
               
                   
                   
                   
                   
                 CCGCGGTCTATTACTGCGG 
               
               
                   
                   
                   
                   
                 CCGGTACGACTACGACGGG 
               
               
                   
                   
                   
                   
                 TACTACGCAATGGACTATTG 
               
               
                   
                   
                   
                   
                 GGGACAGGGAACTCTGGTT 
               
               
                   
                   
                   
                   
                 ACTGTCAGCTCT 
               
               
                   
               
               
                 hROR1 
                 395 
                 DIQMTQSPSSLSASVGDRVTITCRA 
                 396 
                 GATATCCAGATGACTCAAA 
               
               
                 VL_14-2 
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 GCCCATCTTCTCTCAGCGCA 
               
               
                   
                   
                 ANTLESGVPSRFSGSGSGTDFTLTIS 
                   
                 AGCGTGGGTGACCGAGTGA 
               
               
                   
                   
                 SLQPEDFATYYCLQYDEFPYTFGTG 
                   
                 CCATCACCTGCCGGGCGTCT 
               
               
                   
                   
                 TKLEIK 
                   
                 CCTGATATCAACTCATACCT 
               
               
                   
                   
                   
                   
                 GTCCTGGTATCAGCAGAAG 
               
               
                   
                   
                   
                   
                 CCCGGAAAGGCCCCTAAGC 
               
               
                   
                   
                   
                   
                 TGCTGATCTACCGCGCAAAT 
               
               
                   
                   
                   
                   
                 ACACTGGAGAGCGGGGTCC 
               
               
                   
                   
                   
                   
                 CAAGCAGATTCAGTGGGTC 
               
               
                   
                   
                   
                   
                 CGGCAGTGGTACGGACTTT 
               
               
                   
                   
                   
                   
                 ACTCTGACCATCAGCTCCCT 
               
               
                   
                   
                   
                   
                 GCAACCGGAGGACTTTGCT 
               
               
                   
                   
                   
                   
                 ACTTATTACTGTCTCCAGTA 
               
               
                   
                   
                   
                   
                 CGACGAGTTCCCATACACTT 
               
               
                   
                   
                   
                   
                 TCGGAACAGGCACTAAGCT 
               
               
                   
                   
                   
                   
                 GGAGATCAAA 
               
               
                   
               
               
                 hROR1 
                 397 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 398 
                 GAGGTTCAACTTGTGGAAT 
               
               
                 VH_14-3 
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CCGGCGGCGGGTTAGTCCA 
               
               
                   
                   
                 VASISRGGTTYYADSVKGRFTISRD 
                   
                 GCCCGGCGGGAGCTTGCGG 
               
               
                   
                   
                 NSKNTLYLQMNSLRAEDTAVYYCG 
                   
                 CTGTCCTGCGCCGCCTCTGG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 ATTCACTTTTAGCTCCTATG 
               
               
                   
                   
                   
                   
                 CTATGTCTTGGGTAAGGCA 
               
               
                   
                   
                   
                   
                 GGCCCCTGGTAAAGGACTA 
               
               
                   
                   
                   
                   
                 GAGTGGGTGGCCTCGATCT 
               
               
                   
                   
                   
                   
                 CCCGTGGTGGCACTACATA 
               
               
                   
                   
                   
                   
                 CTACGCCGACTCCGTTAAAG 
               
               
                   
                   
                   
                   
                 GCCGGTTTACCATCTCCCGT 
               
               
                   
                   
                   
                   
                 GACAACTCTAAAAATACTTT 
               
               
                   
                   
                   
                   
                 GTACCTGCAAATGAACTCCC 
               
               
                   
                   
                   
                   
                 TGCGGGCAGAAGACACAGC 
               
               
                   
                   
                   
                   
                 CGTGTACTATTGCGGGCGT 
               
               
                   
                   
                   
                   
                 TACGATTACGACGGATATTA 
               
               
                   
                   
                   
                   
                 CGCAATGGACTACTGGGGC 
               
               
                   
                   
                   
                   
                 CAGGGCACACTGGTCACCG 
               
               
                   
                   
                   
                   
                 TGAGCAGC 
               
               
                   
               
               
                 hROR1 
                 399 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 400 
                 GATATACAAATGACTCAGTC 
               
               
                 VL_14-3 
                   
                 SPDINSYLNWYQQKPGKAPKLLIYR 
                   
                 CCCTAGTAGCCTTAGTGCTA 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 GTGTGGGAGACAGAGTGAC 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGG 
                   
                 CATCACCTGCAAAGCATCTC 
               
               
                   
                   
                 GTKVEIK 
                   
                 CTGATATCAATTCCTACCTT 
               
               
                   
                   
                   
                   
                 AACTGGTATCAACAGAAGC 
               
               
                   
                   
                   
                   
                 CTGGCAAAGCTCCAAAGCT 
               
               
                   
                   
                   
                   
                 CCTGATTTATCGCGCGAACA 
               
               
                   
                   
                   
                   
                 GATTGGTCGATGGGGTCCC 
               
               
                   
                   
                   
                   
                 TTCCAGATTCAGCGGCTCA 
               
               
                   
                   
                   
                   
                 GGGTCAGGGACCGATTTCA 
               
               
                   
                   
                   
                   
                 CCCTCACAATTAGTTCACTT 
               
               
                   
                   
                   
                   
                 CAGCCCGAGGACATCGCCA 
               
               
                   
                   
                   
                   
                 CGTATTATTGCCTTCAGTAC 
               
               
                   
                   
                   
                   
                 GATGAGTTCCCTTACACCTT 
               
               
                   
                   
                   
                   
                 TGGCGGGGGAACTAAAGTC 
               
               
                   
                   
                   
                   
                 GAAATTAAG 
               
               
                   
               
               
                 hROR1 
                 401 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 402 
                 GAAGTGCAGCTTGTGGAGT 
               
               
                 VH_14-4 
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CAGGAGGAGGGCTAGTTCA 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 GCCAGGCGGCTCTCTGAGA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 CTATCTTGTGCTGCCTCCGG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 CTTCACATTTAGCTCTTATG 
               
               
                   
                   
                   
                   
                 CAATGTCCTGGGTCCGCCA 
               
               
                   
                   
                   
                   
                 GGCCCCTGGTAAAGGCCTG 
               
               
                   
                   
                   
                   
                 GAATGGGTTGCTTCTATCTC 
               
               
                   
                   
                   
                   
                 TAGAGGCGGAACCACTTAC 
               
               
                   
                   
                   
                   
                 TACCCTGATTCAGTGAAGG 
               
               
                   
                   
                   
                   
                 GGAGATTCACAATTAGTAG 
               
               
                   
                   
                   
                   
                 GGACAACGTGCGGAACATC 
               
               
                   
                   
                   
                   
                 CTCTACCTACAGATGTCAAG 
               
               
                   
                   
                   
                   
                 TTTACGCAGTGAGGACACT 
               
               
                   
                   
                   
                   
                 GCGATGTATTACTGCGGTC 
               
               
                   
                   
                   
                   
                 GATACGATTATGATGGATA 
               
               
                   
                   
                   
                   
                 TTATGCAATGGATTATTGG 
               
               
                   
                   
                   
                   
                 GGCCAGGGCACTCTGGTCA 
               
               
                   
                   
                   
                   
                 CAGTATCTTCC 
               
               
                   
               
               
                 hROR1 
                 403 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 404 
                 GACATCCAGATGACCCAAT 
               
               
                 VL_14-4 
                   
                 SPDINSYLNWYQQKPGKAPKLLIYR 
                   
                 CACCATCGAGTCTTAGTGCA 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDYTLTI 
                   
                 TCCGTTGGGGATAGAGTGA 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGA 
                   
                 CAATCACTTGTAAGGCATCC 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCGGACATCAACTCATATCT 
               
               
                   
                   
                   
                   
                 TAATTGGTATCAGCAAAAG 
               
               
                   
                   
                   
                   
                 CCGGGCAAGGCCCCTAAGC 
               
               
                   
                   
                   
                   
                 TCCTGATTTATAGGGCCAAC 
               
               
                   
                   
                   
                   
                 CGCCTTGTGGATGGAGTCC 
               
               
                   
                   
                   
                   
                 CCTCCCGCTTTAGTGGAAGC 
               
               
                   
                   
                   
                   
                 GGCTCTGGCACAGACTACA 
               
               
                   
                   
                   
                   
                 CCCTGACTATCAGCTCCTTG 
               
               
                   
                   
                   
                   
                 CAGCCTGAGGATTTTGCTAC 
               
               
                   
                   
                   
                   
                 CTACTACTGTCTTCAGTACG 
               
               
                   
                   
                   
                   
                 ATGAATTTCCATACACTTTC 
               
               
                   
                   
                   
                   
                 GGTGCTGGGACAAAAGTGG 
               
               
                   
                   
                   
                   
                 AGATCAAA 
               
               
                   
               
               
                 hROR1 
                 405 
                 EVQLVESGGGLVQPGGSLRLSCAT 
                 406 
                 GAAGTCCAGCTGGTTGAGT 
               
               
                 VH_14-5 
                   
                 SGFTFSSYAMSWMRKAPGKGLEY 
                   
                 CTGGCGGAGGCCTCGTGCA 
               
               
                   
                   
                 VASISRGGTTYYADSVKGRFTISVDK 
                   
                 GCCCGGTGGTTCCTTGCGA 
               
               
                   
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 CTGTCATGCGCTACCAGCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GGTTCACATTCAGCTCTTAT 
               
               
                   
                   
                   
                   
                 GCAATGTCCTGGATGCGGA 
               
               
                   
                   
                   
                   
                 AGGCACCGGGTAAGGGCCT 
               
               
                   
                   
                   
                   
                 GGAGTATGTGGCCTCAATC 
               
               
                   
                   
                   
                   
                 TCCCGAGGAGGCACCACAT 
               
               
                   
                   
                   
                   
                 ACTATGCCGATTCTGTGAAA 
               
               
                   
                   
                   
                   
                 GGCCGATTCACCATTTCTGT 
               
               
                   
                   
                   
                   
                 GGATAAGTCTAAAAACACT 
               
               
                   
                   
                   
                   
                 CTCTACCTCCAGATGAACTC 
               
               
                   
                   
                   
                   
                 CCTACGTGCCGAAGACACA 
               
               
                   
                   
                   
                   
                 GCCGTGTATTATTGCGGGC 
               
               
                   
                   
                   
                   
                 GATACGATTATGACGGTTA 
               
               
                   
                   
                   
                   
                 TTATGCGATGGATTACTGG 
               
               
                   
                   
                   
                   
                 GGTCAAGGCACACTGGTAA 
               
               
                   
                   
                   
                   
                 CAGTGTCTTCC 
               
               
                   
               
               
                 hROR1 
                 407 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 408 
                 GATATTCAGATGACACAATC 
               
               
                 VL_14-5 
                   
                 SPDINSYLNWYQQKPGKAPKLLIYR 
                   
                 ACCTAGCTCACTGTCAGCGA 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDYTLTI 
                   
                 GCGTCGGTGACCGGGTTAC 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGA 
                   
                 TATCACATGCAAAGCCTCAC 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCGATATCAATTCATACCTT 
               
               
                   
                   
                   
                   
                 AACTGGTATCAACAAAAAC 
               
               
                   
                   
                   
                   
                 CAGGAAAGGCTCCAAAGCT 
               
               
                   
                   
                   
                   
                 GCTAATTTATCGGGCCAATC 
               
               
                   
                   
                   
                   
                 GGTTGGTGGATGGCGTCCC 
               
               
                   
                   
                   
                   
                 GTCGAGGTTTAGTGGCTCC 
               
               
                   
                   
                   
                   
                 GGGAGCGGGACAGACTAC 
               
               
                   
                   
                   
                   
                 ACTCTTACAATTTCTTCTCTC 
               
               
                   
                   
                   
                   
                 CAGCCAGAGGACTTCGCAA 
               
               
                   
                   
                   
                   
                 CCTACTACTGCTTGCAGTAC 
               
               
                   
                   
                   
                   
                 GATGAATTTCCATATACCTT 
               
               
                   
                   
                   
                   
                 CGGCGCAGGGACAAAAGT 
               
               
                   
                   
                   
                   
                 GGAAATCAAA 
               
               
                   
               
               
                 hROR1 VH_15 
                 409 
                 EVQLVESGGGLVQPGGSLRLSCVTS 
                 410 
                 GAGGTGCAGCTTGTAGAAA 
               
               
                   
                   
                 GFTFSSYAMSWVRQAPGKGLEWV 
                   
                 GCGGGGGGGGCCTGGTGC 
               
               
                   
                   
                 ASISRGGTTYYSDSVKGRFTISRDNS 
                   
                 AACCTGGCGGGTCCCTGCG 
               
               
                   
                   
                 KNTLYLQMNSLRAEDTAVYYCGRY 
                   
                 GCTTAGTTGCGTTACGAGC 
               
               
                   
                   
                 DYDGYYAMDYWGQGTLVTVSS 
                   
                 GGATTTACATTTTCCAGTTA 
               
               
                   
                   
                   
                   
                 TGCCATGTCTTGGGTGAGA 
               
               
                   
                   
                   
                   
                 CAAGCCCCCGGTAAGGGTC 
               
               
                   
                   
                   
                   
                 TGGAGTGGGTGGCAAGCAT 
               
               
                   
                   
                   
                   
                 TAGCCGAGGCGGCACTACA 
               
               
                   
                   
                   
                   
                 TACTACAGTGATAGTGTGA 
               
               
                   
                   
                   
                   
                 AAGGCCGTTTCACAATCAGT 
               
               
                   
                   
                   
                   
                 AGAGATAATTCTAAAAACA 
               
               
                   
                   
                   
                   
                 CCCTGTACTTGCAGATGAAC 
               
               
                   
                   
                   
                   
                 AGCCTGCGCGCCGAGGATA 
               
               
                   
                   
                   
                   
                 CAGCCGTGTACTACTGTGG 
               
               
                   
                   
                   
                   
                 AAGATACGACTACGATGGA 
               
               
                   
                   
                   
                   
                 TATTATGCGATGGATTACTG 
               
               
                   
                   
                   
                   
                 GGGACAGGGAACCCTTGTC 
               
               
                   
                   
                   
                   
                 ACCGTTTCCTCT 
               
               
                   
               
               
                 hROR1 VL_15 
                 411 
                 DIVLTQSPATLSLSPGERATLSCKAS 
                 412 
                 GACATAGTGTTGACGCAGT 
               
               
                   
                   
                 PDINSYMNWYQQKPGQAPRLLISR 
                   
                 CCCCTGCCACCCTGAGCCTG 
               
               
                   
                   
                 ANRLVDGVPARFSGSGSGTDFTLTI 
                   
                 AGCCCCGGAGAGCGAGCAA 
               
               
                   
                   
                 SSLEPEDFAVYYCLQYDEFPYTFGQ 
                   
                 CGTTAAGTTGCAAGGCCAG 
               
               
                   
                   
                 GTKVEIK 
                   
                 TCCAGATATTAACTCATACA 
               
               
                   
                   
                   
                   
                 TGAATTGGTATCAACAGAA 
               
               
                   
                   
                   
                   
                 ACCAGGCCAGGCTCCTAGA 
               
               
                   
                   
                   
                   
                 CTTCTCATATCTCGGGCAAA 
               
               
                   
                   
                   
                   
                 TCGACTGGTGGATGGAGTA 
               
               
                   
                   
                   
                   
                 CCCGCAAGATTCAGCGGCA 
               
               
                   
                   
                   
                   
                 GCGGCAGCGGAACGGATTT 
               
               
                   
                   
                   
                   
                 CACGCTCACCATCTCTTCCC 
               
               
                   
                   
                   
                   
                 TTGAGCCTGAGGACTTTGC 
               
               
                   
                   
                   
                   
                 AGTCTATTATTGCTTGCAGT 
               
               
                   
                   
                   
                   
                 ATGATGAGTTCCCCTACACA 
               
               
                   
                   
                   
                   
                 TTCGGGCAAGGCACAAAAG 
               
               
                   
                   
                   
                   
                 TGGAAATTAAG 
               
               
                   
               
               
                 hROR1 VH_16 
                 413 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 414 
                 GAGGTGCAGCTGGTGGAG 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 AGCGGAGGGGGCCTTGTCC 
               
               
                   
                   
                 VASISRGGTTYYDPKFQDRATISAD 
                   
                 AACCAGGAGGTAGCCTCAG 
               
               
                   
                   
                 NSKNTAYLQMNSLRAEDTAVYYCG 
                   
                 GCTGTCTTGCGCTGCCTCAG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 GATTTACTTTTTCATCCTAC 
               
               
                   
                   
                   
                   
                 GCAATGAGCTGGGTGCGGC 
               
               
                   
                   
                   
                   
                 AAGCCCCAGGGAAGGGATT 
               
               
                   
                   
                   
                   
                 AGAATGGGTTGCCAGCATT 
               
               
                   
                   
                   
                   
                 TCTAGGGGGGGGACGACCT 
               
               
                   
                   
                   
                   
                 ACTACGATCCGAAGTTTCAG 
               
               
                   
                   
                   
                   
                 GATCGCGCCACTATCTCAGC 
               
               
                   
                   
                   
                   
                 CGATAACTCCAAGAATACT 
               
               
                   
                   
                   
                   
                 GCCTACTTACAGATGAACA 
               
               
                   
                   
                   
                   
                 GCCTGCGGGCCGAAGACAC 
               
               
                   
                   
                   
                   
                 GGCCGTCTACTATTGCGGC 
               
               
                   
                   
                   
                   
                 CGATATGATTACGACGGCT 
               
               
                   
                   
                   
                   
                 ATTACGCCATGGATTACTG 
               
               
                   
                   
                   
                   
                 GGGGCAAGGGACTCTGGTC 
               
               
                   
                   
                   
                   
                 ACAGTGAGCTCT 
               
               
                   
               
               
                 hROR1 VL_16 
                 415 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 416 
                 GATATTCAGATGACCCAGTC 
               
               
                   
                   
                 SPDINSYLNWYQQKPGKAPKVLIYR 
                   
                 GCCCAGCAGTCTCTCGGCCT 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDYTLTI 
                   
                 CAGTGGGCGACCGGGTCAC 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGQ 
                   
                 TATCACTTGCAAAGCAAGTC 
               
               
                   
                   
                 GTKVEIK 
                   
                 CTGATATAAACTCCTATCTT 
               
               
                   
                   
                   
                   
                 AATTGGTATCAGCAGAAGC 
               
               
                   
                   
                   
                   
                 CCGGCAAGGCACCTAAGGT 
               
               
                   
                   
                   
                   
                 TCTGATATATCGCGCAAATC 
               
               
                   
                   
                   
                   
                 GGCTCGTGGATGGAGTACC 
               
               
                   
                   
                   
                   
                 CAGCCGATTTTCCGGCAGC 
               
               
                   
                   
                   
                   
                 GGCTCAGGCACTGACTACA 
               
               
                   
                   
                   
                   
                 CACTGACAATCAGCAGCTT 
               
               
                   
                   
                   
                   
                 GCAGCCTGAAGATTTCGCC 
               
               
                   
                   
                   
                   
                 ACATACTATTGTCTACAGTA 
               
               
                   
                   
                   
                   
                 CGACGAGTTCCCTTATACAT 
               
               
                   
                   
                   
                   
                 TCGGCCAGGGGACCAAGGT 
               
               
                   
                   
                   
                   
                 CGAGATCAAG 
               
               
                   
               
               
                 hROR1 VH_17 
                 417 
                 EVQLVESGGGLVQPGGSLRLSCTG 
                 418 
                 GAGGTCCAACTCGTGGAGA 
               
               
                   
                   
                 SGFTFSSYAMSWLRQVPGEGLEW 
                   
                 GCGGAGGGGGGCTAGTGC 
               
               
                   
                   
                 VSSISRGGTTDYADSVKGRFTISRD 
                   
                 AACCAGGTGGCTCCCTCCG 
               
               
                   
                   
                 DAKKTLSLQMNSLRAEDTAVYYCG 
                   
                 CTTGTCCTGTACGGGCTCG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTMVTVSS 
                   
                 GGGTTCACATTTTCATCCTA 
               
               
                   
                   
                   
                   
                 TGCCATGAGCTGGCTGAGA 
               
               
                   
                   
                   
                   
                 CAGGTGCCTGGCGAGGGCC 
               
               
                   
                   
                   
                   
                 TGGAATGGGTGTCTAGTAT 
               
               
                   
                   
                   
                   
                 CAGCAGAGGGGGTACAACT 
               
               
                   
                   
                   
                   
                 GATTACGCAGATTCCGTCAA 
               
               
                   
                   
                   
                   
                 GGGACGTTTTACCATCTCAA 
               
               
                   
                   
                   
                   
                 GAGACGATGCCAAGAAGAC 
               
               
                   
                   
                   
                   
                 ATTATCACTCCAAATGAACT 
               
               
                   
                   
                   
                   
                 CACTGAGGGCCGAGGACAC 
               
               
                   
                   
                   
                   
                 CGCTGTGTACTATTGTGGG 
               
               
                   
                   
                   
                   
                 AGATACGACTACGACGGAT 
               
               
                   
                   
                   
                   
                 ACTATGCCATGGACTATTG 
               
               
                   
                   
                   
                   
                 GGGACAAGGCACGATGGT 
               
               
                   
                   
                   
                   
                 GACGGTATCTAGC 
               
               
                   
               
               
                 hROR1 VL_17 
                 419 
                 EIVLTQSPATLSVSPGERATLSCKAS 
                 420 
                 GAGATAGTGCTAACCCAGT 
               
               
                   
                   
                 PDINSYLAWYQQKPGQAPRLLFSR 
                   
                 CTCCCGCAACCCTGTCTGTG 
               
               
                   
                   
                 ANRLVDGIPARFTGSGSGTDFTLTIS 
                   
                 TCCCCCGGAGAGCGCGCTA 
               
               
                   
                   
                 SLEPEDFAIYYCLQYDEFPYTFGQGT 
                   
                 CTCTGAGCTGCAAAGCCAG 
               
               
                   
                   
                 KVEIK 
                   
                 CCCGGACATTAATTCCTACC 
               
               
                   
                   
                   
                   
                 TTGCCTGGTATCAGCAGAA 
               
               
                   
                   
                   
                   
                 GCCTGGACAGGCCCCAAGA 
               
               
                   
                   
                   
                   
                 TTGCTCTTTTCACGCGCCAA 
               
               
                   
                   
                   
                   
                 CCGCCTGGTAGATGGTATT 
               
               
                   
                   
                   
                   
                 CCAGCTAGGTTTACGGGCT 
               
               
                   
                   
                   
                   
                 CAGGCAGCGGAACAGACTT 
               
               
                   
                   
                   
                   
                 CACTCTCACTATTAGCTCAT 
               
               
                   
                   
                   
                   
                 TGGAGCCTGAGGACTTTGC 
               
               
                   
                   
                   
                   
                 AATTTACTATTGTCTTCAGT 
               
               
                   
                   
                   
                   
                 ACGACGAGTTCCCATATACT 
               
               
                   
                   
                   
                   
                 TTCGGCCAGGGCACAAAAG 
               
               
                   
                   
                   
                   
                 TAGAGATCAAG 
               
               
                   
               
               
                 hROR1 VH_18 
                 421 
                 EVQLVESGGGLVQPGGSLRLSCSAS 
                 422 
                 GAGGTTCAACTCGTGGAGT 
               
               
                   
                   
                 GFTFSSYAMSWVRQVPGKGLVWI 
                   
                 CTGGAGGCGGGCTAGTGCA 
               
               
                   
                   
                 SSISRGGTTYYADSVRGRFIISRDNA 
                   
                 GCCTGGCGGCTCCCTGCGA 
               
               
                   
                   
                 KNTLYLEMNNLRGEDTAVYYCARY 
                   
                 CTGTCTTGCAGCGCATCAG 
               
               
                   
                   
                 DYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTTACATTCAGTTCTTAT 
               
               
                   
                   
                   
                   
                 GCCATGAGCTGGGTGAGGC 
               
               
                   
                   
                   
                   
                 AGGTGCCCGGCAAGGGTCT 
               
               
                   
                   
                   
                   
                 GGTGTGGATCAGCTCAATC 
               
               
                   
                   
                   
                   
                 TCCAGGGGCGGGACTACAT 
               
               
                   
                   
                   
                   
                 ATTACGCCGATTCGGTCAG 
               
               
                   
                   
                   
                   
                 GGGTCGTTTTATCATTAGCA 
               
               
                   
                   
                   
                   
                 GGGATAATGCCAAGAACAC 
               
               
                   
                   
                   
                   
                 CTTGTATTTGGAGATGAAC 
               
               
                   
                   
                   
                   
                 AACCTAAGAGGCGAAGACA 
               
               
                   
                   
                   
                   
                 CCGCTGTGTACTATTGTGCC 
               
               
                   
                   
                   
                   
                 CGTTACGACTACGATGGGT 
               
               
                   
                   
                   
                   
                 ACTACGCCATGGACTATTG 
               
               
                   
                   
                   
                   
                 GGGCCAGGGAACCTTGGTG 
               
               
                   
                   
                   
                   
                 ACTGTGTCAAGT 
               
               
                   
               
               
                 hROR1 VL_18 
                 423 
                 DIQLTQSPDSLAVSLGERATINCKAS 
                 424 
                 GACATACAGTTGACTCAGTC 
               
               
                   
                   
                 PDINSYLSWYQQRPGQPPRLLIHR 
                   
                 ACCGGATTCGCTGGCAGTT 
               
               
                   
                   
                 ANRLVDGVPDRFSGSGFGTDFTLTI 
                   
                 TCGCTGGGTGAGAGAGCAA 
               
               
                   
                   
                 TSLQAEDVAIYYCLQYDEFPYTFGQ 
                   
                 CCATCAACTGCAAAGCATCT 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCCGATATCAACTCTTATCT 
               
               
                   
                   
                   
                   
                 GTCTTGGTATCAGCAGCGT 
               
               
                   
                   
                   
                   
                 CCGGGACAACCCCCTAGGC 
               
               
                   
                   
                   
                   
                 TGCTTATTCACCGAGCCAAC 
               
               
                   
                   
                   
                   
                 AGGCTGGTGGACGGGGTG 
               
               
                   
                   
                   
                   
                 CCAGACCGCTTCTCGGGAT 
               
               
                   
                   
                   
                   
                 CAGGATTTGGAACCGATTTT 
               
               
                   
                   
                   
                   
                 ACCCTAACAATTACTAGTCT 
               
               
                   
                   
                   
                   
                 CCAAGCGGAAGACGTGGCG 
               
               
                   
                   
                   
                   
                 ATCTATTATTGTCTACAATA 
               
               
                   
                   
                   
                   
                 TGACGAGTTCCCCTACACCT 
               
               
                   
                   
                   
                   
                 TCGGCCAGGGCACGAAGTT 
               
               
                   
                   
                   
                   
                 GGAGATCAAG 
               
               
                   
               
               
                 hROR1 VH_19 
                 425 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 426 
                 GAGGTCCAGCTCGTCGAAT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CCGGTGGAGGGCTAGTTCA 
               
               
                   
                   
                 VASISRGGTTYYADSVKGRFTISADT 
                   
                 GCCAGGCGGCTCATTGCGT 
               
               
                   
                   
                 SKNTAYLQMNSLRAEDTAVYYCAR 
                   
                 TTGTCTTGTGCCGCCTCCGG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 TTTCACATTCTCTTCTTACGC 
               
               
                   
                   
                   
                   
                 TATGTCCTGGGTCCGACAA 
               
               
                   
                   
                   
                   
                 GCCCCAGGAAAAGGCTTGG 
               
               
                   
                   
                   
                   
                 AATGGGTGGCCAGTATCAG 
               
               
                   
                   
                   
                   
                 TAGAGGTGGGACTACATAT 
               
               
                   
                   
                   
                   
                 TATGCCGACTCCGTGAAGG 
               
               
                   
                   
                   
                   
                 GCAGATTCACCATCTCAGCT 
               
               
                   
                   
                   
                   
                 GACACCAGTAAGAACACTG 
               
               
                   
                   
                   
                   
                 CCTACCTACAGATGAACAG 
               
               
                   
                   
                   
                   
                 CCTTCGGGCCGAGGACACC 
               
               
                   
                   
                   
                   
                 GCTGTGTATTACTGTGCCCG 
               
               
                   
                   
                   
                   
                 GTACGATTATGATGGATATT 
               
               
                   
                   
                   
                   
                 ATGCTATGGACTATTGGGG 
               
               
                   
                   
                   
                   
                 TCAGGGGACCTTGGTGACC 
               
               
                   
                   
                   
                   
                 GTCTCTAGC 
               
               
                   
               
               
                 hROR1 VL_19 
                 427 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 428 
                 GACATTCAGATGACTCAATC 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 GCCGAGTTCTCTTAGCGCTT 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 CTGTTGGGGACCGGGTGAC 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGQ 
                   
                 AATCACATGCAAGGCCTCTC 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCGATATAAACTCCTATCTA 
               
               
                   
                   
                   
                   
                 AGCTGGTATCAGCAGAAGC 
               
               
                   
                   
                   
                   
                 CAGGGAAGGCCCCCAAGTT 
               
               
                   
                   
                   
                   
                 GTTAATCTATCGCGCCAACA 
               
               
                   
                   
                   
                   
                 GACTGGTGGATGGGGTGCC 
               
               
                   
                   
                   
                   
                 CTCTCGATTCTCCGGGAGTG 
               
               
                   
                   
                   
                   
                 GCAGTGGGACTGATTTTAC 
               
               
                   
                   
                   
                   
                 ACTGACCATTTCCTCATTGC 
               
               
                   
                   
                   
                   
                 AGCCCGAAGACTTCGCTAC 
               
               
                   
                   
                   
                   
                 CTATTACTGCTTGCAGTACG 
               
               
                   
                   
                   
                   
                 ATGAGTTCCCATATACATTC 
               
               
                   
                   
                   
                   
                 GGTCAGGGGACTAAAGTGG 
               
               
                   
                   
                   
                   
                 AGATAAAA 
               
               
                   
               
               
                 hROR1 VH_20 
                 429 
                 EVQLLESGGGLVQPGGSLRLSCAAS 
                 430 
                 GAGGTACAGCTGCTGGAAT 
               
               
                   
                   
                 GFTFSSYAMSWVRQAPGKGLEWV 
                   
                 CTGGTGGGGGGCTGGTCCA 
               
               
                   
                   
                 SSISRGGTTYYADSVKGRFTISRDNS 
                   
                 GCCAGGGGGGTCACTACGA 
               
               
                   
                   
                 KNTLYLQMNSLRAEDTAVYYCARY 
                   
                 CTGAGCTGCGCTGCCTCCG 
               
               
                   
                   
                 DYDGYYAMDYWGQGTLVTVSS 
                   
                 GTTTTACATTCAGCAGCTAT 
               
               
                   
                   
                   
                   
                 GCAATGTCATGGGTCAGAC 
               
               
                   
                   
                   
                   
                 AGGCACCAGGTAAAGGCCT 
               
               
                   
                   
                   
                   
                 CGAATGGGTATCCTCCATCT 
               
               
                   
                   
                   
                   
                 CACGTGGTGGGACCACTTA 
               
               
                   
                   
                   
                   
                 CTATGCCGATAGTGTGAAG 
               
               
                   
                   
                   
                   
                 GGCAGGTTCACGATCTCAA 
               
               
                   
                   
                   
                   
                 GAGATAATTCAAAGAATAC 
               
               
                   
                   
                   
                   
                 ACTCTATCTACAAATGAACA 
               
               
                   
                   
                   
                   
                 GTTTAAGGGCCGAGGACAC 
               
               
                   
                   
                   
                   
                 CGCTGTTTACTATTGTGCCA 
               
               
                   
                   
                   
                   
                 GATATGACTACGACGGTTA 
               
               
                   
                   
                   
                   
                 TTATGCTATGGATTACTGGG 
               
               
                   
                   
                   
                   
                 GACAAGGAACGCTGGTAAC 
               
               
                   
                   
                   
                   
                 TGTTAGCTCT 
               
               
                   
               
               
                 hROR1 VL_20 
                 431 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 432 
                 GACATCCAAATGACCCAGT 
               
               
                   
                   
                 SPDINSYLSWYQQKPGEAPKLLIYR 
                   
                 CGCCTTCCTCCTTGTCTGCA 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 TCTGTCGGAGATCGGGTGA 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGQ 
                   
                 CGATCACTTGCAAAGCGAG 
               
               
                   
                   
                 GTKVEIK 
                   
                 TCCAGACATCAACTCATATC 
               
               
                   
                   
                   
                   
                 TGTCCTGGTATCAGCAGAA 
               
               
                   
                   
                   
                   
                 GCCGGGAGAGGCACCTAAG 
               
               
                   
                   
                   
                   
                 CTCCTGATCTACAGAGCAAA 
               
               
                   
                   
                   
                   
                 CAGATTAGTGGATGGTGTG 
               
               
                   
                   
                   
                   
                 CCCTCACGGTTTTCTGGCTC 
               
               
                   
                   
                   
                   
                 CGGGTCCGGCACCGATTTC 
               
               
                   
                   
                   
                   
                 ACCTTGACCATCTCATCCCT 
               
               
                   
                   
                   
                   
                 ACAGCCCGAGGATTTCGCT 
               
               
                   
                   
                   
                   
                 ACTTACTATTGCTTACAGTA 
               
               
                   
                   
                   
                   
                 TGATGAGTTTCCATACACCT 
               
               
                   
                   
                   
                   
                 TCGGTCAAGGCACCAAGGT 
               
               
                   
                   
                   
                   
                 TGAGATTAAG 
               
               
                   
               
               
                 hROR1 VH_21 
                 433 
                 EVQLLETGGGLVKPGGSLRLSCAAS 
                 434 
                 GAAGTTCAACTGCTTGAGA 
               
               
                   
                   
                 GFTFSSYAMSWIRQAPGKGLEWV 
                   
                 CCGGAGGCGGCCTGGTAAA 
               
               
                   
                   
                 ASISRGGTTYYGDSVKGRFTISRDH 
                   
                 ACCTGGGGGCTCACTGAGG 
               
               
                   
                   
                 AKNSLYLQMNSLRVEDTAVYYCVR 
                   
                 CTGAGTTGTGCCGCTTCTGG 
               
               
                   
                   
                 YDYDGYYAMDYWGLGTLVTVSS 
                   
                 GTTCACCTTTTCATCCTATG 
               
               
                   
                   
                   
                   
                 CGATGTCATGGATACGGCA 
               
               
                   
                   
                   
                   
                 GGCTCCTGGGAAGGGGCTT 
               
               
                   
                   
                   
                   
                 GAGTGGGTTGCATCAATTT 
               
               
                   
                   
                   
                   
                 CACGAGGTGGGACAACTTA 
               
               
                   
                   
                   
                   
                 TTATGGGGATTCCGTTAAA 
               
               
                   
                   
                   
                   
                 GGTAGATTTACGATCTCTAG 
               
               
                   
                   
                   
                   
                 AGACCATGCCAAAAATTCTC 
               
               
                   
                   
                   
                   
                 TCTATCTCCAGATGAATAGT 
               
               
                   
                   
                   
                   
                 CTTAGGGTGGAGGACACCG 
               
               
                   
                   
                   
                   
                 CTGTGTACTACTGTGTCCGG 
               
               
                   
                   
                   
                   
                 TACGACTATGATGGGTACT 
               
               
                   
                   
                   
                   
                 ATGCTATGGACTATTGGGG 
               
               
                   
                   
                   
                   
                 GCTCGGCACTCTGGTCACT 
               
               
                   
                   
                   
                   
                 GTTAGCTCT 
               
               
                   
               
               
                 hROR1 VL_21 
                 435 
                 AIRMTQSPSFLSASVGDRVTITCKA 
                 436 
                 GCCATCCGCATGACACAATC 
               
               
                   
                   
                 SPDINSYLSWYQQRPGKAPKLLIYR 
                   
                 TCCCTCCTTCCTTTCTGCCAG 
               
               
                   
                   
                 ANRLVDGVPSRFSGGGSGTDFTLTI 
                   
                 TGTCGGGGACAGAGTGACT 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 ATCACATGCAAAGCCAGCC 
               
               
                   
                   
                 GTKLEIK 
                   
                 CAGATATTAATTCGTACCTG 
               
               
                   
                   
                   
                   
                 TCTTGGTATCAGCAGAGGC 
               
               
                   
                   
                   
                   
                 CCGGCAAGGCACCAAAGCT 
               
               
                   
                   
                   
                   
                 GTTGATATATCGGGCCAAC 
               
               
                   
                   
                   
                   
                 CGCTTAGTGGACGGTGTCC 
               
               
                   
                   
                   
                   
                 CCTCTCGATTCAGCGGAGG 
               
               
                   
                   
                   
                   
                 CGGTAGCGGGACGGACTTT 
               
               
                   
                   
                   
                   
                 ACACTGACCATCTCCAGTCT 
               
               
                   
                   
                   
                   
                 CCAACCCGAGGATATTGCC 
               
               
                   
                   
                   
                   
                 ACTTACTATTGTCTTCAGTA 
               
               
                   
                   
                   
                   
                 TGACGAGTTCCCCTACACAT 
               
               
                   
                   
                   
                   
                 TTGGACAGGGCACCAAGCT 
               
               
                   
                   
                   
                   
                 AGAAATTAAG 
               
               
                   
               
               
                 hROR1 VH_22 
                 437 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 438 
                 GAGGTTCAGCTGGTGGAGT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CTGGTGGGGGGCTCGTACA 
               
               
                   
                   
                 VASISRGGTTYYAESLEGRFTISRDD 
                   
                 GCCGGGTGGCTCCCTAAGG 
               
               
                   
                   
                 SKNSLYLQMNSLKTEDTAVYYCARY 
                   
                 CTGAGTTGCGCTGCCTCAG 
               
               
                   
                   
                 DYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTTACCTTCTCAAGCTAC 
               
               
                   
                   
                   
                   
                 GCGATGTCCTGGGTGAGAC 
               
               
                   
                   
                   
                   
                 AGGCCCCTGGCAAAGGACT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTGGCAAGCATT 
               
               
                   
                   
                   
                   
                 AGCCGGGGCGGAACTACCT 
               
               
                   
                   
                   
                   
                 ATTACGCTGAGTCGTTAGA 
               
               
                   
                   
                   
                   
                 GGGGCGGTTTACTATCTCC 
               
               
                   
                   
                   
                   
                 AGAGACGATTCAAAGAACT 
               
               
                   
                   
                   
                   
                 CGTTATACTTGCAGATGAAC 
               
               
                   
                   
                   
                   
                 AGCCTCAAGACCGAGGACA 
               
               
                   
                   
                   
                   
                 CCGCCGTGTACTACTGCGCC 
               
               
                   
                   
                   
                   
                 CGGTACGACTATGACGGGT 
               
               
                   
                   
                   
                   
                 ACTATGCTATGGATTATTGG 
               
               
                   
                   
                   
                   
                 GGACAAGGCACCCTCGTGA 
               
               
                   
                   
                   
                   
                 CCGTCTCTAGC 
               
               
                   
               
               
                 hROR1 VL_22 
                 439 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 440 
                 GACATCCAGATGACACAGT 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKTLIYR 
                   
                 CCCCTTCTTCACTTTCCGCTT 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 CTGTGGGCGACAGGGTGAC 
               
               
                   
                   
                 SSLQPEDFATYYCLQYDEFPYTFGQ 
                   
                 GATCACGTGTAAGGCCTCG 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCAGACATTAATTCGTACTT 
               
               
                   
                   
                   
                   
                 ATCGTGGTATCAGCAGAAA 
               
               
                   
                   
                   
                   
                 CCGGGTAAAGCTCCGAAGA 
               
               
                   
                   
                   
                   
                 CTCTGATCTATAGAGCAAAT 
               
               
                   
                   
                   
                   
                 AGGCTCGTAGACGGTGTCC 
               
               
                   
                   
                   
                   
                 CATCTAGATTTAGTGGGAG 
               
               
                   
                   
                   
                   
                 CGGCAGCGGAACCGACTTC 
               
               
                   
                   
                   
                   
                 ACTCTCACCATCTCATCCCT 
               
               
                   
                   
                   
                   
                 GCAACCGGAGGATTTCGCT 
               
               
                   
                   
                   
                   
                 ACTTACTATTGCTTGCAGTA 
               
               
                   
                   
                   
                   
                 TGACGAGTTTCCATATACGT 
               
               
                   
                   
                   
                   
                 TTGGTCAGGGAACCAAATT 
               
               
                   
                   
                   
                   
                 AGAGATCAAA 
               
               
                   
               
               
                 hROR1 VH_23 
                 441 
                 QVTLRESGPALVKPTQTLTLTCAAS 
                 442 
                 CAGGTAACACTCCGAGAGA 
               
               
                   
                   
                 GFTFSSYAMSWIRQPPGKALEWLA 
                   
                 GTGGGCCAGCTCTCGTGAA 
               
               
                   
                   
                 SISRGGTTYYNPSLKDRLTISKDTSA 
                   
                 GCCCACGCAGACTTTAACAC 
               
               
                   
                   
                 NQVVLKVTNMDPADTATYYCARY 
                   
                 TAACGTGTGCGGCAAGCGG 
               
               
                   
                   
                 DYDGYYAMDYWGQGTTVTVSS 
                   
                 CTTTACATTTTCGAGCTACG 
               
               
                   
                   
                   
                   
                 CGATGAGCTGGATAAGGCA 
               
               
                   
                   
                   
                   
                 ACCTCCTGGGAAGGCGTTG 
               
               
                   
                   
                   
                   
                 GAGTGGTTGGCCTCAATTA 
               
               
                   
                   
                   
                   
                 GCCGGGGTGGCACCACTTA 
               
               
                   
                   
                   
                   
                 CTACAATCCTAGTCTTAAGG 
               
               
                   
                   
                   
                   
                 ACAGACTTACTATTTCAAAA 
               
               
                   
                   
                   
                   
                 GATACGTCCGCCAACCAGG 
               
               
                   
                   
                   
                   
                 TGGTACTGAAGGTCACAAA 
               
               
                   
                   
                   
                   
                 TATGGACCCAGCTGACACT 
               
               
                   
                   
                   
                   
                 GCTACTTACTACTGCGCCCG 
               
               
                   
                   
                   
                   
                 GTACGATTACGATGGTTACT 
               
               
                   
                   
                   
                   
                 ACGCTATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 TCAAGGAACCACAGTGACC 
               
               
                   
                   
                   
                   
                 GTCAGTTCA 
               
               
                   
               
               
                 hROR1 VL_23 
                 443 
                 DIQMTQSPSTLSASVGDRVTITCKA 
                 444 
                 GATATCCAGATGACGCAGT 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 CCCCTTCAACCCTCAGTGCC 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTAFTLTI 
                   
                 AGCGTTGGTGACCGGGTTA 
               
               
                   
                   
                 SSLQPDDFATYYCLQYDEFPYTFGG 
                   
                 CTATCACCTGTAAGGCTAGT 
               
               
                   
                   
                 GTKVEIK 
                   
                 CCCGATATAAATTCCTATTT 
               
               
                   
                   
                   
                   
                 GTCTTGGTATCAGCAGAAG 
               
               
                   
                   
                   
                   
                 CCAGGCAAGGCTCCTAAGC 
               
               
                   
                   
                   
                   
                 TGCTCATCTACCGGGCTAAC 
               
               
                   
                   
                   
                   
                 AGGTTAGTTGACGGTGTGC 
               
               
                   
                   
                   
                   
                 CCTCCCGATTTTCCGGCAGT 
               
               
                   
                   
                   
                   
                 GGCAGCGGGACCGCTTTCA 
               
               
                   
                   
                   
                   
                 CTCTTACAATCTCATCTCTTC 
               
               
                   
                   
                   
                   
                 AACCGGACGACTTCGCTAC 
               
               
                   
                   
                   
                   
                 GTACTACTGCCTCCAATATG 
               
               
                   
                   
                   
                   
                 ATGAGTTTCCATACACATTC 
               
               
                   
                   
                   
                   
                 GGAGGAGGCACAAAAGTC 
               
               
                   
                   
                   
                   
                 GAAATCAAG 
               
               
                   
               
               
                 hROR1 VH_24 
                 445 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 446 
                 GAAGTCCAGCTGGTGGAGT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CCGGCGGAGGCTTGGTTCA 
               
               
                   
                   
                 VSAISRGGTTYYADSVKGRFTISADT 
                   
                 GCCCGGAGGATCTTTGCGA 
               
               
                   
                   
                 SKETAYLQMNSLRAEDTAVYYCGR 
                   
                 CTGTCTTGCGCCGCCAGCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GTTTCACTTTCAGCAGCTAT 
               
               
                   
                   
                   
                   
                 GCCATGAGTTGGGTTAGAC 
               
               
                   
                   
                   
                   
                 AAGCTCCCGGCAAGGGGCT 
               
               
                   
                   
                   
                   
                 GGAATGGGTTAGTGCTATT 
               
               
                   
                   
                   
                   
                 AGCCGGGGAGGGACAACA 
               
               
                   
                   
                   
                   
                 TATTACGCTGACTCTGTCAA 
               
               
                   
                   
                   
                   
                 AGGCCGATTCACCATCTCTG 
               
               
                   
                   
                   
                   
                 CTGACACGAGCAAAGAAAC 
               
               
                   
                   
                   
                   
                 CGCCTACCTCCAAATGAACA 
               
               
                   
                   
                   
                   
                 GCCTGCGAGCTGAGGACAC 
               
               
                   
                   
                   
                   
                 TGCCGTCTACTATTGTGGTC 
               
               
                   
                   
                   
                   
                 GATATGATTATGATGGGTA 
               
               
                   
                   
                   
                   
                 CTATGCAATGGACTATTGG 
               
               
                   
                   
                   
                   
                 GGGCAGGGCACACTGGTGA 
               
               
                   
                   
                   
                   
                 CCGTGAGCTCT 
               
               
                   
               
               
                 hROR1 VL_24 
                 447 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 448 
                 GATATTCAGATGACGCAGA 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 GTCCCTCCTCCCTATCTGCC 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 TCTGTTGGAGATCGAGTCA 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 CCATTACGTGTAAAGCGTCT 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCCGATATCAACAGCTACCT 
               
               
                   
                   
                   
                   
                 CTCTTGGTATCAGCAGAAAC 
               
               
                   
                   
                   
                   
                 CAGGGAAGGCCCCCAAGCT 
               
               
                   
                   
                   
                   
                 GCTGATCTATAGAGCTAATC 
               
               
                   
                   
                   
                   
                 GCTTAGTGGATGGAGTGCC 
               
               
                   
                   
                   
                   
                 AAGCAGGTTCTCCGGGTCC 
               
               
                   
                   
                   
                   
                 GGCAGTGGAACCGATTTCA 
               
               
                   
                   
                   
                   
                 CCTTGACAATAAGTAGCTTG 
               
               
                   
                   
                   
                   
                 CAACCTGAGGATATTGCAA 
               
               
                   
                   
                   
                   
                 CATACTACTGTCTACAGTAC 
               
               
                   
                   
                   
                   
                 GACGAGTTCCCCTACACCTT 
               
               
                   
                   
                   
                   
                 CGGCCAAGGGACAAAGCTG 
               
               
                   
                   
                   
                   
                 GAGATTAAG 
               
               
                   
               
               
                 hROR1 VH_25 
                 449 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 450 
                 GAAGTGCAGCTCGTGGAGA 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 GCGGCGGCGGTCTGGTACA 
               
               
                   
                   
                 VSAISRGGTTYYADSVKGRFTISRD 
                   
                 GCCAGGGGGGTCACTGCGT 
               
               
                   
                   
                 NSKNTLYLQMNSLRAEDTAVYYCG 
                   
                 CTCTCATGTGCTGCGAGTG 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTTACGTTCTCTTCCTAC 
               
               
                   
                   
                   
                   
                 GCTATGTCCTGGGTCAGGC 
               
               
                   
                   
                   
                   
                 AGGCACCGGGGAAGGGCTT 
               
               
                   
                   
                   
                   
                 AGAGTGGGTTAGTGCAATC 
               
               
                   
                   
                   
                   
                 TCTAGGGGCGGTACAACCT 
               
               
                   
                   
                   
                   
                 ACTATGCCGACTCTGTCAAG 
               
               
                   
                   
                   
                   
                 GGCAGGTTTACAATTTCAA 
               
               
                   
                   
                   
                   
                 GAGATAATTCTAAGAATACT 
               
               
                   
                   
                   
                   
                 CTTTACCTACAGATGAATAG 
               
               
                   
                   
                   
                   
                 CTTGCGGGCGGAAGACACA 
               
               
                   
                   
                   
                   
                 GCAGTCTATTATTGTGGCCG 
               
               
                   
                   
                   
                   
                 CTATGACTACGACGGATACT 
               
               
                   
                   
                   
                   
                 ATGCCATGGACTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAAGGCACTTTGGTCACG 
               
               
                   
                   
                   
                   
                 GTGAGCTCT 
               
               
                   
               
               
                 hROR1 VL_25 
                 451 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 452 
                 GACATCCAGATGACCCAGA 
               
               
                   
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 GCCCTAGTTCATTGTCTGCC 
               
               
                   
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 AGTGTGGGGGATAGGGTC 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 ACTATCACGTGTAAGGCTTC 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCCTGACATCAATTCATACC 
               
               
                   
                   
                   
                   
                 TGTCATGGTATCAGCAGAA 
               
               
                   
                   
                   
                   
                 GCCTGGAAAAGCCCCTAAA 
               
               
                   
                   
                   
                   
                 CTGCTGATCTACCGCGCGA 
               
               
                   
                   
                   
                   
                 ATAGGCTTGTGGACGGCGT 
               
               
                   
                   
                   
                   
                 TCCAAGCCGCTTCTCTGGCT 
               
               
                   
                   
                   
                   
                 CTGGATCAGGGACCGACTT 
               
               
                   
                   
                   
                   
                 CACCCTCACGATCTCCAGCC 
               
               
                   
                   
                   
                   
                 TCCAACCCGAGGATATCGC 
               
               
                   
                   
                   
                   
                 CACCTATTATTGCCTTCAGT 
               
               
                   
                   
                   
                   
                 ACGATGAGTTCCCCTATACA 
               
               
                   
                   
                   
                   
                 TTCGGCCAGGGGACAAAGC 
               
               
                   
                   
                   
                   
                 TGGAAATCAAA 
               
               
                   
               
               
                 hROR1 VH_26 
                 453 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 454 
                 GAGGTCCAGCTCGTCGAGT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CGGGTGGGGGCTTGGTGCA 
               
               
                   
                   
                 VSAISRGGTTYYADSVKGRFTISADT 
                   
                 ACCCGGTGGCAGTTTGCGC 
               
               
                   
                   
                 SKETAYLQMNSLRAEDTAVYYCGR 
                   
                 CTGAGCTGCGCCGCGAGCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GGTTCACTTTCAGTTCGTAT 
               
               
                   
                   
                   
                   
                 GCCATGAGTTGGGTGCGAC 
               
               
                   
                   
                   
                   
                 AAGCGCCCGGCAAAGGACT 
               
               
                   
                   
                   
                   
                 GGAGTGGGTGTCAGCCATT 
               
               
                   
                   
                   
                   
                 AGCCGGGGCGGTACTACCT 
               
               
                   
                   
                   
                   
                 ACTATGCGGACTCGGTCAA 
               
               
                   
                   
                   
                   
                 GGGAAGATTCACCATCAGC 
               
               
                   
                   
                   
                   
                 GCTGATACCAGTAAGGAAA 
               
               
                   
                   
                   
                   
                 CCGCTTATCTTCAGATGAAC 
               
               
                   
                   
                   
                   
                 TCCCTGCGTGCCGAGGATA 
               
               
                   
                   
                   
                   
                 CAGCAGTCTACTATTGCGG 
               
               
                   
                   
                   
                   
                 GCGCTACGATTATGACGGA 
               
               
                   
                   
                   
                   
                 TATTATGCCATGGATTACTG 
               
               
                   
                   
                   
                   
                 GGGGCAGGGCACTCTGGTC 
               
               
                   
                   
                   
                   
                 ACAGTCAGCTCT 
               
               
                   
               
               
                 hROR1 VL_26 
                 455 
                 DIQMTQSPSSLSASVGDRVTITCQA 
                 456 
                 GATATTCAGATGACGCAGT 
               
               
                   
                   
                 SPDINSYLNWYQQKPGKAPKLLIYR 
                   
                 CTCCCTCTTCCCTGAGCGCC 
               
               
                   
                   
                 ANNLETGVPSRFSGSGSGTDFTLTI 
                   
                 TCCGTCGGCGATAGAGTTA 
               
               
                   
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 CGATCACCTGTCAGGCCAG 
               
               
                   
                   
                 GTKLEIK 
                   
                 CCCAGATATCAACTCCTATC 
               
               
                   
                   
                   
                   
                 TGAATTGGTATCAGCAAAA 
               
               
                   
                   
                   
                   
                 GCCTGGGAAGGCTCCCAAG 
               
               
                   
                   
                   
                   
                 TTGCTGATCTACAGAGCCAA 
               
               
                   
                   
                   
                   
                 TAACTTAGAGACTGGCGTG 
               
               
                   
                   
                   
                   
                 CCGTCTCGGTTCAGCGGGT 
               
               
                   
                   
                   
                   
                 CCGGCAGTGGAACCGACTT 
               
               
                   
                   
                   
                   
                 TACACTGACCATTTCCAGCC 
               
               
                   
                   
                   
                   
                 TCCAACCTGAGGATATCGCC 
               
               
                   
                   
                   
                   
                 ACATATTATTGTCTCCAGTA 
               
               
                   
                   
                   
                   
                 TGACGAGTTCCCTTACACAT 
               
               
                   
                   
                   
                   
                 TTGGTCAAGGAACTAAACT 
               
               
                   
                   
                   
                   
                 GGAAATCAAA 
               
               
                   
               
               
                 hROR1 VH_27 
                 457 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 458 
                 GAGGTGCAGCTGGTCGAAA 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 GTGGAGGCGGACTCGTGCA 
               
               
                   
                   
                 VSAISRGGTTYYADSVKGRFTISADT 
                   
                 GCCCGGCGGTAGTCTGCGA 
               
               
                   
                   
                 SKETAYLQMNSLRAEDTAVYYCGR 
                   
                 TTGAGCTGTGCCGCGTCCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GCTTTACTTTCTCATCTTACG 
               
               
                   
                   
                   
                   
                 CTATGAGTTGGGTCCGCCA 
               
               
                   
                   
                   
                   
                 GGCCCCAGGCAAAGGACTG 
               
               
                   
                   
                   
                   
                 GAGTGGGTATCAGCCATCA 
               
               
                   
                   
                   
                   
                 GTAGGGGGGGAACTACCTA 
               
               
                   
                   
                   
                   
                 TTACGCAGATTCTGTGAAG 
               
               
                   
                   
                   
                   
                 GGACGCTTCACCATCAGCG 
               
               
                   
                   
                   
                   
                 CGGACACTAGCAAGGAGAC 
               
               
                   
                   
                   
                   
                 TGCCTACCTGCAAATGAATA 
               
               
                   
                   
                   
                   
                 GTCTGAGAGCCGAGGATAC 
               
               
                   
                   
                   
                   
                 CGCCGTGTACTATTGTGGC 
               
               
                   
                   
                   
                   
                 AGGTATGACTACGATGGCT 
               
               
                   
                   
                   
                   
                 ATTATGCTATGGATTACTGG 
               
               
                   
                   
                   
                   
                 GGCCAGGGGACGTTAGTGA 
               
               
                   
                   
                   
                   
                 CAGTAAGCTCT 
               
               
                   
               
               
                 hROR1 VL_27 
                 459 
                 DIQMTQSPSSLSASVGDRVTITCRA 
                 460 
                 GATATTCAGATGACCCAATC 
               
               
                   
                   
                 SPDINSYVAWYQQKPGKAPKLLIYR 
                   
                 CCCTTCTTCTCTGAGCGCTT 
               
               
                   
                   
                 ANFLESGVPSRFSGSRSGTDFTLTIS 
                   
                 CTGTGGGCGATAGAGTTAC 
               
               
                   
                   
                 SLQPEDFATYYCLQYDEFPYTFGQG 
                   
                 AATAACCTGTCGGGCGTCC 
               
               
                   
                   
                 TKVEIK 
                   
                 CCAGACATTAACTCTTATGT 
               
               
                   
                   
                   
                   
                 AGCATGGTATCAGCAAAAG 
               
               
                   
                   
                   
                   
                 CCTGGAAAGGCACCAAAGT 
               
               
                   
                   
                   
                   
                 TACTGATCTACCGGGCCAAT 
               
               
                   
                   
                   
                   
                 TTTCTGGAGTCGGGCGTGC 
               
               
                   
                   
                   
                   
                 CCTCACGATTTAGCGGTAG 
               
               
                   
                   
                   
                   
                 CAGATCAGGCACAGACTTT 
               
               
                   
                   
                   
                   
                 ACTCTGACCATTAGCTCTCT 
               
               
                   
                   
                   
                   
                 GCAACCCGAGGACTTCGCC 
               
               
                   
                   
                   
                   
                 ACCTACTACTGTTTGCAGTA 
               
               
                   
                   
                   
                   
                 TGACGAGTTTCCATACACTT 
               
               
                   
                   
                   
                   
                 TTGGTCAAGGAACCAAAGT 
               
               
                   
                   
                   
                   
                 CGAAATCAAA 
               
               
                   
               
               
                 hROR1 VH_28 
                 461 
                 QIQLVQSGAEVKKPGASVKVSCAA 
                 462 
                 CAGATACAGCTGGTGCAGT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKSFKW 
                   
                 CTGGTGCCGAGGTTAAAAA 
               
               
                   
                   
                 MGSISRGGTTYYSADFKGRFAITKD 
                   
                 GCCCGGAGCCTCGGTTAAA 
               
               
                   
                   
                 TSASTAYMELSSLRSEDTAVYYCAR 
                   
                 GTGAGTTGTGCGGCAAGCG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSS 
                   
                 GATTCACGTTCAGTTCCTAC 
               
               
                   
                   
                   
                   
                 GCTATGTCCTGGGTGCGGC 
               
               
                   
                   
                   
                   
                 AGGCTCCTGGCAAGTCATTT 
               
               
                   
                   
                   
                   
                 AAGTGGATGGGGTCGATCT 
               
               
                   
                   
                   
                   
                 CACGGGGTGGAACCACCTA 
               
               
                   
                   
                   
                   
                 TTACTCTGCCGACTTCAAGG 
               
               
                   
                   
                   
                   
                 GGAGATTTGCGATTACAAA 
               
               
                   
                   
                   
                   
                 AGATACAAGCGCCTCTACG 
               
               
                   
                   
                   
                   
                 GCCTACATGGAGTTAAGTA 
               
               
                   
                   
                   
                   
                 GCCTTAGAAGCGAAGACAC 
               
               
                   
                   
                   
                   
                 GGCGGTGTACTACTGCGCC 
               
               
                   
                   
                   
                   
                 AGATATGACTATGACGGCT 
               
               
                   
                   
                   
                   
                 ACTACGCCATGGACTACTG 
               
               
                   
                   
                   
                   
                 GGGCCAGGGCACACTGGTT 
               
               
                   
                   
                   
                   
                 ACAGTCAGCTCT 
               
               
                   
               
               
                 hROR1 VL_28 
                 463 
                 DIVMTQSPDSLAVSLGERATISCKA 
                 464 
                 GATATCGTGATGACACAAA 
               
               
                   
                   
                 SPDINSYLSWYQQKPGQPPKLLIYR 
                   
                 GCCCAGACAGTCTGGCAGT 
               
               
                   
                   
                 ANRLVDGVPDRFSGSGSRTDFTLTI 
                   
                 GTCCCTCGGCGAGCGCGCT 
               
               
                   
                   
                 SSLQAEDVAVYYCLQYDEFPYTFGQ 
                   
                 ACCATCTCATGCAAAGCTAG 
               
               
                   
                   
                 GTKVEIK 
                   
                 TCCCGACATCAATTCCTATC 
               
               
                   
                   
                   
                   
                 TGTCCTGGTATCAGCAAAA 
               
               
                   
                   
                   
                   
                 ACCAGGCCAACCCCCCAAG 
               
               
                   
                   
                   
                   
                 CTGCTTATCTATCGGGCTAA 
               
               
                   
                   
                   
                   
                 CCGATTAGTCGATGGGGTG 
               
               
                   
                   
                   
                   
                 CCAGATAGATTTTCAGGCTC 
               
               
                   
                   
                   
                   
                 TGGTTCCCGGACAGATTTTA 
               
               
                   
                   
                   
                   
                 CTCTCACGATCTCCTCACTA 
               
               
                   
                   
                   
                   
                 CAGGCAGAAGATGTTGCAG 
               
               
                   
                   
                   
                   
                 TGTATTACTGCCTGCAATAC 
               
               
                   
                   
                   
                   
                 GACGAGTTCCCCTACACCTT 
               
               
                   
                   
                   
                   
                 CGGCCAAGGCACGAAAGTG 
               
               
                   
                   
                   
                   
                 GAGATCAAG 
               
               
                   
               
               
                 hROR scFv 
                 465 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 466 
                 GAAGTGCAACTGGTCGAGT 
               
               
                   
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CTGGGGGCGGCCTTGTGCA 
               
               
                   
                   
                 VSSISRGGTTYYPDSVKGRFTISRDN 
                   
                 ACCTGGAGGCAGCCTTCGA 
               
               
                   
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 CTCAGTTGCGCCGCGTCTG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSSG 
                   
                 GTTTTACCTTCTCCTCTTACG 
               
               
                   
                   
                 GGGSGGGGSGGGGSDIQMTQSPS 
                   
                 CGATGAGCTGGGTTCGCCA 
               
               
                   
                   
                 SLSASVGDRVTITCKASPDINSYLN 
                   
                 GGCCCCCGGCAAGGGACTT 
               
               
                   
                   
                 WYQQKPGKAPKLLIYRANRLVDGV 
                   
                 GAGTGGGTTAGTTCGATCT 
               
               
                   
                   
                 PSRFSGSGSGTDYTLTISSLQPEDFA 
                   
                 CCCGCGGAGGCACCACATA 
               
               
                   
                   
                 TYYCLQYDEFPYTFGAGTKVEIK 
                   
                 TTATCCTGACTCGGTTAAGG 
               
               
                   
                   
                   
                   
                 GACGCTTCACTATCTCTAGG 
               
               
                   
                   
                   
                   
                 GACAATTCAAAGAACACAC 
               
               
                   
                   
                   
                   
                 TGTATCTCCAAATGAACTCC 
               
               
                   
                   
                   
                   
                 TTGCGGGCCGAGGACACTG 
               
               
                   
                   
                   
                   
                 CTGTGTATTATTGCGGACG 
               
               
                   
                   
                   
                   
                 ATACGACTACGATGGGTAT 
               
               
                   
                   
                   
                   
                 TACGCCATGGATTACTGGG 
               
               
                   
                   
                   
                   
                 GGCAAGGTACACTGGTCAC 
               
               
                   
                   
                   
                   
                 TGTGAGTTCG 
               
               
                   
                   
                   
                   
                 GGGGGCGGCGGAAGTGGT 
               
               
                   
                   
                   
                   
                 GGAGGGGGAAGTGGTGGA 
               
               
                   
                   
                   
                   
                 GGAGGAAGCGATATACAGA 
               
               
                   
                   
                   
                   
                 TGACACAGAGCCCTTCAAG 
               
               
                   
                   
                   
                   
                 TTTATCTGCAAGCGTCGGC 
               
               
                   
                   
                   
                   
                 GATCGTGTTACAATAACTTG 
               
               
                   
                   
                   
                   
                 CAAGGCATCTCCCGACATCA 
               
               
                   
                   
                   
                   
                 ATTCCTACCTCAACTGGTAT 
               
               
                   
                   
                   
                   
                 CAGCAGAAGCCTGGGAAG 
               
               
                   
                   
                   
                   
                 GCTCCTAAGCTGCTTATTTA 
               
               
                   
                   
                   
                   
                 CAGAGCAAATCGCCTGGTG 
               
               
                   
                   
                   
                   
                 GACGGCGTGCCCAGTCGGT 
               
               
                   
                   
                   
                   
                 TTTCCGGGTCTGGGAGCGG 
               
               
                   
                   
                   
                   
                 AACGGATTACACACTGACC 
               
               
                   
                   
                   
                   
                 ATCTCAAGCCTGCAACCCGA 
               
               
                   
                   
                   
                   
                 AGACTTCGCTACATATTACT 
               
               
                   
                   
                   
                   
                 GCCTTCAGTATGATGAGTTC 
               
               
                   
                   
                   
                   
                 CCATATACCTTCGGCGCTGG 
               
               
                   
                   
                   
                   
                 GACCAAGGTGGAGATAAAG 
               
               
                   
               
            
           
         
       
     
     Anti-ROR1 CDRs 
     
       
         
           
               
               
               
             
               
                   
               
               
                   
                   
                 SEQ ID NO 
               
               
                   
               
             
            
               
                 IMGT Method 
                   
                   
               
               
                 VH-CDR-1 
                 GFTFSSYA 
                 715 
               
               
                   
               
               
                 VH-CDR-2 
                 ISRGGTT 
                 716 
               
               
                   
               
               
                 VH-CDR-3 
                 GRYDYDGYYAMDY 
                 717 
               
               
                   
               
               
                 Kabat Method 
                   
                   
               
               
                 VH-CDR-1 
                 
                   SYAMS 
                 
                 718 
               
               
                   
               
               
                 VH-CDR-2 
                 
                   AISRGGTTYYADSVKG 
                 
                 719 
               
               
                   
               
               
                 VH-CDR-3 
                 
                   YDYDGYYAMDY 
                 
                 720 
               
               
                   
               
               
                 IMGT Method 
                   
                   
               
               
                 VL-CDR-1 
                 PDINSY 
                 721 
               
               
                   
               
               
                 VL-CDR-2 
                 RAN 
                 722 
               
               
                   
               
               
                 VL-CDR-3 
                 LQYDEFPYT 
                 723 
               
               
                   
               
               
                 Kabat Method 
                   
                   
               
               
                 VL-CDR-1 
                 
                   RASPDINSYLS 
                 
                 724 
               
               
                   
               
               
                 VL-CDR-2 
                 
                   RANTLES 
                 
                 725 
               
               
                   
               
               
                 VL-CDR-3 
                 
                   LQYDEFPYT 
                 
                 723 
               
               
                   
               
            
           
         
       
     
     Portions of ROR1-specific antigen binding domain 
     
       
         
           
               
               
               
             
               
                   
               
             
            
               
                 Portion of VH 
                 GFTFSSYAMSWVRQAPGKGLEWVSSISRGGTTYYPDSVKGRFT 
                 SEQ ID NO: 726 
               
               
                 Domain 
                 ISRDNSKNTLYLQMNSLRAEDTAVYYCGRYDYDGYYAMDY 
                   
               
               
                   
               
               
                 Portion of VL 
                 ASPDINSYLNWYQQKPGKAPKLLIYRANRLVDGVPSRFSGSGS 
                 SEQ ID NO: 727 
               
               
                 Domain 
                 GTDYTLTISSLQPEDFATYYCLQYDEFPYT 
                   
               
               
                   
               
               
                 Portion of VH 
                 SYAMSWVRQAPGKGLEWVSSISRGGTTYYPDSVKGRFTISRDN 
                 SEQ ID NO: 728 
               
               
                 Domain 
                 SKNTLYLQMNSLRAEDTAVYYCGRYDYDGYYAMDY 
                   
               
               
                   
               
               
                 Portion of VL 
                 PDINSYLNWYQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGT 
                 SEQ ID NO: 729 
               
               
                 Domain 
                 DYTLTISSLQPEDFATYYCLQYDEFPYT 
               
               
                   
               
            
           
         
       
     
     Exemplary Spacer Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 CD8α hinge 
                 467 
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                 468 
                 AAGCCCACCACCACCCCTGC 
               
               
                   
                   
                 EACRPAAGGAVHTRGLDFACD 
                   
                 CCCTAGACCTCCAACCCCAG 
               
               
                   
                   
                   
                   
                 CCCCTACAATCGCCAGCCAG 
               
               
                   
                   
                   
                   
                 CCCCTGAGCCTGAGGCCCG 
               
               
                   
                   
                   
                   
                 AAGCCTGTAGACCTGCCGC 
               
               
                   
                   
                   
                   
                 TGGCGGAGCCGTGCACACC 
               
               
                   
                   
                   
                   
                 AGAGGCCTGGATTTCGCCT 
               
               
                   
                   
                   
                   
                 GCGAC 
               
               
                   
               
               
                 CD8α hinge- 
                 469 
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                 470 
                 AAGCCTACCACCACCCCCGC 
               
               
                 homologous 
                   
                 EASRPAAGGAVHTRGLDFASD 
                   
                 ACCTCGTCCTCCAACCCCTG 
               
               
                 stalk 
                   
                   
                   
                 CACCTACGATTGCCAGTCAG 
               
               
                 extension 
                   
                   
                   
                 CCTCTTTCACTGCGGCCTGA 
               
               
                 region 
                   
                   
                   
                 GGCCAGCAGACCAGCTGCC 
               
               
                   
                   
                   
                   
                 GGCGGTGCCGTCCATACAA 
               
               
                   
                   
                   
                   
                 GAGGACTGGACTTCGCGTC 
               
               
                   
                   
                   
                   
                 CGAT 
               
               
                   
               
               
                 CD8α hinge- 
                 469 
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                 471 
                 AAACCTACTACCACTCCAGC 
               
               
                 homologous 
                   
                 EASRPAAGGAVHTRGLDFASD 
                   
                 CCCAAGGCCCCCAACCCCA 
               
               
                 stalk 
                   
                   
                   
                 GCACCGACTATCGCATCACA 
               
               
                 extension 
                   
                   
                   
                 GCCTTTGTCACTGCGTCCTG 
               
               
                 region 
                   
                   
                   
                 AAGCCAGCCGGCCAGCTGC 
               
               
                   
                   
                   
                   
                 AGGGGGGGCCGTCCACACA 
               
               
                   
                   
                   
                   
                 AGGGGACTCGACTTTGCGA 
               
               
                   
                   
                   
                   
                 GTGAT 
               
               
                   
               
               
                 CD8α hinge- 
                 469 
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                 472 
                 AAACCTACTACAACTCCTGC 
               
               
                 homologous 
                   
                 EASRPAAGGAVHTRGLDFASD 
                   
                 CCCCCGGCCTCCTACACCAG 
               
               
                 stalk 
                   
                   
                   
                 CTCCTACTATCGCCTCCCAG 
               
               
                 extension 
                   
                   
                   
                 CCACTCAGTCTCAGACCCGA 
               
               
                 region 
                   
                   
                   
                 GGCTTCTAGGCCAGCGGCC 
               
               
                   
                   
                   
                   
                 GGAGGCGCGGTCCACACCC 
               
               
                   
                   
                   
                   
                 GCGGGCTGGACTTTGCATC 
               
               
                   
                   
                   
                   
                 CGAT 
               
               
                   
               
               
                 CD8α hinge 
                 473 
                 KPTTTPAPRPPTPAPTIASOPLSLRP 
                 474 
                 AAGCCTACCACCACCCCCGC 
               
               
                 and 2 CD8a- 
                   
                 EASRPAAGGAVHTRGLDFASDKPT 
                   
                 ACCTCGTCCTCCAACCCCTG 
               
               
                 homologous 
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 CACCTACGATTGCCAGTCAG 
               
               
                 stalk 
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 CCTCTTTCACTGCGGCCTGA 
               
               
                 extension 
                   
                 APRPPTPAPTIASQPLSLRPEACRPA 
                   
                 GGCCAGCAGACCAGCTGCC 
               
               
                 regions 
                   
                 AGGAVHTRGLDFACD 
                   
                 GGCGGTGCCGTCCATACAA 
               
               
                   
                   
                   
                   
                 GAGGACTGGACTTCGCGTC 
               
               
                   
                   
                   
                   
                 CGATAAACCTACTACCACTC 
               
               
                   
                   
                   
                   
                 CAGCCCCAAGGCCCCCAAC 
               
               
                   
                   
                   
                   
                 CCCAGCACCGACTATCGCAT 
               
               
                   
                   
                   
                   
                 CACAGCCTTTGTCACTGCGT 
               
               
                   
                   
                   
                   
                 CCTGAAGCCAGCCGGCCAG 
               
               
                   
                   
                   
                   
                 CTGCAGGGGGGGCCGTCCA 
               
               
                   
                   
                   
                   
                 CACAAGGGGACTCGACTTT 
               
               
                   
                   
                   
                   
                 GCGAGTGATAAGCCCACCA 
               
               
                   
                   
                   
                   
                 CCACCCCTGCCCCTAGACCT 
               
               
                   
                   
                   
                   
                 CCAACCCCAGCCCCTACAAT 
               
               
                   
                   
                   
                   
                 CGCCAGCCAGCCCCTGAGC 
               
               
                   
                   
                   
                   
                 CTGAGGCCCGAAGCCTGTA 
               
               
                   
                   
                   
                   
                 GACCTGCCGCTGGCGGAGC 
               
               
                   
                   
                   
                   
                 CGTGCACACCAGAGGCCTG 
               
               
                   
                   
                   
                   
                 GATTTCGCCTGCGAC 
               
               
                   
               
            
           
         
       
     
     Exemplary Transmembrane Domain Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 CD8a 
                 475 
                 IYIWAPLAGTCGVLLLSLVITLYCNH 
                 476 
                 ATCTACATCTGGGCCCCTCT 
               
               
                 Trans- 
                   
                 RN 
                   
                 GGCCGGCACCTGTGGCGTG 
               
               
                 membrane 
                   
                   
                   
                 CTGCTGCTGAGCCTGGTCAT 
               
               
                 Domain 
                   
                   
                   
                 CACCCTGTACTGCAACCACC 
               
               
                   
                   
                   
                   
                 GGAAT 
               
               
                   
               
               
                   
                 477 
                 FWVLVVVGGVLACYSLLVTVAFIIF 
                 478 
                 TTTTGGGTGCTGGTGGTGG 
               
               
                 CD28 
                   
                 WVRSKRS 
                   
                 TTGGTGGAGTCCTGGCTTG 
               
               
                 Trans- 
                   
                   
                   
                 CTATAGCTTGCTAGTAACAG 
               
               
                 membrane  
                   
                   
                   
                 TGGCCTTTATTATTTTCTGG 
               
               
                 Domain 
                   
                   
                   
                 GTGAGGAGTAAGAGGAGC 
               
               
                   
               
            
           
         
       
     
     Exemplary Intracellular Signaling Domain Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 CD3ζ signaling 
                 479 
                 RVKFSRSADAPAYQQGQNQLYNEL 
                 480 
                 CGGGTGAAGTTCAGCCGGA 
               
               
                 domain 
                   
                 NLGRREEYDVLDKRRGRDPEMGG 
                   
                 GCGCCGACGCCCCTGCCTA 
               
               
                   
                   
                 KPRRKNPQEGLYNELQKDKMAEA 
                   
                 CCAGCAGGGCCAGAACCAG 
               
               
                   
                   
                 YSEIGMKGERRRGKGHDGLYQGLS 
                   
                 CTGTACAACGAGCTGAACC 
               
               
                   
                   
                 TATKDTYDALHMQALPPR 
                   
                 TGGGCCGGAGGGAGGAGT 
               
               
                   
                   
                   
                   
                 ACGACGTGCTGGACAAGCG 
               
               
                   
                   
                   
                   
                 GAGAGGCCGGGACCCTGA 
               
               
                   
                   
                   
                   
                 GATGGGCGGCAAGCCCCG 
               
               
                   
                   
                   
                   
                 GAGAAAGAACCCTCAGGAG 
               
               
                   
                   
                   
                   
                 GGCCTGTATAACGAACTGC 
               
               
                   
                   
                   
                   
                 AGAAAGACAAGATGGCCGA 
               
               
                   
                   
                   
                   
                 GGCCTACAGCGAGATCGGC 
               
               
                   
                   
                   
                   
                 ATGAAGGGCGAGCGGCGG 
               
               
                   
                   
                   
                   
                 AGGGGCAAGGGCCACGAC 
               
               
                   
                   
                   
                   
                 GGCCTGTACCAGGGCCTGA 
               
               
                   
                   
                   
                   
                 GCACCGCCACCAAGGATAC 
               
               
                   
                   
                   
                   
                 CTACGACGCCCTGCACATGC 
               
               
                   
                   
                   
                   
                 AGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 CD28 co- 
                 481 
                 RSKRSRGGHSDYMNMTPRRPGPT 
                 482 
                 AGGAGCAAGCGGAGCAGA 
               
               
                 stimulatory 
                   
                 RKHYOPYAPPRDFAAYRS 
                   
                 GGCGGCCACAGCGACTACA 
               
               
                 domain 
                   
                   
                   
                 TGAACATGACCCCCCGGAG 
               
               
                   
                   
                   
                   
                 GCCTGGCCCCACCCGGAAG 
               
               
                   
                   
                   
                   
                 CACTACCAGCCCTACGCCCC 
               
               
                   
                   
                   
                   
                 TCCCAGGGACTTCGCCGCCT 
               
               
                   
                   
                   
                   
                 ACCGGAGC 
               
               
                   
               
               
                 4-1BB co- 
                 483 
                 KRGRKKLLYIFKQPFMRPVQTTQEE 
                 484 
                 AAGAGAGGCCGGAAGAAA 
               
               
                 stimulatory 
                   
                 DGCSCRFPEEEEGGCEL 
                   
                 CTGCTGTACATCTTCAAGCA 
               
               
                 domain 
                   
                   
                   
                 GCCCTTCATGCGGCCCGTG 
               
               
                   
                   
                   
                   
                 CAGACCACCCAGGAAGAGG 
               
               
                   
                   
                   
                   
                 ACGGCTGCAGCTGCCGGTT 
               
               
                   
                   
                   
                   
                 CCCCGAGGAAGAGGAAGG 
               
               
                   
                   
                   
                   
                 CGGCTGCGAACTG 
               
               
                   
               
               
                 DNAX- 
                 485 
                 LCARPRRSPAQEDGKVYINMPGRG 
                 486 
                 CTGTGCGCACGCCCACGCC 
               
               
                 activation 
                   
                   
                   
                 GCAGCCCCGCCCAAGAAGA 
               
               
                 protein 10 
                   
                   
                   
                 TGGCAAAGTCTACATCAAC 
               
               
                 (DAP10) co- 
                   
                   
                   
                 ATGCCAGGCAGGGGC 
               
               
                 stimulatory 
                   
                   
                   
                   
               
               
                 domain 
                   
                   
                   
                   
               
               
                   
               
               
                 DNAX- 
                 487 
                 YFLGRLVPRGRGAAEAATRKQRITE 
                 488 
                 TACTTCCTGGGCCGGCTGG 
               
               
                 activation 
                   
                 TESPYQELQGQRSDVYSDLNTQRP 
                   
                 TCCCTCGGGGGCGAGGGGC 
               
               
                 protein 12 
                   
                 YYK 
                   
                 TGCGGAGGCAGCGACCCG 
               
               
                 (DAP12) co- 
                   
                   
                   
                 GAAACAGCGTATCACTGAG 
               
               
                 stimulatory 
                   
                   
                   
                 ACCGAGTCGCCTTATCAGG 
               
               
                   
                   
                   
                   
                 AGCTCCAGGGTCAGAGGTC 
               
               
                   
                   
                   
                   
                 GGATGTCTACAGCGACCTC 
               
               
                   
                   
                   
                   
                 AACACACAGAGGCCGTATT 
               
               
                   
                   
                   
                   
                 ACAAA 
               
               
                   
               
            
           
         
       
     
     Exemplary Signal Peptide Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 GM-CSFRa signal 
                 489 
                 MLLLVTSLLLCELPHPAFLLIP 
                 490 
                 ATGCTGCTGCTGGTGACCA 
               
               
                 peptide 
                   
                   
                   
                 GCCTGCTGCTGTGTGAGCT 
               
               
                   
                   
                   
                   
                 GCCCCACCCCGCCTTTCTGC 
               
               
                   
                   
                   
                   
                 TGATCCCC 
               
               
                   
               
               
                 Ig Kappa signal 
                 491 
                 MRLPAQLLGLLMLWVPGSSG 
                 492 
                 ATGAGGCTCCCTGCTCAGCT 
               
               
                 peptide 
                   
                   
                   
                 CCTGGGGCTGCTAATGCTCT 
               
               
                   
                   
                   
                   
                 GGGTCCCAGGATCCAGTGG 
               
               
                   
                   
                   
                   
                 G 
               
               
                   
               
               
                 Immuno-globulin 
                 493 
                 MDWTWILFLVAAATRVHS 
                 494 
                 ATGGATTGGACCTGGATTCT 
               
               
                 E signal peptide 
                   
                   
                   
                 GTTTCTGGTGGCCGCTGCCA 
               
               
                   
                   
                   
                   
                 CAAGAGTGCACAGC 
               
               
                   
               
               
                 CD8α signal 
                 495 
                 MALPVTALLLPLALLLHAARP 
                 496 
                 ATGGCGCTGCCCGTGACCG 
               
               
                 peptide 
                   
                   
                   
                 CCTTGCTCCTGCCGCTGGCC 
               
               
                   
                   
                   
                   
                 TTGCTGCTCCACGCCGCCAG 
               
               
                   
                   
                   
                   
                 GCCG 
               
               
                   
               
               
                 Mouse Ig VH 
                 497 
                 MGWSCIILFLVATATGVHS 
                 498 
                 ATGGGCTGGTCCTGCATCAT 
               
               
                 region 3 signal 
                   
                   
                   
                 CCTGTTTCTGGTGGCTACCG 
               
               
                 peptide 
                   
                   
                   
                 CCACCGGCGTGCACAGC 
               
               
                   
               
               
                 β2M signal 
                 499 
                 MSRSVALAVLALLSLSGLEA 
                 500 
                 ATGTCTCGCTCCGTGGCCTT 
               
               
                 peptide 
                   
                   
                   
                 AGCTGTGCTCGCGCTACTCT 
               
               
                   
               
               
                 Azurocidin signal 
                 501 
                 MTRLTVLALLAGLLASSRA 
                 502 
                 CTCTTTCTGGCCTGGAGGCT 
               
               
                 peptide 
                   
                   
                   
                 ATGACCCGGCTGACAGTCCT 
               
               
                   
                   
                   
                   
                 GGCCCTGCTGGCTGGTCTG 
               
               
                   
               
               
                 Human Serum 
                 503 
                 MKWVTFISLLFLFSSAYS 
                 504 
                 CTGGCGTCCTCGAGGGCC 
               
               
                 Albumin signal 
                   
                   
                   
                 ATGAAGTGGGTAACCTTTAT 
               
               
                 peptide 
                   
                   
                   
                 TTCCCTTCTTTTTCTCTTTAG 
               
               
                   
                   
                   
                   
                 CTCGGCTTATTCC 
               
               
                   
               
               
                 A2M receptor 
                 505 
                 MGKNKLLHPSLVLLLLVLLPTDA 
                 506 
                 ATGGGGAAGAACAAACTCC 
               
               
                 associated 
                   
                   
                   
                 TTCATCCAAGTCTGGTTCTT 
               
               
                 protein signal 
                   
                   
                   
                 CTCCTCTTGGTCCTCCTGCCC 
               
               
                 peptide 
                   
                   
                   
                 ACAGACGCC 
               
               
                   
               
               
                 IGHV3-23 signal 
                 507 
                 MEFGLSWLFLVAILKGVQC 
                 508 
                 ATGGAGTTTGGGCTGAGCT 
               
               
                 peptide 
                   
                   
                   
                 GGCTTTTTCTTGTGGCTATTT 
               
               
                   
                   
                   
                   
                 TAAAAGGTGTCCAGTGT 
               
               
                   
               
               
                 IGKV1-D33 
                 509 
                 MDMRVPAQLLGLLLLWLSGARC 
                 510 
                 ATGGACATGAGGGTCCCTG 
               
               
                 (HuL1) signal 
                   
                   
                   
                 CTCAGCTCCTGGGGCTCCTG 
               
               
                 peptide 
                   
                   
                   
                 CTGCTCTGGCTCTCAGGTGC 
               
               
                   
                   
                   
                   
                 CAGATGT 
               
               
                   
               
               
                 IGHV3-33(L14F) 
                 511 
                 MEFGLSWVFLVALFRGVQC 
                 512 
                 ATGGAGTTTGGGCTGAGCT 
               
               
                 (HuH7) signal 
                   
                   
                   
                 GGGTTTTCCTCGTTGCTCTTT 
               
               
                 peptide 
                   
                   
                   
                 TTAGAGGTGTCCAGTGT 
               
               
                   
               
               
                 TVB2 (T21A) 
                 513 
                 MGTSLLCWMALCLLGADHADA 
                 514 
                 ATGGGCACCAGCCTCCTCTG 
               
               
                 signal peptide 
                   
                   
                   
                 CTGGATGGCCCTGTGTCTCC 
               
               
                   
                   
                   
                   
                 TGGGGGCAGATCACGCAGA 
               
               
                   
                   
                   
                   
                 TGCT 
               
               
                   
               
               
                 CD52 signal 
                 515 
                 MKRFLFLLLTISLLVMVQIQTGLS 
                 516 
                 ATGAAGCGCTTCCTCTTCCT 
               
               
                 peptide 
                   
                   
                   
                 CCTACTCACCATCAGCCTCC 
               
               
                   
                   
                   
                   
                 TGGTTATGGTACAGATACAA 
               
               
                   
                   
                   
                   
                 ACTGGACTCTCA 
               
               
                   
               
               
                 Low-affinity 
                 517 
                 MGAGATGRAMDGPRLLLLLLLGVS 
                 518 
                 ATGGGGGCAGGTGCCACCG 
               
               
                 nerve growth 
                   
                 LGGA 
                   
                 GCCGCGCCATGGACGGGCC 
               
               
                 factor receptor 
                   
                   
                   
                 GCGCCTGCTGCTGTTGCTGC 
               
               
                 (LNGFR, 
                   
                   
                   
                 TTCTGGGGGTGTCCCTTGGA 
               
               
                 TNFRSF16) signal 
                   
                   
                   
                 GGTGCC 
               
               
                 peptide 
               
               
                   
               
            
           
         
       
     
     Exemplary Cytokine Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 IL-15 
                 519 
                 NWVNVISDLKKIEDLIQSMHIDATL 
                 520 
                 AACTGGGTGAATGTGATCA 
               
               
                   
                   
                 YTESDVHPSCKVTAMKCFLLELQVI 
                   
                 GCGACCTGAAGAAGATCGA 
               
               
                   
                   
                 SLESGDASIHDTVENLIILANNSLSS 
                   
                 GGATCTGATCCAGAGCATG 
               
               
                   
                   
                 NGNVTESGCKECEELEEKNIKEFLQ 
                   
                 CACATTGATGCCACCCTGTA 
               
               
                   
                   
                 SFVHIVQMFINTS 
                   
                 CACAGAATCTGATGTGCAC 
               
               
                   
                   
                   
                   
                 CCTAGCTGTAAAGTGACCG 
               
               
                   
                   
                   
                   
                 CCATGAAGTGTTTTCTGCTG 
               
               
                   
                   
                   
                   
                 GAGCTGCAGGTGATTTCTCT 
               
               
                   
                   
                   
                   
                 GGAAAGCGGAGATGCCTCT 
               
               
                   
                   
                   
                   
                 ATCCACGACACAGTGGAGA 
               
               
                   
                   
                   
                   
                 ATCTGATCATCCTGGCCAAC 
               
               
                   
                   
                   
                   
                 AATAGCCTGAGCAGCAATG 
               
               
                   
                   
                   
                   
                 GCAATGTGACAGAGTCTGG 
               
               
                   
                   
                   
                   
                 CTGTAAGGAGTGTGAGGAG 
               
               
                   
                   
                   
                   
                 CTGGAGGAGAAGAACATCA 
               
               
                   
                   
                   
                   
                 AGGAGTTTCTGCAGAGCTT 
               
               
                   
                   
                   
                   
                 TGTGCACATCGTGCAGATG 
               
               
                   
                   
                   
                   
                 TTCATCAATACAAGC 
               
               
                   
               
               
                 IL-15Rα 
                 521 
                 ITCPPPMSVEHADIWVKSYSLYSRE 
                 522 
                 ATTACATGCCCTCCTCCAAT 
               
               
                   
                   
                 RYICNSGFKRKAGTSSLTECVLNKA 
                   
                 GTCTGTGGAGCACGCCGAT 
               
               
                   
                   
                 TNVAHWTTPSLKCIRDPALVHQRP 
                   
                 ATTTGGGTGAAGTCCTACA 
               
               
                   
                   
                 APPSTVTTAGVTPQPESLSPSGKEP 
                   
                 GCCTGTACAGCAGAGAGAG 
               
               
                   
                   
                 AASSPSSNNTAATTAAIVPGSQLM 
                   
                 ATACATCTGCAACAGCGGC 
               
               
                   
                   
                 PSKSPSTGTTEISSHESSHGTPSQTT 
                   
                 TTTAAGAGAAAGGCCGGCA 
               
               
                   
                   
                 AKNWELTASASHQPPGVYPQGHS 
                   
                 CCTCTTCTCTGACAGAGTGC 
               
               
                   
                   
                 DTTVAISTSTVLLCGLSAVSLLACYLK 
                   
                 GTGCTGAATAAGGCCACAA 
               
               
                   
                   
                 SRQTPPLASVEMEAMEALPVTWG 
                   
                 ATGTGGCCCACTGGACAAC 
               
               
                   
                   
                 TSSRDEDLENCSHHL 
                   
                 ACCTAGCCTGAAGTGCATTA 
               
               
                   
                   
                   
                   
                 GAGATCCTGCCCTGGTCCA 
               
               
                   
                   
                   
                   
                 CCAGAGGCCTGCCCCTCCAT 
               
               
                   
                   
                   
                   
                 CTACAGTGACAACAGCCGG 
               
               
                   
                   
                   
                   
                 AGTGACACCTCAGCCTGAA 
               
               
                   
                   
                   
                   
                 TCTCTGAGCCCTTCTGGAAA 
               
               
                   
                   
                   
                   
                 AGAACCTGCCGCCAGCTCTC 
               
               
                   
                   
                   
                   
                 CTAGCTCTAATAATACCGCC 
               
               
                   
                   
                   
                   
                 GCCACAACAGCCGCCATTG 
               
               
                   
                   
                   
                   
                 TGCCTGGATCTCAGCTGAT 
               
               
                   
                   
                   
                   
                 GCCTAGCAAGTCTCCTAGCA 
               
               
                   
                   
                   
                   
                 CAGGCACAACAGAGATCAG 
               
               
                   
                   
                   
                   
                 CAGCCACGAATCTTCTCACG 
               
               
                   
                   
                   
                   
                 GAACACCTTCTCAGACCACC 
               
               
                   
                   
                   
                   
                 GCCAAGAATTGGGAGCTGA 
               
               
                   
                   
                   
                   
                 CAGCCTCTGCCTCTCACCAG 
               
               
                   
                   
                   
                   
                 CCTCCAGGAGTGTATCCTCA 
               
               
                   
                   
                   
                   
                 GGGCCACTCTGATACAACA 
               
               
                   
                   
                   
                   
                 GTGGCCATCAGCACATCTAC 
               
               
                   
                   
                   
                   
                 AGTGCTGCTGTGTGGACTG 
               
               
                   
                   
                   
                   
                 TCTGCCGTGTCTCTGCTGGC 
               
               
                   
                   
                   
                   
                 CTGTTACCTGAAGTCTAGAC 
               
               
                   
                   
                   
                   
                 AGACACCTCCTCTGGCCTCT 
               
               
                   
                   
                   
                   
                 GTGGAGATGGAGGCCATG 
               
               
                   
                   
                   
                   
                 GAAGCCCTGCCTGTGACAT 
               
               
                   
                   
                   
                   
                 GGGGAACAAGCAGCAGAG 
               
               
                   
                   
                   
                   
                 ATGAGGACCTGGAGAATTG 
               
               
                   
                   
                   
                   
                 TTCTCACCACCTG 
               
               
                   
               
               
                 mbIL15 
                 523 
                 NWVNVISDLKKIEDLIQSMHIDATL 
                 524 
                 AACTGGGTGAATGTGATCA 
               
               
                   
                   
                 YTESDVHPSCKVTAMKCFLLELQVI 
                   
                 GCGACCTGAAGAAGATCGA 
               
               
                   
                   
                 SLESGDASIHDTVENLIILANNSLSS 
                   
                 GGATCTGATCCAGAGCATG 
               
               
                   
                   
                 NGNVTESGCKECEELEEKNIKEFLQ 
                   
                 CACATTGATGCCACCCTGTA 
               
               
                   
                   
                 SFVHIVQMFINTSSGGGSGGGGSG 
                   
                 CACAGAATCTGATGTGCAC 
               
               
                   
                   
                 GGGSGGGGSGGGSLQITCPPPMS 
                   
                 CCTAGCTGTAAAGTGACCG 
               
               
                   
                   
                 VEHADIWVKSYSLYSRERYICNSGF 
                   
                 CCATGAAGTGTTTTCTGCTG 
               
               
                   
                   
                 KRKAGTSSLTECVLNKATNVAHWT 
                   
                 GAGCTGCAGGTGATTTCTCT 
               
               
                   
                   
                 TPSLKCIRDPALVHQRPAPPSTVTT 
                   
                 GGAAAGCGGAGATGCCTCT 
               
               
                   
                   
                 AGVTPQPESLSPSGKEPAASSPSSN 
                   
                 ATCCACGACACAGTGGAGA 
               
               
                   
                   
                 NTAATTAAIVPGSQLMPSKSPSTGT 
                   
                 ATCTGATCATCCTGGCCAAC 
               
               
                   
                   
                 TEISSHESSHGTPSQTTAKNWELTA 
                   
                 AATAGCCTGAGCAGCAATG 
               
               
                   
                   
                 SASHQPPGVYPQGHSDTTVAISTST 
                   
                 GCAATGTGACAGAGTCTGG 
               
               
                   
                   
                 VLLCGLSAVSLLACYLKSRQTPPLAS 
                   
                 CTGTAAGGAGTGTGAGGAG 
               
               
                   
                   
                 VEMEAMEALPVTWGTSSRDEDLE 
                   
                 CTGGAGGAGAAGAACATCA 
               
               
                   
                   
                 NCSHHL 
                   
                 AGGAGTTTCTGCAGAGCTT 
               
               
                   
                   
                   
                   
                 TGTGCACATCGTGCAGATG 
               
               
                   
                   
                   
                   
                 TTCATCAATACAAGCTCTGG 
               
               
                   
                   
                   
                   
                 CGGAGGATCTGGAGGAGG 
               
               
                   
                   
                   
                   
                 CGGATCTGGAGGAGGAGG 
               
               
                   
                   
                   
                   
                 CAGTGGAGGCGGAGGATCT 
               
               
                   
                   
                   
                   
                 GGCGGAGGATCTCTGCAGA 
               
               
                   
                   
                   
                   
                 TTACATGCCCTCCTCCAATG 
               
               
                   
                   
                   
                   
                 TCTGTGGAGCACGCCGATA 
               
               
                   
                   
                   
                   
                 TTTGGGTGAAGTCCTACAG 
               
               
                   
                   
                   
                   
                 CCTGTACAGCAGAGAGAGA 
               
               
                   
                   
                   
                   
                 TACATCTGCAACAGCGGCTT 
               
               
                   
                   
                   
                   
                 TAAGAGAAAGGCCGGCACC 
               
               
                   
                   
                   
                   
                 TCTTCTCTGACAGAGTGCGT 
               
               
                   
                   
                   
                   
                 GCTGAATAAGGCCACAAAT 
               
               
                   
                   
                   
                   
                 GTGGCCCACTGGACAACAC 
               
               
                   
                   
                   
                   
                 CTAGCCTGAAGTGCATTAG 
               
               
                   
                   
                   
                   
                 AGATCCTGCCCTGGTCCACC 
               
               
                   
                   
                   
                   
                 AGAGGCCTGCCCCTCCATCT 
               
               
                   
                   
                   
                   
                 ACAGTGACAACAGCCGGAG 
               
               
                   
                   
                   
                   
                 TGACACCTCAGCCTGAATCT 
               
               
                   
                   
                   
                   
                 CTGAGCCCTTCTGGAAAAG 
               
               
                   
                   
                   
                   
                 AACCTGCCGCCAGCTCTCCT 
               
               
                   
                   
                   
                   
                 AGCTCTAATAATACCGCCGC 
               
               
                   
                   
                   
                   
                 CACAACAGCCGCCATTGTG 
               
               
                   
                   
                   
                   
                 CCTGGATCTCAGCTGATGCC 
               
               
                   
                   
                   
                   
                 TAGCAAGTCTCCTAGCACA 
               
               
                   
                   
                   
                   
                 GGCACAACAGAGATCAGCA 
               
               
                   
                   
                   
                   
                 GCCACGAATCTTCTCACGGA 
               
               
                   
                   
                   
                   
                 ACACCTTCTCAGACCACCGC 
               
               
                   
                   
                   
                   
                 CAAGAATTGGGAGCTGACA 
               
               
                   
                   
                   
                   
                 GCCTCTGCCTCTCACCAGCC 
               
               
                   
                   
                   
                   
                 TCCAGGAGTGTATCCTCAG 
               
               
                   
                   
                   
                   
                 GGCCACTCTGATACAACAG 
               
               
                   
                   
                   
                   
                 TGGCCATCAGCACATCTACA 
               
               
                   
                   
                   
                   
                 GTGCTGCTGTGTGGACTGT 
               
               
                   
                   
                   
                   
                 CTGCCGTGTCTCTGCTGGCC 
               
               
                   
                   
                   
                   
                 TGTTACCTGAAGTCTAGACA 
               
               
                   
                   
                   
                   
                 GACACCTCCTCTGGCCTCTG 
               
               
                   
                   
                   
                   
                 TGGAGATGGAGGCCATGGA 
               
               
                   
                   
                   
                   
                 AGCCCTGCCTGTGACATGG 
               
               
                   
                   
                   
                   
                 GGAACAAGCAGCAGAGAT 
               
               
                   
                   
                   
                   
                 GAGGACCTGGAGAATTGTT 
               
               
                   
                   
                   
                   
                 CTCACCACCTG 
               
               
                   
               
               
                 mbIL15 + IgE 
                 525 
                 MDWTWILFLVAAATRVHSNWVN 
                 526 
                 ATGGATTGGACCTGGATTC 
               
               
                 signal Peptide 
                   
                 VISDLKKIEDLIQSMHIDATLYTESD 
                   
                 TGTTTCTGGTGGCCGCTGCC 
               
               
                   
                   
                 VHPSCKVTAMKCFLLELQVISLESG 
                   
                 ACAAGAGTGCACAGCAACT 
               
               
                   
                   
                 DASIHDTVENLIILANNSLSSNGNVT 
                   
                 GGGTGAATGTGATCAGCGA 
               
               
                   
                   
                 ESGCKECEELEEKNIKEFLQSFVHIV 
                   
                 CCTGAAGAAGATCGAGGAT 
               
               
                   
                   
                 QMFINTSSGGGSGGGGSGGGGSG 
                   
                 CTGATCCAGAGCATGCACA 
               
               
                   
                   
                 GGGSGGGSLQITCPPPMSVEHADI 
                   
                 TTGATGCCACCCTGTACACA 
               
               
                   
                   
                 WVKSYSLYSRERYICNSGFKRKAGT 
                   
                 GAATCTGATGTGCACCCTA 
               
               
                   
                   
                 SSLTECVLNKATNVAHWTTPSLKCI 
                   
                 GCTGTAAAGTGACCGCCAT 
               
               
                   
                   
                 RDPALVHORPAPPSTVTTAGVTPQ 
                   
                 GAAGTGTTTTCTGCTGGAG 
               
               
                   
                   
                 PESLSPSGKEPAASSPSSNNTAATT 
                   
                 CTGCAGGTGATTTCTCTGGA 
               
               
                   
                   
                 AAIVPGSQLMPSKSPSTGTTEISSHE 
                   
                 AAGCGGAGATGCCTCTATC 
               
               
                   
                   
                 SSHGTPSQTTAKNWELTASASHQP 
                   
                 CACGACACAGTGGAGAATC 
               
               
                   
                   
                 PGVYPQGHSDTTVAISTSTVLLCGL 
                   
                 TGATCATCCTGGCCAACAAT 
               
               
                   
                   
                 SAVSLLACYLKSRQTPPLASVEMEA 
                   
                 AGCCTGAGCAGCAATGGCA 
               
               
                   
                   
                 MEALPVTWGTSSRDEDLENCSHHL 
                   
                 ATGTGACAGAGTCTGGCTG 
               
               
                   
                   
                   
                   
                 TAAGGAGTGTGAGGAGCTG 
               
               
                   
                   
                   
                   
                 GAGGAGAAGAACATCAAG 
               
               
                   
                   
                   
                   
                 GAGTTTCTGCAGAGCTTTGT 
               
               
                   
                   
                   
                   
                 GCACATCGTGCAGATGTTC 
               
               
                   
                   
                   
                   
                 ATCAATACAAGCTCTGGCG 
               
               
                   
                   
                   
                   
                 GAGGATCTGGAGGAGGCG 
               
               
                   
                   
                   
                   
                 GATCTGGAGGAGGAGGCA 
               
               
                   
                   
                   
                   
                 GTGGAGGCGGAGGATCTG 
               
               
                   
                   
                   
                   
                 GCGGAGGATCTCTGCAGAT 
               
               
                   
                   
                   
                   
                 TACATGCCCTCCTCCAATGT 
               
               
                   
                   
                   
                   
                 CTGTGGAGCACGCCGATAT 
               
               
                   
                   
                   
                   
                 TTGGGTGAAGTCCTACAGC 
               
               
                   
                   
                   
                   
                 CTGTACAGCAGAGAGAGAT 
               
               
                   
                   
                   
                   
                 ACATCTGCAACAGCGGCTTT 
               
               
                   
                   
                   
                   
                 AAGAGAAAGGCCGGCACCT 
               
               
                   
                   
                   
                   
                 CTTCTCTGACAGAGTGCGT 
               
               
                   
                   
                   
                   
                 GCTGAATAAGGCCACAAAT 
               
               
                   
                   
                   
                   
                 GTGGCCCACTGGACAACAC 
               
               
                   
                   
                   
                   
                 CTAGCCTGAAGTGCATTAG 
               
               
                   
                   
                   
                   
                 AGATCCTGCCCTGGTCCACC 
               
               
                   
                   
                   
                   
                 AGAGGCCTGCCCCTCCATCT 
               
               
                   
                   
                   
                   
                 ACAGTGACAACAGCCGGAG 
               
               
                   
                   
                   
                   
                 TGACACCTCAGCCTGAATCT 
               
               
                   
                   
                   
                   
                 CTGAGCCCTTCTGGAAAAG 
               
               
                   
                   
                   
                   
                 AACCTGCCGCCAGCTCTCCT 
               
               
                   
                   
                   
                   
                 AGCTCTAATAATACCGCCGC 
               
               
                   
                   
                   
                   
                 CACAACAGCCGCCATTGTG 
               
               
                   
                   
                   
                   
                 CCTGGATCTCAGCTGATGCC 
               
               
                   
                   
                   
                   
                 TAGCAAGTCTCCTAGCACA 
               
               
                   
                   
                   
                   
                 GGCACAACAGAGATCAGCA 
               
               
                   
                   
                   
                   
                 GCCACGAATCTTCTCACGGA 
               
               
                   
                   
                   
                   
                 ACACCTTCTCAGACCACCGC 
               
               
                   
                   
                   
                   
                 CAAGAATTGGGAGCTGACA 
               
               
                   
                   
                   
                   
                 GCCTCTGCCTCTCACCAGCC 
               
               
                   
                   
                   
                   
                 TCCAGGAGTGTATCCTCAG 
               
               
                   
                   
                   
                   
                 GGCCACTCTGATACAACAG 
               
               
                   
                   
                   
                   
                 TGGCCATCAGCACATCTACA 
               
               
                   
                   
                   
                   
                 GTGCTGCTGTGTGGACTGT 
               
               
                   
                   
                   
                   
                 CTGCCGTGTCTCTGCTGGCC 
               
               
                   
                   
                   
                   
                 TGTTACCTGAAGTCTAGACA 
               
               
                   
                   
                   
                   
                 GACACCTCCTCTGGCCTCTG 
               
               
                   
                   
                   
                   
                 TGGAGATGGAGGCCATGGA 
               
               
                   
                   
                   
                   
                 AGCCCTGCCTGTGACATGG 
               
               
                   
                   
                   
                   
                 GGAACAAGCAGCAGAGAT 
               
               
                   
                   
                   
                   
                 GAGGACCTGGAGAATTGTT 
               
               
                   
                   
                   
                   
                 CTCACCACCTG 
               
               
                   
               
            
           
         
       
     
     Exemplary Linker Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                   
                 SEQ 
                   
                 SEQ ID 
                   
               
               
                 Linker Name 
                 ID NO 
                 Amino Acids Sequence 
                 NO 
                 Polynucleotide Sequence 
               
               
                   
               
             
            
               
                 Whitlow Linker 
                 527 
                 GSTSGSGKPGSGEGSTKG 
                 528 
                 GGCAGCACCTCCGGCAGCGG 
               
               
                   
                   
                   
                   
                 CAAGCCTGGCAGCGGCGAGG 
               
               
                   
                   
                   
                   
                 GCAGCACCAAGGGC 
               
               
                   
               
               
                 Linker 
                 529 
                 SGGGSGGGGSGGGGSGGGGSGG 
                 530 
                 TCTGGCGGAGGATCTGGAGG 
               
               
                   
                   
                 GSLQ 
                   
                 AGGCGGATCTGGAGGAGGAG 
               
               
                   
                   
                   
                   
                 GCAGTGGAGGCGGAGGATCT 
               
               
                   
                   
                   
                   
                 GGCGGAGGATCTCTGCAG 
               
               
                   
               
               
                 GSG linker 
                 531 
                 GSG 
                 532 
                 GGAAGCGGA 
               
               
                   
               
               
                 SGSG linker 
                 533 
                 SGSG 
                 534 
                 AGTGGCAGCGGC 
               
               
                   
               
               
                 (G4S)3 linker 
                 535 
                 GGGGSGGGGSGGGGS 
                 536 
                 GGTGGCGGTGGCTCGGGCGG 
               
               
                   
                   
                   
                   
                 TGGTGGGTCGGGTGGCGGCG 
               
               
                   
                   
                   
                   
                 GATCT 
               
               
                   
               
               
                 Furin cleavage 
                 537 
                 RAKR 
                 538 
                 CGTGCAAAGCGT 
               
               
                 site/Furinlink1 
                   
                   
                   
                   
               
               
                   
               
               
                 Fmdv 
                 539 
                 RAKRAPVKQTLNFDLLKLAGDVESN 
                 540 
                 AGAGCCAAGAGGGCACCGGT 
               
               
                   
                   
                 PGP 
                   
                 GAAACAGACTTTGAATTTTGA 
               
               
                   
                   
                   
                   
                 CCTTCTGAAGTTGGCAGGAGA 
               
               
                   
                   
                   
                   
                 CGTTGAGTCCAACCCTGGGCC 
               
               
                   
                   
                   
                   
                 C 
               
               
                   
               
               
                 Thosea asigna 
                 541 
                 EGRGSLLTCGDVEENPGP 
                 542 
                 GAGGGCAGAGGAAGTCTGCT 
               
               
                 virus 2A region 
                   
                   
                   
                 AACATGCGGTGACGTCGAGG 
               
               
                 (T2A) 
                   
                   
                   
                 AGAATCCTGGACCT 
               
               
                   
               
               
                 Furin-GSG-T2A 
                 543 
                 RAKRGSGEGRGSLLTCGDVEENPG 
                 544 
                 AGAGCTAAGAGGGGAAGCGG 
               
               
                   
                   
                 P 
                   
                 AGAGGGCAGAGGAAGTCTGC 
               
               
                   
                   
                   
                   
                 TAACATGCGGTGACGTCGAGG 
               
               
                   
                   
                   
                   
                 AGAATCCTGGACCT 
               
               
                   
               
               
                 Furin-SGSG-T2A 
                 545 
                 RAKRSGSGEGRGSLLTCGDVEENP 
                 546 
                 AGGGCCAAGAGGAGTGGCAG 
               
               
                   
                   
                 GP 
                   
                 CGGCGAGGGCAGAGGAAGTC 
               
               
                   
                   
                   
                   
                 TTCTAACATGCGGTGACGTGG 
               
               
                   
                   
                   
                   
                 AGGAGAATCCCGGCCCT 
               
               
                   
               
               
                 Porcine 
                 547 
                 ATNFSLLKQAGDVEENPGP 
                 548 
                 GCAACGAACTTCTCTCTCCTAA 
               
               
                 teschovirus-1 2A 
                   
                   
                   
                 AACAGGCTGGTGATGTGGAG 
               
               
                 region (P2A) 
                   
                   
                   
                 GAGAATCCTGGTCCA 
               
               
                   
               
               
                 GSG-P2A 
                 549 
                 GSGATNFSLLKQAGDVEENPGP 
                 550 
                 GGAAGCGGAGCTACTAACTTC 
               
               
                   
                   
                   
                   
                 AGCCTGCTGAAGCAGGCTGG 
               
               
                   
                   
                   
                   
                 AGACGTGGAGGAGAACCCTG 
               
               
                   
                   
                   
                   
                 GACCT 
               
               
                   
               
               
                 Equine rhinitis A 
                 551 
                 QCTNYALLKLAGDVESNPGP 
                 552 
                 CAGTGTACTAATTATGCTCTCT 
               
               
                 virus 2A region 
                   
                   
                   
                 TGAAATTGGCTGGAGATGTTG 
               
               
                 (E2A) 
                   
                   
                   
                 AGAGCAACCCTGGACCT 
               
               
                   
               
               
                 Foot-and-mouth 
                 553 
                 VKQTLNFDLLKLAGDVESNPGP 
                 554 
                 GTCAAACAGACCCTAAACTTT 
               
               
                 disease virus 2A 
                   
                   
                   
                 GATCTGCTAAAACTGGCCGGG 
               
               
                 region (F2A) 
                   
                   
                   
                 GATGTGGAAAGTAATCCCGGC 
               
               
                   
                   
                   
                   
                 CCC 
               
               
                   
               
               
                 FP2A 
                 555 
                 RAKRAPVKQGSGATNFSLLKQAGD 
                 556 
                 CGTGCAAAGCGTGCACCGGTG 
               
               
                   
                   
                 VEENPGP 
                   
                 AAACAGGGAAGCGGAGCTAC 
               
               
                   
                   
                   
                   
                 TAACTTCAGCCTGCTGAAGCA 
               
               
                   
                   
                   
                   
                 GGCTGGAGACGTGGAGGAGA 
               
               
                   
                   
                   
                   
                 ACCCTGGACCT 
               
               
                   
               
               
                 Linker-GSG 
                 557 
                 APVKQGSG 
                 558 
                 GCACCGGTGAAACAGGGAAG 
               
               
                   
                   
                   
                   
                 CGGA 
               
               
                   
               
               
                 Linker 
                 559 
                 GGGGSGGGSGGGGSGGGGS 
                 560 
                 GGTGGCGGTGGCTCGGGCGG 
               
               
                   
                   
                   
                   
                 TGGTGGGTCGGGTGGCGGCG 
               
               
                   
                   
                   
                   
                 GATCTGGTGGCGGTGGCTCG 
               
               
                   
               
               
                 Linker 
                 561 
                 APVKQ 
                 562 
                 GCACCGGTGAAACAG 
               
               
                   
               
               
                 Linker 
                 563 
                 A(EAAAK)nA (n = 2-5) 
                 564 
               
               
                   
               
            
           
         
       
     
     Exemplary Cell Tag Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                   
                 SEQ ID 
                   
                 SEQ 
                   
               
               
                   
                 NO 
                 Amino Acid Sequence 
                 ID NO 
                 Polynucleotide Sequence 
               
               
                   
               
             
            
               
                 HER1 Domain 
                 565 
                 RKVCNGIGIGEFKDSLSINATNIKHF 
                 566 
                 CGCAAAGTGTGTAACGGAA 
               
               
                 III 
                   
                 KNCTSISGDLHILPVAFRGDSFTHTP 
                   
                 TAGGTATTGGTGAATTTAA 
               
               
                   
                   
                 PLDPQELD 
                   
                 AGACTCACTCTCCATAAATG 
               
               
                   
                   
                 ILKTVKEITGFLLIQAWPENRTDLHA 
                   
                 CTACGAATATTAAACACTTC 
               
               
                   
                   
                 FENLEIIRGRTKQHGQFSLAVVSLNI 
                   
                 AAAAACTGCACCTCCATCAG 
               
               
                   
                   
                 TSLGLRSL 
                   
                 TGGCGATCTCCACATCCTGC 
               
               
                   
                   
                 KEISDGDVIISGNKNLCYANTINWK 
                   
                 CGGTGGCATTTAGGGGTGA 
               
               
                   
                   
                 KLFGTSGQKTKIISNRGENSCKATG 
                   
                 CTCCTTCACACATACTCCTC 
               
               
                   
                   
                 Q 
                   
                 CTCTGGATCCACAGGAACT 
               
               
                   
                   
                   
                   
                 GGATATTCTGAAAACCGTA 
               
               
                   
                   
                   
                   
                 AAGGAAATCACAGGGTTTT 
               
               
                   
                   
                   
                   
                 TGCTGATTCAGGCTTGGCCT 
               
               
                   
                   
                   
                   
                 GAAAACAGGACGGACCTCC 
               
               
                   
                   
                   
                   
                 ATGCCTTTGAGAACCTAGA 
               
               
                   
                   
                   
                   
                 AATCATACGCGGCAGGACC 
               
               
                   
                   
                   
                   
                 AAGCAACATGGTCAGTTTTC 
               
               
                   
                   
                   
                   
                 TCTTGCAGTCGTCAGCCTGA 
               
               
                   
                   
                   
                   
                 ACATAACATCCTTGGGATTA 
               
               
                   
                   
                   
                   
                 CGCTCCCTCAAGGAGATAA 
               
               
                   
                   
                   
                   
                 GTGATGGAGATGTGATAAT 
               
               
                   
                   
                   
                   
                 TTCAGGAAACAAAAATTTGT 
               
               
                   
                   
                   
                   
                 GCTATGCAAATACAATAAA 
               
               
                   
                   
                   
                   
                 CTGGAAAAAACTGTTTGGG 
               
               
                   
                   
                   
                   
                 ACCTCCGGTCAGAAAACCA 
               
               
                   
                   
                   
                   
                 AAATTATAAGCAACAGAGG 
               
               
                   
                   
                   
                   
                 TGAAAACAGCTGCAAGGCC 
               
               
                   
                   
                   
                   
                 ACAGGCCAG 
               
               
                   
               
               
                 HER1 
                 567 
                 VCHALCSPEGCWGPEPRDCVS 
                 568 
                 GTCTGCCATGCCTTGTGCTC 
               
               
                 truncated 
                   
                   
                   
                 CCCCGAGGGCTGCTGGGGC 
               
               
                 Domain IV 
                   
                   
                   
                 CCGGAGCCCAGGGACTGCG 
               
               
                   
                   
                   
                   
                 TCTCT 
               
               
                   
               
               
                 HER1t 
                 569 
                 RKVCNGIGIGEFKDSLSINATNIKHF 
                 570 
                 CGCAAAGTGTGTAACGGAA 
               
               
                   
                   
                 KNCTSISGDLHILPVAFRGDSFTHTP 
                   
                 TAGGTATTGGTGAATTTAA 
               
               
                   
                   
                 PLDPQELDILKTVKEITGFLLIQAWP 
                   
                 AGACTCACTCTCCATAAATG 
               
               
                   
                   
                 ENRTDLHAFENLEIIRGRTKQHGQF 
                   
                 CTACGAATATTAAACACTTC 
               
               
                   
                   
                 SLAVVSLNITSLGLRSLKEISDGDVIIS 
                   
                 AAAAACTGCACCTCCATCAG 
               
               
                   
                   
                 GNKNLCYANTINWKKLFGTSGQKT 
                   
                 TGGCGATCTCCACATCCTGC 
               
               
                   
                   
                 KIISNRGENSCKATGQVCHALCSPE 
                   
                 CGGTGGCATTTAGGGGTGA 
               
               
                   
                   
                 GCWGPEPRDCVSCRNVSRGRECV 
                   
                 CTCCTTCACACATACTCCTC 
               
               
                   
                   
                 DKCNLLEGEPREFVENSECIQCHPE 
                   
                 CTCTGGATCCACAGGAACT 
               
               
                   
                   
                 CLPQAMNITCTGRGPDNCIQCAHY 
                   
                 GGATATTCTGAAAACCGTA 
               
               
                   
                   
                 IDGPHCVKTCPAGVMGENNTLVW 
                   
                 AAGGAAATCACAGGGTTTT 
               
               
                   
                   
                 KYADAGHVCHLCHPNCTYGCTGP 
                   
                 TGCTGATTCAGGCTTGGCCT 
               
               
                   
                   
                 GLEGCPTNGPKIPSIATGMVGALLL 
                   
                 GAAAACAGGACGGACCTCC 
               
               
                   
                   
                 LLVVALGIGLFM 
                   
                 ATGCCTTTGAGAACCTAGA 
               
               
                   
                   
                   
                   
                 AATCATACGCGGCAGGACC 
               
               
                   
                   
                   
                   
                 AAGCAACATGGTCAGTTTTC 
               
               
                   
                   
                   
                   
                 TCTTGCAGTCGTCAGCCTGA 
               
               
                   
                   
                   
                   
                 ACATAACATCCTTGGGATTA 
               
               
                   
                   
                   
                   
                 CGCTCCCTCAAGGAGATAA 
               
               
                   
                   
                   
                   
                 GTGATGGAGATGTGATAAT 
               
               
                   
                   
                   
                   
                 TTCAGGAAACAAAAATTTGT 
               
               
                   
                   
                   
                   
                 GCTATGCAAATACAATAAA 
               
               
                   
                   
                   
                   
                 CTGGAAAAAACTGTTTGGG 
               
               
                   
                   
                   
                   
                 ACCTCCGGTCAGAAAACCA 
               
               
                   
                   
                   
                   
                 AAATTATAAGCAACAGAGG 
               
               
                   
                   
                   
                   
                 TGAAAACAGCTGCAAGGCC 
               
               
                   
                   
                   
                   
                 ACAGGCCAGGTCTGCCATG 
               
               
                   
                   
                   
                   
                 CCTTGTGCTCCCCCGAGGG 
               
               
                   
                   
                   
                   
                 CTGCTGGGGCCCGGAGCCC 
               
               
                   
                   
                   
                   
                 AGGGACTGCGTCTCTTGCC 
               
               
                   
                   
                   
                   
                 GGAATGTCAGCCGAGGCAG 
               
               
                   
                   
                   
                   
                 GGAATGCGTGGACAAGTGC 
               
               
                   
                   
                   
                   
                 AACCTTCTGGAGGGTGAGC 
               
               
                   
                   
                   
                   
                 CAAGGGAGTTTGTGGAGAA 
               
               
                   
                   
                   
                   
                 CTCTGAGTGCATACAGTGC 
               
               
                   
                   
                   
                   
                 CACCCAGAGTGCCTGCCTCA 
               
               
                   
                   
                   
                   
                 GGCCATGAACATCACCTGC 
               
               
                   
                   
                   
                   
                 ACAGGACGGGGACCAGAC 
               
               
                   
                   
                   
                   
                 AACTGTATCCAGTGTGCCCA 
               
               
                   
                   
                   
                   
                 CTACATTGACGGCCCCCACT 
               
               
                   
                   
                   
                   
                 GCGTCAAGACCTGCCCGGC 
               
               
                   
                   
                   
                   
                 AGGAGTCATGGGAGAAAAC 
               
               
                   
                   
                   
                   
                 AACACCCTGGTCTGGAAGT 
               
               
                   
                   
                   
                   
                 ACGCAGACGCCGGCCATGT 
               
               
                   
                   
                   
                   
                 GTGCCACCTGTGCCATCCAA 
               
               
                   
                   
                   
                   
                 ACTGCACCTACGGATGCACT 
               
               
                   
                   
                   
                   
                 GGGCCAGGTCTTGAAGGCT 
               
               
                   
                   
                   
                   
                 GTCCAACGAATGGGCCTAA 
               
               
                   
                   
                   
                   
                 GATCCCGTCCATCGCCACTG 
               
               
                   
                   
                   
                   
                 GGATGGTGGGGGCCCTCCT 
               
               
                   
                   
                   
                   
                 CTTGCTGCTGGTGGTGGCC 
               
               
                   
                   
                   
                   
                 CTGGGGATCGGCCTCTTCAT 
               
               
                   
                   
                   
                   
                 G 
               
               
                   
               
               
                 HER1t-1 
                 571 
                 RKVCNGIGIGEFKDSLSINATNIKHF 
                 572 
                 CGCAAAGTGTGTAACGGAA 
               
               
                   
                   
                 KNCTSISGDLHILPVAFRGDSFTHTP 
                   
                 TAGGTATTGGTGAATTTAA 
               
               
                   
                   
                 PLDPQELDILKTVKEITGFLLIQAWP 
                   
                 AGACTCACTCTCCATAAATG 
               
               
                   
                   
                 ENRTDLHAFENLEIIRGRTKQHGQF 
                   
                 CTACGAATATTAAACACTTC 
               
               
                   
                   
                 SLAVVSLNITSLGLRSLKEISDGDVIIS 
                   
                 AAAAACTGCACCTCCATCAG 
               
               
                   
                   
                 GNKNLCYANTINWKKLFGTSGQKT 
                   
                 TGGCGATCTCCACATCCTGC 
               
               
                   
                   
                 KIISNRGENSCKATGQVCHALCSPE 
                   
                 CGGTGGCATTTAGGGGTGA 
               
               
                   
                   
                 GCWGPEPRDCVSGGGGSGGGSG 
                   
                 CTCCTTCACACATACTCCTC 
               
               
                   
                   
                 GGGSGGGGSFWVLVVVGGVLACY 
                   
                 CTCTGGATCCACAGGAACT 
               
               
                   
                   
                 SLLVTVAFIIFWVRSKRS 
                   
                 GGATATTCTGAAAACCGTA 
               
               
                   
                   
                   
                   
                 AAGGAAATCACAGGGTTTT 
               
               
                   
                   
                   
                   
                 TGCTGATTCAGGCTTGGCCT 
               
               
                   
                   
                   
                   
                 GAAAACAGGACGGACCTCC 
               
               
                   
                   
                   
                   
                 ATGCCTTTGAGAACCTAGA 
               
               
                   
                   
                   
                   
                 AATCATACGCGGCAGGACC 
               
               
                   
                   
                   
                   
                 AAGCAACATGGTCAGTTTTC 
               
               
                   
                   
                   
                   
                 TCTTGCAGTCGTCAGCCTGA 
               
               
                   
                   
                   
                   
                 ACATAACATCCTTGGGATTA 
               
               
                   
                   
                   
                   
                 CGCTCCCTCAAGGAGATAA 
               
               
                   
                   
                   
                   
                 GTGATGGAGATGTGATAAT 
               
               
                   
                   
                   
                   
                 TTCAGGAAACAAAAATTTGT 
               
               
                   
                   
                   
                   
                 GCTATGCAAATACAATAAA 
               
               
                   
                   
                   
                   
                 CTGGAAAAAACTGTTTGGG 
               
               
                   
                   
                   
                   
                 ACCTCCGGTCAGAAAACCA 
               
               
                   
                   
                   
                   
                 AAATTATAAGCAACAGAGG 
               
               
                   
                   
                   
                   
                 TGAAAACAGCTGCAAGGCC 
               
               
                   
                   
                   
                   
                 ACAGGCCAGGTCTGCCATG 
               
               
                   
                   
                   
                   
                 CCTTGTGCTCCCCCGAGGG 
               
               
                   
                   
                   
                   
                 CTGCTGGGGCCCGGAGCCC 
               
               
                   
                   
                   
                   
                 AGGGACTGCGTCTCTGGTG 
               
               
                   
                   
                   
                   
                 GCGGTGGCTCGGGCGGTG 
               
               
                   
                   
                   
                   
                 GTGGGTCGGGTGGCGGCG 
               
               
                   
                   
                   
                   
                 GATCTGGTGGCGGTGGCTC 
               
               
                   
                   
                   
                   
                 GTTTTGGGTGCTGGTGGTG 
               
               
                   
                   
                   
                   
                 GTTGGTGGAGTCCTGGCTT 
               
               
                   
                   
                   
                   
                 GCTATAGCTTGCTAGTAACA 
               
               
                   
                   
                   
                   
                 GTGGCCTTTATTATTTTCTG 
               
               
                   
                   
                   
                   
                 GGTGAGGAGTAAGAGGAG 
               
               
                   
                   
                   
                   
                 CTAA 
               
               
                   
               
               
                 FL CD20 
                 573 
                 MTTPRNSVNGTFPAEPMKGPIAM 
                 574 
                 ATGACAACACCCAGAAATT 
               
               
                   
                   
                 QSGPKPLFRRMSSLVGPTQSFFMR 
                   
                 CAGTAAATGGGACTTTCCC 
               
               
                   
                   
                 ESKTLGAVQIMNGLFHIALGGLLMI 
                   
                 GGCAGAGCCAATGAAAGGC 
               
               
                   
                   
                 PAGIYAPICVTVWYPLWGGIMYIIS 
                   
                 CCTATTGCTATGCAATCTGG 
               
               
                   
                   
                 GSLLAATEKNSRKCLVKGKMIMNS 
                   
                 TCCAAAACCACTCTTCAGGA 
               
               
                   
                   
                 LSLFAAISGMILSIMDILNIKISHFLK 
                   
                 GGATGTCTTCACTGGTGGG 
               
               
                   
                   
                 MESLNFIRAHTPYINIYNCEPANPSE 
                   
                 CCCCACGCAAAGCTTCTTCA 
               
               
                   
                   
                 KNSPSTQYCYSIQSLFLGILSVMLIFA 
                   
                 TGAGGGAATCTAAGACTTT 
               
               
                   
                   
                 FFQELVIAGIVENEWKRTCSRPKSNI 
                   
                 GGGGGCTGTCCAGATTATG 
               
               
                   
                   
                 VLLSAEEKKEQTIEIKEEVVGLTETSS 
                   
                 AATGGGCTCTTCCACATTGC 
               
               
                   
                   
                 QPKNEEDIEIIPIQEEEEEETETNFPE 
                   
                 CCTGGGGGGTCTTCTGATG 
               
               
                   
                   
                 PPQDQESSPIENDSSP 
                   
                 ATCCCAGCAGGGATCTATG 
               
               
                   
                   
                   
                   
                 CACCCATCTGTGTGACTGTG 
               
               
                   
                   
                   
                   
                 TGGTACCCTCTCTGGGGAG 
               
               
                   
                   
                   
                   
                 GCATTATGTATATTATTTCC 
               
               
                   
                   
                   
                   
                 GGATCACTCCTGGCAGCAA 
               
               
                   
                   
                   
                   
                 CGGAGAAAAACTCCAGGAA 
               
               
                   
                   
                   
                   
                 GTGTTTGGTCAAAGGAAAA 
               
               
                   
                   
                   
                   
                 ATGATAATGAATTCATTGAG 
               
               
                   
                   
                   
                   
                 CCTCTTTGCTGCCATTTCTG 
               
               
                   
                   
                   
                   
                 GAATGATTCTTTCAATCATG 
               
               
                   
                   
                   
                   
                 GACATACTTAATATTAAAAT 
               
               
                   
                   
                   
                   
                 TTCCCATTTTTTAAAAATGG 
               
               
                   
                   
                   
                   
                 AGAGTCTGAATTTTATTAGA 
               
               
                   
                   
                   
                   
                 GCTCACACACCATATATTAA 
               
               
                   
                   
                   
                   
                 CATATACAACTGTGAACCA 
               
               
                   
                   
                   
                   
                 GCTAATCCCTCTGAGAAAA 
               
               
                   
                   
                   
                   
                 ACTCCCCATCTACCCAATAC 
               
               
                   
                   
                   
                   
                 TGTTACAGCATACAATCTCT 
               
               
                   
                   
                   
                   
                 GTTCTTGGGCATTTTGTCAG 
               
               
                   
                   
                   
                   
                 TGATGCTGATCTTTGCCTTC 
               
               
                   
                   
                   
                   
                 TTCCAGGAACTTGTAATAGC 
               
               
                   
                   
                   
                   
                 TGGCATCGTTGAGAATGAA 
               
               
                   
                   
                   
                   
                 TGGAAAAGAACGTGCTCCA 
               
               
                   
                   
                   
                   
                 GACCCAAATCTAACATAGTT 
               
               
                   
                   
                   
                   
                 CTCCTGTCAGCAGAAGAAA 
               
               
                   
                   
                   
                   
                 AAAAAGAACAGACTATTGA 
               
               
                   
                   
                   
                   
                 AATAAAAGAAGAAGTGGTT 
               
               
                   
                   
                   
                   
                 GGGCTAACTGAAACATCTTC 
               
               
                   
                   
                   
                   
                 CCAACCAAAGAATGAAGAA 
               
               
                   
                   
                   
                   
                 GACATTGAAATTATTCCAAT 
               
               
                   
                   
                   
                   
                 CCAAGAAGAGGAAGAAGA 
               
               
                   
                   
                   
                   
                 AGAAACAGAGACGAACTTT 
               
               
                   
                   
                   
                   
                 CCAGAACCTCCCCAAGATCA 
               
               
                   
                   
                   
                   
                 GGAATCCTCACCAATAGAA 
               
               
                   
                   
                   
                   
                 AATGACAGCTCTCCT 
               
               
                   
               
               
                 CD20t-1 
                 575 
                 MTTPRNSVNGTFPAEPMKGPIAM 
                 576 
                 ATGACCACACCACGGAACT 
               
               
                   
                   
                 QSGPKPLFRRMSSLVGPTQSFFMR 
                   
                 CTGTGAATGGCACCTTCCCA 
               
               
                   
                   
                 ESKTLGAVQIMNGLFHIALGGLLMI 
                   
                 GCAGAGCCAATGAAGGGAC 
               
               
                   
                   
                 PAGIYAPICVTVWYPLWGGIMYIIS 
                   
                 CAATCGCAATGCAGAGCGG 
               
               
                   
                   
                 GSLLAATEKNSRKCLVKGKMIMNS 
                   
                 ACCCAAGCCTCTGTTTCGGA 
               
               
                   
                   
                 LSLFAAISGMILSIMDILNIKISHFLK 
                   
                 GAATGAGCTCCCTGGTGGG 
               
               
                   
                   
                 MESLNFIRAHTPYINIYNCEPANPSE 
                   
                 CCCAACCCAGTCCTTCTTTA 
               
               
                   
                   
                 KNSPSTQYCYSIQSLFLGILSVMLIFA 
                   
                 TGAGAGAGTCTAAGACACT 
               
               
                   
                   
                 FFQELVIAGIVENEWKRTCSRPKSNI 
                   
                 GGGCGCCGTGCAGATCATG 
               
               
                   
                   
                 VLLSAEEKKEQTIEIKEEVVGLTETSS 
                   
                 AACGGACTGTTCCACATCGC 
               
               
                   
                   
                 QPKNEEDIE 
                   
                 CCTGGGAGGACTGCTGATG 
               
               
                   
                   
                   
                   
                 ATCCCAGCCGGCATCTACGC 
               
               
                   
                   
                   
                   
                 CCCTATCTGCGTGACCGTGT 
               
               
                   
                   
                   
                   
                 GGTACCCTCTGTGGGGCGG 
               
               
                   
                   
                   
                   
                 CATCATGTATATCATCTCCG 
               
               
                   
                   
                   
                   
                 GCTCTCTGCTGGCCGCCACA 
               
               
                   
                   
                   
                   
                 GAGAAGAACAGCAGGAAG 
               
               
                   
                   
                   
                   
                 TGTCTGGTGAAGGGCAAGA 
               
               
                   
                   
                   
                   
                 TGATCATGAATAGCCTGTCC 
               
               
                   
                   
                   
                   
                 CTGTTTGCCGCCATCTCTGG 
               
               
                   
                   
                   
                   
                 CATGATCCTGAGCATCATG 
               
               
                   
                   
                   
                   
                 GACATCCTGAACATCAAGA 
               
               
                   
                   
                   
                   
                 TCAGCCACTTCCTGAAGATG 
               
               
                   
                   
                   
                   
                 GAGAGCCTGAACTTCATCA 
               
               
                   
                   
                   
                   
                 GAGCCCACACCCCTTACATC 
               
               
                   
                   
                   
                   
                 AACATCTATAATTGCGAGCC 
               
               
                   
                   
                   
                   
                 TGCCAACCCATCCGAGAAG 
               
               
                   
                   
                   
                   
                 AATTCTCCAAGCACACAGTA 
               
               
                   
                   
                   
                   
                 CTGTTATTCCATCCAGTCTC 
               
               
                   
                   
                   
                   
                 TGTTCCTGGGCATCCTGTCT 
               
               
                   
                   
                   
                   
                 GTGATGCTGATCTTTGCCTT 
               
               
                   
                   
                   
                   
                 CTTTCAGGAGCTGGTCATC 
               
               
                   
                   
                   
                   
                 GCCGGCATCGTGGAGAACG 
               
               
                   
                   
                   
                   
                 AGTGGAAGAGGACCTGCAG 
               
               
                   
                   
                   
                   
                 CCGCCCCAAGTCCAATATCG 
               
               
                   
                   
                   
                   
                 TGCTGCTGTCCGCCGAGGA 
               
               
                   
                   
                   
                   
                 GAAGAAGGAGCAGACAATC 
               
               
                   
                   
                   
                   
                 GAGATCAAGGAGGAGGTG 
               
               
                   
                   
                   
                   
                 GTGGGCCTGACCGAGACAT 
               
               
                   
                   
                   
                   
                 CTAGCCAGCCTAAGAATGA 
               
               
                   
                   
                   
                   
                 GGAGGATATCGAG 
               
               
                   
               
            
           
         
       
     
     Exemplary Vector Sequences 
     
       
         
           
               
               
               
               
               
             
               
                   
               
             
            
               
                 Human EF1A1 
                   
                   
                 577 
                 GCCGCAATAAAATATCTTTA 
               
               
                 Promoter 
                   
                   
                   
                 TTTTCATTACATCTGTGTGTT 
               
               
                   
                   
                   
                   
                 GGTTTTTTGTGTGAATCGTA 
               
               
                   
                   
                   
                   
                 ACTAACATACGCTCTCCATC 
               
               
                   
                   
                   
                   
                 AAAACAAAACGAAACAAAA 
               
               
                   
                   
                   
                   
                 CAAACTAGCAAAATAGGCT 
               
               
                   
                   
                   
                   
                 GTCCCCAGTGCAAGTGCAG 
               
               
                   
                   
                   
                   
                 GTGCCAGAACATTTCTCTAT 
               
               
                   
                   
                   
                   
                 CGAAGGATCTGCGATCGCT 
               
               
                   
                   
                   
                   
                 CCGGTGCCCGTCAGTGGGC 
               
               
                   
                   
                   
                   
                 AGAGCGCACATCGCCCACA 
               
               
                   
                   
                   
                   
                 GTCCCCGAGAAGTTGGGGG 
               
               
                   
                   
                   
                   
                 GAGGGGTCGGCAATTGAAC 
               
               
                   
                   
                   
                   
                 CGGTGCCTAGAGAAGGTGG 
               
               
                   
                   
                   
                   
                 CGCGGGGTAAACTGGGAAA 
               
               
                   
                   
                   
                   
                 GTGATGTCGTGTACTGGCTC 
               
               
                   
                   
                   
                   
                 CGCCTTTTTCCCGAGGGTGG 
               
               
                   
                   
                   
                   
                 GGGAGAACCGTATATAAGT 
               
               
                   
                   
                   
                   
                 GCAGTAGTCGCCGTGAACG 
               
               
                   
                   
                   
                   
                 TTCTTTTTCGCAACGGGTTT 
               
               
                   
                   
                   
                   
                 GCCGCCAGAACACAG 
               
               
                   
               
               
                 Human CMV 
                   
                   
                 578 
                 GTGATGCGGTTTTGGCAGT 
               
               
                 immediate 
                   
                   
                   
                 ACATCAATGGGCGTGGATA 
               
               
                 Early 
                   
                   
                   
                 GCGGTTTGACTCACGGGGA 
               
               
                 Promoter 
                   
                   
                   
                 TTTCCAAGTCTCCACCCCATT 
               
               
                   
                   
                   
                   
                 GACGTCAATGGGAGTTTGT 
               
               
                   
                   
                   
                   
                 TTTGGCACCAAAATCAACGG 
               
               
                   
                   
                   
                   
                 GACTTTCCAAAATGTCGTAA 
               
               
                   
                   
                   
                   
                 CAACTCCGCCCCATTGACGC 
               
               
                   
                   
                   
                   
                 AAATGGGCGGTAGGCGTGT 
               
               
                   
                   
                   
                   
                 ACGGTGGGAGGTCTATATA 
               
               
                   
                   
                   
                   
                 AGCAGAGCTC 
               
               
                   
               
               
                 ColE1 ORI 
                   
                   
                 579 
                 TGTGAGCAAAAGGCCAGCA 
               
               
                   
                   
                   
                   
                 AAAGGCCAGGAACCGTAAA 
               
               
                   
                   
                   
                   
                 AAGGCCGCGTTGCTGGCGT 
               
               
                   
                   
                   
                   
                 TTTTCCATAGGCTCCGCCCC 
               
               
                   
                   
                   
                   
                 CCTGACGAGCATCACAAAA 
               
               
                   
                   
                   
                   
                 ATCGACGCTCAAGTCAGAG 
               
               
                   
                   
                   
                   
                 GTGGCGAAACCCGACAGGA 
               
               
                   
                   
                   
                   
                 CTATAAAGATACCAGGCGTT 
               
               
                   
                   
                   
                   
                 TCCCCCTGGAAGCTCCCTCG 
               
               
                   
                   
                   
                   
                 TGCGCTCTCCTGTTCCGACC 
               
               
                   
                   
                   
                   
                 CTGCCGCTTACCGGATACCT 
               
               
                   
                   
                   
                   
                 GTCCGCCTTTCTCCCTTCGG 
               
               
                   
                   
                   
                   
                 GAAGCGTGGCGCTTTCTCAT 
               
               
                   
                   
                   
                   
                 AGCTCACGCTGTAGGTATCT 
               
               
                   
                   
                   
                   
                 CAGTTCGGTGTAGGTCGTTC 
               
               
                   
                   
                   
                   
                 GCTCCAAGCTGGGCTGTGT 
               
               
                   
                   
                   
                   
                 GCACGAACCCCCCGTTCAGC 
               
               
                   
                   
                   
                   
                 CCGACCGCTGCGCCTTATCC 
               
               
                   
                   
                   
                   
                 GGTAACTATCGTCTTGAGTC 
               
               
                   
                   
                   
                   
                 CAACCCGGTAAGACACGAC 
               
               
                   
                   
                   
                   
                 TTATCGCCACTGGCAGCAGC 
               
               
                   
                   
                   
                   
                 CACTGGTAACAGGATTAGC 
               
               
                   
                   
                   
                   
                 AGAGCGAGGTATGTAGGCG 
               
               
                   
                   
                   
                   
                 GTGCTACAGAGTTCTTGAA 
               
               
                   
                   
                   
                   
                 GTGGTGGCCTAACTACGGC 
               
               
                   
                   
                   
                   
                 TACACTAGAAGAACAGTATT 
               
               
                   
                   
                   
                   
                 TGGTATCTGCGCTCTGCTGA 
               
               
                   
                   
                   
                   
                 AGCCAGTTACCTTCGGAAAA 
               
               
                   
                   
                   
                   
                 AGAGTTGGTAGCTCTTGATC 
               
               
                   
                   
                   
                   
                 CGG CAAACAAACCACCG CT 
               
               
                   
                   
                   
                   
                 GGTAGCGGTGGTTTTTTTGT 
               
               
                   
                   
                   
                   
                 TTGCAAGCAGCAGATTACG 
               
               
                   
                   
                   
                   
                 CGCAGAAAAAAAGGATCTC 
               
               
                   
                   
                   
                   
                 AAGAAGATCCTTTGATCTTT 
               
               
                   
                   
                   
                   
                 TCTACGGGG 
               
               
                   
               
               
                 Left 
                   
                   
                 580 
                 CTACAGTTGA 
               
               
                 Transposon 
                   
                   
                   
                 AGTCGGAAGT 
               
               
                 Repeat 
                   
                   
                   
                 TTACATACAC TTAAGTTGGA 
               
               
                 Region 
                   
                   
                   
                 GTCATTAAAA CTCGTTTTTC 
               
               
                   
                   
                   
                   
                 AACTACTCCA CAAATTTCTT 
               
               
                   
                   
                   
                   
                 GTTAACAAAC 
               
               
                   
                   
                   
                   
                 AATAGTTTTG 
               
               
                   
                   
                   
                   
                 GCAAGTCAGT 
               
               
                   
                   
                   
                   
                 TAGGACATCT ACTTTGTGCA 
               
               
                   
                   
                   
                   
                 TGACACAAGT CATTTTTCCA 
               
               
                   
                   
                   
                   
                 ACAATTGTTT 
               
               
                   
                   
                   
                   
                 ACAGACAGAT TATTTCACTT 
               
               
                   
                   
                   
                   
                 ATAATTCACT GTATCACAAT 
               
               
                   
                   
                   
                   
                 TCCAGTGGGT 
               
               
                   
                   
                   
                   
                 CAGAAGTTTA 
               
               
                   
                   
                   
                   
                 CATACACTAA 
               
               
                   
                   
                   
                   
                 GTTGACTGTG CCTTTAAACA 
               
               
                   
                   
                   
                   
                 GCTTGGAAAA 
               
               
                   
                   
                   
                   
                 TTCCAGAAAA 
               
               
                   
                   
                   
                   
                 TGATGTCATG GCTTTAG 
               
               
                   
               
               
                 Right 
                   
                   
                 581 
                 GTGGAAGGCT 
               
               
                 Transposon 
                   
                   
                   
                 ACTCGAAATG 
               
               
                 Repeat 
                   
                   
                   
                 TTTGACCCAA GTTAAACAAT 
               
               
                 Region 
                   
                   
                   
                 TTAAAGGCAA 
               
               
                   
                   
                   
                   
                 TGCTACCAAA TACTAATTGA 
               
               
                   
                   
                   
                   
                 GTGTATGTTA ACTTCTGACC 
               
               
                   
                   
                   
                   
                 CACTGGGAAT 
               
               
                   
                   
                   
                   
                 GTGATGAAAG 
               
               
                   
                   
                   
                   
                 AAATAAAAGC 
               
               
                   
                   
                   
                   
                 TGAAATGAAT CATTCTCTCT 
               
               
                   
                   
                   
                   
                 ACTATTATTC TGATATTTCA 
               
               
                   
                   
                   
                   
                 CATTCTTAAA 
               
               
                   
                   
                   
                   
                 ATAAAGTGGT 
               
               
                   
                   
                   
                   
                 GATCCTAACT 
               
               
                   
                   
                   
                   
                 GACCTTAAGA 
               
               
                   
                   
                   
                   
                 CAGGGAATCT 
               
               
                   
                   
                   
                   
                 TTACTCGGAT 
               
               
                   
                   
                   
                   
                 TAAATGTCAG 
               
               
                   
                   
                   
                   
                 GAATTGTGAA 
               
               
                   
                   
                   
                   
                 AAAGTGAGTT 
               
               
                   
                   
                   
                   
                 TAAATGTATT 
               
               
                   
                   
                   
                   
                 TGGCTAAGGT 
               
               
                   
                   
                   
                   
                 GTATGTAAAC TTCCGACTTC 
               
               
                   
                   
                   
                   
                 AACTGTAGG 
               
               
                   
               
            
           
         
       
     
     Exemplary control sequences 
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 miRNA 
                 SEQ 
                 miRNA 
                   
               
               
                 Target 
                 ID NO 
                 backbone 
                 DNA sequence of Pri-miRNA 
               
               
                   
               
             
            
               
                 Scrambled 
                 582 
                 miR206, 
                 GATGCTACAAGTGGCCCACTTCTGAGATGCGGGCTGCTTCT 
               
               
                 control 2 
                   
                 shorter 
                 GGATGACACTGCTTCCCGAGGCATTTCGCCCTATCTGCAAGT 
               
               
                   
                   
                 arms 
                 ACTATGGATTACTTTGCTAGTGGTGTAGATAGGGTGAAATG 
               
               
                   
                   
                   
                 TTTCGGCAAGTGCCTCCTCGCTGGCCCCAGGGTACCACCCGG 
               
               
                   
                   
                   
                 AGCACAGGTTTGGTGACCTT 
               
               
                   
               
               
                 neg. ctl 
                 583 
                 miR150 
                 AGGGACTGGGCCCACGGGGAGGCAGCGTCCCCGAGGCAGC 
               
               
                   c . elegans   
                   
                   
                 AGCGGCAGCGGCGGCTCCTCTCCCCATGGCCCTGTCACAACC 
               
               
                 cel-miR-67 
                   
                   
                 TCCTAGAAAGAGTACTGGGCTCAGACCCTCTTTCAGGCCGTT 
               
               
                   
                   
                   
                 GTGACAGGGACCTGGGGACCCCGGCACCGGCAGGCCCCAA 
               
               
                   
                   
                   
                 GGGGTGAGGTGAGCGGGCATTGGGACCTCCCCTCCCTGTAC 
               
               
                   
                   
                   
                 TC 
               
               
                   
               
               
                 neg. ctl 
                 584 
                 miR204 
                 AGGAGGGTGGGGGTGGAGGCAAGCAGAGGACTTCCTGATC 
               
               
                   c . elegans   
                   
                   
                 GCGTACCCATGGCTACAGTCTTTCTTCATGTGACTCGTGGAC 
               
               
                 cel-miR-67 
                   
                   
                 TTGTACTACACAAAAGTACTGTGAGAATATATGAAGGACAG 
               
               
                   
                   
                   
                 GCTTTAGTGTAGTATGCGTTCAATTGTCATCACTGGCATCTTT 
               
               
                   
                   
                   
                 TTTGATCATTGCACCATCATCAAATGCATTGGGATAACCATG 
               
               
                   
                   
                   
                 AC 
               
               
                   
               
               
                 210 bp 
                 585 
                 — 
                 GGTAAGTCATGACTCCCTACAATGGACATGATCATAGTAGGT 
               
               
                 stuffer 
                   
                   
                 ACTATAAGGCACCTAGCTATACCCTCCTATAGAGAGTTTGAG 
               
               
                   
                   
                   
                 TCTATTGTAGCAAGTCTTTCTTTTAGGGCCTAGGACTCTTCCC 
               
               
                   
                   
                   
                 ACTCTCTTCCATCGCCTAAGCTCTAACTCTTCCTTGTAGTAGA 
               
               
                   
                   
                   
                 AATAAGTCACTTCTAAGGCTGGGACCCTCCTAGACCCTAA 
               
               
                   
               
               
                 Scrambled 
                 586 
                 miR206 
                 TTAGGATGAGTTGAGATCCCAGTGATCTTCTCGCTAAGAGTT 
               
               
                 control 1 
                   
                   
                 TCCTGCCTGGGCAAGGAGGAAAGATGCTACAAGTGGCCCAC 
               
               
                   
                   
                   
                 TTCTGAGATGCGGGCTGCTTCTGGATGACACTGCTTCCCGAG 
               
               
                   
                   
                   
                 GCATTTCGCCCTATCTGCAAGTACTATGGATTACTTTGCTAGT 
               
               
                   
                   
                   
                 GGTGTAGATAGGGTGAAATGTTTCGGCAAGTGCCTCCTCGC 
               
               
                   
                   
                   
                 TGGCCCCAGGGTACCACCCGGAGCACAGGTTTGGTGACCTT 
               
               
                   
                   
                   
                 CTTCCTCATCAGGGCTTTGTGCCAGCAAATGACTCCCTCACC 
               
               
                   
                   
                   
                 AAGGAAGCAAGAGCCTCTGAATCCCATCTGGGCTCTTCCTGA 
               
               
                   
                   
                   
                 ACACCCCTATCTCCCCCTCT 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 14 
               
             
            
               
                   
               
               
                 Additional Sequences 
               
            
           
           
               
               
               
               
               
            
               
                   
                 SEQ ID 
                   
                 SEQ 
                   
               
               
                 Name 
                 NO 
                 Amino Acid Sequence 
                 ID NO 
                 Nucleotide Sequence 
               
               
                   
               
            
           
           
               
            
               
                 CAR Sequences 
               
            
           
           
               
               
               
               
               
            
               
                 Human ROR1 
                 587 
                 PLLALLAALLLAARGAAAQETELSVS 
                 588 
                 ATGCACCGGCCGCGCCGCC 
               
               
                   
                   
                 AELVPTSSWNISSELNKDSYLTLDEP 
                   
                 GCGGGACGCGCCCGCCGCT 
               
               
                   
                   
                 MNNITTSLGQTAELHCKVSGNPPP 
                   
                 CCTGGCGCTGCTGGCCGCG 
               
               
                   
                   
                 TIRWFKNDAPVVQEPRRLSFRSTIY 
                   
                 CTGCTGCTGGCCGCACGCG 
               
               
                   
                   
                 GSRLRIRNLDTTDTGYFQCVATNG 
                   
                 GGGCTGCTGCCCAAGAAAC 
               
               
                   
                   
                 KEVVSSTGVLFVKFGPPPTASPGYS 
                   
                 AGAGCTGTCAGTCAGTGCT 
               
               
                   
                   
                 DEYEEDGFCQPYRGIACARFIGNRT 
                   
                 GAATTAGTGCCTACCTCATC 
               
               
                   
                   
                 VYMESLHMQGEIENQITAAFTMIG 
                   
                 ATGGAACATCTCAAGTGAA 
               
               
                   
                   
                 TSSHLSDKCSQFAIPSLCHYAFPYCD 
                   
                 CTCAACAAAGATTCTTACCT 
               
               
                   
                   
                 ETSSVPKPRDLCRDECEILENVLCQT 
                   
                 GACCCTCGATGAACCAATG 
               
               
                   
                   
                 EYIFARSNPMILMRLKLPNCEDLPQ 
                   
                 AATAACATCACCACGTCTCT 
               
               
                   
                   
                 PESPEAANCIRIGIPMADPINKNHK 
                   
                 GGGCCAGACAGCAGAACTG 
               
               
                   
                   
                 CYNSTGVDYRGTVSVTKSGRQCQP 
                   
                 CACTGCAAAGTCTCTGGGA 
               
               
                   
                   
                 WNSQYPHTHTFTALRFPELNGGHS 
                   
                 ATCCACCTCCCACCATCCGC 
               
               
                   
                   
                 YCRNPGNQKEAPWCFTLDENFKS 
                   
                 TGGTTCAAAAATGATGCTCC 
               
               
                   
                   
                 DLCDIPACDSKDSKEKNKMEILYILV 
                   
                 TGTGGTCCAGGAGCCCCGG 
               
               
                   
                   
                 PSVAIPLAIALLFFFICVCRNNQKSSS 
                   
                 AGGCTCTCCTTTCGGTCCAC 
               
               
                   
                   
                 APVQRQPKHVRGQNVEMSMLNA 
                   
                 CATCTATGGCTCTCGGCTGC 
               
               
                   
                   
                 YKPKSKAKELPLSAVRFMEELGECA 
                   
                 GGATTAGAAACCTCGACAC 
               
               
                   
                   
                 FGKIYKGHLYLPGMDHAQLVAIKTL 
                   
                 CACAGACACAGGCTACTTCC 
               
               
                   
                   
                 KDYNNPQQWTEFQQEASLMAEL 
                   
                 AGTGCGTGGCAACAAACGG 
               
               
                   
                   
                 HHPNIVCLLGAVTQEQPVCMLFEYI 
                   
                 CAAGGAGGTGGTTTCTTCC 
               
               
                   
                   
                 NQGDLHEFLIMRSPHSDVGCSSDE 
                   
                 ACTGGAGTCTTGTTTGTCAA 
               
               
                   
                   
                 DGTVKSSLDHGDFLHIAIQIAAGME 
                   
                 GTTTGGCCCCCCTCCCACTG 
               
               
                   
                   
                 YLSSHFFVHKDLAARNILIGEQLHVK 
                   
                 CAAGTCCAGGATACTCAGA 
               
               
                   
                   
                 ISDLGLSREIYSADYYRVQSKSLLPIR 
                   
                 TGAGTATGAAGAAGATGGA 
               
               
                   
                   
                 WMPPEAIMYGKFSSDSDIWSFGV 
                   
                 TTCTGTCAGCCATACAGAG 
               
               
                   
                   
                 VLWEIFSFGLQPYYGFSNQEVIEMV 
                   
                 GGATTGCATGTGCAAGATT 
               
               
                   
                   
                 RKRQLLPCSEDCPPRMYSLMTECW 
                   
                 TATTGGCAACCGCACCGTCT 
               
               
                   
                   
                 NEIPSRRPRFKDIHVRLRSWEGLSS 
                   
                 ATATGGAGTCTTTGCACATG 
               
               
                   
                   
                 HTSSTTPSGGNATTQTTSLSASPVS 
                   
                 CAAGGGGAAATAGAAAATC 
               
               
                   
                   
                 NLSNPRYPNYMFPSQGITPQGQIA 
                   
                 AGATCACAGCTGCCTTCACT 
               
               
                   
                   
                 GFIGPPIPQNQRFIPINGYPIPPGYA 
                   
                 ATGATTGGCACTTCCAGTCA 
               
               
                   
                   
                 AFPAAHYQPTGPPRVIQHCPPPKS 
                   
                 CTTATCTGATAAGTGTTCTC 
               
               
                   
                   
                 RSPSSASGSTSTGHVTSLPSSGSNQ 
                   
                 AGTTCGCCATTCCTTCCCTG 
               
               
                   
                   
                 EANIPLLPHMSIPNHPGGMGITVF 
                   
                 TGCCACTATGCCTTCCCGTA 
               
               
                   
                   
                 GNKSQKPYKIDSKQASLLGDANIHG 
                   
                 CTGCGATGAAACTTCATCCG 
               
               
                   
                   
                 HTESMISAEL 
                   
                 TCCCAAAGCCCCGTGACTTG 
               
               
                   
                   
                   
                   
                 TGTCGCGATGAATGTGAAA 
               
               
                   
                   
                   
                   
                 TCCTGGAGAATGTCCTGTGT 
               
               
                   
                   
                   
                   
                 CAAACAGAGTACATTTTTGC 
               
               
                   
                   
                   
                   
                 AAGATCAAATCCCATGATTC 
               
               
                   
                   
                   
                   
                 TGATGAGGCTGAAACTGCC 
               
               
                   
                   
                   
                   
                 AAACTGTGAAGATCTCCCCC 
               
               
                   
                   
                   
                   
                 AGCCAGAGAGCCCAGAAGC 
               
               
                   
                   
                   
                   
                 TGCGAACTGTATCCGGATT 
               
               
                   
                   
                   
                   
                 GGAATTCCCATGGCAGATC 
               
               
                   
                   
                   
                   
                 CTATAAATAAAAATCACAA 
               
               
                   
                   
                   
                   
                 GTGTTATAACAGCACAGGT 
               
               
                   
                   
                   
                   
                 GTGGACTACCGGGGGACCG 
               
               
                   
                   
                   
                   
                 TCAGTGTGACCAAATCAGG 
               
               
                   
                   
                   
                   
                 GCGCCAGTGCCAGCCATGG 
               
               
                   
                   
                   
                   
                 AATTCCCAGTATCCCCACAC 
               
               
                   
                   
                   
                   
                 ACACACTTTCACCGCCCTTC 
               
               
                   
                   
                   
                   
                 GTTTCCCAGAGCTGAATGG 
               
               
                   
                   
                   
                   
                 AGGCCATTCCTACTGCCGCA 
               
               
                   
                   
                   
                   
                 ACCCAGGGAATCAAAAGGA 
               
               
                   
                   
                   
                   
                 AGCTCCCTGGTGCTTCACCT 
               
               
                   
                   
                   
                   
                 TGGATGAAAACTTTAAGTCT 
               
               
                   
                   
                   
                   
                 GATCTGTGTGACATCCCAG 
               
               
                   
                   
                   
                   
                 CGTGCGATTCAAAGGATTC 
               
               
                   
                   
                   
                   
                 CAAGGAGAAGAATAAAATG 
               
               
                   
                   
                   
                   
                 GAAATCCTGTACATACTAGT 
               
               
                   
                   
                   
                   
                 GCCAAGTGTGGCCATTCCC 
               
               
                   
                   
                   
                   
                 CTGGCCATTGCTTTACTCTT 
               
               
                   
                   
                   
                   
                 CTTCTTCATTTGCGTCTGTC 
               
               
                   
                   
                   
                   
                 GGAATAACCAGAAGTCATC 
               
               
                   
                   
                   
                   
                 GTCGGCACCAGTCCAGAGG 
               
               
                   
                   
                   
                   
                 CAACCAAAACACGTCAGAG 
               
               
                   
                   
                   
                   
                 GTCAAAATGTAGAGATGTC 
               
               
                   
                   
                   
                   
                 AATGCTGAATGCATATAAA 
               
               
                   
                   
                   
                   
                 CCCAAGAGCAAGGCTAAAG 
               
               
                   
                   
                   
                   
                 AGCTACCTCTTTCTGCTGTA 
               
               
                   
                   
                   
                   
                 CGCTTTATGGAAGAATTGG 
               
               
                   
                   
                   
                   
                 GTGAGTGTGCCTTTGGAAA 
               
               
                   
                   
                   
                   
                 AATCTATAAAGGCCATCTCT 
               
               
                   
                   
                   
                   
                 ATCTCCCAGGCATGGACCAT 
               
               
                   
                   
                   
                   
                 GCTCAGCTGGTTGCTATCAA 
               
               
                   
                   
                   
                   
                 GACCTTGAAAGACTATAAC 
               
               
                   
                   
                   
                   
                 AACCCCCAGCAATGGACGG 
               
               
                   
                   
                   
                   
                 AATTTCAACAAGAAGCCTCC 
               
               
                   
                   
                   
                   
                 CTAATGGCAGAACTGCACC 
               
               
                   
                   
                   
                   
                 ACCCCAATATTGTCTGCCTT 
               
               
                   
                   
                   
                   
                 CTAGGTGCCGTCACTCAGG 
               
               
                   
                   
                   
                   
                 AACAACCTGTGTGCATGCTT 
               
               
                   
                   
                   
                   
                 TTTGAGTATATTAATCAGGG 
               
               
                   
                   
                   
                   
                 GGATCTCCATGAGTTCCTCA 
               
               
                   
                   
                   
                   
                 TCATGAGATCCCCACACTCT 
               
               
                   
                   
                   
                   
                 GATGTTGGCTGCAGCAGTG 
               
               
                   
                   
                   
                   
                 ATGAAGATGGGACTGTGAA 
               
               
                   
                   
                   
                   
                 ATCCAGCCTGGACCACGGA 
               
               
                   
                   
                   
                   
                 GATTTTCTGCACATTGCAAT 
               
               
                   
                   
                   
                   
                 TCAGATTGCAGCTGGCATG 
               
               
                   
                   
                   
                   
                 GAATACCTGTCTAGTCACTT 
               
               
                   
                   
                   
                   
                 CTTTGTCCACAAGGACCTTG 
               
               
                   
                   
                   
                   
                 CAGCTCGCAATATTTTAATC 
               
               
                   
                   
                   
                   
                 GGAGAGCAACTTCATGTAA 
               
               
                   
                   
                   
                   
                 AGATTTCAGACTTGGGGCT 
               
               
                   
                   
                   
                   
                 TTCCAGAGAAATTTACTCCG 
               
               
                   
                   
                   
                   
                 CTGATTACTACAGGGTCCA 
               
               
                   
                   
                   
                   
                 GAGTAAGTCCTTGCTGCCC 
               
               
                   
                   
                   
                   
                 ATTCGCTGGATGCCCCCTGA 
               
               
                   
                   
                   
                   
                 AGCCATCATGTATGGCAAA 
               
               
                   
                   
                   
                   
                 TTCTCTTCTGATTCAGATAT 
               
               
                   
                   
                   
                   
                 CTGGTCCTTTGGGGTTGTCT 
               
               
                   
                   
                   
                   
                 TGTGGGAGATTTTCAGTTTT 
               
               
                   
                   
                   
                   
                 GGACTCCAGCCATATTATG 
               
               
                   
                   
                   
                   
                 GATTCAGTAACCAGGAAGT 
               
               
                   
                   
                   
                   
                 GATTGAGATGGTGAGAAAA 
               
               
                   
                   
                   
                   
                 CGGCAGCTCTTACCATGCTC 
               
               
                   
                   
                   
                   
                 TGAAGACTGCCCACCCAGA 
               
               
                   
                   
                   
                   
                 ATGTACAGCCTCATGACAG 
               
               
                   
                   
                   
                   
                 AGTGCTGGAATGAGATTCC 
               
               
                   
                   
                   
                   
                 TTCTAGGAGACCAAGATTTA 
               
               
                   
                   
                   
                   
                 AAGATATTCACGTCCGGCTT 
               
               
                   
                   
                   
                   
                 CGGTCCTGGGAGGGACTCT 
               
               
                   
                   
                   
                   
                 CAAGTCACACAAGCTCTACT 
               
               
                   
                   
                   
                   
                 ACTCCTTCAGGGGGAAATG 
               
               
                   
                   
                   
                   
                 CCACCACACAGACAACCTCC 
               
               
                   
                   
                   
                   
                 CTCAGTGCCAGCCCAGTGA 
               
               
                   
                   
                   
                   
                 GTAATCTCAGTAACCCCAGA 
               
               
                   
                   
                   
                   
                 TATCCTAATTACATGTTCCC 
               
               
                   
                   
                   
                   
                 GAGCCAGGGTATTACACCA 
               
               
                   
                   
                   
                   
                 CAGGGCCAGATTGCTGGTT 
               
               
                   
                   
                   
                   
                 TCATTGGCCCGCCAATACCT 
               
               
                   
                   
                   
                   
                 CAGAACCAGCGATTCATTCC 
               
               
                   
                   
                   
                   
                 CATCAATGGATACCCAATAC 
               
               
                   
                   
                   
                   
                 CTCCTGGATATGCAGCGTTT 
               
               
                   
                   
                   
                   
                 CCAGCTGCCCACTACCAGCC 
               
               
                   
                   
                   
                   
                 AACAGGTCCTCCCAGAGTG 
               
               
                   
                   
                   
                   
                 ATTCAGCACTGCCCACCTCC 
               
               
                   
                   
                   
                   
                 CAAGAGTCGGTCCCCAAGC 
               
               
                   
                   
                   
                   
                 AGTGCCAGTGGGTCGACTA 
               
               
                   
                   
                   
                   
                 GCACTGGCCATGTGACTAG 
               
               
                   
                   
                   
                   
                 CTTGCCCTCATCAGGATCCA 
               
               
                   
                   
                   
                   
                 ATCAGGAAGCAAATATTCCT 
               
               
                   
                   
                   
                   
                 TTACTACCACACATGTCAAT 
               
               
                   
                   
                   
                   
                 TCCAAATCATCCTGGTGGAA 
               
               
                   
                   
                   
                   
                 TGGGTATCACCGTTTTTGGC 
               
               
                   
                   
                   
                   
                 AACAAATCTCAAAAACCCTA 
               
               
                   
                   
                   
                   
                 CAAAATTGACTCAAAGCAA 
               
               
                   
                   
                   
                   
                 GCATCTTTACTAGGAGACG 
               
               
                   
                   
                   
                   
                 CCAATATTCATGGACACACC 
               
               
                   
                   
                   
                   
                 GAATCTATGATTTCTGCAGA 
               
               
                   
                   
                   
                   
                 ACTG 
               
               
                   
               
               
                 Human ROR1 
                 589 
                 MHRPRRRGTRPPLLALLAALLLAAR 
                 590 
                 ATGCACCGGCCGCGCCGCC 
               
               
                 (1-437) 
                   
                 GAAAQETELSVSAELVPTSSWNISS 
                   
                 GCGGGACGCGCCCGCCGCT 
               
               
                   
                   
                 ELNKDSYLTLDEPMNNITTSLGQTA 
                   
                 CCTGGCGCTGCTGGCCGCG 
               
               
                   
                   
                 ELHCKVSGNPPPTIRWFKNDAPVV 
                   
                 CTGCTGCTGGCCGCACGCG 
               
               
                   
                   
                 QEPRRLSFRSTIYGSRLRIRNLDTTD 
                   
                 GGGCTGCTGCCCAAGAAAC 
               
               
                   
                   
                 TGYFQCVATNGKEVVSSTGVLFVK 
                   
                 AGAGCTGTCAGTCAGTGCT 
               
               
                   
                   
                 FGPPPTASPGYSDEYEEDGFCQPYR 
                   
                 GAATTAGTGCCTACCTCATC 
               
               
                   
                   
                 GIACARFIGNRTVYMESLHMQGEI 
                   
                 ATGGAACATCTCAAGTGAA 
               
               
                   
                   
                 ENQITAAFTMIGTSSHLSDKCSQFA 
                   
                 CTCAACAAAGATTCTTACCT 
               
               
                   
                   
                 IPSLCHYAFPYCDETSSVPKPRDLCR 
                   
                 GACCCTCGATGAACCAATG 
               
               
                   
                   
                 DECEILENVLCQTEYIFARSNPMIL 
                   
                 AATAACATCACCACGTCTCT 
               
               
                   
                   
                 MRLKLPNCEDLPQPESPEAANCIRI 
                   
                 GGGCCAGACAGCAGAACTG 
               
               
                   
                   
                 GIPMADPINKNHKCYNSTGVDYRG 
                   
                 CACTGCAAAGTCTCTGGGA 
               
               
                   
                   
                 TVSVTKSGRQCQPWNSQYPHTHT 
                   
                 ATCCACCTCCCACCATCCGC 
               
               
                   
                   
                 FTALRFPELNGGHSYCRNPGNQKE 
                   
                 TGGTTCAAAAATGATGCTCC 
               
               
                   
                   
                 APWCFTLDENFKSDLCDIPACDSKD 
                   
                 TGTGGTCCAGGAGCCCCGG 
               
               
                   
                   
                 SKEKNKMEILYILVPSVAIPLAIALLF 
                   
                 AGGCTCTCCTTTCGGTCCAC 
               
               
                   
                   
                 FFICVCRNNQKSSSA 
                   
                 CATCTATGGCTCTCGGCTGC 
               
               
                   
                   
                   
                   
                 GGATTAGAAACCTCGACAC 
               
               
                   
                   
                   
                   
                 CACAGACACAGGCTACTTCC 
               
               
                   
                   
                   
                   
                 AGTGCGTGGCAACAAACGG 
               
               
                   
                   
                   
                   
                 CAAGGAGGTGGTTTCTTCC 
               
               
                   
                   
                   
                   
                 ACTGGAGTCTTGTTTGTCAA 
               
               
                   
                   
                   
                   
                 GTTTGGCCCCCCTCCCACTG 
               
               
                   
                   
                   
                   
                 CAAGTCCAGGATACTCAGA 
               
               
                   
                   
                   
                   
                 TGAGTATGAAGAAGATGGA 
               
               
                   
                   
                   
                   
                 TTCTGTCAGCCATACAGAG 
               
               
                   
                   
                   
                   
                 GGATTGCATGTGCAAGATT 
               
               
                   
                   
                   
                   
                 TATTGGCAACCGCACCGTCT 
               
               
                   
                   
                   
                   
                 ATATGGAGTCTTTGCACATG 
               
               
                   
                   
                   
                   
                 CAAGGGGAAATAGAAAATC 
               
               
                   
                   
                   
                   
                 AGATCACAGCTGCCTTCACT 
               
               
                   
                   
                   
                   
                 ATGATTGGCACTTCCAGTCA 
               
               
                   
                   
                   
                   
                 CTTATCTGATAAGTGTTCTC 
               
               
                   
                   
                   
                   
                 AGTTCGCCATTCCTTCCCTG 
               
               
                   
                   
                   
                   
                 TGCCACTATGCCTTCCCGTA 
               
               
                   
                   
                   
                   
                 CTGCGATGAAACTTCATCCG 
               
               
                   
                   
                   
                   
                 TCCCAAAGCCCCGTGACTTG 
               
               
                   
                   
                   
                   
                 TGTCGCGATGAATGTGAAA 
               
               
                   
                   
                   
                   
                 TCCTGGAGAATGTCCTGTGT 
               
               
                   
                   
                   
                   
                 CAAACAGAGTACATTTTTGC 
               
               
                   
                   
                   
                   
                 AAGATCAAATCCCATGATTC 
               
               
                   
                   
                   
                   
                 TGATGAGGCTGAAACTGCC 
               
               
                   
                   
                   
                   
                 AAACTGTGAAGATCTCCCCC 
               
               
                   
                   
                   
                   
                 AGCCAGAGAGCCCAGAAGC 
               
               
                   
                   
                   
                   
                 TGCGAACTGTATCCGGATT 
               
               
                   
                   
                   
                   
                 GGAATTCCCATGGCAGATC 
               
               
                   
                   
                   
                   
                 CTATAAATAAAAATCACAA 
               
               
                   
                   
                   
                   
                 GTGTTATAACAGCACAGGT 
               
               
                   
                   
                   
                   
                 GTGGACTACCGGGGGACCG 
               
               
                   
                   
                   
                   
                 TCAGTGTGACCAAATCAGG 
               
               
                   
                   
                   
                   
                 GCGCCAGTGCCAGCCATGG 
               
               
                   
                   
                   
                   
                 AATTCCCAGTATCCCCACAC 
               
               
                   
                   
                   
                   
                 ACACACTTTCACCGCCCTTC 
               
               
                   
                   
                   
                   
                 GTTTCCCAGAGCTGAATGG 
               
               
                   
                   
                   
                   
                 AGGCCATTCCTACTGCCGCA 
               
               
                   
                   
                   
                   
                 ACCCAGGGAATCAAAAGGA 
               
               
                   
                   
                   
                   
                 AGCTCCCTGGTGCTTCACCT 
               
               
                   
                   
                   
                   
                 TGGATGAAAACTTTAAGTCT 
               
               
                   
                   
                   
                   
                 GATCTGTGTGACATCCCAG 
               
               
                   
                   
                   
                   
                 CGTGCGATTCAAAGGATTC 
               
               
                   
                   
                   
                   
                 CAAGGAGAAGAATAAAATG 
               
               
                   
                   
                   
                   
                 GAAATCCTGTACATACTAGT 
               
               
                   
                   
                   
                   
                 GCCAAGTGTGGCCATTCCC 
               
               
                   
                   
                   
                   
                 CTGGCCATTGCTTTACTCTT 
               
               
                   
                   
                   
                   
                 CTTCTTCATTTGCGTCTGTC 
               
               
                   
                   
                   
                   
                 GGAATAACCAGAAGTCATC 
               
               
                   
                   
                   
                   
                 GTCGGCA 
               
               
                   
               
               
                 Murine ROR1 
                 591 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 592 
                 GACATCAAGATGACCCAGA 
               
               
                 (VL-VH). 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 IgG4 Fc- 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 CD28m-Z 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                   
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                   
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 ESKYGPPCPPCPAPEFEGGPSVFLF 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 PPKPKDTLMISRTPEVTCVVVDVSQ 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 EDPEVQFNWYVDGVEVHNAKTKP 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 REEQFQSTYRVVSVLTVLHQDWLN 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 GKEYKCKVSNKGLPSSIEKTISKAKG 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 QPREPQVYTLPPSQEEMTKNQVSL 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 TCLVKGFYPSDIAVEWESNGQPEN 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 NYKTTPPVLDSDGSFFLYSRLTVDKS 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 QKSLSLSLGKMFWVLVVVGGVLAC 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 YSLLVTVAFIIFWVRSKRSRGGHSD 
                   
                 CAGCACCAAGGGCGAAGTG 
               
               
                   
                   
                 YMNMTPRRPGPTRKHYQPYAPPR 
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                 DFAAYRSRVKFSRSADAPAYQQGQ 
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                 NCILYNELNLGRREEYDVLDKRRGR 
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                 DPEMGGKPRRKNPQEGLYNELQK 
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                 DKMAEAYSEIGMKGERRRGKGHD 
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                 GLYQGLSTATKDTYDALHMQALPP 
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                 R 
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCGAGAGCAAGT 
               
               
                   
                   
                   
                   
                 ACGGCCCTCCCTGCCCCCCT 
               
               
                   
                   
                   
                   
                 TGCCCTGCCCCCGAGTTCGA 
               
               
                   
                   
                   
                   
                 GGGCGGACCCAGCGTGTTC 
               
               
                   
                   
                   
                   
                 CTGTTCCCCCCCAAGCCCAA 
               
               
                   
                   
                   
                   
                 GGACACCCTGATGATCAGC 
               
               
                   
                   
                   
                   
                 CGGACCCCCGAGGTGACCT 
               
               
                   
                   
                   
                   
                 GTGTGGTGGTGGACGTGTC 
               
               
                   
                   
                   
                   
                 CCAGGAGGACCCCGAGGTC 
               
               
                   
                   
                   
                   
                 CAGTTCAACTGGTACGTGG 
               
               
                   
                   
                   
                   
                 ACGGCGTGGAGGTGCACAA 
               
               
                   
                   
                   
                   
                 CGCCAAGACCAAGCCCCGG 
               
               
                   
                   
                   
                   
                 GAGGAGCAGTTCCAGAGCA 
               
               
                   
                   
                   
                   
                 CCTACCGGGTGGTGTCCGT 
               
               
                   
                   
                   
                   
                 GCTGACCGTGCTGCACCAG 
               
               
                   
                   
                   
                   
                 GACTGGCTGAACGGCAAGG 
               
               
                   
                   
                   
                   
                 AATACAAGTGTAAGGTGTC 
               
               
                   
                   
                   
                   
                 CAACAAGGGCCTGCCCAGC 
               
               
                   
                   
                   
                   
                 AGCATCGAGAAAACCATCA 
               
               
                   
                   
                   
                   
                 GCAAGGCCAAGGGCCAGCC 
               
               
                   
                   
                   
                   
                 TCGGGAGCCCCAGGTGTAC 
               
               
                   
                   
                   
                   
                 ACCCTGCCCCCTAGCCAAGA 
               
               
                   
                   
                   
                   
                 GGAGATGACCAAGAATCAG 
               
               
                   
                   
                   
                   
                 GTGTCCCTGACCTGCCTGGT 
               
               
                   
                   
                   
                   
                 GAAGGGCTTCTACCCCAGC 
               
               
                   
                   
                   
                   
                 GACATCGCCGTGGAGTGGG 
               
               
                   
                   
                   
                   
                 AGAGCAACGGCCAGCCCGA 
               
               
                   
                   
                   
                   
                 GAACAACTACAAGACCACC 
               
               
                   
                   
                   
                   
                 CCCCCTGTGCTGGACAGCG 
               
               
                   
                   
                   
                   
                 ACGGCAGCTTCTTCCTGTAC 
               
               
                   
                   
                   
                   
                 AGCAGGCTGACCGTGGACA 
               
               
                   
                   
                   
                   
                 AGAGCCGGTGGCAGGAGG 
               
               
                   
                   
                   
                   
                 GCAACGTCTTTAGCTGCTCC 
               
               
                   
                   
                   
                   
                 GTGATGCACGAGGCCCTGC 
               
               
                   
                   
                   
                   
                 ACAACCACTACACCCAGAA 
               
               
                   
                   
                   
                   
                 GAGCCTGTCCCTGAGCCTG 
               
               
                   
                   
                   
                   
                 GGCAAGATGTTCTGGGTGC 
               
               
                   
                   
                   
                   
                 TGGTCGTGGTGGGTGGCGT 
               
               
                   
                   
                   
                   
                 GCTGGCCTGCTACAGCCTG 
               
               
                   
                   
                   
                   
                 CTGGTGACAGTGGCCTTCA 
               
               
                   
                   
                   
                   
                 TCATCTTTTGGGTGAGGAG 
               
               
                   
                   
                   
                   
                 CAAGCGGAGCAGAGGCGG 
               
               
                   
                   
                   
                   
                 CCACAGCGACTACATGAAC 
               
               
                   
                   
                   
                   
                 ATGACCCCCCGGAGGCCTG 
               
               
                   
                   
                   
                   
                 GCCCCACCCGGAAGCACTA 
               
               
                   
                   
                   
                   
                 CCAGCCCTACGCCCCTCCCA 
               
               
                   
                   
                   
                   
                 GGGACTTCGCCGCCTACCG 
               
               
                   
                   
                   
                   
                 GAGCCGGGTGAAGTTCAGC 
               
               
                   
                   
                   
                   
                 CGGAGCGCCGACGCCCCTG 
               
               
                   
                   
                   
                   
                 CCTACCAGCAGGGCCAGAA 
               
               
                   
                   
                   
                   
                 CCAGCTGTACAACGAGCTG 
               
               
                   
                   
                   
                   
                 AACCTGGGCCGGAGGGAG 
               
               
                   
                   
                   
                   
                 GAGTACGACGTGCTGGACA 
               
               
                   
                   
                   
                   
                 AGCGGAGAGGCCGGGACC 
               
               
                   
                   
                   
                   
                 CTGAGATGGGCGGCAAGCC 
               
               
                   
                   
                   
                   
                 CCGGAGAAAGAACCCTCAG 
               
               
                   
                   
                   
                   
                 GAGGGCCTGTATAACGAAC 
               
               
                   
                   
                   
                   
                 TGCAGAAAGACAAGATGGC 
               
               
                   
                   
                   
                   
                 CGAGGCCTACAGCGAGATC 
               
               
                   
                   
                   
                   
                 GGCATGAAGGGCGAGCGG 
               
               
                   
                   
                   
                   
                 CGGAGGGGCAAGGGCCAC 
               
               
                   
                   
                   
                   
                 GACGGCCTGTACCAGGGCC 
               
               
                   
                   
                   
                   
                 TGAGCACCGCCACCAAGGA 
               
               
                   
                   
                   
                   
                 TACCTACGACGCCCTGCACA 
               
               
                   
                   
                   
                   
                 TGCAGGCCCTGCCCCCCAG 
               
               
                   
                   
                   
                   
                 A 
               
               
                   
               
               
                 Murine ROR1 
                 593 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 594 
                 GACATCAAGATGACCCAGA 
               
               
                 (VL-VH). 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 IgG4 Fcm- 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 CD28m-Z 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                   
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                   
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 QGTSVTVSSESKYGPPCPPCPAPEF 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 LGGPSVFLFPPKPKDTLMISRTPEVT 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 CVVVDVSQEDPEVQFNWYVDGVE 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 VHNAKTKPREEQFNSTYRVVSVLT 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 VLHQDWLNGKEYKCKVSNKGLPSS 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 IEKTISKAKGQPREPQVYTLPPSQEE 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 MTKNQVSLTCLVKGFYPSDIAVEW 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 ESNGQPENNYKTTPPVLDSDGSFFL 
                   
                 GCACCAGCGGCAGCGGCAA 
               
               
                   
                   
                 YSRLTVDKSRWQEGNVFSCSVMH 
                   
                 GCCTGGAAGCGGCGAGGG 
               
               
                   
                   
                 EALHNHYTQKSLSLSLGKMFWVLV 
                   
                 CTCCACCAAGGGCGAAGTG 
               
               
                   
                   
                 VVGGVLACYSLLVTVAFIIFWVRSK 
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                 RSRGGHSDYMNMTPRRPGPTRKH 
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                 YQPYAPPRDFAAYRSRVKFSRSAD 
                   
                 GCGGCAGCCTGAAGCTGAG 
               
               
                   
                   
                 APAYQQGQNQLYNELNLGRREEY 
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                 DVLDKRRGRDPEMGGKPRRKNPQ 
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                 EGLYNELQKDKMAEAYSEIGMKGE 
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                 RRRGKGHDGLYQGLSTATKDTYDA 
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                 LHMQALPPR 
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCCAGGGAACCT 
               
               
                   
                   
                   
                   
                 CCGTGACAGTGTCCAGCGA 
               
               
                   
                   
                   
                   
                 GTCCAAATATGGTCCCCCAT 
               
               
                   
                   
                   
                   
                 GCCCACCATGCCCAGCACCT 
               
               
                   
                   
                   
                   
                 GAGTTCCTGGGGGGACCAT 
               
               
                   
                   
                   
                   
                 CAGTCTTCCTGTTCCCCCCA 
               
               
                   
                   
                   
                   
                 AAACCCAAGGACACTCTCAT 
               
               
                   
                   
                   
                   
                 GATCTCCCGGACCCCTGAG 
               
               
                   
                   
                   
                   
                 GTCACGTGCGTGGTGGTGG 
               
               
                   
                   
                   
                   
                 ACGTGAGCCAGGAAGACCC 
               
               
                   
                   
                   
                   
                 CGAGGTCCAGTTCAACTGG 
               
               
                   
                   
                   
                   
                 TACGTGGATGGCGTGGAGG 
               
               
                   
                   
                   
                   
                 TGCATAATGCCAAGACAAA 
               
               
                   
                   
                   
                   
                 GCCCCGGGAGGAGCAGTTC 
               
               
                   
                   
                   
                   
                 AATAGCACCTACCGGGTGG 
               
               
                   
                   
                   
                   
                 TGTCCGTGCTGACCGTGCT 
               
               
                   
                   
                   
                   
                 GCACCAGGACTGGCTGAAC 
               
               
                   
                   
                   
                   
                 GGCAAGGAATACAAGTGTA 
               
               
                   
                   
                   
                   
                 AGGTGTCCAACAAGGGCCT 
               
               
                   
                   
                   
                   
                 GCCCAGCAGCATCGAGAAA 
               
               
                   
                   
                   
                   
                 ACCATCAGCAAGGCCAAGG 
               
               
                   
                   
                   
                   
                 GCCAGCCTCGGGAGCCCCA 
               
               
                   
                   
                   
                   
                 GGTGTACACCCTGCCCCCTA 
               
               
                   
                   
                   
                   
                 GCCAAGAGGAGATGACCAA 
               
               
                   
                   
                   
                   
                 GAATCAGGTGTCCCTGACC 
               
               
                   
                   
                   
                   
                 TGCCTGGTGAAGGGCTTCT 
               
               
                   
                   
                   
                   
                 ACCCCAGCGACATCGCCGT 
               
               
                   
                   
                   
                   
                 GGAGTGGGAGAGCAACGG 
               
               
                   
                   
                   
                   
                 CCAGCCCGAGAACAACTAC 
               
               
                   
                   
                   
                   
                 AAGACCACCCCCCCTGTGCT 
               
               
                   
                   
                   
                   
                 GGACAGCGACGGCAGCTTC 
               
               
                   
                   
                   
                   
                 TTCCTGTACAGCAGGCTGA 
               
               
                   
                   
                   
                   
                 CCGTGGACAAGAGCCGGTG 
               
               
                   
                   
                   
                   
                 GCAGGAGGGCAACGTCTTT 
               
               
                   
                   
                   
                   
                 AGCTGCTCCGTGATGCACG 
               
               
                   
                   
                   
                   
                 AGGCCCTGCACAACCACTA 
               
               
                   
                   
                   
                   
                 CACCCAGAAGAGCCTGTCC 
               
               
                   
                   
                   
                   
                 CTGAGCCTGGGCAAGATGT 
               
               
                   
                   
                   
                   
                 TCTGGGTGCTGGTCGTGGT 
               
               
                   
                   
                   
                   
                 GGGTGGCGTGCTGGCCTGC 
               
               
                   
                   
                   
                   
                 TACAGCCTGCTGGTGACAG 
               
               
                   
                   
                   
                   
                 TGGCCTTCATCATCTTTTGG 
               
               
                   
                   
                   
                   
                 GTGAGGAGCAAGCGGAGC 
               
               
                   
                   
                   
                   
                 AGAGGCGGCCACAGCGACT 
               
               
                   
                   
                   
                   
                 ACATGAACATGACCCCCCG 
               
               
                   
                   
                   
                   
                 GAGGCCTGGCCCCACCCGG 
               
               
                   
                   
                   
                   
                 AAGCACTACCAGCCCTACG 
               
               
                   
                   
                   
                   
                 CCCCTCCCAGGGACTTCGCC 
               
               
                   
                   
                   
                   
                 GCCTACCGGAGCCGGGTGA 
               
               
                   
                   
                   
                   
                 AGTTCAGCCGGAGCGCCGA 
               
               
                   
                   
                   
                   
                 CGCCCCTGCCTACCAGCAG 
               
               
                   
                   
                   
                   
                 GGCCAGAACCAGCTGTACA 
               
               
                   
                   
                   
                   
                 ACGAGCTGAACCTGGGCCG 
               
               
                   
                   
                   
                   
                 GAGGGAGGAGTACGACGT 
               
               
                   
                   
                   
                   
                 GCTGGACAAGCGGAGAGG 
               
               
                   
                   
                   
                   
                 CCGGGACCCTGAGATGGGC 
               
               
                   
                   
                   
                   
                 GGCAAGCCCCGGAGAAAG 
               
               
                   
                   
                   
                   
                 AACCCTCAGGAGGGCCTGT 
               
               
                   
                   
                   
                   
                 ATAACGAACTGCAGAAAGA 
               
               
                   
                   
                   
                   
                 CAAGATGGCCGAGGCCTAC 
               
               
                   
                   
                   
                   
                 AGCGAGATCGGCATGAAGG 
               
               
                   
                   
                   
                   
                 GCGAGCGGCGGAGGGGCA 
               
               
                   
                   
                   
                   
                 AGGGCCACGACGGCCTGTA 
               
               
                   
                   
                   
                   
                 CCAGGGCCTGAGCACCGCC 
               
               
                   
                   
                   
                   
                 ACCAAGGATACCTACGACG 
               
               
                   
                   
                   
                   
                 CCCTGCACATGCAGGCCCT 
               
               
                   
                   
                   
                   
                 GCCCCCCAGA 
               
               
                   
               
               
                 Murine ROR1 
                 595 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 596 
                 GACATCAAGATGACCCAGA 
               
               
                 (VL-VH). 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 CD8α. 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 CD28z 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                   
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                   
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 EACRPAAGGAVHTRGLDFACDIYI 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 WAPLAGTCGVLLLSLVITLYCNHRN 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 RSKRSRGGHSDYMNMTPRRPGPT 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 RKHYQPYAPPRDFAAYRSRVKFSRS 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 ADAPAYQQGQNQLYNELNLGRRE 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 EYDVLDKRRGRDPEMGGKPRRKN 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 PQEGLYNELQKDKMAEAYSEIGMK 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 GERRRGKGHDGLYQGLSTATKDTY 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 DALHMQALPPR 
                   
                 CAGCACCAAGGGCGAAGTG 
               
               
                   
                   
                   
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                   
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                   
                   
                 GCGGCAGCCTGAAGCTGAG 
               
               
                   
                   
                   
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                   
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                   
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                   
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                   
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCAAGCCCACCA 
               
               
                   
                   
                   
                   
                 CCACCCCTGCCCCTAGACCT 
               
               
                   
                   
                   
                   
                 CCAACCCCAGCCCCTACAAT 
               
               
                   
                   
                   
                   
                 CGCCAGCCAGCCCCTGAGC 
               
               
                   
                   
                   
                   
                 CTGAGGCCCGAAGCCTGTA 
               
               
                   
                   
                   
                   
                 GACCTGCCGCTGGCGGAGC 
               
               
                   
                   
                   
                   
                 CGTGCACACCAGAGGCCTG 
               
               
                   
                   
                   
                   
                 GATTTCGCCTGCGACATCTA 
               
               
                   
                   
                   
                   
                 CATCTGGGCCCCTCTGGCC 
               
               
                   
                   
                   
                   
                 GGCACCTGTGGCGTGCTGC 
               
               
                   
                   
                   
                   
                 TGCTGAGCCTGGTCATCACC 
               
               
                   
                   
                   
                   
                 CTGTACTGCAACCACCGGA 
               
               
                   
                   
                   
                   
                 ATAGGAGCAAGCGGAGCA 
               
               
                   
                   
                   
                   
                 GAGGCGGCCACAGCGACTA 
               
               
                   
                   
                   
                   
                 CATGAACATGACCCCCCGG 
               
               
                   
                   
                   
                   
                 AGGCCTGGCCCCACCCGGA 
               
               
                   
                   
                   
                   
                 AGCACTACCAGCCCTACGCC 
               
               
                   
                   
                   
                   
                 CCTCCCAGGGACTTCGCCG 
               
               
                   
                   
                   
                   
                 CCTACCGGAGCCGGGTGAA 
               
               
                   
                   
                   
                   
                 GTTCAGCCGGAGCGCCGAC 
               
               
                   
                   
                   
                   
                 GCCCCTGCCTACCAGCAGG 
               
               
                   
                   
                   
                   
                 GCCAGAACCAGCTGTACAA 
               
               
                   
                   
                   
                   
                 CGAGCTGAACCTGGGCCGG 
               
               
                   
                   
                   
                   
                 AGGGAGGAGTACGACGTG 
               
               
                   
                   
                   
                   
                 CTGGACAAGCGGAGAGGCC 
               
               
                   
                   
                   
                   
                 GGGACCCTGAGATGGGCG 
               
               
                   
                   
                   
                   
                 GCAAGCCCCGGAGAAAGAA 
               
               
                   
                   
                   
                   
                 CCCTCAGGAGGGCCTGTAT 
               
               
                   
                   
                   
                   
                 AACGAACTGCAGAAAGACA 
               
               
                   
                   
                   
                   
                 AGATGGCCGAGGCCTACAG 
               
               
                   
                   
                   
                   
                 CGAGATCGGCATGAAGGGC 
               
               
                   
                   
                   
                   
                 GAGCGGCGGAGGGGCAAG 
               
               
                   
                   
                   
                   
                 GGCCACGACGGCCTGTACC 
               
               
                   
                   
                   
                   
                 AGGGCCTGAGCACCGCCAC 
               
               
                   
                   
                   
                   
                 CAAGGATACCTACGACGCC 
               
               
                   
                   
                   
                   
                 CTGCACATGCAGGCCCTGC 
               
               
                   
                   
                   
                   
                 CCCCCAGA 
               
               
                   
               
               
                 Murine ROR1 
                 597 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 598 
                 GACATCAAGATGACCCAGA 
               
               
                 (VL-VH). 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 CD8α(2x). 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 CD28z 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                   
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                   
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 EASRPAAGGAVHTRGLDFASDKPT 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAC 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 RPAAGGAVHTRGLDFACDIYIWAP 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCNHRNRSKR 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 SRGGHSDYMNMTPRRPGPTRKHY 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 QPYAPPRDFAAYRSRVKFSRSADA 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 PAYQQGQNQLYNELNLGRREEYD 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 VLDKRRGRDPEMGGKPRRKNPQE 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 GLYNELQKDKMAEAYSEIGMKGER 
                   
                 CAGCACCAAGGGCGAAGTG 
               
               
                   
                   
                 RRGKGHDGLYQGLSTATKDTYDAL 
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                 HMQALPPR 
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                   
                   
                 GCGGCAGCCTGAAGCTGAG 
               
               
                   
                   
                   
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                   
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                   
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                   
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                   
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCAAACCTACTAC 
               
               
                   
                   
                   
                   
                 AACTCCTGCCCCCCGGCCTC 
               
               
                   
                   
                   
                   
                 CTACACCAGCTCCTACTATC 
               
               
                   
                   
                   
                   
                 GCCTCCCAGCCACTCAGTCT 
               
               
                   
                   
                   
                   
                 CAGACCCGAGGCTTCTAGG 
               
               
                   
                   
                   
                   
                 CCAGCGGCCGGAGGCGCG 
               
               
                   
                   
                   
                   
                 GTCCACACCCGCGGGCTGG 
               
               
                   
                   
                   
                   
                 ACTTTGCATCCGATAAGCCC 
               
               
                   
                   
                   
                   
                 ACCACCACCCCTGCCCCTAG 
               
               
                   
                   
                   
                   
                 ACCTCCAACCCCAGCCCCTA 
               
               
                   
                   
                   
                   
                 CAATCGCCAGCCAGCCCCT 
               
               
                   
                   
                   
                   
                 GAGCCTGAGGCCCGAAGCC 
               
               
                   
                   
                   
                   
                 TGTAGACCTGCCGCTGGCG 
               
               
                   
                   
                   
                   
                 GAGCCGTGCACACCAGAGG 
               
               
                   
                   
                   
                   
                 CCTGGATTTCGCCTGCGACA 
               
               
                   
                   
                   
                   
                 TCTACATCTGGGCCCCTCTG 
               
               
                   
                   
                   
                   
                 GCCGGCACCTGTGGCGTGC 
               
               
                   
                   
                   
                   
                 TGCTGCTGAGCCTGGTCATC 
               
               
                   
                   
                   
                   
                 ACCCTGTACTGCAACCACCG 
               
               
                   
                   
                   
                   
                 GAATAGGAGCAAGCGGAG 
               
               
                   
                   
                   
                   
                 CAGAGGCGGCCACAGCGAC 
               
               
                   
                   
                   
                   
                 TACATGAACATGACCCCCCG 
               
               
                   
                   
                   
                   
                 GAGGCCTGGCCCCACCCGG 
               
               
                   
                   
                   
                   
                 AAGCACTACCAGCCCTACG 
               
               
                   
                   
                   
                   
                 CCCCTCCCAGGGACTTCGCC 
               
               
                   
                   
                   
                   
                 GCCTACCGGAGCCGGGTGA 
               
               
                   
                   
                   
                   
                 AGTTCAGCCGGAGCGCCGA 
               
               
                   
                   
                   
                   
                 CGCCCCTGCCTACCAGCAG 
               
               
                   
                   
                   
                   
                 GGCCAGAACCAGCTGTACA 
               
               
                   
                   
                   
                   
                 ACGAGCTGAACCTGGGCCG 
               
               
                   
                   
                   
                   
                 GAGGGAGGAGTACGACGT 
               
               
                   
                   
                   
                   
                 GCTGGACAAGCGGAGAGG 
               
               
                   
                   
                   
                   
                 CCGGGACCCTGAGATGGGC 
               
               
                   
                   
                   
                   
                 GGCAAGCCCCGGAGAAAG 
               
               
                   
                   
                   
                   
                 AACCCTCAGGAGGGCCTGT 
               
               
                   
                   
                   
                   
                 ATAACGAACTGCAGAAAGA 
               
               
                   
                   
                   
                   
                 CAAGATGGCCGAGGCCTAC 
               
               
                   
                   
                   
                   
                 AGCGAGATCGGCATGAAGG 
               
               
                   
                   
                   
                   
                 GCGAGCGGCGGAGGGGCA 
               
               
                   
                   
                   
                   
                 AGGGCCACGACGGCCTGTA 
               
               
                   
                   
                   
                   
                 CCAGGGCCTGAGCACCGCC 
               
               
                   
                   
                   
                   
                 ACCAAGGATACCTACGACG 
               
               
                   
                   
                   
                   
                 CCCTGCACATGCAGGCCCT 
               
               
                   
                   
                   
                   
                 GCCCCCCAGA 
               
               
                   
               
               
                 Murine 
                 599 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 600 
                 GACATCAAGATGACCCAGA 
               
               
                 ROR1 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 (VL-VH). 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 CD8a(3x). 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                 CD28z 
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                   
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 EASRPAAGGAVHTRGLDFASDKPT 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEACRPA 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 AGGAVHTRGLDFACDIYIWAPLAG 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 TCGVLLLSLVITLYCNHRNRSKRSRG 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 GHSDYMNMTPRRPGPTRKHYQPY 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 APPRDFAAYRSRVKFSRSADAPAY 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 QQGQNQLYNELNLGRREEYDVLD 
                   
                 CAGCACCAAGGGCGAAGTG 
               
               
                   
                   
                 KRRGRDPEMGGKPRRKNPQEGLY 
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRR 
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                 GKGHDGLYQGLSTATKDTYDALH 
                   
                 GCGGCAGCCTGAAGCTGAG 
               
               
                   
                   
                 MQALPPR 
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                   
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                   
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                   
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                   
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCAAGCCTACCAC 
               
               
                   
                   
                   
                   
                 CACCCCCGCACCTCGTCCTC 
               
               
                   
                   
                   
                   
                 CAACCCCTGCACCTACGATT 
               
               
                   
                   
                   
                   
                 GCCAGTCAGCCTCTTTCACT 
               
               
                   
                   
                   
                   
                 GCGGCCTGAGGCCAGCAGA 
               
               
                   
                   
                   
                   
                 CCAGCTGCCGGCGGTGCCG 
               
               
                   
                   
                   
                   
                 TCCATACAAGAGGACTGGA 
               
               
                   
                   
                   
                   
                 CTTCGCGTCCGATAAACCTA 
               
               
                   
                   
                   
                   
                 CTACCACTCCAGCCCCAAGG 
               
               
                   
                   
                   
                   
                 CCCCCAACCCCAGCACCGAC 
               
               
                   
                   
                   
                   
                 TATCGCATCACAGCCTTTGT 
               
               
                   
                   
                   
                   
                 CACTGCGTCCTGAAGCCAG 
               
               
                   
                   
                   
                   
                 CCGGCCAGCTGCAGGGGG 
               
               
                   
                   
                   
                   
                 GGCCGTCCACACAAGGGGA 
               
               
                   
                   
                   
                   
                 CTCGACTTTGCGAGTGATA 
               
               
                   
                   
                   
                   
                 AGCCCACCACCACCCCTGCC 
               
               
                   
                   
                   
                   
                 CCTAGACCTCCAACCCCAGC 
               
               
                   
                   
                   
                   
                 CCCTACAATCGCCAGCCAGC 
               
               
                   
                   
                   
                   
                 CCCTGAGCCTGAGGCCCGA 
               
               
                   
                   
                   
                   
                 AGCCTGTAGACCTGCCGCT 
               
               
                   
                   
                   
                   
                 GGCGGAGCCGTGCACACCA 
               
               
                   
                   
                   
                   
                 GAGGCCTGGATTTCGCCTG 
               
               
                   
                   
                   
                   
                 CGACATCTACATCTGGGCCC 
               
               
                   
                   
                   
                   
                 CTCTGGCCGGCACCTGTGG 
               
               
                   
                   
                   
                   
                 CGTGCTGCTGCTGAGCCTG 
               
               
                   
                   
                   
                   
                 GTCATCACCCTGTACTGCAA 
               
               
                   
                   
                   
                   
                 CCACCGGAATAGGAGCAAG 
               
               
                   
                   
                   
                   
                 CGGAGCAGAGGCGGCCAC 
               
               
                   
                   
                   
                   
                 AGCGACTACATGAACATGA 
               
               
                   
                   
                   
                   
                 CCCCCCGGAGGCCTGGCCC 
               
               
                   
                   
                   
                   
                 CACCCGGAAGCACTACCAG 
               
               
                   
                   
                   
                   
                 CCCTACGCCCCTCCCAGGGA 
               
               
                   
                   
                   
                   
                 CTTCGCCGCCTACCGGAGC 
               
               
                   
                   
                   
                   
                 CGGGTGAAGTTCAGCCGGA 
               
               
                   
                   
                   
                   
                 GCGCCGACGCCCCTGCCTA 
               
               
                   
                   
                   
                   
                 CCAGCAGGGCCAGAACCAG 
               
               
                   
                   
                   
                   
                 CTGTACAACGAGCTGAACC 
               
               
                   
                   
                   
                   
                 TGGGCCGGAGGGAGGAGT 
               
               
                   
                   
                   
                   
                 ACGACGTGCTGGACAAGCG 
               
               
                   
                   
                   
                   
                 GAGAGGCCGGGACCCTGA 
               
               
                   
                   
                   
                   
                 GATGGGCGGCAAGCCCCG 
               
               
                   
                   
                   
                   
                 GAGAAAGAACCCTCAGGAG 
               
               
                   
                   
                   
                   
                 GGCCTGTATAACGAACTGC 
               
               
                   
                   
                   
                   
                 AGAAAGACAAGATGGCCGA 
               
               
                   
                   
                   
                   
                 GGCCTACAGCGAGATCGGC 
               
               
                   
                   
                   
                   
                 ATGAAGGGCGAGCGGCGG 
               
               
                   
                   
                   
                   
                 AGGGGCAAGGGCCACGAC 
               
               
                   
                   
                   
                   
                 GGCCTGTACCAGGGCCTGA 
               
               
                   
                   
                   
                   
                 GCACCGCCACCAAGGATAC 
               
               
                   
                   
                   
                   
                 CTACGACGCCCTGCACATGC 
               
               
                   
                   
                   
                   
                 AGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 Murine ROR1 
                 601 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 602 
                 GACATCAAGATGACCCAGA 
               
               
                 (VL-VH). 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 CD8a(4x). 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 CD28z 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                   
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                   
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 KPTTTPAPRPPTPAPTIASQPLSLRP 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 EASRPAAGGAVHTRGLDFASDKPT 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEASRPA 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 AGGAVHTRGLDFASDKPTTTPAPR 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAG 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 GAVHTRGLDFACDIYIWAPLAGTC 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 GVLLLSLVITLYCNHRNRSKRSRGG 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 HSDYMNMTPRRPGPTRKHYQPYA 
                   
                 CAGCACCAAGGGCGAAGTG 
               
               
                   
                   
                 PPRDFAAYRSRVKFSRSADAPAYQ 
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                 QGQNQLYNELNLGRREEYDVLDKR 
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                 RGRDPEMGGKPRRKNPQEGLYNE 
                   
                 GCGGCAGCCTGAAGCTGAG 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGK 
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                 GHDGLYQGLSTATKDTYDALHMQ 
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                 ALPPR 
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                   
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                   
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCAAGCCTACCAC 
               
               
                   
                   
                   
                   
                 CACCCCCGCACCTCGTCCTC 
               
               
                   
                   
                   
                   
                 CAACCCCTGCACCTACGATT 
               
               
                   
                   
                   
                   
                 GCCAGTCAGCCTCTTTCACT 
               
               
                   
                   
                   
                   
                 GCGGCCTGAGGCCAGCAGA 
               
               
                   
                   
                   
                   
                 CCAGCTGCCGGCGGTGCCG 
               
               
                   
                   
                   
                   
                 TCCATACAAGAGGACTGGA 
               
               
                   
                   
                   
                   
                 CTTCGCGTCCGATAAACCTA 
               
               
                   
                   
                   
                   
                 CTACCACTCCAGCCCCAAGG 
               
               
                   
                   
                   
                   
                 CCCCCAACCCCAGCACCGAC 
               
               
                   
                   
                   
                   
                 TATCGCATCACAGCCTTTGT 
               
               
                   
                   
                   
                   
                 CACTGCGTCCTGAAGCCAG 
               
               
                   
                   
                   
                   
                 CCGGCCAGCTGCAGGGGG 
               
               
                   
                   
                   
                   
                 GGCCGTCCACACAAGGGGA 
               
               
                   
                   
                   
                   
                 CTCGACTTTGCGAGTGATA 
               
               
                   
                   
                   
                   
                 AACCTACTACAACTCCTGCC 
               
               
                   
                   
                   
                   
                 CCCCGGCCTCCTACACCAGC 
               
               
                   
                   
                   
                   
                 TCCTACTATCGCCTCCCAGC 
               
               
                   
                   
                   
                   
                 CACTCAGTCTCAGACCCGA 
               
               
                   
                   
                   
                   
                 GGCTTCTAGGCCAGCGGCC 
               
               
                   
                   
                   
                   
                 GGAGGCGCGGTCCACACCC 
               
               
                   
                   
                   
                   
                 GCGGGCTGGACTTTGCATC 
               
               
                   
                   
                   
                   
                 CGATAAGCCCACCACCACCC 
               
               
                   
                   
                   
                   
                 CTGCCCCTAGACCTCCAACC 
               
               
                   
                   
                   
                   
                 CCAGCCCCTACAATCGCCAG 
               
               
                   
                   
                   
                   
                 CCAGCCCCTGAGCCTGAGG 
               
               
                   
                   
                   
                   
                 CCCGAAGCCTGTAGACCTG 
               
               
                   
                   
                   
                   
                 CCGCTGGCGGAGCCGTGCA 
               
               
                   
                   
                   
                   
                 CACCAGAGGCCTGGATTTC 
               
               
                   
                   
                   
                   
                 GCCTGCGACATCTACATCTG 
               
               
                   
                   
                   
                   
                 GGCCCCTCTGGCCGGCACC 
               
               
                   
                   
                   
                   
                 TGTGGCGTGCTGCTGCTGA 
               
               
                   
                   
                   
                   
                 GCCTGGTCATCACCCTGTAC 
               
               
                   
                   
                   
                   
                 TGCAACCACCGGAATAGGA 
               
               
                   
                   
                   
                   
                 GCAAGCGGAGCAGAGGCG 
               
               
                   
                   
                   
                   
                 GCCACAGCGACTACATGAA 
               
               
                   
                   
                   
                   
                 CATGACCCCCCGGAGGCCT 
               
               
                   
                   
                   
                   
                 GGCCCCACCCGGAAGCACT 
               
               
                   
                   
                   
                   
                 ACCAGCCCTACGCCCCTCCC 
               
               
                   
                   
                   
                   
                 AGGGACTTCGCCGCCTACC 
               
               
                   
                   
                   
                   
                 GGAGCCGGGTGAAGTTCAG 
               
               
                   
                   
                   
                   
                 CCGGAGCGCCGACGCCCCT 
               
               
                   
                   
                   
                   
                 GCCTACCAGCAGGGCCAGA 
               
               
                   
                   
                   
                   
                 ACCAGCTGTACAACGAGCT 
               
               
                   
                   
                   
                   
                 GAACCTGGGCCGGAGGGA 
               
               
                   
                   
                   
                   
                 GGAGTACGACGTGCTGGAC 
               
               
                   
                   
                   
                   
                 AAGCGGAGAGGCCGGGAC 
               
               
                   
                   
                   
                   
                 CCTGAGATGGGCGGCAAGC 
               
               
                   
                   
                   
                   
                 CCCGGAGAAAGAACCCTCA 
               
               
                   
                   
                   
                   
                 GGAGGGCCTGTATAACGAA 
               
               
                   
                   
                   
                   
                 CTGCAGAAAGACAAGATGG 
               
               
                   
                   
                   
                   
                 CCGAGGCCTACAGCGAGAT 
               
               
                   
                   
                   
                   
                 CGGCATGAAGGGCGAGCG 
               
               
                   
                   
                   
                   
                 GCGGAGGGGCAAGGGCCA 
               
               
                   
                   
                   
                   
                 CGACGGCCTGTACCAGGGC 
               
               
                   
                   
                   
                   
                 CTGAGCACCGCCACCAAGG 
               
               
                   
                   
                   
                   
                 ATACCTACGACGCCCTGCAC 
               
               
                   
                   
                   
                   
                 ATGCAGGCCCTGCCCCCCA 
               
               
                   
                   
                   
                   
                 GA 
               
               
                   
               
               
                 Murine 
                 603 
                 DIKMTQSPSSMYASLGERVTITCKA 
                 604 
                 GACATCAAGATGACCCAGA 
               
               
                 ROR1 
                   
                 SPDINSYLSWFQQKPGKSPKTLIYR 
                   
                 GCCCCAGCTCTATGTACGCC 
               
               
                 (VL-VH). 
                   
                 ANRLVDGVPSRFSGGGSGQDYSLT 
                   
                 AGCCTGGGCGAGCGCGTGA 
               
               
                 LNGFR ECD. 
                   
                 INSLEYEDMGIYYCLQYDEFPYTFG 
                   
                 CCATCACATGCAAGGCCAG 
               
               
                 CD8TM. 
                   
                 GGTKLEMKGSTSGSGKPGSGEGST 
                   
                 CCCCGACATCAACAGCTACC 
               
               
                 CD28z 
                   
                 KGEVKLVESGGGLVKPGGSLKLSCA 
                   
                 TGTCCTGGTTCCAGCAGAA 
               
               
                   
                   
                 ASGFTFSSYAMSWVRQIPEKRLEW 
                   
                 GCCCGGCAAGAGCCCCAAG 
               
               
                   
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 ACCCTGATCTACCGGGCCA 
               
               
                   
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 ACCGGCTGGTGGACGGCGT 
               
               
                   
                   
                 RYDYDGYYAMDYWGQGTSVTVSS 
                   
                 GCCAAGCAGATTTTCCGGC 
               
               
                   
                   
                 KEACPTGLYTHSGECCKACNLGEG 
                   
                 GGAGGCAGCGGCCAGGAC 
               
               
                   
                   
                 VAQPCGANQTVCEPCLDSVTFSDV 
                   
                 TACAGCCTGACCATCAACA 
               
               
                   
                   
                 VSATEPCKPCTECVGLQSMSAPCV 
                   
                 GCCTGGAATACGAGGACAT 
               
               
                   
                   
                 EADDAVCRCAYGYYQDETTGRCEA 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 CRVCEAGSGLVFSCQDKCINTVCEE 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 CPDGTYSDEANHVDPCLPCTVCED 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 TERQLRECTRWADAECEEIPGRWI 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 TRSTPPEGSDSTAPSTQEPEAPPEQ 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 DLIASTVAGVVTTVMGSSQPVVTR 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 GTTDNIYIWAPLAGTCGVLLLSLVIT 
                   
                 CAGCACCAAGGGCGAAGTG 
               
               
                   
                   
                 LYCNHRNRSKRSRGGHSDYMNMT 
                   
                 AAGCTGGTGGAAAGCGGC 
               
               
                   
                   
                 PRRPGPTRKHYQPYAPPRDFAAYR 
                   
                 GGAGGCCTGGTGAAACCTG 
               
               
                   
                   
                 SRVKFSRSADAPAYQQGONQLYN 
                   
                 GCGGCAGCCTGAAGCTGAG 
               
               
                   
                   
                 ELNLGRREEYDVLDKRRGRDPEMG 
                   
                 CTGCGCCGCCAGCGGCTTC 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAE 
                   
                 ACCTTCAGCAGCTACGCCAT 
               
               
                   
                   
                 AYSEIGMKGERRRGKGHDGLYQGL 
                   
                 GAGCTGGGTCCGACAGATC 
               
               
                   
                   
                 STATKDTYDALHMQALPPR 
                   
                 CCCGAGAAGCGGCTGGAAT 
               
               
                   
                   
                   
                   
                 GGGTGGCCAGCATCAGCAG 
               
               
                   
                   
                   
                   
                 GGGCGGCACCACCTACTAC 
               
               
                   
                   
                   
                   
                 CCCGACAGCGTGAAGGGCC 
               
               
                   
                   
                   
                   
                 GGTTCACCATCAGCCGGGA 
               
               
                   
                   
                   
                   
                 CAACGTGCGGAACATCCTG 
               
               
                   
                   
                   
                   
                 TACCTGCAGATGAGCAGCC 
               
               
                   
                   
                   
                   
                 TGCGGAGCGAGGACACCGC 
               
               
                   
                   
                   
                   
                 CATGTACTACTGCGGCAGA 
               
               
                   
                   
                   
                   
                 TACGACTACGACGGCTACT 
               
               
                   
                   
                   
                   
                 ACGCCATGGATTACTGGGG 
               
               
                   
                   
                   
                   
                 CCAGGGCACCAGCGTGACC 
               
               
                   
                   
                   
                   
                 GTGTCTAGCAAGGAGGCAT 
               
               
                   
                   
                   
                   
                 GCCCCACAGGCCTGTACAC 
               
               
                   
                   
                   
                   
                 ACACAGCGGTGAGTGCTGC 
               
               
                   
                   
                   
                   
                 AAAGCCTGCAACCTGGGCG 
               
               
                   
                   
                   
                   
                 AGGGTGTGGCCCAGCCTTG 
               
               
                   
                   
                   
                   
                 TGGAGCCAACCAGACCGTG 
               
               
                   
                   
                   
                   
                 TGTGAGCCCTGCCTGGACA 
               
               
                   
                   
                   
                   
                 GCGTGACGTTCTCCGACGT 
               
               
                   
                   
                   
                   
                 GGTGAGCGCGACCGAGCC 
               
               
                   
                   
                   
                   
                 GTGCAAGCCGTGCACCGAG 
               
               
                   
                   
                   
                   
                 TGCGTGGGGCTCCAGAGCA 
               
               
                   
                   
                   
                   
                 TGTCGGCGCCGTGCGTGGA 
               
               
                   
                   
                   
                   
                 GGCCGACGACGCCGTGTGC 
               
               
                   
                   
                   
                   
                 CGCTGCGCCTACGGCTACT 
               
               
                   
                   
                   
                   
                 ACCAGGATGAGACGACTGG 
               
               
                   
                   
                   
                   
                 GCGCTGCGAGGCGTGCCGC 
               
               
                   
                   
                   
                   
                 GTGTGCGAGGCGGGCTCG 
               
               
                   
                   
                   
                   
                 GGCCTCGTGTTCTCCTGCCA 
               
               
                   
                   
                   
                   
                 GGACAAGCAGAACACCGTG 
               
               
                   
                   
                   
                   
                 TGCGAGGAGTGCCCCGACG 
               
               
                   
                   
                   
                   
                 GCACGTATTCCGACGAGGC 
               
               
                   
                   
                   
                   
                 CAACCACGTGGACCCGTGC 
               
               
                   
                   
                   
                   
                 CTGCCCTGCACCGTGTGCG 
               
               
                   
                   
                   
                   
                 AGGACACCGAGCGCCAGCT 
               
               
                   
                   
                   
                   
                 CCGCGAGTGCACACGCTGG 
               
               
                   
                   
                   
                   
                 GCCGACGCCGAGTGCGAG 
               
               
                   
                   
                   
                   
                 GAGATCCCTGGCCGTTGGA 
               
               
                   
                   
                   
                   
                 TTACACGGTCCACACCCCCA 
               
               
                   
                   
                   
                   
                 GAGGGCTCGGACAGCACAG 
               
               
                   
                   
                   
                   
                 CCCCCAGCACCCAGGAGCC 
               
               
                   
                   
                   
                   
                 TGAGGCACCTCCAGAACAA 
               
               
                   
                   
                   
                   
                 GACCTCATAGCCAGCACGG 
               
               
                   
                   
                   
                   
                 TGGCAGGTGTGGTGACCAC 
               
               
                   
                   
                   
                   
                 AGTGATGGGCAGCTCCCAG 
               
               
                   
                   
                   
                   
                 CCCGTGGTGACCCGAGGCA 
               
               
                   
                   
                   
                   
                 CCACCGACAACATCTACATC 
               
               
                   
                   
                   
                   
                 TGGGCCCCTCTGGCCGGCA 
               
               
                   
                   
                   
                   
                 CCTGTGGCGTGCTGCTGCT 
               
               
                   
                   
                   
                   
                 GAGCCTGGTCATCACCCTGT 
               
               
                   
                   
                   
                   
                 ACTGCAACCACCGGAATAG 
               
               
                   
                   
                   
                   
                 GAGCAAGCGGAGCAGAGG 
               
               
                   
                   
                   
                   
                 CGGCCACAGCGACTACATG 
               
               
                   
                   
                   
                   
                 AACATGACCCCCCGGAGGC 
               
               
                   
                   
                   
                   
                 CTGGCCCCACCCGGAAGCA 
               
               
                   
                   
                   
                   
                 CTACCAGCCCTACGCCCCTC 
               
               
                   
                   
                   
                   
                 CCAGGGACTTCGCCGCCTA 
               
               
                   
                   
                   
                   
                 CCGGAGCCGGGTGAAGTTC 
               
               
                   
                   
                   
                   
                 AGCCGGAGCGCCGACGCCC 
               
               
                   
                   
                   
                   
                 CTGCCTACCAGCAGGGCCA 
               
               
                   
                   
                   
                   
                 GAACCAGCTGTACAACGAG 
               
               
                   
                   
                   
                   
                 CTGAACCTGGGCCGGAGGG 
               
               
                   
                   
                   
                   
                 AGGAGTACGACGTGCTGGA 
               
               
                   
                   
                   
                   
                 CAAGCGGAGAGGCCGGGA 
               
               
                   
                   
                   
                   
                 CCCTGAGATGGGCGGCAAG 
               
               
                   
                   
                   
                   
                 CCCCGGAGAAAGAACCCTC 
               
               
                   
                   
                   
                   
                 AGGAGGGCCTGTATAACGA 
               
               
                   
                   
                   
                   
                 ACTGCAGAAAGACAAGATG 
               
               
                   
                   
                   
                   
                 GCCGAGGCCTACAGCGAGA 
               
               
                   
                   
                   
                   
                 TCGGCATGAAGGGCGAGCG 
               
               
                   
                   
                   
                   
                 GCGGAGGGGCAAGGGCCA 
               
               
                   
                   
                   
                   
                 CGACGGCCTGTACCAGGGC 
               
               
                   
                   
                   
                   
                 CTGAGCACCGCCACCAAGG 
               
               
                   
                   
                   
                   
                 ATACCTACGACGCCCTGCAC 
               
               
                   
                   
                   
                   
                 ATGCAGGCCCTGCCCCCCA 
               
               
                   
                   
                   
                   
                 GA 
               
               
                   
               
               
                 Murine 
                 605 
                 EVKLVESGGGLVKPGGSLKLSCAAS 
                 606 
                 GAAGTGAAGCTGGTGGAAA 
               
               
                 ROR1 
                   
                 GFTFSSYAMSWVRQIPEKRLEWVA 
                   
                 GCGGCGGAGGCCTGGTGA 
               
               
                 (VH-VL). 
                   
                 SISRGGTTYYPDSVKGRFTISRDNVR 
                   
                 AACCTGGCGGCAGCCTGAA 
               
               
                 CD8a(3x). 
                   
                 NILYLQMSSLRSEDTAMYYCGRYD 
                   
                 GCTGAGCTGCGCCGCCAGC 
               
               
                 41BBz 
                   
                 YDGYYAMDYWGQGTSVTVSSGST 
                   
                 GGCTTCACCTTCAGCAGCTA 
               
               
                   
                   
                 SGSGKPGSGEGSTKGDIKMTQSPS 
                   
                 CGCCATGAGCTGGGTCCGA 
               
               
                   
                   
                 SMYASLGERVTITCKASPDINSYLS 
                   
                 CAGATCCCCGAGAAGCGGC 
               
               
                   
                   
                 WFQQKPGKSPKTLIYRANRLVDGV 
                   
                 TGGAATGGGTGGCCAGCAT 
               
               
                   
                   
                 PSRFSGGGSGQDYSLTINSLEYEDM 
                   
                 CAGCAGGGGCGGCACCACC 
               
               
                   
                   
                 GIYYCLQYDEFPYTFGGGTKLEMKK 
                   
                 TACTACCCCGACAGCGTGA 
               
               
                   
                   
                 PTTTPAPRPPTPAPTIASQPLSLRPE 
                   
                 AGGGCCGGTTCACCATCAG 
               
               
                   
                   
                 ASRPAAGGAVHTRGLDFASDKPTT 
                   
                 CCGGGACAACGTGCGGAAC 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEASR 
                   
                 ATCCTGTACCTGCAGATGA 
               
               
                   
                   
                 PAAGGAVHTRGLDFASDKPTTTPA 
                   
                 GCAGCCTGCGGAGCGAGG 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAA 
                   
                 ACACCGCCATGTACTACTGC 
               
               
                   
                   
                 GGAVHTRGLDFACDIYIWAPLAGT 
                   
                 GGCAGATACGACTACGACG 
               
               
                   
                   
                 CGVLLLSLVITLYCNHRNKRGRKKLL 
                   
                 GCTACTACGCCATGGATTAC 
               
               
                   
                   
                 YIFKQPFMRPVQTTQEEDGCSCRF 
                   
                 TGGGGCCAGGGCACCAGC 
               
               
                   
                   
                 PEEEEGGCELRVKFSRSADAPAYQ 
                   
                 GTGACCGTGTCTAGCGGCA 
               
               
                   
                   
                 QGQNQLYNELNLGRREEYDVLDKR 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 RGRDPEMGGKPRRKNPQEGLYNE 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGK 
                   
                 CAGCACCAAGGGCGACATC 
               
               
                   
                   
                 GHDGLYQGLSTATKDTYDALHMQ 
                   
                 AAGATGACCCAGAGCCCCA 
               
               
                   
                   
                 ALPPR 
                   
                 GCTCTATGTACGCCAGCCTG 
               
               
                   
                   
                   
                   
                 GGCGAGCGCGTGACCATCA 
               
               
                   
                   
                   
                   
                 CATGCAAGGCCAGCCCCGA 
               
               
                   
                   
                   
                   
                 CATCAACAGCTACCTGTCCT 
               
               
                   
                   
                   
                   
                 GGTTCCAGCAGAAGCCCGG 
               
               
                   
                   
                   
                   
                 CAAGAGCCCCAAGACCCTG 
               
               
                   
                   
                   
                   
                 ATCTACCGGGCCAACCGGC 
               
               
                   
                   
                   
                   
                 TGGTGGACGGCGTGCCAAG 
               
               
                   
                   
                   
                   
                 CAGATTTTCCGGCGGAGGC 
               
               
                   
                   
                   
                   
                 AGCGGCCAGGACTACAGCC 
               
               
                   
                   
                   
                   
                 TGACCATCAACAGCCTGGA 
               
               
                   
                   
                   
                   
                 ATACGAGGACATGGGCATC 
               
               
                   
                   
                   
                   
                 TACTACTGCCTGCAGTACGA 
               
               
                   
                   
                   
                   
                 CGAGTTCCCCTACACCTTCG 
               
               
                   
                   
                   
                   
                 GAGGCGGCACCAAGCTGGA 
               
               
                   
                   
                   
                   
                 AATGAAGAAGCCTACCACC 
               
               
                   
                   
                   
                   
                 ACCCCCGCACCTCGTCCTCC 
               
               
                   
                   
                   
                   
                 AACCCCTGCACCTACGATTG 
               
               
                   
                   
                   
                   
                 CCAGTCAGCCTCTTTCACTG 
               
               
                   
                   
                   
                   
                 CGGCCTGAGGCCAGCAGAC 
               
               
                   
                   
                   
                   
                 CAGCTGCCGGCGGTGCCGT 
               
               
                   
                   
                   
                   
                 CCATACAAGAGGACTGGAC 
               
               
                   
                   
                   
                   
                 TTCGCGTCCGATAAACCTAC 
               
               
                   
                   
                   
                   
                 TACCACTCCAGCCCCAAGGC 
               
               
                   
                   
                   
                   
                 CCCCAACCCCAGCACCGACT 
               
               
                   
                   
                   
                   
                 ATCGCATCACAGCCTTTGTC 
               
               
                   
                   
                   
                   
                 ACTGCGTCCTGAAGCCAGC 
               
               
                   
                   
                   
                   
                 CGGCCAGCTGCAGGGGGG 
               
               
                   
                   
                   
                   
                 GCCGTCCACACAAGGGGAC 
               
               
                   
                   
                   
                   
                 TCGACTTTGCGAGTGATAA 
               
               
                   
                   
                   
                   
                 GCCCACCACCACCCCTGCCC 
               
               
                   
                   
                   
                   
                 CTAGACCTCCAACCCCAGCC 
               
               
                   
                   
                   
                   
                 CCTACAATCGCCAGCCAGCC 
               
               
                   
                   
                   
                   
                 CCTGAGCCTGAGGCCCGAA 
               
               
                   
                   
                   
                   
                 GCCTGTAGACCTGCCGCTG 
               
               
                   
                   
                   
                   
                 GCGGAGCCGTGCACACCAG 
               
               
                   
                   
                   
                   
                 AGGCCTGGATTTCGCCTGC 
               
               
                   
                   
                   
                   
                 GACATCTACATCTGGGCCCC 
               
               
                   
                   
                   
                   
                 TCTGGCCGGCACCTGTGGC 
               
               
                   
                   
                   
                   
                 GTGCTGCTGCTGAGCCTGG 
               
               
                   
                   
                   
                   
                 TCATCACCCTGTACTGCAAC 
               
               
                   
                   
                   
                   
                 CACCGGAATAAGAGAGGCC 
               
               
                   
                   
                   
                   
                 GGAAGAAACTGCTGTACAT 
               
               
                   
                   
                   
                   
                 CTTCAAGCAGCCCTTCATGC 
               
               
                   
                   
                   
                   
                 GGCCCGTGCAGACCACCCA 
               
               
                   
                   
                   
                   
                 GGAAGAGGACGGCTGCAG 
               
               
                   
                   
                   
                   
                 CTGCCGGTTCCCCGAGGAA 
               
               
                   
                   
                   
                   
                 GAGGAAGGCGGCTGCGAA 
               
               
                   
                   
                   
                   
                 CTGCGGGTGAAGTTCAGCC 
               
               
                   
                   
                   
                   
                 GGAGCGCCGACGCCCCTGC 
               
               
                   
                   
                   
                   
                 CTACCAGCAGGGCCAGAAC 
               
               
                   
                   
                   
                   
                 CAGCTGTACAACGAGCTGA 
               
               
                   
                   
                   
                   
                 ACCTGGGCCGGAGGGAGG 
               
               
                   
                   
                   
                   
                 AGTACGACGTGCTGGACAA 
               
               
                   
                   
                   
                   
                 GCGGAGAGGCCGGGACCC 
               
               
                   
                   
                   
                   
                 TGAGATGGGCGGCAAGCCC 
               
               
                   
                   
                   
                   
                 CGGAGAAAGAACCCTCAGG 
               
               
                   
                   
                   
                   
                 AGGGCCTGTATAACGAACT 
               
               
                   
                   
                   
                   
                 GCAGAAAGACAAGATGGCC 
               
               
                   
                   
                   
                   
                 GAGGCCTACAGCGAGATCG 
               
               
                   
                   
                   
                   
                 GCATGAAGGGCGAGCGGC 
               
               
                   
                   
                   
                   
                 GGAGGGGCAAGGGCCACG 
               
               
                   
                   
                   
                   
                 ACGGCCTGTACCAGGGCCT 
               
               
                   
                   
                   
                   
                 GAGCACCGCCACCAAGGAT 
               
               
                   
                   
                   
                   
                 ACCTACGACGCCCTGCACAT 
               
               
                   
                   
                   
                   
                 GCAGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 Murine 
                 607 
                 EVKLVESGGGLVKPGGSLKLSCAAS 
                 608 
                 GAAGTGAAGCTGGTGGAAA 
               
               
                 ROR1 
                   
                 GFTFSSYAMSWVRQIPEKRLEWVA 
                   
                 GCGGCGGAGGCCTGGTGA 
               
               
                 (VH-VL). 
                   
                 SISRGGTTYYPDSVKGRFTISRDNVR 
                   
                 AACCTGGCGGCAGCCTGAA 
               
               
                 IgG4 Fcm. 
                   
                 NILYLQMSSLRSEDTAMYYCGRYD 
                   
                 GCTGAGCTGCGCCGCCAGC 
               
               
                 CD8aTM. 
                   
                 YDGYYAMDYWGQGTSVTVSSGST 
                   
                 GGCTTCACCTTCAGCAGCTA 
               
               
                 41BBz 
                   
                 SGSGKPGSGEGSTKGDIKMTQSPS 
                   
                 CGCCATGAGCTGGGTCCGA 
               
               
                   
                   
                 SMYASLGERVTITCKASPDINSYLS 
                   
                 CAGATCCCCGAGAAGCGGC 
               
               
                   
                   
                 WFQQKPGKSPKTLIYRANRLVDGV 
                   
                 TGGAATGGGTGGCCAGCAT 
               
               
                   
                   
                 PSRFSGGGSGQDYSLTINSLEYEDM 
                   
                 CAGCAGGGGCGGCACCACC 
               
               
                   
                   
                 GIYYCLQYDEFPYTFGGGTKLEMKE 
                   
                 TACTACCCCGACAGCGTGA 
               
               
                   
                   
                 SKYGPPCPPCPAPEFEGGPSVFLFP 
                   
                 AGGGCCGGTTCACCATCAG 
               
               
                   
                   
                 PKPKDTLMISRTPEVTCVVVDVSQE 
                   
                 CCGGGACAACGTGCGGAAC 
               
               
                   
                   
                 DPEVQFNWYVDGVEVHNAKTKPR 
                   
                 ATCCTGTACCTGCAGATGA 
               
               
                   
                   
                 EEQFQSTYRVVSVLTVLHQDWLNG 
                   
                 GCAGCCTGCGGAGCGAGG 
               
               
                   
                   
                 KEYKCKVSNKGLPSSIEKTISKAKGQ 
                   
                 ACACCGCCATGTACTACTGC 
               
               
                   
                   
                 PREPQVYTLPPSQEEMTKNQVSLT 
                   
                 GGCAGATACGACTACGACG 
               
               
                   
                   
                 CLVKGFYPSDIAVEWESNGQPENN 
                   
                 GCTACTACGCCATGGATTAC 
               
               
                   
                   
                 YKTTPPVLDSDGSFFLYSRLTVDKSR 
                   
                 TGGGGCCAGGGCACCAGC 
               
               
                   
                   
                 WQEGNVFSCSVMHEALHNHYTQ 
                   
                 GTGACCGTGTCTAGCGGCA 
               
               
                   
                   
                 KSLSLSLGKMIYIWAPLAGTCGVLLL 
                   
                 GCACCTCCGGCAGCGGCAA 
               
               
                   
                   
                 SLVITLYCNHRNKRGRKKLLYIFKQP 
                   
                 GCCTGGCAGCGGCGAGGG 
               
               
                   
                   
                 FMRPVQTTQEEDGCSCRFPEEEEG 
                   
                 CAGCACCAAGGGCGACATC 
               
               
                   
                   
                 GCELRVKFSRSADAPAYQQGQNQ 
                   
                 AAGATGACCCAGAGCCCCA 
               
               
                   
                   
                 LYNELNLGRREEYDVLDKRRGRDPE 
                   
                 GCTCTATGTACGCCAGCCTG 
               
               
                   
                   
                 MGGKPRRKNPQEGLYNELQKDK 
                   
                 GGCGAGCGCGTGACCATCA 
               
               
                   
                   
                 MAEAYSEIGMKGERRRGKGHDGL 
                   
                 CATGCAAGGCCAGCCCCGA 
               
               
                   
                   
                 YQGLSTATKDTYDALHMQALPPR 
                   
                 CATCAACAGCTACCTGTCCT 
               
               
                   
                   
                   
                   
                 GGTTCCAGCAGAAGCCCGG 
               
               
                   
                   
                   
                   
                 CAAGAGCCCCAAGACCCTG 
               
               
                   
                   
                   
                   
                 ATCTACCGGGCCAACCGGC 
               
               
                   
                   
                   
                   
                 TGGTGGACGGCGTGCCAAG 
               
               
                   
                   
                   
                   
                 CAGATTTTCCGGCGGAGGC 
               
               
                   
                   
                   
                   
                 AGCGGCCAGGACTACAGCC 
               
               
                   
                   
                   
                   
                 TGACCATCAACAGCCTGGA 
               
               
                   
                   
                   
                   
                 ATACGAGGACATGGGCATC 
               
               
                   
                   
                   
                   
                 TACTACTGCCTGCAGTACGA 
               
               
                   
                   
                   
                   
                 CGAGTTCCCCTACACCTTCG 
               
               
                   
                   
                   
                   
                 GAGGCGGCACCAAGCTGGA 
               
               
                   
                   
                   
                   
                 AATGAAGGAGAGCAAGTAC 
               
               
                   
                   
                   
                   
                 GGCCCTCCCTGCCCCCCTTG 
               
               
                   
                   
                   
                   
                 CCCTGCCCCCGAGTTCGAG 
               
               
                   
                   
                   
                   
                 GGCGGACCCAGCGTGTTCC 
               
               
                   
                   
                   
                   
                 TGTTCCCCCCCAAGCCCAAG 
               
               
                   
                   
                   
                   
                 GACACCCTGATGATCAGCC 
               
               
                   
                   
                   
                   
                 GGACCCCCGAGGTGACCTG 
               
               
                   
                   
                   
                   
                 TGTGGTGGTGGACGTGTCC 
               
               
                   
                   
                   
                   
                 CAGGAGGACCCCGAGGTCC 
               
               
                   
                   
                   
                   
                 AGTTCAACTGGTACGTGGA 
               
               
                   
                   
                   
                   
                 CGGCGTGGAGGTGCACAAC 
               
               
                   
                   
                   
                   
                 GCCAAGACCAAGCCCCGGG 
               
               
                   
                   
                   
                   
                 AGGAGCAGTTCCAGAGCAC 
               
               
                   
                   
                   
                   
                 CTACCGGGTGGTGTCCGTG 
               
               
                   
                   
                   
                   
                 CTGACCGTGCTGCACCAGG 
               
               
                   
                   
                   
                   
                 ACTGGCTGAACGGCAAGGA 
               
               
                   
                   
                   
                   
                 ATACAAGTGTAAGGTGTCC 
               
               
                   
                   
                   
                   
                 AACAAGGGCCTGCCCAGCA 
               
               
                   
                   
                   
                   
                 GCATCGAGAAAACCATCAG 
               
               
                   
                   
                   
                   
                 CAAGGCCAAGGGCCAGCCT 
               
               
                   
                   
                   
                   
                 CGGGAGCCCCAGGTGTACA 
               
               
                   
                   
                   
                   
                 CCCTGCCCCCTAGCCAAGA 
               
               
                   
                   
                   
                   
                 GGAGATGACCAAGAATCAG 
               
               
                   
                   
                   
                   
                 GTGTCCCTGACCTGCCTGGT 
               
               
                   
                   
                   
                   
                 GAAGGGCTTCTACCCCAGC 
               
               
                   
                   
                   
                   
                 GACATCGCCGTGGAGTGGG 
               
               
                   
                   
                   
                   
                 AGAGCAACGGCCAGCCCGA 
               
               
                   
                   
                   
                   
                 GAACAACTACAAGACCACC 
               
               
                   
                   
                   
                   
                 CCCCCTGTGCTGGACAGCG 
               
               
                   
                   
                   
                   
                 ACGGCAGCTTCTTCCTGTAC 
               
               
                   
                   
                   
                   
                 AGCAGGCTGACCGTGGACA 
               
               
                   
                   
                   
                   
                 AGAGCCGGTGGCAGGAGG 
               
               
                   
                   
                   
                   
                 GCAACGTCTTTAGCTGCTCC 
               
               
                   
                   
                   
                   
                 GTGATGCACGAGGCCCTGC 
               
               
                   
                   
                   
                   
                 ACAACCACTACACCCAGAA 
               
               
                   
                   
                   
                   
                 GAGCCTGTCCCTGAGCCTG 
               
               
                   
                   
                   
                   
                 GGCAAGATGATCTACATCT 
               
               
                   
                   
                   
                   
                 GGGCCCCTCTGGCCGGCAC 
               
               
                   
                   
                   
                   
                 CTGTGGCGTGCTGCTGCTG 
               
               
                   
                   
                   
                   
                 AGCCTGGTCATCACCCTGTA 
               
               
                   
                   
                   
                   
                 CTGCAACCACCGGAATAAG 
               
               
                   
                   
                   
                   
                 AGAGGCCGGAAGAAACTGC 
               
               
                   
                   
                   
                   
                 TGTACATCTTCAAGCAGCCC 
               
               
                   
                   
                   
                   
                 TTCATGCGGCCCGTGCAGA 
               
               
                   
                   
                   
                   
                 CCACCCAGGAAGAGGACGG 
               
               
                   
                   
                   
                   
                 CTGCAGCTGCCGGTTCCCC 
               
               
                   
                   
                   
                   
                 GAGGAAGAGGAAGGCGGC 
               
               
                   
                   
                   
                   
                 TGCGAACTGCGGGTGAAGT 
               
               
                   
                   
                   
                   
                 TCAGCCGGAGCGCCGACGC 
               
               
                   
                   
                   
                   
                 CCCTGCCTACCAGCAGGGC 
               
               
                   
                   
                   
                   
                 CAGAACCAGCTGTACAACG 
               
               
                   
                   
                   
                   
                 AGCTGAACCTGGGCCGGAG 
               
               
                   
                   
                   
                   
                 GGAGGAGTACGACGTGCTG 
               
               
                   
                   
                   
                   
                 GACAAGCGGAGAGGCCGG 
               
               
                   
                   
                   
                   
                 GACCCTGAGATGGGCGGCA 
               
               
                   
                   
                   
                   
                 AGCCCCGGAGAAAGAACCC 
               
               
                   
                   
                   
                   
                 TCAGGAGGGCCTGTATAAC 
               
               
                   
                   
                   
                   
                 GAACTGCAGAAAGACAAGA 
               
               
                   
                   
                   
                   
                 TGGCCGAGGCCTACAGCGA 
               
               
                   
                   
                   
                   
                 GATCGGCATGAAGGGCGA 
               
               
                   
                   
                   
                   
                 GCGGCGGAGGGGCAAGGG 
               
               
                   
                   
                   
                   
                 CCACGACGGCCTGTACCAG 
               
               
                   
                   
                   
                   
                 GGCCTGAGCACCGCCACCA 
               
               
                   
                   
                   
                   
                 AGGATACCTACGACGCCCT 
               
               
                   
                   
                   
                   
                 GCACATGCAGGCCCTGCCC 
               
               
                   
                   
                   
                   
                 CCCAGA 
               
               
                   
               
               
                 Murine 
                 609 
                 DVQITQSPSSLYASLGERVTITCKAS 
                 610 
                 GACGTGCAGATCACCCAGA 
               
               
                 ROR1_v2 VL 
                   
                 PDINSYLSWFQQKPGKSPKTLIYRA 
                   
                 GCCCCAGCAGCCTGTATGC 
               
               
                   
                   
                 NRLVDGVPSRFSGGGSGQDYSLTI 
                   
                 CAGCCTGGGCGAGAGAGTG 
               
               
                   
                   
                 NSLEYEDMGIYYCLQYDEFPYTFGG 
                   
                 ACCATTACCTGCAAGGCCA 
               
               
                   
                   
                 GTKLEMK 
                   
                 GCCCCGACATCAACAGCTA 
               
               
                   
                   
                   
                   
                 CCTGAGCTGGTTCCAGCAG 
               
               
                   
                   
                   
                   
                 AAGCCCGGCAAGAGCCCCA 
               
               
                   
                   
                   
                   
                 AGACCCTGATCTACCGGGC 
               
               
                   
                   
                   
                   
                 CAACAGACTGGTGGATGGC 
               
               
                   
                   
                   
                   
                 GTGCCCAGCAGATTCAGCG 
               
               
                   
                   
                   
                   
                 GCGGAGGCTCTGGCCAGGA 
               
               
                   
                   
                   
                   
                 CTACAGCCTGACCATCAACT 
               
               
                   
                   
                   
                   
                 CCCTGGAATACGAGGACAT 
               
               
                   
                   
                   
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                   
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                   
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                   
                   
                 AGCTGGAAATGAAG 
               
               
                   
               
               
                 Murine 
                 611 
                 EVKLVESGGGLVKPGGSLKLSCAAS 
                 612 
                 GAAGTGAAGCTGGTGGAAT 
               
               
                 ROR1_v2 VH 
                   
                 GFTFSSYAMSWVRQIPEKRLEWVA 
                   
                 CTGGCGGCGGACTCGTGAA 
               
               
                   
                   
                 SISRGGTTYYPDSVKGRFTISRDNVR 
                   
                 GCCTGGCGGCTCTCTGAAG 
               
               
                   
                   
                 NILYLQMSSLRSEDTAMYYCGRYD 
                   
                 CTGTCTTGTGCCGCCAGCG 
               
               
                   
                   
                 YDGYYAMDYWGQGTSVTVSS 
                   
                 GCTTCACCTTCAGCAGCTAC 
               
               
                   
                   
                   
                   
                 GCCATGAGCTGGGTGCGGC 
               
               
                   
                   
                   
                   
                 AGATCCCCGAGAAGCGGCT 
               
               
                   
                   
                   
                   
                 GGAATGGGTGGCCAGCATC 
               
               
                   
                   
                   
                   
                 AGCAGAGGCGGAACCACCT 
               
               
                   
                   
                   
                   
                 ACTACCCCGACTCTGTGAAG 
               
               
                   
                   
                   
                   
                 GGCCGGTTCACCATCAGCC 
               
               
                   
                   
                   
                   
                 GGGACAACGTGCGGAACAT 
               
               
                   
                   
                   
                   
                 CCTGTACCTGCAGATGAGC 
               
               
                   
                   
                   
                   
                 AGCCTGCGGAGCGAGGACA 
               
               
                   
                   
                   
                   
                 CCGCCATGTACTACTGTGGC 
               
               
                   
                   
                   
                   
                 AGATACGACTACGACGGCT 
               
               
                   
                   
                   
                   
                 ACTATGCCATGGATTACTG 
               
               
                   
                   
                   
                   
                 GGGCCAGGGCACCAGCGT 
               
               
                   
                   
                   
                   
                 GACCGTGTCATCT 
               
               
                   
               
               
                 Murine 
                 613 
                 DVQITQSPSSLYASLGERVTITCKAS 
                 614 
                 GACGTGCAGATCACCCAGA 
               
               
                 ROR1_v2 
                   
                 PDINSYLSWFQQKPGKSPKTLIYRA 
                   
                 GCCCCAGCAGCCTGTATGC 
               
               
                 (VL-VH). 
                   
                 NRLVDGVPSRFSGGGSGQDYSLTI 
                   
                 CAGCCTGGGCGAGAGAGTG 
               
               
                 CD8a(3x). 
                   
                 NSLEYEDMGIYYCLQYDEFPYTFGG 
                   
                 ACCATTACCTGCAAGGCCA 
               
               
                 CD28z 
                   
                 GTKLEMKGSTSGSGKPGSGEGSTK 
                   
                 GCCCCGACATCAACAGCTA 
               
               
                   
                   
                 GEVKLVESGGGLVKPGGSLKLSCAA 
                   
                 CCTGAGCTGGTTCCAGCAG 
               
               
                   
                   
                 SGFTFSSYAMSWVRQIPEKRLEWV 
                   
                 AAGCCCGGCAAGAGCCCCA 
               
               
                   
                   
                 ASISRGGTTYYPDSVKGRFTISRDN 
                   
                 AGACCCTGATCTACCGGGC 
               
               
                   
                   
                 VRNILYLQMSSLRSEDTAMYYCGR 
                   
                 CAACAGACTGGTGGATGGC 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTSVTVSSK 
                   
                 GTGCCCAGCAGATTCAGCG 
               
               
                   
                   
                 PTTTPAPRPPTPAPTIASQPLSLRPE 
                   
                 GCGGAGGCTCTGGCCAGGA 
               
               
                   
                   
                 ASRPAAGGAVHTRGLDFASDKPTT 
                   
                 CTACAGCCTGACCATCAACT 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEASR 
                   
                 CCCTGGAATACGAGGACAT 
               
               
                   
                   
                 PAAGGAVHTRGLDFASDKPTTTPA 
                   
                 GGGCATCTACTACTGCCTGC 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAA 
                   
                 AGTACGACGAGTTCCCCTAC 
               
               
                   
                   
                 GGAVHTRGLDFACDIYIWAPLAGT 
                   
                 ACCTTCGGAGGCGGCACCA 
               
               
                   
                   
                 CGVLLLSLVITLYCNHRNRSKRSRG 
                   
                 AGCTGGAAATGAAGGGCA 
               
               
                   
                   
                 GHSDYMNMTPRRPGPTRKHYQPY 
                   
                 GCACAAGCGGCAGCGGCAA 
               
               
                   
                   
                 APPRDFAAYRSRVKFSRSADAPAY 
                   
                 GCCTGGATCTGGCGAGGGA 
               
               
                   
                   
                 QQGQNQLYNELNLGRREEYDVLD 
                   
                 AGCACCAAGGGCGAAGTGA 
               
               
                   
                   
                 KRRGRDPEMGGKPRRKNPQEGLY 
                   
                 AGCTGGTGGAATCTGGCGG 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRR 
                   
                 CGGACTCGTGAAGCCTGGC 
               
               
                   
                   
                 GKGHDGLYQGLSTATKDTYDALH 
                   
                 GGCTCTCTGAAGCTGTCTTG 
               
               
                   
                   
                 MQALPPR 
                   
                 TGCCGCCAGCGGCTTCACCT 
               
               
                   
                   
                   
                   
                 TCAGCAGCTACGCCATGAG 
               
               
                   
                   
                   
                   
                 CTGGGTGCGGCAGATCCCC 
               
               
                   
                   
                   
                   
                 GAGAAGCGGCTGGAATGG 
               
               
                   
                   
                   
                   
                 GTGGCCAGCATCAGCAGAG 
               
               
                   
                   
                   
                   
                 GCGGAACCACCTACTACCCC 
               
               
                   
                   
                   
                   
                 GACTCTGTGAAGGGCCGGT 
               
               
                   
                   
                   
                   
                 TCACCATCAGCCGGGACAA 
               
               
                   
                   
                   
                   
                 CGTGCGGAACATCCTGTAC 
               
               
                   
                   
                   
                   
                 CTGCAGATGAGCAGCCTGC 
               
               
                   
                   
                   
                   
                 GGAGCGAGGACACCGCCAT 
               
               
                   
                   
                   
                   
                 GTACTACTGTGGCAGATAC 
               
               
                   
                   
                   
                   
                 GACTACGACGGCTACTATG 
               
               
                   
                   
                   
                   
                 CCATGGATTACTGGGGCCA 
               
               
                   
                   
                   
                   
                 GGGCACCAGCGTGACCGTG 
               
               
                   
                   
                   
                   
                 TCATCTAAGCCTACCACCAC 
               
               
                   
                   
                   
                   
                 CCCCGCACCTCGTCCTCCAA 
               
               
                   
                   
                   
                   
                 CCCCTGCACCTACGATTGCC 
               
               
                   
                   
                   
                   
                 AGTCAGCCTCTTTCACTGCG 
               
               
                   
                   
                   
                   
                 GCCTGAGGCCAGCAGACCA 
               
               
                   
                   
                   
                   
                 GCTGCCGGCGGTGCCGTCC 
               
               
                   
                   
                   
                   
                 ATACAAGAGGACTGGACTT 
               
               
                   
                   
                   
                   
                 CGCGTCCGATAAACCTACTA 
               
               
                   
                   
                   
                   
                 CCACTCCAGCCCCAAGGCCC 
               
               
                   
                   
                   
                   
                 CCAACCCCAGCACCGACTAT 
               
               
                   
                   
                   
                   
                 CGCATCACAGCCTTTGTCAC 
               
               
                   
                   
                   
                   
                 TGCGTCCTGAAGCCAGCCG 
               
               
                   
                   
                   
                   
                 GCCAGCTGCAGGGGGGGC 
               
               
                   
                   
                   
                   
                 CGTCCACACAAGGGGACTC 
               
               
                   
                   
                   
                   
                 GACTTTGCGAGTGATAAGC 
               
               
                   
                   
                   
                   
                 CCACCACCACCCCTGCCCCT 
               
               
                   
                   
                   
                   
                 AGACCTCCAACCCCAGCCCC 
               
               
                   
                   
                   
                   
                 TACAATCGCCAGCCAGCCCC 
               
               
                   
                   
                   
                   
                 TGAGCCTGAGGCCCGAAGC 
               
               
                   
                   
                   
                   
                 CTGTAGACCTGCCGCTGGC 
               
               
                   
                   
                   
                   
                 GGAGCCGTGCACACCAGAG 
               
               
                   
                   
                   
                   
                 GCCTGGATTTCGCCTGCGA 
               
               
                   
                   
                   
                   
                 CATCTACATCTGGGCCCCTC 
               
               
                   
                   
                   
                   
                 TGGCCGGCACCTGTGGCGT 
               
               
                   
                   
                   
                   
                 GCTGCTGCTGAGCCTGGTC 
               
               
                   
                   
                   
                   
                 ATCACCCTGTACTGCAACCA 
               
               
                   
                   
                   
                   
                 CCGGAATAGGAGCAAGCG 
               
               
                   
                   
                   
                   
                 GAGCAGAGGCGGCCACAG 
               
               
                   
                   
                   
                   
                 CGACTACATGAACATGACC 
               
               
                   
                   
                   
                   
                 CCCCGGAGGCCTGGCCCCA 
               
               
                   
                   
                   
                   
                 CCCGGAAGCACTACCAGCC 
               
               
                   
                   
                   
                   
                 CTACGCCCCTCCCAGGGACT 
               
               
                   
                   
                   
                   
                 TCGCCGCCTACCGGAGCCG 
               
               
                   
                   
                   
                   
                 GGTGAAGTTCAGCCGGAGC 
               
               
                   
                   
                   
                   
                 GCCGACGCCCCTGCCTACCA 
               
               
                   
                   
                   
                   
                 GCAGGGCCAGAACCAGCTG 
               
               
                   
                   
                   
                   
                 TACAACGAGCTGAACCTGG 
               
               
                   
                   
                   
                   
                 GCCGGAGGGAGGAGTACG 
               
               
                   
                   
                   
                   
                 ACGTGCTGGACAAGCGGAG 
               
               
                   
                   
                   
                   
                 AGGCCGGGACCCTGAGATG 
               
               
                   
                   
                   
                   
                 GGCGGCAAGCCCCGGAGA 
               
               
                   
                   
                   
                   
                 AAGAACCCTCAGGAGGGCC 
               
               
                   
                   
                   
                   
                 TGTATAACGAACTGCAGAA 
               
               
                   
                   
                   
                   
                 AGACAAGATGGCCGAGGCC 
               
               
                   
                   
                   
                   
                 TACAGCGAGATCGGCATGA 
               
               
                   
                   
                   
                   
                 AGGGCGAGCGGCGGAGGG 
               
               
                   
                   
                   
                   
                 GCAAGGGCCACGACGGCCT 
               
               
                   
                   
                   
                   
                 GTACCAGGGCCTGAGCACC 
               
               
                   
                   
                   
                   
                 GCCACCAAGGATACCTACG 
               
               
                   
                   
                   
                   
                 ACGCCCTGCACATGCAGGC 
               
               
                   
                   
                   
                   
                 CCTGCCCCCCAGA 
               
               
                   
               
               
                 hROR1 
                 615 
                 EVQLVESGGGLVQPGGSLRLSCAT 
                 616 
                 GAAGTGCAGCTGGTGGAGT 
               
               
                 (VH-VL)_ 
                   
                 SGFTFSSYAMSWMRQAPGKGLE 
                   
                 CTGGCGGCGGTCTGGTGCA 
               
               
                 14. 
                   
                 WVASISRGGTTYYADSVKGRFTISV 
                   
                 GCCCGGCGGCTCTCTGCGC 
               
               
                 CD8a(3x). 
                   
                 DKSKNTLYLQMNSLRAEDTAVYYC 
                   
                 CTCTCCTGTGCCACCTCTGG 
               
               
                 CD28z 
                   
                 GRYDYDGYYAMDYWGQGTLVTVS 
                   
                 TTTTACATTCTCCTCCTACGC 
               
               
                   
                   
                 SGGGGSGGGGSGGGGSDIQMTQ 
                   
                 TATGTCCTGGATGCGGCAA 
               
               
                   
                   
                 SPSSLSASVGDRVTITCKASPDINSY 
                   
                 GCCCCCGGCAAGGGCCTAG 
               
               
                   
                   
                 LNWYQQKPGKAPKLLIYRANRLVD 
                   
                 AGTGGGTCGCCTCAATCAG 
               
               
                   
                   
                 GVPSRFSGSGSGTDYTLTISSLQPED 
                   
                 CAGGGGCGGGACGACTTAT 
               
               
                   
                   
                 FATYYCLQYDEFPYTFGAGTKVEIKK 
                   
                 TATGCCGATTCAGTTAAGG 
               
               
                   
                   
                 PTTTPAPRPPTPAPTIASQPLSLRPE 
                   
                 GGAGATTCACAATTTCCGT 
               
               
                   
                   
                 ASRPAAGGAVHTRGLDFASDKPTT 
                   
                 GGATAAATCCAAGAATACC 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEASR 
                   
                 TTATACCTCCAGATGAACTC 
               
               
                   
                   
                 PAAGGAVHTRGLDFASDKPTTTPA 
                   
                 TCTGCGGGCCGAAGATACG 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAA 
                   
                 GCCGTATATTATTGTGGGA 
               
               
                   
                   
                 GGAVHTRGLDFACDIYIWAPLAGT 
                   
                 GGTATGACTACGACGGATA 
               
               
                   
                   
                 CGVLLLSLVITLYCNHRNRSKRSRG 
                   
                 TTACGCCATGGATTATTGG 
               
               
                   
                   
                 GHSDYMNMTPRRPGPTRKHYQPY 
                   
                 GGGCAGGGGACACTTGTTA 
               
               
                   
                   
                 APPRDFAAYRSRVKFSRSADAPAY 
                   
                 CAGTGAGTTCCGGTGGTGG 
               
               
                   
                   
                 QQGQNQLYNELNLGRREEYDVLD 
                   
                 GGGGTCTGGAGGCGGGGG 
               
               
                   
                   
                 KRRGRDPEMGGKPRRKNPQEGLY 
                   
                 CAGTGGAGGCGGAGGGTC 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRR 
                   
                 TGATATACAGATGACACAG 
               
               
                   
                   
                 GKGHDGLYQGLSTATKDTYDALH 
                   
                 AGCCCTTCAAGTTTATCTGC 
               
               
                   
                   
                 MQALPPR 
                   
                 AAGCGTCGGCGATCGTGTT 
               
               
                   
                   
                   
                   
                 ACAATAACTTGCAAGGCAT 
               
               
                   
                   
                   
                   
                 CTCCCGACATCAATTCCTAC 
               
               
                   
                   
                   
                   
                 CTCAACTGGTATCAGCAGA 
               
               
                   
                   
                   
                   
                 AGCCTGGGAAGGCTCCTAA 
               
               
                   
                   
                   
                   
                 GCTGCTTATTTACAGAGCAA 
               
               
                   
                   
                   
                   
                 ATCGCCTGGTGGACGGCGT 
               
               
                   
                   
                   
                   
                 GCCCAGTCGGTTTTCCGGG 
               
               
                   
                   
                   
                   
                 TCTGGGAGCGGAACGGATT 
               
               
                   
                   
                   
                   
                 ACACACTGACCATCTCAAGC 
               
               
                   
                   
                   
                   
                 CTGCAACCCGAAGACTTCG 
               
               
                   
                   
                   
                   
                 CTACATATTACTGCCTTCAG 
               
               
                   
                   
                   
                   
                 TATGATGAGTTCCCATATAC 
               
               
                   
                   
                   
                   
                 CTTCGGCGCTGGGACCAAG 
               
               
                   
                   
                   
                   
                 GTGGAGATAAAGAAGCCTA 
               
               
                   
                   
                   
                   
                 CCACCACCCCCGCACCTCGT 
               
               
                   
                   
                   
                   
                 CCTCCAACCCCTGCACCTAC 
               
               
                   
                   
                   
                   
                 GATTGCCAGTCAGCCTCTTT 
               
               
                   
                   
                   
                   
                 CACTGCGGCCTGAGGCCAG 
               
               
                   
                   
                   
                   
                 CAGACCAGCTGCCGGCGGT 
               
               
                   
                   
                   
                   
                 GCCGTCCATACAAGAGGAC 
               
               
                   
                   
                   
                   
                 TGGACTTCGCGTCCGATAA 
               
               
                   
                   
                   
                   
                 ACCTACTACCACTCCAGCCC 
               
               
                   
                   
                   
                   
                 CAAGGCCCCCAACCCCAGC 
               
               
                   
                   
                   
                   
                 ACCGACTATCGCATCACAGC 
               
               
                   
                   
                   
                   
                 CTTTGTCACTGCGTCCTGAA 
               
               
                   
                   
                   
                   
                 GCCAGCCGGCCAGCTGCAG 
               
               
                   
                   
                   
                   
                 GGGGGGCCGTCCACACAAG 
               
               
                   
                   
                   
                   
                 GGGACTCGACTTTGCGAGT 
               
               
                   
                   
                   
                   
                 GATAAGCCCACCACCACCCC 
               
               
                   
                   
                   
                   
                 TGCCCCTAGACCTCCAACCC 
               
               
                   
                   
                   
                   
                 CAGCCCCTACAATCGCCAGC 
               
               
                   
                   
                   
                   
                 CAGCCCCTGAGCCTGAGGC 
               
               
                   
                   
                   
                   
                 CCGAAGCCTGTAGACCTGC 
               
               
                   
                   
                   
                   
                 CGCTGGCGGAGCCGTGCAC 
               
               
                   
                   
                   
                   
                 ACCAGAGGCCTGGATTTCG 
               
               
                   
                   
                   
                   
                 CCTGCGACATCTACATCTGG 
               
               
                   
                   
                   
                   
                 GCCCCTCTGGCCGGCACCT 
               
               
                   
                   
                   
                   
                 GTGGCGTGCTGCTGCTGAG 
               
               
                   
                   
                   
                   
                 CCTGGTCATCACCCTGTACT 
               
               
                   
                   
                   
                   
                 GCAACCACCGGAATAGGAG 
               
               
                   
                   
                   
                   
                 CAAGCGGAGCAGAGGCGG 
               
               
                   
                   
                   
                   
                 CCACAGCGACTACATGAAC 
               
               
                   
                   
                   
                   
                 ATGACCCCCCGGAGGCCTG 
               
               
                   
                   
                   
                   
                 GCCCCACCCGGAAGCACTA 
               
               
                   
                   
                   
                   
                 CCAGCCCTACGCCCCTCCCA 
               
               
                   
                   
                   
                   
                 GGGACTTCGCCGCCTACCG 
               
               
                   
                   
                   
                   
                 GAGCCGGGTGAAGTTCAGC 
               
               
                   
                   
                   
                   
                 CGGAGCGCCGACGCCCCTG 
               
               
                   
                   
                   
                   
                 CCTACCAGCAGGGCCAGAA 
               
               
                   
                   
                   
                   
                 CCAGCTGTACAACGAGCTG 
               
               
                   
                   
                   
                   
                 AACCTGGGCCGGAGGGAG 
               
               
                   
                   
                   
                   
                 GAGTACGACGTGCTGGACA 
               
               
                   
                   
                   
                   
                 AGCGGAGAGGCCGGGACC 
               
               
                   
                   
                   
                   
                 CTGAGATGGGCGGCAAGCC 
               
               
                   
                   
                   
                   
                 CCGGAGAAAGAACCCTCAG 
               
               
                   
                   
                   
                   
                 GAGGGCCTGTATAACGAAC 
               
               
                   
                   
                   
                   
                 TGCAGAAAGACAAGATGGC 
               
               
                   
                   
                   
                   
                 CGAGGCCTACAGCGAGATC 
               
               
                   
                   
                   
                   
                 GGCATGAAGGGCGAGCGG 
               
               
                   
                   
                   
                   
                 CGGAGGGGCAAGGGCCAC 
               
               
                   
                   
                   
                   
                 GACGGCCTGTACCAGGGCC 
               
               
                   
                   
                   
                   
                 TGAGCACCGCCACCAAGGA 
               
               
                   
                   
                   
                   
                 TACCTACGACGCCCTGCACA 
               
               
                   
                   
                   
                   
                 TGCAGGCCCTGCCCCCCAG 
               
               
                   
                   
                   
                   
                 A 
               
               
                   
               
               
                 hROR1 
                 617 
                 DIQMTQSPSSLSASVGDRVTITCKA 
                 618 
                 GATATTCAGATGACCCAGTC 
               
               
                 (VL-VH)_ 
                   
                 SPDINSYLSWYQQKPGKAPKLLIYR 
                   
                 ACCTTCGAGTCTGAGCGCA 
               
               
                 05. 
                   
                 ANRLVDGVPSRFSGSGSGTDFTLTI 
                   
                 TCCGTGGGCGACAGAGTGA 
               
               
                 CD8a(3x). 
                   
                 SSLQPEDIATYYCLQYDEFPYTFGQ 
                   
                 CCATTACCTGTAAGGCCAGC 
               
               
                 CD28z 
                   
                 GTKLEIKGGGGSGGGGSGGGGSEV 
                   
                 CCGGACATTAACAGCTACCT 
               
               
                   
                   
                 QLVESGGGLVQPGGSLRLSCAASG 
                   
                 ATCGTGGTATCAGCAAAAG 
               
               
                   
                   
                 FTFSSYAMSWVRQAPGKGLEWVS 
                   
                 CCTGGTAAGGCCCCTAAACT 
               
               
                   
                   
                 SISRGGTTYYPDSVKGRFTISRDNSK 
                   
                 CCTTATCTACAGGGCTAATA 
               
               
                   
                   
                 NTLYLOMNSLRAEDTAVYYCGRYD 
                   
                 GGTTGGTAGACGGGGTGCC 
               
               
                   
                   
                 TAGCCGGTTCTCTGGTTCCG 
                   
                 GCAGCGGTACGGACTTTAC 
               
               
                   
                   
                 YDGYYAMDYWGQGTLVTVSSKPT 
                   
                 TCTGACCATAAGCTCTCTGC 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 AACCAGAAGACATCGCAAC 
               
               
                   
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 ATACTACTGTTTACAATACG 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEASRPA 
                   
                 ACGAATTTCCTTATACCTTT 
               
               
                   
                   
                 AGGAVHTRGLDFASDKPTTTPAPR 
                   
                 GGCCAGGGGACCAAGTTAG 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAG 
                   
                 AGATCAAGGGGGGCGGCG 
               
               
                   
                   
                 GAVHTRGLDFACDIYIWAPLAGTC 
                   
                 GAAGTGGTGGAGGGGGAA 
               
               
                   
                   
                 GVLLLSLVITLYCNHRNRSKRSRGG 
                   
                 GTGGTGGAGGAGGAAGCG 
               
               
                   
                   
                 HSDYMNMTPRRPGPTRKHYQPYA 
                   
                 AAGTGCAACTGGTCGAGTC 
               
               
                   
                   
                 PPRDFAAYRSRVKFSRSADAPAYQ 
                   
                 TGGGGGCGGCCTTGTGCAA 
               
               
                   
                   
                 QGQNQLYNELNLGRREEYDVLDKR 
                   
                 CCTGGAGGCAGCCTTCGAC 
               
               
                   
                   
                 RGRDPEMGGKPRRKNPQEGLYNE 
                   
                 TCAGTTGCGCCGCGTCTGG 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGK 
                   
                 TTTTACCTTCTCCTCTTACGC 
               
               
                   
                   
                 GHDGLYQGLSTATKDTYDALHMQ 
                   
                 GATGAGCTGGGTTCGCCAG 
               
               
                   
                   
                 ALPPR 
                   
                 GCCCCCGGCAAGGGACTTG 
               
               
                   
                   
                   
                   
                 AGTGGGTTAGTTCGATCTCC 
               
               
                   
                   
                   
                   
                 CGCGGAGGCACCACATATT 
               
               
                   
                   
                   
                   
                 ATCCTGACTCGGTTAAGGG 
               
               
                   
                   
                   
                   
                 ACGCTTCACTATCTCTAGGG 
               
               
                   
                   
                   
                   
                 ACAATTCAAAGAACACACT 
               
               
                   
                   
                   
                   
                 GTATCTCCAAATGAACTCCT 
               
               
                   
                   
                   
                   
                 TGCGGGCCGAGGACACTGC 
               
               
                   
                   
                   
                   
                 TGTGTATTATTGCGGACGAT 
               
               
                   
                   
                   
                   
                 ACGACTACGATGGGTATTA 
               
               
                   
                   
                   
                   
                 CGCCATGGATTACTGGGGG 
               
               
                   
                   
                   
                   
                 CAAGGTACACTGGTCACTG 
               
               
                   
                   
                   
                   
                 TGAGTTCGAAGCCTACCACC 
               
               
                   
                   
                   
                   
                 ACCCCCGCACCTCGTCCTCC 
               
               
                   
                   
                   
                   
                 AACCCCTGCACCTACGATTG 
               
               
                   
                   
                   
                   
                 CCAGTCAGCCTCTTTCACTG 
               
               
                   
                   
                   
                   
                 CGGCCTGAGGCCAGCAGAC 
               
               
                   
                   
                   
                   
                 CAGCTGCCGGCGGTGCCGT 
               
               
                   
                   
                   
                   
                 CCATACAAGAGGACTGGAC 
               
               
                   
                   
                   
                   
                 TTCGCGTCCGATAAACCTAC 
               
               
                   
                   
                   
                   
                 TACCACTCCAGCCCCAAGGC 
               
               
                   
                   
                   
                   
                 CCCCAACCCCAGCACCGACT 
               
               
                   
                   
                   
                   
                 ATCGCATCACAGCCTTTGTC 
               
               
                   
                   
                   
                   
                 ACTGCGTCCTGAAGCCAGC 
               
               
                   
                   
                   
                   
                 CGGCCAGCTGCAGGGGGG 
               
               
                   
                   
                   
                   
                 GCCGTCCACACAAGGGGAC 
               
               
                   
                   
                   
                   
                 TCGACTTTGCGAGTGATAA 
               
               
                   
                   
                   
                   
                 GCCCACCACCACCCCTGCCC 
               
               
                   
                   
                   
                   
                 CTAGACCTCCAACCCCAGCC 
               
               
                   
                   
                   
                   
                 CCTACAATCGCCAGCCAGCC 
               
               
                   
                   
                   
                   
                 CCTGAGCCTGAGGCCCGAA 
               
               
                   
                   
                   
                   
                 GCCTGTAGACCTGCCGCTG 
               
               
                   
                   
                   
                   
                 GCGGAGCCGTGCACACCAG 
               
               
                   
                   
                   
                   
                 AGGCCTGGATTTCGCCTGC 
               
               
                   
                   
                   
                   
                 GACATCTACATCTGGGCCCC 
               
               
                   
                   
                   
                   
                 TCTGGCCGGCACCTGTGGC 
               
               
                   
                   
                   
                   
                 GTGCTGCTGCTGAGCCTGG 
               
               
                   
                   
                   
                   
                 TCATCACCCTGTACTGCAAC 
               
               
                   
                   
                   
                   
                 CACCGGAATAGGAGCAAGC 
               
               
                   
                   
                   
                   
                 GGAGCAGAGGCGGCCACA 
               
               
                   
                   
                   
                   
                 GCGACTACATGAACATGAC 
               
               
                   
                   
                   
                   
                 CCCCCGGAGGCCTGGCCCC 
               
               
                   
                   
                   
                   
                 ACCCGGAAGCACTACCAGC 
               
               
                   
                   
                   
                   
                 CCTACGCCCCTCCCAGGGAC 
               
               
                   
                   
                   
                   
                 TTCGCCGCCTACCGGAGCC 
               
               
                   
                   
                   
                   
                 GGGTGAAGTTCAGCCGGAG 
               
               
                   
                   
                   
                   
                 CGCCGACGCCCCTGCCTACC 
               
               
                   
                   
                   
                   
                 AGCAGGGCCAGAACCAGCT 
               
               
                   
                   
                   
                   
                 GTACAACGAGCTGAACCTG 
               
               
                   
                   
                   
                   
                 GGCCGGAGGGAGGAGTAC 
               
               
                   
                   
                   
                   
                 GACGTGCTGGACAAGCGGA 
               
               
                   
                   
                   
                   
                 GAGGCCGGGACCCTGAGAT 
               
               
                   
                   
                   
                   
                 GGGCGGCAAGCCCCGGAG 
               
               
                   
                   
                   
                   
                 AAAGAACCCTCAGGAGGGC 
               
               
                   
                   
                   
                   
                 CTGTATAACGAACTGCAGA 
               
               
                   
                   
                   
                   
                 AAGACAAGATGGCCGAGGC 
               
               
                   
                   
                   
                   
                 CTACAGCGAGATCGGCATG 
               
               
                   
                   
                   
                   
                 AAGGGCGAGCGGCGGAGG 
               
               
                   
                   
                   
                   
                 GGCAAGGGCCACGACGGCC 
               
               
                   
                   
                   
                   
                 TGTACCAGGGCCTGAGCAC 
               
               
                   
                   
                   
                   
                 CGCCACCAAGGATACCTAC 
               
               
                   
                   
                   
                   
                 GACGCCCTGCACATGCAGG 
               
               
                   
                   
                   
                   
                 CCCTGCCCCCCAGATGA 
               
               
                   
               
               
                 hROR1 
                 619 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 620 
                 GAGGTTCAACTTGTGGAAT 
               
               
                 (VH-VL)_ 
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CCGGCGGCGGGTTAGTCCA 
               
               
                 14-3. 
                   
                 VASISRGGTTYYADSVKGRFTISRD 
                   
                 GCCCGGCGGGAGCTTGCGG 
               
               
                 CD8a(3x). 
                   
                 NSKNTLYLQMNSLRAEDTAVYYCG 
                   
                 CTGTCCTGCGCCGCCTCTGG 
               
               
                 CD28z 
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 ATTCACTTTTAGCTCCTATG 
               
               
                   
                   
                 GGGGSGGGGSGGGGSDIQMTQS 
                   
                 CTATGTCTTGGGTAAGGCA 
               
               
                   
                   
                 PSSLSASVGDRVTITCKASPDINSYL 
                   
                 GGCCCCTGGTAAAGGACTA 
               
               
                   
                   
                 NWYQQKPGKAPKLLIYRANRLVDG 
                   
                 GAGTGGGTGGCCTCGATCT 
               
               
                   
                   
                 VPSRFSGSGSGTDFTLTISSLQPEDI 
                   
                 CCCGTGGTGGCACTACATA 
               
               
                   
                   
                 ATYYCLQYDEFPYTFGGGTKVEIKK 
                   
                 CTACGCCGACTCCGTTAAAG 
               
               
                   
                   
                 PTTTPAPRPPTPAPTIASQPLSLRPE 
                   
                 GCCGGTTTACCATCTCCCGT 
               
               
                   
                   
                 ASRPAAGGAVHTRGLDFASDKPTT 
                   
                 GACAACTCTAAAAATACTTT 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEASR 
                   
                 GTACCTGCAAATGAACTCCC 
               
               
                   
                   
                 PAAGGAVHTRGLDFASDKPTTTPA 
                   
                 TGCGGGCAGAAGACACAGC 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAA 
                   
                 CGTGTACTATTGCGGGCGT 
               
               
                   
                   
                 GGAVHTRGLDFACDIYIWAPLAGT 
                   
                 TACGATTACGACGGATATTA 
               
               
                   
                   
                 CGVLLLSLVITLYCNHRNRSKRSRG 
                   
                 CGCAATGGACTACTGGGGC 
               
               
                   
                   
                 GHSDYMNMTPRRPGPTRKHYQPY 
                   
                 CAGGGCACACTGGTCACCG 
               
               
                   
                   
                 APPRDFAAYRSRVKFSRSADAPAY 
                   
                 TGAGCAGCGGGGGCGGAG 
               
               
                   
                   
                 QQGQNQLYNELNLGRREEYDVLD 
                   
                 GAAGTGGAGGAGGCGGTA 
               
               
                   
                   
                 KRRGRDPEMGGKPRRKNPQEGLY 
                   
                 GTGGTGGGGGAGGAAGCG 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRR 
                   
                 ATATACAAATGACTCAGTCC 
               
               
                   
                   
                 GKGHDGLYQGLSTATKDTYDALH 
                   
                 CCTAGTAGCCTTAGTGCTAG 
               
               
                   
                   
                 MQALPPR 
                   
                 TGTGGGAGACAGAGTGACC 
               
               
                   
                   
                   
                   
                 ATCACCTGCAAAGCATCTCC 
               
               
                   
                   
                   
                   
                 TGATATCAATTCCTACCTTA 
               
               
                   
                   
                   
                   
                 ACTGGTATCAACAGAAGCC 
               
               
                   
                   
                   
                   
                 TGGCAAAGCTCCAAAGCTC 
               
               
                   
                   
                   
                   
                 CTGATTTATCGCGCGAACA 
               
               
                   
                   
                   
                   
                 GATTGGTCGATGGGGTCCC 
               
               
                   
                   
                   
                   
                 TTCCAGATTCAGCGGCTCA 
               
               
                   
                   
                   
                   
                 GGGTCAGGGACCGATTTCA 
               
               
                   
                   
                   
                   
                 CCCTCACAATTAGTTCACTT 
               
               
                   
                   
                   
                   
                 CAGCCCGAGGACATCGCCA 
               
               
                   
                   
                   
                   
                 CGTATTATTGCCTTCAGTAC 
               
               
                   
                   
                   
                   
                 GATGAGTTCCCTTACACCTT 
               
               
                   
                   
                   
                   
                 TGGCGGGGGAACTAAAGTC 
               
               
                   
                   
                   
                   
                 GAAATTAAGAAGCCTACCA 
               
               
                   
                   
                   
                   
                 CCACCCCCGCACCTCGTCCT 
               
               
                   
                   
                   
                   
                 CCAACCCCTGCACCTACGAT 
               
               
                   
                   
                   
                   
                 TGCCAGTCAGCCTCTTTCAC 
               
               
                   
                   
                   
                   
                 TGCGGCCTGAGGCCAGCAG 
               
               
                   
                   
                   
                   
                 ACCAGCTGCCGGCGGTGCC 
               
               
                   
                   
                   
                   
                 GTCCATACAAGAGGACTGG 
               
               
                   
                   
                   
                   
                 ACTTCGCGTCCGATAAACCT 
               
               
                   
                   
                   
                   
                 ACTACCACTCCAGCCCCAAG 
               
               
                   
                   
                   
                   
                 GCCCCCAACCCCAGCACCG 
               
               
                   
                   
                   
                   
                 ACTATCGCATCACAGCCTTT 
               
               
                   
                   
                   
                   
                 GTCACTGCGTCCTGAAGCC 
               
               
                   
                   
                   
                   
                 AGCCGGCCAGCTGCAGGG 
               
               
                   
                   
                   
                   
                 GGGGCCGTCCACACAAGGG 
               
               
                   
                   
                   
                   
                 GACTCGACTTTGCGAGTGA 
               
               
                   
                   
                   
                   
                 TAAGCCCACCACCACCCCTG 
               
               
                   
                   
                   
                   
                 CCCCTAGACCTCCAACCCCA 
               
               
                   
                   
                   
                   
                 GCCCCTACAATCGCCAGCCA 
               
               
                   
                   
                   
                   
                 GCCCCTGAGCCTGAGGCCC 
               
               
                   
                   
                   
                   
                 GAAGCCTGTAGACCTGCCG 
               
               
                   
                   
                   
                   
                 CTGGCGGAGCCGTGCACAC 
               
               
                   
                   
                   
                   
                 CAGAGGCCTGGATTTCGCC 
               
               
                   
                   
                   
                   
                 TGCGACATCTACATCTGGG 
               
               
                   
                   
                   
                   
                 CCCCTCTGGCCGGCACCTGT 
               
               
                   
                   
                   
                   
                 GGCGTGCTGCTGCTGAGCC 
               
               
                   
                   
                   
                   
                 TGGTCATCACCCTGTACTGC 
               
               
                   
                   
                   
                   
                 AACCACCGGAATAGGAGCA 
               
               
                   
                   
                   
                   
                 AGCGGAGCAGAGGCGGCC 
               
               
                   
                   
                   
                   
                 ACAGCGACTACATGAACAT 
               
               
                   
                   
                   
                   
                 GACCCCCCGGAGGCCTGGC 
               
               
                   
                   
                   
                   
                 CCCACCCGGAAGCACTACC 
               
               
                   
                   
                   
                   
                 AGCCCTACGCCCCTCCCAGG 
               
               
                   
                   
                   
                   
                 GACTTCGCCGCCTACCGGA 
               
               
                   
                   
                   
                   
                 GCCGGGTGAAGTTCAGCCG 
               
               
                   
                   
                   
                   
                 GAGCGCCGACGCCCCTGCC 
               
               
                   
                   
                   
                   
                 TACCAGCAGGGCCAGAACC 
               
               
                   
                   
                   
                   
                 AGCTGTACAACGAGCTGAA 
               
               
                   
                   
                   
                   
                 CCTGGGCCGGAGGGAGGA 
               
               
                   
                   
                   
                   
                 GTACGACGTGCTGGACAAG 
               
               
                   
                   
                   
                   
                 CGGAGAGGCCGGGACCCT 
               
               
                   
                   
                   
                   
                 GAGATGGGCGGCAAGCCCC 
               
               
                   
                   
                   
                   
                 GGAGAAAGAACCCTCAGGA 
               
               
                   
                   
                   
                   
                 GGGCCTGTATAACGAACTG 
               
               
                   
                   
                   
                   
                 CAGAAAGACAAGATGGCCG 
               
               
                   
                   
                   
                   
                 AGGCCTACAGCGAGATCGG 
               
               
                   
                   
                   
                   
                 CATGAAGGGCGAGCGGCG 
               
               
                   
                   
                   
                   
                 GAGGGGCAAGGGCCACGA 
               
               
                   
                   
                   
                   
                 CGGCCTGTACCAGGGCCTG 
               
               
                   
                   
                   
                   
                 AGCACCGCCACCAAGGATA 
               
               
                   
                   
                   
                   
                 CCTACGACGCCCTGCACATG 
               
               
                   
                   
                   
                   
                 CAGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 hROR1 
                 621 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 622 
                 GAAGTGCAGCTTGTGGAGT 
               
               
                 (VH-VL)_ 
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CAGGAGGAGGGCTAGTTCA 
               
               
                 14-4. 
                   
                 VASISRGGTTYYPDSVKGRFTISRD 
                   
                 GCCAGGCGGCTCTCTGAGA 
               
               
                 CD8a(3x). 
                   
                 NVRNILYLQMSSLRSEDTAMYYCG 
                   
                 CTATCTTGTGCTGCCTCCGG 
               
               
                 CD28z 
                   
                 RYDYDGYYAMDYWGQGTLVTVSS 
                   
                 CTTCACATTTAGCTCTTATG 
               
               
                   
                   
                 GGGGSGGGGSGGGGSDIQMTQS 
                   
                 CAATGTCCTGGGTCCGCCA 
               
               
                   
                   
                 PSSLSASVGDRVTITCKASPDINSYL 
                   
                 GGCCCCTGGTAAAGGCCTG 
               
               
                   
                   
                 NWYQQKPGKAPKLLIYRANRLVDG 
                   
                 GAATGGGTTGCTTCTATCTC 
               
               
                   
                   
                 VPSRFSGSGSGTDYTLTISSLQPEDF 
                   
                 TAGAGGCGGAACCACTTAC 
               
               
                   
                   
                 ATYYCLQYDEFPYTFGAGTKVEIKK 
                   
                 TACCCTGATTCAGTGAAGG 
               
               
                   
                   
                 PTTTPAPRPPTPAPTIASQPLSLRPE 
                   
                 GGAGATTCACAATTAGTAG 
               
               
                   
                   
                 ASRPAAGGAVHTRGLDFASDKPTT 
                   
                 GGACAACGTGCGGAACATC 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEASR 
                   
                 CTCTACCTACAGATGTCAAG 
               
               
                   
                   
                 PAAGGAVHTRGLDFASDKPTTTPA 
                   
                 TTTACGCAGTGAGGACACT 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAA 
                   
                 GCGATGTATTACTGCGGTC 
               
               
                   
                   
                 GGAVHTRGLDFACDIYIWAPLAGT 
                   
                 GATACGATTATGATGGATA 
               
               
                   
                   
                 CGVLLLSLVITLYCNHRNRSKRSRG 
                   
                 TTATGCAATGGATTATTGG 
               
               
                   
                   
                 GHSDYMNMTPRRPGPTRKHYQPY 
                   
                 GGCCAGGGCACTCTGGTCA 
               
               
                   
                   
                 APPRDFAAYRSRVKFSRSADAPAY 
                   
                 CAGTATCTTCCGGCGGCGG 
               
               
                   
                   
                 QQGQNQLYNELNLGRREEYDVLD 
                   
                 TGGTTCTGGCGGTGGTGGA 
               
               
                   
                   
                 KRRGRDPEMGGKPRRKNPQEGLY 
                   
                 AGCGGAGGGGGGGGGTCC 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRR 
                   
                 GACATCCAGATGACCCAAT 
               
               
                   
                   
                 GKGHDGLYQGLSTATKDTYDALH 
                   
                 CACCATCGAGTCTTAGTGCA 
               
               
                   
                   
                 MQALPPR 
                   
                 TCCGTTGGGGATAGAGTGA 
               
               
                   
                   
                   
                   
                 CAATCACTTGTAAGGCATCC 
               
               
                   
                   
                   
                   
                 CCGGACATCAACTCATATCT 
               
               
                   
                   
                   
                   
                 TAATTGGTATCAGCAAAAG 
               
               
                   
                   
                   
                   
                 CCGGGCAAGGCCCCTAAGC 
               
               
                   
                   
                   
                   
                 TCCTGATTTATAGGGCCAAC 
               
               
                   
                   
                   
                   
                 CGCCTTGTGGATGGAGTCC 
               
               
                   
                   
                   
                   
                 CCTCCCGCTTTAGTGGAAGC 
               
               
                   
                   
                   
                   
                 GGCTCTGGCACAGACTACA 
               
               
                   
                   
                   
                   
                 CCCTGACTATCAGCTCCTTG 
               
               
                   
                   
                   
                   
                 CAGCCTGAGGATTTTGCTAC 
               
               
                   
                   
                   
                   
                 CTACTACTGTCTTCAGTACG 
               
               
                   
                   
                   
                   
                 ATGAATTTCCATACACTTTC 
               
               
                   
                   
                   
                   
                 GGTGCTGGGACAAAAGTGG 
               
               
                   
                   
                   
                   
                 AGATCAAAAAGCCTACCAC 
               
               
                   
                   
                   
                   
                 CACCCCCGCACCTCGTCCTC 
               
               
                   
                   
                   
                   
                 CAACCCCTGCACCTACGATT 
               
               
                   
                   
                   
                   
                 GCCAGTCAGCCTCTTTCACT 
               
               
                   
                   
                   
                   
                 GCGGCCTGAGGCCAGCAGA 
               
               
                   
                   
                   
                   
                 CCAGCTGCCGGCGGTGCCG 
               
               
                   
                   
                   
                   
                 TCCATACAAGAGGACTGGA 
               
               
                   
                   
                   
                   
                 CTTCGCGTCCGATAAACCTA 
               
               
                   
                   
                   
                   
                 CTACCACTCCAGCCCCAAGG 
               
               
                   
                   
                   
                   
                 CCCCCAACCCCAGCACCGAC 
               
               
                   
                   
                   
                   
                 TATCGCATCACAGCCTTTGT 
               
               
                   
                   
                   
                   
                 CACTGCGTCCTGAAGCCAG 
               
               
                   
                   
                   
                   
                 CCGGCCAGCTGCAGGGGG 
               
               
                   
                   
                   
                   
                 GGCCGTCCACACAAGGGGA 
               
               
                   
                   
                   
                   
                 CTCGACTTTGCGAGTGATA 
               
               
                   
                   
                   
                   
                 AGCCCACCACCACCCCTGCC 
               
               
                   
                   
                   
                   
                 CCTAGACCTCCAACCCCAGC 
               
               
                   
                   
                   
                   
                 CCCTACAATCGCCAGCCAGC 
               
               
                   
                   
                   
                   
                 CCCTGAGCCTGAGGCCCGA 
               
               
                   
                   
                   
                   
                 AGCCTGTAGACCTGCCGCT 
               
               
                   
                   
                   
                   
                 GGCGGAGCCGTGCACACCA 
               
               
                   
                   
                   
                   
                 GAGGCCTGGATTTCGCCTG 
               
               
                   
                   
                   
                   
                 CGACATCTACATCTGGGCCC 
               
               
                   
                   
                   
                   
                 CTCTGGCCGGCACCTGTGG 
               
               
                   
                   
                   
                   
                 CGTGCTGCTGCTGAGCCTG 
               
               
                   
                   
                   
                   
                 GTCATCACCCTGTACTGCAA 
               
               
                   
                   
                   
                   
                 CCACCGGAATAGGAGCAAG 
               
               
                   
                   
                   
                   
                 CGGAGCAGAGGCGGCCAC 
               
               
                   
                   
                   
                   
                 AGCGACTACATGAACATGA 
               
               
                   
                   
                   
                   
                 CCCCCCGGAGGCCTGGCCC 
               
               
                   
                   
                   
                   
                 CACCCGGAAGCACTACCAG 
               
               
                   
                   
                   
                   
                 CCCTACGCCCCTCCCAGGGA 
               
               
                   
                   
                   
                   
                 CTTCGCCGCCTACCGGAGC 
               
               
                   
                   
                   
                   
                 CGGGTGAAGTTCAGCCGGA 
               
               
                   
                   
                   
                   
                 GCGCCGACGCCCCTGCCTA 
               
               
                   
                   
                   
                   
                 CCAGCAGGGCCAGAACCAG 
               
               
                   
                   
                   
                   
                 CTGTACAACGAGCTGAACC 
               
               
                   
                   
                   
                   
                 TGGGCCGGAGGGAGGAGT 
               
               
                   
                   
                   
                   
                 ACGACGTGCTGGACAAGCG 
               
               
                   
                   
                   
                   
                 GAGAGGCCGGGACCCTGA 
               
               
                   
                   
                   
                   
                 GATGGGCGGCAAGCCCCG 
               
               
                   
                   
                   
                   
                 GAGAAAGAACCCTCAGGAG 
               
               
                   
                   
                   
                   
                 GGCCTGTATAACGAACTGC 
               
               
                   
                   
                   
                   
                 AGAAAGACAAGATGGCCGA 
               
               
                   
                   
                   
                   
                 GGCCTACAGCGAGATCGGC 
               
               
                   
                   
                   
                   
                 ATGAAGGGCGAGCGGCGG 
               
               
                   
                   
                   
                   
                 AGGGGCAAGGGCCACGAC 
               
               
                   
                   
                   
                   
                 GGCCTGTACCAGGGCCTGA 
               
               
                   
                   
                   
                   
                 GCACCGCCACCAAGGATAC 
               
               
                   
                   
                   
                   
                 CTACGACGCCCTGCACATGC 
               
               
                   
                   
                   
                   
                 AGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 hROR1 
                 623 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 624 
                 GAAGTGCAACTGGTCGAGT 
               
               
                 (VH_5-VL_14). 
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CTGGGGGCGGCCTTGTGCA 
               
               
                 CD8a(3x). 
                   
                 VSSISRGGTTYYPDSVKGRFTISRDN 
                   
                 ACCTGGAGGCAGCCTTCGA 
               
               
                 CD28z 
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 CTCAGTTGCGCCGCGTCTG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSSG 
                   
                 GTTTTACCTTCTCCTCTTACG 
               
               
                   
                   
                 GGGSGGGGSGGGGSDIQMTQSPS 
                   
                 CGATGAGCTGGGTTCGCCA 
               
               
                   
                   
                 SLSASVGDRVTITCKASPDINSYLN 
                   
                 GGCCCCCGGCAAGGGACTT 
               
               
                   
                   
                 WYQQKPGKAPKLLIYRANRLVDGV 
                   
                 GAGTGGGTTAGTTCGATCT 
               
               
                   
                   
                 PSRFSGSGSGTDYTLTISSLQPEDFA 
                   
                 CCCGCGGAGGCACCACATA 
               
               
                   
                   
                 TYYCLQYDEFPYTFGAGTKVEIKKPT 
                   
                 TTATCCTGACTCGGTTAAGG 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 GACGCTTCACTATCTCTAGG 
               
               
                   
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 GACAATTCAAAGAACACAC 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEASRPA 
                   
                 TGTATCTCCAAATGAACTCC 
               
               
                   
                   
                 AGGAVHTRGLDFASDKPTTTPAPR 
                   
                 TTGCGGGCCGAGGACACTG 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAG 
                   
                 CTGTGTATTATTGCGGACG 
               
               
                   
                   
                 GAVHTRGLDFACDIYIWAPLAGTC 
                   
                 ATACGACTACGATGGGTAT 
               
               
                   
                   
                 GVLLLSLVITLYCNHRNRSKRSRGG 
                   
                 TACGCCATGGATTACTGGG 
               
               
                   
                   
                 HSDYMNMTPRRPGPTRKHYQPYA 
                   
                 GGCAAGGTACACTGGTCAC 
               
               
                   
                   
                 PPRDFAAYRSRVKFSRSADAPAYQ 
                   
                 TGTGAGTTCGGGGGGCGGC 
               
               
                   
                   
                 QGQNQLYNELNLGRREEYDVLDKR 
                   
                 GGAAGTGGTGGAGGGGGA 
               
               
                   
                   
                 RGRDPEMGGKPRRKNPQEGLYNE 
                   
                 AGTGGTGGAGGAGGAAGC 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGK 
                   
                 GATATACAGATGACACAGA 
               
               
                   
                   
                 GHDGLYQGLSTATKDTYDALHMQ 
                   
                 GCCCTTCAAGTTTATCTGCA 
               
               
                   
                   
                 ALPPR 
                   
                 AGCGTCGGCGATCGTGTTA 
               
               
                   
                   
                   
                   
                 CAATAACTTGCAAGGCATCT 
               
               
                   
                   
                   
                   
                 CCCGACATCAATTCCTACCT 
               
               
                   
                   
                   
                   
                 CAACTGGTATCAGCAGAAG 
               
               
                   
                   
                   
                   
                 CCTGGGAAGGCTCCTAAGC 
               
               
                   
                   
                   
                   
                 TGCTTATTTACAGAGCAAAT 
               
               
                   
                   
                   
                   
                 CGCCTGGTGGACGGCGTGC 
               
               
                   
                   
                   
                   
                 CCAGTCGGTTTTCCGGGTCT 
               
               
                   
                   
                   
                   
                 GGGAGCGGAACGGATTACA 
               
               
                   
                   
                   
                   
                 CACTGACCATCTCAAGCCTG 
               
               
                   
                   
                   
                   
                 CAACCCGAAGACTTCGCTAC 
               
               
                   
                   
                   
                   
                 ATATTACTGCCTTCAGTATG 
               
               
                   
                   
                   
                   
                 ATGAGTTCCCATATACCTTC 
               
               
                   
                   
                   
                   
                 GGCGCTGGGACCAAGGTG 
               
               
                   
                   
                   
                   
                 GAGATAAAGAAGCCTACCA 
               
               
                   
                   
                   
                   
                 CCACCCCCGCACCTCGTCCT 
               
               
                   
                   
                   
                   
                 CCAACCCCTGCACCTACGAT 
               
               
                   
                   
                   
                   
                 TGCCAGTCAGCCTCTTTCAC 
               
               
                   
                   
                   
                   
                 TGCGGCCTGAGGCCAGCAG 
               
               
                   
                   
                   
                   
                 ACCAGCTGCCGGCGGTGCC 
               
               
                   
                   
                   
                   
                 GTCCATACAAGAGGACTGG 
               
               
                   
                   
                   
                   
                 ACTTCGCGTCCGATAAACCT 
               
               
                   
                   
                   
                   
                 ACTACCACTCCAGCCCCAAG 
               
               
                   
                   
                   
                   
                 GCCCCCAACCCCAGCACCG 
               
               
                   
                   
                   
                   
                 ACTATCGCATCACAGCCTTT 
               
               
                   
                   
                   
                   
                 GTCACTGCGTCCTGAAGCC 
               
               
                   
                   
                   
                   
                 AGCCGGCCAGCTGCAGGG 
               
               
                   
                   
                   
                   
                 GGGGCCGTCCACACAAGGG 
               
               
                   
                   
                   
                   
                 GACTCGACTTTGCGAGTGA 
               
               
                   
                   
                   
                   
                 TAAGCCCACCACCACCCCTG 
               
               
                   
                   
                   
                   
                 CCCCTAGACCTCCAACCCCA 
               
               
                   
                   
                   
                   
                 GCCCCTACAATCGCCAGCCA 
               
               
                   
                   
                   
                   
                 GCCCCTGAGCCTGAGGCCC 
               
               
                   
                   
                   
                   
                 GAAGCCTGTAGACCTGCCG 
               
               
                   
                   
                   
                   
                 CTGGCGGAGCCGTGCACAC 
               
               
                   
                   
                   
                   
                 CAGAGGCCTGGATTTCGCC 
               
               
                   
                   
                   
                   
                 TGCGACATCTACATCTGGG 
               
               
                   
                   
                   
                   
                 CCCCTCTGGCCGGCACCTGT 
               
               
                   
                   
                   
                   
                 GGCGTGCTGCTGCTGAGCC 
               
               
                   
                   
                   
                   
                 TGGTCATCACCCTGTACTGC 
               
               
                   
                   
                   
                   
                 AACCACCGGAATAGGAGCA 
               
               
                   
                   
                   
                   
                 AGCGGAGCAGAGGCGGCC 
               
               
                   
                   
                   
                   
                 ACAGCGACTACATGAACAT 
               
               
                   
                   
                   
                   
                 GACCCCCCGGAGGCCTGGC 
               
               
                   
                   
                   
                   
                 CCCACCCGGAAGCACTACC 
               
               
                   
                   
                   
                   
                 AGCCCTACGCCCCTCCCAGG 
               
               
                   
                   
                   
                   
                 GACTTCGCCGCCTACCGGA 
               
               
                   
                   
                   
                   
                 GCCGGGTGAAGTTCAGCCG 
               
               
                   
                   
                   
                   
                 GAGCGCCGACGCCCCTGCC 
               
               
                   
                   
                   
                   
                 TACCAGCAGGGCCAGAACC 
               
               
                   
                   
                   
                   
                 AGCTGTACAACGAGCTGAA 
               
               
                   
                   
                   
                   
                 CCTGGGCCGGAGGGAGGA 
               
               
                   
                   
                   
                   
                 GTACGACGTGCTGGACAAG 
               
               
                   
                   
                   
                   
                 CGGAGAGGCCGGGACCCT 
               
               
                   
                   
                   
                   
                 GAGATGGGCGGCAAGCCCC 
               
               
                   
                   
                   
                   
                 GGAGAAAGAACCCTCAGGA 
               
               
                   
                   
                   
                   
                 GGGCCTGTATAACGAACTG 
               
               
                   
                   
                   
                   
                 CAGAAAGACAAGATGGCCG 
               
               
                   
                   
                   
                   
                 AGGCCTACAGCGAGATCGG 
               
               
                   
                   
                   
                   
                 CATGAAGGGCGAGCGGCG 
               
               
                   
                   
                   
                   
                 GAGGGGCAAGGGCCACGA 
               
               
                   
                   
                   
                   
                 CGGCCTGTACCAGGGCCTG 
               
               
                   
                   
                   
                   
                 AGCACCGCCACCAAGGATA 
               
               
                   
                   
                   
                   
                 CCTACGACGCCCTGCACATG 
               
               
                   
                   
                   
                   
                 CAGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 hROR1 
                 625 
                 EVQLVESGGGLVQPGGSLRLSCAA 
                 626 
                 GAAGTGCAACTGGTCGAGT 
               
               
                 (VH_5-VL_16). 
                   
                 SGFTFSSYAMSWVRQAPGKGLEW 
                   
                 CTGGGGGCGGCCTTGTGCA 
               
               
                 CD8a(3x). 
                   
                 VSSISRGGTTYYPDSVKGRFTISRDN 
                   
                 ACCTGGAGGCAGCCTTCGA 
               
               
                 CD28z 
                   
                 SKNTLYLQMNSLRAEDTAVYYCGR 
                   
                 CTCAGTTGCGCCGCGTCTG 
               
               
                   
                   
                 YDYDGYYAMDYWGQGTLVTVSSG 
                   
                 GTTTTACCTTCTCCTCTTACG 
               
               
                   
                   
                 GGGSGGGGSGGGGSDIQMTQSPS 
                   
                 CGATGAGCTGGGTTCGCCA 
               
               
                   
                   
                 SLSASVGDRVTITCKASPDINSYLN 
                   
                 GGCCCCCGGCAAGGGACTT 
               
               
                   
                   
                 WYQQKPGKAPKVLIYRANRLVDG 
                   
                 GAGTGGGTTAGTTCGATCT 
               
               
                   
                   
                 VPSRFSGSGSGTDYTLTISSLQPEDF 
                   
                 CCCGCGGAGGCACCACATA 
               
               
                   
                   
                 ATYYCLQYDEFPYTFGQGTKVEIKK 
                   
                 TTATCCTGACTCGGTTAAGG 
               
               
                   
                   
                 PTTTPAPRPPTPAPTIASQPLSLRPE 
                   
                 GACGCTTCACTATCTCTAGG 
               
               
                   
                   
                 ASRPAAGGAVHTRGLDFASDKPTT 
                   
                 GACAATTCAAAGAACACAC 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEASR 
                   
                 TGTATCTCCAAATGAACTCC 
               
               
                   
                   
                 PAAGGAVHTRGLDFASDKPTTTPA 
                   
                 TTGCGGGCCGAGGACACTG 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAA 
                   
                 CTGTGTATTATTGCGGACG 
               
               
                   
                   
                 GGAVHTRGLDFACDIYIWAPLAGT 
                   
                 ATACGACTACGATGGGTAT 
               
               
                   
                   
                 CGVLLLSLVITLYCNHRNRSKRSRG 
                   
                 TACGCCATGGATTACTGGG 
               
               
                   
                   
                 GHSDYMNMTPRRPGPTRKHYQPY 
                   
                 GGCAAGGTACACTGGTCAC 
               
               
                   
                   
                 APPRDFAAYRSRVKFSRSADAPAY 
                   
                 TGTGAGTTCGGGGGGCGGC 
               
               
                   
                   
                 QQGQNQLYNELNLGRREEYDVLD 
                   
                 GGAAGTGGTGGAGGGGGA 
               
               
                   
                   
                 KRRGRDPEMGGKPRRKNPQEGLY 
                   
                 AGTGGTGGAGGAGGAAGC 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRR 
                   
                 GATATTCAGATGACCCAGTC 
               
               
                   
                   
                 GKGHDGLYQGLSTATKDTYDALH 
                   
                 GCCCAGCAGTCTCTCGGCCT 
               
               
                   
                   
                 MQALPPR 
                   
                 CAGTGGGCGACCGGGTCAC 
               
               
                   
                   
                   
                   
                 TATCACTTGCAAAGCAAGTC 
               
               
                   
                   
                   
                   
                 CTGATATAAACTCCTATCTT 
               
               
                   
                   
                   
                   
                 AATTGGTATCAGCAGAAGC 
               
               
                   
                   
                   
                   
                 CCGGCAAGGCACCTAAGGT 
               
               
                   
                   
                   
                   
                 TCTGATATATCGCGCAAATC 
               
               
                   
                   
                   
                   
                 GGCTCGTGGATGGAGTACC 
               
               
                   
                   
                   
                   
                 CAGCCGATTTTCCGGCAGC 
               
               
                   
                   
                   
                   
                 GGCTCAGGCACTGACTACA 
               
               
                   
                   
                   
                   
                 CACTGACAATCAGCAGCTT 
               
               
                   
                   
                   
                   
                 GCAGCCTGAAGATTTCGCC 
               
               
                   
                   
                   
                   
                 ACATACTATTGTCTACAGTA 
               
               
                   
                   
                   
                   
                 CGACGAGTTCCCTTATACAT 
               
               
                   
                   
                   
                   
                 TCGGCCAGGGGACCAAGGT 
               
               
                   
                   
                   
                   
                 CGAGATCAAGAAGCCTACC 
               
               
                   
                   
                   
                   
                 ACCACCCCCGCACCTCGTCC 
               
               
                   
                   
                   
                   
                 TCCAACCCCTGCACCTACGA 
               
               
                   
                   
                   
                   
                 TTGCCAGTCAGCCTCTTTCA 
               
               
                   
                   
                   
                   
                 CTGCGGCCTGAGGCCAGCA 
               
               
                   
                   
                   
                   
                 GACCAGCTGCCGGCGGTGC 
               
               
                   
                   
                   
                   
                 CGTCCATACAAGAGGACTG 
               
               
                   
                   
                   
                   
                 GACTTCGCGTCCGATAAACC 
               
               
                   
                   
                   
                   
                 TACTACCACTCCAGCCCCAA 
               
               
                   
                   
                   
                   
                 GGCCCCCAACCCCAGCACC 
               
               
                   
                   
                   
                   
                 GACTATCGCATCACAGCCTT 
               
               
                   
                   
                   
                   
                 TGTCACTGCGTCCTGAAGCC 
               
               
                   
                   
                   
                   
                 AGCCGGCCAGCTGCAGGG 
               
               
                   
                   
                   
                   
                 GGGGCCGTCCACACAAGGG 
               
               
                   
                   
                   
                   
                 GACTCGACTTTGCGAGTGA 
               
               
                   
                   
                   
                   
                 TAAGCCCACCACCACCCCTG 
               
               
                   
                   
                   
                   
                 CCCCTAGACCTCCAACCCCA 
               
               
                   
                   
                   
                   
                 GCCCCTACAATCGCCAGCCA 
               
               
                   
                   
                   
                   
                 GCCCCTGAGCCTGAGGCCC 
               
               
                   
                   
                   
                   
                 GAAGCCTGTAGACCTGCCG 
               
               
                   
                   
                   
                   
                 CTGGCGGAGCCGTGCACAC 
               
               
                   
                   
                   
                   
                 CAGAGGCCTGGATTTCGCC 
               
               
                   
                   
                   
                   
                 TGCGACATCTACATCTGGG 
               
               
                   
                   
                   
                   
                 CCCCTCTGGCCGGCACCTGT 
               
               
                   
                   
                   
                   
                 GGCGTGCTGCTGCTGAGCC 
               
               
                   
                   
                   
                   
                 TGGTCATCACCCTGTACTGC 
               
               
                   
                   
                   
                   
                 AACCACCGGAATAGGAGCA 
               
               
                   
                   
                   
                   
                 AGCGGAGCAGAGGCGGCC 
               
               
                   
                   
                   
                   
                 ACAGCGACTACATGAACAT 
               
               
                   
                   
                   
                   
                 GACCCCCCGGAGGCCTGGC 
               
               
                   
                   
                   
                   
                 CCCACCCGGAAGCACTACC 
               
               
                   
                   
                   
                   
                 AGCCCTACGCCCCTCCCAGG 
               
               
                   
                   
                   
                   
                 GACTTCGCCGCCTACCGGA 
               
               
                   
                   
                   
                   
                 GCCGGGTGAAGTTCAGCCG 
               
               
                   
                   
                   
                   
                 GAGCGCCGACGCCCCTGCC 
               
               
                   
                   
                   
                   
                 TACCAGCAGGGCCAGAACC 
               
               
                   
                   
                   
                   
                 AGCTGTACAACGAGCTGAA 
               
               
                   
                   
                   
                   
                 CCTGGGCCGGAGGGAGGA 
               
               
                   
                   
                   
                   
                 GTACGACGTGCTGGACAAG 
               
               
                   
                   
                   
                   
                 CGGAGAGGCCGGGACCCT 
               
               
                   
                   
                   
                   
                 GAGATGGGCGGCAAGCCCC 
               
               
                   
                   
                   
                   
                 GGAGAAAGAACCCTCAGGA 
               
               
                   
                   
                   
                   
                 GGGCCTGTATAACGAACTG 
               
               
                   
                   
                   
                   
                 CAGAAAGACAAGATGGCCG 
               
               
                   
                   
                   
                   
                 AGGCCTACAGCGAGATCGG 
               
               
                   
                   
                   
                   
                 CATGAAGGGCGAGCGGCG 
               
               
                   
                   
                   
                   
                 GAGGGGCAAGGGCCACGA 
               
               
                   
                   
                   
                   
                 CGGCCTGTACCAGGGCCTG 
               
               
                   
                   
                   
                   
                 AGCACCGCCACCAAGGATA 
               
               
                   
                   
                   
                   
                 CCTACGACGCCCTGCACATG 
               
               
                   
                   
                   
                   
                 CAGGCCCTGCCCCCCAGA 
               
               
                   
               
               
                 hROR1 
                 627 
                 EVQLVESGGGLVQPGGSLRLSCSAS 
                 628 
                 GAGGTTCAACTCGTGGAGT 
               
               
                 (VH_18- 
                   
                 GFTFSSYAMSWVRQVPGKGLVWI 
                   
                 CTGGAGGCGGGCTAGTGCA 
               
               
                 VL_04). 
                   
                 SSISRGGTTYYADSVRGRFIISRDNA 
                   
                 GCCTGGCGGCTCCCTGCGA 
               
               
                 CD8a(3x). 
                   
                 KNTLYLEMNNLRGEDTAVYYCARY 
                   
                 CTGTCTTGCAGCGCATCAG 
               
               
                 CD28z 
                   
                 DYDGYYAMDYWGQGTLVTVSSG 
                   
                 GCTTTACATTCAGTTCTTAT 
               
               
                   
                   
                 GGGSGGGGSGGGGSDIQMTQSPS 
                   
                 GCCATGAGCTGGGTGAGGC 
               
               
                   
                   
                 SLSASVGDRVTITCQASPDINSYLN 
                   
                 AGGTGCCCGGCAAGGGTCT 
               
               
                   
                   
                 WYQQKPGKAPKLLIYRANNLETGV 
                   
                 GGTGTGGATCAGCTCAATC 
               
               
                   
                   
                 PSRFSGSGSGTDFTLTISSLQPEDIA 
                   
                 TCCAGGGGCGGGACTACAT 
               
               
                   
                   
                 TYYCLQYDEFPYTFGQGTKLEIKKPT 
                   
                 ATTACGCCGATTCGGTCAG 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 GGGTCGTTTTATCATTAGCA 
               
               
                   
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 GGGATAATGCCAAGAACAC 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEASRPA 
                   
                 CTTGTATTTGGAGATGAAC 
               
               
                   
                   
                 AGGAVHTRGLDFASDKPTTTPAPR 
                   
                 AACCTAAGAGGCGAAGACA 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAG 
                   
                 CCGCTGTGTACTATTGTGCC 
               
               
                   
                   
                 GAVHTRGLDFACDIYIWAPLAGTC 
                   
                 CGTTACGACTACGATGGGT 
               
               
                   
                   
                 GVLLLSLVITLYCNHRNRSKRSRGG 
                   
                 ACTACGCCATGGACTATTG 
               
               
                   
                   
                 HSDYMNMTPRRPGPTRKHYQPYA 
                   
                 GGGCCAGGGAACCTTGGTG 
               
               
                   
                   
                 PPRDFAAYRSRVKFSRSADAPAYQ 
                   
                 ACTGTGTCAAGTGGCGGGG 
               
               
                   
                   
                 QGQNQLYNELNLGRREEYDVLDKR 
                   
                 GCGGCAGCGGAGGCGGTG 
               
               
                   
                   
                 RGRDPEMGGKPRRKNPQEGLYNE 
                   
                 GCAGCGGAGGCGGCGGTT 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGK 
                   
                 CTGATATTCAAATGACGCAA 
               
               
                   
                   
                 GHDGLYQGLSTATKDTYDALHMQ 
                   
                 AGTCCCAGCAGCCTCTCCGC 
               
               
                   
                   
                 ALPPR 
                   
                 CTCCGTTGGAGACAGGGTG 
               
               
                   
                   
                   
                   
                 ACTATTACATGCCAAGCCAG 
               
               
                   
                   
                   
                   
                 CCCCGATATTAATAGCTACT 
               
               
                   
                   
                   
                   
                 TAAATTGGTATCAGCAGAA 
               
               
                   
                   
                   
                   
                 ACCTGGGAAGGCACCTAAA 
               
               
                   
                   
                   
                   
                 CTTCTCATCTACCGCGCTAA 
               
               
                   
                   
                   
                   
                 CAATCTGGAGACCGGCGTG 
               
               
                   
                   
                   
                   
                 CCGTCTAGATTTTCCGGCTC 
               
               
                   
                   
                   
                   
                 TGGATCAGGGACCGATTTT 
               
               
                   
                   
                   
                   
                 ACTCTGACAATTAGTTCCCT 
               
               
                   
                   
                   
                   
                 GCAACCCGAAGACATCGCC 
               
               
                   
                   
                   
                   
                 ACTTATTATTGCCTGCAATA 
               
               
                   
                   
                   
                   
                 TGATGAGTTTCCTTACACAT 
               
               
                   
                   
                   
                   
                 TTGGTCAGGGAACTAAACT 
               
               
                   
                   
                   
                   
                 AGAGATTAAGAAGCCTACC 
               
               
                   
                   
                   
                   
                 ACCACCCCCGCACCTCGTCC 
               
               
                   
                   
                   
                   
                 TCCAACCCCTGCACCTACGA 
               
               
                   
                   
                   
                   
                 TTGCCAGTCAGCCTCTTTCA 
               
               
                   
                   
                   
                   
                 CTGCGGCCTGAGGCCAGCA 
               
               
                   
                   
                   
                   
                 GACCAGCTGCCGGCGGTGC 
               
               
                   
                   
                   
                   
                 CGTCCATACAAGAGGACTG 
               
               
                   
                   
                   
                   
                 GACTTCGCGTCCGATAAACC 
               
               
                   
                   
                   
                   
                 TACTACCACTCCAGCCCCAA 
               
               
                   
                   
                   
                   
                 GGCCCCCAACCCCAGCACC 
               
               
                   
                   
                   
                   
                 GACTATCGCATCACAGCCTT 
               
               
                   
                   
                   
                   
                 TGTCACTGCGTCCTGAAGCC 
               
               
                   
                   
                   
                   
                 AGCCGGCCAGCTGCAGGG 
               
               
                   
                   
                   
                   
                 GGGGCCGTCCACACAAGGG 
               
               
                   
                   
                   
                   
                 GACTCGACTTTGCGAGTGA 
               
               
                   
                   
                   
                   
                 TAAGCCCACCACCACCCCTG 
               
               
                   
                   
                   
                   
                 CCCCTAGACCTCCAACCCCA 
               
               
                   
                   
                   
                   
                 GCCCCTACAATCGCCAGCCA 
               
               
                   
                   
                   
                   
                 GCCCCTGAGCCTGAGGCCC 
               
               
                   
                   
                   
                   
                 GAAGCCTGTAGACCTGCCG 
               
               
                   
                   
                   
                   
                 CTGGCGGAGCCGTGCACAC 
               
               
                   
                   
                   
                   
                 CAGAGGCCTGGATTTCGCC 
               
               
                   
                   
                   
                   
                 TGCGACATCTACATCTGGG 
               
               
                   
                   
                   
                   
                 CCCCTCTGGCCGGCACCTGT 
               
               
                   
                   
                   
                   
                 GGCGTGCTGCTGCTGAGCC 
               
               
                   
                   
                   
                   
                 TGGTCATCACCCTGTACTGC 
               
               
                   
                   
                   
                   
                 AACCACCGGAATAGGAGCA 
               
               
                   
                   
                   
                   
                 AGCGGAGCAGAGGCGGCC 
               
               
                   
                   
                   
                   
                 ACAGCGACTACATGAACAT 
               
               
                   
                   
                   
                   
                 GACCCCCCGGAGGCCTGGC 
               
               
                   
                   
                   
                   
                 CCCACCCGGAAGCACTACC 
               
               
                   
                   
                   
                   
                 AGCCCTACGCCCCTCCCAGG 
               
               
                   
                   
                   
                   
                 GACTTCGCCGCCTACCGGA 
               
               
                   
                   
                   
                   
                 GCCGGGTGAAGTTCAGCCG 
               
               
                   
                   
                   
                   
                 GAGCGCCGACGCCCCTGCC 
               
               
                   
                   
                   
                   
                 TACCAGCAGGGCCAGAACC 
               
               
                   
                   
                   
                   
                 AGCTGTACAACGAGCTGAA 
               
               
                   
                   
                   
                   
                 CCTGGGCCGGAGGGAGGA 
               
               
                   
                   
                   
                   
                 GTACGACGTGCTGGACAAG 
               
               
                   
                   
                   
                   
                 CGGAGAGGCCGGGACCCT 
               
               
                   
                   
                   
                   
                 GAGATGGGCGGCAAGCCCC 
               
               
                   
                   
                   
                   
                 GGAGAAAGAACCCTCAGGA 
               
               
                   
                   
                   
                   
                 GGGCCTGTATAACGAACTG 
               
               
                   
                   
                   
                   
                 CAGAAAGACAAGATGGCCG 
               
               
                   
                   
                   
                   
                 AGGCCTACAGCGAGATCGG 
               
               
                   
                   
                   
                   
                 CATGAAGGGCGAGCGGCG 
               
               
                   
                   
                   
                   
                 GAGGGGCAAGGGCCACGA 
               
               
                   
                   
                   
                   
                 CGGCCTGTACCAGGGCCTG 
               
               
                   
                   
                   
                   
                 AGCACCGCCACCAAGGATA 
               
               
                   
                   
                   
                   
                 CCTACGACGCCCTGCACATG 
               
               
                   
                   
                   
                   
                 CAGGCCCTGCCCCCCAGA 
               
               
                   
                   
                   
                   
                 GAGGTTCAACTCGTGGAGT 
               
               
                   
                   
                   
                   
                 CTGGAGGCGGGCTAGTGCA 
               
               
                   
                   
                   
                   
                 GCCTGGCGGCTCCCTGCGA 
               
               
                   
                   
                   
                   
                 CTGTCTTGCAGCGCATCAG 
               
               
                   
                   
                   
                   
                 GCTTTACATTCAGTTCTTAT 
               
               
                   
                   
                   
                   
                 GCCATGAGCTGGGTGAGGC 
               
               
                   
                   
                   
                   
                 AGGTGCCCGGCAAGGGTCT 
               
               
                   
                   
                   
                   
                 GGTGTGGATCAGCTCAATC 
               
               
                   
                   
                   
                   
                 TCCAGGGGCGGGACTACAT 
               
               
                   
               
               
                 hROR1 
                 629 
                 EVQLVESGGGLVQPGGSLRLSCSAS 
                 630 
                 ATTACGCCGATTCGGTCAG 
               
               
                 (VH_18- 
                   
                 GFTFSSYAMSWVRQVPGKGLVWI 
                   
                 GGGTCGTTTTATCATTAGCA 
               
               
                 VL_14). 
                   
                 SSISRGGTTYYADSVRGRFIISRDNA 
                   
                 GGGATAATGCCAAGAACAC 
               
               
                 CD8a(3x). 
                   
                 KNTLYLEMNNLRGEDTAVYYCARY 
                   
                 CTTGTATTTGGAGATGAAC 
               
               
                 CD28z 
                   
                 DYDGYYAMDYWGQGTLVTVSSG 
                   
                 AACCTAAGAGGCGAAGACA 
               
               
                   
                   
                 GGGSGGGGSGGGGSDIQMTQSPS 
                   
                 CCGCTGTGTACTATTGTGCC 
               
               
                   
                   
                 SLSASVGDRVTITCKASPDINSYLN 
                   
                 CGTTACGACTACGATGGGT 
               
               
                   
                   
                 WYQQKPGKAPKLLIYRANRLVDGV 
                   
                 ACTACGCCATGGACTATTG 
               
               
                   
                   
                 PSRFSGSGSGTDYTLTISSLQPEDFA 
                   
                 GGGCCAGGGAACCTTGGTG 
               
               
                   
                   
                 TYYCLQYDEFPYTFGAGTKVEIKKPT 
                   
                 ACTGTGTCAAGTGGCGGGG 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEAS 
                   
                 GCGGCAGCGGAGGCGGTG 
               
               
                   
                   
                 RPAAGGAVHTRGLDFASDKPTTTP 
                   
                 GCAGCGGAGGCGGCGGTT 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEASRPA 
                   
                 CTGATATACAGATGACACA 
               
               
                   
                   
                 AGGAVHTRGLDFASDKPTTTPAPR 
                   
                 GAGCCCTTCAAGTTTATCTG 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAG 
                   
                 CAAGCGTCGGCGATCGTGT 
               
               
                   
                   
                 GAVHTRGLDFACDIYIWAPLAGTC 
                   
                 TACAATAACTTGCAAGGCAT 
               
               
                   
                   
                 GVLLLSLVITLYCNHRNRSKRSRGG 
                   
                 CTCCCGACATCAATTCCTAC 
               
               
                   
                   
                 HSDYMNMTPRRPGPTRKHYQPYA 
                   
                 CTCAACTGGTATCAGCAGA 
               
               
                   
                   
                 PPRDFAAYRSRVKFSRSADAPAYQ 
                   
                 AGCCTGGGAAGGCTCCTAA 
               
               
                   
                   
                 QGQNQLYNELNLGRREEYDVLDKR 
                   
                 GCTGCTTATTTACAGAGCAA 
               
               
                   
                   
                 RGRDPEMGGKPRRKNPQEGLYNE 
                   
                 ATCGCCTGGTGGACGGCGT 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGK 
                   
                 GCCCAGTCGGTTTTCCGGG 
               
               
                   
                   
                 GHDGLYQGLSTATKDTYDALHMQ 
                   
                 TCTGGGAGCGGAACGGATT 
               
               
                   
                   
                 ALPPR 
                   
                 ACACACTGACCATCTCAAGC 
               
               
                   
                   
                   
                   
                 CTGCAACCCGAAGACTTCG 
               
               
                   
                   
                   
                   
                 CTACATATTACTGCCTTCAG 
               
               
                   
                   
                   
                   
                 TATGATGAGTTCCCATATAC 
               
               
                   
                   
                   
                   
                 CTTCGGCGCTGGGACCAAG 
               
               
                   
                   
                   
                   
                 GTGGAGATAAAGAAGCCTA 
               
               
                   
                   
                   
                   
                 CCACCACCCCCGCACCTCGT 
               
               
                   
                   
                   
                   
                 CCTCCAACCCCTGCACCTAC 
               
               
                   
                   
                   
                   
                 GATTGCCAGTCAGCCTCTTT 
               
               
                   
                   
                   
                   
                 CACTGCGGCCTGAGGCCAG 
               
               
                   
                   
                   
                   
                 CAGACCAGCTGCCGGCGGT 
               
               
                   
                   
                   
                   
                 GCCGTCCATACAAGAGGAC 
               
               
                   
                   
                   
                   
                 TGGACTTCGCGTCCGATAA 
               
               
                   
                   
                   
                   
                 ACCTACTACCACTCCAGCCC 
               
               
                   
                   
                   
                   
                 CAAGGCCCCCAACCCCAGC 
               
               
                   
                   
                   
                   
                 ACCGACTATCGCATCACAGC 
               
               
                   
                   
                   
                   
                 CTTTGTCACTGCGTCCTGAA 
               
               
                   
                   
                   
                   
                 GCCAGCCGGCCAGCTGCAG 
               
               
                   
                   
                   
                   
                 GGGGGGCCGTCCACACAAG 
               
               
                   
                   
                   
                   
                 GGGACTCGACTTTGCGAGT 
               
               
                   
                   
                   
                   
                 GATAAGCCCACCACCACCCC 
               
               
                   
                   
                   
                   
                 TGCCCCTAGACCTCCAACCC 
               
               
                   
                   
                   
                   
                 CAGCCCCTACAATCGCCAGC 
               
               
                   
                   
                   
                   
                 CAGCCCCTGAGCCTGAGGC 
               
               
                   
                   
                   
                   
                 CCGAAGCCTGTAGACCTGC 
               
               
                   
                   
                   
                   
                 CGCTGGCGGAGCCGTGCAC 
               
               
                   
                   
                   
                   
                 ACCAGAGGCCTGGATTTCG 
               
               
                   
                   
                   
                   
                 CCTGCGACATCTACATCTGG 
               
               
                   
                   
                   
                   
                 GCCCCTCTGGCCGGCACCT 
               
               
                   
                   
                   
                   
                 GTGGCGTGCTGCTGCTGAG 
               
               
                   
                   
                   
                   
                 CCTGGTCATCACCCTGTACT 
               
               
                   
                   
                   
                   
                 GCAACCACCGGAATAGGAG 
               
               
                   
                   
                   
                   
                 CAAGCGGAGCAGAGGCGG 
               
               
                   
                   
                   
                   
                 CCACAGCGACTACATGAAC 
               
               
                   
                   
                   
                   
                 ATGACCCCCCGGAGGCCTG 
               
               
                   
                   
                   
                   
                 GCCCCACCCGGAAGCACTA 
               
               
                   
                   
                   
                   
                 CCAGCCCTACGCCCCTCCCA 
               
               
                   
                   
                   
                   
                 GGGACTTCGCCGCCTACCG 
               
               
                   
                   
                   
                   
                 GAGCCGGGTGAAGTTCAGC 
               
               
                   
                   
                   
                   
                 CGGAGCGCCGACGCCCCTG 
               
               
                   
                   
                   
                   
                 CCTACCAGCAGGGCCAGAA 
               
               
                   
                   
                   
                   
                 CCAGCTGTACAACGAGCTG 
               
               
                   
                   
                   
                   
                 AACCTGGGCCGGAGGGAG 
               
               
                   
                   
                   
                   
                 GAGTACGACGTGCTGGACA 
               
               
                   
                   
                   
                   
                 AGCGGAGAGGCCGGGACC 
               
               
                   
                   
                   
                   
                 CTGAGATGGGCGGCAAGCC 
               
               
                   
                   
                   
                   
                 CCGGAGAAAGAACCCTCAG 
               
               
                   
                   
                   
                   
                 GAGGGCCTGTATAACGAAC 
               
               
                   
                   
                   
                   
                 TGCAGAAAGACAAGATGGC 
               
               
                   
                   
                   
                   
                 CGAGGCCTACAGCGAGATC 
               
               
                   
                   
                   
                   
                 GGCATGAAGGGCGAGCGG 
               
               
                   
                   
                   
                   
                 CGGAGGGGCAAGGGCCAC 
               
               
                   
                   
                   
                   
                 GACGGCCTGTACCAGGGCC 
               
               
                   
                   
                   
                   
                 TGAGCACCGCCACCAAGGA 
               
               
                   
                   
                   
                   
                 TACCTACGACGCCCTGCACA 
               
               
                   
                   
                   
                   
                 TGCAGGCCCTGCCCCCCAG 
               
               
                   
                   
                   
                   
                 A 
               
               
                   
               
               
                 IgG4-Fc 12 
                   
                   
                   
                   
               
               
                 amino acid 
                 631 
                 ESKYGPPCPPCP 
                   
                   
               
               
                 hinge region 
                   
                   
                   
                   
               
               
                   
               
            
           
           
               
            
               
                 RTS-COMPONENTS 
               
            
           
           
               
               
               
               
               
            
               
                 VP16 
                 632 
                 GPKKKRKVAPPTDVSLGDELHLDG 
                 633 
                 GGCCCCAAGAAGAAAAGG 
               
               
                 activation 
                   
                 EDVAMAHADALDDFDLDMLGDG 
                   
                 AAGGTGGCCCCCCCCACCG 
               
               
                 domain 
                   
                 DSPGPGFTPHDSAPYGALDMADF 
                   
                 ACGTGAGCCTGGGCGACGA 
               
               
                   
                   
                 EFEQMFTDALGIDEYGG 
                   
                 GCTGCACCTGGACGGCGAG 
               
               
                   
                   
                   
                   
                 GACGTGGCCATGGCCCACG 
               
               
                   
                   
                   
                   
                 CCGACGCCCTGGACGACTT 
               
               
                   
                   
                   
                   
                 CGACCTGGACATGCTGGGC 
               
               
                   
                   
                   
                   
                 GACGGCGACAGCCCCGGCC 
               
               
                   
                   
                   
                   
                 CCGGCTTCACCCCCCACGAC 
               
               
                   
                   
                   
                   
                 AGCGCCCCCTACGGCGCCC 
               
               
                   
                   
                   
                   
                 TGGACATGGCCGACTTCGA 
               
               
                   
                   
                   
                   
                 GTTCGAGCAGATGTTCACC 
               
               
                   
                   
                   
                   
                 GACGCCCTGGGCATCGACG 
               
               
                   
                   
                   
                   
                 AGTACGGCGGC 
               
               
                   
               
               
                 Retinoid x 
                 634 
                 EMPVDRILEAELAVEQKSDQGVEG 
                 635 
                 GAGATGCCCGTGGACAGGA 
               
               
                 receptor 
                   
                 PGGTGGSGSSPNDPVTNICQAADK 
                   
                 TTCTGGAGGCCGAACTCGC 
               
               
                 (RxR) 
                   
                 QLFTLVEWAKRIPHFSSLPLDDQVIL 
                   
                 CGTGGAGCAGAAAAGCGAC 
               
               
                   
                   
                 LRAGWNELLIASFSHRSIDVRDGILL 
                   
                 CAGGGCGTGGAGGGCCCC 
               
               
                   
                   
                 ATGLHVHRNSAHSAGVGAIFDRVL 
                   
                 GGCGGAACCGGCGGCAGC 
               
               
                   
                   
                 TELVSKMRDMRMDKTELGCLRAII 
                   
                 GGCAGCAGCCCCAACGACC 
               
               
                   
                   
                 LFNPEVRGLKSAQEVELLREKVYAA 
                   
                 CCGTGACCAACATCTGCCA 
               
               
                   
                   
                 LEEYTRTTHPDEPGRFAKLLLRLPSL 
                   
                 GGCCGCCGACAAGCAGCTG 
               
               
                   
                   
                 RSIGLKCLEHLFFFRLIGDVPIDTFLM 
                   
                 TTCACCCTGGTGGAGTGGG 
               
               
                   
                   
                 EMLESPSDS 
                   
                 CCAAGAGGATTCCCCACTTC 
               
               
                   
                   
                   
                   
                 AGCAGCCTGCCCCTGGACG 
               
               
                   
                   
                   
                   
                 ACCAGGTGATCCTGCTGAG 
               
               
                   
                   
                   
                   
                 GGCCGGATGGAACGAGCTG 
               
               
                   
                   
                   
                   
                 CTGATCGCCAGCTTCAGCCA 
               
               
                   
                   
                   
                   
                 CAGGAGCATCGACGTGAGG 
               
               
                   
                   
                   
                   
                 GACGGCATCCTGCTGGCCA 
               
               
                   
                   
                   
                   
                 CCGGCCTGCACGTCCATAG 
               
               
                   
                   
                   
                   
                 GAACAGCGCCCACAGCGCC 
               
               
                   
                   
                   
                   
                 GGAGTGGGCGCCATCTTCG 
               
               
                   
                   
                   
                   
                 ACAGGGTGCTGACCGAGCT 
               
               
                   
                   
                   
                   
                 GGTGAGCAAGATGAGGGA 
               
               
                   
                   
                   
                   
                 CATGAGGATGGACAAGACC 
               
               
                   
                   
                   
                   
                 GAGCTGGGCTGCCTGAGGG 
               
               
                   
                   
                   
                   
                 CCATCATCCTGTTCAACCCC 
               
               
                   
                   
                   
                   
                 GAGGTGAGGGGCCTGAAA 
               
               
                   
                   
                   
                   
                 AGCGCCCAGGAGGTGGAG 
               
               
                   
                   
                   
                   
                 CTGCTGAGGGAGAAGGTGT 
               
               
                   
                   
                   
                   
                 ACGCCGCCCTGGAGGAGTA 
               
               
                   
                   
                   
                   
                 CACCAGGACCACCCACCCC 
               
               
                   
                   
                   
                   
                 GACGAGCCCGGCAGATTCG 
               
               
                   
                   
                   
                   
                 CCAAGCTGCTGCTGAGGCT 
               
               
                   
                   
                   
                   
                 GCCCAGCCTGAGGAGCATC 
               
               
                   
                   
                   
                   
                 GGCCTGAAGTGCCTGGAGC 
               
               
                   
                   
                   
                   
                 ACCTGTTCTTCTTCAGGCTG 
               
               
                   
                   
                   
                   
                 ATCGGCGACGTGCCCATCG 
               
               
                   
                   
                   
                   
                 ACACCTTCCTGATGGAGAT 
               
               
                   
                   
                   
                   
                 GCTGGAGAGCCCCAGCGAC 
               
               
                   
                   
                   
                   
                 AGC 
               
               
                   
               
               
                 VP16-linker- 
                 636 
                 GPKKKRKVAPPTDVSLGDELHLDG 
                 637 
                 GGCCCCAAGAAGAAAAGG 
               
               
                 RxR 
                   
                 EDVAMAHADALDDFDLDMLGDG 
                   
                 AAGGTGGCCCCCCCCACCG 
               
               
                   
                   
                 DSPGPGFTPHDSAPYGALDMADF 
                   
                 ACGTGAGCCTGGGCGACGA 
               
               
                   
                   
                 EFEQMFTDALGIDEYGGEFEMPVD 
                   
                 GCTGCACCTGGACGGCGAG 
               
               
                   
                   
                 RILEAELAVEQKSDQGVEGPGGTG 
                   
                 GACGTGGCCATGGCCCACG 
               
               
                   
                   
                 GSGSSPNDPVTNICQAADKQLFTL 
                   
                 CCGACGCCCTGGACGACTT 
               
               
                   
                   
                 VEWAKRIPHFSSLPLDDQVILLRAG 
                   
                 CGACCTGGACATGCTGGGC 
               
               
                   
                   
                 WNELLIASFSHRSIDVRDGILLATGL 
                   
                 GACGGCGACAGCCCCGGCC 
               
               
                   
                   
                 HVHRNSAHSAGVGAIFDRVLTELV 
                   
                 CCGGCTTCACCCCCCACGAC 
               
               
                   
                   
                 SKMRDMRMDKTELGCLRAIILFNP 
                   
                 AGCGCCCCCTACGGCGCCC 
               
               
                   
                   
                 EVRGLKSAQEVELLREKVYAALEEY 
                   
                 TGGACATGGCCGACTTCGA 
               
               
                   
                   
                 TRTTHPDEPGRFAKLLLRLPSLRSIG 
                   
                 GTTCGAGCAGATGTTCACC 
               
               
                   
                   
                 LKCLEHLFFFRLIGDVPIDTFLMEML 
                   
                 GACGCCCTGGGCATCGACG 
               
               
                   
                   
                 ESPSDS 
                   
                 AGTACGGCGGCGAATTCGA 
               
               
                   
                   
                   
                   
                 GATGCCCGTGGACAGGATT 
               
               
                   
                   
                   
                   
                 CTGGAGGCCGAACTCGCCG 
               
               
                   
                   
                   
                   
                 TGGAGCAGAAAAGCGACCA 
               
               
                   
                   
                   
                   
                 GGGCGTGGAGGGCCCCGG 
               
               
                   
                   
                   
                   
                 CGGAACCGGCGGCAGCGG 
               
               
                   
                   
                   
                   
                 CAGCAGCCCCAACGACCCC 
               
               
                   
                   
                   
                   
                 GTGACCAACATCTGCCAGG 
               
               
                   
                   
                   
                   
                 CCGCCGACAAGCAGCTGTT 
               
               
                   
                   
                   
                   
                 CACCCTGGTGGAGTGGGCC 
               
               
                   
                   
                   
                   
                 AAGAGGATTCCCCACTTCA 
               
               
                   
                   
                   
                   
                 GCAGCCTGCCCCTGGACGA 
               
               
                   
                   
                   
                   
                 CCAGGTGATCCTGCTGAGG 
               
               
                   
                   
                   
                   
                 GCCGGATGGAACGAGCTGC 
               
               
                   
                   
                   
                   
                 TGATCGCCAGCTTCAGCCAC 
               
               
                   
                   
                   
                   
                 AGGAGCATCGACGTGAGG 
               
               
                   
                   
                   
                   
                 GACGGCATCCTGCTGGCCA 
               
               
                   
                   
                   
                   
                 CCGGCCTGCACGTCCATAG 
               
               
                   
                   
                   
                   
                 GAACAGCGCCCACAGCGCC 
               
               
                   
                   
                   
                   
                 GGAGTGGGCGCCATCTTCG 
               
               
                   
                   
                   
                   
                 ACAGGGTGCTGACCGAGCT 
               
               
                   
                   
                   
                   
                 GGTGAGCAAGATGAGGGA 
               
               
                   
                   
                   
                   
                 CATGAGGATGGACAAGACC 
               
               
                   
                   
                   
                   
                 GAGCTGGGCTGCCTGAGGG 
               
               
                   
                   
                   
                   
                 CCATCATCCTGTTCAACCCC 
               
               
                   
                   
                   
                   
                 GAGGTGAGGGGCCTGAAA 
               
               
                   
                   
                   
                   
                 AGCGCCCAGGAGGTGGAG 
               
               
                   
                   
                   
                   
                 CTGCTGAGGGAGAAGGTGT 
               
               
                   
                   
                   
                   
                 ACGCCGCCCTGGAGGAGTA 
               
               
                   
                   
                   
                   
                 CACCAGGACCACCCACCCC 
               
               
                   
                   
                   
                   
                 GACGAGCCCGGCAGATTCG 
               
               
                   
                   
                   
                   
                 CCAAGCTGCTGCTGAGGCT 
               
               
                   
                   
                   
                   
                 GCCCAGCCTGAGGAGCATC 
               
               
                   
                   
                   
                   
                 GGCCTGAAGTGCCTGGAGC 
               
               
                   
                   
                   
                   
                 ACCTGTTCTTCTTCAGGCTG 
               
               
                   
                   
                   
                   
                 ATCGGCGACGTGCCCATCG 
               
               
                   
                   
                   
                   
                 ACACCTTCCTGATGGAGAT 
               
               
                   
                   
                   
                   
                 GCTGGAGAGCCCCAGCGAC 
               
               
                   
                   
                   
                   
                 AGC 
               
               
                   
               
               
                 GAL4 DNA 
                 638 
                 MKLLSSIEQACDICRLKKLKCSKEKP 
                 639 
                 ATGAAGCTGCTGAGCAGCA 
               
               
                 Binding 
                   
                 KCAKCLKNNWECRYSPKTKRSPLTR 
                   
                 TCGAGCAGGCTTGCGACAT 
               
               
                 Domain 
                   
                 AHLTEVESRLERLEQLFLLIFPREDLD 
                   
                 CTGCAGGCTGAAGAAGCTG 
               
               
                   
                   
                 MILKMDSLQDIKALLTGLFVQDNV 
                   
                 AAGTGCAGCAAGGAGAAG 
               
               
                   
                   
                 NKDAVTDRLASVETDMPLTLRQHR 
                   
                 CCCAAGTGCGCCAAGTGCC 
               
               
                   
                   
                 ISATSSSEESSNKGQRQLTVSPEF 
                   
                 TGAAGAACAACTGGGAGTG 
               
               
                   
                   
                   
                   
                 CAGATACAGCCCCAAGACC 
               
               
                   
                   
                   
                   
                 AAGAGGAGCCCCCTGACCA 
               
               
                   
                   
                   
                   
                 GGGCCCACCTGACCGAGGT 
               
               
                   
                   
                   
                   
                 GGAGAGCAGGCTGGAGAG 
               
               
                   
                   
                   
                   
                 GCTGGAGCAGCTGTTCCTG 
               
               
                   
                   
                   
                   
                 CTGATCTTCCCCAGGGAGG 
               
               
                   
                   
                   
                   
                 ACCTGGACATGATCCTGAA 
               
               
                   
                   
                   
                   
                 GATGGACAGCCTGCAAGAC 
               
               
                   
                   
                   
                   
                 ATCAAGGCCCTGCTGACCG 
               
               
                   
                   
                   
                   
                 GCCTGTTCGTGCAGGACAA 
               
               
                   
                   
                   
                   
                 CGTGAACAAGGACGCCGTG 
               
               
                   
                   
                   
                   
                 ACCGACAGGCTGGCCAGCG 
               
               
                   
                   
                   
                   
                 TGGAGACCGACATGCCCCT 
               
               
                   
                   
                   
                   
                 GACCCTGAGGCAGCACAGG 
               
               
                   
                   
                   
                   
                 ATCAGCGCCACCAGCAGCA 
               
               
                   
                   
                   
                   
                 GCGAGGAGAGCAGCAACA 
               
               
                   
                   
                   
                   
                 AGGGCCAGAGGCAGCTGAC 
               
               
                   
                   
                   
                   
                 CGTGAGCCCCGAGTTT 
               
               
                   
               
               
                 Ecdysone 
                 640 
                 IRPECVVPETQCAMKRKEKKAQKE 
                 641 
                 ATCAGGCCCGAGTGCGTGG 
               
               
                 Receptor 
                   
                 KDKLPVSTTTVDDHMPPIMQCEPP 
                   
                 TGCCCGAGACCCAGTGCGC 
               
               
                 Ligand 
                   
                 PPEAARIHEVVPRFLSDKLLVTNRQ 
                   
                 CATGAAAAGGAAGGAGAA 
               
               
                 Binding 
                   
                 KNIPQLTANQQFLIARLIWYQDGYE 
                   
                 GAAGGCCCAGAAGGAGAA 
               
               
                 Domain-VY 
                   
                 QPSDEDLKRITQTWQQADDENEE 
                   
                 GGACAAGCTGCCCGTGAGC 
               
               
                 variant (EcR) 
                   
                 SDTPFRQITEMTILTVQLIVEFAKGL 
                   
                 ACCACCACCGTCGATGACC 
               
               
                   
                   
                 PGFAKISQPDQITLLKACSSEVMML 
                   
                 ACATGCCCCCCATCATGCAG 
               
               
                   
                   
                 RVARRYDAASDSILFANNQAYTRD 
                   
                 TGCGAGCCCCCCCCCCCCGA 
               
               
                   
                   
                 NYRKAGMAEVIEDLLHFCRCMYS 
                   
                 GGCCGCCAGGATTCACGAG 
               
               
                   
                   
                 MALDNIHYALLTAVVIFSDRPGLEQ 
                   
                 GTCGTGCCCAGGTTCCTGA 
               
               
                   
                   
                 PQLVEEIQRYYLNTLRIYILNQLSGS 
                   
                 GCGACAAGCTGCTGGTGAC 
               
               
                   
                   
                 ARSSVIYGKILSILSELRTLGMQNSN 
                   
                 CAACAGGCAGAAGAACATC 
               
               
                   
                   
                 MCISLKLKNRKLPPFLEEIWDVAD 
                   
                 CCCCAGCTGACCGCCAACC 
               
               
                   
                   
                 MSHTQPPPILESPTNL 
                   
                 AGCAGTTCCTGATCGCCAG 
               
               
                   
                   
                   
                   
                 GCTGATCTGGTATCAGGAC 
               
               
                   
                   
                   
                   
                 GGCTACGAGCAGCCCAGCG 
               
               
                   
                   
                   
                   
                 ACGAGGACCTGAAAAGGAT 
               
               
                   
                   
                   
                   
                 CACCCAGACCTGGCAGCAG 
               
               
                   
                   
                   
                   
                 GCCGACGACGAGAACGAG 
               
               
                   
                   
                   
                   
                 GAGAGCGACACCCCCTTCA 
               
               
                   
                   
                   
                   
                 GGCAGATCACCGAGATGAC 
               
               
                   
                   
                   
                   
                 CATCCTGACCGTGCAGCTG 
               
               
                   
                   
                   
                   
                 ATCGTGGAGTTCGCCAAGG 
               
               
                   
                   
                   
                   
                 GCCTGCCCGGATTCGCCAA 
               
               
                   
                   
                   
                   
                 GATCAGCCAGCCCGACCAG 
               
               
                   
                   
                   
                   
                 ATCACCCTGCTGAAGGCTT 
               
               
                   
                   
                   
                   
                 GCAGCAGCGAGGTGATGAT 
               
               
                   
                   
                   
                   
                 GCTGAGGGTGGCCAGGAG 
               
               
                   
                   
                   
                   
                 GTACGACGCCGCCAGCGAC 
               
               
                   
                   
                   
                   
                 AGCATCCTGTTCGCCAACAA 
               
               
                   
                   
                   
                   
                 CCAGGCTTACACCAGGGAC 
               
               
                   
                   
                   
                   
                 AACTACAGGAAGGCTGGCA 
               
               
                   
                   
                   
                   
                 TGGCCGAGGTGATCGAGGA 
               
               
                   
                   
                   
                   
                 CCTCCTGCACTTCTGCAGAT 
               
               
                   
                   
                   
                   
                 GTATGTACAGCATGGCCCT 
               
               
                   
                   
                   
                   
                 GGACAACATCCACTACGCC 
               
               
                   
                   
                   
                   
                 CTGCTGACCGCCGTGGTGA 
               
               
                   
                   
                   
                   
                 TCTTCAGCGACAGGCCCGG 
               
               
                   
                   
                   
                   
                 CCTGGAGCAGCCCCAGCTG 
               
               
                   
                   
                   
                   
                 GTGGAGGAGATCCAGAGGT 
               
               
                   
                   
                   
                   
                 ACTACCTGAACACCCTGAG 
               
               
                   
                   
                   
                   
                 GATCTACATCCTGAACCAGC 
               
               
                   
                   
                   
                   
                 TGAGCGGCAGCGCCAGGA 
               
               
                   
                   
                   
                   
                 GCAGCGTGATCTACGGCAA 
               
               
                   
                   
                   
                   
                 GATCCTGAGCATCCTGAGC 
               
               
                   
                   
                   
                   
                 GAGCTGAGGACCCTGGGAA 
               
               
                   
                   
                   
                   
                 TGCAGAACAGCAATATGTG 
               
               
                   
                   
                   
                   
                 TATCAGCCTGAAGCTGAAG 
               
               
                   
                   
                   
                   
                 AACAGGAAGCTGCCCCCCT 
               
               
                   
                   
                   
                   
                 TCCTGGAGGAGATTTGGGA 
               
               
                   
                   
                   
                   
                 CGTGGCCGACATGAGCCAC 
               
               
                   
                   
                   
                   
                 ACCCAGCCCCCCCCCATCCT 
               
               
                   
                   
                   
                   
                 GGAGAGCCCCACCAACCTG 
               
               
                   
               
               
                 Ecdysone 
                 642 
                 RPECVVPETQCAMKRKEKKAQKEK 
                 643 
                 CGGCCTGAGTGCGTAGTAC 
               
               
                 Receptor 
                   
                 DKLPVSTTTVDDHMPPIMQCEPPP 
                   
                 CCGAGACTCAGTGCGCCAT 
               
               
                 Ligand 
                   
                 PEAARIHEVVPRFLSDKLLVTNRQK 
                   
                 GAAGCGGAAAGAGAAGAA 
               
               
                 Binding 
                   
                 NIPQLTANQQFLIARLIWYQDGYE 
                   
                 AGCACAGAAGGAGAAGGA 
               
               
                 Domain_VY 
                   
                 QPSDEDLKRITQTWQQADDENEE 
                   
                 CAAACTGCCTGTCAGCACG 
               
               
                 variant (EcR) 
                   
                 SDTPFRQITEMTILTVQLIVEFAKGL 
                   
                 ACGACGGTGGACGACCACA 
               
               
                   
                   
                 PGFAKISQPDQITLLKACSSEVMML 
                   
                 TGCCGCCCATTATGCAGTGT 
               
               
                   
                   
                 RVARRYDAASDSILFANNQAYTRD 
                   
                 GAACCTCCACCTCCTGAAGC 
               
               
                   
                   
                 NYRKAGMAEVIEDLLHFCRCMYS 
                   
                 AGCAAGGATTCACGAAGTG 
               
               
                   
                   
                 MALDNIHYALLTAVVIFSDRPGLEQ 
                   
                 GTCCCAAGGTTTCTCTCCGA 
               
               
                   
                   
                 PQLVEEIQRYYLNTLRIYILNQLSGS 
                   
                 CAAGCTGTTGGTGACAAAC 
               
               
                   
                   
                 ARSSVIYGKILSILSELRTLGMQNSN 
                   
                 CGGCAGAAAAACATCCCCC 
               
               
                   
                   
                 MCISLKLKNRKLPPFLEEIWDVAD 
                   
                 AGTTGACAGCCAACCAGCA 
               
               
                   
                   
                 MSHTQPPPILESPTNL 
                   
                 GTTCCTTATCGCCAGGCTCA 
               
               
                   
                   
                   
                   
                 TCTGGTACCAGGACGGGTA 
               
               
                   
                   
                   
                   
                 CGAGCAGCCTTCTGATGAA 
               
               
                   
                   
                   
                   
                 GATTTGAAGAGGATTACGC 
               
               
                   
                   
                   
                   
                 AGACGTGGCAGCAAGCGG 
               
               
                   
                   
                   
                   
                 ACGATGAAAACGAAGAGTC 
               
               
                   
                   
                   
                   
                 GGACACTCCCTTCCGCCAGA 
               
               
                   
                   
                   
                   
                 TCACAGAGATGACTATCCTC 
               
               
                   
                   
                   
                   
                 ACGGTCCAACTTATCGTGG 
               
               
                   
                   
                   
                   
                 AGTTCGCGAAGGGATTGCC 
               
               
                   
                   
                   
                   
                 AGGGTTCGCCAAGATCTCG 
               
               
                   
                   
                   
                   
                 CAGCCTGATCAAATTACGCT 
               
               
                   
                   
                   
                   
                 GCTTAAGGCTTGCTCAAGT 
               
               
                   
                   
                   
                   
                 GAGGTAATGATGCTCCGAG 
               
               
                   
                   
                   
                   
                 TCGCGCGACGATACGATGC 
               
               
                   
                   
                   
                   
                 GGCCTCAGACAGTATTCTGT 
               
               
                   
                   
                   
                   
                 TCGCGAACAACCAAGCGTA 
               
               
                   
                   
                   
                   
                 CACTCGCGACAACTACCGC 
               
               
                   
                   
                   
                   
                 AAGGCTGGCATGGCCGAGG 
               
               
                   
                   
                   
                   
                 TCATCGAGGATCTACTGCAC 
               
               
                   
                   
                   
                   
                 TTCTGCCGGTGCATGTACTC 
               
               
                   
                   
                   
                   
                 TATGGCGTTGGACAACATC 
               
               
                   
                   
                   
                   
                 CATTACGCGCTGCTCACGG 
               
               
                   
                   
                   
                   
                 CTGTCGTCATCTTTTCTGAC 
               
               
                   
                   
                   
                   
                 CGGCCAGGGTTGGAGCAGC 
               
               
                   
                   
                   
                   
                 CGCAACTGGTGGAAGAGAT 
               
               
                   
                   
                   
                   
                 CCAGCGGTACTACCTGAAT 
               
               
                   
                   
                   
                   
                 ACGCTCCGCATCTATATCCT 
               
               
                   
                   
                   
                   
                 GAACCAGCTGAGCGGGTCG 
               
               
                   
                   
                   
                   
                 GCGCGTTCGTCCGTCATATA 
               
               
                   
                   
                   
                   
                 CGGCAAGATCCTCTCAATCC 
               
               
                   
                   
                   
                   
                 TCTCTGAGCTACGCACGCTC 
               
               
                   
                   
                   
                   
                 GGCATGCAAAACTCCAACA 
               
               
                   
                   
                   
                   
                 TGTGCATCTCCCTCAAGCTC 
               
               
                   
                   
                   
                   
                 AAGAACAGAAAGCTGCCGC 
               
               
                   
                   
                   
                   
                 CTTTCCTCGAGGAGATCTG 
               
               
                   
                   
                   
                   
                 GGATGTGGCGGACATGTCG 
               
               
                   
                   
                   
                   
                 CACACCCAACCGCCGCCTAT 
               
               
                   
                   
                   
                   
                 CCTCGAGTCCCCCACGAATC 
               
               
                   
                   
                   
                   
                 TCTAG 
               
               
                   
               
               
                 GAL4-Linker- 
                 644 
                 MKLLSSIEQACDICRLKKLKCSKEKP 
                 645 
                 ATGAAGCTACTGTCTTCTAT 
               
               
                 EcR 
                   
                 KCAKCLKNNWECRYSPKTKRSPLTR 
                   
                 CGAACAAGCATGCGATATT 
               
               
                   
                   
                 AHLTEVESRLERLEQLFLLIFPREDLD 
                   
                 TGCCGACTTAAAAAGCTCA 
               
               
                   
                   
                 MILKMDSLQDIKALLTGLFVQDNV 
                   
                 AGTGCTCCAAAGAAAAACC 
               
               
                   
                   
                 NKDAVTDRLASVETDMPLTLRQHR 
                   
                 GAAGTGCGCCAAGTGTCTG 
               
               
                   
                   
                 ISATSSSEESSNKGQRQLTVSPEFPG 
                   
                 AAGAACAACTGGGAGTGTC 
               
               
                   
                   
                 IRPECVVPETQCAMKRKEKKAQKE 
                   
                 GCTACTCTCCCAAAACCAAA 
               
               
                   
                   
                 KDKLPVSTTTVDDHMPPIMQCEPP 
                   
                 AGGTCTCCGCTGACTAGGG 
               
               
                   
                   
                 PPEAARIHEVVPRFLSDKLLVTNRQ 
                   
                 CACATCTGACAGAAGTGGA 
               
               
                   
                   
                 KNIPQLTANQQFLIARLIWYQDGYE 
                   
                 ATCAAGGCTAGAAAGACTG 
               
               
                   
                   
                 QPSDEDLKRITQTWQQADDENEE 
                   
                 GAACAGCTATTTCTACTGAT 
               
               
                   
                   
                 SDTPFRQITEMTILTVQLIVEFAKGL 
                   
                 TTTTCCTCGAGAAGACCTTG 
               
               
                   
                   
                 PGFAKISQPDQITLLKACSSEVMML 
                   
                 ACATGATTTTGAAAATGGAT 
               
               
                   
                   
                 RVARRYDAASDSILFANNQAYTRD 
                   
                 TCTTTACAGGATATAAAAGC 
               
               
                   
                   
                 NYRKAGMAEVIEDLLHFCRCMYS 
                   
                 ATTGTTAACAGGATTATTTG 
               
               
                   
                   
                 MALDNIHYALLTAVVIFSDRPGLEQ 
                   
                 TACAAGATAATGTGAATAA 
               
               
                   
                   
                 PQLVEEIQRYYLNTLRIYILNQLSGS 
                   
                 AGATGCCGTCACAGATAGA 
               
               
                   
                   
                 ARSSVIYGKILSILSELRTLGMQNSN 
                   
                 TTGGCTTCAGTGGAGACTG 
               
               
                   
                   
                 MCISLKLKNRKLPPFLEEIWDVAD 
                   
                 ATATGCCTCTAACATTGAGA 
               
               
                   
                   
                 MSHTQPPPILESPTNL 
                   
                 CAGCATAGAATAAGTGCGA 
               
               
                   
                   
                   
                   
                 CATCATCATCGGAAGAGAG 
               
               
                   
                   
                   
                   
                 TAGTAACAAAGGTCAAAGA 
               
               
                   
                   
                   
                   
                 CAGTTGACTGTATCGCCGG 
               
               
                   
                   
                   
                   
                 AATTCCCGGGGATCCGGCC 
               
               
                   
                   
                   
                   
                 TGAGTGCGTAGTACCCGAG 
               
               
                   
                   
                   
                   
                 ACTCAGTGCGCCATGAAGC 
               
               
                   
                   
                   
                   
                 GGAAAGAGAAGAAAGCAC 
               
               
                   
                   
                   
                   
                 AGAAGGAGAAGGACAAAC 
               
               
                   
                   
                   
                   
                 TGCCTGTCAGCACGACGAC 
               
               
                   
                   
                   
                   
                 GGTGGACGACCACATGCCG 
               
               
                   
                   
                   
                   
                 CCCATTATGCAGTGTGAACC 
               
               
                   
                   
                   
                   
                 TCCACCTCCTGAAGCAGCAA 
               
               
                   
                   
                   
                   
                 GGATTCACGAAGTGGTCCC 
               
               
                   
                   
                   
                   
                 AAGGTTTCTCTCCGACAAGC 
               
               
                   
                   
                   
                   
                 TGTTGGTGACAAACCGGCA 
               
               
                   
                   
                   
                   
                 GAAAAACATCCCCCAGTTG 
               
               
                   
                   
                   
                   
                 ACAGCCAACCAGCAGTTCCT 
               
               
                   
                   
                   
                   
                 TATCGCCAGGCTCATCTGGT 
               
               
                   
                   
                   
                   
                 ACCAGGACGGGTACGAGCA 
               
               
                   
                   
                   
                   
                 GCCTTCTGATGAAGATTTGA 
               
               
                   
                   
                   
                   
                 AGAGGATTACGCAGACGTG 
               
               
                   
                   
                   
                   
                 GCAGCAAGCGGACGATGAA 
               
               
                   
                   
                   
                   
                 AACGAAGAGTCGGACACTC 
               
               
                   
                   
                   
                   
                 CCTTCCGCCAGATCACAGA 
               
               
                   
                   
                   
                   
                 GATGACTATCCTCACGGTCC 
               
               
                   
                   
                   
                   
                 AACTTATCGTGGAGTTCGC 
               
               
                   
                   
                   
                   
                 GAAGGGATTGCCAGGGTTC 
               
               
                   
                   
                   
                   
                 GCCAAGATCTCGCAGCCTG 
               
               
                   
                   
                   
                   
                 ATCAAATTACGCTGCTTAAG 
               
               
                   
                   
                   
                   
                 GCTTGCTCAAGTGAGGTAA 
               
               
                   
                   
                   
                   
                 TGATGCTCCGAGTCGCGCG 
               
               
                   
                   
                   
                   
                 ACGATACGATGCGGCCTCA 
               
               
                   
                   
                   
                   
                 GACAGTATTCTGTTCGCGA 
               
               
                   
                   
                   
                   
                 ACAACCAAGCGTACACTCG 
               
               
                   
                   
                   
                   
                 CGACAACTACCGCAAGGCT 
               
               
                   
                   
                   
                   
                 GGCATGGCCGAGGTCATCG 
               
               
                   
                   
                   
                   
                 AGGATCTACTGCACTTCTGC 
               
               
                   
                   
                   
                   
                 CGGTGCATGTACTCTATGG 
               
               
                   
                   
                   
                   
                 CGTTGGACAACATCCATTAC 
               
               
                   
                   
                   
                   
                 GCGCTGCTCACGGCTGTCG 
               
               
                   
                   
                   
                   
                 TCATCTTTTCTGACCGGCCA 
               
               
                   
                   
                   
                   
                 GGGTTGGAGCAGCCGCAAC 
               
               
                   
                   
                   
                   
                 TGGTGGAAGAGATCCAGCG 
               
               
                   
                   
                   
                   
                 GTACTACCTGAATACGCTCC 
               
               
                   
                   
                   
                   
                 GCATCTATATCCTGAACCAG 
               
               
                   
                   
                   
                   
                 CTGAGCGGGTCGGCGCGTT 
               
               
                   
                   
                   
                   
                 CGTCCGTCATATACGGCAA 
               
               
                   
                   
                   
                   
                 GATCCTCTCAATCCTCTCTG 
               
               
                   
                   
                   
                   
                 AGCTACGCACGCTCGGCAT 
               
               
                   
                   
                   
                   
                 GCAAAACTCCAACATGTGC 
               
               
                   
                   
                   
                   
                 ATCTCCCTCAAGCTCAAGAA 
               
               
                   
                   
                   
                   
                 CAGAAAGCTGCCGCCTTTCC 
               
               
                   
                   
                   
                   
                 TCGAGGAGATCTGGGATGT 
               
               
                   
                   
                   
                   
                 GGCGGACATGTCGCACACC 
               
               
                   
                   
                   
                   
                 CAACCGCCGCCTATCCTCGA 
               
               
                   
                   
                   
                   
                 GTCCCCCACGAATCTCTAG 
               
               
                   
               
               
                 GAL4-Linker- 
                 646 
                 MKLLSSIEQACDICRLKKLKCSKEKP 
                 647 
                 ATGAAGCTGCTGAGCAGCA 
               
               
                 EcR 
                   
                 KCAKCLKNNWECRYSPKTKRSPLTR 
                   
                 TCGAGCAGGCTTGCGACAT 
               
               
                   
                   
                 AHLTEVESRLERLEQLFLLIFPREDLD 
                   
                 CTGCAGGCTGAAGAAGCTG 
               
               
                   
                   
                 MILKMDSLQDIKALLTGLFVQDNV 
                   
                 AAGTGCAGCAAGGAGAAG 
               
               
                   
                   
                 NKDAVTDRLASVETDMPLTLRQHR 
                   
                 CCCAAGTGCGCCAAGTGCC 
               
               
                   
                   
                 ISATSSSEESSNKGQRQLTVSPEFPG 
                   
                 TGAAGAACAACTGGGAGTG 
               
               
                   
                   
                 RPECVVPETQCAMKRKEKKAQKEK 
                   
                 CAGATACAGCCCCAAGACC 
               
               
                   
                   
                 DKLPVSTTTVDDHMPPIMQCEPPP 
                   
                 AAGAGGAGCCCCCTGACCA 
               
               
                   
                   
                 PEAARIHEVVPRFLSDKLLVTNRQK 
                   
                 GGGCCCACCTGACCGAGGT 
               
               
                   
                   
                 NIPQLTANQQFLIARLIWYQDGYE 
                   
                 GGAGAGCAGGCTGGAGAG 
               
               
                   
                   
                 QPSDEDLKRITQTWQQADDENEE 
                   
                 GCTGGAGCAGCTGTTCCTG 
               
               
                   
                   
                 SDTPFRQITEMTILTVQLIVEFAKGL 
                   
                 CTGATCTTCCCCAGGGAGG 
               
               
                   
                   
                 PGFAKISQPDQITLLKACSSEVMML 
                   
                 ACCTGGACATGATCCTGAA 
               
               
                   
                   
                 RVARRYDAASDSILFANNQAYTRD 
                   
                 GATGGACAGCCTGCAAGAC 
               
               
                   
                   
                 NYRKAGMAEVIEDLLHFCRCMYS 
                   
                 ATCAAGGCCCTGCTGACCG 
               
               
                   
                   
                 MALDNIHYALLTAVVIFSDRPGLEQ 
                   
                 GCCTGTTCGTGCAGGACAA 
               
               
                   
                   
                 PQLVEEIQRYYLNTLRIYILNQLSGS 
                   
                 CGTGAACAAGGACGCCGTG 
               
               
                   
                   
                 ARSSVIYGKILSILSELRTLGMQNSN 
                   
                 ACCGACAGGCTGGCCAGCG 
               
               
                   
                   
                 MCISLKLKNRKLPPFLEEIWDVAD 
                   
                 TGGAGACCGACATGCCCCT 
               
               
                   
                   
                 MSHTQPPPILESPTNL 
                   
                 GACCCTGAGGCAGCACAGG 
               
               
                   
                   
                   
                   
                 ATCAGCGCCACCAGCAGCA 
               
               
                   
                   
                   
                   
                 GCGAGGAGAGCAGCAACA 
               
               
                   
                   
                   
                   
                 AGGGCCAGAGGCAGCTGAC 
               
               
                   
                   
                   
                   
                 CGTGAGCCCCGAGTTTCCC 
               
               
                   
                   
                   
                   
                 GGGCGGCCTGAGTGCGTAG 
               
               
                   
                   
                   
                   
                 TACCCGAGACTCAGTGCGC 
               
               
                   
                   
                   
                   
                 CATGAAGCGGAAAGAGAA 
               
               
                   
                   
                   
                   
                 GAAAGCACAGAAGGAGAA 
               
               
                   
                   
                   
                   
                 GGACAAACTGCCTGTCAGC 
               
               
                   
                   
                   
                   
                 ACGACGACGGTGGACGACC 
               
               
                   
                   
                   
                   
                 ACATGCCGCCCATTATGCAG 
               
               
                   
                   
                   
                   
                 TGTGAACCTCCACCTCCTGA 
               
               
                   
                   
                   
                   
                 AGCAGCAAGGATTCACGAA 
               
               
                   
                   
                   
                   
                 GTGGTCCCAAGGTTTCTCTC 
               
               
                   
                   
                   
                   
                 CGACAAGCTGTTGGTGACA 
               
               
                   
                   
                   
                   
                 AACCGGCAGAAAAACATCC 
               
               
                   
                   
                   
                   
                 CCCAGTTGACAGCCAACCA 
               
               
                   
                   
                   
                   
                 GCAGTTCCTTATCGCCAGGC 
               
               
                   
                   
                   
                   
                 TCATCTGGTACCAGGACGG 
               
               
                   
                   
                   
                   
                 GTACGAGCAGCCTTCTGAT 
               
               
                   
                   
                   
                   
                 GAAGATTTGAAGAGGATTA 
               
               
                   
                   
                   
                   
                 CGCAGACGTGGCAGCAAGC 
               
               
                   
                   
                   
                   
                 GGACGATGAAAACGAAGA 
               
               
                   
                   
                   
                   
                 GTCGGACACTCCCTTCCGCC 
               
               
                   
                   
                   
                   
                 AGATCACAGAGATGACTAT 
               
               
                   
                   
                   
                   
                 CCTCACGGTCCAACTTATCG 
               
               
                   
                   
                   
                   
                 TGGAGTTCGCGAAGGGATT 
               
               
                   
                   
                   
                   
                 GCCAGGGTTCGCCAAGATC 
               
               
                   
                   
                   
                   
                 TCGCAGCCTGATCAAATTAC 
               
               
                   
                   
                   
                   
                 GCTGCTTAAGGCTTGCTCAA 
               
               
                   
                   
                   
                   
                 GTGAGGTAATGATGCTCCG 
               
               
                   
                   
                   
                   
                 AGTCGCGCGACGATACGAT 
               
               
                   
                   
                   
                   
                 GCGGCCTCAGACAGTATTC 
               
               
                   
                   
                   
                   
                 TGTTCGCGAACAACCAAGC 
               
               
                   
                   
                   
                   
                 GTACACTCGCGACAACTACC 
               
               
                   
                   
                   
                   
                 GCAAGGCTGGCATGGCCGA 
               
               
                   
                   
                   
                   
                 GGTCATCGAGGATCTACTG 
               
               
                   
                   
                   
                   
                 CACTTCTGCCGGTGCATGTA 
               
               
                   
                   
                   
                   
                 CTCTATGGCGTTGGACAAC 
               
               
                   
                   
                   
                   
                 ATCCATTACGCGCTGCTCAC 
               
               
                   
                   
                   
                   
                 GGCTGTCGTCATCTTTTCTG 
               
               
                   
                   
                   
                   
                 ACCGGCCAGGGTTGGAGCA 
               
               
                   
                   
                   
                   
                 GCCGCAACTGGTGGAAGAG 
               
               
                   
                   
                   
                   
                 ATCCAGCGGTACTACCTGA 
               
               
                   
                   
                   
                   
                 ATACGCTCCGCATCTATATC 
               
               
                   
                   
                   
                   
                 CTGAACCAGCTGAGCGGGT 
               
               
                   
                   
                   
                   
                 CGGCGCGTTCGTCCGTCAT 
               
               
                   
                   
                   
                   
                 ATACGGCAAGATCCTCTCAA 
               
               
                   
                   
                   
                   
                 TCCTCTCTGAGCTACGCACG 
               
               
                   
                   
                   
                   
                 CTCGGCATGCAAAACTCCA 
               
               
                   
                   
                   
                   
                 ACATGTGCATCTCCCTCAAG 
               
               
                   
                   
                   
                   
                 CTCAAGAACAGAAAGCTGC 
               
               
                   
                   
                   
                   
                 CGCCTTTCCTCGAGGAGATC 
               
               
                   
                   
                   
                   
                 TGGGATGTGGCGGACATGT 
               
               
                   
                   
                   
                   
                 CGCACACCCAACCGCCGCCT 
               
               
                   
                   
                   
                   
                 ATCCTCGAGTCCCCCACGAA 
               
               
                   
                   
                   
                   
                 TCTCTAG 
               
               
                   
               
               
                 EMCV IRES 
                   
                   
                 702 
                 CCCCCTCTCCCTCCCCCCCCC 
               
               
                   
                   
                   
                   
                 CTAACGTTACTGGCCGAAG 
               
               
                   
                   
                   
                   
                 CCGCTTGGAATAAGGCCGG 
               
               
                   
                   
                   
                   
                 TGTGCGTTTGTCTATATGTT 
               
               
                   
                   
                   
                   
                 ATTTTCCACCATATTGCCGT 
               
               
                   
                   
                   
                   
                 CTTTTGGCAATGTGAGGGC 
               
               
                   
                   
                   
                   
                 CCGGAAACCTGGCCCTGTC 
               
               
                   
                   
                   
                   
                 TTCTTGACGAGCATTCCTAG 
               
               
                   
                   
                   
                   
                 GGGTCTTTCCCCTCTCGCCA 
               
               
                   
                   
                   
                   
                 AAGGAATGCAAGGTCTGTT 
               
               
                   
                   
                   
                   
                 GAATGTCGTGAAGGAAGCA 
               
               
                   
                   
                   
                   
                 GTTCCTCTGGAAGCTTCTTG 
               
               
                   
                   
                   
                   
                 AAGACAAACAACGTCTGTA 
               
               
                   
                   
                   
                   
                 GCGACCCTTTGCAGGCAGC 
               
               
                   
                   
                   
                   
                 GGAACCCCCCACCTGGCGA 
               
               
                   
                   
                   
                   
                 CAGGTGCCTCTGCGGCCAA 
               
               
                   
                   
                   
                   
                 AAGCCACGTGTATAAGATA 
               
               
                   
                   
                   
                   
                 CACCTGCAAAGGCGGCACA 
               
               
                   
                   
                   
                   
                 ACCCCAGTGCCACGTTGTG 
               
               
                   
                   
                   
                   
                 AGTTGGATAGTTGTGGAAA 
               
               
                   
                   
                   
                   
                 GAGTCAAATGGCTCTCCTCA 
               
               
                   
                   
                   
                   
                 AGCGTATTCAACAAGGGGC 
               
               
                   
                   
                   
                   
                 TGAAGGATGCCCAGAAGGT 
               
               
                   
                   
                   
                   
                 ACCCCATTGTATGGGATCTG 
               
               
                   
                   
                   
                   
                 ATCTGGGGCCTCGGTGCAC 
               
               
                   
                   
                   
                   
                 ATGCTTTACATGTGTTTAGT 
               
               
                   
                   
                   
                   
                 CGAGGTTAAAAAACGTCTA 
               
               
                   
                   
                   
                   
                 GGCCCCCCGAACCACGGGG 
               
               
                   
                   
                   
                   
                 ACGTGGTTTTCCTTTGAAAA 
               
               
                   
                   
                   
                   
                 ACACGATC 
               
               
                   
               
               
                 2xRbm3 IRES 
                   
                   
                 703 
                 ACTAGTTTTATAATTTCTTCT 
               
               
                   
                   
                   
                   
                 TCCAGAATTTCTGACATTTT 
               
               
                   
                   
                   
                   
                 ATAATTTCTTCTTCCAGAAG 
               
               
                   
                   
                   
                   
                 ACTCACAACCTC